Joys	O
and	O
F	O
.	O

2	O
cases	O
of	O
type	O
II	O
tyrosinosis	O
(	O
Richner	O
-	O
Hanhart	O
syndrome	O
)	O

Following	O
conditioning	O
,	O
a	O
single	O
coat	O
of	O
adhesive	O
was	O
applied	O
and	O
light	O
-	O
cured	O
.	O

The	O
East	O
African	O
dik	O
-	O
dik	O
antelope	O
represents	O
a	O
miniature	O
model	O
ruminant	O
for	O
comparative	O
studies	O
.	O

Evaluation	O
of	O
automatic	O
blood	O
cell	O
counters	O
.	O

Auditory	O
threshold	O
shifts	O
,	O
as	O
measured	O
by	O
the	O
auditory	O
evoked	O
brainstem	O
response	O
,	O
were	O
measured	O
at	O
2	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
20	O
and	O
24	O
kHz	O
.	O

A	O
portion	O
of	O
Region	O
II	O
also	O
resembles	O
part	O
of	O
the	O
human	O
c	B-GENE
-	I-GENE
jun	I-GENE
oncoprotein	O
'	O
s	O
leucine	O
zipper	O
,	O
which	O
in	O
turn	O
,	O
has	O
been	O
demonstrated	O
to	O
be	O
the	O
heterodimerization	O
site	O
between	O
the	O
jun	B-GENE
and	O
fos	B-GENE
oncoproteins	I-GENE
.	O

Of	O
the	O
117	O
patients	O
(	O
out	O
of	O
the	O
136	O
)	O
with	O
serologic	O
evidence	O
of	O
chronic	O
thyroiditis	O
who	O
could	O
be	O
studied	O
,	O
eight	O
(	O
7	O
%	O
)	O
had	O
hyperthyroidism	O
and	O
45	O
(	O
38	O
%	O
)	O
were	O
hypothyroid	O
.	O

All	O
other	O
normal	O
and	O
transformed	O
lymphoid	O
and	O
nonlymphoid	O
cell	O
lines	O
and	O
normal	O
tissues	O
were	O
negative	O
for	O
PANG	B-GENE
expression	O
except	O
for	O
the	O
brain	O
,	O
wherein	O
unique	O
4	O
.	O
0	O
-	O
and	O
6	O
.	O
1	O
-	O
kb	O
transcripts	O
were	O
detected	O
.	O

Type	O
I	O
position	O
-	O
vestibular	O
-	O
pause	O
(	O
PVP	O
I	O
)	O
and	O
vestibular	O
-	O
only	O
(	O
V	O
I	O
)	O
neurons	O
,	O
as	O
well	O
as	O
a	O
smaller	O
number	O
of	O
other	O
type	O
I	O
and	O
type	O
II	O
eye	O
-	O
plus	O
-	O
vestibular	O
neurons	O
were	O
studied	O
.	O

Risk	O
of	O
infection	O
in	O
the	O
treatment	O
of	O
fractures	O

Marine	O
oils	O
and	O
cardiovascular	O
reactivity	O
.	O

Influence	O
of	O
cyclo	B-GENE
-	I-GENE
oxygenase	I-GENE
inhibition	O
and	O
of	O
leukotriene	B-GENE
receptor	I-GENE
blockade	O
on	O
pulmonary	O
vascular	O
pressure	O
/	O
cardiac	O
index	O
relationships	O
in	O
hyperoxic	O
and	O
in	O
hypoxic	O
dogs	O
.	O

The	O
HMG	B-GENE
domain	I-GENE
of	O
both	O
HMG20	B-GENE
proteins	I-GENE
is	O
most	O
similar	O
to	O
that	O
of	O
yeast	B-GENE
NHP6A	I-GENE
(	O
38	O
%	O
to	O
42	O
%	O
)	O
.	O

The	O
antigen	B-GENE
-	I-GENE
specific	I-GENE
IgG4	I-GENE
antibody	I-GENE
seems	O
to	O
be	O
an	O
index	O
in	O
evaluating	O
immunotherapy	O
objectively	O
.	O

This	O
strategy	O
was	O
used	O
to	O
place	O
both	O
the	O
Tn903	B-GENE
neo	I-GENE
gene	I-GENE
and	O
the	O
Rhodosporidium	B-GENE
toruloides	I-GENE
phenylalanine	I-GENE
ammonia	I-GENE
lyase	I-GENE
(	O
PAL	B-GENE
)	O
-	O
encoding	O
gene	O
under	O
the	O
transcriptional	O
control	O
of	O
pPGK	B-GENE
:	O
:	O
REP2	B-GENE
.	O

Here	O
we	O
describe	O
the	O
cloning	O
,	O
tissue	O
-	O
specific	O
expression	O
pattern	O
,	O
and	O
functional	O
characterization	O
of	O
two	O
novel	O
TEF	B-GENE
-	I-GENE
1	I-GENE
isoforms	I-GENE
,	O
TEF	B-GENE
-	I-GENE
1beta	I-GENE
and	O
TEF	B-GENE
-	I-GENE
1gamma	I-GENE
.	O

The	O
experimental	O
group	O
consisted	O
of	O
61	O
examinees	O
class	O
II	O
/	O
2	O
orthodontic	O
anomalies	O
.	O

Phosphatidylinositol	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
requirement	O
in	O
activation	O
of	O
the	O
ras	B-GENE
/	O
C	B-GENE
-	I-GENE
raf	I-GENE
-	I-GENE
1	I-GENE
/	O
MEK	B-GENE
/	O
ERK	B-GENE
and	O
p70	B-GENE
(	O
s6k	B-GENE
)	O
signaling	O
cascade	O
by	O
the	O
insulinomimetic	O
agent	O
vanadyl	O
sulfate	O
.	O

This	O
apparently	O
anomalous	O
structure	O
/	O
activity	O
relationship	O
raises	O
important	O
issues	O
for	O
understanding	O
the	O
evolution	O
of	O
regulatory	O
peptides	O
and	O
the	O
mechanisms	O
that	O
control	O
their	O
expression	O
.	O

In	O
the	O
same	O
period	O
we	O
pointed	O
out	O
an	O
increase	O
of	O
hematocrit	O
(	O
from	O
29	O
%	O
to	O
35	O
%	O
)	O
and	O
of	O
the	O
Hb	B-GENE
(	O
from	O
9	O
.	O
3	O
to	O
11	O
.	O
2	O
g	O
/	O
dl	O
)	O
.	O

The	O
C	O
-	O
LIP	O
also	O
was	O
compared	O
with	O
transcather	O
arterial	O
embolization	O
(	O
TAE	O
;	O
C	O
-	O
LIP	O
followed	O
by	O
gelatin	O
sponge	O
)	O
and	O
percutaneous	O
ethanol	O
injection	O
therapy	O
(	O
PEIT	O
)	O
.	O

The	O
ORF1	O
product	O
was	O
required	O
for	O
competence	O
,	O
while	O
ORF2	O
,	O
which	O
was	O
cotranscribed	O
with	O
ORF1	O
and	O
encoded	O
a	O
predicted	O
protein	O
of	O
126	O
amino	O
acids	O
,	O
was	O
not	O
.	O

2	O
.	O

Cotransfection	O
of	O
Ets	B-GENE
-	I-GENE
2	I-GENE
and	O
p44	B-GENE
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
(	I-GENE
MAP	I-GENE
)	I-GENE
kinase	I-GENE
expression	O
vectors	O
strongly	O
potentiated	O
HB	B-GENE
-	O
EGF	B-GENE
promoter	O
activation	O
in	O
response	O
to	O
deltaRaf	B-GENE
-	I-GENE
1	I-GENE
:	O
ER	B-GENE
.	O

Bitter	O
cassava	O
contains	O
cyanogenic	O
glycosides	O
;	O
processing	O
breaks	O
them	O
down	O
to	O
acetone	O
cyanohydrin	O
and	O
hydrogen	O
cyanide	O
.	O

Sequence	O
analysis	O
of	O
the	O
promoter	O
region	O
showed	O
no	O
TATA	O
box	O
but	O
identified	O
consensus	O
binding	O
motifs	O
for	O
Sp1	B-GENE
,	O
CREB	B-GENE
,	O
and	O
half	O
sites	O
of	O
the	O
estrogen	B-GENE
receptor	I-GENE
binding	I-GENE
site	I-GENE
.	O

Unique	O
to	O
this	O
system	O
,	O
the	O
activity	O
of	O
TraR	B-GENE
is	O
negatively	O
modulated	O
by	O
an	O
antiactivator	O
called	O
TraM	B-GENE
.	O

Thus	O
,	O
an	O
increase	O
in	O
plasma	B-GENE
TBG	I-GENE
and	O
a	O
shift	O
from	O
adrenal	O
androgen	O
and	O
mineralocorticoid	O
steroid	O
secretion	O
towards	O
cortisol	O
secretion	O
may	O
be	O
endocrine	O
markers	O
for	O
progression	O
of	O
the	O
disease	O
in	O
patients	O
with	O
HIV	O
-	O
infection	O
.	O

Such	O
studied	O
acquired	O
with	O
low	O
energy	O
or	O
medium	O
energy	O
collimation	O
and	O
a	O
window	O
centered	O
on	O
the	O
159	O
keV	O
123I	O
photopeak	O
contain	O
appreciable	O
septal	O
breakthrough	O
signals	O
originating	O
from	O
Compton	O
scatter	O
of	O
high	O
energy	O
photons	O
primarily	O
from	O
124I	O
.	O

Dissolution	O
of	O
the	O
Pt	O
-	O
30	O
%	O
Ir	O
microelectrode	O
tip	O
was	O
observed	O
by	O
scanning	O
electron	O
microscopy	O
at	O
charge	O
densities	O
as	O
low	O
as	O
200	O
microC	O
/	O
cm2	O
X	O
ph	O
(	O
1	O
A	O
/	O
cm2	O
)	O
,	O
whereas	O
erosion	O
of	O
activated	O
iridium	O
microelectrodes	O
occurred	O
only	O
at	O
the	O
highest	O
charge	O
and	O
current	O
densities	O
(	O
3200	O
microC	O
/	O
cm2	O
X	O
ph	O
,	O
16	O
A	O
/	O
cm2	O
)	O
.	O

E1A	B-GENE
represses	O
apolipoprotein	B-GENE
AI	I-GENE
enhancer	I-GENE
activity	O
in	O
liver	O
cells	O
through	O
a	O
pRb	B-GENE
-	O
and	O
CBP	B-GENE
-	O
independent	O
pathway	O
.	O

Ganciclovir	O
and	O
foscarnet	O
efficacy	O
in	O
AIDS	O
-	O
related	O
CMV	O
polyradiculopathy	O
.	O

JCAHO	O
asks	O
for	O
hospitals	O
'	O
patience	O
.	O

Conservative	O
treatment	O
of	O
bladder	O
carcinoma	O
by	O
partial	O
cystectomy	O
and	O
interstitial	O
iridium	O
192	O
.	O

The	O
spermicide	O
nonoxynol	O
-	O
9	O
is	O
a	O
member	O
of	O
a	O
homologous	O
series	O
of	O
alkylphenol	O
-	O
ethoxylates	O
(	O
polyethoxyethanols	O
)	O
of	O
general	O
formula	O
C9H19	O
-	O
C6H6	O
-	O
O	O
-	O
(	O
CH2CH2O	O
)	O
n	O
-	O
1	O
CH2CH2OH	O
.	O

A	O
raised	O
amplitude	O
of	O
the	O
aggregation	O
of	O
plates	O
and	O
a	O
decrease	O
in	O
the	O
threshold	O
of	O
their	O
sensitivity	O
to	O
ADP	O
were	O
established	O
in	O
the	O
persons	O
with	O
types	O
IIa	O
and	O
IIb	O
HLP	O
and	O
in	O
CHD	O
without	O
HLP	O
.	O

Dominant	O
negative	O
Sos	B-GENE
did	O
not	O
affect	O
carbachol	O
stimulation	O
of	O
HA	B-GENE
-	O
ERK2	B-GENE
but	O
inhibited	O
the	O
stimulatory	O
effect	O
of	O
EGF	B-GENE
by	O
60	O
%	O
.	O

[	O
Pulmonary	O
vascular	O
resistance	O
(	O
PVR	O
)	O
during	O
10	O
%	O
O2	O
-	O
PVR	O
during	O
21	O
%	O
O2	O
/	O
PVR	O
during	O
21	O
%	O
O2	O
]	O
x	O
100	O
was	O
termed	O
as	O
hypoxic	O
pulmonary	O
vasoconstriction	O
(	O
HPV	O
)	O
.	O

While	O
all	O
deletions	O
within	O
the	O
sequence	O
coding	O
for	O
the	O
mature	O
tRNA	O
led	O
to	O
inactivity	O
of	O
the	O
mutated	O
genes	O
,	O
substitution	O
of	O
the	O
central	O
portion	O
by	O
concatenated	B-GENE
Hind	I-GENE
III	I-GENE
linkers	I-GENE
produced	O
gene	O
units	O
active	O
in	O
transcription	O
.	O

Identification	O
and	O
characterization	O
of	O
two	O
putative	O
human	B-GENE
arginine	I-GENE
methyltransferases	I-GENE
(	O
HRMT1L1	B-GENE
and	O
HRMT1L2	B-GENE
)	O
.	O

Remarkably	O
,	O
U21	B-GENE
contains	O
a	O
long	O
stretch	O
(	O
13	O
nt	O
.	O
)	O
of	O
complementarity	O
to	O
a	O
highly	O
conserved	O
sequence	O
in	O
28S	B-GENE
rRNA	I-GENE
.	O

Immunohistochemically	O
,	O
anticytokeratin	B-GENE
19	I-GENE
antibody	I-GENE
revealed	O
strong	O
staining	O
in	O
both	O
epithelial	O
and	O
sarcomatous	O
MPM	O
tissues	O
.	O

Analysis	O
of	O
Standard	O
Reference	O
Material	O
1846	O
,	O
Infant	O
Formula	O
,	O
gave	O
a	O
mean	O
value	O
of	O
0	O
.	O
95	O
+	O
/	O
-	O
0	O
.	O
088	O
mg	O
vitamin	O
K	O
/	O
kg	O
(	O
K	O
or	O
K1	O
?	O
)	O
(	O
n	O
=	O
31	O
)	O
with	O
a	O
coefficient	O
of	O
variation	O
of	O
9	O
.	O
26	O
.	O

Data	O
from	O
in	O
vitro	O
splicing	O
assays	O
,	O
UV	O
crosslinking	O
and	O
RNA	O
-	O
binding	O
competition	O
experiments	O
indicates	O
a	O
strong	O
correlation	O
between	O
the	O
binding	O
affinities	O
of	O
PSI	B-GENE
for	O
the	O
SELEX	O
sequences	O
and	O
their	O
ability	O
to	O
modulate	O
splicing	O
of	O
P	B-GENE
element	I-GENE
IVS3	B-GENE
in	O
vitro	O
.	O

Factors	O
involved	O
in	O
specific	O
transcription	O
by	O
mammalian	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
:	O
purification	O
,	O
genetic	O
specificity	O
,	O
and	O
TATA	O
box	O
-	O
promoter	O
interactions	O
of	O
TFIID	B-GENE
.	O

EsaR	B-GENE
can	O
repress	O
its	O
own	O
expression	O
but	O
seems	O
not	O
to	O
regulate	O
the	O
expression	O
of	O
esaI	B-GENE
.	O

Charcoal	O
-	O
facilitated	O
dialysis	O
.	O

The	O
structure	O
of	O
these	O
genes	O
suggests	O
a	O
common	O
ancestor	O
for	O
all	O
viperid	B-GENE
PLA2	I-GENE
genes	I-GENE
.	O

Quantitative	O
analysis	O
of	O
plasmid	O
loss	O
rates	O
in	O
cdc28	B-GENE
-	I-GENE
1N	I-GENE
strains	O
carrying	O
plasmids	O
with	O
multiple	O
replication	O
origins	O
suggests	O
that	O
a	O
defect	O
in	O
initiating	O
DNA	O
replication	O
probably	O
causes	O
this	O
plasmid	O
loss	O
phenotype	O
.	O

Bullous	O
angiolymphoid	O
hyperplasia	O
with	O
eosinophilia	O

Our	O
results	O
show	O
that	O
,	O
from	O
a	O
thermodynamical	O
standpoint	O
,	O
melatonin	O
may	O
directly	O
scavenge	O
hydroxyl	O
radicals	O
both	O
in	O
vacuum	O
and	O
in	O
aqueous	O
solution	O
.	O

Neither	O
ethanol	O
nor	O
estrogen	O
has	O
been	O
shown	O
to	O
cause	O
UROD	B-GENE
-	O
deficiency	O
in	O
animals	O
.	O

CONCLUSION	O
:	O
Treatment	O
of	O
sepsis	O
with	O
the	O
platelet	B-GENE
-	I-GENE
activating	I-GENE
factor	I-GENE
antagonist	O
BB	O
-	O
882	O
offers	O
no	O
advantage	O
over	O
placebo	O
on	O
survival	O
,	O
hemodynamic	O
status	O
,	O
respiratory	O
function	O
,	O
or	O
organ	O
failure	O
scores	O
.	O

Also	O
,	O
transient	O
overexpression	O
of	O
this	O
protein	O
in	O
C2C12	O
cells	O
reduced	O
the	O
transcription	O
of	O
a	O
CAT	B-GENE
-	O
reporter	O
regulated	O
by	O
an	O
E12	B-GENE
/	O
MyoD	B-GENE
driven	O
enhancer	O
.	O

She	O
drank	O
alcohol	O
once	O
or	O
twice	O
a	O
week	O
and	O
regularly	O
took	O
an	O
analgesic	O
preparation	O
,	O
containing	O
aspirin	O
and	O
acetaminophen	O
,	O
for	O
alleviation	O
of	O
headaches	O
.	O

Diffuse	O
myalgias	O
were	O
more	O
frequent	O
in	O
patients	O
with	O
than	O
without	O
an	O
MMF	O
lesion	O
at	O
deltoid	O
muscle	O
biopsy	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
hormone	O
receptor	O
status	O
between	O
the	O
cases	O
without	O
lymph	O
node	O
metastases	O
and	O
with	O
lymph	O
node	O
metastases	O
,	O
'	O
clandestine	O
'	O
or	O
macrometastases	O
.	O

Infant	O
aged	O
3	O
.	O
5	O
years	O
presents	O
persistence	O
of	O
primordial	O
vitreous	O
body	O
with	O
crystalline	O
dislocation	O
in	O
the	O
camera	O
aquosa	O
and	O
secondary	O
buphthalmos	O
of	O
the	O
left	O
eye	O
and	O
microphthalmos	O
with	O
dislocation	O
of	O
the	O
crystalline	O
in	O
the	O
vitreous	O
body	O
of	O
the	O
right	O
eye	O
.	O

BACKGROUND	O
AND	O
DESIGN	O
:	O
Fifty	O
-	O
nine	O
melanocytic	O
nevi	O
with	O
eccentric	O
foci	O
of	O
hyperpigmentation	O
(	O
"	O
small	O
dark	O
dots	O
"	O
)	O
that	O
measured	O
primarily	O
1	O
to	O
2	O
mm	O
in	O
diameter	O
were	O
prospectively	O
examined	O
to	O
determine	O
the	O
histologic	O
correlates	O
of	O
the	O
dark	O
dots	O
.	O

CONCLUSIONS	O
:	O
Using	O
icodextrin	O
-	O
based	O
instead	O
of	O
glucose	O
-	O
based	O
PD	O
fluids	O
can	O
largely	O
reduce	O
the	O
formation	O
of	O
Amadori	O
albumin	B-GENE
and	O
AGEs	O
.	O

The	O
Mauriceville	O
and	O
Varkud	O
mitochondrial	O
plasmids	O
are	O
closely	O
related	O
,	O
closed	O
-	O
circular	O
DNAs	O
(	O
3	O
.	O
6	O
and	O
3	O
.	O
7	O
kb	O
,	O
respectively	O
)	O
that	O
have	O
characteristics	O
of	O
mtDNA	O
introns	O
and	O
retroid	O
elements	O
.	O

Biol	O
.	O

As	O
in	O
Tb	O
,	O
U6	B-GENE
is	O
a	O
single	O
-	O
copy	O
gene	O
and	O
two	O
tRNA	O
genes	O
,	O
tRNAGln	B-GENE
and	O
tRNAIle	B-GENE
,	O
are	O
found	O
upstream	O
to	O
the	O
gene	O
.	O

Association	O
of	O
stress	O
during	O
delivery	O
with	O
increased	O
numbers	O
of	O
nucleated	O
cells	O
and	O
hematopoietic	O
progenitor	O
cells	O
in	O
umbilical	O
cord	O
blood	O
.	O

An	O
aromatic	O
stacking	O
interaction	O
between	O
subunits	O
helps	O
mediate	O
DNA	O
sequence	O
specificity	O
:	O
operator	O
site	O
discrimination	O
by	O
phage	B-GENE
lambda	I-GENE
cI	I-GENE
repressor	I-GENE
.	O

Symptoms	O
,	O
however	O
,	O
appear	O
to	O
correlate	O
poorly	O
with	O
oesophagitis	O
;	O
hence	O
,	O
severe	O
symptoms	O
do	O
not	O
indicate	O
there	O
is	O
greater	O
oesophageal	O
damage	O
.	O

This	O
relatively	O
simple	O
and	O
easily	O
performed	O
technique	O
of	O
measuring	O
deep	O
muscle	O
temperature	O
appears	O
to	O
be	O
a	O
useful	O
adjunct	O
in	O
choosing	O
the	O
amputation	O
level	O
.	O

Multistep	O
transformation	O
by	O
defined	O
fragments	O
of	O
herpes	O
simplex	O
virus	O
type	O
2	O
DNA	O
:	O
oncogenic	O
region	O
and	O
its	O
gene	O
product	O
.	O

The	O
two	O
drugs	O
increase	O
the	O
rate	O
of	O
early	O
diastolic	O
filling	O
.	O

A	O
4	O
.	O
8	O
-	O
kilobase	O
BamHI	B-GENE
-	O
HindIII	B-GENE
fragment	O
encoding	O
the	O
entire	B-GENE
Neurospora	I-GENE
crassa	I-GENE
CuZn	I-GENE
superoxide	I-GENE
dismutase	I-GENE
gene	I-GENE
(	O
herein	O
designated	O
sod	B-GENE
-	I-GENE
1	I-GENE
)	O
was	O
isolated	O
from	O
a	O
genomic	O
library	O
using	O
two	O
60	O
-	O
base	O
deoxyoligonucleotide	O
probes	O
corresponding	O
to	O
the	O
published	O
N	O
.	O
crassa	O
amino	O
acid	O
sequence	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
adenoviral	B-GENE
12S	I-GENE
E1A	I-GENE
protein	I-GENE
modulates	O
the	O
phosphorylation	O
status	O
of	O
p130	B-GENE
and	O
p107	B-GENE
without	O
apparent	O
changes	O
in	O
the	O
cell	O
cycle	O
dependent	O
phosphorylation	O
of	O
the	O
retinoblastoma	B-GENE
protein	I-GENE
.	O

Individual	O
mutations	O
in	O
motifs	O
III	O
,	O
IV	O
,	O
and	O
V	O
had	O
distinctive	O
effects	O
on	O
the	O
affinity	O
of	O
enzyme	O
for	O
GTP	O
,	O
the	O
rate	O
of	O
covalent	O
catalysis	O
(	O
EpG	O
formation	O
)	O
,	O
or	O
the	O
transfer	O
of	O
GMP	O
from	O
enzyme	O
to	O
RNA	O
.	O

In	O
this	O
paper	O
we	O
report	O
that	O
ligand	O
binding	O
induced	O
tyrosine	O
phosphorylation	O
in	O
BaF3	O
cells	O
engineered	O
to	O
express	O
the	O
murine	B-GENE
Mpl	I-GENE
receptor	I-GENE
(	O
BaF3	O
/	O
mMpl	B-GENE
)	O
.	O

Genome	O
plasticity	O
in	O
the	O
distal	O
tail	O
fiber	O
locus	O
of	O
the	O
T	O
-	O
even	O
bacteriophage	O
:	O
recombination	O
between	O
conserved	O
motifs	O
swaps	O
adhesin	B-GENE
specificity	O
.	O

Inactivity	O
of	O
the	O
human	B-GENE
cytomegalovirus	I-GENE
(	I-GENE
HCMV	I-GENE
)	I-GENE
major	I-GENE
immediate	I-GENE
-	I-GENE
early	I-GENE
regulatory	I-GENE
region	I-GENE
(	O
MIERR	B-GENE
)	O
,	O
which	O
is	O
composed	O
of	O
promoter	O
,	O
enhancer	O
,	O
unique	O
region	O
,	O
and	O
modulator	O
,	O
is	O
linked	O
to	O
lack	O
of	O
HCMV	O
replication	O
in	O
latently	O
infected	O
cells	O
and	O
in	O
other	O
nonpermissive	O
cell	O
types	O
,	O
including	O
human	O
embryonal	O
NTera2	O
carcinoma	O
(	O
NT2	O
)	O
cells	O
.	O

In	O
some	O
early	O
B	O
cells	O
and	O
Abelson	O
murine	O
leukemia	O
virus	O
-	O
transformed	O
pre	O
-	O
B	O
-	O
cell	O
lines	O
,	O
LT	B-GENE
mRNA	I-GENE
is	O
constitutively	O
expressed	O
.	O

Female	O
Wistar	O
rats	O
were	O
fed	O
a	O
liquid	O
diet	O
,	O
Sustacal	O
,	O
which	O
contained	O
ethanol	O
(	O
40	O
%	O
of	O
calories	O
)	O
or	O
isocaloric	O
sucrose	O
.	O

The	O
5	O
'	O
flanking	O
region	O
contains	O
potential	O
binding	O
sites	O
for	O
TATA	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
,	O
Sp1	B-GENE
,	O
nuclear	B-GENE
factor	I-GENE
1	I-GENE
(	O
NF1	B-GENE
)	O
,	O
CAAT	B-GENE
-	I-GENE
box	I-GENE
binding	I-GENE
protein	I-GENE
(	O
C	B-GENE
/	I-GENE
EBP	I-GENE
)	O
,	O
hepatocyte	B-GENE
nuclear	I-GENE
factors	I-GENE
1	I-GENE
and	I-GENE
5	I-GENE
(	O
HNF1	B-GENE
,	O
HNF5	B-GENE
)	O
and	O
activator	B-GENE
proteins	I-GENE
1	I-GENE
and	I-GENE
2	I-GENE
(	O
AP1	B-GENE
,	O
AP2	B-GENE
)	O
.	O

The	O
median	O
post	O
-	O
treatment	O
,	O
pre	O
-	O
operative	O
serum	B-GENE
PSA	I-GENE
was	O
0	O
.	O
4	O
ng	O
/	O
ml	O
.	O

In	O
contrast	O
,	O
transiently	O
transfected	O
cells	O
expressing	O
EBNA	B-GENE
-	I-GENE
3	I-GENE
revealed	O
a	O
sixfold	O
increase	O
in	O
EBNA	B-GENE
-	I-GENE
3	I-GENE
protein	I-GENE
expression	O
from	O
the	O
genomic	O
EBNA	B-GENE
-	I-GENE
3	I-GENE
gene	I-GENE
compared	O
to	O
EBNA	B-GENE
-	I-GENE
3	I-GENE
cDNA	I-GENE
.	O

By	O
progressive	O
5	O
'	O
-	O
deletion	O
studies	O
,	O
we	O
have	O
identified	O
a	O
248	O
-	O
bp	O
DNA	O
fragment	O
(	O
-	O
1018	O
to	O
-	O
771	O
,	O
relative	O
to	O
the	O
translation	O
start	O
site	O
)	O
at	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
human	B-GENE
GnRHR	I-GENE
gene	I-GENE
that	O
is	O
responsible	O
for	O
the	O
GnRHa	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
human	B-GENE
GnRHR	I-GENE
promoter	I-GENE
activity	O
.	O

This	O
finding	O
is	O
the	O
first	O
example	O
of	O
utilization	O
of	O
noncomplementary	O
dinucleotide	O
primer	O
by	O
an	O
RNA	B-GENE
polymerase	I-GENE
.	O

Mucin	B-GENE
gene	I-GENE
expression	O
has	O
been	O
shown	O
to	O
be	O
altered	O
in	O
many	O
intestinal	O
diseases	O
and	O
especially	O
cancers	O
of	O
the	O
gastrointestinal	O
tract	O
.	O

In	O
both	O
cases	O
,	O
at	O
the	O
end	O
of	O
exposure	O
the	O
same	O
level	O
of	O
blood	B-GENE
carboxyhemoglobin	I-GENE
(	O
COHb	B-GENE
)	O
(	O
about	O
50	O
%	O
)	O
was	O
reached	O
.	O

The	O
Delta6CCI	O
virus	O
was	O
extremely	O
attenuated	O
in	O
replication	O
capacity	O
yet	O
retained	O
infectiousness	O
for	O
CEMx174	O
and	O
MT4	O
cells	O
.	O

Weak	O
promoter	O
activity	O
was	O
observed	O
for	O
the	O
promoter	O
of	O
the	O
C1	B-GENE
and	O
C2	B-GENE
ORFs	O
(	O
C1	B-GENE
-	O
C2	B-GENE
gene	O
)	O
and	O
for	O
the	O
promoter	O
of	O
the	O
V1	B-GENE
ORF	I-GENE
.	O

In	O
addition	O
,	O
the	O
calbindin	B-GENE
-	I-GENE
D28K	I-GENE
promoter	I-GENE
is	O
composed	O
of	O
a	O
variety	O
of	O
simple	O
repeated	O
sequences	O
,	O
some	O
of	O
which	O
are	O
components	O
of	O
putative	O
regulatory	O
signals	O
.	O

Acute	O
idiopathic	O
thrombocytopenic	O
purpura	O
presenting	O
a	O
high	O
serum	O
level	O
of	O
immunoglobulin	B-GENE
E	I-GENE
and	O
eosinophilia	O
in	O
an	O
elderly	O
patient	O
.	O

VDR	B-GENE
/	O
RXR	B-GENE
bound	O
well	O
to	O
the	O
VDREs	O
and	O
to	O
DR4	O
and	O
DR5	O
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Swim	O
-	O
over	O
:	O
an	O
alternative	O
method	O
for	O
harvesting	O
motile	O
spermatozoa	O
.	O

Significant	O
increases	O
in	O
mean	O
serum	O
E2	O
concentration	O
(	O
100	O
to	O
150	O
pg	O
/	O
ml	O
)	O
were	O
noted	O
at	O
6	O
and	O
8	O
hours	O
after	O
administration	O
on	O
day	O
1	O
and	O
at	O
8	O
hours	O
on	O
day	O
4	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
RSTD	O
predicts	O
coronary	O
anatomy	O
during	O
acute	O
coronary	O
occlusion	O
.	O

We	O
were	O
able	O
to	O
detect	O
significant	O
differences	O
in	O
functional	O
residual	O
capacity	O
adjusted	O
for	O
weight	O
or	O
height	O
,	O
and	O
compliance	O
of	O
the	O
respiratory	O
system	O
adjusted	O
for	O
weight	O
or	O
lung	O
volume	O
in	O
the	O
ILD	O
infants	O
compared	O
to	O
the	O
healthy	O
controls	O
or	O
infants	O
who	O
had	O
PPHN	O
,	O
indicating	O
that	O
these	O
PFTs	O
were	O
sensitive	O
enough	O
to	O
determine	O
abnormal	O
lung	O
function	O
in	O
this	O
age	O
group	O
.	O

In	O
Experiment	O
2	O
,	O
we	O
again	O
used	O
classification	O
,	O
but	O
the	O
fixed	O
standard	O
75	O
was	O
not	O
at	O
the	O
center	O
of	O
the	O
range	O
of	O
target	O
numbers	O
(	O
20	O
,	O
21	O
,	O
.	O
.	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
matrilysin	B-GENE
-	I-GENE
2	I-GENE
also	O
contains	O
a	O
threonine	O
residue	O
adjacent	O
to	O
the	O
Zn	O
-	O
binding	O
site	O
that	O
has	O
been	O
defined	O
as	O
a	O
specific	O
feature	O
of	O
matrilysin	B-GENE
.	O

Testosterone	O
,	O
free	O
testosterone	O
,	O
non	B-GENE
-	I-GENE
sex	I-GENE
hormone	I-GENE
-	I-GENE
binding	I-GENE
globulin	I-GENE
-	O
bound	O
testosterone	O
,	O
and	O
free	O
androgen	O
index	O
:	O
which	O
testosterone	O
measurement	O
is	O
most	O
relevant	O
to	O
reproductive	O
and	O
sexual	O
function	O
in	O
men	O
with	O
epilepsy	O
?	O

Thus	O
,	O
elongin	B-GENE
C	I-GENE
is	O
found	O
to	O
oligomerize	O
in	O
solution	O
and	O
to	O
undergo	O
significant	O
structural	O
rearrangements	O
upon	O
binding	O
of	O
two	O
different	O
partner	O
proteins	O
.	O

Targeted	O
disruption	O
of	O
the	O
OGG1	B-GENE
gene	I-GENE
in	O
yeast	O
revealed	O
a	O
second	O
OG	B-GENE
glycosylase	I-GENE
/	I-GENE
lyase	I-GENE
protein	I-GENE
,	O
tentatively	O
named	O
Ogg2	B-GENE
,	O
which	O
differs	O
from	O
Ogg1	B-GENE
in	O
that	O
it	O
preferentially	O
acts	O
on	O
OG	O
:	O
G	O
.	O

For	O
this	O
purpose	O
,	O
we	O
used	O
a	O
series	O
of	O
plasmid	O
constructs	O
encoding	O
different	O
forms	O
of	O
the	O
envelope	B-GENE
glycoprotein	I-GENE
E	I-GENE
of	I-GENE
the	I-GENE
flavivirus	I-GENE
tick	I-GENE
-	I-GENE
borne	I-GENE
encephalitis	I-GENE
virus	I-GENE
.	O

The	O
nucleotide	O
sequence	O
directly	O
upstream	O
of	O
fimA	B-GENE
contains	O
two	O
open	O
reading	O
frames	O
,	O
ORF5	O
and	O
ORF1	O
,	O
whose	O
deduced	O
protein	O
products	O
are	O
homologous	O
to	O
members	O
of	O
a	O
superfamily	O
of	O
ATP	B-GENE
-	I-GENE
binding	I-GENE
cassette	I-GENE
membrane	I-GENE
transport	I-GENE
proteins	I-GENE
,	O
including	O
both	O
prokaryotic	O
and	O
eukaryotic	O
uptake	O
and	O
export	O
systems	O
.	O

Optically	O
detected	O
librons	O
and	O
phonons	O
in	O
crystalline	O
C60	O
.	O

Classical	O
ligand	O
-	O
activated	O
nuclear	O
receptors	O
(	O
e	O
.	O
g	O
.	O
thyroid	B-GENE
hormone	I-GENE
receptor	I-GENE
,	O
retinoic	B-GENE
acid	I-GENE
receptor	I-GENE
)	O
,	O
orphan	B-GENE
nuclear	I-GENE
receptors	I-GENE
(	O
e	O
.	O
g	O
.	O

Site	O
S	O
-	O
II	O
also	O
spans	O
a	O
23	O
bp	O
sequence	O
containing	O
two	O
tandem	O
consensus	O
binding	O
sites	O
with	O
three	O
base	O
pair	O
mismatches	O
in	O
each	O
and	O
a	O
one	O
base	O
pair	O
deletion	O
.	O

To	O
this	O
end	O
,	O
an	O
expression	O
cassette	O
consisting	O
of	O
the	O
gene	O
for	O
a	O
green	B-GENE
fluorescent	I-GENE
protein	I-GENE
(	O
GFP	B-GENE
)	O
flanked	O
at	O
its	O
3	O
'	O
end	O
by	O
EAV	O
-	O
specific	O
transcription	O
-	O
regulating	O
sequences	O
was	O
constructed	O
.	O

Toxicity	O
was	O
significant	O
in	O
selected	O
cases	O
;	O
three	O
patients	O
developed	O
WBC	O
counts	O
less	O
than	O
1	O
,	O
000	O
/	O
mm3	O
and	O
one	O
of	O
these	O
patients	O
died	O
with	O
sepsis	O
.	O

Indeed	O
,	O
it	O
is	O
shown	O
that	O
it	O
mediates	O
the	O
formation	O
of	O
disulfide	O
-	O
linked	O
homodimers	O
and	O
that	O
the	O
formation	O
of	O
homo	O
-	O
and	O
heterodimers	O
are	O
mutually	O
excluded	O
.	O

The	O
study	O
was	O
repeated	O
after	O
administration	O
of	O
oral	O
amiodarone	O
,	O
50	O
mg	O
/	O
kg	O
/	O
day	O
for	O
2	O
days	O
in	O
8	O
divided	O
doses	O
(	O
mean	O
dose	O
6	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
4	O
g	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
the	O
idea	O
that	O
the	O
neuron	B-GENE
-	I-GENE
specific	I-GENE
SCG10	I-GENE
gene	I-GENE
evolved	O
by	O
duplication	O
and	O
modification	O
of	O
the	O
more	O
broadly	O
expressed	O
stathmin	B-GENE
/	O
Lap18	B-GENE
gene	O
.	O

Vibrio	O
fluvialis	O
(	O
group	O
F	O
vibrio	O
)	O
in	O
Maharashtra	O
.	O

The	O
gene	O
encoding	O
TRP	B-GENE
-	I-GENE
2	I-GENE
maps	O
to	O
mouse	O
chromosome	O
14	O
,	O
in	O
the	O
region	O
of	O
the	O
coat	B-GENE
colour	I-GENE
mutation	I-GENE
slaty	I-GENE
.	O

Ketamine	O
in	O
the	O
treatment	O
of	O
bronchospasm	O
during	O
mechanical	O
ventilation	O
.	O

An	O
implant	O
may	O
release	O
a	O
drug	O
either	O
by	O
diffusion	O
concurrent	O
with	O
dissolution	O
of	O
the	O
polymeric	O
implant	O
material	O
without	O
depolymerization	O
(	O
Type	O
A	O
)	O
or	O
by	O
bioerosion	O
involving	O
depolymerization	O
(	O
Type	O
B	O
)	O
.	O

In	O
addition	O
a	O
greater	O
proportion	O
of	O
women	O
in	O
the	O
sweeping	O
group	O
had	O
a	O
cervical	O
dilatation	O
of	O
4	O
cm	O
or	O
more	O
at	O
the	O
first	O
vaginal	O
examination	O
in	O
the	O
labour	O
ward	O
(	O
16	O
/	O
33	O
(	O
49	O
%	O
)	O
vs	O
5	O
/	O
32	O
(	O
16	O
%	O
)	O
;	O
OR	O
4	O
.	O
39	O
;	O
95	O
%	O
CI	O
1	O
.	O
56	O
to	O
12	O
.	O
32	O
;	O
P	O
=	O
0	O
.	O
005	O
)	O
.	O

Reliability	O
of	O
cervical	O
range	O
of	O
motion	O
using	O
the	O
OSI	O
CA	O
6000	O
spine	O
motion	O
analyser	O
on	O
asymptomatic	O
and	O
symptomatic	O
subjects	O
.	O

Expression	O
of	O
Bcl	B-GENE
-	I-GENE
XL	I-GENE
inhibited	O
the	O
association	O
of	O
Apaf	B-GENE
-	I-GENE
1	I-GENE
with	O
caspase	B-GENE
-	I-GENE
9	I-GENE
in	O
mammalian	O
cells	O
.	O

There	O
was	O
a	O
trend	O
toward	O
an	O
association	O
between	O
IENF	O
and	O
sural	O
nerve	O
unmyelinated	O
fiber	O
densities	O
(	O
r	O
=	O
0	O
.	O
32	O
,	O
p	O
=	O
0	O
.	O
054	O
)	O
.	O

As	O
an	O
oral	O
,	O
nontoxic	O
compound	O
with	O
a	O
mechanism	O
of	O
action	O
distinct	O
from	O
that	O
of	O
ABL	B-GENE
tyrosine	I-GENE
kinase	I-GENE
inhibition	O
,	O
FTI	O
SCH66336	O
shows	O
promise	O
for	O
the	O
treatment	O
of	O
BCR	B-GENE
/	O
ABL	B-GENE
-	O
induced	O
leukemia	O
.	O

Here	O
we	O
have	O
examined	O
the	O
ability	O
of	O
the	O
cellular	O
protein	O
YB	B-GENE
-	I-GENE
1	I-GENE
to	O
modulate	O
transcription	O
of	O
the	O
HIV	B-GENE
-	I-GENE
1	I-GENE
promoter	I-GENE
in	O
a	O
human	O
astrocytic	O
cell	O
line	O
(	O
U	O
-	O
87MG	O
)	O
,	O
a	O
neuronal	O
cell	O
line	O
(	O
SK	O
-	O
N	O
-	O
MC	O
)	O
and	O
lymphoid	O
cells	O
(	O
Jurkat	O
)	O
by	O
transfection	O
assay	O
.	O

The	O
distribution	O
phase	O
is	O
followed	O
by	O
an	O
elimination	O
phase	O
with	O
a	O
much	O
longer	O
half	O
-	O
life	O
(	O
mean	O
value	O
375	O
min	O
)	O
and	O
a	O
volume	O
of	O
distribution	O
of	O
approximately	O
200	O
-	O
400	O
l	O
.	O

Potentiation	O
of	O
the	O
thrombolytic	O
efficacy	O
of	O
single	B-GENE
-	I-GENE
chain	I-GENE
urokinase	I-GENE
(	O
Pro	B-GENE
-	I-GENE
urokinase	I-GENE
)	O
by	O
heparin	O
.	O

Using	O
mouse	O
-	O
human	O
somatic	O
hybrids	O
and	O
FISH	O
analysis	O
,	O
the	O
PE	B-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
is	O
localized	O
to	O
human	O
chromosome	O
19q13	O
.	O
2	O
,	O
a	O
region	O
involved	O
in	O
translocations	O
and	O
deletions	O
in	O
leukemias	O
and	O
several	O
solid	O
tumors	O
,	O
suggesting	O
that	O
this	O
novel	O
ETS	B-GENE
factor	I-GENE
may	O
play	O
a	O
role	O
in	O
carcinogenesis	O
.	O

Within	O
the	O
span	O
of	O
attenuator	O
region	O
encoding	O
the	O
three	O
stem	O
-	O
loop	O
structures	O
of	O
mRNA	O
secondary	O
configuration	O
,	O
hot	O
spots	O
of	O
base	O
-	O
residue	O
divergence	O
were	O
localized	O
to	O
looped	O
-	O
out	O
regions	O
.	O

Heparin	O
had	O
no	O
effect	O
on	O
rAC	B-GENE
-	I-GENE
st	I-GENE
myosin	I-GENE
light	I-GENE
chain	I-GENE
phosphatase	I-GENE
activity	O
,	O
while	O
the	O
B	O
subunit	O
-	O
containing	O
forms	O
were	O
stimulated	O
2	O
-	O
3	O
-	O
fold	O
.	O

Neither	O
of	O
these	O
proteins	O
,	O
individually	O
or	O
as	O
a	O
pair	O
,	O
can	O
bind	O
the	O
alpha	B-GENE
-	I-GENE
globin	I-GENE
3	I-GENE
'	I-GENE
UTR	I-GENE
unless	O
they	O
are	O
complexed	O
with	O
the	O
remaining	O
non	O
-	O
poly	O
(	O
C	O
)	O
binding	O
proteins	O
of	O
the	O
alpha	B-GENE
-	I-GENE
complex	I-GENE
.	O

These	O
findings	O
suggest	O
that	O
the	O
increase	O
in	O
V	O
O2	O
may	O
have	O
been	O
a	O
consequence	O
of	O
the	O
increase	O
in	O
Q	O
O2	O
rather	O
than	O
a	O
response	O
to	O
the	O
procedure	O
itself	O
.	O

A	O
unified	O
approach	O
to	O
the	O
standardization	O
of	O
allergens	O
.	O

Although	O
the	O
N13	O
-	O
N20	O
interpeak	O
interval	O
remained	O
stable	O
because	O
of	O
the	O
parallel	O
shift	O
of	O
the	O
2	O
peaks	O
,	O
the	O
central	O
conduction	O
time	O
measured	O
from	O
onset	O
latencies	O
of	O
N11	O
and	O
N20	O
significantly	O
increased	O
.	O

Using	O
sequence	O
information	O
from	O
human	B-GENE
BMAL1	I-GENE
(	O
hBMAL1	B-GENE
)	O
cDNAs	O
previously	O
reported	O
by	O
our	O
laboratory	O
,	O
we	O
have	O
isolated	O
and	O
characterized	O
cDNAs	O
encoding	O
three	O
splice	O
variants	O
of	O
the	O
mouse	B-GENE
BMAL1	I-GENE
(	O
mBMAL1	B-GENE
)	O
gene	O
.	O

Biologically	O
significant	O
amounts	O
of	O
platelet	B-GENE
activating	I-GENE
factor	I-GENE
were	O
eluted	O
from	O
the	O
sorbent	O
during	O
the	O
entire	O
treatment	O
time	O
.	O

Because	O
a	O
close	O
correlation	O
between	O
regional	O
decreases	O
in	O
FMZ	O
binding	O
and	O
spiking	O
activity	O
was	O
recently	O
demonstrated	O
in	O
neocortical	O
epilepsies	O
,	O
abnormal	O
peri	O
-	O
lesional	O
FMZ	O
binding	O
may	O
bear	O
some	O
relation	O
to	O
the	O
mechanisms	O
of	O
epileptogenesis	O
in	O
symptomatic	O
epilepsies	O
.	O

These	O
observations	O
indicate	O
that	O
there	O
are	O
multiple	O
mechanisms	O
by	O
which	O
an	O
individual	O
transcript	O
can	O
be	O
degraded	O
following	O
deadenylation	O
.	O

Van	O
der	O
Ende	O
,	O
R	O
.	O

These	O
results	O
suggest	O
that	O
UBP41	B-GENE
may	O
play	O
an	O
important	O
role	O
in	O
the	O
recycling	O
of	O
ubiquitin	B-GENE
by	O
hydrolysis	O
of	O
branched	B-GENE
poly	I-GENE
-	I-GENE
ubiquitin	I-GENE
chains	I-GENE
generated	O
by	O
the	O
action	O
of	O
26	B-GENE
S	I-GENE
proteasome	I-GENE
on	O
poly	O
-	O
ubiquitinated	O
protein	O
substrates	O
,	O
as	O
well	O
as	O
in	O
the	O
production	O
of	O
free	O
ubiquitin	B-GENE
from	O
linear	B-GENE
poly	I-GENE
-	I-GENE
ubiquitin	I-GENE
chains	I-GENE
and	O
of	O
certain	O
ribosomal	O
proteins	O
from	O
ubiquitin	B-GENE
fusion	I-GENE
proteins	I-GENE
.	O

In	O
the	O
present	O
study	O
,	O
beta	O
-	O
funaltrexamine	O
(	O
beta	O
-	O
FNA	O
)	O
and	O
naltrindole	O
(	O
NTI	O
)	O
(	O
nonequilibrium	O
mu	O
-	O
and	O
delta	O
-	O
antagonist	O
,	O
respectively	O
)	O
were	O
used	O
to	O
precipitate	O
withdrawal	O
in	O
butorphanol	O
-	O
dependent	O
rats	O
.	O

Both	O
Z	B-GENE
and	O
R	B-GENE
expression	O
resulted	O
in	O
PML	O
dispersion	O
in	O
EBV	O
-	O
positive	O
cells	O
.	O

Based	O
on	O
peptide	O
map	O
similarities	O
,	O
partial	O
amino	O
-	O
terminal	O
sequence	O
data	O
,	O
and	O
common	O
genetic	O
origin	O
,	O
it	O
is	O
suggested	O
that	O
p60	B-GENE
and	O
p62	B-GENE
have	O
identical	O
amino	O
acid	O
sequences	O
carboxy	O
-	O
terminal	O
to	O
the	O
p60	B-GENE
initiator	O
methionine	O
(	O
residue	O
21	O
of	O
p62	B-GENE
)	O
.	O

Two	O
other	O
patients	O
underwent	O
PRFR	O
.	O

From	O
February	O
1991	O
to	O
August	O
1997	O
,	O
124	O
patients	O
with	O
endometrial	O
carcinoma	O
were	O
treated	O
postoperatively	O
with	O
high	O
-	O
dose	O
-	O
rate	O
vaginal	O
vault	O
brachytherapy	O
as	O
the	O
only	O
adjuvant	O
treatment	O
.	O

In	O
order	O
to	O
examine	O
the	O
potential	O
role	O
of	O
transcriptional	O
silencing	O
during	O
productive	O
HSV	O
-	O
1	O
infection	O
,	O
recombinant	O
viruses	O
were	O
generated	O
in	O
which	O
wild	B-GENE
-	I-GENE
type	I-GENE
or	I-GENE
mutant	I-GENE
ICP34	I-GENE
.	I-GENE
5	I-GENE
promoters	I-GENE
controlling	O
the	O
expression	O
of	O
a	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
reporter	I-GENE
gene	I-GENE
were	O
inserted	O
into	O
the	O
thymidine	B-GENE
kinase	I-GENE
gene	I-GENE
of	O
the	O
viral	O
genome	O
.	O

The	O
"	O
cracked	O
-	O
tooth	O
"	O
syndrome	O
.	O

The	O
atp	B-GENE
1	I-GENE
and	O
atp	B-GENE
2	I-GENE
types	O
of	O
cDNA	O
sequences	O
were	O
the	O
most	O
redundant	O
among	O
the	O
28	O
different	O
isoperoxidases	B-GENE
identified	O
among	O
about	O
200	O
peroxidase	B-GENE
encoding	I-GENE
ESTs	I-GENE
.	O

In	O
patients	O
with	O
type	O
IA	O
maple	O
syrup	O
urine	O
disease	O
,	O
the	O
E1alpha	B-GENE
subunit	I-GENE
is	O
affected	O
,	O
resulting	O
in	O
the	O
loss	O
of	O
E1	B-GENE
and	O
branched	B-GENE
-	I-GENE
chain	I-GENE
ketoacid	I-GENE
dehydrogenase	I-GENE
catalytic	O
activities	O
.	O

Benign	O
intramural	O
tumors	O
of	O
the	O
esophagus	O

We	O
conclude	O
that	O
(	O
a	O
)	O
the	O
likelihood	O
of	O
detecting	O
carcinoma	O
or	O
atypical	O
hyperplasia	O
exclusively	O
in	O
the	O
adipose	O
tissue	O
component	O
of	O
grossly	O
benign	O
breast	O
biopsies	O
is	O
extremely	O
low	O
,	O
and	O
(	O
b	O
)	O
a	O
possible	O
cost	O
-	O
effective	O
method	O
of	O
sampling	O
grossly	O
benign	O
breast	O
biopsies	O
consists	O
of	O
initially	O
submitting	O
a	O
maximum	O
of	O
10	O
blocks	O
of	O
fibrous	O
parenchyma	O
for	O
each	O
case	O
,	O
then	O
examining	O
the	O
remaining	O
tissue	O
histologically	O
only	O
if	O
carcinoma	O
or	O
atypical	O
hyperplasia	O
is	O
found	O
among	O
these	O
blocks	O
.	O

Transcriptional	O
analysis	O
of	O
a	O
series	O
of	O
deletion	O
mutants	O
of	O
the	O
gene	O
in	O
the	O
nuclear	O
extracts	O
prepared	O
from	O
the	O
middle	O
silk	O
gland	O
of	O
2	O
-	O
day	O
-	O
old	O
fifth	O
instar	O
larvae	O
revealed	O
the	O
presence	O
of	O
multiple	O
cis	O
-	O
regulatory	O
elements	O
located	O
both	O
upstream	O
and	O
downstream	O
of	O
the	O
initiation	O
site	O
.	O

RNA	O
blot	O
hybridizations	O
identified	O
an	O
1	O
.	O
8	O
-	O
kb	O
mRNA	O
common	O
to	O
cytochrome	B-GENE
b6	I-GENE
and	O
subunit	O
IV	O
,	O
and	O
an	O
intensely	O
hybridizing	O
0	O
.	O
8	O
-	O
kb	O
mRNA	O
specific	O
to	O
the	O
subunit	O
IV	O
gene	O
probe	O
.	O

The	O
micturition	O
pressure	O
was	O
significantly	O
decreased	O
only	O
after	O
injection	O
with	O
BUP	O
-	O
4	O
in	O
both	O
normal	O
and	O
obstructed	O
rats	O
.	O

Over	O
a	O
period	O
of	O
15	O
days	O
16	O
%	O
of	O
the	O
dose	O
administered	O
was	O
excreted	O
with	O
faeces	O
and	O
0	O
.	O
9	O
%	O
in	O
the	O
urine	O
.	O

ME1a1	B-GENE
,	O
a	O
16	O
-	O
base	O
-	O
pair	O
nuclear	O
factor	O
binding	O
site	O
residing	O
between	O
the	O
c	B-GENE
-	I-GENE
MYC	I-GENE
P1	I-GENE
and	I-GENE
P2	I-GENE
transcription	I-GENE
initiation	I-GENE
sites	I-GENE
,	O
is	O
required	O
for	O
P2	O
activity	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
activity	O
of	O
ILK	B-GENE
is	O
constitutively	O
elevated	O
in	O
PTEN	B-GENE
mutant	I-GENE
cells	O
.	O

Respiratory	O
interaction	O
after	O
spinal	O
anesthesia	O
and	O
sedation	O
with	O
midazolam	O
.	O

Finally	O
a	O
10	O
-	O
nucleotide	O
region	O
flanking	O
the	O
exon	O
4	O
protein	O
-	O
binding	O
site	O
is	O
homologous	O
to	O
instability	O
elements	O
within	O
five	O
other	O
transcripts	O
,	O
suggesting	O
that	O
a	O
common	O
coding	O
region	O
determinant	O
may	O
exist	O
.	O

The	O
Van	O
der	O
Hoeve	O
'	O
s	O
syndrome	O
lesions	O
as	O
poorly	O
mineralized	O
,	O
with	O
low	O
calcium	O
salt	O
and	O
apparent	O
increase	O
of	O
phosphates	O
.	O

The	O
galactose	B-GENE
transporter	I-GENE
shows	O
both	O
sequence	O
and	O
structural	O
homology	O
with	O
a	O
superfamily	O
of	O
sugar	B-GENE
transporters	I-GENE
which	O
includes	O
the	O
human	B-GENE
HepG2	I-GENE
-	I-GENE
erythrocyte	I-GENE
and	I-GENE
fetal	I-GENE
muscle	I-GENE
glucose	I-GENE
transporters	I-GENE
,	O
the	O
rat	B-GENE
brain	I-GENE
and	I-GENE
liver	I-GENE
glucose	I-GENE
transporters	I-GENE
,	O
the	O
Escherichia	B-GENE
coli	I-GENE
xylose	I-GENE
and	I-GENE
arabinose	I-GENE
permeases	I-GENE
,	O
and	O
the	O
S	B-GENE
.	I-GENE
cerevisiae	I-GENE
glucose	I-GENE
,	I-GENE
maltose	I-GENE
,	I-GENE
and	I-GENE
galactose	I-GENE
transporters	I-GENE
.	O

Members	O
of	O
the	O
myocyte	B-GENE
-	I-GENE
specific	I-GENE
enhancer	I-GENE
-	I-GENE
binding	I-GENE
factor	I-GENE
2	I-GENE
(	O
MEF2	B-GENE
)	O
family	O
of	O
transcription	O
factors	O
bind	O
a	O
conserved	O
A	O
/	O
T	O
-	O
rich	O
sequence	O
in	O
the	O
control	O
regions	O
of	O
numerous	O
muscle	O
-	O
specific	O
genes	O
.	O

To	O
estimate	O
the	O
locations	O
of	O
sources	O
with	O
the	O
TF	O
-	O
MUSIC	O
algorithm	O
,	O
we	O
first	O
set	O
the	O
target	O
region	O
on	O
the	O
spectrogram	O
of	O
the	O
somatosensory	O
responses	O
.	O

Bacteriologic	O
culture	O
of	O
pancreatic	O
tissue	O
was	O
positive	O
in	O
6	O
/	O
8	O
IB	O
and	O
3	O
/	O
17	O
NIB	O
rats	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

The	O
LA	O
50s	O
derived	O
from	O
this	O
combined	O
data	O
when	O
compared	O
with	O
our	O
earlier	O
series	O
from	O
1965	O
to	O
1970	O
also	O
did	O
not	O
show	O
a	O
significant	O
change	O
in	O
mortality	O
.	O

Two	O
-	O
dimensional	O
gel	O
electrophoresis	O
of	O
anti	B-GENE
-	I-GENE
p59fyn	I-GENE
immunoprecipitates	O
obtained	O
from	O
non	O
-	O
transformed	O
resting	O
human	O
T	O
lymphocytes	O
resulted	O
in	O
the	O
identification	O
of	O
an	O
oligomeric	O
protein	O
complex	O
which	O
is	O
constitutively	O
formed	O
between	O
Fyn	B-GENE
and	O
several	O
additional	O
phosphoproteins	O
(	O
pp43	B-GENE
,	O
pp72	B-GENE
,	O
pp85	B-GENE
,	O
the	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
Pyk2	B-GENE
,	O
as	O
well	O
as	O
the	O
two	O
recently	O
cloned	O
adaptor	O
proteins	O
,	O
SKAP55	B-GENE
and	O
SLAP	B-GENE
-	I-GENE
130	I-GENE
)	O
.	O

Although	O
the	O
OC	B-GENE
promoter	I-GENE
is	O
activated	O
in	O
a	O
C	O
terminus	O
dependent	O
manner	O
,	O
the	O
MDR	B-GENE
,	O
LTR	O
and	O
BSP	B-GENE
promoters	I-GENE
are	O
repressed	O
by	O
three	O
distinct	O
mechanisms	O
,	O
either	O
independent	O
of	O
or	O
involving	O
the	O
AML	B-GENE
C	I-GENE
terminus	I-GENE
,	O
or	O
requiring	O
only	O
the	O
conserved	O
C	O
-	O
terminal	O
pentapeptide	O
VWRPY	O
.	O

A	O
developmentally	O
modulated	O
chromatin	O
structure	O
at	O
the	O
mouse	B-GENE
immunoglobulin	I-GENE
kappa	I-GENE
3	I-GENE
'	I-GENE
enhancer	I-GENE
.	O

The	O
COOH	O
-	O
terminal	O
region	O
of	O
the	O
transcripts	O
contained	O
fifteen	O
triplet	O
repeats	O
(	O
GCT	O
;	O
alanine	O
)	O
at	O
nucleotide	O
465	O
to	O
509	O
,	O
which	O
is	O
significantly	O
expanded	O
compared	O
to	O
the	O
rat	B-GENE
RL14	I-GENE
.	O

E2F	B-GENE
-	I-GENE
1	I-GENE
is	O
a	O
transcription	O
factor	O
that	O
regulates	O
cell	O
cycle	O
progression	O
into	O
S	O
-	O
phase	O
.	O

Both	O
toxins	O
in	O
a	O
dose	O
10	O
-	O
fold	O
surpassing	O
the	O
maximum	O
permissible	O
concentration	O
increased	O
activity	O
of	O
glutathione	B-GENE
peroxidase	I-GENE
in	O
brain	O
tissue	O
;	O
moreover	O
,	O
toluene	O
increased	O
chemiluminescence	O
intensity	O
,	O
which	O
attested	O
to	O
activation	O
of	O
free	O
radical	O
processes	O
.	O

Several	O
7SL	B-GENE
RNA	I-GENE
-	I-GENE
encoding	I-GENE
sequences	I-GENE
and	O
various	O
intergenic	O
spacers	O
were	O
amplified	O
from	O
the	O
individual	O
HindIII	B-GENE
fragments	I-GENE
of	O
about	O
1	O
.	O
3	O
and	O
2	O
.	O
8	O
kb	O
.	O

Movement	O
time	O
and	O
kinematic	O
characteristics	O
were	O
analyzed	O
together	O
with	O
the	O
magnitude	O
of	O
cerebral	O
blood	O
flow	O
to	O
identify	O
areas	O
of	O
brain	O
activity	O
proportionate	O
to	O
task	O
and	O
movement	O
variables	O
.	O

In	O
resting	O
3T3	O
cells	O
,	O
jun	B-GENE
-	I-GENE
D	I-GENE
is	O
expressed	O
at	O
a	O
higher	O
level	O
compared	O
to	O
c	B-GENE
-	I-GENE
jun	I-GENE
and	O
jun	B-GENE
-	I-GENE
B	I-GENE
,	O
and	O
its	O
transcription	O
is	O
stimulated	O
only	O
slightly	O
by	O
serum	O
growth	O
factors	O
.	O

Diltiazem	O
decreased	O
the	O
total	O
body	O
clearance	O
from	O
34	O
.	O
0	O
+	O
/	O
-	O
8	O
.	O
0	O
to	O
28	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
1	O
mL	O
/	O
min	O
(	O
P	O
less	O
than	O
.	O
01	O
)	O
,	O
and	O
prolonged	O
the	O
elimination	O
half	O
-	O
life	O
from	O
12	O
.	O
6	O
+	O
/	O
-	O
3	O
.	O
0	O
to	O
14	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
hours	O
(	O
P	O
less	O
than	O
.	O
01	O
)	O
of	O
antipyrine	O
without	O
any	O
changes	O
in	O
volume	O
of	O
distribution	O
.	O

Their	O
conduction	O
velocity	O
ranged	O
from	O
0	O
.	O
23	O
to	O
0	O
.	O
98	O
m	O
/	O
sec	O
(	O
group	O
C	O
)	O
.	O

Dilutions	O
of	O
H	B-GENE
-	I-GENE
2b	I-GENE
or	I-GENE
H	I-GENE
-	I-GENE
2d	I-GENE
NP	I-GENE
peptides	I-GENE
indicated	O
that	O
3	O
-	O
4	O
logs	O
less	O
H	B-GENE
-	I-GENE
2b	I-GENE
NP	I-GENE
peptide	I-GENE
was	O
required	O
to	O
sensitize	O
syngeneic	O
target	O
cells	O
for	O
CTL	O
-	O
specific	O
lysis	O
,	O
suggesting	O
that	O
the	O
differing	O
affinities	O
of	O
H	O
-	O
2b	O
and	O
H	O
-	O
2d	O
major	B-GENE
histocompatibility	I-GENE
complex	I-GENE
molecules	I-GENE
for	O
their	O
peptides	O
likely	O
account	O
for	O
the	O
total	O
removal	O
of	O
NP	O
CTL	O
in	O
the	O
H	O
-	O
2b	O
mice	O
but	O
only	O
partial	O
removal	O
in	O
H	O
-	O
2d	O
mice	O
made	O
to	O
express	O
thymic	O
NP	O
.	O

Differential	O
sensitivity	O
of	O
the	O
MMPI	O
-	O
2	O
depression	O
scales	O
and	O
subscales	O
.	O

However	O
,	O
such	O
a	O
mechanism	O
was	O
not	O
detected	O
in	O
preliminary	O
observations	O
on	O
M	O
.	O
synoviae	O
.	O

A	O
fine	O
-	O
structure	O
deletion	O
map	O
of	O
human	O
chromosome	O
11p	O
:	O
analysis	O
of	O
J1	O
series	O
hybrids	O
.	O

The	O
existence	O
of	O
these	O
two	O
categories	O
of	O
strains	O
offers	O
a	O
new	O
genetic	O
system	O
in	O
which	O
the	O
properties	O
of	O
a	O
potential	O
invertebrate	O
retrovirus	O
can	O
be	O
tested	O
.	O

N	O
-	O
Substituted	O
trimethylsilylcarbamates	O
were	O
tested	O
as	O
derivatizing	O
reagents	O
for	O
gas	O
chromatographic	O
analysis	O
.	O

A	O
region	O
approximately	O
100	O
bp	O
upstream	O
from	O
the	O
transcription	O
start	O
point	O
of	O
virB	B-GENE
was	O
identified	O
as	O
being	O
necessary	O
for	O
full	O
activation	O
of	O
this	O
promoter	O
by	O
VirF	B-GENE
.	O

PATIENTS	O
and	O
METHODS	O
:	O
Thallium	O
-	O
201	O
myocardial	O
scintigraphy	O
was	O
performed	O
at	O
rest	O
and	O
after	O
0	O
.	O
56	O
mg	O
/	O
kg	O
intravenous	O
dipyridamole	O
during	O
four	O
minutes	O
in	O
16	O
patients	O
with	O
sarcoidosis	O
.	O

The	O
electrocardiogram	O
.	O

The	O
two	O
IL6	B-GENE
mRNA	I-GENE
species	O
are	O
generated	O
by	O
alternative	O
polyadenylation	O
at	O
sites	O
separated	O
by	O
a	O
distance	O
of	O
1	O
.	O
2	O
kilobases	O
.	O

Biol	O
.	O

Analysis	O
of	O
this	O
sequence	O
combined	O
with	O
that	O
previously	O
reported	O
for	O
the	O
5	O
'	O
-	O
flanking	O
region	O
directly	O
proximal	O
to	O
the	O
start	O
of	O
transcription	O
revealed	O
several	O
putative	O
regulatory	O
sequences	O
.	O

In	O
the	O
last	O
20	O
years	O
,	O
the	O
therapeutic	O
uses	O
of	O
botulinum	B-GENE
toxin	I-GENE
,	O
a	O
potent	O
neurotoxin	O
,	O
have	O
been	O
investigated	O
.	O

Arhythmacanthus	O
Yamaguti	O
,	O
1935	O
is	O
maintained	O
as	O
a	O
synonym	O
of	O
Heterosentis	O
because	O
the	O
distinction	O
between	O
two	O
and	O
three	O
hook	O
types	O
is	O
made	O
equivocal	O
when	O
the	O
transition	O
between	O
the	O
apical	O
and	O
subapical	O
hooks	O
is	O
gradual	O
.	O

Linear	O
eight	O
-	O
or	O
nine	O
-	O
residue	O
D	O
-	O
peptides	O
derived	O
from	O
the	O
pocket	O
-	O
binding	O
domain	O
of	O
the	O
cyclic	O
molecules	O
also	O
bind	O
specifically	O
.	O

No	O
recombination	O
signal	O
sequences	O
have	O
been	O
found	O
contiguous	O
to	O
the	O
recombination	O
point	O
.	O

Development	O
of	O
a	O
yeast	O
system	O
to	O
assay	O
mutational	O
specificity	O
.	O

AgMNPV	O
and	O
Orgyia	O
pseudotsugata	O
MNPV	O
(	O
OpMNPV	O
)	O
are	O
similar	O
in	O
terms	O
of	O
promoter	O
structure	O
and	O
polyhedrin	B-GENE
primary	I-GENE
sequence	I-GENE
,	O
and	O
the	O
polyhedrin	B-GENE
gene	I-GENE
of	O
both	O
viruses	O
is	O
transcribed	O
in	O
the	O
anti	O
-	O
clockwise	O
direction	O
in	O
relation	O
to	O
their	O
physical	O
maps	O
.	O

Efficacy	O
and	O
field	O
evaluation	O
of	O
Bacillus	O
thuringiensis	O
(	O
H	O
-	O
14	O
)	O
and	O
B	O
.	O
sphaericus	O
against	O
floodwater	O
mosquitoes	O
in	O
California	O
.	O

Thus	O
E14	O
.	O
1TG3B1	O
is	O
a	O
useful	O
ES	O
cell	O
line	O
for	O
modifying	O
the	O
mouse	O
genome	O
using	O
the	O
HPRT	B-GENE
gene	I-GENE
as	O
a	O
selection	O
marker	O
and	O
for	O
transmission	O
at	O
a	O
high	O
frequency	O
into	O
the	O
mouse	O
germ	O
line	O
.	O

It	O
was	O
concluded	O
that	O
both	O
of	O
these	O
surgical	O
procedures	O
were	O
as	O
effective	O
as	O
pinealectomy	O
in	O
reversing	O
the	O
pineal	O
-	O
induced	O
alterations	O
in	O
the	O
reproductive	O
physiology	O
of	O
the	O
blind	O
-	O
anosmic	O
female	O
rat	O
.	O

However	O
,	O
an	O
intrinsic	O
DNA	O
-	O
binding	O
subunit	O
for	O
HiNF	B-GENE
-	I-GENE
D	I-GENE
was	O
not	O
identified	O
.	O

Expression	O
of	O
constitutively	O
active	O
MEK1	B-GENE
,	O
the	O
kinase	O
that	O
activates	O
ERKs	B-GENE
,	O
or	O
overexpression	O
of	O
ERK2	B-GENE
,	O
but	O
not	O
JNK1	B-GENE
,	O
inhibited	O
Stat3	B-GENE
activation	O
.	O

We	O
have	O
isolated	O
a	O
Drosophila	O
melanogaster	O
(	O
Dm	O
)	O
cDNA	O
encoding	O
a	O
polypeptide	O
that	O
has	O
extensive	O
sequence	O
similarity	O
to	O
the	O
mammalian	B-GENE
MAPKAPK	I-GENE
-	I-GENE
2	I-GENE
.	O

The	O
sequence	O
data	O
now	O
permit	O
a	O
detailed	O
interpretation	O
of	O
the	O
X	O
-	O
ray	O
crystallographic	O
structure	O
of	O
the	O
enzyme	O
and	O
the	O
cloning	O
and	O
expression	O
of	O
the	O
clostridial	O
gene	O
will	O
facilitate	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Recent	O
studies	O
have	O
revealed	O
unconventional	O
myosin	B-GENE
V	I-GENE
to	O
be	O
an	O
important	O
actin	B-GENE
-	O
based	O
molecular	O
motor	O
involved	O
in	O
vesicular	O
movement	O
.	O

EGFR	B-GENE
levels	O
were	O
found	O
to	O
be	O
elevated	O
5	O
-	O
,	O
3	O
.	O

It	O
bound	O
to	O
vitamin	B-GENE
D	I-GENE
receptor	I-GENE
(	O
VDR	B-GENE
)	O
but	O
not	O
retinoic	B-GENE
acid	I-GENE
Xalpha	I-GENE
receptor	I-GENE
(	O
RXRalpha	B-GENE
)	O
in	O
the	O
human	O
T	O
cell	O
line	O
MT2	O
cells	O
.	O

The	O
Functional	O
Independence	O
Measure	O
:	O
a	O
comparative	O
study	O
of	O
clinician	O
and	O
self	O
ratings	O
.	O

A	O
high	O
-	O
resolution	O
restriction	O
map	O
of	O
over	O
200	O
kb	O
of	O
contiguous	O
DNA	O
containing	O
N	B-GENE
-	I-GENE
myc	I-GENE
has	O
been	O
generated	O
by	O
subcloning	O
YACs	O
into	O
cosmids	O
.	O

Prevention	O
of	O
transfusion	O
reactions	O
by	O
the	O
use	O
of	O
saline	O
washed	O
red	O
blood	O
cells	O
.	O

Two	O
patients	O
had	O
immediate	O
adverse	O
effects	O
from	O
NMF	O
;	O
one	O
had	O
a	O
grand	O
mal	O
seizure	O
and	O
the	O
other	O
developed	O
severe	O
abdominal	O
pain	O
.	O

As	O
hypothesized	O
,	O
believers	O
showed	O
relatively	O
higher	O
right	O
hemispheric	O
activation	O
and	O
reduced	O
hemispheric	O
asymmetry	O
of	O
functional	O
complexity	O
.	O

Intensification	O
of	O
human	O
myocardial	O
contractile	O
activity	O
as	O
affected	O
by	O
blood	O
serum	O

Pregnancy	O
screening	O
by	O
uterine	O
artery	O
Doppler	O
velocimetry	O
-	O
-	O
which	O
criterion	O
performs	O
best	O
?	O

OBJECTIVE	O
:	O
To	O
test	O
whether	O
repeating	O
Doppler	O
studies	O
of	O
the	O
uteroplacental	O
circulation	O
late	O
in	O
gestation	O
will	O
improve	O
the	O
test	O
'	O
s	O
power	O
for	O
predicting	O
pregnancy	O
-	O
induced	O
hypertension	O
and	O
fetal	O
growth	O
restriction	O
(	O
FGR	O
)	O
,	O
and	O
whether	O
analysis	O
based	O
on	O
a	O
combination	O
of	O
quantitative	O
and	O
qualitative	O
assessments	O
of	O
the	O
uterine	O
arterial	O
waveforms	O
will	O
yield	O
better	O
results	O
than	O
analysis	O
based	O
on	O
either	O
alone	O
.	O

These	O
characteristics	O
of	O
N22	O
/	O
P22	O
indicate	O
that	O
it	O
is	O
a	O
localized	O
synaptically	O
dependent	O
event	O
conforming	O
to	O
a	O
transverse	O
dipole	O
with	O
dorsal	O
negativity	O
and	O
a	O
simultaneous	O
anterior	O
positivity	O
.	O

Effects	O
of	O
ionizing	O
radiation	O
in	O
the	O
human	O
oral	O
cavity	O
and	O
oropharynx	O
:	O
results	O
of	O
a	O
survey	O
.	O

FDA	O
regulations	O
for	O
growth	O
factors	O
and	O
related	O
products	O
.	O

Pulmonary	O
hypertension	O
,	O
with	O
or	O
without	O
coronary	O
arterial	O
narrowing	O
,	O
is	O
the	O
major	O
condition	O
leading	O
to	O
isolated	O
atrial	O
infarction	O
.	O

The	O
most	O
frequent	O
causes	O
of	O
the	O
meningitis	O
was	O
the	O
external	O
ventricular	O
drainage	O
(	O
14	O
.	O
8	O
%	O
)	O
,	O
post	O
-	O
neurosurgical	O
(	O
0	O
.	O
8	O
%	O
)	O
and	O
head	O
injury	O
(	O
0	O
.	O
0007	O
%	O
)	O
.	O

Some	O
research	O
studies	O
have	O
related	O
this	O
kind	O
of	O
tumors	O
with	O
prolonged	O
ingestion	O
of	O
H2	O
inhibitors	O
and	O
others	O
antacid	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
level	O
of	O
oxidative	O
stress	O
in	O
healthy	O
controls	O
(	O
CTL	O
)	O
compared	O
with	O
CRF	O
and	O
HD	O
patients	O
before	O
(	O
pre	O
-	O
HD	O
)	O
and	O
after	O
(	O
post	O
-	O
HD	O
)	O
the	O
dialysis	O
session	O
,	O
carried	O
out	O
on	O
a	O
high	O
biocompatible	O
polyacrylonitrile	O
membrane	O
AN69	O
.	O

Hrs	B-GENE
has	O
a	O
FYVE	O
double	O
zinc	O
finger	O
domain	O
,	O
which	O
specifically	O
binds	O
phosphatidylinositol	O
(	O
3	O
)	O
-	O
phosphate	O
and	O
is	O
conserved	O
in	O
several	O
proteins	O
involved	O
in	O
vesicular	O
traffic	O
.	O

Only	O
nine	O
patients	O
were	O
offered	O
surgery	O
(	O
six	O
were	O
resected	O
and	O
three	O
were	O
found	O
inoperable	O
)	O
.	O

Twelve	O
patients	O
had	O
stage	O
IBG3	O
,	O
14	O
had	O
ICG1	O
,	O
9	O
had	O
ICG2	O
,	O
and	O
3	O
had	O
ICG3	O
disease	O
.	O

IgM	B-GENE
and	O
IgG	B-GENE
anti	I-GENE
A	I-GENE
and	O
anti	B-GENE
B	I-GENE
antibody	I-GENE
status	O
of	O
100	O
antenatal	O
O	O
group	O
mothers	O
(	O
who	O
had	O
non	O
O	O
group	O
husbands	O
)	O
were	O
studied	O
.	O

The	O
pheromone	O
response	O
pathway	O
activates	O
transcription	O
of	O
Ty5	B-GENE
retrotransposons	I-GENE
located	O
within	O
silent	O
chromatin	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

EMSA	O
with	O
crude	O
nuclear	O
extracts	O
demonstrated	O
that	O
stimulation	O
with	O
CD40L	B-GENE
results	O
in	O
the	O
induction	O
of	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
complexes	I-GENE
that	O
bind	O
to	O
each	O
of	O
the	O
three	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
sites	I-GENE
and	O
are	O
composed	O
mainly	O
of	O
p50	B-GENE
and	O
RelB	B-GENE
,	O
but	O
also	O
include	O
c	B-GENE
-	I-GENE
Rel	I-GENE
and	O
p65	B-GENE
.	O

In	O
the	O
budding	O
yeast	O
,	O
Saccharomyces	O
cerevisiae	O
,	O
replicators	O
can	O
function	O
outside	O
the	O
chromosome	O
as	O
autonomously	O
replicating	O
sequence	O
(	O
ARS	O
)	O
elements	O
;	O
however	O
,	O
within	O
chromosome	O
III	O
,	O
certain	O
ARSs	O
near	O
the	O
transcriptionally	O
silent	O
HML	B-GENE
locus	I-GENE
show	O
no	O
replication	O
origin	O
activity	O
.	O

Among	O
booked	O
patients	O
the	O
maternal	O
mortality	O
rate	O
was	O
0	O
.	O
32	O
and	O
among	O
unbooked	O
patients	O
11	O
.	O
13	O
per	O
1000	O
deliveries	O
.	O

RESULTS	O
:	O
The	O
binding	O
of	O
99mTc	O
d	O
,	O
1	O
-	O
HMPAO	O
to	O
human	O
placenta	O
ranged	O
from	O
2	O
.	O
95	O
%	O
+	O
/	O
-	O
1	O
.	O
5	O
%	O
to	O
5	O
.	O
82	O
%	O
+	O
/	O
-	O
0	O
.	O
3	O
%	O
per	O
1	O
ml	O
standard	O
solution	O
.	O

These	O
results	O
were	O
corroborated	O
in	O
a	O
subsequent	O
study	O
in	O
which	O
30	O
hypogonadal	O
men	O
were	O
supplemented	O
with	O
SLT	O
5	O
mg	O
three	O
times	O
daily	O
for	O
6	O
months	O
.	O

The	O
recombinant	O
contains	O
the	O
normal	O
beta	B-GENE
A	I-GENE
-	I-GENE
globin	I-GENE
gene	I-GENE
,	O
the	O
mutant	O
gene	O
and	O
Ylp	O
vector	O
sequences	O
between	O
the	O
two	O
copies	O
.	O

Although	O
metabolized	O
by	O
the	O
cytochrome	B-GENE
P	I-GENE
-	I-GENE
450	I-GENE
(	O
CYP	B-GENE
)	O
system	O
,	O
venlafaxine	O
inhibits	O
CYP	B-GENE
2D6	I-GENE
and	I-GENE
3A4	I-GENE
to	O
a	O
far	O
lesser	O
extent	O
than	O
do	O
the	O
SSRIs	O
.	O

Reduction	O
in	O
dosage	O
restored	O
normal	O
taste	O
sense	O
in	O
all	O
three	O
,	O
but	O
in	O
two	O
the	O
drug	O
had	O
to	O
be	O
discontinued	O
because	O
of	O
persisting	O
high	O
transaminase	O
levels	O
.	O

Codon	O
usage	O
in	O
C	O
.	O
reinhardtii	O
mitochondria	O
is	O
highly	O
biased	O
,	O
with	O
eight	O
codons	O
entirely	O
absent	O
from	O
all	O
protein	O
-	O
coding	O
genes	O
;	O
however	O
,	O
even	O
though	O
codon	O
usage	O
is	O
restricted	O
,	O
it	O
appears	O
that	O
C	O
.	O
reinhardtii	O
mtDNA	O
cannot	O
encode	O
the	O
minimum	O
number	O
of	O
tRNAs	O
needed	O
to	O
support	O
mitochondrial	O
protein	O
synthesis	O
.	O

Amino	O
acid	O
sequence	O
comparison	O
revealed	O
significant	O
homology	O
between	O
the	O
yeast	B-GENE
and	I-GENE
Escherichia	I-GENE
coli	I-GENE
gamma	I-GENE
-	I-GENE
glutamyl	I-GENE
kinases	I-GENE
throughout	O
their	O
lengths	O
.	O

Transfection	O
experiments	O
using	O
preformed	O
triplexes	O
with	O
a	O
reporter	O
plasmid	O
containing	O
the	O
collagen	B-GENE
promoter	I-GENE
sequence	I-GENE
showed	O
significant	O
inhibition	O
of	O
transcription	O
when	O
compared	O
with	O
a	O
control	O
phosphorothioate	O
ODN	O
.	O

The	O
likelihood	O
that	O
a	O
common	O
region	O
of	O
deletions	O
would	O
contain	O
a	O
tumor	O
suppressor	O
is	O
strongly	O
enhanced	O
by	O
coincidence	O
of	O
that	O
region	O
with	O
a	O
chromosome	O
fragment	O
suppressing	O
tumorigenicity	O
upon	O
introduction	O
in	O
tumor	O
cells	O
.	O

Collectively	O
,	O
the	O
results	O
suggest	O
that	O
ARF	B-GENE
binding	O
to	O
Mdm2	B-GENE
induces	O
a	O
conformational	O
change	O
that	O
facilitates	O
nucleolar	O
import	O
of	O
the	O
ARF	B-GENE
-	O
Mdm2	B-GENE
complex	O
and	O
p53	B-GENE
-	O
dependent	O
cell	O
cycle	O
arrest	O
.	O

Effect	O
of	O
Azadirachta	O
indica	O
hydroalcoholic	O
leaf	O
extract	O
on	O
the	O
cardiovascular	O
system	O
.	O

The	O
210	O
kDa	O
precursor	O
is	O
converted	O
slowly	O
(	O
t	O
1	O
/	O
2	O
=	O
2	O
h	O
)	O
by	O
proteolytic	O
processing	O
into	O
a	O
125	O
kDa	O
(	O
alpha	O
'	O
)	O
and	O
83	O
kDa	O
(	O
beta	O
'	O
)	O
species	O
.	O

The	O
leader	O
sequence	O
of	O
the	O
isolated	O
cDNA	O
clone	O
contains	O
several	O
small	O
open	O
reading	O
frames	O
upstream	O
of	O
the	O
initiation	O
codon	O
of	O
the	O
largest	O
open	O
reading	O
frame	O
coding	O
for	O
the	O
homeodomain	B-GENE
protein	I-GENE
.	O

Colorectal	O
carcinoma	O
:	O
therapeutic	O
approach	O
in	O
patients	O
already	O
treated	O
with	O
metastasis	O
resection	O

As	O
a	O
last	O
resort	O
,	O
it	O
may	O
be	O
possible	O
to	O
maintain	O
a	O
patient	O
on	O
dialysis	O
in	O
reasonable	O
health	O
with	O
a	O
DiaTAP	O
button	O
graft	O
complex	O
infected	O
with	O
Staphylococcus	O
epidermidis	O
and	O
intermittent	O
positive	O
blood	O
cultures	O
using	O
long	O
term	O
vancomycin	O
therapy	O
.	O

Twelve	O
genomic	O
fragments	O
containing	O
novel	O
response	O
elements	O
are	O
described	O
,	O
and	O
the	O
transcription	O
unit	O
associated	O
with	O
one	O
of	O
them	O
,	O
NN	B-GENE
-	I-GENE
84AG	I-GENE
,	O
was	O
characterized	O
in	O
detail	O
.	O

Foreigners	O
return	O
.	O

Nickel	O
is	O
the	O
most	O
common	O
cause	O
of	O
allergic	O
contact	O
dermatitis	O
in	O
Singapore	O
,	O
resulting	O
in	O
positive	O
reactions	O
in	O
patch	O
tests	O
between	O
7	O
and	O
14	O
%	O
.	O

The	O
first	O
symptoms	O
of	O
enzootic	O
calcinosis	O
were	O
noted	O
in	O
March	O
1998	O
,	O
when	O
some	O
of	O
the	O
cows	O
developed	O
locomotor	O
abnormalities	O
.	O

We	O
mapped	O
the	O
DGCR6	B-GENE
gene	I-GENE
to	O
chromosome	O
22q11	O
within	O
a	O
low	O
copy	O
repeat	O
,	O
termed	O
sc11	O
.	O
1a	O
,	O
and	O
identified	O
a	O
second	O
copy	O
of	O
the	O
gene	O
,	O
DGCR6L	B-GENE
,	O
within	O
the	O
duplicate	O
locus	O
,	O
termed	O
sc11	O
.	O
1b	O
.	O

Attenuation	O
from	O
the	O
vit	B-GENE
A2	I-GENE
consensus	O
ERE	O
is	O
not	O
necessarily	O
dependent	O
on	O
DNA	O
binding	O
as	O
the	O
TR	B-GENE
alpha	I-GENE
DNA	O
binding	O
mutant	O
was	O
still	O
able	O
to	O
inhibit	O
E	O
-	O
dependent	O
transactivation	O
.	O

The	O
recruitment	O
of	O
constitutively	O
phosphorylated	O
p185	B-GENE
(	O
neu	B-GENE
)	O
and	O
the	O
activated	O
mitogenic	O
pathway	O
proteins	O
to	O
this	O
membrane	O
-	O
microfilament	O
interaction	O
site	O
provides	O
a	O
physical	O
model	O
for	O
integrating	O
the	O
assembly	O
of	O
the	O
mitogenic	O
pathway	O
with	O
the	O
transmission	O
of	O
growth	O
factor	O
signal	O
to	O
the	O
cytoskeleton	O
.	O

Two	O
mutants	O
,	O
each	O
representative	O
of	O
a	O
separate	O
pet	B-GENE
complementation	O
group	O
,	O
have	O
been	O
analyzed	O
.	O

Molecular	O
analysis	O
of	O
the	O
pRA2	O
partitioning	O
region	O
:	O
ParB	B-GENE
autoregulates	O
parAB	B-GENE
transcription	O
and	O
forms	O
a	O
nucleoprotein	O
complex	O
with	O
the	O
plasmid	O
partition	O
site	O
,	O
parS	B-GENE
.	O

The	O
purpose	O
of	O
the	O
study	O
reported	O
here	O
was	O
to	O
investigate	O
whether	O
differences	O
in	O
T1	O
and	O
T2	O
between	O
tumors	O
are	O
mainly	O
a	O
consequence	O
of	O
differences	O
in	O
the	O
fractional	O
volume	O
of	O
the	O
extracellular	O
compartment	O
.	O

The	O
levels	O
of	O
NPY	B-GENE
-	O
ir	O
in	O
the	O
rat	O
vas	O
deferens	O
were	O
not	O
affected	O
by	O
either	O
surgical	O
or	O
pharmacological	O
treatment	O
.	O

The	O
dichloromethane	O
is	O
removed	O
,	O
mobile	O
phase	O
solvent	O
is	O
added	O
,	O
and	O
aliquots	O
are	O
injected	O
onto	O
a	O
PRP	O
-	O
1	O
liquid	O
chromatographic	O
column	O
;	O
fluazifop	O
acid	O
is	O
separated	O
from	O
coextracted	O
compounds	O
and	O
detected	O
at	O
an	O
applied	O
potential	O
of	O
+	O
1	O
.	O
25	O
V	O
,	O
using	O
an	O
amperometric	O
electrochemical	O
detector	O
in	O
the	O
oxidation	O
mode	O
.	O

The	O
diagnostic	O
accuracy	O
of	O
serum	O
PE	B-GENE
-	I-GENE
1	I-GENE
was	O
0	O
.	O
80	O
,	O
and	O
that	O
of	O
amylase	B-GENE
0	O
.	O
97	O
.	O

Alternative	O
splicing	O
of	O
ClC	B-GENE
-	I-GENE
6	I-GENE
(	O
a	O
member	O
of	O
the	O
CIC	B-GENE
chloride	I-GENE
-	I-GENE
channel	I-GENE
family	I-GENE
)	O
transcripts	O
generates	O
three	O
truncated	O
isoforms	O
one	O
of	O
which	O
,	O
ClC	B-GENE
-	I-GENE
6c	I-GENE
,	O
is	O
kidney	O
-	O
specific	O
.	O

Because	O
single	O
-	O
chamber	O
rate	O
-	O
adaptive	O
atrial	O
pacing	O
leaves	O
the	O
patient	O
exposed	O
to	O
the	O
risk	O
of	O
future	O
development	O
of	O
AV	O
block	O
and	O
DDD	O
pacing	O
does	O
not	O
provide	O
chronotropic	O
support	O
,	O
it	O
is	O
likely	O
that	O
the	O
new	O
rate	O
-	O
adaptive	O
dual	O
-	O
chamber	O
(	O
DDDR	O
)	O
devices	O
will	O
be	O
used	O
in	O
a	O
significant	O
number	O
of	O
these	O
patients	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
JHRLSS	O
has	O
been	O
used	O
in	O
prior	O
studies	O
to	O
assess	O
RLS	O
severity	O
,	O
but	O
has	O
not	O
previously	O
been	O
validated	O
in	O
relation	O
to	O
direct	O
measures	O
of	O
the	O
morbidity	O
associated	O
with	O
RLS	O
.	O

These	O
observations	O
lead	O
to	O
the	O
proposal	O
that	O
the	O
RNAP	B-GENE
II	I-GENE
CTD	I-GENE
might	O
be	O
an	O
in	O
vivo	O
target	O
for	O
the	O
activated	O
p42mapk	B-GENE
and	O
p44mapk	B-GENE
MAP	I-GENE
kinases	I-GENE
.	O

The	O
various	O
available	O
data	O
strongly	O
suggesting	O
an	O
environmental	O
toxic	O
origin	O
for	O
the	O
"	O
sperm	O
fall	O
"	O
will	O
be	O
presented	O
as	O
well	O
as	O
the	O
most	O
frequently	O
suspected	O
class	O
of	O
substances	O
,	O
the	O
xenoestrogens	O
.	O

We	O
have	O
separated	O
a	O
dermatan	O
sulfate	O
proteoglycan	O
,	O
epiphycan	O
,	O
from	O
decorin	B-GENE
and	O
biglycan	O
by	O
using	O
dissociative	O
extraction	O
of	O
bovine	O
fetal	O
epiphyseal	O
cartilage	O
,	O
followed	O
by	O
sequential	O
ion	O
-	O
exchange	O
,	O
gel	O
permeation	O
,	O
hydrophobic	O
,	O
and	O
Zn2	O
+	O
chelate	O
chromatographic	O
steps	O
.	O

Visual	O
response	O
properties	O
of	O
neurons	O
in	O
four	O
extrastriate	O
visual	O
areas	O
of	O
the	O
owl	O
monkey	O
(	O
Aotus	O
trivirgatus	O
)	O
:	O
a	O
quantitative	O
comparison	O
of	O
medial	O
,	O
dorsomedial	O
,	O
dorsolateral	O
,	O
and	O
middle	O
temporal	O
areas	O
.	O

Glomerular	O
mesangial	O
cells	O
expressed	O
an	O
abundant	O
1	O
.	O
1	O
kb	O
mRNA	O
transcript	O
for	O
Id1	B-GENE
,	O
but	O
in	O
contrast	O
to	O
other	O
cell	O
types	O
Id1	B-GENE
mRNA	I-GENE
was	O
expressed	O
in	O
both	O
randomly	O
cycling	O
cells	O
and	O
in	O
serum	O
-	O
deprived	O
,	O
quiescent	O
cultures	O
.	O

There	O
was	O
no	O
apparent	O
effect	O
of	O
growth	O
temperature	O
on	O
the	O
steady	O
-	O
state	O
levels	O
of	O
fad7	B-GENE
mRNA	I-GENE
in	O
wild	O
type	O
plants	O
.	O

Difficulties	O
bound	O
to	O
measuring	O
of	O
sputum	O
viscosity	O

RESULTS	O
:	O
Significant	O
changes	O
from	O
pretreatment	O
to	O
posttreatment	O
were	O
observed	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
overall	O
results	O
of	O
this	O
paper	O
are	O
consistent	O
with	O
the	O
conclusion	O
that	O
the	O
carboxyl	O
-	O
terminal	O
LBD	O
is	O
not	O
sufficient	O
for	O
mediating	O
PR	B-GENE
dimerization	O
and	O
that	O
multiple	O
regions	O
,	O
including	O
the	O
hinge	O
and	O
amino	O
-	O
terminal	O
sequences	O
,	O
contribute	O
either	O
directly	O
or	O
indirectly	O
to	O
homodimerization	O
of	O
PR	B-GENE
.	O

The	O
equilibrium	O
dissociation	O
binding	O
constant	O
for	O
the	O
interaction	O
of	O
TnrA	B-GENE
with	O
the	O
nrgAB	B-GENE
promoter	I-GENE
fragment	I-GENE
was	O
7	O
.	O
7	O
nM	O
under	O
the	O
conditions	O
used	O
here	O
.	O

Effect	O
of	O
a	O
high	O
-	O
intensity	O
SHF	O
field	O
on	O
the	O
blood	O
coagulation	O
system	O

It	O
is	O
now	O
well	O
accepted	O
that	O
the	O
p53	B-GENE
C	I-GENE
-	I-GENE
terminus	I-GENE
plays	O
a	O
central	O
role	O
in	O
controlling	O
the	O
activity	O
of	O
the	O
wild	O
-	O
type	O
molecule	O
.	O

The	O
activity	O
of	O
the	O
minimal	O
promoter	O
was	O
found	O
to	O
be	O
controlled	O
by	O
a	O
combination	O
of	O
the	O
activities	O
of	O
the	O
transcription	O
factors	O
Sp1	B-GENE
,	O
Sp3	B-GENE
,	O
and	O
NF	B-GENE
-	I-GENE
Y	I-GENE
.	O

We	O
evaluated	O
the	O
likelihood	O
of	O
tissues	O
to	O
be	O
positive	O
for	O
carcinoembryonic	B-GENE
antigen	I-GENE
and	O
the	O
intensity	O
of	O
carcinoembryonic	B-GENE
antigen	I-GENE
staining	O
in	O
specimens	O
of	O
villous	O
adenomas	O
,	O
mixed	O
polypoid	O
villous	O
adenomas	O
,	O
polypoid	O
adenomas	O
,	O
and	O
diverticulitis	O
using	O
the	O
peroxidase	B-GENE
-	O
antiperoxidase	B-GENE
technique	O
.	O

Mapping	O
results	O
suggested	O
that	O
the	O
complementation	O
group	O
identified	O
by	O
these	O
mutants	O
is	O
allelic	O
to	O
the	O
ag	B-GENE
alpha	I-GENE
1	I-GENE
mutation	O
identified	O
previously	O
.	O

Comparison	O
with	O
the	O
sequence	O
databanks	O
show	O
that	O
Tactile	B-GENE
is	O
a	O
member	O
of	O
the	O
immunoglobulin	B-GENE
gene	I-GENE
superfamily	I-GENE
,	O
with	O
similarity	O
to	O
Drosophila	B-GENE
amalgam	I-GENE
,	O
the	O
melanoma	B-GENE
Ag	I-GENE
MUC	I-GENE
-	I-GENE
18	I-GENE
,	O
members	O
of	O
the	O
carcinoembryonic	B-GENE
Ag	I-GENE
family	I-GENE
,	O
the	O
poliovirus	B-GENE
receptor	I-GENE
,	O
and	O
the	O
neural	B-GENE
cell	I-GENE
adhesion	I-GENE
molecule	I-GENE
.	O

Liquid	O
chromatography	O
with	O
amperometric	O
detection	O
(	O
LC	O
/	O
AD	O
)	O
is	O
used	O
to	O
determine	O
fluazifop	O
acid	O
produced	O
from	O
the	O
metabolism	O
or	O
base	O
hydrolysis	O
of	O
fluazifop	O
-	O
butyl	O
in	O
soybeans	O
and	O
soybean	O
oil	O
.	O

Saccharomyces	O
cerevisiae	O
has	O
been	O
used	O
widely	O
both	O
as	O
a	O
model	O
system	O
for	O
unraveling	O
the	O
biochemical	O
,	O
genetic	O
,	O
and	O
molecular	O
details	O
of	O
gene	O
expression	O
and	O
the	O
secretion	O
process	O
,	O
and	O
as	O
a	O
host	O
for	O
the	O
production	O
of	O
heterologous	O
proteins	O
of	O
biotechnological	O
interest	O
.	O

Neural	O
blockade	O
in	O
chronic	O
and	O
cancer	O
pain	O
.	O

Differential	O
regulation	O
of	O
the	O
pre	B-GENE
-	I-GENE
C	I-GENE
and	O
pregenomic	O
promoters	O
of	O
human	O
hepatitis	O
B	O
virus	O
by	O
members	O
of	O
the	O
nuclear	B-GENE
receptor	I-GENE
superfamily	I-GENE
.	O

Mutational	O
analysis	O
of	O
essential	O
IncP	O
alpha	O
plasmid	O
transfer	O
genes	O
traF	B-GENE
and	O
traG	B-GENE
and	O
involvement	O
of	O
traF	B-GENE
in	O
phage	O
sensitivity	O
.	O

A	O
cis	O
-	O
acting	O
DNA	O
element	O
located	O
between	O
TATA	O
box	O
and	O
transcription	O
initiation	O
site	O
is	O
critical	O
in	O
response	O
to	O
regulatory	O
sequences	O
in	O
human	O
angiotensinogen	B-GENE
gene	I-GENE
.	O

This	O
study	O
was	O
designed	O
to	O
compare	O
the	O
efficacy	O
of	O
efegatran	O
plus	O
streptokinase	B-GENE
versus	O
heparin	O
plus	O
accelerated	O
tissue	B-GENE
plasminogen	I-GENE
activator	I-GENE
(	O
TPA	B-GENE
)	O
in	O
coronary	O
reperfusion	O
in	O
acute	O
MI	O
.	O

We	O
used	O
expression	O
cloning	O
to	O
identify	O
interleukin	B-GENE
-	I-GENE
6	I-GENE
(	O
IL	B-GENE
-	I-GENE
6	I-GENE
)	O
as	O
one	O
factor	O
that	O
suppressed	O
growth	O
of	O
a	O
pre	O
-	O
B	O
-	O
cell	O
variant	O
line	O
,	O
1A9	O
-	O
M	O
.	O

Control	O
Tmuscle	O
was	O
35	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
7	O
degrees	O
C	O
,	O
with	O
control	O
Wi	O
,	O
max	O
being	O
51	O
.	O
6	O
(	O
SD	O
8	O
.	O
7	O
)	O
W	O
.	O
kg	O
-	O
1	O
.	O

The	O
results	O
suggest	O
that	O
the	O
role	O
of	O
S	O
.	O
argyrostoma	O
in	O
the	O
dissemination	O
of	O
Trichinella	O
larvae	O
in	O
nature	O
is	O
limited	O
in	O
comparison	O
to	O
the	O
role	O
played	O
by	O
mammals	O
with	O
scavenger	O
and	O
cannibalistic	O
behavior	O
.	O

Experimental	O
adhesion	O
prophylaxis	O
with	O
recombinant	B-GENE
tissue	I-GENE
plasminogen	I-GENE
activator	I-GENE
.	O

Atcys1	B-GENE
,	O
Athyp1	B-GENE
,	O
AKin10	B-GENE
and	O
the	O
ORF	O
are	O
very	O
close	O
to	O
each	O
other	O
and	O
organized	O
in	O
the	O
same	O
polarity	O
;	O
hence	O
,	O
the	O
intergenic	O
regions	O
probably	O
contain	O
,	O
within	O
less	O
than	O
0	O
.	O
5	O
kb	O
,	O
all	O
the	O
regulatory	O
elements	O
necessary	O
to	O
govern	O
initiation	O
and	O
termination	O
of	O
transcription	O
.	O

Paracrine	O
activation	O
of	O
the	O
HIV	B-GENE
-	I-GENE
1	I-GENE
LTR	I-GENE
promoter	I-GENE
by	O
the	O
viral	B-GENE
Tat	I-GENE
protein	I-GENE
is	O
mechanistically	O
similar	O
to	O
trans	O
-	O
activation	O
within	O
a	O
cell	O
.	O

The	O
primary	O
structure	O
and	O
cotranscription	O
of	O
the	O
petCA	B-GENE
genes	I-GENE
encoding	O
the	O
Rieske	B-GENE
-	I-GENE
FeS	I-GENE
(	O
nuclear	B-GENE
encoded	I-GENE
in	I-GENE
plants	I-GENE
)	O
and	O
apocytochrome	B-GENE
f	I-GENE
proteins	I-GENE
has	O
been	O
described	O
previously	O
(	O
Kallas	O
,	O
T	O
.	O
,	O
Spiller	O
,	O
S	O
.	O
,	O
and	O
Malkin	O
,	O
R	O
.	O

Southern	O
blot	O
analysis	O
of	O
endonuclease	O
-	O
digested	O
genomic	O
DNA	O
from	O
primary	O
chick	O
embryo	O
fibroblasts	O
(	O
CEF	O
)	O
suggested	O
that	O
MEK2	B-GENE
is	O
a	O
single	O
-	O
copy	O
gene	O
in	O
this	O
vertebrate	O
species	O
.	O

One	O
complex	O
most	O
likely	O
contained	O
Sp1	B-GENE
,	O
and	O
another	O
complex	O
showed	O
S	O
-	O
phase	O
-	O
specific	O
binding	O
,	O
suggesting	O
a	O
direct	O
role	O
in	O
the	O
cell	O
-	O
cycle	O
-	O
dependent	O
R1	B-GENE
gene	I-GENE
expression	O
.	O

Induction	O
of	O
anaesthesia	O
was	O
standardised	O
:	O
fentanyl	O
(	O
3	O
micrograms	O
/	O
kg	O
)	O
,	O
thiopentone	O
(	O
5	O
mg	O
/	O
kg	O
)	O
,	O
atracurium	O
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
)	O
.	O

Vasoactive	B-GENE
intestinal	I-GENE
peptide	I-GENE
and	O
pituitary	B-GENE
adenylate	I-GENE
cyclase	I-GENE
-	I-GENE
activating	I-GENE
polypeptide	I-GENE
inhibit	O
nuclear	B-GENE
factor	I-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
-	I-GENE
dependent	I-GENE
gene	I-GENE
activation	O
at	O
multiple	O
levels	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
.	O

Iodine	O
-	O
123	O
was	O
satisfactorily	O
imaged	O
only	O
with	O
the	O
MEC	O
and	O
pinhole	O
collimators	O
,	O
which	O
in	O
turn	O
yielded	O
MTF	O
values	O
comparable	O
to	O
those	O
measured	O
for	O
99mTc	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
indicate	O
that	O
the	O
C	O
-	O
terminal	O
24	O
amino	O
acids	O
are	O
sufficient	O
for	O
NodO	B-GENE
secretion	O
although	O
the	O
region	O
adjacent	O
to	O
this	O
domain	O
appears	O
to	O
affect	O
secretion	O
efficiency	O
.	O

We	O
found	O
that	O
120	O
bp	O
of	O
the	O
enhancer	O
'	O
s	O
transcriptional	O
core	O
becomes	O
DNase	B-GENE
I	I-GENE
hypersensitive	O
early	O
in	O
B	O
-	O
cell	O
development	O
.	O

Pokeweed	B-GENE
antiviral	I-GENE
protein	I-GENE
(	O
PAP	B-GENE
)	O
from	O
Phytolacca	O
americana	O
is	O
a	O
highly	O
specific	O
N	B-GENE
-	I-GENE
glycosidase	I-GENE
removing	O
adenine	O
residues	O
(	O
A4324	O
in	O
28S	B-GENE
rRNA	I-GENE
and	O
A2660	O
in	O
23S	B-GENE
rRNA	I-GENE
)	O
from	O
intact	O
ribosomes	O
of	O
both	O
eukaryotes	O
and	O
prokaryotes	O
.	O

Conventionally	O
,	O
four	O
nominal	O
allotypic	O
variants	O
,	O
b4	O
,	O
b5	O
,	O
b6	O
and	O
b9	O
have	O
been	O
shown	O
to	O
be	O
co	O
-	O
dominantly	O
expressed	O
at	O
the	O
Ckappa1	B-GENE
gene	I-GENE
locus	I-GENE
.	O

Patients	O
with	O
an	O
enzymatic	O
activity	O
below	O
X	O
-	O
-	O
1	O
manifested	O
a	O
decrease	O
of	O
the	O
content	O
of	O
IgA	B-GENE
,	O
IgG	B-GENE
,	O
IgM	B-GENE
,	O
T	O
and	O
B	O
lymphocytes	O
,	O
and	O
of	O
phagocytic	O
activity	O
of	O
neutrophils	O
as	O
compared	O
to	O
patients	O
exhibiting	O
a	O
high	O
enzymatic	O
activity	O
.	O

Eight	O
patients	O
received	O
1	O
.	O
5	O
mg	O
of	O
adefovir	O
dipivoxil	O
per	O
kg	O
of	O
body	O
weight	O
,	O
and	O
six	O
patients	O
received	O
3	O
.	O
0	O
mg	O
of	O
adefovir	O
dipivoxil	O
per	O
kg	O
.	O

Pseudosubstrate	O
(	O
19	O
-	O
36	O
)	O
,	O
derived	O
from	O
the	O
C	O
-	O
terminus	O
of	O
Ca	B-GENE
-	I-GENE
dependent	I-GENE
PKC	I-GENE
isotypes	I-GENE
,	O
inhibited	O
beta	B-GENE
-	I-GENE
PKC	I-GENE
but	O
not	O
nPKC	B-GENE
activity	O
using	O
either	O
Histone	B-GENE
IIIS	I-GENE
or	O
peptide	O
(	O
19	O
-	O
31	O
)	O
as	O
substrate	O
.	O

The	O
alpha	O
-	O
subunit	O
by	O
itself	O
binds	O
to	O
telomeric	O
DNA	O
.	O

Thirty	O
-	O
one	O
age	O
-	O
matched	O
,	O
conscious	O
,	O
virgin	O
,	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
and	O
spontaneously	O
hypertensive	O
rats	O
(	O
SHRs	O
)	O
were	O
individually	O
injected	O
with	O
a	O
single	O
subcutaneous	O
dose	O
of	O
85	O
mg	O
/	O
kg	O
dl	O
-	O
isoproterenol	O
to	O
determine	O
the	O
degree	O
and	O
time	O
course	O
of	O
drug	O
-	O
induced	O
cardiac	O
failure	O
and	O
functional	O
recovery	O
.	O

From	O
all	O
clinically	O
important	O
yeasts	O
species	O
,	O
a	O
total	O
of	O
96	O
%	O
were	O
identified	O
by	O
ATB	O
method	O
according	O
to	O
conventional	O
methods	O
.	O

The	O
authors	O
report	O
the	O
clinicopathologic	O
findings	O
in	O
four	O
cases	O
of	O
adult	O
women	O
with	O
rhabdomyosarcomas	O
that	O
originated	O
in	O
the	O
endometrium	O
or	O
cervix	O
,	O
or	O
both	O
.	O

By	O
deletion	O
analysis	O
of	O
the	O
MLS1	B-GENE
control	O
region	O
,	O
we	O
identified	O
two	O
sites	O
,	O
UAS1	O
and	O
UAS2	O
,	O
as	O
important	O
for	O
efficient	O
derepression	O
of	O
the	O
gene	O
.	O

Improved	O
cosmesis	O
,	O
extension	O
of	O
the	O
scope	O
of	O
the	O
problems	O
that	O
can	O
be	O
addressed	O
with	O
this	O
repair	O
(	O
including	O
treatment	O
of	O
a	O
distal	O
urethrocutaneous	O
fistula	O
)	O
and	O
the	O
ease	O
with	O
which	O
the	O
Arap	O
procedure	O
can	O
be	O
performed	O
are	O
the	O
advantages	O
that	O
this	O
operation	O
has	O
over	O
other	O
1	O
-	O
stage	O
distal	O
hypospadias	O
repairs	O
.	O

Occupational	O
exposure	O
to	O
hepatitis	O
B	O
virus	O
and	O
human	O
immunodeficiency	O
virus	O
:	O
a	O
comparative	O
risk	O
analysis	O
.	O

Dd	B-GENE
PK1	I-GENE
RNA	I-GENE
decreases	O
after	O
6	O
h	O
of	O
starvation	O
to	O
re	O
-	O
accumulate	O
once	O
the	O
cells	O
have	O
aggregated	O
.	O

Both	O
carbachol	O
(	O
100	O
microM	O
)	O
and	O
EGF	B-GENE
(	O
10	O
nM	O
)	O
induced	O
Ras	B-GENE
activation	O
.	O

Sural	O
nerve	O
biopsy	O
showed	O
mild	O
thickening	O
of	O
the	O
perineurium	O
,	O
vascular	O
alterations	O
with	O
inflammatory	O
cell	O
infiltration	O
in	O
the	O
perineurium	O
,	O
and	O
remarkable	O
loss	O
of	O
large	O
and	O
small	O
myelinated	O
fibers	O
.	O

Five	O
-	O
year	O
survivals	O
amounted	O
to	O
100	O
%	O
,	O
86	O
.	O
2	O
%	O
,	O
59	O
.	O
4	O
%	O
,	O
29	O
.	O
8	O
%	O
,	O
and	O
20	O
%	O
for	O
stages	O
I	O
,	O
II	O
,	O
III	O
,	O
IVA	O
and	O
IVB	O
respectively	O
.	O

Once	O
more	O
Hong	O
Kong	O
influenza	O
in	O
the	O
Netherlands	O

Conversely	O
,	O
when	O
VDR	B-GENE
is	O
overexpressed	O
,	O
vitamin	O
D3	O
attenuates	O
9	O
-	O
cis	O
RA	O
induction	O
from	O
an	O
RXR	B-GENE
-	O
responsive	O
element	O
.	O

HeLa	O
and	O
Jurkat	O
cell	O
lines	O
carrying	O
the	O
nef	B-GENE
gene	I-GENE
linked	O
to	O
the	O
CMV	O
promoter	O
or	O
the	O
HIV	B-GENE
-	I-GENE
1	I-GENE
LTR	I-GENE
were	O
isolated	O
by	O
coselection	O
for	O
neomycin	O
resistance	O
.	O

In	O
canrenoate	O
-	O
treated	O
rats	O
,	O
ANP	B-GENE
infusion	O
caused	O
greater	O
increases	O
in	O
sodium	O
excretion	O
(	O
FENA	O
from	O
3	O
.	O
05	O
+	O
/	O
-	O
0	O
.	O
71	O
to	O
7	O
.	O
21	O
+	O
/	O
-	O
0	O
.	O
45	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
;	O
n	O
=	O
8	O
)	O
than	O
saline	O
infusion	O
(	O
FENA	O
from	O
4	O
.	O
16	O
+	O
/	O
-	O
1	O
.	O
11	O
to	O
5	O
.	O
47	O
+	O
/	O
-	O
0	O
.	O
66	O
%	O
;	O
n	O
=	O
6	O
)	O
,	O
despite	O
the	O
hypocapnia	O
.	O

Furthermore	O
,	O
we	O
have	O
identified	O
a	O
soluble	O
form	O
of	O
ERp57	B-GENE
/	O
GRP58	B-GENE
by	O
Western	O
blotting	O
and	O
biosynthetic	O
labeling	O
.	O

Our	O
results	O
suggest	O
that	O
proteasome	O
inhibition	O
leads	O
to	O
upregulation	O
of	O
specific	O
members	O
of	O
transcription	O
factor	O
families	O
controlling	O
cellular	O
stress	O
response	O
and	O
proliferation	O
.	O

Thus	O
,	O
prostacyclin	O
enhanced	O
the	O
autoregulative	O
property	O
of	O
the	O
inner	O
ear	O
vessels	O
.	O

Serotonin	B-GENE
receptors	I-GENE
in	O
suicide	O
victims	O
with	O
major	O
depression	O
.	O

Effects	O
of	O
methiothepin	O
and	O
lysergic	O
acid	O
diethylamide	O
on	O
serotonin	O
release	O
in	O
vitro	O
and	O
serotonin	O
synthesis	O
in	O
vivo	O
:	O
possible	O
relation	O
to	O
serotonin	B-GENE
autoreceptor	I-GENE
function	O
.	O

Nucleotide	O
sequences	O
between	O
the	O
env	B-GENE
gene	I-GENE
and	O
the	O
LTR	B-GENE
of	I-GENE
SFV	I-GENE
-	I-GENE
1	I-GENE
were	O
determined	O
.	O

Two	O
separate	O
NF1	B-GENE
-	I-GENE
binding	I-GENE
loci	I-GENE
were	O
also	O
found	O
in	O
the	O
equivalent	O
IE68	B-GENE
gene	I-GENE
of	O
HCMV	O
(	O
Towne	O
)	O
DNA	O
,	O
but	O
in	O
this	O
case	O
the	O
DNA	O
sequence	O
and	O
competition	O
filter	O
binding	O
experiments	O
indicated	O
a	O
maximum	O
of	O
only	O
four	O
to	O
five	O
consensus	O
binding	O
sites	O
encompassing	O
the	O
promoter	O
-	O
enhancer	O
region	O
.	O

Area	O
under	O
the	O
drug	O
concentration	O
-	O
time	O
curves	O
(	O
AUC0	O
-	O
24	O
hr	O
)	O
for	O
MTX	O
were	O
2379	O
and	O
3534	O
ng	O
*	O
hr	O
/	O
ml	O
from	O
PG	O
-	O
2	O
.	O
5	O
%	O
Azone	O
and	O
PG	O
-	O
7	O
.	O
5	O
%	O
Azone	O
systems	O
respectively	O
.	O

Expression	O
in	O
early	O
postnatal	O
pituitary	O
and	O
in	O
pre	O
-	O
somatotrophic	O
cells	O
suggests	O
that	O
Zn	B-GENE
-	I-GENE
16	I-GENE
could	O
play	O
a	O
role	O
in	O
pituitary	O
development	O
prior	O
to	O
somatotroph	O
differentiation	O
.	O

The	O
novel	O
hematopoietic	B-GENE
growth	I-GENE
factor	I-GENE
FLT3	I-GENE
ligand	I-GENE
(	O
FL	B-GENE
)	O
is	O
the	O
cognate	O
ligand	O
for	O
the	O
FLT3	B-GENE
,	O
tyrosine	B-GENE
kinase	I-GENE
receptor	I-GENE
(	O
R	B-GENE
)	O
,	O
also	O
referred	O
to	O
as	O
FLK	B-GENE
-	I-GENE
2	I-GENE
and	O
STK	B-GENE
-	I-GENE
1	I-GENE
.	O

Significant	O
clinical	O
differences	O
between	O
the	O
patients	O
treated	O
with	O
and	O
without	O
AMB	O
were	O
longer	O
survival	O
time	O
following	O
diagnosis	O
of	O
illness	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
more	O
frequent	O
cranial	O
nerve	O
signs	O
in	O
the	O
treated	O
patients	O
(	O
P	O
=	O
0	O
.	O
089	O
)	O
.	O

RT	O
-	O
PCR	O
indicated	O
that	O
p21	B-GENE
mRNA	I-GENE
was	O
induced	O
1	O
.	O
4	O
-	O
,	O
2	O
.	O
0	O
-	O
,	O
and	O
3	O
.	O
1	O
-	O
fold	O
in	O
the	O
2	O
-	O
day	O
neonatal	O
,	O
7	O
-	O
day	O
neonatal	O
,	O
and	O
adult	O
stages	O
,	O
respectively	O
,	O
compared	O
to	O
the	O
17	O
-	O
day	O
fetal	O
stage	O
.	O

This	O
report	O
describes	O
a	O
patient	O
with	O
a	O
previous	O
inferior	O
acute	O
myocardial	O
infarction	O
who	O
developed	O
right	O
ventricular	O
infarction	O
with	O
significant	O
anterior	O
lead	O
ST	O
segment	O
elevation	O
(	O
V1	O
-	O
V4	O
)	O
caused	O
by	O
the	O
loss	O
of	O
two	O
large	O
right	O
ventricular	O
branches	O
during	O
a	O
coronary	O
angioplasty	O
of	O
the	O
right	O
coronary	O
artery	O
.	O

It	O
also	O
suggests	O
that	O
there	O
is	O
another	O
pathway	O
which	O
can	O
activate	O
SWI4	B-GENE
transcription	O
in	O
the	O
absence	O
of	O
SWI6	B-GENE
.	O

Some	O
reflexions	O
apropos	O
of	O
a	O
personal	O
statistical	O
study	O
of	O
513	O
arterial	O
embolisms	O

Energy	O
expenditure	O
was	O
obtained	O
using	O
a	O
primed	O
,	O
3	O
-	O
hour	O
infusion	O
of	O
NaH	O
(	O
13	O
)	O
CO	O
(	O
3	O
'	O
)	O
,	O
breath	O
(	O
13	O
)	O
CO	O
(	O
2	O
)	O
enrichment	O
determination	O
by	O
isotope	O
ratio	O
mass	O
spectroscopy	O
,	O
and	O
the	O
application	O
of	O
a	O
standard	O
regression	O
equation	O
.	O

Oncogenic	O
activation	O
of	O
the	O
tyrosine	B-GENE
kinase	I-GENE
domain	I-GENE
of	O
the	O
human	B-GENE
trk	I-GENE
proto	I-GENE
-	I-GENE
oncogene	I-GENE
by	O
fusion	O
to	O
a	O
cell	O
adhesion	O
molecule	O
.	O

The	O
absolute	O
concentrations	O
of	O
alpha	B-GENE
2	I-GENE
-	I-GENE
plasmin	I-GENE
inhibitor	O
,	O
alpha	B-GENE
2	I-GENE
-	I-GENE
macroglobulin	I-GENE
,	O
and	O
antithrombin	B-GENE
III	I-GENE
increased	O
with	O
exercise	O
(	O
all	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
but	O
when	O
concentrations	O
were	O
corrected	O
for	O
acute	O
shifts	O
of	O
plasma	O
water	O
during	O
exercise	O
,	O
the	O
quantity	O
of	O
these	O
inhibitors	O
actually	O
decreased	O
(	O
all	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

Each	O
of	O
these	O
genes	O
contains	O
a	O
putative	O
upstream	O
ORF	O
,	O
while	O
STA2	B-GENE
has	O
two	O
additional	O
in	O
-	O
frame	O
AUG	O
codons	O
5	O
'	O
to	O
the	O
major	O
cistron	O
.	O

Members	O
of	O
the	O
Ras	B-GENE
subfamily	I-GENE
of	O
small	B-GENE
GTP	I-GENE
-	I-GENE
binding	I-GENE
proteins	I-GENE
have	O
been	O
shown	O
to	O
be	O
promiscuous	O
towards	O
a	O
variety	O
of	O
putative	O
effector	O
molecules	O
such	O
as	O
the	O
protein	B-GENE
kinase	I-GENE
c	I-GENE
-	I-GENE
Raf	I-GENE
and	O
the	O
Ral	B-GENE
-	I-GENE
specific	I-GENE
guanine	I-GENE
nucleotide	I-GENE
exchange	I-GENE
factor	I-GENE
(	O
Ral	B-GENE
-	I-GENE
GEF	I-GENE
)	O
.	O

Almost	O
complete	O
sequence	O
identity	O
was	O
found	O
between	O
the	O
3	O
'	O
end	O
of	O
the	O
DXS6673E	B-GENE
gene	I-GENE
and	O
two	O
expressed	O
sequence	O
tags	O
(	O
ESTs	O
)	O
and	O
between	O
the	O
5	O
'	O
end	O
of	O
the	O
DXS6673E	B-GENE
gene	I-GENE
and	O
a	O
third	O
EST	O
.	O

Leukocyte	O
cultures	O
,	O
prepared	O
from	O
blood	O
drawn	O
from	O
these	O
18	O
children	O
at	O
6	O
months	O
of	O
age	O
,	O
produced	O
lower	O
yields	O
of	O
IFN	B-GENE
than	O
those	O
of	O
the	O
remaining	O
53	O
children	O
,	O
when	O
stimulated	O
with	O
adenovirus	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
coronavirus	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
or	O
rhinovirus	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

Morphine	O
produced	O
a	O
dose	O
-	O
dependent	O
bradycardia	O
followed	O
by	O
tachycardia	O
.	O

To	O
identify	O
these	O
sites	O
,	O
the	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
3T3	O
-	O
L1	O
adipocyte	B-GENE
insulin	I-GENE
receptor	I-GENE
of	O
the	O
mouse	O
was	O
determined	O
.	O

We	O
present	O
a	O
case	O
of	O
carcinoma	O
of	O
the	O
breast	O
presenting	O
concurrently	O
with	O
SSc	O
that	O
subsequently	O
progressed	O
to	O
dialysis	O
-	O
dependent	O
renal	O
failure	O
in	O
just	O
1	O
month	O
.	O

For	O
example	O
,	O
introduction	O
of	O
immunogenic	O
and	O
purification	O
tag	O
sequences	O
into	O
the	O
C	O
-	O
terminal	O
coding	O
region	O
significantly	O
decreased	O
bop	B-GENE
gene	I-GENE
mRNA	I-GENE
and	O
protein	O
accumulation	O
.	O

The	O
uncomplicated	O
cases	O
of	O
typhoid	O
fever	O
were	O
found	O
to	O
have	O
an	O
intact	O
CMIR	O
as	O
compared	O
to	O
the	O
complicated	O
cases	O
.	O

Organ	O
transplantation	O
in	O
Denmark	O
.	O

327	O
and	O
736	O
protocols	O
of	O
postmortem	O
examinations	O
from	O
Moscow	O
hospitals	O
N	O
31	O
and	O
57	O
,	O
respectively	O
,	O
were	O
evaluated	O
statistically	O
.	O

Fibromuscular	O
intimal	O
thickening	O
was	O
seen	O
in	O
the	O
ascending	O
and	O
thoracic	O
aorta	O
of	O
the	O
swine	O
fed	O
62	O
,	O
500	O
IU	O
of	O
vitamin	O
D3	O
/	O
kg	O
of	O
diet	O
for	O
three	O
months	O
duration	O
;	O
and	O
after	O
3	O
months	O
of	O
vitamin	O
D3	O
withdrawal	O
,	O
atherosclerotic	O
lesions	O
were	O
found	O
.	O

Is	O
leishmaniasis	O
endemic	O
on	O
the	O
island	O
of	O
Minorca	O
(	O
Spain	O
)	O
?	O

A	O
human	O
visceral	O
case	O
after	O
living	O
13	O
years	O
in	O
Minorca	O
.	O

The	O
susceptibility	O
of	O
the	O
PPNG	O
strains	O
to	O
clinically	O
relevant	O
antibiotics	O
varied	O
with	O
the	O
plasmid	O
pattern	O
;	O
this	O
stresses	O
the	O
necessity	O
of	O
permanent	O
surveillance	O
of	O
gonococcal	O
infections	O
and	O
of	O
regular	O
evaluation	O
of	O
the	O
recommendations	O
for	O
antimicrobial	O
treatment	O
.	O

Of	O
these	O
carriers	O
149	O
were	O
diagnosed	O
to	O
be	O
asymptomatic	O
clinically	O
,	O
biochemically	O
and	O
echographically	O
.	O

In	O
the	O
absence	O
of	O
E1A243	B-GENE
,	O
YY1	B-GENE
represses	O
CRE	O
-	O
dependent	O
transcription	O
of	O
c	B-GENE
-	I-GENE
fos	I-GENE
by	O
physically	O
interacting	O
with	O
ATF	B-GENE
/	O
CREB	B-GENE
proteins	O
bound	O
to	O
the	O
-	O
67	O
CRE	O
.	O

The	O
gene	O
sequence	O
also	O
identified	O
a	O
340	O
-	O
nucleotide	O
RNA	O
in	O
total	O
yeast	O
RNA	O
and	O
in	O
purified	O
RNase	B-GENE
MRP	I-GENE
enzyme	I-GENE
preparations	O
.	O

Mechanisms	O
of	O
tachyphylaxis	O
in	O
regional	O
anesthesia	O
of	O
long	O
duration	O

Transcriptional	O
regulation	O
of	O
the	O
GluR2	B-GENE
gene	I-GENE
:	O
neural	O
-	O
specific	O
expression	O
,	O
multiple	O
promoters	O
,	O
and	O
regulatory	O
elements	O
.	O

The	O
bactericidal	O
activity	O
of	O
six	O
new	O
rifamycin	O
derivatives	O
-	O
-	O
rifabutin	O
(	O
RBU	O
)	O
,	O
FCE	O
22250	O
(	O
F22	O
)	O
,	O
rifapentine	O
(	O
RPE	O
)	O
,	O
CGP	O
29861	O
(	O
C29	O
)	O
,	O
CGP	O
7040	O
(	O
C70	O
)	O
and	O
CGP	O
27557	O
(	O
C27	O
)	O
and	O
rifampicin	O
(	O
RMP	O
)	O
-	O
-	O
have	O
been	O
measured	O
against	O
log	O
phase	O
and	O
,	O
as	O
a	O
better	O
test	O
of	O
sterilising	O
activity	O
,	O
against	O
stationary	O
phase	O
cultures	O
of	O
Mycobacterium	O
tuberculosis	O
,	O
H37Rv	O
.	O

This	O
establishes	O
Rad3	B-GENE
/	O
Mec1	B-GENE
as	O
the	O
only	O
conserved	O
protein	O
which	O
is	O
required	O
for	O
all	O
the	O
DNA	O
structure	O
checkpoints	O
in	O
both	O
yeast	O
model	O
systems	O
.	O

A	O
36	O
year	O
-	O
old	O
woman	O
was	O
given	O
Ergotamine	O
Tartrate	O
4	O
.	O
5	O
mg	O
p	O
.	O
d	O
.	O
during	O
seven	O
days	O
,	O
after	O
an	O
abortion	O
(	O
a	O
still	O
birth	O
)	O
.	O

The	O
effects	O
of	O
these	O
mutations	O
on	O
protein	O
function	O
require	O
further	O
examination	O
.	O

Hailey	O
-	O
Hailey	O
disease	O
is	O
caused	O
by	O
mutations	O
in	O
ATP2C1	B-GENE
encoding	O
a	O
novel	O
Ca	O
(	O
2	O
+	O
)	O
pump	O
.	O

Moreover	O
,	O
the	O
same	O
mutations	O
alter	O
the	O
structure	O
of	O
junB	B-GENE
5	O
'	O
flanking	O
DNA	O
within	O
chromatin	O
.	O

Serum	B-GENE
TNF	I-GENE
concentrations	O
were	O
elevated	O
at	O
diagnosis	O
and	O
gradually	O
decreased	O
toward	O
the	O
reference	O
limits	O
by	O
week	O
16	O
.	O

A	O
0	O
.	O
5	O
rating	O
was	O
intended	O
to	O
characterize	O
subjects	O
in	O
whom	O
mild	O
cognitive	O
impairment	O
due	O
to	O
senile	O
dementia	O
of	O
the	O
Alzheimer	O
type	O
was	O
suspected	O
but	O
was	O
insufficient	O
in	O
degree	O
to	O
warrant	O
a	O
diagnosis	O
of	O
definite	O
dementia	O
.	O

Thromboelastography	O
is	O
a	O
test	O
that	O
could	O
potentially	O
correlate	O
with	O
the	O
degree	O
of	O
anticoagulation	O
produced	O
by	O
low	O
molecular	O
weight	O
heparin	O
.	O

Calcification	O
of	O
a	O
cariogenic	O
Streptococcus	O
and	O
of	O
Corynebacterium	O
(	O
Bacterionema	O
)	O
matruchotii	O
.	O

Sequence	O
divergence	O
is	O
observed	O
in	O
untranslated	O
regions	O
which	O
allows	O
the	O
definition	O
of	O
gene	O
-	O
specific	O
probes	O
.	O

Appropriate	O
restriction	O
sites	O
allow	O
one	O
to	O
insert	O
virtually	O
any	O
desired	O
cDNA	O
fragment	O
directly	O
behind	O
the	O
epitope	O
-	O
specific	O
sequence	O
and	O
before	O
a	O
long	O
poly	O
(	O
A	O
)	O
tail	O
.	O

Serial	O
followup	O
strength	O
data	O
for	O
2	O
patients	O
were	O
compared	O
to	O
change	O
in	O
creatinine	B-GENE
kinase	I-GENE
(	O
CK	B-GENE
)	O
levels	O
.	O

Recently	O
,	O
a	O
mutation	O
in	O
the	O
amino	O
-	O
terminus	O
of	O
IB1	B-GENE
was	O
associated	O
with	O
diabetes	O
.	O

Nevertheless	O
cryopreservation	O
of	O
spermatozoa	O
in	O
a	O
medium	O
containing	O
neither	O
SP	O
nor	O
biological	O
substances	O
could	O
offer	O
an	O
acceptable	O
cryoprotection	O
of	O
spermatozoa	O
to	O
be	O
used	O
in	O
assisted	O
fertilization	O
procedures	O
,	O
especially	O
for	O
intracytoplasmic	O
sperm	O
injection	O
.	O

Depending	O
on	O
the	O
location	O
and	O
size	O
of	O
the	O
mass	O
,	O
a	O
wide	O
range	O
of	O
clinical	O
presentations	O
is	O
associated	O
with	O
the	O
lesion	O
.	O

Histopathological	O
features	O
of	O
relapsed	O
leprosy	O
.	O

Differential	O
expression	O
was	O
confirmed	O
by	O
Northern	O
blot	O
analysis	O
employing	O
multiple	O
normal	O
and	O
tumor	O
cell	O
lines	O
.	O

Intra	O
-	O
operative	O
ultrasound	O
(	O
IOUS	O
)	O
has	O
been	O
widely	O
used	O
in	O
an	O
attempt	O
to	O
overcome	O
these	O
difficulties	O
,	O
but	O
is	O
limited	O
by	O
its	O
two	O
-	O
dimensional	O
nature	O
,	O
inter	O
-	O
user	O
variability	O
,	O
and	O
image	O
obliteration	O
with	O
ablative	O
or	O
resectional	O
techniques	O
.	O

These	O
results	O
were	O
compared	O
with	O
those	O
obtained	O
in	O
-	O
D	O
mothers	O
and	O
pups	O
,	O
after	O
giving	O
the	O
mothers	O
an	O
oral	O
supplement	O
(	O
10	O
i	O
.	O
u	O
.	O
vitamin	O
D3	O
/	O
day	O
)	O
during	O
the	O
period	O
of	O
lactation	O
(	O
20	O
days	O
)	O
.	O

There	O
are	O
four	O
polyglutamine	O
motifs	O
interspersed	O
with	O
histidine	O
-	O
rich	O
regions	O
.	O

Basal	O
components	O
of	O
the	O
transcription	O
apparatus	O
(	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
,	O
TATA	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
)	O
contain	O
activation	O
domains	O
:	O
is	O
the	O
repetitive	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
of	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
a	O
"	O
portable	O
enhancer	O
domain	O
"	O
?	O

Regions	O
rich	O
in	O
serine	O
,	O
threonine	O
,	O
and	O
proline	O
residues	O
can	O
be	O
found	O
in	O
transcriptional	O
activation	O
domains	O
,	O
as	O
well	O
as	O
in	O
the	O
N	O
-	O
terminal	O
parts	O
of	O
mammalian	B-GENE
TATA	I-GENE
-	I-GENE
binding	I-GENE
proteins	I-GENE
,	O
where	O
they	O
are	O
interrupted	O
by	O
polyglutamine	O
stretches	O
.	O

The	O
contraceptive	O
pattern	O
of	O
157	O
women	O
was	O
analysed	O
and	O
13	O
.	O
8	O
percent	O
were	O
using	O
inefficient	O
methods	O
.	O

No	O
drop	O
in	O
oxygen	O
saturation	O
(	O
SaO2	O
)	O
or	O
visual	O
evidence	O
of	O
transient	O
electroencephalographic	O
(	O
EEG	O
)	O
arousals	O
can	O
be	O
found	O
at	O
repeat	O
polysomnography	O
.	O

To	O
determine	O
the	O
signal	B-GENE
recognition	I-GENE
particle	I-GENE
(	O
SRP	B-GENE
)	O
-	O
SRP	B-GENE
receptor	I-GENE
(	O
Srb	B-GENE
)	O
system	O
in	O
Bacillus	O
subtilis	O
(	O
Bs	O
)	O
,	O
we	O
cloned	O
the	O
Bs	B-GENE
srb	I-GENE
gene	I-GENE
,	O
which	O
encodes	O
a	O
homologue	O
of	O
the	O
mammalian	B-GENE
SRP	I-GENE
receptor	I-GENE
alpha	I-GENE
-	I-GENE
subunit	I-GENE
[	O
Oguro	O
et	O
al	O
.	O
,	O
DNA	O
Res	O
.	O

Refugees	O
living	O
in	O
Lund	O
and	O
repatriated	O
to	O
Chile	O
considered	O
their	O
health	O
as	O
bad	O
in	O
a	O
higher	O
proportion	O
than	O
their	O
Swedish	O
counterparts	O
,	O
with	O
an	O
odds	O
ratio	O
of	O
3	O
.	O
48	O
(	O
2	O
.	O
03	O
-	O
5	O
.	O
66	O
)	O
and	O
4	O
.	O
78	O
(	O
2	O
.	O
1	O
-	O
10	O
.	O
25	O
)	O
respectively	O
.	O

The	O
results	O
indicate	O
that	O
increased	O
pulmonary	O
blood	O
flow	O
and	O
decreased	O
pulmonary	O
vascular	O
resistance	O
with	O
advancing	O
gestation	O
are	O
due	O
to	O
an	O
increase	O
in	O
the	O
total	O
number	O
of	O
vessels	O
and	O
increased	O
vasomotor	O
reactivity	O
is	O
related	O
to	O
an	O
increase	O
in	O
the	O
total	O
amount	O
of	O
smooth	O
muscle	O
while	O
the	O
thickness	O
of	O
muscle	O
in	O
individual	O
vessels	O
remains	O
constant	O
.	O

Its	O
hydropathy	O
profile	O
predicts	O
seven	O
transmembrane	O
spans	O
and	O
a	O
hydrophilic	O
amino	O
terminus	O
of	O
approximately	O
100	O
residues	O
,	O
and	O
it	O
suggests	O
the	O
presence	O
of	O
an	O
amphiphilic	O
alpha	O
-	O
helix	O
(	O
L	O
-	O
61	O
to	O
F	O
-	O
97	O
)	O
in	O
close	O
proximity	O
to	O
the	O
first	O
strongly	O
hydrophobic	O
segment	O
of	O
ProW	B-GENE
.	O

Between	O
the	O
subgroups	O
of	O
dementia	O
disorders	O
there	O
were	O
no	O
significant	O
differences	O
in	O
basal	O
cortisol	O
levels	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
expression	O
of	O
the	O
gene	O
for	O
the	O
reproductive	O
neuropeptide	O
,	O
GnRH	B-GENE
,	O
is	O
repressed	O
by	O
the	O
glutamate	O
/	O
NO	O
/	O
cyclic	O
GMP	O
(	O
cGMP	O
)	O
signal	O
transduction	O
pathway	O
through	O
cGMP	B-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
in	O
the	O
hypothalamic	O
GnRH	B-GENE
-	O
secreting	O
neuronal	O
cell	O
line	O
GT1	O
-	O
7	O
.	O

A	O
comparison	O
of	O
the	O
promoters	O
for	O
muMIP	B-GENE
-	I-GENE
1	I-GENE
beta	I-GENE
and	O
muMIP	B-GENE
-	I-GENE
1	I-GENE
alpha	I-GENE
reveals	O
a	O
conserved	O
CK	O
-	O
1	O
element	O
,	O
but	O
transient	O
expression	O
studies	O
in	O
RAW	O
264	O
.	O
7	O
macrophages	O
with	O
proximal	O
fragments	O
of	O
either	O
the	O
muMIP	B-GENE
-	I-GENE
1	I-GENE
beta	I-GENE
or	O
the	O
muMIP	B-GENE
-	I-GENE
1	I-GENE
alpha	I-GENE
5	I-GENE
'	I-GENE
promoter	I-GENE
fused	O
to	O
a	O
human	B-GENE
growth	I-GENE
hormone	I-GENE
reporter	I-GENE
gene	I-GENE
link	O
LPS	O
-	O
inducibility	O
in	O
both	O
to	O
promoter	O
segments	O
near	O
to	O
,	O
but	O
not	O
identical	O
with	O
,	O
the	O
consensus	O
CK	O
-	O
1	O
sequence	O
.	O

This	O
may	O
explain	O
in	O
part	O
a	O
secular	O
trend	O
towards	O
reduced	O
birthweight	O
for	O
gestation	O
in	O
preterm	O
infants	O
.	O

Arterial	O
blood	O
gas	O
tensions	O
were	O
similar	O
across	O
all	O
ventilation	O
modes	O
.	O

Disability	O
insurance	O
under	O
social	O
security	O
.	O

It	O
contains	O
25	O
exons	O
coding	O
for	O
a	O
4	O
.	O
7kb	O
transcript	O
including	O
large	O
5	O
'	O
-	O
and	O
3	O
'	O
-	O
(	O
1218bp	O
and	O
701bp	O
,	O
respectively	O
)	O
untranslated	O
regions	O
(	O
UTRs	O
)	O
.	O

The	O
number	O
of	O
polymerases	O
active	O
in	O
vitro	O
at	O
the	O
E	O
strand	O
promoter	O
was	O
similar	O
to	O
the	O
number	O
of	O
polymerases	O
at	O
the	O
L	O
strand	O
promoter	O
.	O

Moreover	O
,	O
the	O
ability	O
to	O
selectivity	O
arrest	O
elongation	O
by	O
polIII	B-GENE
at	O
defined	O
positions	O
within	O
the	O
tRNA	O
gene	O
transcription	O
unit	O
has	O
permitted	O
the	O
identification	O
of	O
discrete	O
functional	O
properties	O
of	O
paused	O
mammalian	B-GENE
polIII	I-GENE
ternary	I-GENE
complexes	I-GENE
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
new	O
member	O
of	O
the	O
rat	B-GENE
placental	I-GENE
prolactin	I-GENE
(	O
PRL	B-GENE
)	O
family	O
,	O
PRL	B-GENE
-	O
like	O
protein	B-GENE
H	I-GENE
.	O

The	O
prescription	O
for	O
apoplexy	O
includes	O
C1	O
-	O
7	O
,	O
T1	O
-	O
9	O
and	O
L2	O
-	O
4	O
.	O

Grade	O
3	O
mucositis	O
was	O
reported	O
in	O
1	O
patient	O
.	O

However	O
,	O
it	O
remains	O
an	O
open	O
question	O
whether	O
vertebrate	B-GENE
Hox	I-GENE
genes	I-GENE
expressed	O
under	O
the	O
control	O
of	O
Drosophila	O
regulatory	O
sequences	O
can	O
substitute	O
the	O
function	O
of	O
Drosophila	B-GENE
Hox	I-GENE
genes	I-GENE
.	O

The	O
molecular	O
basis	O
for	O
commitment	O
of	O
progenitors	O
to	O
the	O
eosinophil	O
lineage	O
and	O
mechanisms	O
by	O
which	O
eosinophil	O
-	O
specific	O
genes	O
are	O
expressed	O
and	O
regulated	O
during	O
differentiation	O
is	O
unknown	O
.	O

Cloning	O
and	O
primary	O
structure	O
of	O
neurocan	O
,	O
a	O
developmentally	O
regulated	O
,	O
aggregating	O
chondroitin	O
sulfate	O
proteoglycan	O
of	O
brain	O
.	O

The	O
newly	O
recognised	O
skeletogenital	O
syndrome	O
.	O

VII	O
.	O

The	O
development	O
and	O
distribution	O
of	O
Trypanosoma	O
congolense	O
,	O
T	O
vivax	O
and	O
T	O
brucei	O
in	O
the	O
skin	O
of	O
goats	O
was	O
examined	O
after	O
the	O
animals	O
were	O
bitten	O
by	O
infected	O
Glossina	O
morsitans	O
centralis	O
.	O

The	O
variations	O
were	O
caused	O
by	O
opposite	O
shifts	O
in	O
TSH	B-GENE
frequency	O
distribution	O
in	O
mothers	O
and	O
neonates	O
.	O

Cells	O
containing	O
alpha	O
subunits	O
that	O
lacked	O
a	O
distal	O
domain	O
(	O
term	O
-	O
3	O
)	O
or	O
had	O
the	O
alternatively	O
spliced	O
alpha	O
-	O
2	O
distal	O
domain	O
showed	O
markedly	O
decreased	O
ability	O
to	O
support	O
tyrosine	O
phosphorylation	O
of	O
Jak	B-GENE
-	I-GENE
2	I-GENE
and	O
its	O
substrates	O
or	O
to	O
up	O
-	O
regulate	O
CD86	B-GENE
.	O

Clinical	O
and	O
biological	O
correlates	O
of	O
panic	O
states	O
.	O

Finally	O
,	O
the	O
mechanism	O
of	O
ASK1	B-GENE
activation	O
involves	O
,	O
in	O
part	O
,	O
homo	O
-	O
oligomerization	O
.	O

Also	O
,	O
the	O
human	B-GENE
glycoprotein	I-GENE
alpha	I-GENE
-	I-GENE
subunit	I-GENE
promoter	I-GENE
was	O
induced	O
10	O
-	O
fold	O
by	O
FSK	B-GENE
in	O
GH4	O
rat	O
pituitary	O
cells	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

The	O
differential	O
investigation	O
of	O
lipoproteins	O
,	O
however	O
,	O
showed	O
that	O
the	O
high	B-GENE
-	I-GENE
density	I-GENE
lipoprotein	I-GENE
(	O
HDL	B-GENE
)	O
fractions	O
are	O
absolutely	O
or	O
relatively	O
decreased	O
with	O
respect	O
to	O
low	B-GENE
-	I-GENE
density	I-GENE
lipoproteins	I-GENE
(	O
LDL	B-GENE
)	O
in	O
cerebral	O
infarcts	O
and	O
in	O
transient	O
ischaemic	O
attacks	O
.	O

The	O
mean	O
weight	O
and	O
height	O
velocities	O
were	O
148	O
%	O
and	O
122	O
%	O
of	O
the	O
standard	O
,	O
respectively	O
.	O

Using	O
autoantibodies	O
from	O
a	O
Sjogren	O
'	O
s	O
syndrome	O
patient	O
,	O
we	O
have	O
previously	O
identified	O
a	O
230	O
-	O
kDa	O
peripheral	O
membrane	O
protein	O
associated	O
with	O
the	O
cytosolic	O
face	O
of	O
the	O
trans	O
-	O
Golgi	O
(	O
Kooy	O
,	O
J	O
.	O
,	O
Toh	O
,	O
B	O
.	O

The	O
need	O
in	O
the	O
small	O
hospital	O
.	O

3	O
.	O

The	O
used	O
expression	O
system	O
could	O
allow	O
to	O
produce	O
mutated	O
forms	O
of	O
SsEF	B-GENE
-	I-GENE
2	I-GENE
obtained	O
by	O
mutagenesis	O
of	O
the	O
corresponding	O
gene	O
.	O

Statistics	O
of	O
the	O
past	O
5	O
years	O

Mucosal	O
application	O
of	O
NCX	O
-	O
4016	O
,	O
however	O
,	O
did	O
not	O
cause	O
PD	O
reduction	O
and	O
luminal	O
H	O
+	O
loss	O
,	O
but	O
produced	O
a	O
marked	O
hyperemia	O
,	O
resulting	O
in	O
no	O
damage	O
in	O
the	O
stomach	O
of	O
both	O
normal	O
and	O
STZ	O
-	O
diabetic	O
rats	O
.	O

The	O
RNA	O
-	O
binding	O
and	O
RNA	B-GENE
-	I-GENE
DNA	I-GENE
helicase	I-GENE
activities	O
of	O
the	O
Escherichia	B-GENE
coli	I-GENE
transcription	I-GENE
termination	I-GENE
factor	I-GENE
rho	I-GENE
have	O
been	O
investigated	O
using	O
natural	O
RNA	O
molecules	O
that	O
are	O
255	O
and	O
391	O
nucleotide	O
residues	O
in	O
length	O
and	O
that	O
contain	O
the	O
trp	B-GENE
t	I-GENE
'	I-GENE
rho	I-GENE
-	I-GENE
dependent	I-GENE
termination	I-GENE
sequence	I-GENE
of	O
E	O
.	O
coli	O
.	O

The	O
resulting	O
integrated	O
physical	O
,	O
genetic	O
,	O
and	O
cytogenetic	O
map	O
constitutes	O
a	O
resource	O
for	O
the	O
characterization	O
of	O
genes	O
that	O
may	O
be	O
involved	O
in	O
the	O
WAGR	O
syndrome	O
.	O

L	O
.	O
,	O
Greer	O
,	O
J	O
.	O

&	O
Carter	O
,	O
G	O
.	O

Lithium	O
phthalocyanine	O
(	O
LiPc	O
)	O
is	O
a	O
prototype	O
of	O
another	O
generation	O
of	O
synthetic	O
,	O
metallic	O
-	O
organic	O
,	O
paramagnetic	O
crystallites	O
that	O
appear	O
very	O
useful	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
electron	O
paramagnetic	O
resonance	O
oximetry	O
.	O

Rats	O
with	O
one	O
olfactory	O
bulb	O
removed	O
and	O
the	O
contralateral	O
naris	O
closed	O
can	O
detect	O
odors	O
.	O

The	O
H	O
-	O
reflex	O
recovery	O
curve	O
was	O
obtained	O
after	O
stimulation	O
of	O
the	O
median	O
nerve	O
at	O
the	O
elbow	O
and	O
recording	O
from	O
the	O
flexor	O
carpi	O
radialis	O
.	O

Recruitment	O
of	O
an	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
complex	I-GENE
is	O
mediated	O
by	O
the	O
constitutive	O
activation	O
domain	O
in	O
CREB	B-GENE
,	O
independently	O
of	O
CREB	B-GENE
phosphorylation	O
.	O

Promoter	O
activity	O
was	O
high	O
in	O
cell	O
lines	O
that	O
expressed	O
high	O
levels	O
of	O
endogenous	O
D3	B-GENE
mRNA	I-GENE
,	O
as	O
indicated	O
by	O
Northern	O
blot	O
analyses	O
,	O
and	O
was	O
significantly	O
reduced	O
when	O
the	O
promoter	O
was	O
truncated	O
to	O
-	O
122	O
bp	O
.	O

Antimicrobial	O
substance	O
isolated	O
from	O
an	O
acorn	O
extract	O
.	O

Caries	O
and	O
parodontitis	O
have	O
been	O
one	O
of	O
the	O
most	O
spread	O
diseases	O
of	O
mankind	O
.	O

The	O
mean	O
values	O
of	O
the	O
first	O
three	O
components	O
were	O
not	O
significantly	O
different	O
in	O
ARVD	O
patients	O
and	O
control	O
subjects	O
.	O

WRN	B-GENE
helicase	I-GENE
resolves	O
alternate	O
DNA	O
structures	O
including	O
tetraplex	O
and	O
triplex	O
DNA	O
,	O
and	O
Holliday	O
junctions	O
.	O

BCL	B-GENE
-	I-GENE
2	I-GENE
,	O
an	O
inhibitor	O
of	O
apoptosis	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
,	O
has	O
been	O
reported	O
to	O
prevent	O
oxidative	O
stress	O
-	O
induced	O
cell	O
death	O
.	O

Selective	O
translation	O
initiation	O
by	O
ribosome	O
jumping	O
in	O
adenovirus	O
-	O
infected	O
and	O
heat	O
-	O
shocked	O
cells	O
.	O

Biol	O
.	O

One	O
RNA	O
construct	O
which	O
consisted	O
of	O
112	O
nucleotides	O
(	O
nt	O
)	O
from	O
nt	O
639	O
to	O
nt	O
750	O
formed	O
a	O
heterodimeric	O
complex	O
with	O
the	O
RNA	O
which	O
consisted	O
of	O
200	O
nucleotides	O
from	O
nt	O
551	O
to	O
nt	O
750	O
.	O

These	O
RZR	B-GENE
subtypes	O
represent	O
members	O
of	O
a	O
new	O
family	O
of	O
orphan	B-GENE
nuclear	I-GENE
receptors	I-GENE
that	O
most	O
likely	O
regulate	O
specific	O
gene	O
expression	O
.	O

Primary	O
adrenal	O
hypersensitivity	O
to	O
ACTH	B-GENE
drive	O
in	O
obesity	O
has	O
also	O
been	O
suggested	O
.	O

Downregulation	O
of	O
FUS	B-GENE
expression	O
in	O
BCR	B-GENE
/	O
ABL	B-GENE
-	O
expressing	O
32Dcl3	O
cells	O
was	O
associated	O
with	O
suppression	O
of	O
growth	O
factor	O
-	O
independent	O
colony	O
formation	O
,	O
restoration	O
of	O
G	B-GENE
-	I-GENE
CSF	I-GENE
-	O
induced	O
granulocytic	O
differentiation	O
and	O
reduced	O
tumorigenic	O
potential	O
in	O
vivo	O
.	O

We	O
have	O
overexpressed	O
,	O
purified	O
,	O
characterized	O
,	O
and	O
crystallized	O
the	O
BTB	B-GENE
/	O
POZ	O
domain	O
from	O
PLZF	B-GENE
(	O
PLZF	B-GENE
-	O
BTB	B-GENE
/	O
POZ	O
)	O
.	O

As	O
such	O
the	O
findings	O
support	O
existing	O
studies	O
that	O
have	O
identified	O
given	O
social	O
characteristics	O
of	O
drink	O
drivers	O
.	O

Increase	O
in	O
urinary	O
calcium	O
and	O
oxalate	O
after	O
fructose	O
infusion	O
.	O

Wherever	O
the	O
site	O
of	O
the	O
conditioning	O
stimulation	O
,	O
these	O
modifications	O
disappeared	O
after	O
ischaemia	O
of	O
the	O
leg	O
.	O

The	O
roxithromycin	O
doses	O
that	O
were	O
chosen	O
for	O
these	O
studies	O
were	O
less	O
than	O
achievable	O
blood	O
levels	O
.	O

Transformation	O
of	O
the	O
sconC3	B-GENE
mutant	I-GENE
with	O
sconB	B-GENE
+	I-GENE
restores	O
the	O
wild	O
-	O
type	O
phenotype	O
.	O

The	O
muscles	O
from	O
the	O
ischemic	O
group	O
had	O
significantly	O
lower	O
(	O
P	O
less	O
than	O
.	O
05	O
)	O
values	O
for	O
capillary	O
density	O
and	O
capillary	O
to	O
fiber	O
ratio	O
and	O
significantly	O
higher	O
intercapillary	O
distance	O
than	O
those	O
from	O
the	O
normal	O
group	O
.	O

Discrimination	O
between	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
showed	O
evidence	O
for	O
the	O
presence	O
of	O
HIV	O
-	O
1	O
only	O
.	O

Molecular	O
cloning	O
and	O
sequencing	O
of	O
a	O
cDNA	O
encoding	O
SR	B-GENE
beta	I-GENE
revealed	O
that	O
SR	B-GENE
beta	I-GENE
is	O
a	O
transmembrane	O
protein	O
and	O
,	O
like	O
SR	B-GENE
alpha	I-GENE
and	O
SRP54	B-GENE
,	O
is	O
a	O
member	O
of	O
the	O
GTPase	B-GENE
superfamily	I-GENE
.	O

The	O
bearing	O
of	O
season	O
and	O
sequence	O
of	O
calving	O
on	O
frequency	O
of	O
male	O
,	O
female	O
and	O
total	O
calvings	O
in	O
Hariana	O
cows	O
.	O

On	O
the	O
other	O
hand	O
,	O
hepatic	O
arterial	O
infusion	O
therapy	O
prolongs	O
the	O
survival	O
of	O
H3	O
patients	O
only	O
.	O

5	O
micrograms	O
/	O
l	O
was	O
detected	O
in	O
urine	O
from	O
some	O
non	O
-	O
occupationally	O
exposed	O
persons	O
.	O

The	O
Babcock	O
Surgical	O
Clinic	O
.	O

The	O
plant	O
hormone	O
auxin	O
transcriptionally	O
activates	O
early	B-GENE
genes	I-GENE
.	O

This	O
sequence	O
,	O
Thr	O
-	O
Gly	O
-	O
X	O
-	O
X	O
-	O
Gly	O
-	O
Asp	O
-	O
Gly	O
-	O
Lys	O
-	O
Ile	O
-	O
Phe	O
,	O
forms	O
part	O
of	O
the	O
B	O
-	O
loop	O
and	O
is	O
conserved	O
in	O
a	O
wide	O
variety	O
of	O
organisms	O
that	O
include	O
bacteria	O
,	O
algae	O
and	O
archeabacteria	O
.	O

Study	O
of	O
antinuclear	O
autoantibodies	O
by	O
immunofluorescence	O
technic	O
in	O
collagen	B-GENE
diseases	O

Interestingly	O
,	O
continuation	O
of	O
the	O
interferon	B-GENE
therapy	O
in	O
the	O
presence	O
of	O
a	O
mild	O
-	O
to	O
-	O
moderate	O
exacerbation	O
of	O
sarcoidosis	O
may	O
be	O
safe	O
in	O
a	O
minority	O
of	O
patients	O
with	O
noncritical	O
organ	O
involvement	O
.	O

Resistance	O
to	O
the	O
simulated	O
physiologic	O
environment	O
was	O
tested	O
by	O
measured	O
retention	O
of	O
mechanical	O
properties	O
after	O
immersion	O
times	O
in	O
pseudo	O
-	O
extracellular	O
fluid	O
(	O
PECF	O
)	O
at	O
37	O
degrees	O
C	O
for	O
as	O
long	O
as	O
three	O
years	O
.	O

The	O
recombinant	O
protein	O
was	O
purified	O
to	O
homogeneity	O
by	O
(	O
NH4	O
)	O
2SO4	O
-	O
precipitation	O
and	O
affinity	O
chromatography	O
on	O
5	O
'	O
AMP	O
-	O
Sepharose	O
.	O

Three	O
of	O
the	O
short	O
ORFs	O
in	O
the	O
central	O
region	O
of	O
BIV	O
have	O
been	O
identified	O
by	O
location	O
and	O
structural	O
similarity	O
to	O
the	O
nonstructural	O
/	O
regulatory	O
genes	O
(	O
vif	B-GENE
,	O
tat	B-GENE
,	O
and	O
rev	B-GENE
)	O
of	O
other	O
lentiviruses	O
;	O
we	O
also	O
discovered	O
two	O
unique	O
ORFs	O
,	O
termed	O
W	O
and	O
Y	O
,	O
which	O
may	O
serve	O
as	O
exons	O
for	O
novel	O
genes	O
.	O

Oseltamivir	O
(	O
GS4104	O
)	O
,	O
which	O
can	O
be	O
administered	O
orally	O
,	O
is	O
the	O
prodrug	O
of	O
GS4071	O
,	O
a	O
potent	O
and	O
selective	O
inhibitor	O
of	O
influenzavirus	B-GENE
neuraminidases	I-GENE
.	O

(	O
2	O
)	O
Erythroid	O
32D	O
Epo1	B-GENE
cells	O
showed	O
a	O
lower	O
level	O
of	O
bulk	O
PKC	B-GENE
catalytic	O
activity	O
,	O
lacked	O
the	O
expression	O
of	O
epsilon	B-GENE
and	I-GENE
eta	I-GENE
PKC	I-GENE
isoforms	I-GENE
,	O
and	O
showed	O
a	O
weak	O
or	O
absent	O
upregulation	O
of	O
the	O
remaining	O
isoforms	O
,	O
except	O
betaI	B-GENE
,	O
upon	O
readdition	O
of	O
Epo	B-GENE
to	O
growth	O
factor	O
-	O
starved	O
cells	O
.	O

However	O
,	O
as	O
determined	O
by	O
PCR	O
with	O
primers	O
specific	O
for	O
the	O
26	O
-	O
kDa	O
product	O
,	O
the	O
majority	O
of	O
cats	O
at	O
2	O
and	O
4	O
weeks	O
p	O
.	O
t	O
.	O
had	O
gastric	O
fluid	O
samples	O
which	O
were	O
positive	O
for	O
H	O
.	O
pylori	O
and	O
three	O
of	O
three	O
cats	O
at	O
2	O
weeks	O
p	O
.	O
t	O
.	O
had	O
dental	O
plaque	O
which	O
was	O
positive	O
for	O
H	O
.	O
pylori	O
.	O

SNAC	O
or	O
PBS	O
was	O
infused	O
for	O
6	O
.	O
5	O
h	O
,	O
beginning	O
30	O
min	O
before	O
ischemia	O
and	O
continuing	O
throughout	O
the	O
duration	O
of	O
reperfusion	O
.	O

Removal	O
of	O
the	O
GST	B-GENE
domain	I-GENE
from	O
GST	B-GENE
-	O
Tax	B-GENE
by	O
thrombin	B-GENE
restores	O
Tax	B-GENE
'	O
s	O
ability	O
to	O
assemble	O
a	O
ternary	O
Tax	B-GENE
-	O
CREB	B-GENE
-	O
21	O
-	O
bp	O
-	O
repeat	O
complex	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Previous	O
work	O
has	O
shown	O
that	O
spleen	B-GENE
necrosis	I-GENE
virus	I-GENE
(	I-GENE
SNV	I-GENE
)	I-GENE
long	I-GENE
terminal	I-GENE
repeats	I-GENE
(	O
LTRs	O
)	O
are	O
associated	O
with	O
Rex	B-GENE
/	O
Rex	B-GENE
-	O
responsive	O
element	O
-	O
independent	O
expression	O
of	O
bovine	O
leukemia	O
virus	O
RNA	O
and	O
supports	O
the	O
hypothesis	O
that	O
SNV	O
RNA	O
contains	O
a	O
cis	O
-	O
acting	O
element	O
that	O
interacts	O
with	O
cellular	B-GENE
Rex	I-GENE
-	I-GENE
like	I-GENE
proteins	I-GENE
.	O

Early	O
disagnosis	O
of	O
cancer	O
-	O
-	O
50	O
per	O
cent	O
of	O
all	O
patients	O
could	O
be	O
cured	O

In	O
the	O
normal	O
,	O
basal	O
(	O
unstimulated	O
)	O
condition	O
there	O
were	O
no	O
significant	O
correlations	O
(	O
p	O
greater	O
than	O
0	O
.	O
05	O
)	O
between	O
the	O
systolic	O
blood	O
pressure	O
and	O
dopamine	O
(	O
r	O
=	O
0	O
.	O
09	O
)	O
,	O
norepinephrine	O
(	O
r	O
=	O
0	O
.	O
26	O
)	O
,	O
or	O
epinephrine	O
(	O
r	O
=	O
0	O
.	O
27	O
)	O
,	O
nor	O
were	O
there	O
significant	O
correlations	O
between	O
melatonin	O
and	O
dopamine	O
(	O
r	O
=	O
-	O
0	O
.	O
01	O
)	O
,	O
norepinephrine	O
(	O
r	O
=	O
-	O
0	O
.	O
26	O
)	O
,	O
or	O
growth	B-GENE
hormone	I-GENE
(	O
r	O
=	O
0	O
.	O
17	O
)	O
.	O

We	O
propose	O
that	O
the	O
technique	O
of	O
low	O
-	O
frequency	O
kindling	O
is	O
a	O
useful	O
experimental	O
model	O
in	O
assessing	O
the	O
effects	O
of	O
antipsychotic	O
or	O
antiepileptic	O
drugs	O
on	O
the	O
excitability	O
of	O
the	O
limbic	O
regions	O
.	O

desmethyltrimebutine	O
was	O
inactive	O
.	O

RANTES	B-GENE
(	O
regulated	B-GENE
upon	I-GENE
activation	I-GENE
,	I-GENE
normally	I-GENE
T	I-GENE
-	I-GENE
cell	I-GENE
expressed	I-GENE
and	I-GENE
presumably	I-GENE
secreted	I-GENE
)	O
is	O
a	O
CC	O
chemokine	O
which	O
recruits	O
and	O
activates	O
monocytes	O
,	O
lymphocytes	O
,	O
and	O
eosinophils	O
,	O
all	O
cell	O
types	O
present	O
in	O
the	O
lung	O
inflammatory	O
infiltrate	O
induced	O
by	O
RSV	O
infection	O
.	O

We	O
describe	O
a	O
case	O
of	O
acetaminophen	O
overdose	O
that	O
was	O
treated	O
with	O
both	O
hemodialysis	O
(	O
HD	O
)	O
and	O
NAC	O
due	O
to	O
severe	O
intoxication	O
and	O
slow	O
drug	O
clearance	O
.	O

A	O
method	O
for	O
the	O
simultaneous	O
determination	O
of	O
de	O
(	O
N	O
-	O
methyl	O
)	O
-	O
N	O
-	O
ethyl	O
-	O
8	O
,	O
9	O
-	O
anhydroerythromycin	O
A	O
6	O
,	O
9	O
-	O
hemiacetal	O
(	O
EM523	O
,	O
I	O
)	O
and	O
its	O
three	O
metabolites	O
in	O
human	O
plasma	O
and	O
urine	O
has	O
been	O
developed	O
using	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
with	O
chemiluminescence	O
(	O
CL	O
)	O
detection	O
.	O

The	O
major	O
promoter	O
responds	O
strongly	O
to	O
virus	O
-	O
encoded	O
trans	O
activators	O
EIA	B-GENE
and	O
EIV	B-GENE
and	O
contains	O
four	O
elements	O
:	O
a	O
TAGA	O
motif	O
analogous	O
to	O
the	O
TATA	O
box	O
,	O
two	O
EIIF	B-GENE
sites	I-GENE
present	O
in	O
an	O
inverted	O
orientation	O
,	O
and	O
an	O
ATF	B-GENE
/	O
CREB	B-GENE
site	O
.	O

However	O
,	O
reoperation	O
for	O
bulky	O
cervical	O
disease	O
(	O
group	O
3	O
)	O
rarely	O
results	O
in	O
normal	O
calcitonin	B-GENE
levels	O
and	O
is	O
associated	O
with	O
a	O
high	O
incidence	O
of	O
permanent	O
hypoparathyroidism	O
.	O

To	O
confirm	O
the	O
GapIII	B-GENE
protein	I-GENE
activity	O
,	O
constructs	O
containing	O
different	O
GapIII	B-GENE
-	O
GRD	B-GENE
domains	O
were	O
transformed	O
into	O
iral	B-GENE
mutant	O
yeast	O
to	O
determine	O
their	O
relative	O
ability	O
to	O
replace	O
IRA1	B-GENE
functionally	O
.	O

Modification	O
of	O
the	O
growth	O
of	O
Tetrahymena	O
by	O
compounds	O
which	O
affect	O
the	O
adrenergic	O
mechanism	O
.	O

The	O
gene	O
is	O
essential	O
for	O
yeast	O
vegetative	O
growth	O
.	O

These	O
cell	O
lines	O
,	O
selected	O
for	O
the	O
ability	O
to	O
support	O
the	O
replication	O
of	O
a	O
temperature	O
-	O
sensitive	O
VP5	B-GENE
mutant	I-GENE
,	O
were	O
used	O
to	O
isolate	O
VP5	B-GENE
and	O
VP23	B-GENE
null	O
mutants	O
.	O

NF	B-GENE
-	I-GENE
kappaB	I-GENE
,	O
which	O
is	O
probably	O
important	O
for	O
basal	O
activity	O
of	O
the	O
human	B-GENE
NOS	I-GENE
II	I-GENE
promoter	I-GENE
,	O
is	O
unlikely	O
to	O
function	O
as	O
a	O
major	O
effector	O
of	O
CM	O
in	O
DLD	O
-	O
1	O
cells	O
.	O

Canalith	O
repositioning	O
is	O
the	O
mainstay	O
of	O
treatment	O
.	O

Because	O
the	O
Pit	B-GENE
-	I-GENE
1	I-GENE
sites	I-GENE
in	O
the	O
hGH	B-GENE
-	I-GENE
N	I-GENE
gene	I-GENE
promoter	I-GENE
are	O
insufficient	O
for	O
such	O
gene	O
activation	O
in	O
vivo	O
,	O
these	O
data	O
suggested	O
a	O
unique	O
chromatin	O
-	O
mediated	O
developmental	O
role	O
for	O
Pit	B-GENE
-	I-GENE
1	I-GENE
in	O
the	O
hGH	B-GENE
LCR	I-GENE
.	O

In	O
patients	O
who	O
respond	O
to	O
quetiapine	O
,	O
therapy	O
should	O
be	O
continued	O
at	O
the	O
optimal	O
dose	O
that	O
maintains	O
remission	O
,	O
within	O
the	O
range	O
of	O
150	O
to	O
750	O
mg	O
/	O
d	O
.	O

Behaviorally	O
,	O
a	O
pain	O
-	O
tolerant	O
group	O
(	O
PT	O
=	O
29	O
Ss	O
)	O
tolerated	O
the	O
entire	O
3	O
-	O
min	O
test	O
(	O
means	O
=	O
180	O
+	O
/	O
-	O
0	O
sec	O
)	O
,	O
while	O
a	O
pain	O
-	O
sensitive	O
group	O
(	O
PS	O
=	O
13	O
Ss	O
)	O
averaged	O
only	O
50	O
.	O
31	O
+	O
/	O
-	O
20	O
.	O
81	O
sec	O
of	O
the	O
cold	O
-	O
pressor	O
test	O
(	O
t	O
=	O
16	O
.	O
75	O
,	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
,	O
replicating	O
our	O
earlier	O
studies	O
.	O

V	O
.	O

A	O
triple	O
Ser	O
-	O
-	O
>	O
Ala	O
mutant	O
form	O
of	O
yeast	O
eIF	B-GENE
-	I-GENE
2	I-GENE
alpha	I-GENE
was	O
found	O
to	O
be	O
no	O
longer	O
phosphorylated	O
by	O
either	O
of	O
the	O
yeast	O
(	O
or	O
mammalian	O
)	O
casein	B-GENE
kinase	I-GENE
activities	O
in	O
vitro	O
.	O

Similar	O
observations	O
were	O
made	O
with	O
unilateral	O
pneumothorax	O
of	O
15	O
cmH2O	O
for	O
30	O
min	O
.	O

In	O
293	O
cells	O
,	O
expression	O
of	O
the	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
inhibitor	O
,	O
I	B-GENE
kappa	I-GENE
B	I-GENE
-	I-GENE
alpha	I-GENE
,	O
reduced	O
the	O
stimulatory	O
activity	O
of	O
LMP	B-GENE
.	O

The	O
E1	B-GENE
nuclear	I-GENE
transport	I-GENE
motif	I-GENE
is	O
highly	O
conserved	O
in	O
the	O
animal	O
and	O
human	O
papillomaviruses	O
and	O
is	O
encoded	O
in	O
a	O
similar	O
region	O
in	O
the	O
related	O
E1	B-GENE
genes	I-GENE
.	O

The	O
studied	O
protein	O
fragments	O
consist	O
of	O
residues	O
Arg183	O
-	O
His267	O
of	O
the	O
human	B-GENE
ER	I-GENE
and	O
residues	O
Lys438	O
-	O
Gln520	O
of	O
the	O
rat	O
GR	B-GENE
.	O

The	O
revertant	O
TATA	O
boxes	O
accelerated	O
the	O
kinetics	O
of	O
HIV	O
replication	O
when	O
present	O
in	O
the	O
context	O
of	O
an	O
LTR	O
containing	O
a	O
Sp1	B-GENE
mutation	O
(	O
deletion	O
or	O
site	O
specific	O
)	O
;	O
no	O
effect	O
was	O
observed	O
on	O
the	O
infectivity	O
of	O
wild	O
-	O
type	O
HIV	O
.	O

Basing	O
on	O
experimental	O
toxicity	O
research	O
it	O
was	O
established	O
that	O
,	O
out	O
of	O
50	O
atmosphere	O
metal	O
corrosion	O
inhibitors	O
,	O
some	O
14	O
per	O
cent	O
were	O
found	O
extremely	O
hazardous	O
,	O
42	O
per	O
cent	O
-	O
-	O
of	O
high	O
level	O
hazardous	O
,	O
33	O
percent	O
-	O
-	O
of	O
moderate	O
and	O
11	O
per	O
cent	O
-	O
-	O
of	O
low	O
hazardous	O
.	O

In	O
conclusion	O
,	O
we	O
observed	O
a	O
great	O
regeneration	O
ability	O
following	O
mechanical	O
injury	O
in	O
the	O
nasal	O
mucosa	O
.	O

In	O
11	O
patients	O
with	O
Horton	O
'	O
s	O
headache	O
morphological	O
investigations	O
(	O
differential	O
white	O
blood	O
cell	O
count	O
)	O
,	O
cytoenzymatic	O
determinations	O
(	O
alkaline	B-GENE
and	I-GENE
acid	I-GENE
phosphatase	I-GENE
,	O
non	B-GENE
-	I-GENE
specific	I-GENE
esterase	I-GENE
)	O
and	O
cytoimmunological	O
tests	O
(	O
IgM	B-GENE
and	O
IgG	B-GENE
binding	O
)	O
were	O
carried	O
out	O
on	O
capillary	O
blood	O
neutrophils	O
obtained	O
from	O
the	O
area	O
of	O
pain	O
,	O
non	O
-	O
painful	O
area	O
of	O
the	O
skin	O
on	O
the	O
head	O
on	O
the	O
contralateral	O
side	O
,	O
and	O
from	O
the	O
finger	O
.	O

A	O
vector	O
containing	O
a	O
transcriptionally	O
inactive	O
neomycin	B-GENE
phosphotransferase	I-GENE
II	I-GENE
gene	I-GENE
was	O
used	O
to	O
select	O
promoter	O
sequences	O
from	O
a	O
pool	O
of	O
random	O
genomic	O
DNA	O
fragments	O
.	O

In	O
co	O
-	O
transfection	O
studies	O
,	O
an	O
AP	B-GENE
-	I-GENE
2	I-GENE
but	O
not	O
an	O
Egr	B-GENE
-	I-GENE
1	I-GENE
expression	O
vector	O
activated	O
VPF	B-GENE
/	O
VEGF	B-GENE
transcription	O
,	O
thus	O
indicating	O
that	O
AP	B-GENE
-	I-GENE
2	I-GENE
protein	I-GENE
is	O
functionally	O
important	O
in	O
TGF	B-GENE
alpha	I-GENE
-	O
induced	O
VPF	B-GENE
/	O
VEGF	B-GENE
gene	O
expression	O
.	O

The	O
original	O
technique	O
was	O
developed	O
in	O
the	O
1960	O
'	O
s	O
to	O
analyze	O
the	O
inner	O
ear	O
fluid	O
as	O
a	O
diagnostic	O
procedure	O
(	O
i	O
.	O
e	O
.	O
,	O
diagnostic	O
labyrinthotomy	O
)	O
in	O
acoustic	O
neuroma	O
suspects	O
.	O

However	O
,	O
there	O
has	O
not	O
been	O
any	O
evidence	O
of	O
A	O
.	O
salmonicida	O
infections	O
,	O
specifically	O
furunculosis	O
,	O
associated	O
with	O
the	O
fish	O
in	O
this	O
loch	O
.	O

Thus	O
,	O
YMIP	B-GENE
is	O
a	O
functional	O
homolog	O
of	O
RMIP	B-GENE
and	O
represents	O
a	O
new	O
component	O
of	O
the	O
yeast	O
mitochondrial	O
import	O
machinery	O
.	O

Reverse	B-GENE
transcriptase	I-GENE
and	O
protease	O
activities	O
of	O
avian	O
leukosis	O
virus	O
Gag	B-GENE
-	O
Pol	B-GENE
fusion	O
proteins	O
expressed	O
in	O
insect	O
cells	O
.	O

The	O
incidence	O
of	O
cryptosporidiosis	O
in	O
young	O
children	O
was	O
determined	O
by	O
staining	O
of	O
faecal	O
specimens	O
with	O
a	O
modified	O
Kinyoun	O
stain	O
.	O

Thus	O
,	O
multiple	O
myogenic	O
factors	O
that	O
vary	O
qualitatively	O
and	O
quantitatively	O
may	O
be	O
responsible	O
for	O
the	O
different	O
and	O
complex	O
modulatory	O
programs	O
of	O
actin	B-GENE
gene	I-GENE
expression	O
observed	O
during	O
in	O
vivo	O
muscle	O
differentiation	O
.	O

The	O
codon	O
usage	O
is	O
particularly	O
marked	O
for	O
the	O
gag	B-GENE
,	O
pol	B-GENE
,	O
and	O
env	B-GENE
genes	I-GENE
.	O

All	O
patients	O
diagnosed	O
of	O
H	O
.	O
influenza	O
type	O
b	O
meningitis	O
were	O
less	O
than	O
3	O
years	O
old	O
.	O

There	O
occurred	O
a	O
linear	O
relationship	O
between	O
the	O
drop	O
in	O
glucose	B-GENE
-	I-GENE
6	I-GENE
-	I-GENE
phosphatase	I-GENE
dehydrogenase	I-GENE
activity	O
and	O
in	O
vitamin	O
E	O
level	O
,	O
on	O
one	O
hand	O
,	O
and	O
the	O
duration	O
of	O
poisoning	O
with	O
sodium	O
nitrite	O
.	O

Residues	O
removed	O
from	O
transcripts	O
by	O
splicing	O
were	O
identified	O
.	O

The	O
M	O
-	O
3	O
subtype	O
was	O
an	O
adverse	O
prognostic	O
factor	O
.	O

These	O
data	O
define	O
a	O
conserved	O
pathway	O
wherein	O
sequential	O
histone	B-GENE
modifications	O
establish	O
a	O
"	O
histone	B-GENE
code	O
"	O
essential	O
for	O
the	O
epigenetic	O
inheritance	O
of	O
heterochromatin	O
assembly	O
.	O

Five	O
-	O
year	O
prospective	O
study	O
of	O
peripheral	O
white	O
blood	O
cells	O
in	O
infectious	O
mononucleosis	O
.	O

Water	O
content	O
and	O
equilibrium	O
water	O
partition	O
in	O
immature	O
cartilage	O
.	O

Expression	O
of	O
a	O
dominant	B-GENE
-	I-GENE
negative	I-GENE
ras	I-GENE
gene	I-GENE
also	O
blocks	O
TIS10	B-GENE
/	O
PGS2	B-GENE
induction	O
by	O
v	B-GENE
-	I-GENE
src	I-GENE
.	O

(	O
1989	O
)	O
,	O
which	O
is	O
identical	O
to	O
the	O
SSC1	B-GENE
gene	I-GENE
(	O
Smith	O
et	O
al	O
.	O
,	O
1988	O
)	O
.	O

Previous	O
analysis	O
of	O
the	O
98	O
-	O
bp	O
sequence	O
has	O
delineated	O
several	O
protein	O
-	O
binding	O
domains	O
that	O
are	O
recognized	O
by	O
nuclear	O
factors	O
present	O
in	O
human	O
brain	O
cells	O
.	O

The	O
identified	O
isolates	O
of	O
CSF	O
(	O
20	O
of	O
29	O
)	O
were	O
:	O
ECHO	O
30	O
(	O
9	O
)	O
,	O
ECHO	O
11	O
(	O
7	O
)	O
,	O
ECHO	O
9	O
(	O
3	O
)	O
and	O
ECHO	O
7	O
(	O
1	O
)	O
.	O

Full	B-GENE
-	I-GENE
length	I-GENE
AT	I-GENE
-	I-GENE
PHH1	I-GENE
,	O
and	O
both	O
AT	B-GENE
-	I-GENE
PHH1	I-GENE
and	O
AT	B-GENE
-	I-GENE
PHH1	I-GENE
delta	I-GENE
C	I-GENE
-	I-GENE
513	I-GENE
(	O
truncated	O
to	O
be	O
approximately	O
the	O
size	O
of	O
microbial	B-GENE
photolyase	I-GENE
genes	I-GENE
)	O
cDNAs	O
,	O
were	O
overexpressed	O
,	O
respectively	O
,	O
in	O
yeast	O
and	O
Escherichia	O
coli	O
mutants	O
hypersensitive	O
to	O
ultraviolet	O
light	O
.	O

Naval	O
personnel	O
who	O
exceed	O
standards	O
for	O
%	O
BF	O
can	O
be	O
separated	O
from	O
active	O
duty	O
.	O

No	O
significant	O
differences	O
existed	O
between	O
the	O
two	O
age	O
groups	O
in	O
baseline	O
characteristics	O
,	O
including	O
treatment	O
protocol	O
,	O
performance	O
status	O
,	O
and	O
serum	B-GENE
lactate	I-GENE
dehydrogenase	I-GENE
(	O
LDH	B-GENE
)	O
level	O
.	O

Hepatitis	B-GENE
B	I-GENE
surface	I-GENE
antigen	I-GENE
was	O
detected	O
in	O
2	O
patients	O
,	O
with	O
negative	O
hepatitis	B-GENE
C	I-GENE
virus	I-GENE
antibody	I-GENE
.	O

The	O
presence	O
of	O
the	O
RV	O
5	O
'	O
(	O
+	O
)	O
SL	O
sequence	O
had	O
the	O
primary	O
enhancing	O
effect	O
on	O
translation	O
.	O

There	O
was	O
a	O
general	O
broadening	O
of	O
proton	O
resonances	O
for	O
a	O
three	O
-	O
nucleotide	O
segment	O
centered	O
about	O
the	O
lesion	O
site	O
which	O
resulted	O
in	O
a	O
tentative	O
assignment	O
for	O
the	O
sugar	O
protons	O
of	O
the	O
C7	O
residue	O
in	O
the	O
spectrum	O
of	O
the	O
adduct	O
duplex	O
.	O

No	O
difference	O
in	O
telomere	O
length	O
was	O
seen	O
in	O
mutants	O
affected	O
in	O
the	O
regulation	O
of	O
Cdc2	B-GENE
,	O
whereas	O
some	O
of	O
the	O
DNA	O
repair	O
mutants	O
examined	O
had	O
slightly	O
longer	O
telomeres	O
than	O
did	O
the	O
wild	O
type	O
.	O

Comparison	O
of	O
remnant	O
-	O
like	O
lipoprotein	O
particles	O
in	O
postmenopausal	O
women	O
with	O
and	O
without	O
coronary	O
artery	O
disease	O
and	O
in	O
men	O
with	O
coronary	O
artery	O
disease	O
.	O

Further	O
,	O
the	O
reduction	O
in	O
5	O
-	O
hydroxytryptophan	O
(	O
5	O
-	O
HTP	O
)	O
accumulation	O
by	O
LSD	O
showed	O
regional	O
differences	O
in	O
inhibition	O
by	O
methiothepin	O
(	O
hypothalamus	O
greater	O
than	O
cortex	O
greater	O
than	O
striatum	O
)	O
which	O
paralleled	O
the	O
autoreceptor	O
antagonist	O
activity	O
of	O
methiothepin	O
in	O
vitro	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Internal	O
modes	O
of	O
a	O
soliton	O
.	O

They	O
also	O
discuss	O
the	O
existing	O
nomenclature	O
.	O

ACE	B-GENE
-	I-GENE
2	I-GENE
has	O
a	O
hydrophobic	O
C	O
terminus	O
of	O
H	O
type	O
.	O

Umweltchem	O
.	O

The	O
gene	O
structure	O
of	O
Elk1	B-GENE
spans	O
15	O
.	O
2	O
kb	O
and	O
consists	O
of	O
seven	O
exons	O
and	O
six	O
introns	O
.	O

Northern	O
blot	O
analysis	O
of	O
total	O
cellular	O
RNA	O
indicated	O
that	O
xylP	B-GENE
encodes	O
a	O
1	O
.	O
3	O
-	O
kb	O
transcript	O
which	O
is	O
induced	O
by	O
xylan	O
.	O

Although	O
there	O
are	O
no	O
octamer	O
elements	O
in	O
the	O
adenovirus	O
genome	O
that	O
are	O
known	O
to	O
be	O
important	O
for	O
transcription	O
,	O
there	O
are	O
octamer	O
elements	O
in	O
the	O
viral	O
terminal	O
repeat	O
sequences	O
.	O

Here	O
,	O
we	O
present	O
evidence	O
that	O
exposure	O
of	O
DT40	O
lymphoma	O
B	O
cells	O
to	O
low	O
energy	O
electromagnetic	O
field	O
(	O
EMF	O
)	O
results	O
in	O
a	O
tyrosine	B-GENE
kinase	I-GENE
-	O
dependent	O
activation	O
of	O
phospholipase	B-GENE
Cgamma2	I-GENE
(	O
PLC	B-GENE
-	I-GENE
gamma2	I-GENE
)	O
leading	O
to	O
increased	O
inositol	O
phospholipid	O
turnover	O
.	O

An	O
11	O
-	O
month	O
-	O
old	O
girl	O
suffering	O
from	O
Dandy	O
-	O
Walker	O
malformation	O
(	O
DWM	O
)	O
associated	O
with	O
tetralogy	O
of	O
Fallot	O
(	O
TOF	O
)	O
is	O
presented	O
.	O

This	O
generalization	O
of	O
MFP	O
involves	O
defining	O
an	O
appropriate	O
high	O
-	O
resolution	O
cost	O
function	O
,	O
parametrizing	O
the	O
search	O
space	O
of	O
the	O
environment	O
and	O
source	O
,	O
constructing	O
solutions	O
of	O
the	O
wave	O
equation	O
,	O
and	O
utilizing	O
a	O
nonlinear	O
optimization	O
method	O
to	O
search	O
the	O
parameter	O
landscape	O
for	O
the	O
global	O
minimum	O
of	O
the	O
cost	O
function	O
.	O

A	O
dose	O
-	O
dependent	O
fall	O
in	O
GABA	O
content	O
was	O
observed	O
;	O
GABA	O
decrease	O
was	O
evident	O
15	O
min	O
after	O
the	O
administration	O
,	O
reached	O
its	O
nadir	O
at	O
60	O
min	O
and	O
disappeared	O
at	O
120	O
minutes	O
.	O

Two	O
splice	O
variants	O
of	O
ALF1	B-GENE
cDNA	I-GENE
have	O
been	O
found	O
,	O
differing	O
by	O
a	O
72	O
-	O
bp	O
insertion	O
,	O
coding	O
for	O
putative	O
proteins	O
of	O
682	O
and	O
706	O
amino	O
acids	O
.	O

Efficacy	O
of	O
cervical	O
spine	O
immobilization	O
methods	O
.	O

The	O
class	B-GENE
II	I-GENE
Escherichia	I-GENE
coli	I-GENE
alanine	I-GENE
tRNA	I-GENE
synthetase	I-GENE
aminoacylates	I-GENE
RNA	I-GENE
miniduplexes	I-GENE
,	O
which	O
reconstruct	O
the	O
acceptor	O
end	O
of	O
alanine	B-GENE
tRNA	I-GENE
with	O
the	O
critical	O
G3	O
:	O
U70	O
base	O
pair	O
.	O

Twenty	O
eligible	O
patients	O
with	O
cirrhosis	O
were	O
randomized	O
into	O
two	O
groups	O
:	O
10	O
patients	O
treated	O
with	O
6	O
million	O
units	O
of	O
natural	O
IFN	B-GENE
-	I-GENE
beta	I-GENE
twice	O
a	O
week	O
for	O
36	O
months	O
and	O
10	O
patients	O
without	O
IFN	B-GENE
therapy	O
.	O

The	O
results	O
indicate	O
that	O
hrpRS	B-GENE
and	O
hrpL	B-GENE
are	O
part	O
of	O
a	O
regulatory	O
cascade	O
in	O
which	O
HrpR	B-GENE
and	O
HrpS	B-GENE
activate	O
expression	O
of	O
hrpL	B-GENE
and	O
HrpL	B-GENE
,	O
a	O
putative	O
sigma	B-GENE
factor	I-GENE
,	O
induces	O
expression	O
of	O
HrpL	B-GENE
-	I-GENE
responsive	I-GENE
genes	I-GENE
.	O

BACKGROUND	O
:	O
The	O
c	B-GENE
-	I-GENE
myc	I-GENE
proto	I-GENE
-	I-GENE
oncogene	I-GENE
has	O
been	O
suggested	O
to	O
play	O
key	O
roles	O
in	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
transformation	O
and	O
apoptosis	O
.	O

These	O
findings	O
suggest	O
one	O
potential	O
mechanism	O
for	O
direct	O
recruitment	O
of	O
distal	O
regulatory	O
regions	O
of	O
the	O
globin	B-GENE
loci	I-GENE
to	O
the	O
individual	O
promoters	O
.	O

By	O
in	O
vitro	O
immunoprecipitations	O
and	O
gel	O
shift	O
assays	O
,	O
we	O
identified	O
two	O
classes	O
of	O
high	O
affinity	O
Engrailed	B-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
upstream	O
of	O
each	O
of	O
the	O
two	O
polyhomeotic	O
transcription	O
units	O
.	O

A	O
possible	O
role	O
for	O
the	O
mixed	O
function	O
oxidase	B-GENE
enzyme	O
system	O
in	O
the	O
requirement	O
for	O
selenium	O
in	O
the	O
rat	O
.	O

Moreover	O
,	O
the	O
hypoxia	O
-	O
induced	O
expression	O
of	O
the	O
endogenous	O
Epo	B-GENE
gene	I-GENE
was	O
significantly	O
inhibited	O
in	O
Hep3B	O
cells	O
stably	O
transfected	O
with	O
HNF	B-GENE
-	I-GENE
4	I-GENE
delta	I-GENE
C	I-GENE
.	O

The	O
general	O
transcription	B-GENE
factor	I-GENE
IIA	I-GENE
(	O
TFIIA	B-GENE
)	O
interacts	O
with	O
the	O
TATA	B-GENE
binding	I-GENE
protein	I-GENE
(	O
TBP	B-GENE
)	O
and	O
promoter	O
DNA	O
to	O
mediate	O
transcription	O
activation	O
in	O
vitro	O
.	O

Training	O
for	O
audit	O
.	O

The	O
content	O
of	O
glucosamine	O
and	O
galactosamine	O
in	O
tartar	O

ID	O
-	O
PaGIA	O
diphtheria	B-GENE
toxin	I-GENE
polymer	O
particle	O
diagnostic	O
agent	O
manufactured	O
by	O
DiaMed	O
AG	O
,	O
Switzerland	O
,	O
was	O
tried	O
at	O
bacteriological	O
laboratory	O
of	O
Institute	O
of	O
Childhood	O
Infections	O
in	O
St	O
.	O

CD4	B-GENE
lymphocyte	O
and	O
viral	O
load	O
levels	O
suggested	O
an	O
optimal	O
response	O
to	O
ARV	O
therapy	O
at	O
the	O
time	O
LD	O
developed	O
.	O

Homozygous	O
null	O
embryos	O
also	O
displayed	O
abnormalities	O
in	O
heart	O
development	O
,	O
consistent	O
with	O
the	O
conclusion	O
that	O
Tek	B-GENE
is	O
necessary	O
for	O
endocardial	O
/	O
myocardial	O
interactions	O
during	O
development	O
.	O

The	O
non	O
-	O
role	O
of	O
fluoride	O
in	O
the	O
control	O
of	O
plasma	O
calcium	O
in	O
the	O
parathyroidectomized	O
rat	O
.	O

Alternative	O
splicing	O
of	O
fibroblast	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
2	I-GENE
(	O
FGF	B-GENE
-	I-GENE
R2	I-GENE
)	O
is	O
an	O
example	O
of	O
highly	O
regulated	O
alternative	O
splicing	O
in	O
which	O
exons	O
IIIb	O
and	O
IIIc	O
are	O
utilized	O
in	O
a	O
mutually	O
exclusive	O
manner	O
in	O
different	O
cell	O
types	O
.	O

ORF	O
2	O
potentially	O
encoded	O
a	O
hydrophobic	O
protein	O
of	O
29	O
,	O
705	O
Da	O
with	O
six	O
potential	O
membrane	O
-	O
spanning	O
regions	O
.	O

Effects	O
of	O
a	O
perfluorochemical	O
blood	O
substitute	O
on	O
diazepam	O
binding	O
by	O
human	B-GENE
albumin	I-GENE
.	O

Isolation	O
of	O
cDNAs	B-GENE
encoding	I-GENE
gibbon	I-GENE
and	I-GENE
monkey	I-GENE
platelet	I-GENE
and	I-GENE
T	I-GENE
cell	I-GENE
activation	I-GENE
antigen	I-GENE
1	I-GENE
(	O
PTA1	B-GENE
)	O
.	O

Since	O
the	O
regulation	O
of	O
SWI4	B-GENE
is	O
required	O
for	O
normal	O
cell	O
cycle	O
progression	O
,	O
we	O
have	O
characterized	O
cis	O
-	O
and	O
trans	O
-	O
acting	O
regulators	O
of	O
SWI4	B-GENE
transcription	O
.	O

Liquid	O
chromatographic	O
method	O
for	O
determination	O
of	O
citreoviridin	O
in	O
corn	O
and	O
rice	O
.	O

Surprisingly	O
,	O
there	O
is	O
no	O
sequence	O
homology	O
between	O
this	O
region	O
of	O
Ly	B-GENE
-	I-GENE
6E	I-GENE
and	O
the	O
established	O
consensus	O
for	O
the	O
interferon	B-GENE
-	I-GENE
stimulated	I-GENE
response	I-GENE
element	I-GENE
,	O
which	O
has	O
been	O
shown	O
functionally	O
important	O
to	O
all	O
previously	O
characterized	O
alpha	B-GENE
/	I-GENE
beta	I-GENE
interferon	I-GENE
-	O
inducible	O
promoters	O
.	O

ICAM	B-GENE
-	I-GENE
1	I-GENE
has	O
been	O
suggested	O
a	O
predictor	O
of	O
the	O
onset	O
of	O
GO	O
.	O

Adjacent	O
to	O
those	O
lesions	O
,	O
and	O
in	O
homologous	O
contralateral	O
structures	O
,	O
FMZ	O
binding	O
was	O
analysed	O
in	O
four	O
pairs	O
of	O
cortical	O
9	O
x	O
9	O
-	O
mm	O
regions	O
of	O
interest	O
(	O
ROIs	O
)	O
placed	O
on	O
transaxial	O
and	O
coronal	O
slices	O
,	O
respectively	O
,	O
as	O
well	O
as	O
in	O
the	O
lesion	O
volume	O
and	O
its	O
mirror	O
region	O
.	O

In	O
the	O
SPK	O
and	O
PTA	O
category	O
,	O
anti	O
-	O
T	O
-	O
cell	O
therapy	O
significantly	O
lowered	O
the	O
risk	O
of	O
graft	O
loss	O
.	O

These	O
changes	O
in	O
virus	O
entry	O
features	O
may	O
result	O
in	O
coronaviruses	O
with	O
novel	O
pathogenic	O
properties	O
.	O

In	O
the	O
present	O
article	O
,	O
the	O
causes	O
of	O
death	O
or	O
ill	O
-	O
being	O
as	O
found	O
in	O
10	O
consecutive	O
carcinogenicity	O
studies	O
-	O
-	O
5	O
studies	O
with	O
2400	O
OFA	O
(	O
Sprague	O
-	O
Dawley	O
-	O
derived	O
)	O
and	O
Wistar	O
rats	O
and	O
5	O
studies	O
with	O
2400	O
OF1	O
and	O
NMRI	O
mice	O
-	O
-	O
were	O
re	O
-	O
examined	O
.	O

Analysis	O
of	O
lacZ	B-GENE
transcriptional	I-GENE
fusions	I-GENE
shows	O
that	O
the	O
KdgR	B-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
negatively	O
affect	O
the	O
expression	O
of	O
rsmB	B-GENE
.	O

Many	O
factors	O
do	O
influence	O
the	O
educational	O
outcome	O
in	O
students	O
and	O
large	O
statistical	O
power	O
(	O
such	O
as	O
meta	O
analysis	O
)	O
should	O
be	O
helpful	O
to	O
eliminate	O
many	O
sources	O
of	O
error	O
.	O

The	O
relation	O
between	O
myocardial	B-GENE
beta	I-GENE
-	I-GENE
adrenergic	I-GENE
receptor	I-GENE
and	O
left	O
ventricular	O
(	O
LV	O
)	O
function	O
was	O
studied	O
in	O
10	O
patients	O
,	O
aged	O
41	O
to	O
61	O
years	O
(	O
average	O
51	O
)	O
,	O
with	O
LV	O
volume	O
overload	O
mainly	O
due	O
to	O
chronic	O
mitral	O
regurgitation	O
.	O

In	O
transient	O
cotransfection	O
assays	O
using	O
Chang	O
liver	O
cells	O
(	O
CCL	O
13	O
)	O
,	O
pM1	O
DNA	O
exerts	O
a	O
6	O
-	O
to	O
10	O
-	O
fold	O
trans	O
-	O
activating	O
effect	O
on	O
the	O
expression	O
of	O
the	O
pSV2CAT	O
reporter	O
plasmid	O
.	O

As	O
expected	O
,	O
the	O
insulin	B-GENE
effect	O
to	O
increase	O
ras	B-GENE
GTP	I-GENE
formation	O
and	O
MAP	B-GENE
kinase	I-GENE
activity	O
was	O
negligible	O
in	O
A	O
/	O
K1018	O
cells	O
but	O
normal	O
,	O
or	O
supernormal	O
,	O
in	O
Y	O
/	O
F2	O
cells	O
.	O

Expression	O
of	O
the	O
human	O
T	B-GENE
cell	I-GENE
receptor	I-GENE
(	I-GENE
TCR	I-GENE
)	I-GENE
alpha	I-GENE
gene	I-GENE
is	O
regulated	O
by	O
a	O
T	O
cell	O
-	O
specific	O
transcriptional	O
enhancer	O
that	O
is	O
located	O
4	O
.	O
5	O
kilobases	O
(	O
kb	O
)	O
3	O
'	O
to	O
the	O
C	B-GENE
alpha	I-GENE
gene	I-GENE
segment	I-GENE
.	O

I	O
report	O
here	O
that	O
induction	O
of	O
HSP82	B-GENE
is	O
regulated	O
by	O
the	O
early	O
meiotic	O
IME1	B-GENE
-	O
IME2	B-GENE
transcriptional	O
cascade	O
.	O

This	O
report	O
substantiates	O
that	O
at	O
least	O
two	O
of	O
the	O
18	O
kDa	O
hsps	B-GENE
in	O
maize	O
are	O
products	O
of	O
different	O
but	O
related	O
genes	O
.	O

Ga	O
-	O
67	O
and	O
Tl	O
-	O
201	O
scintigraphy	O
in	O
extramedullary	O
plasmacytoma	O
:	O
a	O
case	O
report	O
.	O

Oligonucleotide	O
competitors	O
were	O
used	O
to	O
evaluate	O
the	O
accessibility	O
of	O
the	O
TATA	O
-	O
binding	O
site	O
in	O
TIF	B-GENE
-	I-GENE
IB	I-GENE
,	O
TFIID	B-GENE
,	O
and	O
TFIIIB	B-GENE
.	O

The	O
findings	O
suggest	O
that	O
,	O
although	O
iodine	O
deficiency	O
is	O
the	O
most	O
probable	O
cause	O
of	O
goiter	O
among	O
immigrants	O
of	O
the	O
1928	O
cohort	O
,	O
where	O
the	O
native	O
population	O
is	O
concerned	O
(	O
both	O
men	O
and	O
women	O
)	O
,	O
some	O
other	O
goitrogenic	O
factor	O
(	O
s	O
)	O
must	O
be	O
involved	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
case	O
in	O
which	O
a	O
probable	O
association	O
between	O
cholelithiasis	O
and	O
Wildervanck	O
'	O
s	O
syndrome	O
has	O
been	O
recorded	O
.	O

Schistosoma	O
mansoni	O
schistosomiasis	O
]	O
Schistosomosis	O
are	O
parasitic	O
diseases	O
caused	O
by	O
blood	O
flukes	O
of	O
the	O
Schistosoma	O
genus	O
.	O

Our	O
data	O
,	O
however	O
,	O
did	O
not	O
suggest	O
the	O
existence	O
of	O
a	O
conversion	O
factor	O
for	O
LDF	O
signal	O
to	O
absolute	O
flow	O
values	O
from	O
experiment	O
to	O
experiment	O
.	O

Insertion	O
of	O
short	O
oligonucleotides	O
encoding	O
the	O
basic	O
amino	O
acid	O
motifs	O
726	O
-	O
GRKRKSP	O
-	O
732	O
from	O
IE175	B-GENE
and	O
500	O
-	O
VRPRKRR	O
-	O
506	O
from	O
IE110	B-GENE
into	O
deleted	O
cytoplasmic	O
forms	O
of	O
the	O
two	O
proteins	O
restored	O
the	O
karyophilic	O
phenotype	O
and	O
confirmed	O
that	O
these	O
motifs	O
are	O
both	O
necessary	O
and	O
sufficient	O
for	O
proper	O
nuclear	O
localization	O
.	O

Control	O
examination	O
was	O
performed	O
at	O
the	O
end	O
of	O
each	O
period	O
.	O

Addition	O
of	O
phalloidin	O
-	O
stabilized	O
F	B-GENE
-	I-GENE
actin	I-GENE
nuclei	O
and	O
phalloidin	O
restored	O
L266D	O
actin	B-GENE
'	O
s	O
ability	O
to	O
polymerize	O
at	O
4	O
degrees	O
C	O
.	O

The	O
protein	O
product	O
of	O
orfD	B-GENE
,	O
which	O
is	O
probably	O
a	O
new	O
tra	B-GENE
gene	I-GENE
(	O
named	O
traX	B-GENE
)	O
,	O
contains	O
65	O
%	O
hydrophobic	O
amino	O
acids	O
,	O
especially	O
rich	O
in	O
alanine	O
and	O
leucine	O
.	O

Pure	O
T1	O
and	O
dual	O
-	O
T1	O
images	O
were	O
visually	O
evaluated	O
for	O
image	O
quality	O
(	O
IQ	O
)	O
on	O
a	O
five	O
-	O
point	O
scale	O
(	O
0	O
=	O
unacceptable	O
to	O
4	O
=	O
excellent	O
)	O
.	O

The	O
Thr161Val	O
mutation	O
causes	O
a	O
lethal	O
phenotype	O
in	O
the	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
,	O
while	O
replacement	O
of	O
Thr161	O
with	O
glutamic	O
acid	O
,	O
potentially	O
mimicking	O
phosphorylation	O
,	O
causes	O
uncoordination	O
of	O
mitosis	O
and	O
multiple	O
cytokinesis	O
.	O

The	O
effect	O
of	O
hydrostatic	O
pressure	O
on	O
the	O
swimming	O
activity	O
of	O
three	O
hyponeustonic	O
crustacea	O
,	O
Anomalocera	O
patersoni	O
,	O
Pontella	O
mediterranea	O
,	O
Labidocera	O
wollastoni	O

Animals	O
were	O
put	O
to	O
death	O
8	O
weeks	O
later	O
and	O
the	O
grafts	O
were	O
sterilely	O
explanted	O
and	O
analyzed	O
via	O
microbiologic	O
culture	O
and	O
standard	O
histologic	O
procedures	O
for	O
evidence	O
of	O
infection	O
.	O

Recently	O
,	O
roles	O
also	O
have	O
been	O
suggested	O
for	O
the	O
nuclear	O
trans	O
-	O
factor	O
GATA	B-GENE
-	I-GENE
1	I-GENE
in	O
regulating	O
progenitor	O
cell	O
proliferation	O
.	O

Six	O
distinct	O
Ets	B-GENE
mRNAs	I-GENE
were	O
identified	O
:	O
Ets2	B-GENE
,	O
Fli1	B-GENE
,	O
GABPalpha	B-GENE
,	O
SAP1	B-GENE
,	O
Elk1	B-GENE
,	O
and	O
PE1	B-GENE
.	O

During	O
the	O
observation	O
period	O
of	O
0	O
.	O
4	O
-	O
30	O
weeks	O
,	O
cardiac	O
white	O
spots	O
on	O
the	O
right	O
ventricle	O
of	O
BALB	O
/	O
c	O
mice	O
were	O
first	O
detected	O
at	O
three	O
weeks	O
(	O
6	O
of	O
20	O
mice	O
;	O
30	O
%	O
)	O
,	O
and	O
the	O
maximal	O
incidence	O
of	O
cardiac	O
white	O
spots	O
was	O
obtained	O
at	O
nine	O
weeks	O
(	O
39	O
of	O
44	O
mice	O
;	O
88	O
%	O
)	O
.	O

The	O
early	O
dg	O
.	O
of	O
rejection	O
and	O
especially	O
acute	O
rejection	O
,	O
it	O
'	O
s	O
adequate	O
management	O
,	O
decreased	O
risk	O
for	O
the	O
future	O
chronic	O
rejection	O
nephropathy	O
.	O

These	O
two	O
repeat	O
motifs	O
are	O
organized	O
in	O
an	O
extremely	O
well	O
-	O
ordered	O
pattern	O
in	O
each	O
domain	O
,	O
which	O
suggests	O
that	O
SbHRGP3	B-GENE
belongs	O
to	O
a	O
new	O
group	O
of	O
proteins	O
having	O
the	O
repeat	O
motifs	O
of	O
two	O
distinct	O
groups	O
of	O
dicot	B-GENE
extensins	I-GENE
.	O

Allergic	O
reaction	O
to	O
Patent	O
Blue	O
Violet	O
during	O
lymphography	O
.	O

Naphthalene	O
and	O
paradichlorobenzene	O
in	O
clinical	O
toxicology	O

The	O
most	O
important	O
one	O
among	O
them	O
is	O
Cyclosporin	O
A	O
,	O
which	O
is	O
a	O
selective	O
immunosuppressive	O
drug	O
.	O

Both	O
NUP98	B-GENE
-	O
HOXA9	B-GENE
chimeras	O
transformed	O
NIH	O
3T3	O
fibroblasts	O
,	O
and	O
this	O
transformation	O
required	O
the	O
HOXA9	B-GENE
domains	I-GENE
for	O
DNA	O
binding	O
and	O
PBX	B-GENE
interaction	O
.	O

RESULTS	O
:	O
Patients	O
in	O
Group	O
A	O
had	O
a	O
higher	O
incidence	O
of	O
posterolateral	O
wall	O
motion	O
abnormalities	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
on	O
radionuclide	O
ventriculography	O
,	O
a	O
larger	O
infarct	O
area	O
(	O
as	O
evidenced	O
by	O
higher	O
peak	O
creatine	B-GENE
kinase	I-GENE
levels	O
)	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
and	O
a	O
lower	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
at	O
hospital	O
discharge	O
(	O
p	O
<	O
0	O
.	O
008	O
)	O
than	O
those	O
in	O
Group	O
B	O
.	O

The	O
MSL	B-GENE
complex	I-GENE
is	O
specifically	O
localized	O
on	O
the	O
male	O
X	O
chromosome	O
to	O
increase	O
its	O
expression	O
approximately	O
2	O
-	O
fold	O
.	O

The	O
Pro	O
-	O
258	O
-	O
-	O
>	O
Leu	O
(	O
P258L	O
)	O
mutation	O
caused	O
constitutive	O
receptor	O
signaling	O
that	O
was	O
equivalent	O
to	O
about	O
45	O
%	O
of	O
the	O
maximum	O
level	O
observed	O
in	O
wild	O
-	O
type	O
cells	O
stimulated	O
with	O
alpha	B-GENE
-	I-GENE
factor	I-GENE
.	O

However	O
,	O
cotransfection	O
studies	O
indicate	O
that	O
RVR	B-GENE
does	O
not	O
activate	O
transcription	O
when	O
this	O
hormone	O
response	O
element	O
is	O
linked	O
to	O
a	O
reporter	O
gene	O
but	O
rather	O
acts	O
as	O
a	O
potent	O
competitive	O
repressor	O
of	O
ROR	B-GENE
alpha	I-GENE
function	O
.	O

An	O
infectious	O
origin	O
should	O
always	O
be	O
excluded	O
since	O
specific	O
etiologic	O
therapy	O
may	O
be	O
implemented	O
.	O

SETTING	O
-	O
-	O
Delhi	O
,	O
urban	O
India	O
,	O
1985	O
-	O
6	O
.	O

(	O
ii	O
)	O
opening	O
of	O
KATP	O
attenuates	O
,	O
inhibition	O
of	O
the	O
channel	O
exacerbates	O
functional	O
consequences	O
of	O
coronary	O
occlusion	O
,	O
and	O
(	O
iii	O
)	O
KATP	O
opening	O
attenuates	O
reperfusion	O
-	O
induced	O
VF	O
,	O
but	O
it	O
triggers	O
ischemia	O
-	O
induced	O
VF	O
.	O

ATP	O
gamma	O
S	O
inhibition	O
can	O
be	O
overcome	O
by	O
high	O
concentrations	O
of	O
ATP	O
,	O
dATP	O
,	O
araATP	O
,	O
or	O
ddATP	O
.	O

The	O
selenium	O
level	O
and	O
glutathione	B-GENE
peroxidase	I-GENE
activity	O
in	O
the	O
blood	O
,	O
liver	O
,	O
and	O
stomach	O
mucosa	O
were	O
significantly	O
higher	O
in	O
the	O
high	O
-	O
selenium	O
diet	O
group	O
than	O
in	O
the	O
low	O
-	O
selenium	O
diet	O
group	O
.	O

Increasing	O
the	O
RH	O
beyond	O
32	O
%	O
resulted	O
in	O
solvation	O
of	O
the	O
peroxy	O
radical	O
,	O
sterically	O
hindering	O
the	O
radical	O
from	O
entering	O
the	O
propagation	O
transition	O
state	O
.	O

Previous	O
genetic	O
studies	O
led	O
to	O
the	O
conclusion	O
that	O
nitrate	O
and	O
nitrite	O
induction	O
of	O
nasF	B-GENE
operon	I-GENE
expression	O
is	O
determined	O
by	O
a	O
transcriptional	O
antitermination	O
mechanism	O
.	O

The	O
effect	O
of	O
acute	O
,	O
mid	O
-	O
cervical	O
spinal	O
cord	O
lesions	O
on	O
neuronal	O
and	O
reflex	O
activity	O
evoked	O
by	O
the	O
noxious	O
visceral	O
stimulus	O
,	O
colorectal	O
distension	O
(	O
CRD	O
;	O
80	O
mmHg	O
,	O
20	O
s	O
)	O
,	O
was	O
determined	O
in	O
halothane	O
-	O
anesthetized	O
rats	O
.	O

A	O
mutant	B-GENE
areA	I-GENE
product	I-GENE
truncated	O
immediately	O
after	O
the	O
last	O
residue	O
of	O
the	O
highly	O
conserved	O
GATA	B-GENE
(	I-GENE
DNA	I-GENE
-	I-GENE
binding	I-GENE
)	I-GENE
domain	I-GENE
retains	O
partial	O
function	O
.	O

Thromboplastic	O
and	O
fibrynolytic	O
activity	O
of	O
the	O
blood	O
after	O
administration	O
of	O
intralipid	O
in	O
men	O
with	O
history	O
of	O
myocardial	O
infarction	O
up	O
to	O
45	O
year	O
of	O
life	O

We	O
have	O
characterized	O
a	O
panel	O
of	O
6	O
monoclonal	O
antibodies	O
raised	O
against	O
human	B-GENE
platelet	I-GENE
talin	I-GENE
by	O
Western	O
blotting	O
,	O
immune	O
precipitation	O
,	O
and	O
immunofluorescence	O
,	O
and	O
shown	O
that	O
antibodies	B-GENE
TA205	I-GENE
and	O
TD77	B-GENE
disrupt	O
actin	B-GENE
stress	O
fibers	O
and	O
focal	O
adhesions	O
,	O
and	O
inhibit	O
cell	O
motility	O
when	O
microinjected	O
into	O
human	O
fibroblasts	O
.	O

This	O
paper	O
summarises	O
the	O
experimental	O
evidence	O
upon	O
which	O
the	O
clinical	O
trials	O
of	O
aldose	B-GENE
reductase	I-GENE
inhibitors	O
in	O
diabetic	O
patients	O
have	O
been	O
initiated	O
and	O
the	O
results	O
of	O
published	O
drug	O
trials	O
in	O
these	O
patients	O
.	O

Diffuse	O
white	O
matter	O
injury	O
can	O
be	O
attributed	O
to	O
radiation	O
and	O
associated	O
with	O
neurological	O
deficits	O
,	O
but	O
leukoencephalopathy	O
is	O
rarely	O
observed	O
in	O
the	O
absence	O
of	O
chemotherapy	O
.	O

However	O
,	O
artificially	O
ventilated	O
rats	O
,	O
pretreated	O
with	O
MK	O
-	O
801	O
,	O
were	O
more	O
sensitive	O
(	O
lethal	O
cocaine	O
dose	O
,	O
76	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
0	O
mg	O
/	O
kg	O
,	O
n	O
=	O
5	O
)	O
than	O
vehicle	O
pretreated	O
rats	O
(	O
129	O
.	O
4	O
+	O
/	O
-	O
15	O
.	O
8	O
mg	O
/	O
kg	O
,	O
n	O
=	O
6	O
)	O
,	O
indicating	O
that	O
MK	O
-	O
801	O
may	O
increase	O
both	O
the	O
respiratory	O
and	O
the	O
cardiac	O
toxicity	O
of	O
cocaine	O
in	O
urethane	O
anesthetized	O
rats	O
.	O

This	O
region	O
also	O
contains	O
a	O
gene	O
specifying	O
a	O
Leu	B-GENE
-	I-GENE
tRNA	I-GENE
precursor	I-GENE
and	O
a	O
remnant	O
of	O
a	O
tau	O
element	O
.	O

Splenectomized	O
patients	O
are	O
predisposed	O
toward	O
developing	O
overwhelming	O
bacterial	O
infections	O
.	O

The	O
recently	O
developed	O
gamma	B-GENE
-	I-GENE
interferon	I-GENE
(	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
)	O
assay	O
system	O
for	O
the	O
diagnosis	O
of	O
bovine	O
tuberculosis	O
in	O
cattle	O
has	O
been	O
accredited	O
by	O
the	O
Standing	O
Committee	O
on	O
Agriculture	O
for	O
use	O
in	O
Australia	O
.	O

This	O
0	O
.	O
74	O
kb	O
cDNA	O
contains	O
an	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
477	O
bp	O
encoding	O
a	O
polypeptide	O
of	O
159	O
amino	O
acids	O
(	O
aa	O
)	O
which	O
differs	O
at	O
only	O
one	O
position	O
(	O
position	O
65	O
)	O
from	O
the	O
human	B-GENE
U1	I-GENE
-	I-GENE
C	I-GENE
protein	I-GENE
.	O

Mycoplasma	O
hominis	O
infections	O
are	O
easily	O
missed	O
because	O
conventional	O
methods	O
for	O
bacterial	O
detection	O
may	O
fail	O
.	O

METHODS	O
:	O
302	O
consecutive	O
patients	O
with	O
BS	O
and	O
438	O
patients	O
with	O
other	O
rheumatological	O
conditions	O
were	O
surveyed	O
for	O
the	O
presence	O
or	O
absence	O
of	O
the	O
features	O
of	O
BS	O
by	O
means	O
of	O
a	O
standard	O
form	O
which	O
had	O
been	O
prepared	O
according	O
to	O
ISG	O
criteria	O
.	O

We	O
have	O
now	O
identified	O
,	O
after	O
21	O
serial	O
undiluted	O
passages	O
of	O
MHV	O
,	O
a	O
small	B-GENE
DI	I-GENE
RNA	I-GENE
,	O
DIssF	B-GENE
,	O
which	O
is	O
efficiently	O
packaged	O
into	O
virions	O
.	O

In	O
a	O
recent	O
measles	O
epidemic	O
in	O
El	O
Paso	O
,	O
TX	O
,	O
120	O
,	O
000	O
records	O
were	O
screened	O
using	O
these	O
criteria	O
,	O
and	O
as	O
a	O
result	O
13	O
,	O
000	O
students	O
were	O
vaccinated	O
.	O

In	O
these	O
constructs	O
,	O
GUS	B-GENE
expression	O
was	O
driven	O
by	O
promoter	O
regions	O
derived	O
from	O
the	O
Arabidopsis	B-GENE
alcohol	I-GENE
dehydrogenase	I-GENE
(	O
Adh1	B-GENE
)	O
,	O
maize	B-GENE
ubiquitin	I-GENE
(	O
Ubi1	B-GENE
)	O
,	O
rice	B-GENE
actin	I-GENE
(	O
Act1	B-GENE
)	O
and	O
CaMV	B-GENE
35S	I-GENE
genes	I-GENE
.	O

Both	O
Rep78	B-GENE
and	O
Rep68	B-GENE
cut	O
the	O
terminal	O
AAV	O
sequence	O
at	O
the	O
same	O
site	O
(	O
nucleotide	O
124	O
)	O
.	O

In	O
this	O
regard	O
,	O
it	O
differs	O
from	O
a	O
recently	O
reported	O
BFA	O
-	O
sensitive	O
ARF	B-GENE
-	O
GEP	B-GENE
that	O
contains	O
a	O
Sec7	B-GENE
domain	I-GENE
.	O

Circulating	O
platelets	O
may	O
be	O
activated	O
by	O
exposed	O
triple	O
-	O
helical	O
collagen	B-GENE
in	O
atherosclerotic	O
lesions	O
in	O
Mg	O
-	O
deficient	O
ruminants	O
.	O

The	O
potency	O
of	O
the	O
effect	O
of	O
Nim	O
(	O
0	O
.	O
5	O
mg	O
.	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
was	O
similar	O
to	O
that	O
of	O
NBP	O
(	O
10	O
mg	O
.	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
.	O

Inhibition	O
of	O
histalog	O
-	O
stimulated	O
gastric	O
secretion	O
by	O
40	O
749	O
RP	O
,	O
a	O
new	O
long	O
-	O
acting	O
gastric	O
antisecretory	O
agent	O
.	O

The	O
Spo0F	B-GENE
residues	I-GENE
making	O
up	O
the	O
hydrophobic	O
patch	O
are	O
very	O
similar	O
in	O
all	O
response	O
regulators	O
suggesting	O
that	O
the	O
binding	O
is	O
initiated	O
through	O
the	O
same	O
residues	O
in	O
all	O
interacting	O
response	O
regulator	O
-	O
kinase	O
pairs	O
.	O

Me	O
(	O
2	O
)	O
SO	O
-	O
induced	O
neuronal	O
differentiation	O
of	O
N1E	O
-	O
115	O
neuroblastoma	O
cells	O
increased	O
both	O
the	O
expression	O
of	O
the	O
endogenous	B-GENE
Ntr	I-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
and	O
reporter	O
genes	O
driven	O
by	O
NTR	B-GENE
-	I-GENE
1	I-GENE
promoter	I-GENE
sequences	I-GENE
by	O
3	O
-	O
4	O
-	O
fold	O
.	O

3	O
.	O
04	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
large	O
accelerations	O
/	O
30	O
min	O
(	O
1	O
.	O
46	O
+	O
/	O
-	O
1	O
.	O
96	O
vs	O
.	O

Resistance	O
ratios	O
for	O
the	O
other	O
field	O
strains	O
obtained	O
by	O
comparison	O
with	O
the	O
R5	O
strain	O
ranged	O
from	O
24	O
.	O
5	O
to	O
239	O
for	O
topical	O
application	O
and	O
from	O
1	O
.	O
2	O
to	O
9	O
.	O
8	O
for	O
the	O
glass	O
jar	O
method	O
.	O

A	O
water	O
-	O
vapour	O
giga	O
-	O
maser	O
in	O
the	O
active	O
galaxy	O
TXFS2226	O
-	O
184	O
.	O

In	O
the	O
United	O
States	O
high	O
-	O
MW	O
HES	O
480	O
which	O
is	O
difficult	O
to	O
degrade	O
is	O
most	O
frequently	O
used	O
and	O
results	O
in	O
a	O
larger	O
in	O
vivo	O
MW	O
and	O
subsequent	O
decrease	O
in	O
factor	B-GENE
VIII	I-GENE
/	O
von	B-GENE
Willebrand	I-GENE
factor	I-GENE
levels	O
.	O

Among	O
six	O
different	O
library	O
isolates	O
containing	O
6	B-GENE
.	I-GENE
5	I-GENE
-	I-GENE
to	I-GENE
7	I-GENE
-	I-GENE
kb	I-GENE
IAP	I-GENE
units	I-GENE
,	O
some	O
restriction	O
sites	O
were	O
highly	O
conserved	O
whereas	O
others	O
varied	O
in	O
both	O
occurrence	O
and	O
position	O
.	O

Cytokine	O
-	O
induced	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
DNA	O
binding	O
activity	O
,	O
RelA	B-GENE
nuclear	O
translocation	O
,	O
I	B-GENE
kappa	I-GENE
B	I-GENE
alpha	I-GENE
degradation	O
,	O
I	B-GENE
kappa	I-GENE
B	I-GENE
serine	O
32	O
phosphorylation	O
,	O
and	O
I	B-GENE
kappa	I-GENE
B	I-GENE
kinase	I-GENE
(	O
IKK	B-GENE
)	O
activity	O
were	O
blocked	O
by	O
curcumin	O
treatment	O
.	O

1	O
.	O

Actins	B-GENE
show	O
two	O
different	O
forms	O
of	O
N	O
-	O
terminal	O
processing	O
dependent	O
on	O
their	O
N	O
-	O
terminal	O
sequence	O
.	O

A	O
comparison	O
of	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
T	O
.	O
thermophilus	O
enzyme	O
with	O
that	O
of	O
the	O
Escherichia	O
coli	O
enzyme	O
showed	O
(	O
i	O
)	O
a	O
37	O
%	O
overall	O
similarity	O
;	O
(	O
ii	O
)	O
the	O
conservation	O
of	O
the	O
Ser	O
residue	O
,	O
which	O
is	O
known	O
to	O
be	O
phosphorylated	O
in	O
the	O
E	O
.	O
coli	O
enzyme	O
,	O
and	O
of	O
the	O
surrounding	O
sequence	O
;	O
and	O
(	O
iii	O
)	O
the	O
presence	O
of	O
141	O
extra	O
residues	O
at	O
the	O
C	O
terminus	O
of	O
the	O
T	O
.	O
thermophilus	O
enzyme	O
.	O

However	O
,	O
alterations	O
in	O
electrostatic	O
and	O
hydrophobic	O
interactions	O
created	O
by	O
the	O
three	O
amino	O
acid	O
substitutions	O
prevent	O
the	O
conformational	O
change	O
in	O
the	O
enzyme	O
usually	O
produced	O
by	O
calmodulin	B-GENE
binding	O
.	O

We	O
found	O
that	O
T3	O
(	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
selectively	O
stimulates	O
transcription	O
from	O
rGH	B-GENE
-	O
TRE	O
-	O
and	O
TREpal	O
-	O
,	O
but	O
not	O
ME	O
-	O
TRE	O
-	O
and	O
F2	O
-	O
TRE	O
-	O
,	O
containing	O
templates	O
in	O
which	O
these	O
TREs	O
are	O
linked	O
in	O
front	O
of	O
the	O
rGH	B-GENE
minimal	I-GENE
promoter	I-GENE
containing	O
only	O
the	O
TATA	B-GENE
box	I-GENE
binding	I-GENE
protein	I-GENE
,	O
but	O
not	O
any	O
other	O
proximal	O
binding	O
protein	O
,	O
sequence	O
.	O

All	O
ribosomal	B-GENE
protein	I-GENE
(	O
rp	B-GENE
)	O
gene	O
promoters	O
from	O
Saccharomyces	O
cerevisiae	O
studied	O
so	O
far	O
contain	O
either	O
(	O
usually	O
two	O
)	O
binding	O
sites	O
for	O
the	O
global	O
gene	O
regulator	O
Rap1p	B-GENE
or	O
one	O
binding	O
site	O
for	O
another	O
global	O
factor	O
,	O
Abf1p	B-GENE
.	O

All	O
three	O
NR	B-GENE
isoforms	O
are	O
expressed	O
in	O
cv	O
.	O

All	O
three	O
NR	B-GENE
isoforms	I-GENE
are	O
expressed	O
in	O
cv	O
.	O

Heme	B-GENE
oxygenase	I-GENE
1	I-GENE
is	O
an	O
essential	O
enzyme	O
in	O
heme	O
catabolism	O
that	O
cleaves	O
heme	O
to	O
form	O
biliverdin	O
,	O
iron	O
,	O
and	O
carbon	O
monoxide	O
.	O

The	O
results	O
are	O
discussed	O
in	O
relation	O
to	O
acoustical	O
models	O
of	O
sound	O
propagation	O
and	O
physiology	O
,	O
and	O
it	O
is	O
suggested	O
that	O
height	O
-	O
dependent	O
degradation	O
within	O
a	O
forest	O
is	O
an	O
important	O
selection	O
pressure	O
for	O
transmissibility	O
in	O
avian	O
communication	O
.	O

The	O
suppression	O
was	O
also	O
demonstrated	O
in	O
a	O
transient	O
expression	O
assay	O
in	O
vivo	O
using	O
isolated	O
barley	O
endosperms	O
.	O

We	O
have	O
cloned	O
cDNA	O
and	O
genomic	O
DNA	O
for	O
a	O
mouse	O
gene	O
encoding	O
a	O
protein	O
with	O
significant	O
sequence	O
similarity	O
to	O
conserved	O
domains	O
found	O
in	O
proteins	O
of	O
the	O
Spo11p	B-GENE
family	I-GENE
.	O

While	O
determination	O
of	O
the	O
protein	O
content	O
of	O
the	O
formulae	O
gave	O
no	O
valid	O
information	O
,	O
RAST	O
/	O
EAST	O
inhibition	O
was	O
highest	O
for	O
cow	O
'	O
s	O
milk	O
,	O
followed	O
by	O
the	O
partially	O
hydrolysed	O
whey	O
formula	O
,	O
partially	O
hydrolysed	O
whey	O
/	O
casein	B-GENE
formula	O
,	O
soy	B-GENE
/	I-GENE
pork	I-GENE
collagen	I-GENE
formula	O
,	O
and	O
the	O
amino	O
acid	O
formula	O
.	O

To	O
determine	O
which	O
sequences	O
in	O
the	O
rat	B-GENE
P450c17	I-GENE
promoter	I-GENE
may	O
be	O
responsible	O
for	O
basal	O
and	O
cAMP	O
-	O
stimulated	O
gene	O
transcription	O
,	O
deletion	O
constructs	O
containing	O
between	O
-	O
1	O
,	O
560	O
and	O
-	O
53	O
base	O
pairs	O
of	O
5	O
'	O
-	O
flanking	O
DNA	O
from	O
the	O
rat	B-GENE
P450c17	I-GENE
gene	I-GENE
were	O
ligated	O
to	O
plasmids	O
expressing	O
the	O
reporter	O
gene	O
luciferase	B-GENE
and	O
transfected	O
into	O
two	O
mouse	O
cell	O
lines	O
,	O
adrenal	O
Y	O
-	O
1	O
cells	O
,	O
and	O
testicular	O
Leydig	O
MA	O
-	O
10	O
cells	O
.	O

The	O
transcription	O
initiation	O
site	O
was	O
determined	O
by	O
S1	B-GENE
nuclease	I-GENE
mapping	O
.	O

Certain	O
transcript	O
patterns	O
in	O
Epifagus	O
plastids	O
are	O
highly	O
complex	O
and	O
similar	O
to	O
those	O
of	O
tobacco	O
operons	O
.	O

The	O
ensembles	O
are	O
considered	O
to	O
be	O
one	O
of	O
the	O
forms	O
of	O
activity	O
of	O
the	O
structured	O
morphofunctional	O
cortical	O
units	O
,	O
i	O
.	O
e	O
.	O
the	O
columns	O
.	O

Autonomic	O
dysfunctions	O
were	O
restricted	O
to	O
tonic	O
pupils	O
.	O

This	O
region	O
contains	O
a	O
motif	O
with	O
partial	O
identity	O
with	O
the	O
binding	O
site	O
for	O
the	O
ubiquitous	O
transcription	O
factor	O
upstream	B-GENE
stimulatory	I-GENE
factor	I-GENE
(	O
USF	B-GENE
)	O
,	O
which	O
binds	O
to	O
the	O
human	B-GENE
insulin	I-GENE
promoter	I-GENE
.	O

The	O
RAS	B-GENE
-	O
cyclic	B-GENE
AMP	I-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
cAPK	B-GENE
pathway	O
prevents	O
the	O
UAS	O
activity	O
of	O
IREu	B-GENE
in	O
the	O
presence	O
of	O
glucose	O
as	O
the	O
sole	O
carbon	O
source	O
,	O
while	O
the	O
transcriptional	O
activators	O
Msn2p	B-GENE
and	O
Msn4p	B-GENE
promote	O
the	O
UAS	O
activity	O
of	O
this	O
repeat	O
in	O
the	O
presence	O
of	O
acetate	O
.	O

Polymyxin	O
B	O
was	O
given	O
intravenously	O
for	O
1	O
week	O
postburn	O
in	O
doses	O
designed	O
to	O
neutralize	O
circulating	O
endotoxemia	O
.	O

Internal	O
biliary	O
drainage	O
,	O
unlike	O
external	O
drainage	O
,	O
does	O
not	O
suppress	O
the	O
regeneration	O
of	O
cholestatic	O
rat	O
liver	O
after	O
partial	O
hepatectomy	O
.	O

RT	O
-	O
PCR	O
and	O
in	O
situ	O
hybridization	O
analyses	O
of	O
a	O
time	O
course	O
of	O
juvenile	O
testis	O
development	O
indicate	O
that	O
Spo11	B-GENE
expression	O
begins	O
in	O
early	O
meiotic	O
Prophase	O
I	O
,	O
prior	O
to	O
the	O
pachytene	O
stage	O
,	O
with	O
increasing	O
accumulation	O
of	O
mRNA	O
through	O
the	O
pachytene	O
stage	O
.	O

The	O
number	O
of	O
lactotropes	O
,	O
somatotropes	O
,	O
thyrotropes	O
,	O
and	O
gonadotropes	O
was	O
not	O
altered	O
compared	O
with	O
controls	O
,	O
indicating	O
that	O
in	O
the	O
adult	O
pituitary	O
,	O
POMC	B-GENE
products	I-GENE
are	O
not	O
required	O
to	O
maintain	O
the	O
distribution	O
of	O
cell	O
types	O
.	O

As	O
assessed	O
by	O
a	O
genetic	O
assay	O
that	O
measures	O
AAI	O
-	O
dependent	O
DNA	O
binding	O
,	O
TraM	B-GENE
inhibited	O
TraR	B-GENE
function	O
before	O
and	O
after	O
the	O
transcription	O
factor	O
had	O
bound	O
to	O
its	O
DNA	O
recognition	O
site	O
.	O

Limits	O
of	O
energy	O
turnover	O
in	O
relation	O
to	O
physical	O
performance	O
were	O
addressed	O
in	O
terms	O
of	O
upper	O
and	O
lower	O
limit	O
,	O
changes	O
during	O
a	O
training	O
programme	O
and	O
how	O
to	O
regulate	O
energy	O
balance	O
at	O
a	O
changing	O
energy	O
turnover	O
.	O

Phorbol	O
esters	O
stimulated	O
phosphorylation	O
of	O
CSK	B-GENE
35H	I-GENE
proteins	I-GENE
,	O
thus	O
emphasizing	O
that	O
sequences	O
isolated	O
according	O
to	O
PKC	B-GENE
binding	O
activity	O
in	O
vitro	O
are	O
also	O
PKC	B-GENE
substrates	O
in	O
vivo	O
.	O

Catch	O
-	O
up	O
growth	O
was	O
observed	O
only	O
for	O
a	O
12	O
-	O
month	O
period	O
in	O
4	O
children	O
with	O
a	O
bone	O
age	O
of	O
7	O
to	O
8	O
years	O
.	O

Recombinant	B-GENE
prenylcysteine	I-GENE
lyase	I-GENE
was	O
produced	O
in	O
a	O
baculovirus	O
-	O
Sf9	O
expression	O
system	O
.	O

These	O
results	O
support	O
the	O
diagnostic	O
validity	O
of	O
NFPD	O
in	O
CP	O
/	O
NCA	O
patients	O
,	O
because	O
such	O
patients	O
had	O
a	O
family	O
history	O
of	O
panic	O
disorder	O
similar	O
to	O
patients	O
with	O
a	O
more	O
classical	O
panic	O
disorder	O
presentation	O
.	O

In	O
a	O
previous	O
study	O
(	O
Brandl	O
,	O
C	O
.	O

In	O
vivo	O
dimethyl	O
sulfate	O
footprinting	O
of	O
the	O
cyclin	B-GENE
E	I-GENE
promoter	I-GENE
revealed	O
several	O
regions	O
of	O
protection	O
and	O
hypersensitivity	O
that	O
were	O
unique	O
to	O
infected	O
cells	O
.	O

Structure	O
and	O
regulation	O
of	O
the	O
gene	O
encoding	O
the	O
neuron	O
-	O
specific	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
substrate	O
neurogranin	B-GENE
(	O
RC3	B-GENE
protein	I-GENE
)	O
.	O

Mutations	O
of	O
the	O
RET	B-GENE
gene	I-GENE
,	O
encoding	O
a	O
receptor	B-GENE
tyrosine	I-GENE
kinase	I-GENE
,	O
have	O
been	O
associated	O
with	O
the	O
inherited	O
cancer	O
syndromes	O
MEN	O
2A	O
and	O
MEN	O
2B	O
.	O

The	O
promoter	O
region	O
showed	O
no	O
consensus	O
TATA	O
box	O
but	O
it	O
contains	O
CCAAT	O
and	O
CreA	B-GENE
boxes	O
known	O
to	O
be	O
involved	O
in	O
both	O
stress	O
and	O
carbon	O
-	O
catabolite	O
regulation	O
of	O
fungal	O
promoters	O
.	O

Diabetes	O
care	O
:	O
a	O
guideline	O
to	O
the	O
facilities	O
needed	O
to	O
support	O
internationally	O
endorsed	O
standards	O
.	O

We	O
also	O
provide	O
evidence	O
that	O
gar2	B-GENE
is	O
phosphorylated	O
in	O
vitro	O
by	O
a	O
p13	B-GENE
(	O
suc1	B-GENE
)	O
-	O
Sepharose	O
-	O
bound	O
kinase	O
from	O
Schizosaccharomyces	O
pombe	O
extracts	O
that	O
displays	O
cell	O
cycle	O
-	O
regulated	O
activity	O
similar	O
to	O
that	O
of	O
the	O
p34	B-GENE
(	O
cdc2	B-GENE
(	O
kinase	O
.	O

A	O
control	O
group	O
of	O
nine	O
women	O
(	O
age	O
23	O
-	O
40	O
years	O
)	O
on	O
oral	O
contraceptives	O
(	O
Nordette	O
-	O
28	O
)	O
was	O
also	O
studied	O
four	O
times	O
during	O
a	O
pill	O
cycle	O
.	O

TPBF	B-GENE
has	O
two	O
potential	O
coiled	O
-	O
coil	O
regions	O
,	O
a	O
basic	O
region	O
,	O
a	O
proline	O
-	O
rich	O
region	O
,	O
a	O
histidine	O
-	O
rich	O
N	O
terminus	O
,	O
and	O
a	O
nuclear	O
targeting	O
sequence	O
.	O

Biol	O
.	O

However	O
,	O
a	O
10	O
-	O
-	O
15	O
%	O
lengthening	O
of	O
the	O
partial	O
thromboplastin	B-GENE
time	O
is	O
evident	O
after	O
24	O
hours	O
of	O
storage	O
.	O

40	O
,	O
000	O
)	O
.	O

These	O
two	O
contigs	O
contain	O
a	O
total	O
of	O
163	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
in	O
26	O
-	O
29	O
putative	O
operons	O
;	O
56	O
ORFs	O
could	O
be	O
identified	O
with	O
reasonable	O
certainty	O
.	O

Members	O
of	O
the	O
meis1	B-GENE
and	O
pbx	B-GENE
homeodomain	I-GENE
protein	I-GENE
families	I-GENE
cooperatively	O
bind	O
a	O
cAMP	O
-	O
responsive	O
sequence	O
(	O
CRS1	O
)	O
from	O
bovine	B-GENE
CYP17	I-GENE
.	O

As	O
regards	O
lipid	O
metabolism	O
,	O
the	O
mean	O
values	O
for	O
total	O
triglycerides	O
,	O
cholesterol	O
,	O
LDL	B-GENE
-	I-GENE
cholesterol	I-GENE
and	O
HDL	B-GENE
-	I-GENE
cholesterol	I-GENE
seen	O
at	O
the	O
end	O
of	O
five	O
years	O
of	O
Norplant	O
-	O
2	O
rod	O
use	O
and	O
six	O
months	O
postremoval	O
were	O
similar	O
to	O
the	O
preinsertion	O
mean	O
.	O

The	O
novel	O
Notch	B-GENE
homologue	I-GENE
mouse	B-GENE
Notch	I-GENE
3	I-GENE
lacks	O
specific	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
repeats	I-GENE
and	O
is	O
expressed	O
in	O
proliferating	O
neuroepithelium	O
.	O

Gene	O
and	O
pseudogene	O
of	O
the	O
mouse	O
cation	O
-	O
dependent	O
mannose	B-GENE
6	I-GENE
-	I-GENE
phosphate	I-GENE
receptor	I-GENE
.	O

Approximately	O
20	O
%	O
of	O
ALCLs	O
that	O
express	O
ALK	B-GENE
do	O
not	O
contain	O
the	O
t	O
(	O
2	O
;	O
5	O
)	O
,	O
suggesting	O
that	O
other	O
genetic	O
abnormalities	O
can	O
result	O
in	O
aberrant	O
ALK	B-GENE
expression	O
.	O

The	O
primary	O
CT	O
findings	O
were	O
misinterpreted	O
as	O
a	O
brain	O
infarct	O
or	O
possibly	O
a	O
tumour	O
.	O

A	O
case	O
of	O
M	O
hemoglobinosis	O

The	O
fatigue	O
exercise	O
showed	O
relatively	O
high	O
blood	O
lactate	O
concentration	O
[	O
12	O
.	O
5	O
(	O
SD	O
2	O
.	O
6	O
)	O
mmol	O
x	O
l	O
(	O
-	O
1	O
)	O
]	O
and	O
an	O
increase	O
of	O
serum	B-GENE
creatine	I-GENE
kinase	I-GENE
(	O
CK	B-GENE
)	O
activity	O
delayed	O
by	O
2	O
days	O
[	O
540	O
(	O
SD	O
407	O
)	O
U	O
x	O
l	O
(	O
-	O
1	O
)	O
]	O
.	O

A	O
patient	O
is	O
described	O
with	O
skin	O
lesions	O
resembling	O
Kaposi	O
'	O
s	O
sarcoma	O
(	O
KS	O
)	O
.	O

Novel	O
multigene	O
families	O
encoding	O
highly	O
repetitive	O
peptide	O
sequences	O
.	O

Seven	O
clones	O
encoding	O
interferon	B-GENE
response	I-GENE
element	I-GENE
binding	I-GENE
factors	I-GENE
have	O
been	O
isolated	O
from	O
a	O
mouse	O
fibroblast	O
lambda	O
gt11	O
cDNA	O
library	O
by	O
using	O
a	O
32P	O
end	O
-	O
labeled	O
tandem	O
trimer	O
of	O
the	O
mouse	B-GENE
(	I-GENE
2	I-GENE
'	I-GENE
-	I-GENE
5	I-GENE
'	I-GENE
)	I-GENE
oligoadenylate	I-GENE
synthetase	I-GENE
gene	I-GENE
interferon	O
response	O
element	O
as	O
a	O
probe	O
.	O

However	O
,	O
L	B-GENE
-	I-GENE
plastin	I-GENE
has	O
been	O
found	O
in	O
many	O
types	O
of	O
malignant	O
human	O
cells	O
of	O
non	O
-	O
hemopoietic	O
origin	O
suggesting	O
that	O
its	O
expression	O
is	O
induced	O
accompanying	O
tumorigenesis	O
in	O
solid	O
tissues	O
.	O

The	O
second	O
complex	O
,	O
when	O
purified	O
,	O
contained	O
four	O
protein	O
components	O
including	O
the	O
36	O
-	O
kDa	O
protein	O
.	O

The	O
role	O
of	O
HIV	B-GENE
tat	I-GENE
,	O
which	O
is	O
the	O
main	O
enhancing	O
factor	O
for	O
viral	B-GENE
LTR	I-GENE
,	O
in	O
the	O
regulation	O
of	O
IL	B-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
transcription	O
has	O
been	O
studied	O
following	O
transient	O
expression	O
of	O
the	O
tat	B-GENE
gene	I-GENE
in	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
-	O
activated	O
Jurkat	O
cells	O
transfected	O
with	O
IL	B-GENE
-	I-GENE
2	I-GENE
promoter	O
-	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
reporter	O
constructs	O
.	O

Comparison	O
of	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
M	B-GENE
RNA	I-GENE
product	I-GENE
of	I-GENE
Uukuniemi	I-GENE
virus	I-GENE
with	O
that	O
of	O
Punta	O
Toro	O
and	O
Rift	O
Valley	O
fever	O
viruses	O
showed	O
in	O
both	O
cases	O
a	O
weak	O
homology	O
that	O
was	O
more	O
pronounced	O
for	O
the	O
proteins	O
located	O
at	O
the	O
COOH	O
-	O
terminal	O
end	O
of	O
the	O
precursor	O
.	O

Contraction	O
of	O
the	O
tracheal	O
muscle	O
and	O
the	O
activity	O
of	O
stretch	O
receptors	O
in	O
the	O
trachea	O

Due	O
to	O
its	O
relatively	O
soluble	O
chemical	O
form	O
,	O
90Sr	O
was	O
rapidly	O
translocated	O
from	O
lung	O
to	O
bone	O
where	O
a	O
substantial	O
portion	O
was	O
retained	O
for	O
a	O
long	O
period	O
of	O
time	O
.	O

To	O
evaluate	O
the	O
relative	O
accuracy	O
of	O
continuous	O
wave	O
(	O
CW	O
)	O
and	O
high	O
pulse	O
repetition	O
frequency	O
(	O
HPRF	O
)	O
Doppler	O
for	O
estimating	O
aortic	O
transvalvular	O
pressure	O
gradients	O
,	O
Doppler	O
examinations	O
with	O
both	O
devices	O
were	O
obtained	O
in	O
87	O
consecutive	O
patients	O
with	O
aortic	O
valve	O
disease	O
.	O

Histamine	O
-	O
2	O
blockade	O
in	O
psoriasis	O

Estimation	O
of	O
L	O
-	O
alanine	O
in	O
serum	O
or	O
plasma	O
using	O
the	O
LKB	O
reaction	O
rate	O
analyser	O
.	O

Analysis	O
of	O
its	O
genomic	O
region	O
revealed	O
that	O
the	O
13	O
-	O
kb	O
Cdc6	B-GENE
gene	I-GENE
is	O
divided	O
into	O
12	O
exons	O
by	O
11	O
introns	O
.	O

We	O
have	O
performed	O
toeprinting	O
analyses	O
on	O
repA	B-GENE
mRNA	I-GENE
of	O
plasmid	O
R1	O
,	O
both	O
free	O
and	O
in	O
duplex	O
with	O
the	O
antisense	O
RNA	O
,	O
CopA	B-GENE
.	O

Type	O
II	O
could	O
be	O
divided	O
further	O
into	O
two	O
forms	O
(	O
IIA	O
and	O
IIB	O
)	O
that	O
may	O
represent	O
two	O
underscribed	O
species	O
or	O
developmental	O
stages	O
of	O
the	O
same	O
species	O
.	O

Each	O
recombinant	O
product	O
was	O
a	O
fusion	O
protein	O
with	O
a	O
B	O
domain	O
of	O
Staphylococcal	B-GENE
protein	I-GENE
A	I-GENE
(	O
SPA	B-GENE
)	O
.	O

An	O
FP	B-GENE
mutant	I-GENE
,	O
AcFP875	B-GENE
-	I-GENE
2	I-GENE
,	O
had	O
a	O
1	O
.	O
6	O
-	O
kbp	O
insertion	O
of	O
S	O
.	O
frugiperda	O
DNA	O
near	O
the	O
5	O
'	O
end	O
of	O
these	O
transcripts	O
which	O
by	O
S1	B-GENE
analysis	O
were	O
shown	O
to	O
initiate	O
within	O
the	O
host	O
cell	O
sequence	O
.	O

These	O
data	O
suggest	O
that	O
other	O
Ras	B-GENE
effectors	I-GENE
can	O
collaborate	O
with	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
and	O
with	O
each	O
other	O
to	O
activate	O
Pak	B-GENE
.	O

MSSPs	B-GENE
are	O
believed	O
to	O
regulate	O
DNA	O
replication	O
,	O
transcription	O
,	O
apopotosis	O
and	O
cell	O
cycle	O
progression	O
by	O
interacting	O
with	O
the	O
C	B-GENE
-	I-GENE
MYC	I-GENE
protein	I-GENE
.	O

Mutations	O
at	O
the	O
extreme	O
C	O
-	O
terminus	O
of	O
EIAV	B-GENE
Tat	I-GENE
impaired	O
both	O
RNA	O
binding	O
and	O
activation	O
domain	O
functions	O
,	O
suggesting	O
effects	O
on	O
secondary	O
or	O
tertiary	O
structure	O
.	O

A	O
114	O
-	O
base	O
pair	O
sequence	O
of	O
predominantly	O
repeating	O
purine	O
-	O
pyrimidine	O
nucleotides	O
separates	O
these	O
two	O
d	O
(	O
AC	O
)	O
repeats	O
.	O

We	O
have	O
shown	O
previously	O
that	O
in	O
contrast	O
to	O
other	O
extracellular	O
matrix	O
molecules	O
pepsin	B-GENE
-	O
solubilized	O
collagen	B-GENE
VI	I-GENE
(	O
CVI	B-GENE
)	O
can	O
stimulate	O
DNA	O
synthesis	O
of	O
various	O
mesenchymal	O
cell	O
types	O
,	O
apparently	O
independent	O
of	O
integrin	B-GENE
-	O
mediated	O
signal	O
transduction	O
.	O

Experimental	O
data	O
showed	O
that	O
these	O
abnormal	O
proteins	O
are	O
constitutively	O
localized	O
in	O
the	O
nucleus	O
,	O
have	O
lost	O
the	O
transcriptional	O
repressor	O
functions	O
typical	O
of	O
normal	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B2p52	I-GENE
and	O
may	O
be	O
capable	O
of	O
transactivation	O
activity	O
.	O

The	O
human	B-GENE
cytomegalovirus	I-GENE
(	I-GENE
HCMV	I-GENE
)	I-GENE
major	I-GENE
immediate	I-GENE
-	I-GENE
early	I-GENE
protein	I-GENE
IE2	I-GENE
is	O
a	O
nuclear	O
phosphoprotein	O
that	O
is	O
believed	O
to	O
be	O
a	O
key	O
regulator	O
in	O
both	O
lytic	O
and	O
latent	O
infections	O
.	O

Evidence	O
for	O
a	O
role	O
of	O
endogenous	B-GENE
corticotropin	I-GENE
-	I-GENE
releasing	I-GENE
factor	I-GENE
in	O
cold	O
,	O
ether	O
,	O
immobilization	O
,	O
and	O
traumatic	O
stress	O
.	O

In	O
addition	O
,	O
severe	O
vision	O
loss	O
can	O
be	O
seen	O
with	O
interferon	B-GENE
alfa	I-GENE
-	I-GENE
2b	I-GENE
-	O
associated	O
retinopathy	O
.	O

Proteins	O
known	O
to	O
bind	O
the	O
PEPCK	B-GENE
CRE	O
include	O
the	O
CRE	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	O
CREB	B-GENE
)	O
and	O
members	O
of	O
the	O
CCAAT	B-GENE
/	I-GENE
enhancer	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	O
C	B-GENE
/	I-GENE
EBP	I-GENE
)	O
family	O
.	O

Although	O
IL	B-GENE
-	I-GENE
2	I-GENE
and	O
IFN	B-GENE
-	I-GENE
alpha	I-GENE
activated	O
STAT1	B-GENE
alpha	I-GENE
and	O
STAT5	B-GENE
,	O
IL	B-GENE
-	I-GENE
2	I-GENE
predominantly	O
activated	O
STAT5	B-GENE
,	O
while	O
IFN	B-GENE
-	I-GENE
alpha	I-GENE
predominantly	O
activated	O
STAT1	B-GENE
alpha	I-GENE
.	O

Copyright	O
2000	O
Academic	O
Press	O
.	O

Ten	O
volunteers	O
were	O
tested	O
at	O
18	O
,	O
000	O
ft	O
(	O
5	O
,	O
486	O
m	O
)	O
,	O
and	O
through	O
12	O
,	O
000	O
,	O
8	O
,	O
000	O
,	O
and	O
5	O
,	O
000	O
ft	O
(	O
3	O
,	O
657	O
,	O
2	O
,	O
438	O
,	O
and	O
1	O
,	O
524	O
m	O
)	O
with	O
directional	O
sounds	O
recorded	O
via	O
a	O
dummy	O
head	O
microphone	O
and	O
presented	O
binaurally	O
.	O

Nodular	O
involvement	O
of	O
the	O
left	O
lung	O
and	O
infiltration	O
of	O
the	O
mucosa	O
of	O
the	O
left	O
lower	O
lobe	O
bronchus	O
followed	O
very	O
gradually	O
and	O
a	O
monoclonal	O
gammopathy	O
(	O
IgA	B-GENE
-	I-GENE
-	I-GENE
Type	I-GENE
Kappa	I-GENE
)	O
was	O
demonstrated	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
spontaneous	O
reports	O
of	O
suspected	O
adverse	O
drug	O
reactions	O
,	O
observed	O
in	O
elderly	O
patients	O
(	O
over	O
65	O
years	O
of	O
age	O
)	O
in	O
Sicily	O
(	O
Italy	O
)	O
during	O
the	O
period	O
from	O
1	O
January	O
1995	O
to	O
31	O
December	O
1997	O
.	O

I	O
.	O

We	O
demonstrate	O
that	O
Ddc1p	B-GENE
interacts	O
physically	O
in	O
vivo	O
with	O
Mec3p	B-GENE
,	O
and	O
this	O
interaction	O
requires	O
Rad17p	B-GENE
.	O

The	O
presence	O
in	O
such	O
patients	O
of	O
antibodies	O
to	O
adrenaline	O
and	O
noradrenaline	O
is	O
indicative	O
of	O
considerable	O
disruption	O
of	O
catecholamine	O
biotransformation	O
.	O

However	O
,	O
for	O
the	O
evaluable	O
cases	O
,	O
the	O
performances	O
of	O
the	O
CD3500	O
and	O
the	O
STKS	O
were	O
broadly	O
similar	O
and	O
generally	O
correlated	O
well	O
with	O
the	O
manual	O
reference	O
procedure	O
.	O

Either	O
a	O
UV	O
detector	O
set	O
at	O
268	O
nm	O
or	O
an	O
electrochemical	O
(	O
EC	O
)	O
detector	O
set	O
at	O
a	O
potential	O
of	O
+	O
0	O
.	O
9	O
V	O
(	O
versus	O
Ag	O
/	O
AgCl	O
/	O
3	O
M	O
NaCl	O
)	O
was	O
used	O
to	O
monitor	O
the	O
drug	O
.	O

Muscle	B-GENE
GSH	I-GENE
-	I-GENE
Px	I-GENE
activity	O
after	O
prolonged	O
exercise	O
,	O
training	O
,	O
and	O
selenium	O
supplementation	O
.	O

The	O
Authors	O
have	O
proposed	O
to	O
develop	O
this	O
research	O
employing	O
a	O
preparation	O
containing	O
exclusively	O
a	O
cortisonic	O
,	O
the	O
desametazone	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
alterations	O
of	O
the	O
dentinogenesis	O
to	O
be	O
attributed	O
to	O
such	O
component	O
.	O

Previous	O
studies	O
showed	O
that	O
mutations	O
in	O
the	O
6K	O
protein	O
led	O
to	O
the	O
slow	O
release	O
of	O
aberrant	O
,	O
multi	O
-	O
cored	O
infectious	O
virions	O
.	O

M	B-GENE
-	I-GENE
66	I-GENE
identified	O
the	O
14	O
-	O
kDa	O
protein	O
in	O
another	O
MMTV	O
bearing	O
T	O
-	O
cell	O
lymphoma	O
,	O
EL	O
-	O
4	O
.	O

ECG	O
-	O
gated	O
myocardial	O
Technetium	O
-	O
99m	O
sestamibi	O
SPECT	O
is	O
a	O
useful	O
technique	O
to	O
measure	O
myocardial	O
perfusion	O
and	O
function	O
simultaneously	O
.	O

These	O
results	O
suggest	O
that	O
G	B-GENE
beta	I-GENE
gamma	I-GENE
-	O
stimulated	O
Shc	B-GENE
phosphorylation	O
represents	O
an	O
early	O
step	O
in	O
the	O
pathway	O
leading	O
to	O
p21ras	B-GENE
activation	O
,	O
similar	O
to	O
the	O
mechanism	O
utilized	O
by	O
growth	B-GENE
factor	I-GENE
tyrosine	I-GENE
kinase	I-GENE
receptors	I-GENE
.	O

We	O
recommend	O
that	O
paracervical	O
block	O
with	O
lignocaine	O
should	O
be	O
used	O
in	O
conjunction	O
with	O
i	O
.	O
v	O
.	O
sedation	O
/	O
analgesia	O
during	O
egg	O
collection	O
performed	O
through	O
the	O
transvaginal	O
route	O
under	O
ultrasound	O
guidance	O
(	O
TUGOR	O
)	O
to	O
reduce	O
the	O
pain	O
of	O
the	O
procedure	O
.	O

To	O
understand	O
the	O
function	O
of	O
receptor	B-GENE
-	I-GENE
linked	I-GENE
tyrosine	I-GENE
phosphatases	I-GENE
in	O
neural	O
development	O
,	O
we	O
sought	O
to	O
identify	O
LAR	B-GENE
isoforms	I-GENE
preferentially	O
expressed	O
in	O
the	O
nervous	O
system	O
and	O
cellular	O
processes	O
regulating	O
LAR	B-GENE
alternative	O
splicing	O
.	O

Transitory	O
subclinical	O
and	O
permanent	O
hypothyroidism	O
in	O
the	O
course	O
of	O
subacute	O
thyroiditis	O
(	O
de	O
Quervain	O
)	O
.	O

Thrombotic	O
thrombocytopenic	O
purpura	O
in	O
systemic	O
lupus	O
erythematosus	O
.	O

Rifabutin	O
has	O
substantial	O
efficacy	O
when	O
combined	O
with	O
other	O
agents	O
.	O

In	O
experiments	O
with	O
the	O
D1	O
antagonist	O
SCH	O
23390	O
,	O
buprenorphine	O
-	O
induced	O
depression	O
was	O
consistently	O
blocked	O
,	O
but	O
facilitation	O
was	O
unaffected	O
.	O

(	O
1992	O
)	O
J	O
.	O

Sp1	B-GENE
can	O
activate	O
transcription	O
through	O
immunoglobulin	B-GENE
kappa	I-GENE
-	I-GENE
chain	I-GENE
enhancer	I-GENE
or	O
P	B-GENE
-	I-GENE
selectin	I-GENE
promoter	I-GENE
NF	B-GENE
-	I-GENE
kappaB	I-GENE
sites	I-GENE
.	O

p50	B-GENE
homodimers	I-GENE
replace	O
Sp1	B-GENE
from	O
the	O
P	B-GENE
-	I-GENE
selectin	I-GENE
promoter	I-GENE
by	O
binding	O
site	O
competition	O
and	O
thereby	O
either	O
inhibit	O
basal	O
Sp1	B-GENE
-	O
driven	O
expression	O
or	O
,	O
in	O
concert	O
with	O
Bcl	B-GENE
-	I-GENE
3	I-GENE
,	O
stimulate	O
expression	O
.	O

A	O
yeast	O
DNA	O
fragment	O
carrying	O
the	O
gene	B-GENE
CP	I-GENE
A1	I-GENE
encoding	O
the	O
small	O
subunit	O
of	O
the	O
arginine	O
pathway	O
carbamoyl	B-GENE
-	I-GENE
phosphate	I-GENE
synthetase	I-GENE
has	O
been	O
sequenced	O
.	O

Interestingly	O
,	O
these	O
response	O
elements	O
display	O
dramatically	O
reduced	O
affinity	O
for	O
retinoic	B-GENE
acid	I-GENE
receptor	I-GENE
-	O
retinoid	B-GENE
-	I-GENE
X	I-GENE
receptor	I-GENE
heterodimers	O
.	O

The	O
delta	B-GENE
srb10	I-GENE
mutation	I-GENE
also	O
influenced	O
on	O
the	O
transcript	O
levels	O
of	O
meiosis	O
-	O
inducing	O
genes	O
called	O
IME1	B-GENE
and	O
IME2	B-GENE
:	O
the	O
mutation	O
elevated	O
the	O
transcript	O
level	O
of	O
IME1	B-GENE
but	O
reduced	O
that	O
of	O
IME2	B-GENE
,	O
resulting	O
in	O
partial	O
defects	O
in	O
premeiotic	O
DNA	O
synthesis	O
and	O
meiosis	O
.	O

Upstream	O
activation	O
sites	O
of	O
the	O
CYC1	B-GENE
gene	I-GENE
of	O
Saccharomyces	O
cerevisiae	O
are	O
active	O
when	O
inverted	O
but	O
not	O
when	O
placed	O
downstream	O
of	O
the	O
"	O
TATA	O
box	O
"	O
.	O

The	O
most	O
important	O
risk	O
factors	O
are	O
:	O
1	O
)	O
genetic	O
;	O
2	O
)	O
Epstein	O
-	O
Barr	O
virus	O
(	O
infectious	O
mononucleosis	O
)	O
;	O
3	O
)	O
congenital	O
and	O
acquired	O
immunodeficiency	O
;	O
4	O
)	O
occupational	O
exposure	O
(	O
the	O
wood	O
industry	O
)	O
.	O

The	O
gene	O
product	O
of	O
cotS	B-GENE
was	O
confirmed	O
to	O
be	O
identical	O
to	O
Cot40	B-GENE
-	I-GENE
2	I-GENE
by	O
SDS	O
-	O
PAGE	O
and	O
immunoblotting	O
from	O
Escherichia	O
coli	O
transformed	O
with	O
a	O
plasmid	O
containing	O
the	O
cotS	B-GENE
region	I-GENE
.	O

A	O
2	B-GENE
.	I-GENE
4	I-GENE
-	I-GENE
kb	I-GENE
MAPKAPK	I-GENE
-	I-GENE
2	I-GENE
message	I-GENE
is	O
expressed	O
throughout	O
development	O
,	O
while	O
two	O
shorter	O
transcripts	O
of	O
2	O
.	O
3	O
and	O
1	O
.	O
8	O
kb	O
appear	O
to	O
be	O
specifically	O
expressed	O
in	O
the	O
germline	O
.	O

Apart	O
from	O
iron	O
regulation	O
,	O
sodA	B-GENE
expression	O
was	O
affected	O
by	O
changes	O
in	O
DNA	O
topology	O
induced	O
by	O
coumermycin	O
A	O
but	O
not	O
by	O
the	O
global	O
virulence	O
regulatory	O
Bvg	B-GENE
system	I-GENE
.	O

Lithium	O
delays	O
the	O
circadian	O
rhythm	O
of	O
wheel	O
-	O
running	O
in	O
Syrian	O
hamsters	O
at	O
plasma	O
concentrations	O
(	O
0	O
.	O
59	O
-	O
0	O
.	O
74	O
mM	O
)	O
that	O
also	O
cause	O
toxic	O
weight	O
loss	O
.	O

The	O
significance	O
of	O
the	O
phenolphthalein	B-GENE
sulphatase	I-GENE
test	O
for	O
the	O
differentiation	O
and	O
identification	O
of	O
Nocardia	O
species	O
.	O

We	O
conclude	O
that	O
Hansel	O
'	O
s	O
stain	O
substantially	O
improves	O
the	O
recognition	O
of	O
eosinophiluria	O
as	O
compared	O
with	O
Wright	O
'	O
s	O
stain	O
.	O

c	B-GENE
-	I-GENE
Fos	I-GENE
transcriptional	O
activity	O
stimulated	O
by	O
H	B-GENE
-	I-GENE
Ras	I-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
distinct	O
from	O
JNK	B-GENE
and	O
ERK	B-GENE
.	O

Quantitative	O
evaluation	O
of	O
the	O
steady	O
state	O
kinetics	O
of	O
MEK	B-GENE
inhibition	O
by	O
these	O
compounds	O
reveals	O
that	O
U0126	O
has	O
approximately	O
100	O
-	O
fold	O
higher	O
affinity	O
for	O
deltaN3	B-GENE
-	I-GENE
S218E	I-GENE
/	I-GENE
S222D	I-GENE
MEK	I-GENE
than	O
does	O
PD098059	O
.	O

She	O
has	O
since	O
developed	O
a	O
positive	O
anti	B-GENE
-	I-GENE
cardiolipin	I-GENE
antibody	I-GENE
but	O
does	O
not	O
meet	O
diagnostic	O
criteria	O
for	O
systemic	O
lupus	O
erythematosis	O
.	O

CONCLUSION	O
:	O
The	O
presence	O
of	O
known	O
autoimmune	O
disease	O
in	O
a	O
woman	O
with	O
POF	O
should	O
not	O
dissuade	O
the	O
clinician	O
from	O
evaluating	O
for	O
a	O
potential	O
genetic	O
cause	O
.	O

Both	O
parents	O
are	O
clinically	O
normal	O
and	O
unrelated	O
.	O

The	O
DNA	O
sequences	O
predict	O
proteins	O
for	O
SRP54sc	B-GENE
and	O
SRP54sp	B-GENE
that	O
are	O
47	O
%	O
and	O
52	O
%	O
identical	O
to	O
SRP54mam	B-GENE
,	O
respectively	O
.	O

Another	O
cis	O
-	O
acting	O
element	O
,	O
exonic	O
splicing	O
suppressor	O
1	O
(	O
ESS1	O
)	O
,	O
represses	O
use	O
of	O
the	O
nt	O
3225	O
3	O
'	O
splice	O
site	O
.	O

Although	O
methods	O
to	O
align	O
the	O
control	O
and	O
activation	O
fMR	O
images	O
may	O
correct	O
for	O
some	O
of	O
this	O
motional	O
error	O
,	O
they	O
will	O
be	O
incomplete	O
in	O
correcting	O
for	O
those	O
that	O
depend	O
on	O
spatial	O
orientation	O
.	O

In	O
the	O
ultramarathon	O
runner	O
the	O
testosterone	O
levels	O
sharply	O
rose	O
at	O
the	O
beginning	O
of	O
the	O
training	O
session	O
(	O
from	O
the	O
7	O
,	O
20	O
ng	O
/	O
ml	O
to	O
11	O
,	O
50	O
ng	O
/	O
ml	O
after	O
20	O
'	O
training	O
)	O
,	O
and	O
subsequently	O
decrease	O
after	O
3	O
hours	O
(	O
9	O
,	O
20	O
ng	O
/	O
ml	O
)	O
and	O
at	O
the	O
end	O
of	O
the	O
6	O
hours	O
training	O
(	O
4	O
,	O
60	O
ng	O
/	O
ml	O
)	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
m	B-GENE
-	I-GENE
Staf	I-GENE
is	O
highly	O
homologous	O
to	O
that	O
of	O
Staf	B-GENE
,	O
another	O
selenocysteine	B-GENE
tRNA	I-GENE
gene	I-GENE
transcription	I-GENE
activating	I-GENE
factor	I-GENE
of	O
Xenopus	O
laevis	O
.	O

However	O
,	O
laparoscopy	O
failed	O
to	O
establish	O
inoperability	O
in	O
any	O
cases	O
of	O
carcinoma	O
spread	O
to	O
areas	O
not	O
accessible	O
to	O
laparoscopic	O
visualization	O
.	O

Limited	O
role	O
for	O
PCR	O
-	O
based	O
diagnosis	O
of	O
Whipple	O
'	O
s	O
disease	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

In	O
ischemic	O
and	O
hypoxic	O
hypoxia	O
,	O
a	O
strong	O
correlation	O
was	O
found	O
between	O
cyt	O
a	O
,	O
a3	O
oxidation	O
level	O
and	O
VO2	O
in	O
both	O
ischemic	O
and	O
hypoxic	O
hypoxia	O
(	O
r2	O
=	O
.	O
90	O
and	O
.	O
87	O
,	O
respectively	O
)	O
.	O

The	O
sequence	O
similarity	O
has	O
suggested	O
that	O
SCG10	B-GENE
and	O
stathmin	B-GENE
have	O
been	O
derived	O
from	O
structurally	O
and	O
evolutionarily	O
related	O
genes	O
.	O

When	O
considered	O
with	O
the	O
known	O
neurotoxic	O
effects	O
on	O
children	O
of	O
"	O
low	O
levels	O
"	O
of	O
exposure	O
to	O
lead	O
,	O
these	O
results	O
also	O
suggest	O
that	O
either	O
an	O
excessively	O
narrow	O
margin	O
of	O
safety	O
or	O
insufficient	O
safety	O
is	O
provided	O
by	O
present	O
U	O
.	O
S	O
.	O
guidelines	O
,	O
which	O
classify	O
an	O
elevated	O
blood	O
lead	O
concentration	O
as	O
25	O
micrograms	O
/	O
dl	O
or	O
greater	O
.	O

Whereas	O
,	O
in	O
the	O
single	O
-	O
chambered	O
body	O
box	O
,	O
PenH	O
units	O
(	O
Enhanced	O
Pause	O
)	O
reflect	O
"	O
effort	O
of	O
breathing	O
.	O
"	O
This	O
is	O
measured	O
as	O
the	O
pause	O
between	O
inspiration	O
and	O
expiration	O
.	O

The	O
cwg2	B-GENE
-	I-GENE
1	I-GENE
mutation	I-GENE
was	O
identified	O
as	O
a	O
guanine	O
to	O
adenine	O
substitution	O
at	O
nucleotide	O
604	O
of	O
the	O
coding	O
region	O
,	O
originating	O
the	O
change	O
A202T	O
in	O
the	O
cwg2p	B-GENE
.	O

Abnormal	O
calcium	O
metabolism	O
in	O
normocalcaemic	O
sarcoidosis	O
.	O

These	O
genes	O
are	O
expressed	O
within	O
a	O
few	O
hours	O
of	O
the	O
initiation	O
of	O
development	O
;	O
their	O
mRNAs	O
accumulate	O
to	O
a	O
peak	O
at	O
12	O
hr	O
and	O
persist	O
until	O
culmination	O
.	O

First	O
,	O
two	O
MCTs	O
using	O
a	O
long	O
electrode	O
,	O
3	O
cm	O
in	O
size	O
,	O
were	O
performed	O
in	O
the	O
central	O
area	O
of	O
the	O
tumor	O
,	O
and	O
eight	O
MCTs	O
by	O
a	O
short	O
electrode	O
,	O
2	O
cm	O
in	O
size	O
,	O
were	O
done	O
in	O
the	O
peripheral	O
and	O
surrounding	O
area	O
of	O
the	O
tumor	O
.	O

The	O
bovine	B-GENE
PGHS	I-GENE
-	I-GENE
2	I-GENE
cDNA	I-GENE
was	O
cloned	O
by	O
a	O
combination	O
of	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
cDNA	O
library	O
screening	O
.	O

Functional	O
flow	O
was	O
evaluated	O
using	O
laser	O
Doppler	O
flowmetry	O
(	O
LDF	O
)	O
,	O
for	O
which	O
the	O
output	O
signal	O
,	O
blood	O
cell	O
flux	O
(	O
BCF	O
)	O
,	O
is	O
expressed	O
in	O
terms	O
of	O
volts	O
.	O

66	O
:	O
469	O
-	O
479	O
,	O
1992	O
)	O
.	O

These	O
results	O
provide	O
evidence	O
of	O
a	O
bypass	O
of	O
p53	B-GENE
-	O
induced	O
Waf1	B-GENE
/	O
Cip1	B-GENE
-	O
mediated	O
cell	O
cycle	O
regulatory	O
pathways	O
by	O
a	O
member	O
of	O
the	O
myb	B-GENE
oncogene	I-GENE
family	I-GENE
.	O

Extracellular	B-GENE
-	I-GENE
regulated	I-GENE
kinase	I-GENE
(	O
ERK	B-GENE
)	O
activation	O
and	O
molecular	O
coupling	O
of	O
the	O
adaptor	O
proteins	O
p130	B-GENE
Crk	B-GENE
-	I-GENE
associated	I-GENE
substrate	I-GENE
(	O
CAS	B-GENE
)	O
and	O
c	B-GENE
-	I-GENE
CrkII	I-GENE
(	O
Crk	B-GENE
)	O
represent	O
two	O
distinct	O
pathways	O
that	O
induce	O
cell	O
invasion	O
and	O
protect	O
cells	O
from	O
apoptosis	O
in	O
a	O
three	O
-	O
dimensional	O
collagen	B-GENE
matrix	O
.	O

DNA	O
hybridization	O
analysis	O
revealed	O
that	O
both	O
pigmented	O
and	O
nonpigmented	O
cells	O
of	O
Y	O
.	O
pestis	O
possess	O
a	O
DNA	O
locus	O
homologous	O
to	O
the	O
Escherichia	B-GENE
coli	I-GENE
fur	I-GENE
gene	I-GENE
.	O

The	O
genetic	O
basis	O
for	O
the	O
expression	O
of	O
a	O
latent	O
VH	B-GENE
allotype	I-GENE
in	O
the	O
rabbit	O
was	O
investigated	O
.	O

NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
p65	B-GENE
,	O
p50	B-GENE
,	O
and	O
Rel	B-GENE
functionally	O
synergize	O
with	O
C	B-GENE
/	I-GENE
EBP	I-GENE
alpha	I-GENE
,	O
C	B-GENE
/	I-GENE
EBP	I-GENE
beta	I-GENE
,	O
and	O
C	B-GENE
/	I-GENE
EBP	I-GENE
delta	I-GENE
.	O

A	O
5	O
.	O
0	O
-	O
kb	O
transcript	O
detected	O
by	O
the	O
differential	O
display	O
amplicon	O
3G1	O
was	O
found	O
to	O
correlate	O
strongly	O
with	O
RAG1	B-GENE
mRNA	I-GENE
expression	O
in	O
various	O
human	O
cell	O
lines	O
.	O

Because	O
L	B-GENE
-	I-GENE
plastin	I-GENE
expression	O
in	O
tissue	O
-	O
specifically	O
regulated	O
in	O
both	O
humans	O
and	O
rodents	O
,	O
it	O
is	O
likely	O
that	O
similar	O
mechanisms	O
regulate	O
L	B-GENE
-	I-GENE
plastin	I-GENE
gene	I-GENE
expression	O
in	O
human	O
and	O
rodent	O
cells	O
and	O
that	O
they	O
could	O
be	O
identified	O
by	O
comparing	O
the	O
function	O
and	O
nucleotide	O
sequences	O
of	O
the	O
human	O
and	O
murine	O
L	B-GENE
-	I-GENE
plastin	I-GENE
gene	O
promoters	O
.	O

It	O
is	O
transparent	O
,	O
cheap	O
to	O
be	O
made	O
,	O
and	O
easy	O
to	O
empty	O
and	O
was	O
tested	O
in	O
118	O
animals	O
for	O
two	O
and	O
four	O
weeks	O
.	O

All	O
clones	O
and	O
strains	O
produced	O
have	O
been	O
deposited	O
in	O
the	O
EUROFAN	O
genetic	O
stock	O
centre	O
(	O
EUROSCARF	O
,	O
Frankfurt	O
)	O
.	O

This	O
approach	O
places	O
gHoxb	B-GENE
-	I-GENE
1	I-GENE
into	O
the	O
normal	O
embryonic	O
spatiotemporal	O
context	O
in	O
which	O
lab	O
acts	O
.	O

Here	O
we	O
describe	O
the	O
identification	O
and	O
characterization	O
of	O
several	O
Sp100	B-GENE
splice	I-GENE
variant	I-GENE
proteins	I-GENE
and	O
support	O
their	O
existence	O
by	O
elucidation	O
of	O
the	O
3	O
'	O
-	O
end	O
of	O
the	O
Sp100	B-GENE
gene	I-GENE
.	O

During	O
the	O
following	O
9	O
1	O
/	O
2	O
years	O
three	O
sequential	O
liver	O
biopsies	O
were	O
performed	O
.	O

A	O
motif	O
(	O
TGATGTCA	O
)	O
which	O
matches	O
a	O
CREB	B-GENE
site	I-GENE
and	O
is	O
similar	O
to	O
an	O
AP	B-GENE
-	I-GENE
1	I-GENE
site	I-GENE
is	O
embedded	O
within	O
ER2	B-GENE
.	O

The	O
effects	O
of	O
the	O
transfected	O
receptors	O
were	O
associated	O
with	O
antagonism	O
of	O
activator	B-GENE
protein	I-GENE
1	I-GENE
(	O
AP	B-GENE
-	I-GENE
1	I-GENE
)	O
activity	O
.	O

Evolution	O
of	O
lesions	O
did	O
not	O
necessarily	O
follow	O
a	O
regular	O
progression	O
through	O
the	O
later	O
stages	O
of	O
the	O
vitelliform	O
classification	O
.	O

The	O
utility	O
of	O
such	O
analyses	O
in	O
the	O
design	O
of	O
ceramic	O
/	O
substrate	O
bilayer	O
systems	O
for	O
optimal	O
resistance	O
to	O
lifetime	O
-	O
threatening	O
damage	O
is	O
discussed	O
.	O

Thus	O
,	O
dpp	B-GENE
and	O
omb	B-GENE
promote	O
both	O
dorsal	O
leg	O
cell	O
fate	O
as	O
well	O
as	O
transdetermination	O
-	O
competent	O
leg	O
disc	O
cells	O
.	O

The	O
present	O
study	O
examined	O
the	O
dependence	O
of	O
difference	O
tone	O
level	O
[	O
L	O
(	O
f2	O
-	O
f1	O
)	O
]	O
on	O
the	O
following	O
parameters	O
of	O
the	O
two	O
-	O
tone	O
input	O
:	O
f1	O
,	O
f2	O
/	O
f1	O
(	O
f2	O
greater	O
than	O
f1	O
)	O
,	O
L1	O
,	O
L2	O
,	O
and	O
L1	O
=	O
L2	O
.	O

In	O
the	O
case	O
of	O
congenital	O
protein	B-GENE
C	I-GENE
deficiency	O
,	O
vitamin	O
K	O
antagonists	O
must	O
be	O
started	O
cautiously	O
due	O
to	O
the	O
risk	O
of	O
skin	O
necrosis	O
.	O

Y15170	B-GENE
(	O
Surf	B-GENE
-	I-GENE
2	I-GENE
,	O
Surf	B-GENE
-	I-GENE
4	I-GENE
)	O
,	O
Y15171	B-GENE
(	O
Surf	B-GENE
-	I-GENE
3	I-GENE
,	O
Surf	B-GENE
-	I-GENE
1	I-GENE
,	O
Surf	B-GENE
-	I-GENE
6	I-GENE
)	O
,	O
and	O
Y15172	B-GENE
(	O
Surf	B-GENE
-	I-GENE
5	I-GENE
.	O
)	O
]	O

Formalin	O
activated	O
both	O
SNO	O
NS	O
and	O
NnS	O
neurones	O
,	O
but	O
,	O
when	O
they	O
responded	O
,	O
NS	O
neurones	O
(	O
n	O
=	O
5	O
)	O
showed	O
only	O
the	O
first	O
phase	O
of	O
activity	O
while	O
NnS	O
neurones	O
showed	O
either	O
one	O
(	O
n	O
=	O
13	O
)	O
or	O
two	O
phases	O
(	O
n	O
=	O
6	O
)	O
.	O

The	O
-	O
64	O
/	O
-	O
37	O
region	O
interacted	O
with	O
purified	O
Sp1	B-GENE
and	O
an	O
unidentified	O
protein	O
(	O
s	O
)	O
,	O
proximal	B-GENE
regulatory	I-GENE
factor	I-GENE
(	I-GENE
s	I-GENE
)	I-GENE
I	I-GENE
(	O
PRF	B-GENE
-	I-GENE
I	I-GENE
)	O
.	O

The	O
mean	O
transfer	O
ratios	O
of	O
the	O
drug	O
into	O
the	O
genital	O
tissues	O
to	O
the	O
concentration	O
in	O
the	O
uterine	O
arterial	O
blood	O
were	O
such	O
that	O
the	O
transfer	O
ratio	O
into	O
the	O
portio	O
vaginalis	O
was	O
the	O
highest	O
,	O
followed	O
by	O
the	O
uterine	O
cervix	O
and	O
the	O
myometrium	O
,	O
and	O
that	O
into	O
the	O
oviduct	O
was	O
the	O
lowest	O
with	O
about	O
1	O
/	O
2	O
that	O
into	O
the	O
portio	O
vaginalis	O
.	O

Pentazocine	O
analgesia	O
:	O
is	O
there	O
a	O
niche	O
for	O
Talwin	O
Nx	O
?	O

Pentazocine	O
can	O
be	O
a	O
useful	O
analgesic	O
agent	O
for	O
the	O
management	O
of	O
acute	O
dental	O
pain	O
.	O

A	O
series	O
of	O
5	O
'	O
-	O
deletions	O
revealed	O
that	O
the	O
fragment	O
-	O
218	O
to	O
+	O
4	O
from	O
the	O
TSS	O
had	O
the	O
highest	O
promoter	O
activity	O
,	O
nearly	O
1000	O
-	O
fold	O
greater	O
than	O
the	O
promoterless	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
construct	I-GENE
.	O

In	O
44	O
evaluable	O
patients	O
the	O
response	O
rate	O
was	O
50	O
%	O
,	O
with	O
one	O
complete	O
response	O
.	O

Metastasis	O
of	O
colon	O
carcinoma	O
to	O
the	O
lip	O
.	O

In	O
one	O
acromegalic	O
patient	O
visual	O
improvement	O
was	O
obtained	O
while	O
the	O
abnormal	O
GH	B-GENE
secretion	O
remained	O
unaltered	O
.	O

Binding	O
affinities	O
of	O
different	O
nucleotide	O
mono	O
-	O
,	O
di	O
-	O
and	O
triphosphates	O
and	O
non	O
-	O
hydrolyzable	O
analogs	O
indicate	O
that	O
the	O
beta	O
-	O
phosphate	O
moiety	O
is	O
required	O
for	O
substrate	O
binding	O
.	O

The	O
central	O
(	O
R	O
)	O
domain	O
is	O
responsible	O
for	O
receptor	O
-	O
binding	O
activity	O
whereas	O
the	O
N	O
-	O
terminal	O
(	O
T	O
)	O
domain	O
mediates	O
translocation	O
,	O
the	O
process	O
by	O
which	O
the	O
C	O
-	O
terminal	O
cytotoxic	O
domain	O
is	O
transported	O
from	O
the	O
receptor	O
to	O
the	O
site	O
of	O
its	O
cytotoxicity	O
.	O

Localization	O
of	O
the	O
brachial	O
plexus	O
with	O
the	O
nerve	O
stimulator	O
is	O
equally	O
effective	O
at	O
the	O
interscalene	O
,	O
supraclavicular	O
,	O
and	O
axillary	O
sites	O
.	O

Additionally	O
,	O
a	O
CaCO3	O
-	O
CO2	O
/	O
N2	O
buffered	O
solution	O
was	O
necessary	O
to	O
maintain	O
a	O
pH	O
of	O
8	O
.	O

Nitrogen	O
-	O
hydrogen	O
tautomerism	O
in	O
porphyrins	O
and	O
chlorins	O
.	O

Using	O
anchored	O
PCR	O
,	O
a	O
VL	B-GENE
element	I-GENE
rearranged	O
to	O
CL2	B-GENE
was	O
isolated	O
.	O

Eight	O
recombinant	O
DNA	O
clones	O
of	O
endogenous	O
murine	O
leukemia	O
virus	O
(	O
MuLV	O
)	O
-	O
related	O
DNA	O
sequences	O
have	O
been	O
isolated	O
from	O
a	O
lambdaphage	O
genomic	O
library	O
of	O
Balb	O
/	O
c	O
mouse	O
DNA	O
.	O

In	O
this	O
article	O
we	O
propose	O
to	O
find	O
out	O
the	O
percentage	O
of	O
normal	O
occlusion	O
and	O
the	O
distribution	O
of	O
maloclusions	O
,	O
according	O
to	O
the	O
anteroposterior	O
relationship	O
between	O
the	O
dental	O
archs	O
(	O
following	O
the	O
ANGLE3	O
classification	O
)	O
.	O

Sequence	O
analysis	O
suggests	O
that	O
TtrA	B-GENE
contains	O
a	O
molybdopterin	O
guanine	O
dinucleotide	O
cofactor	O
and	O
a	O
[	O
4Fe	O
-	O
4S	O
]	O
cluster	O
,	O
that	O
TtrB	B-GENE
binds	O
four	O
[	O
4Fe	O
-	O
4S	O
]	O
clusters	O
,	O
and	O
that	O
TtrC	B-GENE
is	O
an	O
integral	O
membrane	O
protein	O
containing	O
a	O
quinol	O
oxidation	O
site	O
.	O

The	O
bioavailability	O
of	O
etodolac	O
from	O
capsules	O
exposed	O
to	O
stressed	O
conditions	O
was	O
compared	O
in	O
both	O
dogs	O
and	O
humans	O
to	O
capsules	O
stored	O
at	O
RT	O
conditions	O
.	O

The	O
results	O
confirm	O
that	O
a	O
single	O
base	O
change	O
in	O
the	O
branchpoint	O
consensus	O
sequence	O
of	O
an	O
intron	O
can	O
cause	O
human	O
disease	O
although	O
this	O
sequence	O
is	O
poorly	O
conserved	O
in	O
mammals	O
.	O

Re	O
:	O
"	O
Assessing	O
the	O
direction	O
of	O
causality	O
in	O
cross	O
-	O
sectional	O
studies	O
"	O
.	O

CONCLUSION	O
:	O
There	O
are	O
no	O
differences	O
in	O
the	O
measurement	O
data	O
derived	O
from	O
this	O
method	O
and	O
actual	O
measurement	O
data	O
from	O
an	O
object	O
created	O
by	O
the	O
computer	O
-	O
aided	O
dental	O
design	O
program	O
.	O

Clinical	O
findings	O
were	O
:	O
height	O
183	O
cm	O
,	O
weight	O
62	O
kg	O
,	O
increased	O
length	O
of	O
lower	O
limbs	O
,	O
P2	O
-	O
A2	O
pilosity	O
and	O
micropenis	O
.	O

Both	O
strains	O
grew	O
very	O
poorly	O
,	O
or	O
not	O
at	O
all	O
,	O
on	O
nonfermentable	O
carbon	O
sources	O
and	O
exhibited	O
,	O
at	O
most	O
,	O
only	O
5	O
%	O
of	O
wild	B-GENE
-	I-GENE
type	I-GENE
ubiquinol	I-GENE
-	I-GENE
cytochrome	I-GENE
c	I-GENE
oxidoreductase	I-GENE
activity	O
.	O

Exposure	O
of	O
peripheral	O
blood	O
T	O
cells	O
from	O
young	O
subjects	O
to	O
PHA	B-GENE
or	O
cross	O
-	O
linked	O
anti	B-GENE
-	I-GENE
CD3	I-GENE
monoclonal	I-GENE
antibodies	I-GENE
stimulated	O
rapid	O
increases	O
in	O
MAPK	B-GENE
and	O
MEK	B-GENE
enzymatic	O
activity	O
.	O

Re	O
-	O
examining	O
methylbenzene	O
(	O
toluene	O
)	O
as	O
a	O
treatment	O
for	O
Ancylostomum	O
caninum	O
.	O

In	O
the	O
point	O
mutant	O
we	O
observed	O
normal	O
repair	O
of	O
endonuclease	B-GENE
III	I-GENE
site	I-GENE
(	O
i	O
.	O
e	O
.	O
as	O
wild	O
type	O
)	O
,	O
but	O
no	O
removal	O
of	O
CPDs	O
at	O
the	O
MAT	B-GENE
alpha	I-GENE
and	O
HML	B-GENE
alpha	I-GENE
loci	I-GENE
.	O

Ischemic	O
heart	O
disease	O
,	O
age	O
of	O
more	O
than	O
75	O
years	O
,	O
and	O
the	O
fact	O
that	O
the	O
patient	O
was	O
a	O
woman	O
were	O
independent	O
predictors	O
of	O
poor	O
cardiac	O
function	O
.	O

Felodipine	O
did	O
not	O
alter	O
the	O
baseline	O
FEV1	O
,	O
but	O
showed	O
a	O
small	O
significant	O
inhibitory	O
effect	O
upon	O
histamine	O
and	O
AMP	O
induced	O
bronchoconstriction	O
.	O

The	O
mutant	O
allele	O
of	O
the	O
alpha	B-GENE
1	I-GENE
-	I-GENE
tubulin	I-GENE
gene	I-GENE
was	O
designated	O
tua1	B-GENE
-	I-GENE
1	I-GENE
.	O

Effects	O
of	O
dopamine	O
and	O
of	O
a	O
dopaminergic	O
blocker	O
,	O
haloperidol	O
,	O
on	O
the	O
responses	O
of	O
carotid	O
body	O
chemoreceptors	O
to	O
hypoxia	O
and	O
hypercapnia	O
were	O
investigated	O
in	O
16	O
anesthetized	O
cats	O
.	O

Marked	O
thrombocytopenia	O
,	O
depletion	O
of	O
serum	B-GENE
fibrinogen	I-GENE
and	O
prolonged	O
prothrombin	B-GENE
and	O
activated	O
partial	O
thromboplastin	B-GENE
time	O
,	O
were	O
recorded	O
at	O
5	O
to	O
10	O
and	O
30	O
to	O
40	O
minutes	O
after	O
intravenous	O
envenomation	O
.	O

Serum	O
induction	O
of	O
a	O
MEF2	B-GENE
reporter	I-GENE
gene	I-GENE
was	O
not	O
observed	O
in	O
a	O
line	O
of	O
NIH	O
3T3	O
cells	O
which	O
contain	O
low	O
MEF2	B-GENE
site	I-GENE
binding	O
activity	O
.	O

Competitive	O
mobility	O
shift	O
assays	O
using	O
either	O
alphaT3	O
-	O
1	O
nuclear	O
extract	O
or	O
recombinant	B-GENE
SF	I-GENE
-	I-GENE
1	I-GENE
protein	I-GENE
clearly	O
indicated	O
that	O
SF	B-GENE
-	I-GENE
1	I-GENE
is	O
able	O
to	O
interact	O
specifically	O
with	O
this	O
GSE	B-GENE
element	I-GENE
positioned	O
at	O
-	O
134	O
.	O

Restriction	O
maps	O
of	O
the	O
cloned	O
plasmids	O
revealed	O
that	O
their	O
chromosomal	O
inserts	O
consisted	O
of	O
overlapping	O
fragments	O
.	O

Schwab	O
and	O
England	O
ADL	O
scores	O
in	O
the	O
"	O
off	O
"	O
state	O
were	O
improved	O
by	O
18	O
%	O
and	O
in	O
the	O
"	O
on	O
"	O
state	O
the	O
scores	O
declined	O
by	O
2	O
%	O
.	O

In	O
addition	O
,	O
marked	O
hypertension	O
accompanied	O
this	O
disorder	O
and	O
all	O
abnormalities	O
,	O
including	O
the	O
hypertension	O
,	O
responded	O
to	O
1	B-GENE
-	I-GENE
desamino	I-GENE
-	I-GENE
8	I-GENE
-	I-GENE
D	I-GENE
-	I-GENE
arginine	I-GENE
vasopressin	I-GENE
therapy	O
.	O

Localization	O
of	O
67	O
exons	O
on	O
a	O
YAC	O
contig	O
spanning	O
1	O
.	O
5	O
Mb	O
around	O
the	O
multidrug	B-GENE
resistance	I-GENE
gene	I-GENE
region	I-GENE
of	O
human	O
chromosome	O
7q21	O
.	O
1	O
.	O

In	O
both	O
settings	O
,	O
it	O
can	O
be	O
phosphorylated	O
by	O
cyclin	B-GENE
D	I-GENE
-	I-GENE
dependent	I-GENE
kinases	I-GENE
,	O
suggesting	O
that	O
its	O
transcriptional	O
activity	O
may	O
normally	O
be	O
regulated	O
through	O
such	O
mechanisms	O
.	O

It	O
is	O
now	O
estimated	O
that	O
inactivation	O
mutants	O
of	O
PTEN	B-GENE
exist	O
in	O
60	O
%	O
of	O
all	O
forms	O
of	O
solid	O
tumors	O
.	O

Based	O
on	O
a	O
type	O
I	O
error	O
of	O
0	O
.	O
05	O
,	O
our	O
study	O
had	O
a	O
power	O
greater	O
than	O
or	O
equal	O
to	O
75	O
%	O
to	O
detect	O
group	O
differences	O
in	O
treatment	O
effect	O
of	O
greater	O
than	O
or	O
equal	O
to	O
15	O
%	O
to	O
20	O
%	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
risk	O
factors	O
for	O
background	O
diabetic	O
retinopathy	O
(	O
BDR	O
)	O
and	O
PDR	O
by	O
following	O
394	O
Japanese	O
patients	O
with	O
early	O
-	O
onset	O
type	O
2	O
diabetes	O
diagnosed	O
before	O
30	O
years	O
of	O
age	O
(	O
mean	O
age	O
27	O
,	O
mean	O
blood	O
pressure	O
at	O
entry	O
116	O
/	O
73	O
mm	O
Hg	O
)	O
.	O

Also	O
,	O
samples	O
of	O
serum	O
were	O
absorbed	O
with	O
the	O
various	O
solid	O
-	O
phase	O
allergens	O
and	O
the	O
reactivity	O
of	O
the	O
remaining	O
IgE	B-GENE
antibodies	I-GENE
was	O
determined	O
.	O

Computer	O
-	O
aided	O
"	O
FRAME	O
"	O
analysis	O
revealed	O
four	O
possible	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
,	O
three	O
in	O
one	O
direction	O
and	O
one	O
in	O
the	O
opposite	O
direction	O
.	O

Southern	O
blot	O
analysis	O
using	O
probes	O
from	O
the	O
3	O
'	O
portions	O
of	O
the	O
genomic	O
and	O
B	B-GENE
.	I-GENE
napus	I-GENE
MA	I-GENE
and	O
MB	B-GENE
cDNA	I-GENE
clones	O
showed	O
that	O
MA	B-GENE
type	I-GENE
myrosinases	B-GENE
are	O
encoded	O
by	O
approximately	O
4	O
genes	O
,	O
while	O
MB	B-GENE
type	I-GENE
myrosinases	B-GENE
are	O
encoded	O
by	O
more	O
than	O
10	O
genes	O
in	O
B	O
.	O
napus	O
.	O

In	O
general	O
,	O
the	O
filtration	O
rate	O
in	O
relevant	O
areas	O
appears	O
to	O
be	O
an	O
integrative	O
and	O
easily	O
determined	O
parameter	O
,	O
reflecting	O
hormonal	O
and	O
neurogenic	O
vascular	O
as	O
well	O
as	O
local	O
interstitial	O
control	O
of	O
the	O
Starling	O
forces	O
.	O

Translation	O
of	O
specific	O
cellular	O
genes	O
from	O
the	O
chimeric	O
viral	O
-	O
cellular	O
transcripts	O
seems	O
to	O
be	O
unlikely	O
.	O

Possible	O
relationship	O
between	O
hyperinsulinemia	O
and	O
glomerular	O
hypertrophy	O
in	O
nephrosclerosis	O
.	O

These	O
data	O
suggest	O
that	O
ADAM	B-GENE
-	I-GENE
TS12	I-GENE
may	O
play	O
roles	O
in	O
pulmonary	O
cells	O
during	O
fetal	O
development	O
or	O
in	O
tumor	O
processes	O
through	O
its	O
proteolytic	O
activity	O
or	O
as	O
a	O
molecule	O
potentially	O
involved	O
in	O
regulation	O
of	O
cell	O
adhesion	O
.	O

A	O
polypeptide	O
encoded	O
by	O
the	O
NTS	O
16	O
open	O
reading	O
frame	O
has	O
sequence	O
similarity	O
to	O
the	O
catalytic	O
domain	O
of	O
several	O
receptor	B-GENE
protein	I-GENE
kinases	I-GENE
from	I-GENE
plants	I-GENE
including	O
the	O
S	B-GENE
-	I-GENE
receptor	I-GENE
kinases	I-GENE
implicated	O
in	O
the	O
rejection	O
of	O
self	O
-	O
pollen	O
in	O
Brassica	O
species	O
and	O
the	O
Pto	B-GENE
gene	I-GENE
product	I-GENE
of	I-GENE
tomato	I-GENE
which	O
confers	O
resistance	O
to	O
a	O
bacterial	O
pathogen	O
.	O

A	O
Dictyostelium	O
transformant	O
overexpressing	O
DdPTPa	B-GENE
does	O
not	O
develop	O
normally	O
.	O

100	O
more	O
than	O
in	O
the	O
summer	O
coat	O
)	O
.	O

However	O
,	O
the	O
relative	O
binding	O
affinity	O
for	O
the	O
motifs	O
is	O
different	O
.	O

These	O
differences	O
are	O
smaller	O
than	O
those	O
described	O
in	O
standard	O
textbooks	O
.	O

This	O
c	B-GENE
-	I-GENE
Jun	I-GENE
activity	O
is	O
inhibited	O
by	O
c	B-GENE
-	I-GENE
Fos	I-GENE
,	O
another	O
protooncoprotein	O
that	O
can	O
dimerize	O
with	O
c	B-GENE
-	I-GENE
Jun	I-GENE
to	O
form	O
the	O
transcription	O
factor	O
AP	B-GENE
-	I-GENE
1	I-GENE
.	O

The	O
XS2	B-GENE
gene	I-GENE
down	O
-	O
regulates	O
but	O
does	O
not	O
abolish	O
expression	O
of	O
LU	B-GENE
genes	I-GENE
and	O
does	O
not	O
affect	O
expression	O
of	O
CD44	B-GENE
.	O

Northern	O
analysis	O
of	O
RNA	O
samples	O
isolated	O
from	O
ammonium	O
-	O
grown	O
cultures	O
of	O
the	O
ntcA	B-GENE
mutant	I-GENE
showed	O
reduced	O
amounts	O
of	O
glnA	B-GENE
message	I-GENE
and	O
the	O
absence	O
of	O
a	O
1	O
.	O
7	O
-	O
kb	O
transcript	O
.	O

Upstream	O
of	O
-	O
37	O
,	O
the	O
5	O
'	O
untranslated	O
sequences	O
of	O
the	O
isolates	O
differ	O
in	O
both	O
length	O
and	O
sequence	O
.	O

Null	O
alleles	O
of	O
SAS4	B-GENE
and	O
SAS5	B-GENE
bypassed	O
the	O
role	O
of	O
the	O
Abf1p	B-GENE
binding	I-GENE
site	I-GENE
of	O
the	O
HMR	B-GENE
-	I-GENE
E	I-GENE
silencer	I-GENE
but	O
not	O
the	O
role	O
of	O
the	O
ACS	B-GENE
or	O
Rap1p	B-GENE
binding	I-GENE
site	I-GENE
.	O

Surprisingly	O
,	O
the	O
RXR	B-GENE
-	O
specific	O
ligand	O
9	O
-	O
cis	O
-	O
retinoic	O
acid	O
induced	O
binding	O
of	O
SRC	B-GENE
-	I-GENE
1	I-GENE
to	O
the	O
RXR	B-GENE
component	I-GENE
of	O
the	O
TRE	O
-	O
bound	O
heterodimer	O
.	O

Anecdotal	O
observations	O
scattered	O
throughout	O
the	O
literature	O
have	O
often	O
provided	O
clues	O
to	O
underlying	O
variations	O
in	O
humans	O
'	O
ability	O
to	O
handle	O
dietary	O
chemicals	O
.	O

As	O
expected	O
,	O
homologous	B-GENE
loxP	I-GENE
sequences	I-GENE
efficiently	O
underwent	O
Cre	B-GENE
-	O
mediated	O
recombination	O
.	O

Effects	O
of	O
repeated	O
exposures	O
of	O
hydrogen	O
sulphide	O
on	O
rat	O
hippocampal	O
EEG	O
.	O

The	O
ORF3	O
probe	O
also	O
hybridized	O
to	O
a	O
540	O
bp	O
transcript	O
consistent	O
with	O
the	O
size	O
of	O
ORF3	O
alone	O
and	O
supportive	O
of	O
the	O
mutagenesis	O
data	O
of	O
non	O
-	O
linkage	O
.	O

Studies	O
on	O
the	O
organic	O
matrix	O
of	O
human	O
ear	O
ossicles	O

However	O
,	O
kidneys	O
perfused	O
for	O
72	O
hr	O
demonstrated	O
more	O
similar	O
renal	O
functions	O
when	O
tested	O
by	O
either	O
IMPK	O
or	O
IBPK	O
.	O

The	O
ectopic	O
expression	O
of	O
Oct	B-GENE
-	I-GENE
3	I-GENE
/	I-GENE
4	I-GENE
in	O
hybrid	O
cells	O
under	O
a	O
constitutive	O
promoter	O
is	O
sufficient	O
for	O
transcriptional	O
activation	O
of	O
an	O
octamer	O
-	O
dependent	O
promoter	O
.	O

RESULTS	O
:	O
The	O
age	O
distribution	O
was	O
28	O
to	O
83	O
years	O
old	O
(	O
mean	O
was	O
54	O
.	O
1	O
years	O
)	O
.	O

DNA	O
-	O
protein	O
UV	O
cross	O
-	O
linking	O
studies	O
indicated	O
that	O
UHF	B-GENE
-	I-GENE
1	I-GENE
has	O
an	O
electrophoretic	O
mobility	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
acrylamide	O
gels	O
of	O
approximately	O
85	O
kDa	O
and	O
suggested	O
that	O
additional	O
proteins	O
,	O
specific	O
to	O
each	O
promoter	O
,	O
bind	O
to	O
each	O
site	O
.	O

In	O
cases	O
of	O
1	O
degrees	O
HPT	O
,	O
the	O
plasma	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D	O
level	O
rose	O
significantly	O
in	O
all	O
cases	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
although	O
the	O
pattern	O
of	O
the	O
increase	O
was	O
not	O
uniform	O
.	O

4	O
.	O
26	O
+	O
/	O
-	O
1	O
.	O
54	O
mmol	O
/	O
l	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
systolic	O
BP	O
responses	O
to	O
intravenous	O
norepinephrine	O
and	O
angiotensin	B-GENE
II	I-GENE
were	O
significantly	O
higher	O
on	O
glibenclamide	O
than	O
on	O
metformin	O
(	O
P	O
<	O
0	O
.	O
02	O
and	O
P	O
<	O
0	O
.	O
05	O
,	O
respectively	O
)	O
.	O

Control	O
of	O
fatty	O
liver	O
syndrome	O
in	O
a	O
Jersey	O
herd	O
by	O
a	O
change	O
of	O
diet	O
and	O
the	O
use	O
of	O
recombinant	O
bovine	O
somatotrophin	B-GENE
.	O

Precipitation	O
using	O
GST	B-GENE
fusion	I-GENE
proteins	I-GENE
containing	O
Fyn	B-GENE
SH2	B-GENE
,	O
SH3	B-GENE
,	O
and	O
SH2	B-GENE
/	O
SH3	B-GENE
domains	O
revealed	O
that	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
bound	O
principally	O
to	O
the	O
SH3	B-GENE
domain	I-GENE
of	O
Fyn	B-GENE
.	O

Fluorimetric	O
determination	O
of	O
methylmercury	O
as	O
an	O
ion	O
-	O
association	O
complex	O
with	O
rhodamine	O
B	O
in	O
the	O
presence	O
of	O
iodide	O
.	O

Unlike	O
the	O
mammalian	O
proteins	O
,	O
XFGF3	B-GENE
is	O
efficiently	O
secreted	O
as	O
a	O
Mr	O
31	O
,	O
000	O
glycoprotein	O
,	O
gp31	B-GENE
,	O
which	O
undergoes	O
proteolytic	O
cleavage	O
to	O
produce	O
an	O
NH2	O
-	O
terminally	O
truncated	O
product	O
,	O
gp27	B-GENE
.	O

Tristetraprolin	B-GENE
(	O
TTP	B-GENE
)	O
is	O
the	O
prototype	O
of	O
a	O
group	O
of	O
potential	O
transcription	O
factors	O
that	O
contain	O
two	O
or	O
more	O
unusual	O
CCCH	O
zinc	O
fingers	O
.	O

Unusual	O
course	O
of	O
plasmocytosis	O
.	O

Binding	O
of	O
U2	B-GENE
small	I-GENE
nuclear	I-GENE
ribonucleoprotein	I-GENE
(	O
snRNP	O
)	O
to	O
the	O
pre	O
-	O
mRNA	O
is	O
an	O
early	O
and	O
important	O
step	O
in	O
spliceosome	O
assembly	O
.	O

In	O
addition	O
,	O
we	O
observe	O
that	O
the	O
hUBF	B-GENE
-	I-GENE
promoter	I-GENE
interaction	O
is	O
highly	O
sensitive	O
to	O
the	O
antagonistic	O
effects	O
of	O
cisplatin	O
-	O
DNA	O
adducts	O
.	O

Mss4	B-GENE
also	O
acts	O
as	O
a	O
relatively	O
inefficient	O
guanine	B-GENE
nucleotide	I-GENE
exchange	I-GENE
factor	I-GENE
(	O
GEF	B-GENE
)	O
.	O

Prolonged	O
heavy	O
work	O
effected	O
an	O
increase	O
of	O
10	O
.	O
3	O
plus	O
or	O
minus	O
0	O
.	O
9	O
mmHg	O
in	O
in	O
vivo	O
P50	O
(	O
7	O
.	O
30	O
PH	O
-	O
v	O
,	O
41	O
degrees	O
C	O
-	O
v	O
,	O
and	O
45	O
Pv	O
-	O
CO2	O
)	O
;	O
due	O
entirely	O
to	O
the	O
additive	O
effects	O
of	O
increased	O
venous	O
temperature	O
and	O
[	O
H	O
+	O
]	O
.	O

The	O
RFLP	O
patterns	O
of	O
the	O
isolates	O
from	O
six	O
of	O
these	O
patients	O
remained	O
essentially	O
unchanged	O
(	O
two	O
strains	O
showed	O
one	O
additional	O
band	O
)	O
despite	O
the	O
development	O
of	O
drug	O
resistance	O
.	O

Plasma	O
and	O
erthrocyte	O
lipid	O
profile	O
and	O
lipoprotein	B-GENE
lipase	I-GENE
activity	O
in	O
postheparin	O
plasma	O
on	O
vasectomized	O
rabbits	O
were	O
studied	O
and	O
also	O
the	O
incidence	O
of	O
atherosclerosis	O
in	O
different	O
arterial	O
beds	O
.	O

TEMTU	O
and	O
DPTU	O
were	O
the	O
most	O
potent	O
teratogens	O
.	O

We	O
have	O
shown	O
that	O
the	O
epidural	O
(	O
EPI	O
)	O
delivery	O
of	O
morphine	O
encapsulated	O
in	O
multivesicular	O
liposomes	O
(	O
DepoFoam	O
drug	O
delivery	O
system	O
)	O
produces	O
a	O
sustained	O
clearance	O
of	O
morphine	O
and	O
a	O
prolonged	O
analgesia	O
.	O

A	O
case	O
of	O
AIDS	O
-	O
related	O
complex	O
(	O
ARC	O
/	O
LAS	O
)	O
in	O
a	O
health	O
worker	O

The	O
mechanism	O
of	O
the	O
induction	O
of	O
3beta	B-GENE
-	I-GENE
HSD	I-GENE
type	I-GENE
1	I-GENE
gene	I-GENE
expression	O
was	O
further	O
characterized	O
in	O
ZR	O
-	O
75	O
-	O
1	O
human	O
breast	O
cancer	O
cells	O
.	O

From	O
this	O
library	O
,	O
LEU2	B-GENE
and	O
HIS3	B-GENE
cDNAs	O
were	O
recovered	O
at	O
a	O
frequency	O
of	O
about	O
1	O
in	O
10	O
(	O
4	O
)	O
and	O
in	O
12	O
out	O
of	O
13	O
cases	O
these	O
were	O
expressed	O
in	O
a	O
galactose	O
-	O
dependent	O
manner	O
.	O

Here	O
,	O
we	O
identify	O
Rsc3	B-GENE
and	O
Rsc30	B-GENE
as	O
novel	O
components	O
of	O
the	O
essential	O
yeast	B-GENE
remodeler	I-GENE
RSC	I-GENE
complex	I-GENE
.	O

We	O
also	O
observed	O
that	O
the	O
predictive	O
ability	O
of	O
the	O
selected	O
attitudes	O
and	O
orientations	O
increased	O
considerably	O
from	O
1975	O
to	O
1982	O
.	O

Electromobility	O
shift	O
and	O
cotransfection	O
assays	O
demonstrated	O
that	O
HNF1alpha	B-GENE
,	O
but	O
not	O
HNF4	B-GENE
,	O
bound	O
to	O
its	O
cognate	O
site	O
and	O
transactivated	O
G6Pase	B-GENE
gene	I-GENE
expression	O
.	O

Comparison	O
with	O
the	O
bHLH	B-GENE
/	O
PAS	B-GENE
family	O
genes	O
revealed	O
that	O
the	O
intron	O
/	O
exon	O
splice	O
pattern	O
of	O
mBMAL1	B-GENE
most	O
closely	O
matches	O
that	O
of	O
the	O
mAhr	B-GENE
,	O
which	O
suggests	O
that	O
BMAL1	B-GENE
and	O
Ahr	B-GENE
belong	O
to	O
the	O
same	O
subclass	O
and	O
may	O
be	O
derived	O
from	O
a	O
common	O
primordial	O
gene	O
.	O

In	O
three	O
of	O
the	O
seven	O
,	O
inhalation	O
of	O
2	O
ml	O
normal	O
saline	O
produced	O
FEV1	O
falls	O
of	O
25	O
%	O
to	O
30	O
%	O
,	O
but	O
these	O
falls	O
were	O
not	O
as	O
great	O
as	O
each	O
subject	O
'	O
s	O
reactions	O
to	O
the	O
test	O
solutions	O
.	O

Stable	O
transfection	O
of	O
the	O
BL	O
cell	O
line	O
Raji	O
with	O
constructs	O
containing	O
core	O
promoter	O
mutations	O
confirmed	O
that	O
the	O
proximal	O
Sp1	B-GENE
site	I-GENE
and	O
the	O
TATA	O
box	O
are	O
essential	O
for	O
the	O
activation	O
of	O
promoter	O
P1	O
by	O
the	O
Ig	B-GENE
kappa	I-GENE
enhancers	I-GENE
.	O

Is	O
clopidogrel	O
superior	O
to	O
aspirin	O
in	O
secondary	O
prevention	O
of	O
vascular	O
disease	O
?	O

The	O
cornerstone	O
in	O
clinical	O
evidence	O
of	O
the	O
relative	O
efficacy	O
of	O
thienopyridines	O
(	O
clopidogrel	O
,	O
ticlopidine	O
)	O
versus	O
aspirin	O
in	O
the	O
secondary	O
prevention	O
of	O
vascular	O
disease	O
is	O
the	O
Clopidogrel	O
versus	O
Aspirin	O
in	O
Patients	O
at	O
Risk	O
of	O
Ischaemic	O
Events	O
trial	O
.	O

These	O
results	O
indicate	O
that	O
the	O
total	O
number	O
of	O
subunit	O
c	O
in	O
F0	B-GENE
should	O
be	O
a	O
multiple	O
of	O
2	O
and	O
3	O
.	O

UF	O
-	O
021	O
ophthalmic	O
solution	O
(	O
0	O
.	O
03	O
to	O
0	O
.	O
24	O
%	O
)	O
,	O
when	O
topically	O
applied	O
to	O
the	O
eyes	O
of	O
rabbits	O
,	O
caused	O
dose	O
-	O
dependent	O
IOP	O
reduction	O
(	O
2	O
.	O
8	O
to	O
5	O
.	O
2	O
mmHg	O
)	O
,	O
without	O
transient	O
IOP	O
rise	O
.	O

The	O
continuing	O
development	O
of	O
ligands	O
that	O
function	O
as	O
selective	O
estrogens	O
or	O
antiestrogens	O
for	O
ERalpha	B-GENE
or	O
ERbeta	B-GENE
should	O
allow	O
optimized	O
tissue	O
selectivity	O
of	O
these	O
agents	O
for	O
menopausal	O
hormone	O
replacement	O
therapy	O
and	O
the	O
treatment	O
and	O
prevention	O
of	O
breast	O
cancer	O
.	O

From	O
two	O
inhibitor	O
scaffolds	O
,	O
we	O
have	O
identified	O
potent	O
and	O
selective	O
inhibitors	O
for	O
sensitized	O
kinases	O
from	O
five	O
distinct	O
subfamilies	O
.	O

RESULTS	O
:	O
Average	O
age	O
at	O
symptom	O
onset	O
was	O
41	O
.	O
2	O
years	O
.	O

A	O
role	O
for	O
glycogen	B-GENE
synthase	I-GENE
kinase	I-GENE
-	I-GENE
3	I-GENE
in	O
the	O
control	O
of	O
gene	O
expression	O
.	O

Tolerance	O
test	O
of	O
HB	O
419	O
in	O
animal	O
experiments	O

Possibly	O
,	O
the	O
scr1	B-GENE
-	I-GENE
1	I-GENE
mutation	I-GENE
does	O
not	O
affect	O
signal	O
recognition	O
or	O
translational	O
arrest	O
but	O
instead	O
results	O
in	O
maintenance	O
of	O
translational	O
arrest	O
of	O
AEP	B-GENE
synthesis	O
.	O

A	O
total	O
of	O
194	O
STSs	O
map	O
to	O
this	O
interval	O
of	O
3	O
Mb	O
,	O
giving	O
an	O
average	O
marker	O
resolution	O
of	O
approximately	O
one	O
per	O
15	O
kb	O
.	O

Brainstem	O
auditory	O
evoked	O
responses	O
(	O
BAERs	O
)	O
and	O
quantitative	O
saccadic	O
eye	O
movement	O
studies	O
provide	O
information	O
on	O
the	O
integrity	O
of	O
pathways	O
traversing	O
the	O
brainstem	O
.	O

Latanoprost	O
produces	O
an	O
additional	O
reduction	O
of	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
when	O
used	O
in	O
combination	O
with	O
timolol	O
,	O
pilocarpine	O
,	O
acetazolamide	O
and	O
dipivefrin	O
.	O

In	O
patients	O
with	O
type	O
II	O
tumors	O
,	O
the	O
pattern	O
of	O
lymphatic	O
spread	O
was	O
primarily	O
directed	O
toward	O
the	O
paracardial	O
,	O
lesser	O
curvature	O
,	O
and	O
left	O
gastric	O
artery	O
nodes	O
;	O
esophagectomy	O
offered	O
no	O
survival	O
benefit	O
over	O
extended	O
gastrectomy	O
in	O
these	O
patients	O
.	O

In	O
contrast	O
to	O
the	O
wild	O
-	O
type	O
protein	O
,	O
expression	O
of	O
p45	B-GENE
NF	B-GENE
-	I-GENE
E2	I-GENE
lacking	O
this	O
activation	O
domain	O
in	O
an	O
NF	B-GENE
-	I-GENE
E2	I-GENE
null	O
cell	O
line	O
fails	O
to	O
support	O
enhancer	O
-	O
dependent	O
transcription	O
in	O
transient	O
assays	O
.	O

Levels	O
of	O
the	O
MEK	B-GENE
inhibitor	O
PD98059	O
that	O
block	O
EGF	B-GENE
-	O
induced	O
mitogenesis	O
and	O
MAP	B-GENE
kinase	I-GENE
phosphorylation	O
also	O
abrogate	O
EGF	B-GENE
-	O
induced	O
focal	O
adhesion	O
disassembly	O
and	O
cell	O
motility	O
.	O

Finally	O
,	O
there	O
are	O
a	O
growing	O
number	O
of	O
arguments	O
favouring	O
the	O
use	O
of	O
ACE	B-GENE
inhibitors	O
very	O
early	O
in	O
patients	O
with	O
diabetes	O
mellitus	O
.	O

These	O
corrections	O
do	O
not	O
involve	O
sequences	O
predicted	O
to	O
function	O
as	O
transcription	O
factor	O
binding	O
sites	O
.	O

Because	O
of	O
the	O
small	O
number	O
of	O
visceral	O
angiography	O
procedures	O
performed	O
(	O
38	O
)	O
,	O
no	O
definitive	O
conclusions	O
could	O
be	O
drawn	O
as	O
to	O
the	O
differences	O
between	O
ionic	O
and	O
nonionic	O
agents	O
regarding	O
grade	O
-	O
2	O
and	O
grade	O
-	O
3	O
adverse	O
events	O
.	O

The	O
predicted	O
L	B-GENE
mRNA	I-GENE
was	O
6398	O
nucleotides	O
long	O
and	O
contained	O
a	O
single	O
open	O
reading	O
frame	O
corresponding	O
to	O
an	O
L	B-GENE
protein	I-GENE
encompassing	I-GENE
2109	I-GENE
amino	I-GENE
acids	I-GENE
with	O
a	O
MW	O
of	O
241	O
,	O
546	O
.	O

Like	O
scrotal	O
testes	O
,	O
undescended	O
testes	O
were	O
hypointense	O
to	O
fat	O
on	O
sequences	O
with	O
a	O
short	O
repetition	O
time	O
(	O
TR	O
)	O
and	O
echo	O
time	O
(	O
TE	O
)	O
in	O
all	O
cases	O
,	O
and	O
hyperintense	O
or	O
isointense	O
to	O
fat	O
on	O
long	O
TR	O
/	O
TE	O
sequences	O
in	O
all	O
but	O
two	O
cases	O
.	O

We	O
found	O
that	O
both	O
the	O
E26	O
virus	O
-	O
encoded	O
v	B-GENE
-	I-GENE
ets	I-GENE
and	O
the	O
myeloid	B-GENE
/	I-GENE
B	I-GENE
-	I-GENE
cell	I-GENE
-	I-GENE
specific	I-GENE
factor	I-GENE
PU	I-GENE
.	I-GENE
1	I-GENE
bind	O
efficiently	O
to	O
this	O
site	O
in	O
vitro	O
.	O

MS	O
characteristics	O
of	O
coumarins	O
,	O
psoralens	O
and	O
polymethoxylated	O
flavones	O
with	O
different	O
substitution	O
patterns	O
were	O
determined	O
on	O
the	O
basis	O
of	O
the	O
response	O
obtained	O
with	O
the	O
APcI	O
interface	O
.	O

Macroscopic	O
researches	O
on	O
heart	O
vascularization	O
have	O
indicated	O
that	O
the	O
angioarchitecture	O
of	O
the	O
conducting	O
system	O
differs	O
from	O
that	O
of	O
the	O
normal	O
myocardium	O
.	O

Deleting	O
SNF1	B-GENE
repressed	O
meiosis	O
at	O
the	O
same	O
three	O
steps	O
that	O
were	O
inhibited	O
by	O
glucose	O
,	O
suggesting	O
that	O
glucose	O
blocks	O
meiosis	O
by	O
inhibiting	O
Snf1	B-GENE
.	O

The	O
images	O
showed	O
rapid	O
,	O
predominantly	O
urinary	O
excretion	O
of	O
99mTc	O
ciprofloxacin	O
,	O
with	O
low	O
to	O
absent	O
brain	O
,	O
lung	O
and	O
bone	O
marrow	O
uptake	O
and	O
low	O
liver	O
uptake	O
and	O
excretion	O
.	O

Relations	O
between	O
adrenergic	O
mechanisms	O
and	O
analgesic	O
effects	O

Self	O
or	O
foreign	O
cellular	O
proteins	O
provide	O
peptides	O
for	O
presentation	O
by	O
major	B-GENE
histocompatibility	I-GENE
complex	I-GENE
(	I-GENE
MHC	I-GENE
)	I-GENE
class	I-GENE
I	I-GENE
molecules	I-GENE
on	O
the	O
surface	O
of	O
antigen	O
presenting	O
cells	O
(	O
APC	O
)	O
.	O

By	O
an	O
induced	O
-	O
fit	O
mechanism	O
,	O
contacts	O
with	O
the	O
anticodon	O
can	O
activate	O
formation	O
of	O
a	O
robust	O
transition	O
state	O
at	O
a	O
site	O
over	O
70	O
A	O
away	O
.	O

In	O
Experiment	O
1	O
,	O
pups	O
that	O
had	O
received	O
an	O
injection	O
of	O
the	O
noncompetitive	O
N	B-GENE
-	I-GENE
methyl	I-GENE
-	I-GENE
D	I-GENE
-	I-GENE
aspartate	I-GENE
receptor	I-GENE
antagonist	O
MK	O
-	O
801	O
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
either	O
30	O
min	O
before	O
or	O
immediately	O
after	O
conditioning	O
spent	O
less	O
time	O
over	O
the	O
conditioned	O
odor	O
than	O
saline	O
-	O
treated	O
controls	O
.	O

Evaluation	O
of	O
the	O
Du	O
Pont	O
aca	O
ammonia	O
procedure	O
.	O

A	O
new	O
non	O
-	O
LTR	O
retrotransposon	O
provides	O
evidence	O
for	O
multiple	O
distinct	O
site	O
-	O
specific	O
elements	O
in	O
Crithidia	O
fasciculata	O
miniexon	O
arrays	O
.	O

The	O
seco	O
-	O
steroid	O
hormone	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
is	O
known	O
to	O
induce	O
the	O
expression	O
of	O
a	O
calcium	O
binding	O
protein	O
termed	O
calbindin	B-GENE
-	I-GENE
D28K	I-GENE
in	O
a	O
variety	O
of	O
target	O
tissues	O
.	O

Entry	O
of	O
yeast	O
cells	O
into	O
the	O
mitotic	O
cell	O
cycle	O
(	O
Start	O
)	O
involves	O
a	O
form	O
of	O
the	O
CDC28	B-GENE
kinase	I-GENE
that	O
associates	O
with	O
G1	O
-	O
specific	O
cyclins	B-GENE
encoded	O
by	O
CLN1	B-GENE
and	O
CLN2	B-GENE
(	O
ref	O
.	O

A	O
third	O
is	O
a	O
partial	O
element	O
terminating	O
at	O
a	O
probable	O
internal	O
restriction	O
site	O
used	O
for	O
cloning	O
.	O

In	O
76	O
%	O
of	O
59	O
lead	O
-	O
toxic	O
children	O
,	O
bone	O
lead	O
values	O
measured	O
by	O
LXRF	O
were	O
equal	O
to	O
or	O
greater	O
than	O
those	O
measured	O
in	O
normal	O
and	O
industrially	O
exposed	O
adults	O
.	O

Sequence	O
analysis	O
of	O
the	O
sMtCK	B-GENE
genomic	I-GENE
upstream	I-GENE
sequences	I-GENE
reveals	O
a	O
typical	O
TATAA	O
box	O
within	O
the	O
80	O
base	O
pairs	O
(	O
bp	O
)	O
that	O
,	O
by	O
transfection	O
experiments	O
,	O
are	O
sufficient	O
to	O
promote	O
expression	O
of	O
chimeric	O
plasmids	O
with	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
reporter	I-GENE
.	O

Sequence	O
analysis	O
of	O
the	O
sMtCK	B-GENE
genomic	I-GENE
upstream	I-GENE
sequences	I-GENE
reveals	O
a	O
typical	O
TATAA	O
box	O
within	O
the	O
80	O
base	O
pairs	O
(	O
bp	O
)	O
that	O
,	O
by	O
transfection	O
experiments	O
,	O
are	O
sufficient	O
to	O
promote	O
expression	O
of	O
chimeric	O
plasmids	O
with	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
reporter	I-GENE
.	O

CONCLUSION	O
:	O
Patients	O
wit	O
clinically	O
palpable	O
neck	O
disease	O
(	O
N1	O
-	O
3	O
)	O
,	O
histological	O
evidence	O
of	O
metastatic	O
nodal	O
disease	O
,	O
extracapsular	O
spread	O
,	O
and	O
three	O
or	O
more	O
positive	O
lymph	O
nodes	O
are	O
at	O
greater	O
risk	O
of	O
developing	O
failure	O
at	O
distant	O
sites	O
.	O

The	O
fast	O
real	O
-	O
time	O
digital	O
processing	O
of	O
the	O
N2	O
and	O
flow	O
signals	O
incorporated	O
filtering	O
,	O
delay	O
compensation	O
,	O
and	O
corrections	O
for	O
the	O
effects	O
of	O
changes	O
in	O
gas	O
composition	O
and	O
temperature	O
.	O

They	O
were	O
found	O
to	O
stimulate	O
at	O
nanomolar	O
concentrations	O
the	O
turnover	O
of	O
biosynthetically	O
labeled	O
ceramide	O
,	O
glucosylceramide	O
,	O
and	O
lactosylceramide	O
.	O

Petrous	O
meningioma	O
en	O
plaque	O
presenting	O
as	O
a	O
right	O
middle	O
ear	O
tumor	O
.	O

In	O
order	O
to	O
study	O
the	O
influence	O
of	O
iron	O
overload	O
on	O
the	O
polymorphonuclear	O
leucocyte	O
(	O
PMN	O
)	O
metabolism	O
of	O
patients	O
on	O
chronic	O
hemodialysis	O
,	O
generation	O
of	O
superoxide	O
anion	O
(	O
O2	O
-	O
)	O
by	O
PMN	O
in	O
whole	O
blood	O
was	O
compared	O
in	O
two	O
groups	O
of	O
hemodialyzed	O
patients	O
:	O
group	O
A	O
consisted	O
of	O
twenty	O
-	O
one	O
individuals	O
with	O
serum	O
ferritin	B-GENE
levels	O
above	O
1000	O
ng	O
/	O
ml	O
and	O
group	O
B	O
of	O
nineteen	O
individuals	O
with	O
serum	O
ferritin	B-GENE
levels	O
below	O
1000	O
ng	O
/	O
ml	O
.	O

Mo	O
+	O
SV	O
M	O
-	O
MuLV	O
-	O
inoculated	O
animals	O
became	O
moribund	O
at	O
3	O
to	O
13	O
months	O
postinoculation	O
,	O
whereas	O
delta	O
Mo	O
+	O
SV	O
M	O
-	O
MuLV	O
-	O
inoculated	O
animals	O
became	O
moribund	O
at	O
6	O
to	O
24	O
months	O
postinoculation	O
.	O

Crosstalk	O
among	O
the	O
pathways	O
may	O
explain	O
how	O
some	O
forms	O
of	O
stress	O
can	O
contribute	O
to	O
the	O
development	O
of	O
a	O
malignancy	O
.	O

These	O
results	O
suggest	O
that	O
VP1	B-GENE
was	O
efficiently	O
transported	O
to	O
the	O
nucleus	O
and	O
localized	O
in	O
the	O
discrete	O
subnuclear	O
regions	O
,	O
possibly	O
with	O
VP2	B-GENE
and	O
VP3	B-GENE
.	O

It	O
is	O
concluded	O
that	O
axillo	O
-	O
axillary	O
by	O
-	O
pass	O
is	O
a	O
simple	O
solution	O
for	O
a	O
complex	O
haemodynamic	O
,	O
clinical	O
and	O
therapeutic	O
problem	O
.	O

Combination	O
of	O
a	O
Shwachman	O
syndrome	O
and	O
a	O
complex	O
granulocyte	O
function	O
disorder	O
in	O
a	O
girl	O

Moreover	O
,	O
it	O
is	O
the	O
assumptions	O
behind	O
steady	O
-	O
state	O
O2	O
uptake	O
that	O
do	O
not	O
permit	O
proper	O
interpretation	O
of	O
energy	O
expenditure	O
during	O
EPOC	O
;	O
1	O
l	O
O2	O
not	O
=	O
20	O
.	O
9	O
kJ	O
.	O

Experiments	O
showed	O
that	O
temporary	O
arrest	O
of	O
pulmonary	O
circulation	O
under	O
conditions	O
of	O
extracorporeal	O
circulation	O
is	O
attended	O
by	O
the	O
development	O
of	O
ischemia	O
of	O
the	O
respiratory	O
pulmonary	O
tissue	O
.	O

The	O
Arabidopsis	B-GENE
FAD7	I-GENE
gene	I-GENE
encodes	O
a	O
chloroplast	B-GENE
omega	I-GENE
-	I-GENE
3	I-GENE
fatty	I-GENE
acid	I-GENE
desaturase	I-GENE
that	O
catalyzes	O
the	O
desaturation	O
of	O
lipid	O
-	O
linked	O
dienoic	O
fatty	O
acids	O
(	O
18	O
:	O
2	O
and	O
16	O
:	O
2	O
)	O
.	O

Near	O
term	O
,	O
under	O
experimental	O
conditions	O
,	O
maternal	O
and	O
fetal	O
blood	O
gases	O
,	O
pH	O
,	O
uterine	O
and	O
umbilical	O
blood	O
flows	O
were	O
measured	O
or	O
calculated	O
.	O

The	O
regurgitation	O
of	O
large	O
vitreous	O
injections	O
.	O

Zebrafish	O
cyclops	B-GENE
(	O
cyc	B-GENE
)	O
encodes	O
a	O
Transforming	B-GENE
Growth	I-GENE
Factor	I-GENE
beta	I-GENE
(	O
TGFbeta	B-GENE
)	O
signaling	O
factor	O
closely	O
related	O
to	O
mouse	O
Nodal	B-GENE
.	O

UDP	B-GENE
-	I-GENE
Gal	I-GENE
:	I-GENE
Gal	I-GENE
beta	I-GENE
1	I-GENE
-	I-GENE
-	I-GENE
-	I-GENE
-	I-GENE
4GlcNAc	I-GENE
alpha	I-GENE
1	I-GENE
-	I-GENE
-	I-GENE
-	I-GENE
-	I-GENE
3	I-GENE
-	I-GENE
galactosyltransferase	I-GENE
is	O
a	O
terminal	B-GENE
glycosyltransferase	I-GENE
that	O
is	O
widely	O
expressed	O
in	O
a	O
variety	O
of	O
mammalian	O
species	O
,	O
with	O
the	O
notable	O
exception	O
of	O
man	O
,	O
apes	O
,	O
and	O
Old	O
World	O
monkeys	O
.	O

The	O
first	O
group	O
of	O
sequential	O
BMB	O
showed	O
a	O
significant	O
progress	O
to	O
myelofibrosis	O
in	O
so	O
-	O
called	O
"	O
Chronic	O
Megakaryocytic	O
-	O
Granulocytic	O
Myelosis	O
"	O
-	O
-	O
CMGM	O
-	O
,	O
which	O
corresponds	O
to	O
Agnogenic	O
Myeloid	O
Metaplasia	O
-	O
AMM	O
-	O
in	O
72	O
.	O
4	O
%	O
(	O
21	O
/	O
29	O
patients	O
)	O
,	O
as	O
well	O
as	O
in	O
CML	O
with	O
megakaryocytic	O
increase	O
-	O
CML	O
.	O
MI	O
-	O
in	O
39	O
.	O
2	O
%	O
(	O
20	O
/	O
51	O
)	O
.	O

T	O
.	O
,	O
Mahasneh	O
,	O
A	O
.	O
,	O
and	O
Cote	O
,	O
G	O
.	O

If	O
delay	O
has	O
occurred	O
between	O
centrifugation	O
and	O
the	O
measurement	O
,	O
causing	O
substantial	O
loss	O
of	O
CO2	O
,	O
equilibration	O
of	O
the	O
sample	O
with	O
a	O
gas	O
mixture	O
corresponding	O
to	O
PCO2	O
=	O
5	O
.	O
3	O
kPa	O
prior	O
to	O
the	O
measurement	O
is	O
recommended	O
.	O

This	O
domain	O
,	O
although	O
adjacent	O
to	O
the	O
5	O
'	O
edge	O
of	O
the	O
SD	O
sequence	O
,	O
does	O
not	O
inhibit	O
ribosome	O
binding	O
as	O
long	O
as	O
the	O
single	O
-	O
stranded	O
region	O
of	O
domain	O
3	O
is	O
present	O
.	O

Combined	O
expression	O
of	O
c	B-GENE
-	I-GENE
Jun	I-GENE
and	O
p65	B-GENE
induced	O
vigorous	O
transcription	O
of	O
IL	B-GENE
-	I-GENE
2	I-GENE
promoter	O
-	O
and	O
CD28RE	B-GENE
-	I-GENE
driven	I-GENE
reporter	I-GENE
constructs	I-GENE
in	O
both	O
LFA	B-GENE
-	I-GENE
3	I-GENE
-	O
and	O
B7	B-GENE
-	I-GENE
1	I-GENE
-	O
costimulated	O
Jurkat	O
cells	O
.	O

Unlike	O
ARF	B-GENE
,	O
the	O
ARP	B-GENE
immunoreactivity	O
was	O
detected	O
in	O
plasma	O
membranes	O
but	O
not	O
in	O
cytosol	O
of	O
fractionated	O
3T3	O
-	O
L1	O
cells	O
.	O

USF	B-GENE
synthesized	O
in	O
an	O
in	O
vitro	O
transcription	O
and	O
translation	O
system	O
also	O
binds	O
to	O
the	O
ADH	B-GENE
promoter	I-GENE
as	O
well	O
as	O
to	O
the	O
MLP	O
.	O

The	O
tyrosine	B-GENE
hydroxylase	I-GENE
gene	I-GENE
(	O
TH	B-GENE
)	O
contains	O
a	O
single	O
copy	O
of	O
a	O
consensus	O
CRE	O
at	O
-	O
45	O
to	O
-	O
38	O
base	O
pair	O
(	O
bp	O
)	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
.	O

Restriction	O
analysis	O
and	O
Southern	O
hybridization	O
revealed	O
the	O
presence	O
of	O
Tn5422	B-GENE
in	O
all	O
the	O
plasmid	O
-	O
mediated	O
cadmium	O
-	O
resistant	O
L	O
.	O
monocytogenes	O
strains	O
tested	O
but	O
not	O
in	O
strains	O
encoding	O
cadmium	O
resistance	O
on	O
the	O
chromosome	O
.	O

Wild	B-GENE
-	I-GENE
type	I-GENE
AT1A	I-GENE
receptors	I-GENE
,	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
,	O
rapidly	O
internalized	O
after	O
Ang	B-GENE
II	I-GENE
stimulation	O
[	O
t1	O
/	O
2	O
2	O
.	O
3	O
min	O
;	O
maximal	O
level	O
of	O
internalization	O
(	O
Ymax	O
)	O
78	O
.	O
2	O
%	O
]	O
,	O
as	O
did	O
mutant	O
receptors	O
carrying	O
single	O
acidic	O
substitutions	O
(	O
T332E	O
,	O
t1	O
/	O
2	O
2	O
.	O
7	O
min	O
,	O
Ymax	O
76	O
.	O
3	O
%	O
;	O
S335D	O
,	O
t1	O
/	O
2	O
2	O
.	O
4	O
min	O
,	O
Ymax	O
76	O
.	O
7	O
%	O
;	O
T336E	O
,	O
t1	O
/	O
2	O
2	O
.	O
5	O
min	O
,	O
Ymax	O
78	O
.	O
2	O
%	O
;	O
S338D	O
,	O
t1	O
/	O
2	O
2	O
.	O
6	O
min	O
,	O
Ymax	O
78	O
.	O
4	O
%	O
)	O
.	O

Feline	O
leukemia	O
viruses	O
(	O
FeLVs	O
)	O
,	O
which	O
are	O
replication	O
-	O
competent	O
oncoretroviruses	O
of	O
the	O
domestic	O
cat	O
species	O
,	O
are	O
contagiously	O
transmitted	O
in	O
natural	O
environments	O
.	O

Neuromyelitis	O
optica	O
(	O
Devic	O
'	O
s	O
syndrome	O
)	O
:	O
not	O
always	O
multiple	O
sclerosis	O
.	O

Arterial	O
radioactivity	O
content	O
after	O
the	O
intravenous	O
administration	O
of	O
HMPAO	O
in	O
seven	O
human	O
subjects	O
was	O
analyzed	O
.	O

In	O
the	O
brain	O
,	O
muscarinic	B-GENE
receptors	I-GENE
mediate	O
motor	O
and	O
memory	O
function	O
by	O
interaction	O
with	O
their	O
ligand	O
acetylcholine	O
.	O

Quantitation	O
of	O
exocrine	B-GENE
IgA	I-GENE
in	O
human	O
serum	O
in	O
health	O
and	O
disease	O
.	O

This	O
phenomenon	O
did	O
not	O
require	O
DNA	O
binding	O
by	O
the	O
"	O
interfering	O
"	O
receptor	O
but	O
required	O
it	O
to	O
be	O
hormone	O
-	O
bound	O
,	O
indicating	O
that	O
a	O
transcriptionally	O
active	O
form	O
of	O
the	O
interfering	O
receptor	O
is	O
essential	O
for	O
the	O
interfering	O
effect	O
.	O

We	O
use	O
the	O
term	O
corticosteroid	O
-	O
dependent	O
IA	O
to	O
refer	O
to	O
the	O
serious	O
problem	O
of	O
chronic	O
IA	O
requiring	O
maintenance	O
prednisone	O
therapy	O
.	O

Insulin	B-GENE
-	I-GENE
like	I-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
-	I-GENE
2	I-GENE
(	O
IGF	B-GENE
-	I-GENE
BP	I-GENE
-	I-GENE
2	I-GENE
)	O
transcription	O
in	O
rat	O
liver	O
varies	O
with	O
developmental	O
age	O
and	O
fasting	O
.	O

The	O
dnaQ	B-GENE
-	O
lacZ	B-GENE
and	O
the	O
rnh	B-GENE
-	O
lacZ	B-GENE
fused	O
genes	O
were	O
constructed	O
and	O
hybrid	O
proteins	O
with	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
activity	O
were	O
produced	O
.	O

Moreover	O
,	O
this	O
enhancement	O
of	O
transcriptional	O
activation	O
by	O
COUP	B-GENE
-	I-GENE
TFI	I-GENE
requires	O
specifically	O
the	O
AF	O
-	O
1	O
transactivation	O
function	O
of	O
ER	B-GENE
and	O
can	O
be	O
observed	O
in	O
the	O
presence	O
of	O
E2	O
or	O
4	O
-	O
hydroxytamoxifen	O
but	O
not	O
ICI	O
164384	O
.	O

Furthermore	O
,	O
we	O
have	O
identified	O
a	O
43	O
-	O
bp	O
region	O
of	O
the	O
24p3	B-GENE
promoter	I-GENE
required	O
for	O
the	O
Dex	O
responsiveness	O
.	O

The	O
novel	O
approach	O
to	O
insulin	B-GENE
administration	O
known	O
as	O
chronic	O
intermittent	O
intravenous	O
insulin	B-GENE
therapy	O
(	O
CIIIT	O
)	O
delivers	O
insulin	B-GENE
in	O
a	O
pulsatile	O
fashion	O
and	O
achieves	O
physiological	O
insulin	B-GENE
concentration	O
in	O
the	O
portal	O
vein	O
.	O

We	O
found	O
three	O
out	O
of	O
four	O
original	O
(	O
Volkan	O
'	O
s	O
)	O
groups	O
of	O
linking	O
objects	O
,	O
but	O
also	O
an	O
additional	O
one	O
,	O
hitherto	O
undescribed	O
,	O
comprising	O
objects	O
used	O
for	O
designing	O
a	O
memorial	O
shrine	O
to	O
the	O
deceased	O
.	O

The	O
immuno	O
-	O
purified	O
mRNA	O
in	O
the	O
polysome	O
complex	O
was	O
used	O
to	O
prepare	O
cDNA	O
with	O
which	O
to	O
probe	O
a	O
D	O
.	O
melanogaster	O
genomic	O
library	O
.	O

A	O
gene	O
in	O
Drosophila	O
melanogaster	O
that	O
maps	O
cytologically	O
to	O
2C1	O
-	O
3	O
on	O
the	O
distal	O
portion	O
of	O
the	O
X	O
-	O
chromosome	O
encodes	O
a	O
member	O
of	O
the	O
steroid	B-GENE
/	I-GENE
thyroid	I-GENE
hormone	I-GENE
receptor	I-GENE
superfamily	I-GENE
.	O

Endocrine	O
cells	O
were	O
studied	O
by	O
means	O
of	O
Grimelius	O
'	O
silver	O
staining	O
and	O
immunostaining	O
for	O
chromogranin	B-GENE
,	O
a	O
general	O
marker	O
of	O
endocrine	O
cells	O
.	O

We	O
also	O
demonstrate	O
that	O
preformed	O
triplexes	O
are	O
quite	O
stable	O
when	O
precipitated	O
with	O
ethanol	O
and	O
resuspended	O
in	O
water	O
.	O

The	O
Twentieth	O
Anniversary	O
of	O
the	O
Pomeranian	O
Medical	O
Academy	O
.	O

Plastic	O
solution	O
of	O
elbow	O
joint	O
ankylosis	O
with	O
a	O
decorticated	O
cylindrical	O
flap	O

National	O
Institutes	O
of	O
Health	O
Consensus	O
Development	O
Conference	O
Statement	O
.	O

We	O
have	O
identified	O
in	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
the	O
Drosophila	B-GENE
copia	I-GENE
retrotransposon	I-GENE
,	O
3	O
'	O
to	O
the	O
left	O
LTR	O
,	O
a	O
sequence	O
for	O
transcriptional	O
regulation	O
by	O
homeoproteins	O
.	O

Nephrectomy	O
applied	O
to	O
cattle	O

The	O
8	O
patients	O
receiving	O
Ir192	O
implant	O
in	O
addition	O
to	O
external	O
radiation	O
showed	O
improved	O
(	O
p	O
=	O
0	O
.	O
06	O
)	O
survival	O
compared	O
to	O
the	O
9	O
receiving	O
external	O
only	O
:	O
median	O
15	O
months	O
(	O
range	O
1	O
.	O
5	O
-	O
34	O
+	O
months	O
)	O
versus	O
7	O
months	O
(	O
range	O
2	O
.	O
5	O
-	O
21	O
months	O
)	O
.	O

The	O
electrodes	O
themselves	O
do	O
not	O
need	O
to	O
be	O
polished	O
prior	O
to	O
their	O
use	O
but	O
are	O
observed	O
to	O
be	O
slightly	O
recessed	O
from	O
the	O
surrounding	O
insulating	O
surface	O
.	O

In	O
hemodialyzed	O
patients	O
(	O
Epo	B-GENE
and	O
Non	O
-	O
Epo	B-GENE
group	O
)	O
leptin	B-GENE
levels	O
were	O
significantly	O
higher	O
when	O
compared	O
to	O
CAPD	O
patients	O
(	O
Epo	B-GENE
and	O
Non	O
-	O
Epo	B-GENE
group	O
,	O
respectively	O
)	O
.	O

Aryl	B-GENE
hydrocarbon	I-GENE
receptor	I-GENE
nuclear	I-GENE
translocator	I-GENE
(	O
ARNT	B-GENE
)	O
is	O
a	O
component	O
of	O
the	O
transcription	O
factors	O
,	O
aryl	B-GENE
hydrocarbon	I-GENE
receptor	I-GENE
(	O
AhR	B-GENE
)	O
and	O
hypoxia	B-GENE
-	I-GENE
inducible	I-GENE
factor	I-GENE
1	I-GENE
,	O
which	O
transactivate	O
their	O
target	O
genes	O
,	O
such	O
as	O
CYP1A1	B-GENE
and	O
erythropoietin	B-GENE
,	O
in	O
response	O
to	O
xenobiotic	O
aromatic	O
hydrocarbons	O
and	O
to	O
low	O
O2	O
concentration	O
,	O
respectively	O
.	O

Characterization	O
of	O
the	O
microtubule	O
binding	O
domain	O
of	O
microtubule	B-GENE
actin	I-GENE
crosslinking	I-GENE
factor	I-GENE
(	O
MACF	B-GENE
)	O
:	O
identification	O
of	O
a	O
novel	O
group	O
of	O
microtubule	B-GENE
associated	I-GENE
proteins	I-GENE
.	O

Polysome	O
and	O
40S	B-GENE
ribosome	I-GENE
fractions	O
were	O
severely	O
decreased	O
in	O
the	O
krr1	B-GENE
mutant	I-GENE
and	O
Kri1p	B-GENE
-	O
depleted	O
cells	O
.	O

FASEB	O
Federal	O
Funding	O
Consensus	O
Conference	O
FY	O
2000	O
.	O

Analysis	O
of	O
a	O
set	O
of	O
deletion	O
constructs	O
in	O
transient	O
transfection	O
assays	O
measuring	O
heterologous	O
reporter	O
gene	O
(	O
luciferase	B-GENE
)	O
activity	O
demonstrated	O
that	O
the	O
182	O
-	O
bp	O
5	O
'	O
-	O
flanking	O
region	O
provides	O
full	O
promoter	O
activity	O
in	O
IL	B-GENE
-	I-GENE
2	I-GENE
-	O
stimulated	O
L2	O
cells	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
KRAB	B-GENE
domain	I-GENE
present	O
in	O
the	O
non	O
-	O
finger	O
region	O
of	O
many	O
ZFP	B-GENE
genes	I-GENE
quenches	O
transcription	O
possibly	O
due	O
to	O
specific	O
protein	O
-	O
protein	O
interactions	O
between	O
the	O
KRAB	B-GENE
-	I-GENE
A	I-GENE
domain	I-GENE
and	O
components	O
of	O
the	O
proximal	O
transcriptional	O
apparatus	O
.	O

PATIENTS	O
AND	O
METHOD	O
:	O
Since	O
1986	O
,	O
62	O
patients	O
were	O
irradiated	O
stereotactically	O
.	O

Systematic	O
functional	O
analysis	O
of	O
V1a	B-GENE
/	I-GENE
V2	I-GENE
hybrid	I-GENE
receptors	I-GENE
showed	O
that	O
the	O
second	O
intracellular	O
loop	O
of	O
the	O
V1a	B-GENE
receptor	I-GENE
is	O
required	O
and	O
sufficient	O
for	O
efficient	O
coupling	O
to	O
Gq	B-GENE
/	I-GENE
11	I-GENE
,	O
whereas	O
the	O
third	O
intracellular	O
loop	O
of	O
the	O
V2	B-GENE
receptor	I-GENE
is	O
required	O
and	O
sufficient	O
for	O
coupling	O
to	O
Gs	B-GENE
.	O

A	O
genetic	O
screen	O
applied	O
to	O
mutants	O
in	O
the	O
branch	O
site	O
region	O
shows	O
that	O
all	O
positions	O
in	O
the	O
conserved	O
TACTAAC	O
sequence	O
are	O
important	O
for	O
intron	O
recognition	O
.	O

To	O
determine	O
whether	O
P35	B-GENE
could	O
activate	O
the	O
39k	O
promoter	O
in	O
the	O
absence	O
of	O
IE1	B-GENE
,	O
the	O
p35	B-GENE
open	O
reading	O
frame	O
was	O
cloned	O
under	O
the	O
control	O
of	O
the	O
ie1	B-GENE
promoter	I-GENE
.	O

Autoradiographic	O
localisation	O
of	O
its	O
cellular	O
distribution	O
in	O
the	O
kidney	O
.	O

Structure	O
and	O
expression	O
of	O
the	O
mouse	B-GENE
growth	I-GENE
hormone	I-GENE
receptor	I-GENE
/	O
growth	B-GENE
hormone	I-GENE
binding	I-GENE
protein	I-GENE
gene	I-GENE
.	O

Modification	O
of	O
enteral	O
resorption	O
by	O
cytostatic	O
therapy	O

We	O
report	O
two	O
patients	O
receiving	O
maintenance	O
valproate	O
,	O
one	O
with	O
resolving	O
acute	O
hepatitis	O
C	O
and	O
the	O
other	O
with	O
chronic	O
persistent	O
hepatitis	O
C	O
,	O
with	O
incidental	O
microvesicular	O
steatosis	O
demonstrated	O
on	O
oil	O
-	O
red	O
O	O
stains	O
.	O

Mutation	O
analysis	O
demonstrates	O
that	O
the	O
motif	O
TCCCCT	O
is	O
critical	O
for	O
PyRo1	B-GENE
interaction	O
.	O

This	O
loss	O
was	O
independent	O
of	O
drug	O
concentration	O
and	O
a	O
correction	O
factor	O
was	O
employed	O
to	O
calculate	O
the	O
true	O
free	O
diazepam	O
concentration	O
.	O

High	O
resolution	O
computed	O
tomography	O
of	O
the	O
lungs	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

Therefore	O
,	O
high	O
set	O
-	O
up	O
accuracy	O
and	O
reproducibility	O
are	O
mandatory	O
.	O

Novel	O
intronic	O
promoter	O
in	O
the	O
rat	B-GENE
ER	I-GENE
alpha	I-GENE
gene	I-GENE
responsible	O
for	O
the	O
transient	O
transcription	O
of	O
a	O
variant	O
receptor	O
.	O

The	O
hypertension	O
with	O
elevated	O
PRA	O
,	O
however	O
,	O
was	O
resistant	O
to	O
the	O
angiotensin	B-GENE
II	I-GENE
(	O
AII	B-GENE
)	O
analog	O
[	O
Sar1	O
,	O
Ile8	O
]	O
ALL	O
.	O

Ivermectin	O
uptake	O
and	O
distribution	O
in	O
the	O
plasma	O
and	O
tissue	O
of	O
Sudanese	O
and	O
Mexican	O
patients	O
infected	O
with	O
Onchocerca	O
volvulus	O
.	O

Online	O
LATCH	O
demonstrates	O
a	O
shift	O
in	O
identification	O
of	O
the	O
library	O
as	O
an	O
isolated	O
unit	O
to	O
an	O
interactive	O
resource	O
center	O
.	O

No	O
mutations	O
were	O
found	O
in	O
follicular	O
adenomas	O
.	O

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
discuss	O
the	O
factors	O
involved	O
in	O
the	O
selection	O
of	O
antibodies	O
,	O
radionuclides	O
and	O
labeling	O
methods	O
in	O
the	O
development	O
of	O
radioimmunotherapy	O
(	O
RIT	O
)	O
for	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
(	O
NHL	O
)	O
from	O
a	O
single	O
clinical	O
study	O
site	O
through	O
multicenter	O
trials	O
and	O
commercialization	O
.	O

These	O
data	O
show	O
that	O
PTH	B-GENE
and	O
cAMP	O
can	O
repress	O
collagen	B-GENE
promoter	I-GENE
activity	O
in	O
calvariae	O
from	O
transgenic	O
mice	O
,	O
suggesting	O
that	O
the	O
alpha	B-GENE
1	I-GENE
(	I-GENE
I	I-GENE
)	I-GENE
collagen	I-GENE
promoter	I-GENE
may	O
contain	O
cis	O
elements	O
down	O
-	O
stream	O
of	O
-	O
2	O
.	O
3	O
kilobases	O
that	O
mediate	O
PTH	B-GENE
and	O
cAMP	O
repression	O
of	O
collagen	B-GENE
gene	I-GENE
expression	O
in	O
bone	O
.	O

Reconstitution	O
of	O
complexes	O
containing	O
p62	B-GENE
and	O
the	O
src	B-GENE
family	I-GENE
kinase	I-GENE
p59fyn	B-GENE
in	O
HeLa	O
cells	O
demonstrated	O
that	O
complex	O
formation	O
resulted	O
in	O
tyrosine	O
phosphorylation	O
of	O
p62	B-GENE
and	O
was	O
mediated	O
by	O
both	O
the	O
SH3	B-GENE
and	O
SH2	B-GENE
domains	I-GENE
of	O
p59fyn	B-GENE
.	O

The	O
second	O
patient	O
had	O
received	O
pituitary	B-GENE
-	I-GENE
derived	I-GENE
growth	I-GENE
hormone	I-GENE
for	O
treatment	O
of	O
growth	B-GENE
hormone	I-GENE
deficiency	O
,	O
secondary	O
to	O
a	O
third	O
ventricle	O
teratoma	O
,	O
exised	O
13	O
yr	O
earlier	O
.	O

The	O
AGM	B-GENE
and	I-GENE
NIH	I-GENE
/	I-GENE
Swiss	I-GENE
mouse	I-GENE
CCR5	I-GENE
proteins	I-GENE
are	O
97	O
.	O
7	O
to	O
98	O
.	O
3	O
%	O
and	O
79	O
.	O
8	O
%	O
identical	O
to	O
the	O
human	O
protein	O
,	O
respectively	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
signal	O
transduction	O
pathways	O
that	O
are	O
involved	O
in	O
OM	B-GENE
-	O
induced	O
LDLR	B-GENE
transcription	O
.	O

A	O
study	O
was	O
performed	O
to	O
compare	O
the	O
ONLINE	O
and	O
EMIT	O
II	O
immunoassays	O
with	O
gas	O
chromatographic	O
/	O
mass	O
spectrometric	O
(	O
GC	O
/	O
MS	O
)	O
analysis	O
of	O
methaqualone	O
metabolites	O
on	O
urine	O
using	O
samples	O
obtained	O
from	O
a	O
clinical	O
study	O
.	O

Adjuvant	O
therapy	O
for	O
colon	O
cancer	O
]	O
Surgery	O
alone	O
may	O
fail	O
to	O
cure	O
a	O
considerable	O
number	O
of	O
locally	O
advanced	O
colon	O
cancers	O
.	O

Whole	O
-	O
mount	O
in	O
situ	O
hybridization	O
to	O
early	O
mouse	O
embryos	O
of	O
9	O
.	O
5	O
-	O
10	O
.	O
5	O
days	O
indicated	O
a	O
complex	O
pattern	O
of	O
Arp1	B-GENE
expression	O
spatially	O
overlapping	O
with	O
the	O
expression	O
of	O
All1	B-GENE
.	O

We	O
have	O
identified	O
and	O
characterized	O
the	O
structure	O
of	O
the	O
Spec1	B-GENE
gene	I-GENE
in	O
the	O
sea	O
urchin	O
Strongylocentrotus	O
purpuratus	O
.	O

To	O
begin	O
to	O
understand	O
this	O
role	O
,	O
we	O
overexpressed	O
ATF	B-GENE
-	I-GENE
2	I-GENE
in	O
a	O
human	O
cancer	O
cell	O
line	O
.	O

In	O
order	O
to	O
define	O
potential	O
candidate	O
genes	O
for	O
inherited	O
disorders	O
characterized	O
by	O
aberrant	O
gene	O
expression	O
,	O
we	O
utilized	O
Kruppel	B-GENE
-	I-GENE
related	I-GENE
sequences	I-GENE
to	O
isolate	O
zinc	O
finger	O
-	O
containing	O
cDNAs	O
.	O

Analysis	O
of	O
the	O
gag	B-GENE
and	O
rev	B-GENE
proteins	I-GENE
in	O
the	O
transfected	O
cells	O
demonstrated	O
that	O
these	O
proteins	O
were	O
not	O
detectable	O
in	O
cells	O
transfected	O
with	O
the	O
tat	B-GENE
mutants	I-GENE
but	O
could	O
be	O
readily	O
detected	O
when	O
the	O
mutations	O
were	O
complemented	O
in	O
trans	O
with	O
a	O
tat	B-GENE
expression	O
vector	O
.	O

The	O
ability	O
to	O
maintain	O
expression	O
of	O
FAS1	B-GENE
in	O
nmt1	B-GENE
-	O
451Dino2	B-GENE
Delta	O
cells	O
suggests	O
the	O
existence	O
of	O
another	O
transcription	O
factor	O
,	O
or	O
factors	O
,	O
whose	O
expression	O
/	O
activity	O
is	O
inversely	O
related	O
to	O
overall	O
levels	O
of	O
cellular	O
protein	O
N	O
-	O
myristoy	O
-	O
lation	O
.	O

Small	B-GENE
GTPases	I-GENE
of	O
the	O
Ypt	B-GENE
/	O
Rab	B-GENE
family	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
vesicular	O
transport	O
.	O

Dopamine	B-GENE
beta	I-GENE
-	I-GENE
hydroxylase	I-GENE
(	O
DBH	B-GENE
)	O
catalyzes	O
the	O
conversion	O
of	O
dopamine	O
to	O
noradrenaline	O
and	O
is	O
selectively	O
expressed	O
in	O
noradrenergic	O
and	O
adrenergic	O
neurons	O
and	O
neuroendocrine	O
cells	O
.	O

This	O
result	O
indicates	O
that	O
separate	O
complexes	O
exist	O
containing	O
ankyrin	B-GENE
and	O
fodrin	B-GENE
with	O
either	O
uvomorulin	B-GENE
or	O
Na	B-GENE
+	I-GENE
,	I-GENE
K	I-GENE
+	I-GENE
-	I-GENE
ATPase	I-GENE
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

Indirect	O
plasma	O
parameters	O
such	O
as	O
vitamin	O
E	O
,	O
thiol	O
and	O
uric	O
acid	O
levels	O
were	O
also	O
quantified	O
.	O

These	O
results	O
indicate	O
that	O
baculovirus	O
-	O
expressed	O
TR	B-GENE
mediates	O
transcriptional	O
activation	O
and	O
repression	O
in	O
a	O
promoter	O
-	O
specific	O
manner	O
in	O
vitro	O
.	O

Certain	O
spt10	B-GENE
spontaneous	O
alleles	O
are	O
good	O
suppressors	O
but	O
have	O
a	O
normal	O
growth	O
rate	O
,	O
suggesting	O
that	O
the	O
SPT10	B-GENE
protein	I-GENE
may	O
have	O
two	O
distinct	O
functions	O
.	O

This	O
spindle	O
defect	O
of	O
pds1	B-GENE
mutants	I-GENE
results	O
from	O
a	O
temperature	O
-	O
sensitive	O
step	O
that	O
occurs	O
around	O
the	O
G1	O
/	O
S	O
boundary	O
about	O
the	O
time	O
of	O
spindle	O
assembly	O
.	O

Pitx2	B-GENE
rescues	O
the	O
GABAergic	O
differentiation	O
defect	O
and	O
partially	O
rescues	O
the	O
axon	O
guidance	O
and	O
behavioral	O
phenotypes	O
of	O
unc	B-GENE
-	I-GENE
30	I-GENE
mutants	I-GENE
,	O
indicating	O
a	O
high	O
degree	O
of	O
functional	O
conservation	O
between	O
these	O
evolutionarily	O
related	O
genes	O
.	O

Derepression	O
of	O
gene	O
expression	O
mediated	O
by	O
the	O
5	O
'	O
upstream	O
region	O
of	O
the	O
isocitrate	B-GENE
lyase	I-GENE
gene	I-GENE
of	I-GENE
Candida	I-GENE
tropicalis	I-GENE
is	O
controlled	O
by	O
two	O
distinct	O
regulatory	O
pathways	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Stimulation	O
of	O
[	O
3H	O
]	O
PA	O
production	O
upon	O
CD3	B-GENE
cross	O
-	O
linking	O
was	O
77	O
%	O
lower	O
in	O
permeabilized	O
CD45	B-GENE
-	I-GENE
cells	O
than	O
in	O
CD45	B-GENE
+	I-GENE
cells	O
,	O
consistent	O
with	O
the	O
reduced	O
activity	O
of	O
p59fyn	B-GENE
in	O
CD45	B-GENE
-	I-GENE
cells	O
.	O

Fenoldopam	O
,	O
a	O
dopamine	B-GENE
receptor	I-GENE
agonist	O
,	O
has	O
been	O
shown	O
,	O
in	O
animal	O
experiments	O
,	O
to	O
improve	O
renal	O
perfusion	O
.	O

One	O
-	O
third	O
of	O
the	O
men	O
with	O
azoospermia	O
and	O
with	O
sperm	O
density	O
of	O
less	O
than	O
10	O
million	O
had	O
marked	O
FSH	B-GENE
elevation	O
and	O
our	O
experience	O
confirms	O
the	O
work	O
of	O
others	O
that	O
this	O
indicates	O
a	O
poor	O
prognosis	O
.	O

The	O
resulting	O
R	B-GENE
protein	I-GENE
terminates	O
five	O
codons	O
downstream	O
of	O
the	O
frameshift	O
site	O
at	O
the	O
V	B-GENE
protein	I-GENE
stop	O
codon	O
.	O

Both	O
verapamil	O
and	O
propranolol	O
can	O
exhibit	O
additive	O
effects	O
with	O
adenosine	O
in	O
prolonging	O
AV	O
nodal	O
conduction	O
time	O
;	O
however	O
,	O
only	O
verapamil	O
can	O
reduce	O
the	O
dose	O
of	O
adenosine	O
required	O
to	O
produce	O
AV	O
nodal	O
block	O
.	O

Selected	O
parameters	O
:	O
heart	O
rate	O
(	O
HR	O
)	O
,	O
arterial	O
blood	O
pressure	O
(	O
ABP	O
)	O
and	O
arterial	O
O2	O
saturation	O
(	O
SaO2	O
)	O
monitored	O
by	O
pulsoximetry	O
were	O
measured	O
during	O
the	O
procedure	O
.	O

The	O
PSD2	B-GENE
gene	I-GENE
was	O
heterologously	O
expressed	O
by	O
infection	O
of	O
Sf	O
-	O
9	O
insect	O
cells	O
with	O
recombinant	O
baculovirus	O
,	O
resulting	O
in	O
a	O
10	O
-	O
fold	O
increase	O
in	O
PSD	B-GENE
activity	O
.	O

Chrispeels	O
[	O
1993	O
]	O
EMBO	O
J	O
12	O
:	O
2241	O
-	O
2247	O
)	O
.	O

Co	O
-	O
transfection	O
of	O
a	O
tat	B-GENE
expressing	O
plasmid	O
with	O
these	O
viruses	O
containing	O
the	O
tat	B-GENE
ORF	I-GENE
mutations	O
resulted	O
in	O
higher	O
levels	O
of	O
virus	O
production	O
demonstrating	O
that	O
the	O
effects	O
of	O
both	O
mutants	O
are	O
tat	B-GENE
specific	O
.	O

It	O
has	O
been	O
reported	O
that	O
rat	O
blood	O
chloroform	O
levels	O
were	O
significantly	O
decreased	O
after	O
treatment	O
with	O
ClO2	O
.	O

63	O
.	O
3	O
micromol	O
/	O
1	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
extrapolated	O
to	O
infinity	O
AUC	O
9	O
(	O
0	O
-	O
infinity	O
)	O
(	O
518	O
.	O
7	O
vs	O
.	O

We	O
also	O
show	O
by	O
immunogold	O
electron	O
microscopy	O
immunocytochemistry	O
that	O
amphiphysin	B-GENE
I	I-GENE
is	O
localized	O
in	O
the	O
nerve	O
terminal	O
cytomatrix	O
and	O
is	O
partially	O
associated	O
with	O
endocytic	O
intermediates	O
.	O

Infants	O
who	O
died	O
in	O
the	O
first	O
12	O
hours	O
from	O
'	O
IVH	O
only	O
'	O
had	O
suffered	O
severe	O
birth	O
asphyxia	O
but	O
in	O
those	O
who	O
died	O
later	O
the	O
main	O
symptom	O
was	O
recurrent	O
apnoea	O
.	O

The	O
H2	B-GENE
receptor	I-GENE
antagonists	O
and	O
sucralfate	O
cost	O
about	O
the	O
same	O
and	O
have	O
few	O
side	O
effects	O
.	O

The	O
normal	O
cell	O
cycle	O
is	O
regulated	O
by	O
several	O
molecules	O
,	O
such	O
as	O
the	O
tumor	B-GENE
-	I-GENE
suppressor	I-GENE
protein	I-GENE
pRb	I-GENE
,	O
the	O
G1	B-GENE
cyclins	I-GENE
,	O
the	O
cyclin	B-GENE
-	I-GENE
dependent	I-GENE
kinases	I-GENE
,	O
and	O
their	O
inhibitors	O
.	O

Analysis	O
of	O
clearance	O
curve	O
of	O
rose	O
bengal	O
-	O
I	O
-	O
131	O

Volume	O
of	O
distribution	O
of	O
total	O
DMDZ	O
(	O
range	O
,	O
1	O
.	O
33	O
to	O
6	O
.	O
30	O
l	O
/	O
kg	O
)	O
and	O
of	O
unbound	O
DMDZ	O
after	O
correction	O
for	O
protein	O
binding	O
(	O
range	O
,	O
43	O
to	O
243	O
l	O
/	O
kg	O
)	O
was	O
larger	O
in	O
women	O
than	O
in	O
men	O
of	O
all	O
ages	O
,	O
and	O
in	O
the	O
elderly	O
as	O
opposed	O
to	O
the	O
young	O
.	O

The	O
N	O
-	O
terminal	O
115	O
amino	O
acids	O
correspond	O
to	O
a	O
putative	O
DNA	O
-	O
binding	O
domain	O
and	O
show	O
significant	O
sequence	O
similarity	O
with	O
other	O
cloned	O
IFN	B-GENE
response	I-GENE
factors	I-GENE
(	O
IRF	B-GENE
-	I-GENE
1	I-GENE
and	O
IRF	B-GENE
-	I-GENE
2	I-GENE
)	O
.	O

Three	O
experiments	O
contrasted	O
the	O
effects	O
of	O
6	O
-	O
hydroxydopamine	O
-	O
induced	O
lesions	O
of	O
the	O
ventral	O
noradrenergic	O
and	O
dorsal	O
noradrenergic	O
projections	O
,	O
predominantly	O
to	O
hypothalamus	O
and	O
cortex	O
,	O
respectively	O
,	O
upon	O
body	O
weight	O
changes	O
and	O
food	O
-	O
related	O
behaviour	O
in	O
the	O
rat	O
.	O

Hepatitis	O
B	O
vaccine	O

This	O
construct	O
,	O
termed	O
pDeltaCREC	B-GENE
/	O
EBP	B-GENE
,	O
binds	O
C	B-GENE
/	I-GENE
EBPalpha	I-GENE
and	I-GENE
beta	I-GENE
but	O
not	O
CREB	B-GENE
,	O
yet	O
it	O
confers	O
a	O
nearly	O
complete	O
glucocorticoid	O
response	O
when	O
transiently	O
transfected	O
into	O
H4IIE	O
rat	O
hepatoma	O
cells	O
.	O

The	O
two	O
bases	O
immediately	O
flanking	O
the	O
5	O
'	O
end	O
of	O
the	O
element	O
proved	O
to	O
be	O
very	O
important	O
to	O
its	O
function	O
as	O
a	O
UAS	O
element	O
as	O
did	O
the	O
two	O
bases	O
immediately	O
3	O
'	O
of	O
the	O
bHLH	O
core	O
motif	O
.	O

For	O
the	O
5HT5A	B-GENE
receptor	I-GENE
the	O
addition	O
of	O
yohimbine	O
resulted	O
in	O
a	O
similar	O
but	O
smaller	O
effect	O
.	O

A	O
major	O
task	O
for	O
sports	O
scientists	O
may	O
be	O
to	O
verify	O
empirically	O
the	O
nature	O
of	O
an	O
integrated	O
model	O
of	O
the	O
sport	O
performer	O
.	O

In	O
the	O
cell	O
-	O
free	O
import	O
assay	O
,	O
beta	B-GENE
-	I-GENE
catenin	I-GENE
rapidly	O
migrates	O
into	O
the	O
nucleus	O
without	O
the	O
exogenous	O
addition	O
of	O
cytosol	O
,	O
Ran	B-GENE
,	O
or	O
ATP	O
/	O
GTP	O
.	O

Phosphorylation	O
of	O
myosin	B-GENE
-	I-GENE
binding	I-GENE
subunit	I-GENE
(	O
MBS	B-GENE
)	O
of	O
myosin	B-GENE
phosphatase	I-GENE
by	O
Rho	B-GENE
-	I-GENE
kinase	I-GENE
in	O
vivo	O
.	O

Since	O
RCC1p	B-GENE
acts	O
as	O
GNRP	B-GENE
for	O
Ran	B-GENE
,	O
a	O
small	B-GENE
nuclear	I-GENE
GTPase	I-GENE
of	O
the	O
ras	B-GENE
superfamily	I-GENE
,	O
we	O
have	O
identified	O
two	O
homologs	O
of	O
Ran	B-GENE
in	O
S	O
.	O
cerevisiae	O
(	O
CNR1	B-GENE
and	O
CNR2	B-GENE
)	O
.	O

SELECTION	O
CRITERIA	O
:	O
Randomised	O
and	O
possibly	O
randomised	O
trials	O
using	O
acupuncture	O
to	O
treat	O
asthma	O
and	O
asthma	O
-	O
like	O
symptoms	O
.	O

Although	O
previous	O
data	O
have	O
suggested	O
that	O
Rev	B-GENE
uses	O
the	O
same	O
export	O
pathway	O
as	O
uracil	O
-	O
rich	O
small	O
nuclear	O
RNAs	O
and	O
5S	B-GENE
ribosomal	I-GENE
RNA	I-GENE
,	O
the	O
CTE	O
seems	O
to	O
interact	O
with	O
evolutionarily	O
conserved	O
factors	O
that	O
are	O
essential	O
for	O
cellular	O
mRNA	O
export	O
.	O

The	O
two	O
ParA	B-GENE
proteins	I-GENE
that	O
are	O
produced	O
as	O
a	O
result	O
of	O
independent	O
translation	O
initiation	O
at	O
two	O
different	O
start	O
codons	O
within	O
the	O
same	O
open	O
reading	O
frame	O
were	O
overexpressed	O
in	O
Escherichia	O
coli	O
and	O
partially	O
purified	O
.	O

Such	O
an	O
increase	O
in	O
the	O
steady	O
-	O
state	O
testicular	B-GENE
TIMP	I-GENE
-	I-GENE
2	I-GENE
mRNA	I-GENE
level	O
apparently	O
is	O
not	O
the	O
result	O
of	O
an	O
up	O
-	O
regulation	O
by	O
germ	O
cells	O
because	O
germ	O
cells	O
cocultured	O
with	O
Sertoli	O
cells	O
failed	O
to	O
elicit	O
an	O
increase	O
in	O
the	O
Sertoli	O
cell	O
steady	O
-	O
state	O
TIMP	B-GENE
-	I-GENE
2	I-GENE
mRNA	I-GENE
level	O
.	O

Retroviral	O
transduction	O
of	O
T	B-GENE
/	I-GENE
T	I-GENE
(	I-GENE
L	I-GENE
)	I-GENE
causes	O
a	O
rapidly	O
fatal	O
myeloproliferative	O
disease	O
in	O
a	O
murine	O
bone	O
marrow	O
transplant	O
(	O
BMT	O
)	O
model	O
,	O
whereas	O
T	B-GENE
/	I-GENE
T	I-GENE
(	I-GENE
F	I-GENE
)	I-GENE
causes	O
a	O
long	O
-	O
latency	O
,	O
pre	O
-	O
B	O
-	O
cell	O
lymphoblastic	O
lymphoma	O
.	O

Correlation	O
between	O
intraocular	O
involvement	O
and	O
systemic	O
outcome	O
was	O
poor	O
.	O

The	O
induced	O
respiratory	O
burst	O
was	O
investigated	O
by	O
the	O
intracellular	O
oxidative	O
transformation	O
of	O
dihydrorhodamine	O
123	O
to	O
the	O
fluorescent	O
dye	O
rhodamine	O
123	O
via	O
flow	O
cytometry	O
.	O

Data	O
from	O
119	O
men	O
and	O
40	O
women	O
undergoing	O
coronary	O
angiography	O
provide	O
an	O
opportunity	O
to	O
compare	O
these	O
associations	O
in	O
relation	O
to	O
a	O
direct	O
and	O
continuous	O
measure	O
of	O
atherosclerosis	O
while	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
income	O
,	O
hypertension	O
,	O
serum	O
cholesterol	O
,	O
smoking	O
,	O
angina	O
,	O
diabetes	O
,	O
family	O
history	O
of	O
heart	O
disease	O
,	O
Type	O
A	O
behavior	O
pattern	O
,	O
and	O
hostility	O
.	O

SIN	O
-	O
1	O
had	O
no	O
influence	O
on	O
either	O
the	O
ischemic	O
parameters	O
in	O
the	O
surface	O
electrocardiogram	O
(	O
ECG	O
)	O
or	O
the	O
intracoronary	O
ECG	O
.	O

The	O
E1	B-GENE
replication	I-GENE
protein	I-GENE
of	O
bovine	O
papillomavirus	O
type	O
1	O
contains	O
an	O
extended	O
nuclear	O
localization	O
signal	O
that	O
includes	O
a	O
p34cdc2	B-GENE
phosphorylation	O
site	O
.	O

Zhu	O
,	O
V	O
.	O

Young	O
CD	O
-	O
1	O
mice	O
,	O
4	O
days	O
old	O
,	O
exposed	O
to	O
0	O
.	O
1	O
%	O
nicotine	O
sulfate	O
on	O
gestational	O
days	O
6	O
-	O
20	O
were	O
compared	O
with	O
untreated	O
pups	O
of	O
the	O
same	O
age	O
to	O
determine	O
its	O
effect	O
on	O
the	O
development	O
of	O
mandibular	O
first	O
molars	O
.	O

In	O
contrast	O
,	O
the	O
lumenal	O
domains	O
of	O
Sec12p	B-GENE
,	O
Stl1p	B-GENE
and	O
Stl2p	B-GENE
are	O
very	O
different	O
in	O
size	O
and	O
do	O
not	O
show	O
any	O
appreciable	O
homology	O
.	O

Creatine	B-GENE
kinase	I-GENE
release	O
after	O
hepatic	O
artery	O
embolization	O
in	O
patients	O
with	O
carcinoid	O
tumors	O
.	O

Antidepressant	O
-	O
like	O
properties	O
of	O
some	O
serotonin	B-GENE
receptor	I-GENE
ligands	O
and	O
calcium	O
channel	O
antagonists	O
measured	O
with	O
the	O
forced	O
swimming	O
test	O
in	O
mice	O
.	O

Metformin	O
plasma	O
concentrations	O
remained	O
unchanged	O
except	O
for	O
patients	O
transferred	O
from	O
1	O
.	O
5	O
to	O
2	O
.	O
0	O
g	O
daily	O
to	O
850	O
mg	O
twice	O
daily	O
;	O
in	O
these	O
patients	O
plasma	O
concentrations	O
increased	O
from	O
1	O
.	O
83	O
+	O
/	O
-	O
0	O
.	O
87	O
to	O
2	O
.	O
50	O
+	O
/	O
-	O
0	O
.	O
89	O
micrograms	O
/	O
l	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
Turbutest	O
is	O
a	O
valuable	O
tool	O
in	O
asthmatic	O
patients	O
'	O
training	O
,	O
allowing	O
identification	O
and	O
improvement	O
of	O
an	O
inadequate	O
inhalation	O
technique	O
with	O
Turbuhaler	O
.	O

Preliminary	O
use	O
of	O
the	O
Nottingham	O
Eczema	O
Severity	O
Score	O
would	O
support	O
further	O
development	O
as	O
a	O
research	O
tool	O
for	O
a	O
simple	O
assessment	O
of	O
disease	O
severity	O
that	O
could	O
be	O
used	O
in	O
epidemiological	O
studies	O
.	O

Like	O
Epo	B-GENE
,	O
HNF	B-GENE
-	I-GENE
4	I-GENE
is	O
expressed	O
in	O
kidney	O
,	O
liver	O
,	O
and	O
Hep3B	O
cells	O
but	O
not	O
in	O
HeLa	O
cells	O
.	O

In	O
a	O
screen	O
for	O
genes	O
with	O
oncogenic	O
potential	O
expressed	O
by	O
the	O
murine	O
B6SUtA1	O
myeloid	O
progenitor	O
cell	O
line	O
,	O
we	O
isolated	O
a	O
2	O
.	O

We	O
conducted	O
a	O
clinical	O
and	O
pathologic	O
review	O
of	O
nine	O
patients	O
with	O
immature	O
ovarian	O
teratoma	O
.	O

The	O
recovered	O
calves	O
were	O
tested	O
for	O
immunity	O
to	O
homologous	O
severe	O
challenge	O
,	O
50	O
or	O
73	O
days	O
after	O
the	O
first	O
infection	O
.	O

By	O
Felix	O
Lagrange	O
,	O
1918	O
.	O

Despite	O
significant	O
lethality	O
and	O
cardiovascular	O
dysfunction	O
,	O
in	O
the	O
septic	O
group	O
on	O
Days	O
1	O
and	O
2	O
,	O
septic	O
versus	O
control	O
animals	O
had	O
no	O
significant	O
differences	O
in	O
mean	O
metabolic	O
cart	O
measured	O
(	O
Vo2DIR	O
,	O
ml	O
/	O
kg	O
/	O
min	O
;	O
Day	O
1	O
:	O
11	O
.	O
9	O
versus	O
12	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
81	O
;	O
Day	O
2	O
:	O
14	O
.	O
2	O
versus	O
13	O
.	O
5	O
,	O
p	O
=	O
0	O
.	O
72	O
,	O
respectively	O
)	O
and	O
intravascular	O
catheter	O
calculated	O
(	O
Vo2INDIR	O
,	O
ml	O
/	O
kg	O
/	O
min	O
;	O
Day	O
1	O
:	O
11	O
.	O
2	O
versus	O
11	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
99	O
;	O
Day	O
2	O
:	O
12	O
.	O
8	O
versus	O
15	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
49	O
,	O
respectively	O
)	O
.	O

The	O
expression	O
of	O
the	O
yam8	B-GENE
(	I-GENE
+	I-GENE
)	I-GENE
cDNA	I-GENE
in	O
the	O
mid1	B-GENE
mutant	I-GENE
cells	O
partially	O
remediated	O
the	O
mid	O
phenotype	O
and	O
resulted	O
in	O
a	O
slight	O
increase	O
in	O
Ca	O
(	O
2	O
+	O
)	O
uptake	O
activity	O
.	O

Haycocknema	O
perplexum	O
n	O
.	O

g	O
.	O
,	O
n	O
.	O

sp	O
.	O

The	O
use	O
of	O
this	O
model	O
for	O
investigating	O
pathophysiologically	O
significant	O
issues	O
in	O
denervating	O
diseases	O
is	O
illustrated	O
with	O
five	O
different	O
sets	O
of	O
parameters	O
.	O

Two	O
of	O
these	O
six	O
cases	O
showed	O
mucosal	O
spread	O
without	O
stromal	O
invasion	O
(	O
type	O
A	O
)	O
;	O
the	O
remaining	O
four	O
cases	O
presented	O
a	O
direct	O
extension	O
(	O
type	O
B	O
)	O
from	O
muscle	O
-	O
invasive	O
carcinomas	O
of	O
the	O
bladder	O
.	O

The	O
promoter	O
of	O
the	O
rat	B-GENE
PGS	I-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
contains	O
a	O
CAAT	B-GENE
enhancer	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
consensus	I-GENE
site	I-GENE
(	I-GENE
CAAT	I-GENE
box	I-GENE
)	I-GENE
which	O
can	O
confer	O
hormone	O
inducibility	O
to	O
a	O
PGS	B-GENE
-	I-GENE
2	I-GENE
.	O
CAT	B-GENE
reporter	O
gene	O
,	O
as	O
well	O
as	O
a	O
putative	O
E	O
-	O
box	O
region	O
.	O

The	O
promoter	O
region	O
(	O
P1	O
)	O
corresponding	O
to	O
the	O
main	O
group	O
of	O
transcription	O
initiation	O
sites	O
is	O
devoid	O
of	O
TATA	O
and	O
CAAT	O
boxes	O
but	O
has	O
putative	O
binding	O
sites	O
for	O
the	O
transcription	B-GENE
factor	I-GENE
SP1	I-GENE
and	O
is	O
embedded	O
in	O
a	O
large	O
G	O
+	O
C	O
-	O
rich	O
domain	O
of	O
a	O
CpG	O
island	O
,	O
features	O
shared	O
by	O
the	O
promoters	O
of	O
constitutively	O
expressed	O
housekeeping	O
genes	O
.	O

Tonsillectomy	O
is	O
an	O
effective	O
means	O
of	O
prophylaxis	O
for	O
upper	O
respiratory	O
infection	O
in	O
habitual	O
angina	O
patients	O
.	O

This	O
is	O
in	O
contrast	O
with	O
the	O
classical	O
'	O
oxygen	O
debt	O
hypothesis	O
'	O
,	O
which	O
states	O
that	O
the	O
oxygen	O
debt	O
and	O
lactate	O
clearance	O
are	O
linked	O
.	O

There	O
were	O
9	O
patients	O
in	O
NYHA	O
class	O
III	O
and	O
8	O
in	O
class	O
IV	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

All	O
of	O
these	O
data	O
suggest	O
that	O
replication	O
of	O
UV	O
-	O
damaged	O
templates	O
occurs	O
in	O
vitro	O
as	O
it	O
does	O
in	O
vivo	O
and	O
that	O
this	O
replication	O
results	O
in	O
mutation	O
fixation	O
.	O

Contrary	O
to	O
expectations	O
,	O
we	O
find	O
a	O
relatively	O
high	O
level	O
of	O
variation	O
in	O
the	O
stripe	B-GENE
2	I-GENE
enhancer	O
region	O
,	O
including	O
point	O
substitutions	O
and	O
insertion	O
/	O
deletions	O
in	O
binding	O
sites	O
,	O
and	O
a	O
comparable	O
level	O
of	O
variation	O
in	O
the	O
other	O
noncoding	O
regions	O
.	O

The	O
effect	O
of	O
six	O
arginine	O
mutations	O
of	O
oxidative	O
phosphorylation	O
and	O
AAC	B-GENE
expression	O
.	O

The	O
5	O
'	O
ends	O
of	O
F3R	B-GENE
late	O
transcripts	O
were	O
located	O
to	O
an	O
A	O
within	O
the	O
sequence	O
5	O
'	O
-	O
TAAAG	O
,	O
41	O
nt	O
downstream	O
from	O
the	O
early	O
promoter	O
and	O
17	O
nt	O
upstream	O
from	O
the	O
initiation	O
codon	O
.	O

The	O
detector	O
has	O
the	O
advantage	O
of	O
finding	O
both	O
ST	O
segment	O
deviations	O
and	O
entire	O
ST	O
-	O
T	O
complex	O
changes	O
thereby	O
providing	O
a	O
wider	O
characterization	O
of	O
the	O
potential	O
ischemic	O
events	O
.	O

The	O
following	O
evidence	O
indicates	O
that	O
the	O
69	O
-	O
kD	O
protein	O
is	O
a	O
common	O
,	O
rather	O
than	O
a	O
U1	B-GENE
-	O
specific	O
,	O
protein	O
,	O
possibly	O
associating	O
with	O
the	O
snRNP	O
core	O
particles	O
by	O
protein	O
-	O
protein	O
interaction	O
.	O

They	O
suggest	O
that	O
decreased	O
steady	O
-	O
state	O
levels	O
of	O
IME1	B-GENE
and	O
IME2	B-GENE
mRNA	I-GENE
were	O
not	O
merely	O
the	O
result	O
of	O
non	O
-	O
specific	O
adverse	O
affects	O
on	O
nucleic	O
acid	O
metabolism	O
caused	O
by	O
the	O
yvh1	B-GENE
disruption	O
.	O

The	O
Ets	B-GENE
-	I-GENE
1	I-GENE
binding	I-GENE
site	I-GENE
was	O
localized	O
to	O
a	O
17	O
-	O
base	O
pair	O
(	O
bp	O
)	O
region	O
from	O
the	O
3	O
'	O
end	O
of	O
T	B-GENE
alpha	I-GENE
2	I-GENE
.	O

We	O
remain	O
convinced	O
that	O
antilymphocyte	B-GENE
globulin	I-GENE
(	O
ALG	B-GENE
)	O
is	O
a	O
potent	O
immunosuppressive	O
agent	O
in	O
humans	O
.	O

When	O
transiently	O
transfected	O
into	O
K562	O
cells	O
,	O
this	O
Lg	B-GENE
genomic	O
clone	O
is	O
actively	O
transcribed	O
,	O
suggesting	O
that	O
,	O
although	O
it	O
possesses	O
the	O
characteristics	O
of	O
a	O
processed	O
pseudogene	O
,	O
it	O
is	O
likely	O
to	O
correspond	O
to	O
the	O
gene	O
encoding	O
this	O
new	O
ferritin	B-GENE
subunit	I-GENE
.	O

Age	O
was	O
categorized	O
into	O
four	O
groups	O
:	O
20	O
-	O
44	O
,	O
45	O
-	O
64	O
,	O
65	O
-	O
74	O
,	O
and	O
75	O
+	O
.	O
RESULTS	O
:	O
At	O
the	O
initiation	O
of	O
dialysis	O
PD	O
patients	O
were	O
approximately	O
6	O
years	O
younger	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
than	O
HD	O
patients	O
.	O

The	O
effect	O
of	O
low	O
dosage	O
radiation	O
on	O
metabolism	O
and	O
function	O
of	O
the	O
rat	O
kidney	O
damaged	O
by	O
ischemia	O

The	O
temporal	O
and	O
static	O
plasma	O
concentration	O
-	O
effect	O
relationships	O
were	O
evaluated	O
by	O
pharmacodynamic	O
modeling	O
and	O
linear	O
regression	O
.	O

Serum	O
lipids	O
and	O
lipoproteins	O
of	O
29	O
insulin	B-GENE
dependent	O
diabetic	O
children	O
have	O
been	O
determined	O
and	O
related	O
to	O
the	O
metabolic	O
status	O
of	O
the	O
patients	O
.	O

Thus	O
,	O
TRAF2	B-GENE
initiates	O
SAPK	B-GENE
and	O
p38	B-GENE
activation	O
by	O
binding	O
two	O
proximal	O
protein	O
kinases	O
:	O
GCK	B-GENE
and	O
RIP	B-GENE
.	O

The	O
Cili	B-GENE
-	I-GENE
2	I-GENE
sequences	I-GENE
possess	O
similarity	O
to	O
the	O
RNaseH	B-GENE
domain	I-GENE
of	O
Lian	B-GENE
-	O
Aa1	B-GENE
,	O
a	O
mosquito	B-GENE
non	I-GENE
-	I-GENE
LTR	I-GENE
retrotransposon	I-GENE
.	O

Samples	O
from	O
1415	O
neurological	O
patients	O
were	O
used	O
to	O
study	O
the	O
diagnostic	O
value	O
of	O
acid	B-GENE
alpha	I-GENE
1	I-GENE
-	I-GENE
glycoprotein	I-GENE
in	O
the	O
lumbar	O
cerebrospinal	O
fluid	O
.	O

Protein	B-GENE
C	I-GENE
deficiency	O
or	O
protein	B-GENE
S	I-GENE
deficiency	O
was	O
the	O
only	O
identified	O
risk	O
factor	O
for	O
5	O
.	O
4	O
%	O
(	O
2	O
patients	O
)	O
and	O
13	O
.	O
5	O
%	O
(	O
5	O
patients	O
)	O
,	O
respectively	O
,	O
of	O
these	O
37	O
children	O
.	O

Conserved	O
and	O
distinct	O
roles	O
of	O
kreisler	B-GENE
in	O
regulation	O
of	O
the	O
paralogous	O
Hoxa3	B-GENE
and	O
Hoxb3	B-GENE
genes	I-GENE
.	O

Isolation	O
of	O
Weeksella	O
virosa	O
(	O
formerly	O
CDC	O
group	O
IIf	O
)	O
from	O
a	O
vaginal	O
sample	O
.	O

Several	O
artifacts	O
occurred	O
that	O
interfered	O
with	O
visualization	O
of	O
the	O
diaphragm	O
.	O

Among	O
these	O
360	O
ZFPs	B-GENE
,	O
a	O
novel	O
ZFP	B-GENE
cDNA	I-GENE
named	O
HFHZ	B-GENE
(	O
human	B-GENE
fetal	I-GENE
heart	I-GENE
ZFP	I-GENE
)	O
with	O
sequence	O
homology	O
to	O
a	O
Kruppel	B-GENE
-	I-GENE
associated	I-GENE
box	I-GENE
(	O
KRAB	B-GENE
)	O
was	O
identified	O
.	O

The	O
responsiveness	O
of	O
visual	O
cortex	O
(	O
VC	O
)	O
and	O
superior	O
colliculus	O
(	O
SC	O
)	O
was	O
simultaneously	O
compared	O
following	O
conditioning	O
"	O
ON	O
"	O
or	O
"	O
OFF	O
"	O
stimulation	O
,	O
in	O
the	O
rabbit	O
.	O

The	O
m7GpppN	O
cap	O
structure	O
of	O
eukaryotic	O
mRNA	O
is	O
formed	O
cotranscriptionally	O
by	O
the	O
sequential	O
action	O
of	O
three	O
enzymes	O
:	O
RNA	B-GENE
triphosphatase	I-GENE
,	O
RNA	B-GENE
guanylyltransferase	I-GENE
,	O
and	O
RNA	B-GENE
(	I-GENE
guanine	I-GENE
-	I-GENE
7	I-GENE
)	I-GENE
-	I-GENE
methyltransferase	I-GENE
.	O

Following	O
seizure	O
induction	O
,	O
MABP	O
increased	O
to	O
105	O
mm	O
Hg	O
and	O
brain	O
pHi	O
fell	O
to	O
6	O
.	O
79	O
+	O
/	O
-	O
0	O
.	O
03	O
within	O
15	O
min	O
and	O
remained	O
at	O
this	O
level	O
for	O
1	O
h	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Therefore	O
,	O
PC	B-GENE
-	I-GENE
PLC	I-GENE
is	O
a	O
component	O
of	O
a	O
signal	O
transduction	O
pathway	O
leading	O
to	O
transcription	O
of	O
c	B-GENE
-	I-GENE
fos	I-GENE
and	O
junB	B-GENE
that	O
collaborates	O
with	O
c	B-GENE
-	I-GENE
myc	I-GENE
and	O
is	O
independent	O
of	O
PKC	B-GENE
-	I-GENE
delta	I-GENE
and	O
Ras	B-GENE
activation	O
.	O

Mutations	O
in	O
the	O
VPS45	B-GENE
gene	I-GENE
,	O
a	O
SEC1	B-GENE
homologue	O
,	O
result	O
in	O
vacuolar	O
protein	O
sorting	O
defects	O
and	O
accumulation	O
of	O
membrane	O
vesicles	O
.	O

A	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
,	O
performed	O
separately	O
for	O
men	O
and	O
women	O
for	O
differences	O
among	O
the	O
three	O
phobic	O
groups	O
on	O
field	O
dependence	O
,	O
showed	O
significance	O
(	O
rho	O
less	O
than	O
.	O
05	O
)	O
for	O
the	O
females	O
,	O
with	O
the	O
famale	O
agoraphobic	O
being	O
more	O
field	O
dependent	O
than	O
the	O
female	O
simple	O
phobic	O
groups	O
,	O
but	O
not	O
for	O
the	O
males	O
.	O

They	O
also	O
negatively	O
modulate	O
the	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
catalytic	O
activity	O
but	O
to	O
different	O
extents	O
,	O
dependent	O
on	O
the	O
unique	O
N	O
-	O
terminal	O
structure	O
of	O
each	O
isoform	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
silymarin	O
may	O
exert	O
a	O
strong	O
anticarcinogenic	O
effect	O
against	O
PCA	O
and	O
that	O
this	O
effect	O
is	O
likely	O
to	O
involve	O
impairment	O
of	O
erbB1	B-GENE
-	O
SHC	B-GENE
-	O
mediated	O
signaling	O
pathway	O
,	O
induction	O
of	O
CDKIs	B-GENE
,	O
and	O
a	O
resultant	O
G1	O
arrest	O
.	O

In	O
acute	O
-	O
phase	O
livers	O
,	O
we	O
observed	O
a	O
dramatic	O
reduction	O
in	O
HNF	B-GENE
-	I-GENE
3	I-GENE
alpha	I-GENE
expression	O
which	O
correlates	O
with	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
its	O
target	O
gene	O
,	O
the	O
TTR	B-GENE
gene	I-GENE
.	O

The	O
identification	O
of	O
the	O
hepatitis	O
C	O
virus	O
as	O
the	O
major	O
cause	O
of	O
liver	O
disease	O
both	O
in	O
dialysis	O
patients	O
and	O
in	O
transplant	O
patients	O
has	O
focused	O
attention	O
on	O
the	O
epidemiology	O
and	O
the	O
impact	O
of	O
continuing	O
infection	O
in	O
these	O
patient	O
groups	O
.	O

Exposure	O
to	O
higher	O
TPA	O
concentrations	O
decreased	O
the	O
content	O
of	O
these	O
transcripts	O
.	O

PAO	O
blocks	O
turnover	O
of	O
the	O
phosphoryl	O
group	O
of	O
pp15	B-GENE
,	O
causing	O
its	O
accumulation	O
,	O
and	O
thereby	O
appears	O
to	O
interrupt	O
signal	O
transmission	O
from	O
the	O
receptor	O
to	O
the	O
glucose	O
-	O
transport	O
system	O
.	O

In	O
conclusion	O
:	O
(	O
i	O
)	O
TECRA	O
kit	O
is	O
suggested	O
to	O
be	O
used	O
for	O
screening	O
SE	O
producing	O
strains	O
;	O
(	O
ii	O
)	O
SET	O
-	O
RPLA	O
and	O
RIDASCREEN	O
kits	O
are	O
suitable	O
for	O
epidemiological	O
investigation	O
of	O
SE	O
types	O
,	O
but	O
the	O
lack	O
of	O
ability	O
for	O
detecting	O
SEE	O
,	O
long	O
time	O
required	O
for	O
testing	O
with	O
SET	O
-	O
RPLA	O
kit	O
and	O
high	O
background	O
when	O
using	O
RIDASCREEN	O
kit	O
must	O
be	O
overcome	O
;	O
and	O
(	O
iii	O
)	O
because	O
of	O
the	O
complicated	O
test	O
procedures	O
and	O
the	O
lack	O
of	O
ability	O
for	O
detecting	O
SEE	O
,	O
the	O
practicality	O
of	O
SET	O
-	O
EIA	O
kit	O
in	O
screening	O
and	O
epidemiological	O
research	O
purposes	O
is	O
low	O
.	O

PURPOSE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
first	O
embryo	O
cleavage	O
(	O
FEC	O
)	O
25	O
-	O
27	O
h	O
after	O
intracytoplasmic	O
sperm	O
injection	O
(	O
ICSI	O
)	O
as	O
a	O
parameter	O
for	O
the	O
embryo	O
selection	O
process	O
.	O

Mutagenesis	O
of	O
IM1	B-GENE
enhances	O
the	O
ability	O
of	O
c	B-GENE
-	I-GENE
Fos	I-GENE
to	O
activate	O
an	O
AP1	B-GENE
bearing	I-GENE
promoter	I-GENE
.	O

Sequence	O
analysis	O
revealed	O
that	O
the	O
MEMA	B-GENE
protein	I-GENE
is	O
identical	O
with	O
a	O
160	B-GENE
kDa	I-GENE
nuclear	I-GENE
'	I-GENE
domain	I-GENE
rich	I-GENE
in	I-GENE
serines	I-GENE
'	I-GENE
(	I-GENE
DRS	I-GENE
)	I-GENE
protein	I-GENE
occurring	O
free	O
in	O
the	O
nucleoplasm	O
and	O
in	O
U2	B-GENE
-	I-GENE
ribonucleoprotein	I-GENE
structures	I-GENE
.	O

By	O
using	O
the	O
full	O
-	O
length	O
cytoplasmic	O
domain	O
and	O
mutants	O
with	O
progressive	O
carboxy	O
-	O
terminal	O
deletions	O
,	O
internal	O
deletions	O
,	O
or	O
point	O
mutations	O
,	O
we	O
identified	O
the	O
first	O
150	O
amino	O
acid	O
residues	O
of	O
LIFR	B-GENE
as	O
the	O
minimal	O
region	O
necessary	O
for	O
signaling	O
.	O

Methods	O
used	O
include	O
Cobb	O
angle	O
and	O
a	O
segmental	O
evaluation	O
(	O
T7	O
-	O
T12	O
)	O
of	O
each	O
of	O
convex	O
and	O
concave	O
rib	O
-	O
vertebra	O
angles	O
(	O
RVAs	O
)	O
,	O
rib	O
-	O
vertebra	O
angle	O
differences	O
(	O
RVADs	O
)	O
,	O
vertebral	O
rotation	O
,	O
tilt	O
and	O
displacement	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
the	O
distal	O
half	O
(	O
Stem	O
2	O
)	O
of	O
the	O
conserved	O
base	O
-	O
paired	O
stem	O
structure	O
found	O
in	O
all	O
hY	B-GENE
RNAs	I-GENE
also	O
plays	O
a	O
critical	O
role	O
in	O
the	O
export	O
process	O
.	O

Value	O
of	O
the	O
method	O
of	O
passive	O
hemagglutination	O
with	O
polysaccharide	O
C	O
in	O
detecting	O
C	B-GENE
-	I-GENE
reactive	I-GENE
protein	I-GENE
as	O
compared	O
to	O
precipitation	O
in	O
capillaries	O
and	O
slide	O
latex	O
test	O
with	O
anti	B-GENE
-	I-GENE
CRP	I-GENE
serum	O

The	O
experimental	O
design	O
represents	O
a	O
2	O
x	O
3	O
factorial	O
arrangement	O
of	O
treatments	O
with	O
three	O
dietary	O
levels	O
of	O
incorporation	O
of	O
RSB	O
(	O
0	O
,	O
50	O
,	O
and	O
100	O
%	O
)	O
,	O
and	O
chickens	O
either	O
infected	O
or	O
uninfected	O
.	O

Human	B-GENE
LAF	I-GENE
-	I-GENE
4	I-GENE
readily	O
hybridized	O
with	O
genes	O
in	O
mouse	O
and	O
chicken	O
,	O
thus	O
showing	O
that	O
this	O
gene	O
family	O
has	O
been	O
highly	O
conserved	O
during	O
vertebrate	O
evolution	O
.	O

These	O
incisors	O
were	O
studied	O
by	O
scanning	O
electron	O
microscopy	O
-	O
energy	O
dispersive	O
spectroscopy	O
analysis	O
(	O
SEM	O
-	O
EDS	O
)	O
and	O
light	O
microscopy	O
to	O
examine	O
the	O
calciotraumatic	O
lines	O
of	O
strontium	O
in	O
the	O
rat	O
incisor	O
labial	O
dentin	O
.	O

The	O
elevations	O
achieved	O
by	O
LDEE	O
given	O
s	O
.	O
c	O
.	O
were	O
higher	O
than	O
those	O
achieved	O
after	O
i	O
.	O
p	O
.	O
administration	O
and	O
lasted	O
for	O
longer	O
periods	O
.	O

This	O
regulation	O
requires	O
two	O
HMG	B-GENE
-	I-GENE
box	I-GENE
proteins	I-GENE
:	O
the	O
ubiquitous	O
Ste11	B-GENE
transcription	I-GENE
factor	I-GENE
and	O
the	O
M	O
cell	O
-	O
controlling	O
protein	O
Mat1	B-GENE
-	I-GENE
Mc	I-GENE
.	O

Finger	B-GENE
associated	I-GENE
box	I-GENE
-	I-GENE
zinc	I-GENE
finger	I-GENE
proteins	I-GENE
(	O
FAX	B-GENE
-	I-GENE
ZFPs	I-GENE
)	O
constitute	O
a	O
subfamily	O
of	O
the	O
many	O
C2H2	B-GENE
type	I-GENE
ZFPs	I-GENE
in	O
Xenopus	O
laevis	O
.	O

In	O
connective	O
tissue	O
,	O
cell	O
structure	O
contributes	O
to	O
type	B-GENE
I	I-GENE
collagen	I-GENE
expression	O
.	O

Evidence	O
for	O
a	O
novel	O
MAPKKK	B-GENE
-	O
independent	O
pathway	O
controlling	O
the	O
stress	O
activated	O
Sty1	B-GENE
/	O
Spc1	B-GENE
MAP	O
kinase	O
in	O
fission	O
yeast	O
.	O

This	O
means	O
that	O
the	O
loss	O
of	O
recessives	O
must	O
be	O
calculated	O
by	O
using	O
a	O
hypergeometric	O
and	O
not	O
a	O
binomial	O
model	O
as	O
Fisher	O
did	O
.	O

A	O
sheep	O
testicular	O
cDNA	O
library	O
constructed	O
in	O
pcDNA1	O
vector	O
was	O
screened	O
with	O
a	O
probe	O
generated	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
corresponding	O
to	O
a	O
1	O
.	O
6	O
kb	O
fragment	O
of	O
the	O
rat	B-GENE
luteinizing	I-GENE
hormone	I-GENE
receptor	I-GENE
cDNA	I-GENE
.	O

The	O
mobility	O
shift	O
assay	O
of	O
the	O
65	O
bp	O
(	O
-	O
318	O
/	O
-	O
254	O
)	O
fragment	O
with	O
nuclear	O
extract	O
from	O
the	O
dark	O
-	O
adapted	O
sample	O
showed	O
an	O
additional	O
band	O
,	O
not	O
seen	O
with	O
the	O
light	O
-	O
grown	O
sample	O
.	O

The	O
activity	O
of	O
Rac1	B-GENE
leads	O
to	O
STAT3	B-GENE
translocation	O
to	O
the	O
nucleus	O
coincident	O
with	O
STAT3	B-GENE
-	O
dependent	O
gene	O
expression	O
.	O

Piperacillin	O
-	O
tazobactam	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
gram	O
-	O
negative	O
,	O
gram	O
-	O
positive	O
,	O
aerobic	O
,	O
and	O
anaerobic	O
bacteria	O
.	O

Subjects	O
were	O
16	O
male	O
chronic	O
schizophrenics	O
consisting	O
of	O
8	O
DST	O
suppressors	O
and	O
8	O
nonsuppressors	O
.	O

In	O
Denmark	O
only	O
1	O
-	O
3	O
cases	O
of	O
transfusion	O
-	O
associated	O
hepatitis	O
NANB	O
(	O
TAH	O
-	O
NANB	O
)	O
are	O
registered	O
annually	O
or	O
about	O
1	O
case	O
per	O
100	O
,	O
000	O
units	O
transfused	O
.	O

The	O
GEF	B-GENE
and	O
GAP	B-GENE
activities	O
for	O
Ypt1p	B-GENE
localize	O
to	O
particulate	O
cellular	O
fractions	O
.	O

RESULTS	O
:	O
The	O
cardiac	O
index	O
significantly	O
changed	O
with	O
varying	O
PaCO2	O
levels	O
(	O
hypocapnia	O
,	O
-	O
9	O
%	O
;	O
hypercapnia	O
,	O
13	O
%	O
)	O
.	O

A	O
mouse	B-GENE
brain	I-GENE
beta	I-GENE
-	I-GENE
spectrin	I-GENE
of	O
cDNA	O
was	O
identified	O
within	O
a	O
lambda	O
Gt11	O
expression	O
library	O
using	O
an	O
antibody	O
which	O
specifically	O
binds	O
with	O
the	O
235	B-GENE
kDa	I-GENE
spectrin	I-GENE
beta	I-GENE
-	I-GENE
subunit	I-GENE
.	O

Upon	O
tyrosine	O
phosphorylation	O
at	O
the	O
ITIMs	O
,	O
these	O
molecules	O
recruit	O
SH2	B-GENE
domain	O
-	O
containing	O
phosphatases	O
such	O
as	O
SH2	B-GENE
-	O
containing	O
tyrosine	B-GENE
phosphatase	I-GENE
-	I-GENE
1	I-GENE
and	O
negatively	O
regulate	O
cell	O
activity	O
.	O

The	O
promoter	O
for	O
HMG	B-GENE
-	I-GENE
CoA	I-GENE
synthase	I-GENE
contains	O
two	O
binding	O
sites	O
for	O
the	O
sterol	B-GENE
regulatory	I-GENE
element	I-GENE
-	I-GENE
binding	I-GENE
proteins	I-GENE
(	O
SREBPs	B-GENE
)	O
.	O

Repeated	O
administration	O
of	O
GRg2	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
significantly	O
improved	O
the	O
CYP	O
-	O
induced	O
recognitional	O
deficits	O
by	O
increasing	O
the	O
CYP	O
-	O
decreased	O
rate	O
from	O
55	O
.	O
8	O
+	O
/	O
-	O
9	O
.	O
6	O
to	O
80	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
2	O
in	O
d	O
3	O
learning	O
acquisition	O
(	O
F	O
(	O
1	O
,	O
14	O
)	O
=	O
5	O
.	O
6	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
from	O
53	O
.	O
4	O
+	O
/	O
-	O
8	O
.	O
4	O
to	O
60	O
.	O
0	O
+	O
/	O
-	O
8	O
.	O
2	O
in	O
48	O
h	O
memory	O
acquisition	O
(	O
F	O
(	O
1	O
,	O
14	O
)	O
=	O
7	O
.	O
5	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
from	O
55	O
.	O
0	O
+	O
/	O
-	O
5	O
.	O
5	O
to	O
88	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
in	O
24	O
h	O
memory	O
retention	O
(	O
F	O
(	O
1	O
,	O
12	O
)	O
27	O
.	O
5	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
as	O
well	O
as	O
from	O
60	O
.	O
0	O
+	O
/	O
-	O
6	O
.	O
8	O
to	O
85	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
9	O
in	O
48	O
h	O
memory	O
retrieval	O
(	O
F	O
(	O
1	O
,	O
12	O
)	O
=	O
5	O
.	O
2	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
respectively	O
.	O

Forty	O
4	O
-	O
month	O
old	O
SD	O
female	O
rats	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
,	O
namely	O
sham	O
operation	O
,	O
bilateral	O
ovariectomy	O
,	O
ovariectomy	O
plus	O
supplementary	O
ethinyl	O
estradiol	O
(	O
0	O
.	O
2	O
microgram	O
/	O
100	O
g	O
B	O
.	O

Defects	O
in	O
the	O
Schizosaccharomyces	O
pombe	O
(	O
Sp	O
)	O
cell	O
cycle	O
-	O
controlling	O
genes	O
prevent	O
the	O
cell	O
cycle	O
progression	O
.	O

Perfusion	O
technique	O
for	O
perfusion	O
-	O
assisted	O
direct	O
coronary	O
artery	O
bypass	O
(	O
PADCAB	O
)	O
.	O

Here	O
we	O
provide	O
the	O
first	O
evidence	O
for	O
the	O
involvement	O
of	O
GCN1	B-GENE
-	O
GCN2	B-GENE
interaction	O
in	O
activation	O
of	O
GCN2	B-GENE
per	O
se	O
.	O

The	O
7	O
-	O
day	O
treatment	O
resulted	O
in	O
a	O
decrease	O
in	O
mitochondrial	O
uptake	O
of	O
Rh123	O
and	O
an	O
increase	O
in	O
NAO	O
uptake	O
.	O

The	O
results	O
raise	O
the	O
possibility	O
that	O
pH	O
induced	O
post	O
-	O
translational	O
modifications	O
of	O
DdRPA	B-GENE
are	O
involved	O
in	O
events	O
that	O
halt	O
cell	O
proliferation	O
and	O
induce	O
differentiation	O
in	O
Dictyostelium	O
.	O

Liquid	O
chromatographic	O
method	O
for	O
analysis	O
of	O
all	O
-	O
rac	O
-	O
alpha	O
-	O
tocopheryl	O
acetate	O
and	O
retinyl	O
palmitate	O
in	O
milk	O
-	O
based	O
infant	O
formula	O
using	O
matrix	O
solid	O
-	O
phase	O
dispersion	O
.	O

This	O
transcriptional	O
regulation	O
occurs	O
through	O
modulation	O
of	O
the	O
forkhead	B-GENE
transcription	I-GENE
factor	I-GENE
FKHR	B-GENE
-	I-GENE
L1	I-GENE
,	O
and	O
IL	B-GENE
-	I-GENE
3	I-GENE
inhibited	O
FKHR	B-GENE
-	I-GENE
L1	I-GENE
activity	O
in	O
a	O
PI3K	B-GENE
-	O
dependent	O
manner	O
.	O

TIP30	B-GENE
has	O
an	O
intrinsic	O
kinase	O
activity	O
required	O
for	O
up	O
-	O
regulation	O
of	O
a	O
subset	O
of	O
apoptotic	O
genes	O
.	O

Analysis	O
of	O
hematopoietic	B-GENE
growth	I-GENE
factor	I-GENE
prescriptions	O
in	O
19	O
french	O
cancer	O
centers	O

We	O
propose	O
that	O
CTS1	B-GENE
and	I-GENE
CTS2	I-GENE
of	I-GENE
Ci	I-GENE
are	O
members	O
of	O
two	O
distinct	O
classes	O
of	O
fungal	B-GENE
chitinases	I-GENE
,	O
an	O
observation	O
not	O
previously	O
reported	O
for	O
a	O
single	O
fungus	O
.	O

The	O
HiNF	B-GENE
-	I-GENE
D	I-GENE
(	O
CDP	B-GENE
/	O
cut	B-GENE
)	O
complex	O
with	O
the	O
H4	B-GENE
promoter	I-GENE
is	O
immunoreactive	O
with	O
antibodies	O
against	O
CDP	B-GENE
/	O
cut	B-GENE
and	O
pRB	B-GENE
but	O
not	O
p107	B-GENE
,	O
whereas	O
the	O
CDP	B-GENE
/	O
cut	B-GENE
complex	O
with	O
a	O
nonhistone	O
promoter	O
(	O
gp91	B-GENE
-	O
phox	B-GENE
)	O
reacts	O
only	O
with	O
CDP	B-GENE
and	O
p107	B-GENE
antibodies	O
.	O

The	O
biosynthesis	O
and	O
stability	O
of	O
the	O
three	O
mutant	O
proteins	O
were	O
similar	O
to	O
those	O
of	O
the	O
wild	B-GENE
-	I-GENE
type	I-GENE
erbB	I-GENE
protein	I-GENE
,	O
and	O
all	O
three	O
retained	O
the	O
ability	O
to	O
transform	O
chicken	O
embryo	O
fibroblasts	O
.	O

Binding	O
activity	O
in	O
rat	O
liver	O
nuclear	O
extracts	O
includes	O
these	O
orphan	O
receptors	O
as	O
judged	O
from	O
electromobility	O
supershift	O
experiments	O
and	O
from	O
results	O
obtained	O
with	O
expressed	O
receptors	O
,	O
although	O
the	O
element	O
in	O
CYP2C11	B-GENE
did	O
not	O
bind	O
HNF	B-GENE
-	I-GENE
4	I-GENE
.	O

Isolation	O
and	O
characterization	O
of	O
the	O
rat	O
chromosomal	O
gene	O
for	O
a	O
polypeptide	O
(	O
pS1	B-GENE
)	O
antigenically	O
related	O
to	O
statin	B-GENE
.	O

The	O
experience	O
of	O
the	O
lateral	O
rhinotomy	O
approach	O
in	O
transsphenoidal	O
surgery	O
of	O
acromegaly	O
has	O
been	O
favourable	O
.	O

This	O
unique	O
location	O
of	O
cavernous	O
malformation	O
is	O
associated	O
with	O
a	O
risk	O
of	O
permanent	O
loss	O
of	O
the	O
vision	O
.	O

The	O
study	O
of	O
calcium	O
metabolism	O
in	O
ten	O
thalassaemic	O
children	O
comperatively	O
with	O
controls	O
after	O
oral	O
administration	O
of	O
47Ca	O
has	O
shown	O
diminished	O
intestinal	O
absorption	O
.	O

Sak	B-GENE
kinase	I-GENE
gene	O
structure	O
and	O
transcriptional	O
regulation	O
.	O

This	O
paper	O
presents	O
the	O
reasons	O
why	O
countries	O
to	O
which	O
Chagas	O
disease	O
is	O
endemic	O
should	O
carry	O
out	O
the	O
relevant	O
research	O
themselves	O
.	O

These	O
data	O
reveal	O
a	O
complex	O
network	O
of	O
interactions	O
between	O
GTPases	B-GENE
in	O
the	O
ARF	B-GENE
family	I-GENE
and	O
their	O
effectors	O
and	O
reveal	O
a	O
potential	O
for	O
cross	O
-	O
talk	O
not	O
demonstrated	O
previously	O
.	O

The	O
interferon	B-GENE
-	O
induced	O
RNA	B-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
PKR	B-GENE
)	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
cellular	O
defense	O
against	O
viral	O
infection	O
and	O
,	O
in	O
addition	O
,	O
has	O
been	O
suggested	O
to	O
be	O
a	O
tumor	O
suppressor	O
gene	O
because	O
of	O
its	O
growth	O
-	O
suppressive	O
properties	O
.	O

Immunoreactive	O
AR	B-GENE
content	O
in	O
transfected	O
COS	O
-	O
1	O
cells	O
was	O
not	O
influenced	O
by	O
exposure	O
to	O
8	O
-	O
Br	O
-	O
cAMP	O
.	O

A	O
peculiar	O
people	O
:	O
"	O
the	O
physiological	O
aspects	O
of	O
Mormonism	O
1850	O
-	O
1975	O
.	O
"	O

Hypomorphic	O
dSLBP	B-GENE
alleles	I-GENE
support	O
zygotic	O
development	O
but	O
cause	O
female	O
sterility	O
.	O

The	O
transverse	O
magnetization	O
decays	O
mentioned	O
above	O
exhibited	O
two	O
components	O
,	O
a	O
T2	O
fast	O
(	O
T2f	O
)	O
and	O
a	O
T2	O
slow	O
(	O
T2s	O
)	O
component	O
.	O

Molecular	O
cloning	O
and	O
functional	O
characterization	O
of	O
murine	B-GENE
sphingosine	I-GENE
kinase	I-GENE
.	O

Substrates	O
for	O
p210	B-GENE
(	O
bcr	B-GENE
-	O
abl	B-GENE
)	O
are	O
likely	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
CML	O
.	O

The	O
CCAAT	O
core	O
sequence	O
mutants	O
in	O
which	O
both	O
CIII	O
and	O
CI	O
/	O
CII	O
were	O
abolished	O
,	O
also	O
increased	O
the	O
promoter	O
activity	O
.	O

In	O
cellular	O
supernatant	O
fraction	O
,	O
SHRSP	O
showed	O
a	O
decrease	O
of	O
magnesium	O
in	O
many	O
tissues	O
and	O
an	O
elevation	O
of	O
the	O
calcium	O
to	O
magnesium	O
ratio	O
when	O
compared	O
to	O
age	O
-	O
matched	O
WKY	O
and	O
SHRSR	O
.	O

This	O
sequence	O
is	O
almost	O
identical	O
with	O
that	O
of	O
human	B-GENE
luteinizing	I-GENE
hormone	I-GENE
(	O
Sairam	O
,	O
M	O
.	O

We	O
now	O
demonstrate	O
that	O
CCAAT	B-GENE
/	I-GENE
enhancer	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	I-GENE
C	I-GENE
/	I-GENE
EBP	I-GENE
)	I-GENE
delta	I-GENE
is	O
a	O
major	O
component	O
of	O
a	O
PGE2	O
-	O
stimulated	O
DNA	O
-	O
protein	O
complex	O
involving	O
HS3D	B-GENE
and	O
find	O
that	O
C	B-GENE
/	I-GENE
EBPdelta	I-GENE
transactivates	O
IGF	B-GENE
-	I-GENE
I	I-GENE
promoter	I-GENE
1	I-GENE
through	O
this	O
site	O
.	O

Protein	B-GENE
cHMGI	I-GENE
binds	O
preferentially	O
to	O
AT	O
-	O
rich	O
DNA	O
with	O
a	O
half	O
-	O
saturation	O
value	O
of	O
1	O
.	O
1	O
nM	O
.	O

The	O
patients	O
were	O
divided	O
into	O
ischaemia	O
and	O
non	O
-	O
ischaemia	O
groups	O
on	O
the	O
basis	O
of	O
the	O
change	O
in	O
lactate	O
extraction	O
ratio	O
during	O
balloon	O
inflation	O
.	O

PABP	B-GENE
is	O
a	O
modular	O
protein	O
,	O
with	O
four	O
N	O
-	O
terminal	O
RNA	O
-	O
binding	O
domains	O
and	O
an	O
extensive	O
C	O
terminus	O
.	O

RESULTS	O
:	O
Glaucoma	O
suspects	O
were	O
divided	O
into	O
two	O
groups	O
according	O
to	O
their	O
SWAP	O
results	O
:	O
high	O
risk	O
(	O
with	O
SWAP	O
abnormalities	O
)	O
and	O
low	O
risk	O
(	O
with	O
normal	O
SWAP	O
result	O
)	O
.	O

Factors	O
influencing	O
direct	O
-	O
immersion	O
(	O
DI	O
)	O
-	O
SPME	O
process	O
were	O
also	O
checked	O
and	O
chosen	O
experimentally	O
.	O

Polarised	O
expression	O
of	O
human	O
intestinal	O
N	B-GENE
-	I-GENE
benzoyl	I-GENE
-	I-GENE
L	I-GENE
-	I-GENE
tyrosyl	I-GENE
-	I-GENE
p	I-GENE
-	I-GENE
aminobenzoic	I-GENE
acid	I-GENE
hydrolase	I-GENE
(	O
human	B-GENE
meprin	I-GENE
)	O
alpha	O
and	O
beta	O
subunits	O
in	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
cells	O
.	O

Transactivation	O
of	O
oIFNtau	B-GENE
enhancer	O
-	O
reporter	O
constructs	O
was	O
primarily	O
regulated	O
by	O
three	O
regions	O
containing	O
AP	B-GENE
-	I-GENE
1	I-GENE
site	I-GENE
,	O
GATA	B-GENE
like	I-GENE
sequence	I-GENE
and	O
site	O
(	O
s	O
)	O
unidentified	O
.	O

Reporter	O
gene	O
expression	O
analyses	O
indicate	O
that	O
both	O
WASP	B-GENE
promoters	I-GENE
show	O
high	O
levels	O
of	O
expression	O
in	O
different	O
hematopoietic	O
cell	O
lines	O
.	O

Single	O
amino	O
acid	O
substitutions	O
at	O
the	O
acyl	O
-	O
CoA	O
-	O
binding	O
domain	O
interrupt	O
14	O
[	O
C	O
]	O
palmitoyl	O
-	O
CoA	O
binding	O
of	O
ACBP2	B-GENE
,	O
an	O
Arabidopsis	O
acyl	B-GENE
-	I-GENE
CoA	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
with	O
ankyrin	B-GENE
repeats	O
.	O

Urine	O
antibodies	O
could	O
not	O
be	O
demonstrated	O
in	O
any	O
other	O
cases	O
.	O

Advanced	O
adenoma	O
was	O
defined	O
as	O
an	O
adenoma	O
larger	O
than	O
10	O
mm	O
or	O
an	O
adenoma	O
of	O
any	O
size	O
with	O
villous	O
component	O
,	O
high	O
-	O
grade	O
dysplasia	O
or	O
invasive	O
carcinoma	O
.	O

The	O
customary	O
coupling	O
reagent	O
sulfanilic	O
acid	O
has	O
been	O
replaced	O
by	O
1	O
,	O
3	O
-	O
dimethylbarbituric	O
acid	O
;	O
CNCl	O
is	O
produced	O
in	O
the	O
flow	O
through	O
system	O
directly	O
from	O
KCN	O
and	O
chloramine	O
T	O
.	O

This	O
sequenced	O
region	O
of	O
the	O
V	O
beta	O
locus	O
contains	O
an	O
average	O
number	O
of	O
repetitive	O
DNA	O
elements	O
(	O
21	O
Alu	B-GENE
,	O
three	O
L1	B-GENE
,	O
three	O
MER	O
,	O
and	O
three	O
retrovirus	O
-	O
related	O
elements	O
.	O

Defects	O
of	O
fibrillin	B-GENE
(	O
FBN1	B-GENE
)	O
,	O
a	O
glycoprotein	O
component	O
of	O
the	O
extracellular	O
microfibril	O
,	O
cause	O
Marfan	O
syndrome	O
.	O

The	O
requirement	O
of	O
3	O
'	O
complementarity	O
for	O
a	O
ligation	O
reaction	O
is	O
reaffirmed	O
by	O
results	O
from	O
1	O
nt	O
insertions	O
on	O
either	O
the	O
3	O
'	O
-	O
or	O
5	O
'	O
-	O
side	O
of	O
the	O
nick	O
.	O

Transcriptional	O
activity	O
was	O
measured	O
by	O
slot	O
-	O
blot	O
hybridization	O
with	O
steady	O
-	O
state	O
RNA	O
isolated	O
from	O
lacZ	B-GENE
+	I-GENE
M	I-GENE
.	I-GENE
smegmatis	I-GENE
clones	O
.	O

Furthermore	O
,	O
strains	O
with	O
mutant	B-GENE
RPM1	I-GENE
genes	I-GENE
also	O
accumulate	O
precursor	B-GENE
Rpm1r	I-GENE
,	O
suggesting	O
that	O
mutations	O
in	O
either	O
gene	O
can	O
lead	O
to	O
similar	O
biogenesis	O
defects	O
.	O

Nonvascular	O
ophthalmic	O
and	O
neurologic	O
disorders	O
that	O
can	O
be	O
confused	O
with	O
amaurosis	O
fugax	O
are	O
listed	O
,	O
and	O
an	O
algorithm	O
for	O
evaluation	O
(	O
which	O
includes	O
ophthalmic	O
examination	O
,	O
laboratory	O
studies	O
,	O
and	O
noninvasive	O
carotid	O
artery	O
studies	O
)	O
is	O
given	O
.	O

Fans	O
in	O
tunnels	O
and	O
open	O
windows	O
at	O
aboveground	O
locations	O
appeared	O
to	O
greatly	O
reduce	O
the	O
likelihood	O
of	O
high	O
PH3	O
concentrations	O
in	O
enclosed	O
areas	O
.	O

SELECTION	O
CRITERIA	O
:	O
Randomised	O
trials	O
comparing	O
children	O
undergoing	O
systematic	O
therapy	O
focusing	O
on	O
the	O
family	O
in	O
conjunction	O
with	O
asthma	O
medication	O
,	O
with	O
children	O
taking	O
asthma	O
medication	O
only	O
.	O

Midge	O
control	O
in	O
flood	O
channels	O
.	O

In	O
19	O
patients	O
vagotomy	O
not	O
only	O
curbed	O
the	O
bleeding	O
but	O
provided	O
definitive	O
therapy	O
(	O
Visick	O
I	O
-	O
II	O
)	O
;	O
4	O
patients	O
died	O
(	O
mortality	O
rate	O
16	O
%	O
)	O
.	O

Here	O
we	O
show	O
that	O
these	O
synthetic	O
binding	O
sites	O
have	O
a	O
more	O
restricted	O
and	O
specific	O
ability	O
to	O
enhance	O
transcription	O
when	O
assayed	O
in	O
transformed	O
embryos	O
.	O

Workload	O
,	O
UAPs	O
,	O
and	O
you	O
.	O

One	O
of	O
these	O
elements	O
,	O
the	O
homeodomain	B-GENE
-	I-GENE
binding	I-GENE
element	I-GENE
,	O
was	O
identified	O
to	O
mediate	O
negative	O
regulation	O
.	O

The	O
therapeutic	O
action	O
of	O
cyclosporin	O
A	O
(	O
Sandimmun	O
)	O
:	O
its	O
application	O
in	O
rheumatoid	O
arthritis	O
.	O

This	O
study	O
indicates	O
that	O
the	O
phenotype	O
of	O
myofibrillar	O
disarray	O
seen	O
in	O
HCM	O
patients	O
which	O
harbor	O
either	O
of	O
these	O
two	O
mutations	O
may	O
not	O
be	O
directly	O
due	O
to	O
the	O
failure	O
of	O
the	O
mutant	B-GENE
myosin	I-GENE
heavy	I-GENE
chain	I-GENE
protein	I-GENE
to	O
assemble	O
and	O
form	O
normal	O
sarcomeres	O
,	O
but	O
may	O
rather	O
be	O
a	O
secondary	O
effect	O
possibly	O
resulting	O
from	O
the	O
chronic	O
stress	O
of	O
decreased	O
beta	B-GENE
MHC	I-GENE
function	O
.	O

On	O
long	O
-	O
term	O
follow	O
-	O
up	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
incidence	O
of	O
hospitalizations	O
(	O
1	O
per	O
2	O
.	O
1	O
vs	O
.	O

Three	O
mutants	O
(	O
pms1	B-GENE
,	O
pms2	B-GENE
and	O
pms3	B-GENE
)	O
isolated	O
earlier	O
from	O
MW104	O
-	O
1B	O
were	O
shown	O
to	O
correct	O
in	O
vitro	O
constructed	O
plasmids	O
with	O
defined	O
DNA	O
mismatches	O
(	O
G	O
/	O
T	O
,	O
A	O
/	O
C	O
,	O
G	O
/	O
G	O
,	O
etc	O
.	O
)	O
poorly	O
(	O
Kramer	O
et	O
al	O
.	O
,	O
1989a	O
)	O
.	O

Modality	O
-	O
specific	O
areas	O
(	O
e	O
.	O
g	O
.	O
,	O
right	O
Wernicke	O
,	O
left	O
fusiform	O
gyrus	O
,	O
Broca	O
BA44	O
,	O
supramarginal	O
gyrus	O
)	O
,	O
appear	O
to	O
cope	O
with	O
the	O
computations	O
relevant	O
to	O
making	O
contact	O
with	O
these	O
more	O
abstract	O
dimensions	O
.	O

Platelet	O
counts	O
and	O
function	O
as	O
well	O
as	O
fibrinogen	B-GENE
and	O
von	B-GENE
Willebrand	I-GENE
factor	I-GENE
(	O
vWF	B-GENE
)	O
levels	O
were	O
determined	O
in	O
each	O
sample	O
.	O

The	O
DNase	B-GENE
I	I-GENE
footprint	O
extended	O
5	O
'	O
in	O
the	O
silencer	O
region	O
to	O
include	O
an	O
inverted	O
repeat	O
of	O
a	O
six	O
-	O
nucleotide	O
motif	O
(	O
epsilon	O
-	O
267	O
to	O
-	O
278	O
bp	O
)	O
which	O
shares	O
5	O
of	O
6	O
bases	O
with	O
the	O
GATA	B-GENE
-	I-GENE
1	I-GENE
consensus	I-GENE
sequence	I-GENE
.	O

Because	O
results	O
of	O
recent	O
randomized	O
trials	O
indicate	O
minimal	O
efficacy	O
of	O
continuing	O
MAC	O
prophylaxis	O
in	O
patients	O
who	O
respond	O
to	O
potent	O
combination	O
antiretroviral	O
therapy	O
,	O
the	O
observed	O
high	O
incidence	O
of	O
macrolide	O
-	O
resistant	O
bacterial	O
colonization	O
of	O
the	O
respiratory	O
tract	O
in	O
this	O
trial	O
supports	O
the	O
discontinuation	O
of	O
macrolide	O
prophylaxis	O
in	O
all	O
AIDS	O
patients	O
whose	O
CD4	B-GENE
counts	O
have	O
risen	O
above	O
100	O
cells	O
/	O
microL	O
.	O

With	O
certain	O
exceptions	O
the	O
method	O
was	O
considered	O
suitable	O
in	O
the	O
routine	O
intravenous	O
cholangiography	O
.	O

These	O
data	O
should	O
be	O
useful	O
in	O
developing	O
reagents	O
for	O
heterozygote	O
detection	O
and	O
prenatal	O
diagnosis	O
of	O
11	B-GENE
beta	I-GENE
-	I-GENE
hydroxylase	I-GENE
deficiency	O
,	O
the	O
second	O
most	O
frequent	O
cause	O
of	O
congenital	O
adrenal	O
hyperplasia	O
.	O

Effects	O
of	O
a	O
low	O
-	O
energy	O
laser	O
beam	O
on	O
the	O
cells	O
of	O
the	O
newt	O
embryo	O

One	O
of	O
these	O
is	O
surrounded	O
by	O
an	O
adenine	O
-	O
uridine	O
rich	O
region	O
that	O
can	O
form	O
an	O
11	O
-	O
base	O
pair	O
stem	O
structure	O
.	O

No	O
evidence	O
of	O
either	O
positive	O
or	O
negative	O
chemography	O
was	O
found	O
.	O

The	O
first	O
identification	O
of	O
the	O
active	O
37LRP	B-GENE
/	O
p40	B-GENE
gene	O
presented	O
in	O
this	O
study	O
is	O
a	O
critical	O
step	O
toward	O
the	O
isolation	O
of	O
the	O
corresponding	O
human	O
gene	O
and	O
the	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
up	O
-	O
regulation	O
of	O
its	O
expression	O
during	O
tumor	O
invasion	O
and	O
metastasis	O
.	O

Inclusion	O
in	O
this	O
family	O
of	O
proteins	O
suggests	O
that	O
FliQ	B-GENE
and	O
FliR	B-GENE
may	O
participate	O
in	O
an	O
export	O
pathway	O
required	O
for	O
flagellum	O
assembly	O
.	O

Both	O
factors	O
demonstrated	O
significant	O
correlations	O
with	O
rCBF	O
in	O
the	O
medial	O
prefrontal	O
cortex	O
and	O
frontal	O
polar	O
cortex	O
while	O
for	O
each	O
factor	O
there	O
were	O
also	O
unique	O
patterns	O
of	O
correlations	O
with	O
posterior	O
brain	O
regions	O
.	O

In	O
our	O
studies	O
,	O
we	O
utilized	O
HIV	O
-	O
1	O
HXB2	B-GENE
and	O
HIV	O
-	O
1	O
Z2Z6	B-GENE
core	I-GENE
enhancers	I-GENE
because	O
the	O
Z2Z6	B-GENE
strain	O
has	O
a	O
single	O
point	O
mutation	O
flanking	O
the	O
right	O
ETS	B-GENE
-	I-GENE
binding	I-GENE
site	I-GENE
.	O

We	O
also	O
found	O
that	O
environmental	O
conditions	O
for	O
meiosis	O
finely	O
regulate	O
the	O
transcript	O
levels	O
of	O
KIN28	B-GENE
and	O
CCL1	B-GENE
,	O
such	O
that	O
nitrogen	O
starvation	O
first	O
elevates	O
them	O
but	O
subsequent	O
alkalization	O
of	O
medium	O
decreases	O
them	O
.	O

In	O
sterilized	O
milk	O
there	O
was	O
a	O
slight	O
decrease	O
of	O
linoleic	O
acid	O
(	O
C18	O
:	O
2n6	O
;	O
-	O
0	O
.	O
7	O
%	O
vs	O
.	O
fresh	O
;	O
P	O
=	O
0	O
.	O
006	O
)	O
and	O
arachidonic	O
acid	O
(	O
C20	O
:	O
4n6	O
;	O
-	O
2	O
.	O
5	O
%	O
;	O
P	O
=	O
0	O
.	O
045	O
)	O
.	O

Eight	O
-	O
four	O
ACOAs	O
were	O
tested	O
in	O
order	O
to	O
examine	O
the	O
fit	O
of	O
the	O
model	O
to	O
the	O
data	O
by	O
path	O
analysis	O
with	O
LISREL	O
VII	O
.	O

Platelet	B-GENE
-	I-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
-	O
dependent	O
activation	O
of	O
phosphatidylinositol	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
is	O
regulated	O
by	O
receptor	O
binding	O
of	O
SH2	B-GENE
-	I-GENE
domain	I-GENE
-	I-GENE
containing	I-GENE
proteins	I-GENE
which	O
influence	O
Ras	B-GENE
activity	O
.	O

Relatively	O
large	O
DNA	O
rearrangements	O
spanning	O
the	O
region	O
with	O
tandem	O
direct	O
repeats	O
encoding	O
the	O
carboxy	O
-	O
terminal	O
histone	B-GENE
H1	I-GENE
-	I-GENE
like	I-GENE
structure	O
of	O
AlgP	B-GENE
were	O
detected	O
in	O
several	O
strains	O
upon	O
conversion	O
from	O
the	O
mucoid	O
to	O
the	O
nonmucoid	O
phenotype	O
.	O

A	O
study	O
in	O
vivo	O
of	O
adrenergic	B-GENE
receptors	I-GENE
in	O
the	O
rectum	O
and	O
in	O
the	O
internal	O
and	O
sphincter	O
of	O
the	O
cat	O
.	O

Dermatology	O
is	O
no	O
exception	O
.	O

A	O
2	O
kb	O
transcript	O
was	O
isolated	O
from	O
brain	O
that	O
encodes	O
a	O
approximately	O
57	O
kDa	O
protein	O
;	O
the	O
predicted	O
protein	O
contains	O
the	O
known	O
N	B-GENE
-	I-GENE
terminal	I-GENE
Ets	I-GENE
domain	I-GENE
of	O
PE1	B-GENE
and	O
a	O
novel	O
C	O
-	O
terminal	O
domain	O
with	O
signficant	O
homology	O
to	O
murine	B-GENE
ERF	I-GENE
.	O

The	O
recovery	O
rates	O
for	O
the	O
MB	O
/	O
BacT	O
,	O
MGIT	O
960	O
,	O
and	O
solid	O
media	O
were	O
91	O
.	O
6	O
,	O
87	O
.	O
4	O
,	O
and	O
54	O
.	O
7	O
%	O
,	O
respectively	O
,	O
for	O
all	O
mycobacteria	O
;	O
the	O
recovery	O
rates	O
were	O
93	O
.	O
6	O
,	O
88	O
.	O
9	O
,	O
and	O
63	O
.	O
4	O
%	O
,	O
respectively	O
,	O
for	O
M	O
.	O
tuberculosis	O
complex	O
alone	O
,	O
and	O
87	O
.	O
5	O
,	O
84	O
.	O
4	O
,	O
and	O
37	O
.	O
5	O
%	O
,	O
respectively	O
,	O
for	O
all	O
nontuberculous	O
mycobacteria	O
.	O

The	O
somatoform	O
conundrum	O
:	O
a	O
question	O
of	O
nosological	O
valves	O
.	O

The	O
muskox	O
is	O
a	O
new	O
host	O
record	O
for	O
T	O
.	O
gondii	O
.	O

Sequence	O
analysis	O
and	O
identification	O
of	O
two	O
hyp	B-GENE
regulatory	I-GENE
mutants	I-GENE
.	O

However	O
,	O
the	O
signaling	O
cascade	O
utilized	O
by	O
the	O
urokinase	B-GENE
receptor	I-GENE
is	O
only	O
incompletely	O
understood	O
.	O

Proteinuria	O
in	O
a	O
young	O
man	O
.	O

The	O
high	B-GENE
density	I-GENE
lipoprotein	I-GENE
(	I-GENE
HDL	I-GENE
)	I-GENE
receptor	I-GENE
mediates	O
the	O
uptake	O
of	O
cholesterol	O
and	O
cholesteryl	O
esters	O
,	O
substrates	O
for	O
steroidogenesis	O
,	O
from	O
an	O
HDL	B-GENE
particle	O
in	O
the	O
adrenal	O
gland	O
and	O
gonads	O
.	O

The	O
mechanism	O
involves	O
Gbetagamma	B-GENE
subunit	O
-	O
mediated	O
increases	O
in	O
tyrosine	O
phosphorylation	O
of	O
the	O
Shc	B-GENE
adapter	I-GENE
protein	I-GENE
,	O
Shc	B-GENE
*	O
Grb2	B-GENE
complex	O
formation	O
,	O
and	O
recruitment	O
of	O
Ras	B-GENE
guanine	I-GENE
nucleotide	I-GENE
exchange	I-GENE
factor	I-GENE
activity	O
.	O

Regarding	O
"	O
the	O
relation	O
between	O
sexual	O
orientation	O
and	O
penile	O
size	O
,	O
"	O
by	O
A	O
.	O

Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
viral	B-GENE
interferon	I-GENE
regulatory	I-GENE
factor	I-GENE
confers	O
resistance	O
to	O
the	O
antiproliferative	O
effect	O
of	O
interferon	B-GENE
-	I-GENE
alpha	I-GENE
.	O

Adjuvant	O
and	O
neoadjuvant	O
treatment	O
of	O
breast	O
cancer	O
.	O

The	O
enhanced	O
binding	O
of	O
c	B-GENE
-	I-GENE
Abl	I-GENE
to	O
DNA	O
containing	O
5	O
-	O
methylcytosine	O
residues	O
may	O
result	O
from	O
an	O
increased	O
propensity	O
of	O
the	O
double	O
helix	O
to	O
denature	O
locally	O
coupled	O
with	O
a	O
protein	O
-	O
induced	O
reduction	O
in	O
the	O
base	O
stacking	O
interaction	O
.	O

Enterococcus	O
faecium	O
strains	O
with	O
vanA	O
-	O
mediated	O
glycopeptide	O
resistance	O
were	O
isolated	O
by	O
enrichment	O
culture	O
from	O
the	O
intestines	O
and	O
feces	O
of	O
several	O
animal	O
species	O
,	O
mainly	O
horses	O
and	O
dogs	O
(	O
8	O
%	O
positive	O
)	O
,	O
chickens	O
(	O
7	O
%	O
positive	O
)	O
,	O
and	O
pigs	O
(	O
6	O
%	O
positive	O
)	O
.	O

Most	O
likely	O
they	O
might	O
represent	O
regulatory	O
RNAs	O
or	O
transcribed	O
transposable	O
elements	O
.	O

In	O
contrast	O
,	O
gel	O
mobility	O
shift	O
experiments	O
have	O
failed	O
to	O
reveal	O
that	O
HAP2	B-GENE
or	O
HAP3	B-GENE
binds	O
to	O
domain	O
1	O
or	O
that	O
hap3	B-GENE
mutations	O
affect	O
the	O
complexes	O
bound	O
to	O
it	O
.	O

One	O
group	O
(	O
n	O
=	O
9	O
)	O
was	O
premedicated	O
with	O
midazolam	O
,	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
,	O
and	O
atropine	O
0	O
.	O
2	O
-	O
0	O
.	O
4	O
mg	O
i	O
.	O
m	O
.	O

The	O
evaluation	O
was	O
performed	O
using	O
a	O
retrospective	O
study	O
design	O
with	O
newborn	O
blood	O
samples	O
from	O
three	O
screening	O
centres	O
.	O

Here	O
we	O
report	O
the	O
purification	O
of	O
this	O
larger	O
form	O
as	O
an	O
approximately	O
320	O
-	O
kDa	O
particle	O
that	O
contains	O
mRNP3	B-GENE
+	I-GENE
4	I-GENE
and	O
nine	O
additional	O
polypeptides	O
,	O
including	O
mRNA	O
-	O
binding	O
polypeptides	O
of	O
34	O
and	O
36	O
kDa	O
and	O
a	O
doublet	O
of	O
110	O
/	O
105	O
kDa	O
that	O
proved	O
to	O
be	O
nucleolin	B-GENE
.	O

Yeast	O
mutants	O
lacking	O
a	O
functional	O
NOP1	B-GENE
gene	I-GENE
can	O
be	O
complemented	O
by	O
human	B-GENE
fibrillarin	I-GENE
but	O
are	O
temperature	O
sensitive	O
for	O
growth	O
and	O
impaired	O
in	O
pre	O
-	O
rRNA	O
processing	O
.	O

Once	O
the	O
proliferation	O
of	O
fibroblasts	O
and	O
collagen	B-GENE
synthesis	O
had	O
led	O
to	O
an	O
increase	O
of	O
mechanical	O
strength	O
,	O
no	O
negative	O
effect	O
on	O
wound	O
healing	O
could	O
be	O
detected	O
applying	O
the	O
same	O
chemotherapeutic	O
agents	O
.	O

We	O
calculated	O
differences	O
in	O
late	O
occlusion	O
rates	O
by	O
the	O
chi2	O
(	O
chi	O
-	O
square	O
)	O
test	O
,	O
and	O
found	O
these	O
differences	O
were	O
significant	O
(	O
P	O
=	O
.	O
04	O
)	O
.	O

In	O
co	O
-	O
transfection	O
studies	O
,	O
the	O
expression	O
of	O
c	B-GENE
-	I-GENE
Jun	I-GENE
plus	O
c	B-GENE
-	I-GENE
Fos	I-GENE
enhanced	O
the	O
transactivation	O
of	O
oIFNtau	B-GENE
-	O
CAT	B-GENE
but	O
the	O
expression	O
of	O
GATA	B-GENE
-	I-GENE
1	I-GENE
,	O
GATA	B-GENE
-	I-GENE
2	I-GENE
or	O
GATA	B-GENE
-	I-GENE
3	I-GENE
did	O
not	O
.	O

Another	O
stem	O
-	O
loop	O
called	O
structure	O
III	O
near	O
the	O
3	O
'	O
-	O
end	O
of	O
repY	B-GENE
sequesters	O
both	O
the	O
5	O
'	O
-	O
rCGCC	O
-	O
3	O
'	O
sequence	O
and	O
the	O
repZ	B-GENE
ribosome	I-GENE
-	I-GENE
binding	I-GENE
site	I-GENE
.	O

The	O
results	O
indicate	O
that	O
the	O
relationship	O
between	O
comprehension	O
and	O
production	O
is	O
different	O
at	O
different	O
stages	O
in	O
development	O
.	O

An	O
epidemiological	O
survey	O
of	O
rheumatic	O
valve	O
disease	O
and	O
rheumatic	O
fever	O
in	O
primary	O
and	O
secondary	O
school	O
students	O
in	O
Jiangxi	O
Province	O

Finally	O
,	O
some	O
point	O
mutations	O
in	O
the	O
Gag	B-GENE
-	O
Pol	B-GENE
PR	O
domain	O
inhibited	O
activation	O
of	O
RT	B-GENE
in	O
trans	O
by	O
a	O
wild	O
-	O
type	O
PR	B-GENE
,	O
suggesting	O
that	O
the	O
correct	O
conformation	O
of	O
the	O
PR	B-GENE
domain	O
in	O
Gag	B-GENE
-	O
Pol	B-GENE
is	O
prerequisite	O
for	O
activation	O
of	O
RT	B-GENE
.	O

Women	O
'	O
s	O
opportunities	O
for	O
paid	O
work	O
outside	O
the	O
home	O
are	O
constrained	O
by	O
their	O
role	O
as	O
primary	O
carer	O
within	O
the	O
family	O
,	O
writes	O
Trudy	O
Wynne	O
.	O

The	O
activity	O
of	O
the	O
EGF	B-GENE
receptor	I-GENE
promoter	I-GENE
can	O
be	O
modulated	O
by	O
E1A	B-GENE
protein	I-GENE
and	O
receptor	O
RNA	O
levels	O
increased	O
by	O
stimulation	O
with	O
phorbol	O
ester	O
or	O
fetal	O
calf	O
serum	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
that	O
Sp1	B-GENE
binds	O
to	O
two	O
different	O
regions	O
in	O
the	O
proximal	O
promoter	O
,	O
a	O
typical	O
Sp1	B-GENE
site	I-GENE
located	O
at	O
(	O
-	O
38	O
;	O
-	O
33	O
)	O
and	O
a	O
G	O
/	O
C	O
-	O
rich	O
region	O
between	O
(	O
-	O
67	O
;	O
-	O
62	O
)	O
.	O

Changes	O
in	O
immunologic	O
reactivity	O
in	O
subjects	O
receiving	O
transfer	B-GENE
factor	I-GENE
could	O
not	O
be	O
distinguished	O
from	O
those	O
in	O
subjects	O
receiving	O
placebo	O
.	O

A	O
pre	O
-	O
boutonniere	O
deformity	O
was	O
simulated	O
by	O
dividing	O
the	O
central	O
slip	O
.	O

Identification	O
of	O
a	O
consensus	O
cyclin	B-GENE
-	I-GENE
dependent	I-GENE
kinase	I-GENE
phosphorylation	I-GENE
site	I-GENE
unique	O
to	O
the	O
nuclear	O
form	O
of	O
human	B-GENE
deoxyuridine	I-GENE
triphosphate	I-GENE
nucleotidohydrolase	I-GENE
.	O

In	O
contrast	O
,	O
neither	O
I	O
.	O
argentina	O
nor	O
I	O
.	O
theezans	O
exerted	O
any	O
effect	O
on	O
BF	O
or	O
intestinal	O
propulsion	O
.	O

BiP670	B-GENE
retains	O
basal	O
and	O
Ca2	O
+	O
ionophore	O
A23187	O
-	O
inducible	O
activities	O
.	O

Antimicrobial	O
Susceptibility	O
of	O
Klebsiella	O
pneumoniae	O
Producing	O
Extended	B-GENE
-	I-GENE
Spectrum	I-GENE
beta	I-GENE
-	I-GENE
lactamase	I-GENE
(	O
ESBL	B-GENE
)	O
Isolated	O
in	O
Hospitals	O
in	O
Brazil	O
.	O

The	O
LTR	O
-	O
binding	O
activities	O
of	O
VBP	B-GENE
,	O
a1	B-GENE
/	I-GENE
EBP	I-GENE
,	O
and	O
B	B-GENE
-	I-GENE
cell	I-GENE
nuclear	I-GENE
extract	I-GENE
protein	I-GENE
were	O
compared	O
and	O
mapped	O
by	O
gel	O
shift	O
,	O
DNase	B-GENE
I	I-GENE
footprinting	O
,	O
and	O
methylation	O
interference	O
assays	O
.	O

Estral	O
cycle	O
in	O
white	O
rats	O
in	O
the	O
low	O
and	O
high	O
mountains	O
of	O
Kirghizia	O

These	O
results	O
indicate	O
that	O
ATF	B-GENE
-	I-GENE
2	I-GENE
plays	O
a	O
central	O
role	O
in	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
signaling	O
by	O
acting	O
as	O
a	O
common	O
nuclear	O
target	O
of	O
both	O
Smad	B-GENE
and	O
TAK1	B-GENE
pathways	O
.	O

Similarly	O
,	O
in	O
mammalian	O
cells	O
PBP74	B-GENE
is	O
synthesized	O
as	O
a	O
pre	O
-	O
protein	O
that	O
requires	O
membrane	O
potential	O
-	O
dependent	O
import	O
into	O
mitochondria	O
for	O
its	O
maturation	O
.	O

Capnography	O
curves	O
of	O
40	O
HVS	O
patients	O
,	O
40	O
non	O
-	O
HVS	O
patients	O
with	O
psycho	O
-	O
somatic	O
complaints	O
and	O
26	O
healthy	O
controls	O
were	O
analyzed	O
.	O

Topological	O
and	O
mutational	O
analysis	O
of	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
Ste14p	I-GENE
,	O
founding	O
member	O
of	O
the	O
isoprenylcysteine	B-GENE
carboxyl	I-GENE
methyltransferase	I-GENE
family	I-GENE
.	O

This	O
model	O
is	O
supported	O
by	O
experiments	O
showing	O
that	O
Cdr2	B-GENE
associates	O
with	O
the	O
N	B-GENE
-	I-GENE
terminal	I-GENE
regulatory	I-GENE
domain	I-GENE
of	I-GENE
Wee1	I-GENE
in	O
cell	O
lysates	O
and	O
phosphorylates	O
Wee1	B-GENE
in	O
vitro	O
.	O

These	O
results	O
support	O
a	O
model	O
in	O
which	O
p53	B-GENE
protein	I-GENE
contributes	O
to	O
the	O
maintenance	O
of	O
genomic	O
integrity	O
through	O
recombinational	O
repair	O
.	O

TG	O
-	O
day	O
and	O
TG	O
-	O
night	O
were	O
19	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
1	O
%	O
,	O
26	O
.	O
6	O
+	O
/	O
-	O
5	O
.	O
3	O
%	O
,	O
(	O
750	O
mm3	O
<	O
T	O
.	O

Consistent	O
with	O
previous	O
reports	O
,	O
addition	O
of	O
a	O
myristoylation	O
signal	O
to	O
mSos1	B-GENE
(	O
MyrSos1	B-GENE
)	O
rendered	O
it	O
transforming	O
for	O
NIH	O
3T3	O
cells	O
and	O
deletion	O
of	O
the	O
mSos	B-GENE
C	I-GENE
terminus	I-GENE
(	O
MyrSos1	B-GENE
-	I-GENE
deltaC	I-GENE
)	O
did	O
not	O
interfere	O
with	O
this	O
activity	O
.	O

The	O
U14	B-GENE
genes	I-GENE
of	O
mouse	O
as	O
well	O
as	O
rat	O
,	O
hamster	O
,	O
human	O
,	O
Xenopus	O
and	O
trout	O
are	O
encoded	O
within	O
introns	O
of	O
the	O
constitutively	O
expressed	O
70	B-GENE
-	I-GENE
kDa	I-GENE
-	I-GENE
cognate	I-GENE
-	I-GENE
heat	I-GENE
-	I-GENE
shock	I-GENE
protein	I-GENE
gene	I-GENE
(	O
hsc70	B-GENE
)	O
.	O

Expression	O
of	O
human	B-GENE
RACK1	I-GENE
efficiently	O
relieves	O
E1A	B-GENE
-	O
mediated	O
growth	O
inhibition	O
in	O
HF7c	O
and	O
protects	O
human	O
tumor	O
cells	O
from	O
E1A	B-GENE
-	O
induced	O
apoptosis	O
.	O

The	O
mutations	O
did	O
not	O
affect	O
the	O
repression	O
of	O
CPA1	B-GENE
by	O
arginine	O
.	O

Therefore	O
,	O
this	O
study	O
has	O
demonstrated	O
that	O
prenatal	O
disturbance	O
can	O
induce	O
a	O
lasting	O
change	O
in	O
cytokine	O
biology	O
,	O
which	O
persists	O
well	O
beyond	O
the	O
fetal	O
and	O
infant	O
stage	O
.	O

Dynamics	O
of	O
hospital	O
stay	O
in	O
peptic	O
ulcer	O
patients	O

In	O
all	O
cells	O
,	O
the	O
accumulation	O
of	O
high	O
Dsg	B-GENE
protein	I-GENE
levels	O
required	O
calcium	O
and	O
was	O
not	O
observed	O
in	O
low	O
calcium	O
(	O
0	O
.	O
05	O
-	O
0	O
.	O
07	O
mM	O
)	O
media	O
.	O

During	O
a	O
28	O
-	O
week	O
promotion	O
bioassay	O
,	O
groups	O
of	O
30	O
male	O
CD	O
-	O
1	O
mice	O
were	O
treated	O
once	O
with	O
50	O
microliter	O
of	O
either	O
DMBA	O
(	O
1	O
.	O
0	O
mg	O
/	O
ml	O
)	O
or	O
acetone	O
,	O
rested	O
for	O
2	O
weeks	O
,	O
and	O
then	O
treated	O
twice	O
per	O
week	O
with	O
test	O
material	O
for	O
the	O
remaining	O
25	O
weeks	O
.	O

Here	O
,	O
we	O
identified	O
three	O
cis	O
-	O
elements	O
required	O
for	O
replication	O
within	O
the	O
200	O
bp	O
promoter	O
,	O
using	O
autonomously	O
replicating	O
plasmids	O
carrying	O
various	O
mutations	O
and	O
deletions	O
.	O

The	O
foregoing	O
results	O
show	O
that	O
CXD	O
has	O
high	O
efficacy	O
and	O
safety	O
and	O
it	O
can	O
be	O
said	O
that	O
it	O
is	O
a	O
drug	O
required	O
in	O
the	O
pediatric	O
field	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
indicate	O
that	O
inhibition	O
of	O
p27	B-GENE
(	O
KIP1	B-GENE
)	O
transcription	O
through	O
PI3K	B-GENE
-	O
induced	O
FKHR	B-GENE
-	I-GENE
L1	I-GENE
phosphorylation	O
provides	O
a	O
novel	O
mechanism	O
of	O
regulating	O
cytokine	O
-	O
mediated	O
survival	O
and	O
proliferation	O
.	O

Following	O
EPI	O
-	O
C0401	O
,	O
but	O
not	O
saline	O
or	O
DepoFoam	O
vehicle	O
,	O
there	O
were	O
transient	O
(	O
<	O
72	O
hr	O
)	O
decreases	O
in	O
food	O
consumption	O
,	O
arousal	O
,	O
hindlimb	O
muscle	O
tone	O
,	O
and	O
body	O
temperature	O
.	O

Morphogenesis	O
of	O
the	O
trochanter	O
produced	O
by	O
femoral	O
regeneration	O
in	O
the	O
phasmid	O
Carausius	O
morosus	O
Br	O

Rarely	O
,	O
patients	O
with	O
locally	O
advanced	O
,	O
uncontrollable	O
,	O
non	O
-	O
metastatic	O
prostatic	O
cancer	O
enjoy	O
prolonged	O
survival	O
.	O

We	O
observed	O
abundant	O
levels	O
of	O
Rev	B-GENE
-	O
erbA	B-GENE
alpha	I-GENE
mRNA	O
in	O
dividing	O
C2C12	O
myoblasts	O
,	O
which	O
were	O
suppressed	O
when	O
the	O
cells	O
differentiated	O
into	O
postmitotic	O
multinucleated	O
myotubes	O
.	O

Fowlpox	O
virus	O
encodes	O
nonessential	O
homologs	O
of	O
cellular	B-GENE
alpha	I-GENE
-	I-GENE
SNAP	I-GENE
,	O
PC	B-GENE
-	I-GENE
1	I-GENE
,	O
and	O
an	O
orphan	O
human	O
homolog	O
of	O
a	O
secreted	O
nematode	O
protein	O
.	O

The	O
case	O
for	O
completing	O
the	O
lymphadenectomy	O
when	O
positive	O
lymph	O
nodes	O
are	O
found	O
during	O
radical	O
hysterectomy	O
for	O
cervical	O
carcinoma	O
.	O

A	O
chicken	B-GENE
paxillin	I-GENE
cDNA	I-GENE
was	O
also	O
cloned	O
and	O
is	O
predicted	O
to	O
encode	O
a	O
protein	O
approximately	O
90	O
%	O
identical	O
to	O
human	B-GENE
paxil	I-GENE
-	I-GENE
lin	I-GENE
.	O

SvO2	O
can	O
be	O
determined	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
gene	O
is	O
contained	O
within	O
a	O
1	O
.	O
8	O
-	O
kilobase	O
AccI	B-GENE
-	O
EcoRI	B-GENE
restriction	O
fragment	O
mapping	O
at	O
map	O
coordinates	O
0	O
.	O
136	O
to	O
0	O
.	O
148	O
in	O
the	O
UL	O
region	O
of	O
the	O
EHV	O
-	O
1	O
genome	O
and	O
is	O
transcribed	O
from	O
right	O
to	O
left	O
.	O

RESULTS	O
:	O
The	O
main	O
effect	O
of	O
muscle	O
pain	O
,	O
compared	O
to	O
non	O
-	O
painful	O
stimulation	O
,	O
was	O
a	O
significant	O
and	O
long	O
-	O
lasting	O
increase	O
of	O
delta	O
(	O
1	O
-	O
3	O
Hz	O
)	O
power	O
and	O
an	O
alpha	O
-	O
1	O
(	O
9	O
-	O
11	O
Hz	O
)	O
power	O
increase	O
over	O
the	O
contralateral	O
parietal	O
locus	O
.	O

WR	O
-	O
2721	O
(	O
S	O
-	O
2	O
-	O
(	O
3	O
aminopropylamino	O
)	O
ethylphosphorothioic	O
acid	O
)	O
has	O
been	O
investigated	O
for	O
its	O
ability	O
to	O
protect	O
gut	O
,	O
lung	O
,	O
and	O
testis	O
,	O
as	O
well	O
as	O
fibrosarcoma	O
(	O
FSa	O
)	O
tumor	O
nodules	O
,	O
in	O
the	O
lungs	O
of	O
mice	O
from	O
gamma	O
-	O
radiation	O
injury	O
.	O

Naturally	O
acquired	O
antibodies	O
were	O
demonstrated	O
in	O
some	O
rabbits	O
kept	O
on	O
commercial	O
farms	O
.	O

Potency	O
of	O
enflurane	O
in	O
dogs	O
:	O
comparison	O
with	O
halothane	O
and	O
isoflurane	O
.	O

Classification	O
according	O
to	O
the	O
ILAR	O
criteria	O
was	O
possible	O
in	O
321	O
patients	O
;	O
290	O
patients	O
had	O
a	O
disease	O
duration	O
>	O
or	O
=	O
3	O
months	O
and	O
were	O
classified	O
according	O
to	O
the	O
EULAR	O
criteria	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
twofold	O
:	O
(	O
1	O
)	O
to	O
present	O
a	O
parallel	O
form	O
of	O
the	O
Gudjonsson	O
Suggestibility	O
Scale	O
(	O
GSS	O
,	O
Form	O
1	O
)	O
;	O
(	O
2	O
)	O
to	O
study	O
test	O
-	O
retest	O
reliabilities	O
of	O
interrogative	O
suggestibility	O
.	O

Two	O
patients	O
were	O
treated	O
successfully	O
with	O
a	O
combination	O
of	O
metronidazole	O
(	O
a	O
tissue	O
amoebicide	O
)	O
and	O
diloxanide	O
(	O
a	O
lumenal	O
amoebicide	O
)	O
.	O

Transcription	O
initiation	O
sites	O
of	O
the	O
rat	O
II	B-GENE
beta	I-GENE
-	I-GENE
,	I-GENE
III	I-GENE
beta	I-GENE
,	I-GENE
and	I-GENE
O	I-GENE
beta	I-GENE
-	I-GENE
globin	I-GENE
genes	O
were	O
determined	O
to	O
be	O
52	O
base	O
pairs	O
(	O
bp	O
)	O
5	O
'	O
-	O
upstream	O
of	O
the	O
translation	O
initiation	O
codon	O
(	O
ATG	O
)	O
,	O
in	O
each	O
gene	O
by	O
primer	O
extension	O
analysis	O
.	O

The	O
GPI	O
anchor	O
moiety	O
is	O
either	O
absent	O
or	O
present	O
at	O
a	O
very	O
low	O
level	O
in	O
the	O
polypeptide	O
expressed	O
from	O
the	O
cDNA	O
that	O
contained	O
both	O
the	O
signal	O
peptide	O
and	O
GPI	O
signal	O
sequences	O
.	O

All	O
samples	O
exhibited	O
a	O
decline	O
in	O
ethanol	O
concentration	O
,	O
with	O
most	O
losses	O
falling	O
within	O
the	O
expected	O
20	O
to	O
40	O
mg	O
%	O
range	O
.	O

A	O
chimeric	O
VP16	B-GENE
-	O
Tat	B-GENE
construct	O
containing	O
the	O
leucine	O
mutations	O
showed	O
no	O
increased	O
AP	B-GENE
-	I-GENE
1	I-GENE
responsiveness	O
in	O
comparison	O
with	O
that	O
of	O
the	O
VP16	B-GENE
activation	I-GENE
domain	I-GENE
alone	O
.	O

CONCLUSIONS	O
:	O
This	O
randomized	O
study	O
shows	O
that	O
Vivostat	O
fibrin	B-GENE
sealant	O
is	O
effective	O
in	O
preventing	O
air	O
leakage	O
after	O
small	O
lung	O
resections	O
in	O
pigs	O
,	O
even	O
at	O
high	O
inspiratory	O
pressures	O
.	O

Splice	O
variations	O
in	O
genes	O
coding	O
for	O
the	O
transmembrane	B-GENE
FGF	I-GENE
receptor	I-GENE
(	O
FGFR	B-GENE
)	O
result	O
in	O
isoforms	O
that	O
vary	O
in	O
the	O
ectodomain	O
,	O
intracellular	O
juxtamembrane	O
domain	O
,	O
and	O
the	O
intracellular	O
kinase	O
domain	O
.	O

A	O
short	O
sequence	O
surrounding	O
the	O
major	O
JNK	B-GENE
phosphorylation	O
site	O
of	O
c	B-GENE
-	I-GENE
Jun	I-GENE
is	O
conserved	O
in	O
c	B-GENE
-	I-GENE
Fos	I-GENE
and	O
is	O
part	O
of	O
its	O
activation	O
domain	O
,	O
suggesting	O
that	O
c	B-GENE
-	I-GENE
Fos	I-GENE
may	O
be	O
similarly	O
regulated	O
.	O

Essential	O
features	O
of	O
this	O
model	O
are	O
bending	O
of	O
the	O
DNA	O
double	O
helix	O
and	O
contact	O
of	O
operator	O
sites	O
with	O
repressor	O
domains	O
bearing	O
sequence	O
homologies	O
with	O
the	O
helix	O
-	O
turn	O
-	O
helix	O
(	O
HTH	O
)	O
motifs	O
of	O
other	O
DNA	O
-	O
binding	O
proteins	O
.	O

Staphylococcal	B-GENE
enterotoxin	I-GENE
A	I-GENE
involvement	O
in	O
the	O
illness	O
of	O
a	O
20	O
-	O
month	O
-	O
old	O
burn	O
patient	O
.	O

The	O
variable	O
phenotype	O
of	O
the	O
allotetraploids	O
could	O
not	O
be	O
explained	O
by	O
cytological	O
abnormalities	O
.	O

In	O
HCMV	O
(	O
Towne	O
)	O
-	O
infected	O
HF	O
cells	O
at	O
24	O
to	O
48	O
h	O
,	O
IE2	B-GENE
also	O
accumulated	O
in	O
newly	O
formed	O
viral	O
DNA	O
replication	O
compartments	O
containing	O
the	O
polymerase	B-GENE
processivity	I-GENE
factor	I-GENE
(	O
UL44	B-GENE
)	O
,	O
the	O
single	B-GENE
-	I-GENE
stranded	I-GENE
DNA	I-GENE
binding	I-GENE
protein	I-GENE
(	O
SSB	B-GENE
;	O
UL57	B-GENE
)	O
,	O
the	O
UL112	B-GENE
-	I-GENE
113	I-GENE
accessory	I-GENE
protein	I-GENE
,	O
and	O
newly	O
incorporated	O
bromodeoxyuridine	O
(	O
BrdU	O
)	O
.	O

We	O
have	O
followed	O
37	O
phenytoin	O
-	O
treated	O
patients	O
with	O
reduced	O
serum	B-GENE
IgA	I-GENE
concentrations	O
for	O
2	O
-	O
7	O
years	O
.	O

Identification	O
of	O
mutations	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
proto	B-GENE
-	I-GENE
oncogene	I-GENE
c	I-GENE
-	I-GENE
kit	I-GENE
in	O
a	O
human	O
mast	O
cell	O
leukemia	O
cell	O
line	O
causing	O
ligand	O
-	O
independent	O
activation	O
of	O
c	B-GENE
-	I-GENE
kit	I-GENE
product	I-GENE
.	O

During	O
the	O
years	O
1980	O
-	O
87	O
a	O
total	O
of	O
287	O
persons	O
received	O
disability	O
pensions	O
in	O
the	O
municipality	O
of	O
Nordreisa	O
in	O
northern	O
Norway	O
.	O

A	O
method	O
for	O
establishing	O
stimulus	O
control	O
of	O
ethanol	O
responding	O
was	O
developed	O
.	O

Three	O
classes	O
of	O
test	O
objects	O
were	O
considered	O
:	O
(	O
1	O
)	O
a	O
multicompartment	O
test	O
object	O
for	O
31P	O
MRS	O
measurements	O
performed	O
with	O
slice	O
-	O
selective	O
sequences	O
;	O
(	O
2	O
)	O
a	O
two	O
-	O
compartment	O
test	O
object	O
for	O
volume	O
-	O
selection	O
1H	O
MRS	O
;	O
and	O
(	O
3	O
)	O
two	O
-	O
compartment	O
test	O
objects	O
for	O
assessing	O
the	O
performance	O
of	O
experimental	O
systems	O
using	O
ISIS	O
as	O
volume	O
localization	O
sequence	O
in	O
31P	O
MRS	O
.	O

Airflow	O
through	O
the	O
dust	O
trap	O
was	O
controlled	O
with	O
a	O
vacuum	O
pump	O
.	O

Moreover	O
,	O
Lck	B-GENE
was	O
reversibly	O
co	O
-	O
immunoprecipitated	O
with	O
p95Vav	B-GENE
,	O
and	O
the	O
stoichiometry	O
of	O
binding	O
increased	O
in	O
anti	B-GENE
-	I-GENE
CD3	I-GENE
-	O
treated	O
Jurkat	O
cells	O
.	O

The	O
binding	O
of	O
PH	B-GENE
domains	I-GENE
to	O
Gbetagamma	B-GENE
was	O
inhibited	O
by	O
preincubation	O
of	O
Gbetagamma	B-GENE
with	O
the	O
GDP	O
-	O
bound	O
but	O
not	O
the	O
GTP	O
-	O
bound	O
form	O
of	O
Gialpha	B-GENE
.	O

A	O
mutation	O
in	O
the	O
C	O
domain	O
of	O
Rb	B-GENE
,	O
L901Q	O
,	O
has	O
been	O
identified	O
that	O
completely	O
abolishes	O
cdk4	B-GENE
/	O
D1	B-GENE
phosphorylation	O
of	O
the	O
isolated	O
C	O
domain	O
.	O

The	O
highly	O
amyloidogenic	O
42	O
-	O
residue	O
form	O
of	O
Abeta	B-GENE
(	O
Abeta42	B-GENE
)	O
is	O
the	O
first	O
species	O
to	O
be	O
deposited	O
in	O
both	O
sporadic	O
and	O
familial	O
AD	O
.	O

A	O
strong	O
trithorax	B-GENE
binding	I-GENE
site	I-GENE
was	O
found	O
at	O
the	O
cytological	O
location	O
of	O
the	O
fork	B-GENE
head	I-GENE
gene	I-GENE
,	O
a	O
region	O
-	O
specific	O
homeotic	B-GENE
gene	I-GENE
not	O
located	O
within	O
a	O
homeotic	B-GENE
complex	I-GENE
.	O

Copyright	O
2000	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Protein	B-GENE
kinase	I-GENE
A	I-GENE
-	I-GENE
Ialpha	I-GENE
subunit	O
-	O
directed	O
antisense	O
inhibition	O
of	O
ovarian	O
cancer	O
cell	O
growth	O
:	O
crosstalk	O
with	O
tyrosine	B-GENE
kinase	I-GENE
signaling	O
pathway	O
.	O

This	O
short	O
communication	O
compares	O
a	O
novel	O
fluorimetric	O
microplate	O
enzyme	O
immunoassay	O
(	O
FEIA	O
)	O
with	O
a	O
commercial	O
time	O
-	O
resolved	O
fluoroimmunoassay	O
for	O
the	O
determination	O
of	O
thyrotropin	B-GENE
in	O
dried	O
blood	O
spots	O
.	O

One	O
of	O
these	O
factors	O
,	O
HRF	B-GENE
-	I-GENE
1	I-GENE
,	O
recognizes	O
a	O
cis	O
element	O
consisting	O
of	O
an	O
inverted	O
palindromic	O
motif	O
.	O

The	O
regulation	O
of	O
PGHS	B-GENE
-	I-GENE
2	I-GENE
mRNA	I-GENE
and	O
protein	O
was	O
studied	O
in	O
primary	O
cultures	O
of	O
bovine	O
uterine	O
stromal	O
cells	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
;	O
100	O
nM	O
)	O
.	O

Because	O
the	O
DPPD	B-GENE
gene	I-GENE
is	O
not	O
present	O
in	O
non	O
-	O
tuberculous	O
bacilli	O
,	O
these	O
results	O
suggest	O
that	O
this	O
molecule	O
can	O
be	O
an	O
additional	O
tool	O
for	O
a	O
more	O
specific	O
diagnosis	O
of	O
tuberculosis	O
.	O

Using	O
PRL	B-GENE
-	I-GENE
R	I-GENE
tagged	O
both	O
in	O
the	O
N	O
-	O
terminal	O
or	O
C	O
-	O
terminal	O
regions	O
of	O
the	O
mature	O
receptor	O
excludes	O
the	O
possibility	O
of	O
a	O
cleaved	O
fragment	O
which	O
could	O
have	O
been	O
subsequently	O
imported	O
into	O
the	O
nucleus	O
.	O

Double	O
mutant	O
analysis	O
suggests	O
that	O
Rad54p	B-GENE
and	O
Mus81p	B-GENE
act	O
in	O
one	O
pathway	O
for	O
the	O
repair	O
of	O
,	O
or	O
tolerance	O
to	O
,	O
UV	O
-	O
induced	O
DNA	O
damage	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
Galpha11	B-GENE
Q209L	I-GENE
stimulated	O
Src	B-GENE
family	I-GENE
kinase	O
activity	O
and	O
induced	O
tyrosine	O
phosphorylation	O
of	O
several	O
proteins	O
in	O
HEK	O
-	O
293	O
cells	O
.	O

The	O
similar	O
phenotypes	O
of	O
bur6	B-GENE
and	O
bur3	B-GENE
(	O
mot1	B-GENE
)	O
mutations	O
suggest	O
that	O
Bur6p	B-GENE
and	O
Mot1p	B-GENE
have	O
related	O
,	O
but	O
not	O
identical	O
,	O
functions	O
in	O
modulating	O
the	O
activity	O
of	O
the	O
general	O
transcription	O
machinery	O
in	O
vivo	O
.	O

Sp1	B-GENE
binds	O
two	O
sites	O
in	O
the	O
CD11c	B-GENE
promoter	I-GENE
in	O
vivo	O
specifically	O
in	O
myeloid	O
cells	O
and	O
cooperates	O
with	O
AP1	B-GENE
to	O
activate	O
transcription	O
.	O

An	O
additional	O
9	O
patients	O
achieved	O
normal	O
levels	O
with	O
adjunctive	O
drug	O
therapy	O
.	O

Small	B-GENE
Maf	I-GENE
proteins	I-GENE
heterodimerize	O
with	O
Fos	B-GENE
and	O
may	O
act	O
as	O
competitive	O
repressors	O
of	O
the	O
NF	B-GENE
-	I-GENE
E2	I-GENE
transcription	I-GENE
factor	I-GENE
.	O

The	O
isolated	O
POT1	B-GENE
clones	O
hybridized	O
to	O
a	O
1	O
.	O
4	O
kb	O
RNA	O
species	O
,	O
which	O
was	O
induced	O
approximately	O
30	O
-	O
fold	O
when	O
oleate	O
was	O
the	O
carbon	O
source	O
.	O

TcPO2	O
measurement	O
appears	O
to	O
be	O
a	O
reliable	O
technique	O
that	O
can	O
influence	O
ischaemic	O
ulcer	O
management	O
.	O

As	O
a	O
part	O
of	O
a	O
large	O
examination	O
,	O
total	O
and	O
free	O
serum	O
cholesterol	O
,	O
total	O
lipid	O
and	O
triglyceride	O
levels	O
were	O
determined	O
.	O

In	O
the	O
10	O
patients	O
with	O
a	O
more	O
severe	O
degree	O
of	O
steatorrhea	O
the	O
decrease	O
in	O
fat	O
loss	O
approached	O
20	O
%	O
and	O
a	O
close	O
relationship	O
was	O
found	O
(	O
r	O
=	O
0	O
.	O
84	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
between	O
the	O
extent	O
of	O
the	O
fatty	O
acid	O
loss	O
on	O
placebo	O
and	O
the	O
decrease	O
of	O
this	O
loss	O
on	O
taurine	O
.	O

Naltrexone	O
hydrochloride	O
is	O
a	O
synthetic	O
opioid	B-GENE
receptor	I-GENE
antagonist	O
recently	O
used	O
in	O
efforts	O
to	O
provide	O
rapid	O
opioid	O
detoxification	O
.	O

Uses	O
of	O
orthoclone	O
OKT3	O
for	O
prophylaxis	O
of	O
rejection	O
and	O
induction	O
in	O
initial	O
nonfunction	O
in	O
kidney	O
transplantation	O
.	O

Uses	O
of	O
orthoclone	O
OKT3	B-GENE
for	O
prophylaxis	O
of	O
rejection	O
and	O
induction	O
in	O
initial	O
nonfunction	O
in	O
kidney	O
transplantation	O
.	O

Genomic	O
DNA	O
hybridization	O
suggests	O
that	O
SpSHR2	B-GENE
is	O
a	O
single	O
-	O
copy	O
gene	O
in	O
the	O
S	O
.	O
purpuratus	O
genome	O
.	O

We	O
concluded	O
that	O
activation	O
of	O
c	B-GENE
-	I-GENE
fosER	I-GENE
mediated	O
transcriptional	O
inhibition	O
of	O
p21	B-GENE
(	O
Cip1	B-GENE
/	O
WAF1	B-GENE
)	O
through	O
a	O
previously	O
uncharacterized	O
AP	B-GENE
-	I-GENE
1	I-GENE
site	I-GENE
,	O
revealing	O
an	O
important	O
role	O
for	O
c	B-GENE
-	I-GENE
fos	I-GENE
in	O
negative	O
control	O
of	O
cell	O
cycle	O
regulatory	O
genes	O
.	O

Treatment	O
of	O
ischemic	O
heart	O
disease	O
in	O
the	O
elderly	O

An	O
inactive	O
analog	O
of	O
wortmannin	O
,	O
WM12	O
,	O
did	O
not	O
affect	O
TCR	B-GENE
/	O
CD3	B-GENE
-	O
induced	O
Erk2	B-GENE
activation	O
,	O
and	O
wortmannin	O
had	O
no	O
effect	O
on	O
the	O
activity	O
of	O
Erk2	B-GENE
when	O
added	O
directly	O
to	O
the	O
in	O
vitro	O
assays	O
.	O

There	O
were	O
no	O
interfering	O
peaks	O
in	O
the	O
quantitation	O
of	O
sulbactam	O
.	O

A	O
larval	B-GENE
albumin	I-GENE
-	I-GENE
like	I-GENE
protein	I-GENE
was	O
not	O
detectable	O
by	O
silver	O
staining	O
in	O
serum	O
of	O
tadpoles	O
before	O
the	O
beginning	O
of	O
metamorphosis	O
at	O
stage	O
48	O
.	O

Western	O
blotting	O
(	O
immunoblotting	O
)	O
with	O
an	O
antiserum	O
to	O
a	O
partial	O
SOD	B-GENE
expressed	O
in	O
Escherichia	O
coli	O
revealed	O
two	O
proteins	O
with	O
estimated	O
molecular	O
masses	O
of	O
19	O
and	O
29	O
kDa	O
.	O

The	O
mouse	B-GENE
M	I-GENE
-	I-GENE
lysozyme	I-GENE
downstream	I-GENE
enhancer	I-GENE
has	O
been	O
previously	O
characterized	O
on	O
several	O
levels	O
of	O
gene	O
regulation	O
.	O

The	O
above	O
results	O
mean	O
that	O
the	O
increase	O
in	O
alpha	B-GENE
-	I-GENE
adrenergic	I-GENE
receptors	I-GENE
makes	O
the	O
prostate	O
,	O
which	O
has	O
been	O
already	O
hypertrophied	O
,	O
less	O
elastic	O
,	O
inhibiting	O
external	O
urinary	O
sphincter	O
function	O
.	O

Sweet	O
oranges	O
,	O
mandarin	O
,	O
grapefruit	O
,	O
lemon	O
,	O
and	O
lime	O
are	O
generally	O
used	O
for	O
processing	O
.	O

Plasmids	O
were	O
constructed	O
with	O
the	O
mouse	O
promoter	O
region	O
linked	O
to	O
the	O
reporter	B-GENE
gene	I-GENE
chloramphenicol	I-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
,	O
and	O
transiently	O
and	O
stably	O
transfected	O
in	O
the	O
INS	O
-	O
1	O
cells	O
.	O

These	O
results	O
are	O
very	O
useful	O
for	O
deciding	O
on	O
the	O
doses	O
of	O
hormones	O
and	O
the	O
expected	O
serum	O
estradiol	O
level	O
in	O
HRT	O
for	O
Japanese	O
women	O
.	O

Hypothermia	O
After	O
Cardiac	O
Arrest	O
(	O
HACA	O
)	O
Study	O
Group	O
.	O

TRAF2	B-GENE
is	O
known	O
to	O
associate	O
with	O
TRADD	B-GENE
,	O
and	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
N	O
-	O
terminal	O
deletion	O
TRAF2	B-GENE
mutant	I-GENE
was	O
found	O
to	O
partially	O
inhibit	O
LMP1	B-GENE
-	O
induced	O
JNK	B-GENE
activation	O
in	O
293	O
cells	O
.	O

Lung	O
function	O
tests	O
(	O
EFR	O
)	O
were	O
performed	O
on	O
these	O
patients	O
for	O
a	O
period	O
of	O
19	O
.	O
2	O
+	O
/	O
-	O
3	O
.	O
4	O
months	O
.	O

RESULTS	O
:	O
Factors	O
associated	O
with	O
significantly	O
(	O
P	O
<	O
.	O
05	O
)	O
increased	O
risk	O
of	O
treatment	O
failure	O
in	O
a	O
Cox	O
multivariate	O
analysis	O
included	O
age	O
older	O
than	O
45	O
years	O
(	O
relative	O
hazard	O
,	O
1	O
.	O
17	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
02	O
-	O
1	O
.	O
33	O
)	O
,	O
Karnofsky	O
performance	O
score	O
less	O
than	O
90	O
%	O
(	O
1	O
.	O
27	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
07	O
-	O
1	O
.	O
51	O
)	O
,	O
absence	O
of	O
hormone	O
receptors	O
(	O
1	O
.	O
31	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
15	O
-	O
1	O
.	O
51	O
)	O
,	O
prior	O
use	O
of	O
adjuvant	O
chemotherapy	O
(	O
1	O
.	O
31	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
10	O
-	O
1	O
.	O
56	O
)	O
,	O
initial	O
disease	O
-	O
free	O
survival	O
interval	O
after	O
adjuvant	O
treatment	O
of	O
no	O
more	O
than	O
18	O
months	O
(	O
1	O
.	O
99	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
62	O
-	O
2	O
.	O
43	O
)	O
,	O
metastases	O
in	O
the	O
liver	O
(	O
1	O
.	O
47	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
20	O
-	O
1	O
.	O
80	O
)	O
or	O
central	O
nervous	O
system	O
(	O
1	O
.	O
56	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
99	O
-	O
2	O
.	O
46	O
[	O
approaches	O
significance	O
]	O
)	O
vs	O
soft	O
tissue	O
,	O
bone	O
,	O
or	O
lung	O
,	O
3	O
or	O
more	O
sites	O
of	O
metastatic	O
disease	O
(	O
1	O
.	O
32	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
13	O
-	O
1	O
.	O
54	O
)	O
,	O
and	O
incomplete	O
response	O
vs	O
complete	O
response	O
to	O
standard	O
-	O
dose	O
chemotherapy	O
(	O
1	O
.	O
65	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
36	O
-	O
1	O
.	O
99	O
)	O
.	O

A	O
contiguous	O
and	O
sequentially	O
occupied	O
secondary	O
Fur	B-GENE
-	I-GENE
binding	I-GENE
site	I-GENE
in	O
entC	B-GENE
was	O
protected	O
at	O
higher	O
Fur	B-GENE
concentrations	O
,	O
extending	O
the	O
protected	O
region	O
to	O
+	O
49	O
,	O
and	O
sequestering	O
the	O
putative	O
Shine	O
-	O
Dalgarno	O
sequence	O
.	O

As	O
a	O
result	O
,	O
beta	O
-	O
apo	O
-	O
8	O
'	O
-	O
carotenoic	O
acid	O
ethyl	O
ester	O
(	O
apo	O
-	O
EE	O
)	O
was	O
used	O
as	O
a	O
reference	O
standard	O
in	O
Experiments	O
4	O
to	O
6	O
.	O

The	O
evidence	O
in	O
support	O
of	O
this	O
was	O
derived	O
from	O
the	O
fact	O
that	O
the	O
affinity	O
or	O
interaction	O
between	O
the	O
two	O
subunits	O
was	O
impaired	O
as	O
indicated	O
by	O
the	O
first	O
order	O
rate	O
constant	O
of	O
hCG	B-GENE
alpha	I-GENE
1	I-GENE
beta	I-GENE
(	O
km	O
=	O
4	O
.	O
1	O
x	O
10	O
(	O
-	O
2	O
)	O
min	O
-	O
1	O
)	O
at	O
pH	O
3	O
.	O
0	O
at	O
23	O
degrees	O
C	O
which	O
is	O
one	O
order	O
of	O
magnitude	O
greater	O
relative	O
to	O
rehCG	B-GENE
(	O
kw	O
=	O
4	O
.	O
6	O
x	O
10	O
(	O
-	O
3	O
)	O
min	O
-	O
1	O
)	O
.	O

The	O
differential	O
diagnosis	O
of	O
both	O
affections	O
is	O
based	O
on	O
the	O
clinical	O
course	O
,	O
sialography	O
and	O
CT	O
examination	O
which	O
along	O
with	O
modern	O
ATB	O
treatment	O
significantly	O
modify	O
hitherto	O
used	O
surgical	O
therapy	O
.	O

To	O
identify	O
nuclear	O
regulatory	O
factors	O
,	O
we	O
have	O
located	O
and	O
functionally	O
characterized	O
the	O
CCR5	B-GENE
gene	I-GENE
promoter	I-GENE
.	O

A	O
single	O
NMSC	O
was	O
present	O
in	O
69	O
.	O
4	O
%	O
,	O
two	O
in	O
16	O
%	O
,	O
three	O
in	O
6	O
.	O
4	O
%	O
,	O
four	O
in	O
3	O
.	O
5	O
%	O
,	O
five	O
to	O
nine	O
in	O
4	O
.	O
2	O
%	O
,	O
and	O
0	O
.	O
5	O
%	O
had	O
ten	O
or	O
more	O
.	O

Epstein	B-GENE
-	I-GENE
Barr	I-GENE
virus	I-GENE
-	I-GENE
encoded	I-GENE
latent	I-GENE
membrane	I-GENE
protein	I-GENE
1	I-GENE
activates	O
the	O
JNK	B-GENE
pathway	O
through	O
its	O
extreme	O
C	O
terminus	O
via	O
a	O
mechanism	O
involving	O
TRADD	B-GENE
and	O
TRAF2	B-GENE
.	O

OBJECTIVES	O
:	O
The	O
objective	O
of	O
this	O
review	O
was	O
to	O
assess	O
the	O
effects	O
of	O
prophylactic	O
prostaglandin	O
use	O
in	O
the	O
third	O
stage	O
of	O
labour	O
.	O

Successful	O
use	O
of	O
transureteroureterostomy	O
to	O
salvage	O
ureterosigmoidostomy	O
after	O
anastomotic	O
failure	O
.	O

Analysis	O
of	O
promoter	O
and	O
androgen	O
regulatory	O
sequences	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
rat	O
androgen	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
gene	O
.	O

Botulinum	B-GENE
toxin	I-GENE
:	O
preferred	O
treatment	O
for	O
hemifacial	O
spasm	O
.	O

25	O
-	O
OH	O
-	O
D3	O
did	O
not	O
adversely	O
affect	O
animal	O
health	O
at	O
the	O
proposed	O
use	O
level	O
of	O
99	O
micrograms	O
/	O
kg	O
feed	O
when	O
replacing	O
vitamin	O
D3	O
in	O
turkey	O
rations	O
.	O

The	O
other	O
transmembrane	O
regions	O
as	O
well	O
as	O
the	O
nucleoplasmic	O
domain	O
are	O
not	O
required	O
for	O
sorting	O
.	O

During	O
organogenesis	O
,	O
HFH	B-GENE
-	I-GENE
8	I-GENE
expression	O
is	O
found	O
in	O
the	O
splanchnic	O
mesoderm	O
in	O
close	O
apposition	O
of	O
the	O
gut	O
endoderm	O
,	O
suggesting	O
a	O
role	O
in	O
mesenchymal	O
-	O
epithelial	O
induction	O
of	O
lung	O
and	O
gut	O
morphogenesis	O
.	O

Angiotensin	B-GENE
II	I-GENE
induces	O
nuclear	B-GENE
factor	I-GENE
(	I-GENE
NF	I-GENE
)	I-GENE
-	I-GENE
kappaB1	I-GENE
isoforms	I-GENE
to	O
bind	O
the	O
angiotensinogen	B-GENE
gene	I-GENE
acute	O
-	O
phase	O
response	O
element	O
:	O
a	O
stimulus	O
-	O
specific	O
pathway	O
for	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
activation	O
.	O

Furthermore	O
,	O
this	O
kinase	O
-	O
deficient	O
mutant	O
inhibited	O
2	O
-	O
MeSADP	O
-	O
induced	O
caspase	B-GENE
-	I-GENE
3	I-GENE
stimulation	O
and	O
the	O
associated	O
decrease	O
in	O
cell	O
number	O
.	O

C	B-GENE
/	I-GENE
EBPbeta	I-GENE
LIP	I-GENE
overexpressing	O
HC11	O
cells	O
did	O
not	O
express	O
beta	B-GENE
-	I-GENE
casein	I-GENE
mRNA	I-GENE
(	O
mammary	O
epithelial	O
cell	O
differentiation	O
marker	O
)	O
in	O
response	O
to	O
lactogenic	O
hormones	O
.	O

Bacteria	O
can	O
also	O
cause	O
a	O
labyrinthitis	O
acting	O
directly	O
on	O
the	O
inner	O
ear	O
:	O
among	O
these	O
,	O
Treponemas	O
Pallidum	O
,	O
a	O
spirochaete	O
which	O
causes	O
syphilis	O
and	O
Borrelia	O
Burgdorferi	O
,	O
a	O
spirochaete	O
that	O
causes	O
Lyme	O
Disease	O
,	O
must	O
be	O
mentioned	O
.	O

Factor	B-GENE
VIII	I-GENE
procoagulant	O
activity	O
,	O
antigen	O
concentration	O
and	O
von	B-GENE
Willebrand	I-GENE
activity	O
as	O
ristocetin	B-GENE
cofactor	I-GENE
were	O
determined	O
several	O
times	O
in	O
10	O
patients	O
with	O
DIC	O
.	O

The	O
git1	B-GENE
,	O
git3	B-GENE
,	O
git5	B-GENE
,	O
git7	B-GENE
,	O
git8	B-GENE
and	O
git10	B-GENE
genes	I-GENE
act	O
upstream	O
of	O
adenylate	B-GENE
cyclase	I-GENE
,	O
presumably	O
encoding	O
an	O
adenylate	B-GENE
cyclase	I-GENE
activation	O
pathway	O
.	O

Intravesical	O
chemotherapy	O
.	O

The	O
study	O
included	O
139	O
eyes	O
with	O
presumed	O
ocular	O
histoplasmosis	O
syndrome	O
(	O
POHS	O
)	O
and	O
age	O
-	O
related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
.	O

HBB	O
concentration	O
in	O
the	O
fetuses	O
indicated	O
little	O
,	O
if	O
any	O
accumulation	O
.	O

In	O
a	O
heterologous	O
transcriptional	O
system	O
in	O
which	O
the	O
upstream	O
regions	O
of	O
oIFNtau	B-GENE
were	O
inserted	O
in	O
front	O
of	O
simian	B-GENE
virus	I-GENE
40	I-GENE
(	I-GENE
SV40	I-GENE
)	I-GENE
promoter	I-GENE
,	O
the	O
regions	O
between	O
bases	O
-	O
654	O
and	O
-	O
555	O
were	O
determined	O
as	O
being	O
the	O
enhancer	O
region	O
required	O
for	O
oIFNtau	B-GENE
-	O
SV40	O
-	O
CAT	B-GENE
transactivation	O
.	O

RVEF	O
and	O
LVEF	O
both	O
increased	O
by	O
about	O
14	O
%	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
and	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Consistent	O
with	O
the	O
hypothesis	O
that	O
it	O
acts	O
as	O
transcriptional	O
regulator	O
,	O
wild	B-GENE
-	I-GENE
type	I-GENE
p53	I-GENE
protein	I-GENE
binds	O
DNA	O
and	O
activates	O
transcription	O
of	O
several	O
promoters	O
.	O

To	O
search	O
for	O
transcriptional	O
regulators	O
,	O
we	O
used	O
a	O
fragment	O
of	O
the	O
SpHE	B-GENE
promoter	I-GENE
containing	O
several	O
individual	O
elements	O
instead	O
of	O
the	O
conventional	O
bait	O
that	O
contains	O
a	O
multimerized	O
cis	O
element	O
.	O

However	O
,	O
mandibular	O
position	O
(	O
S	O
-	O
N	O
-	O
B	O
and	O
S	O
-	O
N	O
-	O
Pog	O
)	O
was	O
found	O
to	O
be	O
significantly	O
more	O
retrusive	O
in	O
Class	O
II	O
when	O
compared	O
with	O
Class	O
I	O
subjects	O
.	O

These	O
data	O
support	O
a	O
possible	O
biological	O
significance	O
of	O
the	O
frameshift	O
to	O
occur	O
at	O
this	O
position	O
of	O
the	O
large	O
overlap	O
by	O
including	O
the	O
putative	O
RNA	O
template	O
-	O
binding	O
site	O
of	O
the	O
PLRV	B-GENE
replicase	I-GENE
in	O
the	O
ORF2a	B-GENE
/	I-GENE
ORF2b	I-GENE
transframe	I-GENE
protein	I-GENE
.	O

Consequently	O
,	O
significant	O
differences	O
between	O
the	O
measured	O
and	O
calculated	O
methods	O
were	O
noted	O
in	O
oxygen	O
uptake	O
(	O
213	O
+	O
/	O
-	O
41	O
ml	O
/	O
min	O
vs	O
193	O
+	O
/	O
-	O
25	O
ml	O
/	O
min	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
oxygen	O
delivery	O
(	O
780	O
+	O
/	O
-	O
297	O
ml	O
/	O
min	O
vs	O
716	O
+	O
/	O
-	O
296	O
ml	O
/	O
min	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
cardiac	O
output	O
(	O
5	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
2	O
L	O
/	O
min	O
vs	O
5	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
8	O
L	O
/	O
min	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
mRNAs	O
of	O
the	O
GRF	B-GENE
genes	I-GENE
are	O
encoded	O
by	O
six	O
exons	O
interrupted	O
by	O
five	O
introns	O
.	O

For	O
this	O
purpose	O
,	O
a	O
simple	O
respiration	O
-	O
control	O
device	O
has	O
been	O
developed	O
that	O
enables	O
the	O
patient	O
to	O
monitor	O
breath	O
-	O
holding	O
during	O
successive	O
scans	O
.	O

In	O
an	O
attempt	O
to	O
understand	O
Wee1	B-GENE
regulation	O
during	O
cell	O
cycle	O
,	O
yeast	O
two	O
-	O
hybrid	O
screening	O
was	O
used	O
to	O
identify	O
Wee1	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	I-GENE
s	I-GENE
)	I-GENE
.	O

C	B-GENE
/	I-GENE
EBP	I-GENE
alpha	I-GENE
also	O
activates	O
the	O
promoter	O
of	O
the	O
rat	B-GENE
class	I-GENE
-	I-GENE
I	I-GENE
ADH	I-GENE
gene	I-GENE
in	O
a	O
sequence	O
-	O
specific	O
manner	O
[	O
Potter	O
et	O
al	O
.	O
,	O
Arch	O
.	O

C	B-GENE
/	I-GENE
EBP	I-GENE
alpha	I-GENE
also	O
activates	O
the	O
promoter	O
of	O
the	O
rat	B-GENE
class	I-GENE
-	I-GENE
I	I-GENE
ADH	I-GENE
gene	I-GENE
in	O
a	O
sequence	O
-	O
specific	O
manner	O
[	O
Potter	O
et	O
al	O
.	O
,	O
Arch	O
.	O

Two	O
polyadenylation	O
sites	O
were	O
used	O
,	O
one	O
at	O
the	O
end	O
of	O
the	O
early	B-GENE
(	I-GENE
E	I-GENE
)	I-GENE
region	I-GENE
of	O
the	O
viral	O
DNA	O
,	O
the	O
other	O
at	O
the	O
end	O
of	O
the	O
late	B-GENE
(	I-GENE
L	I-GENE
)	I-GENE
region	I-GENE
.	O

Examination	O
of	O
DNA	O
:	O
protein	O
binding	O
complexes	O
by	O
gel	O
-	O
shift	O
analysis	O
indicated	O
that	O
nuclear	O
factors	O
from	O
both	O
proliferative	O
and	O
growth	O
-	O
arrested	O
cells	O
bound	O
to	O
the	O
DNA	O
fragment	O
spanning	O
-	O
949	O
-	O
-	O
722	O
bp	O
.	O

A	O
new	O
vector	O
,	O
pHBK280	O
,	O
was	O
designed	O
to	O
facilitate	O
this	O
analysis	O
.	O

Our	O
results	O
confirm	O
the	O
participation	O
of	O
intron	O
1	O
in	O
transcriptional	O
regulation	O
of	O
the	O
c	B-GENE
-	I-GENE
myb	I-GENE
gene	I-GENE
(	O
in	O
mouse	O
and	O
human	O
)	O
and	O
implicate	O
multiple	O
and	O
complex	O
regulatory	O
mechanisms	O
of	O
activation	O
during	O
myelomonocytic	O
differentiation	O
and	O
leukemic	O
cell	O
growth	O
control	O
.	O

This	O
TC	B-GENE
-	I-GENE
II	I-GENE
enhanson	I-GENE
,	O
which	O
is	O
identical	O
to	O
the	O
kappa	B-GENE
B	I-GENE
motif	I-GENE
from	O
the	O
kappa	B-GENE
chain	I-GENE
enhancer	I-GENE
,	O
was	O
active	O
in	O
both	O
lymphoid	O
and	O
non	O
-	O
lymphoid	O
cells	O
,	O
which	O
contrasts	O
with	O
the	O
previously	O
reported	O
lymphoid	O
cell	O
specificity	O
of	O
the	O
kappa	B-GENE
B	I-GENE
motif	I-GENE
.	O

50	O
kDa	O
and	O
130	O
-	O
170	O
kDa	O
were	O
detected	O
.	O

The	O
coefficient	O
of	O
determination	O
,	O
r2	O
,	O
of	O
the	O
other	O
scores	O
ranged	O
from	O
0	O
.	O
56	O
to	O
0	O
.	O
61	O
.	O

Mutations	O
in	O
the	O
nuclear	B-GENE
gene	I-GENE
CBP1	I-GENE
of	I-GENE
Saccharomyces	I-GENE
cerevisiae	I-GENE
result	O
in	O
degradation	O
of	O
mitochondrially	B-GENE
encoded	I-GENE
cytochrome	I-GENE
b	I-GENE
(	O
cob	B-GENE
)	O
RNA	O
;	O
thus	O
,	O
the	O
cells	O
are	O
unable	O
to	O
respire	O
.	O

Plasma	B-GENE
secretin	I-GENE
,	O
pancreozymin	B-GENE
,	O
and	O
somatostatin	B-GENE
-	I-GENE
like	I-GENE
hormone	I-GENE
in	O
chronic	O
renal	O
failure	O
patients	O
.	O

DNase	B-GENE
I	I-GENE
genomic	O
footprinting	O
revealed	O
that	O
the	O
c	B-GENE
-	I-GENE
Myb	I-GENE
site	I-GENE
is	O
occupied	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
in	O
vivo	O
.	O

Minor	O
differences	O
were	O
noted	O
with	O
latamoxef	O
producing	O
mild	O
persistant	O
elevation	O
of	O
prothrombin	B-GENE
time	O
(	O
0	O
.	O
7	O
second	O
)	O
associated	O
with	O
depression	O
of	O
factor	B-GENE
II	I-GENE
and	O
factor	B-GENE
VII	I-GENE
.	O

A	O
deletion	O
series	O
of	O
the	O
5	O
'	O
flanking	O
region	O
was	O
created	O
from	O
position	O
-	O
1329	O
to	O
-	O
74	O
relative	O
to	O
the	O
transcriptional	O
initiation	O
site	O
and	O
similarly	O
examined	O
in	O
transgenic	O
tobacco	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
relatively	O
weak	O
transcriptional	O
silencing	O
by	O
the	O
native	O
VDR	B-GENE
was	O
observed	O
using	O
the	O
osteopontin	B-GENE
VDRE	O
.	O

The	O
U17	B-GENE
/	O
U16	B-GENE
and	O
the	O
U16	B-GENE
+	I-GENE
gene	I-GENE
products	I-GENE
transactivated	O
the	O
HIV	B-GENE
LTR	I-GENE
.	O

We	O
conclude	O
that	O
,	O
in	O
comparison	O
to	O
reports	O
from	O
other	O
regions	O
,	O
Scandinavian	O
renal	O
transplant	O
recipients	O
are	O
at	O
high	O
risk	O
of	O
dying	O
of	O
IHD	O
.	O

Monospecific	O
antibodies	O
raised	O
against	O
rat	B-GENE
cytochrome	I-GENE
P	I-GENE
-	I-GENE
450	I-GENE
1A1	I-GENE
recognized	O
a	O
protein	O
in	O
the	O
hepatic	O
microsomes	O
of	O
the	O
double	O
-	O
crested	O
cormorant	O
,	O
and	O
also	O
in	O
those	O
of	O
the	O
great	O
blue	O
heron	O
(	O
Ardea	O
herodias	O
)	O
,	O
using	O
immunoblotting	O
.	O

Implication	O
of	O
PAF	B-GENE
and	O
acetylhydrolase	B-GENE
(	O
PAF	B-GENE
-	I-GENE
AH	I-GENE
)	O
activity	O
in	O
periodontal	O
disease	O
.	O

Botulinum	B-GENE
toxin	I-GENE
A	I-GENE
in	O
the	O
treatment	O
of	O
hemiplegic	O
spastic	O
foot	O
drop	O
-	O
-	O
clinical	O
and	O
functional	O
outcomes	O
.	O

Results	O
of	O
this	O
study	O
indicate	O
that	O
GLC	O
of	O
short	O
chain	O
fatty	O
acids	O
produced	O
on	O
agar	O
medium	O
by	O
anaerobes	O
,	O
combined	O
with	O
simple	O
tests	O
such	O
as	O
Gram	O
'	O
s	O
stain	O
and	O
colonial	O
morphology	O
,	O
may	O
allow	O
fir	O
direct	O
presumptive	O
genus	O
identification	O
from	O
an	O
initial	O
pure	O
agar	O
culture	O
.	O

We	O
describe	O
a	O
novel	O
cytoplasmic	B-GENE
tyrosine	I-GENE
kinase	I-GENE
,	O
termed	O
BPK	B-GENE
(	O
B	B-GENE
cell	I-GENE
progenitor	I-GENE
kinase	I-GENE
)	O
,	O
which	O
is	O
expressed	O
in	O
all	O
stages	O
of	O
the	O
B	O
lineage	O
and	O
in	O
myeloid	O
cells	O
.	O

The	O
enzyme	O
displays	O
optimal	O
activity	O
at	O
about	O
0	O
.	O
5	O
mM	O
pantoate	O
(	O
k	O
(	O
cat	O
)	O
0	O
.	O
63	O
s	O
(	O
-	O
1	O
)	O
)	O
and	O
at	O
pH	O
7	O
.	O
8	O
.	O

During	O
the	O
period	O
from	O
May	O
to	O
August	O
,	O
1978	O
,	O
an	O
epidemic	O
of	O
hand	O
,	O
foot	O
and	O
mouth	O
disease	O
(	O
HFMD	O
)	O
occurred	O
in	O
Gifu	O
prefecture	O
.	O

The	O
interaction	O
between	O
piroxicam	O
and	O
poloxamer	O
was	O
studied	O
by	O
x	O
-	O
ray	O
diffractometry	O
(	O
XRD	O
)	O
,	O
infrared	O
(	O
IR	O
)	O
spectroscopy	O
and	O
differential	O
thermal	O
analysis	O
(	O
DTA	O
)	O
with	O
a	O
solid	O
dispersion	O
,	O
coprecipitate	O
,	O
or	O
physical	O
mixture	O
.	O

RNase	B-GENE
protection	O
analysis	O
of	O
two	O
rRNA	O
fragments	O
whose	O
genes	O
are	O
adjacent	O
provided	O
evidence	O
for	O
a	O
polycistronic	O
transcript	O
containing	O
sequences	O
from	O
both	O
,	O
as	O
well	O
as	O
separate	O
small	O
RNAs	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
report	O
our	O
experience	O
with	O
seven	O
children	O
with	O
active	O
small	O
bowel	O
Crohn	O
'	O
s	O
disease	O
given	O
a	O
casein	B-GENE
-	O
based	O
,	O
polymeric	O
feed	O
rich	O
in	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
2	I-GENE
(	O
Specific	O
Polymeric	O
Diet	O
;	O
Nestle	O
-	O
Clintec	O
;	O
Vevey	O
,	O
Switzerland	O
)	O
as	O
complete	O
nutrition	O
for	O
8	O
weeks	O
.	O

Consistent	O
effects	O
on	O
pVHL	B-GENE
function	O
were	O
observed	O
for	O
all	O
mutations	O
within	O
each	O
subclass	O
.	O

Interestingly	O
,	O
the	O
interaction	O
of	O
ZAP	B-GENE
-	I-GENE
70	I-GENE
with	O
the	O
motif	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
both	O
ZAP	B-GENE
-	I-GENE
70	I-GENE
SH2	B-GENE
domains	I-GENE
and	O
both	O
of	O
the	O
tyrosine	O
residues	O
in	O
the	O
motif	O
,	O
suggesting	O
that	O
ZAP	B-GENE
-	I-GENE
70	I-GENE
interacts	O
with	O
two	O
phosphotyrosine	O
residues	O
and	O
that	O
the	O
binding	O
of	O
the	O
two	O
SH2	B-GENE
domains	I-GENE
is	O
cooperative	O
.	O

Neither	O
mutant	O
exhibited	O
derepression	O
of	O
the	O
silent	B-GENE
mating	I-GENE
type	I-GENE
loci	I-GENE
.	O

Pokeweed	B-GENE
mitogen	I-GENE
(	O
PWM	B-GENE
)	O
or	O
anti	B-GENE
-	I-GENE
CD3	I-GENE
significantly	O
increases	O
c	B-GENE
-	I-GENE
jun	I-GENE
messenger	I-GENE
RNA	I-GENE
(	I-GENE
mRNA	I-GENE
)	I-GENE
levels	O
in	O
T	O
cells	O
.	O

There	O
is	O
now	O
a	O
significative	O
difference	O
between	O
age	O
group	O
1	O
-	O
5	O
and	O
the	O
others	O
(	O
p	O
Less	O
Than	O
0	O
,	O
02	O
)	O
.	O

Apart	O
from	O
two	O
proline	O
-	O
rich	O
regions	O
(	O
amino	O
acids	O
1	O
-	O
117	O
and	O
239	O
-	O
270	O
)	O
,	O
p230	B-GENE
contains	O
a	O
very	O
high	O
frequency	O
of	O
heptad	O
repeats	O
,	O
characteristic	O
of	O
alpha	O
-	O
helices	O
that	O
form	O
dimeric	O
coiled	O
-	O
coil	O
structures	O
.	O

p230	B-GENE
also	O
includes	O
the	O
sequence	O
ESLALEELEL	O
(	O
amino	O
acids	O
538	O
-	O
546	O
)	O
,	O
a	O
motif	O
found	O
in	O
the	O
granin	B-GENE
family	I-GENE
of	O
acidic	O
proteins	O
present	O
in	O
secretory	O
granules	O
of	O
neuroendocrine	O
cells	O
.	O

This	O
implies	O
that	O
the	O
groups	O
do	O
not	O
just	O
differ	O
along	O
one	O
dimension	O
,	O
but	O
along	O
three	O
dimensions	O
.	O

The	O
genome	O
organization	O
of	O
the	O
mite	O
-	O
transmitted	O
wheat	O
streak	O
mosaic	O
virus	O
(	O
WSMV	O
)	O
appears	O
to	O
parallel	O
that	O
of	O
members	O
of	O
the	O
Potyviridae	O
with	O
monopartite	O
genomes	O
,	O
but	O
there	O
are	O
substantial	O
amino	O
acid	O
dissimilarities	O
with	O
other	O
potyviral	O
polyproteins	O
.	O

Treatment	O
of	O
Graves	O
'	O
disease	O
.	O

The	O
carboxyl	O
-	O
terminal	O
CCCC	O
module	O
is	O
structurally	O
related	O
to	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
erythroid	B-GENE
transcription	I-GENE
factor	I-GENE
GATA	I-GENE
-	I-GENE
1	I-GENE
.	O

Three	O
women	O
have	O
had	O
abnormal	O
endocervical	O
follow	O
up	O
cytology	O
suggestive	O
of	O
residual	O
disease	O
.	O

Taste	O
reactivity	O
tests	O
were	O
used	O
to	O
examine	O
the	O
orofacial	O
responses	O
of	O
alcohol	O
preferring	O
(	O
P	O
)	O
rats	O
and	O
alcohol	O
nonpreferring	O
(	O
NP	O
)	O
rats	O
to	O
the	O
taste	O
of	O
alcohol	O
.	O

The	O
cis	O
-	O
acting	O
elements	O
that	O
control	O
promoter	O
activity	O
include	O
binding	O
sites	O
for	O
transcription	O
factors	O
Sp1	B-GENE
and	O
alphaCbf	B-GENE
,	O
a	O
60	B-GENE
-	I-GENE
kDa	I-GENE
CCAAT	I-GENE
box	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
.	O

The	O
level	O
of	O
serum	B-GENE
creatine	I-GENE
kinase	I-GENE
was	O
significantly	O
high	O
2	O
days	O
after	O
ESWIB	O
,	O
but	O
it	O
recovered	O
in	O
a	O
week	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
AIF	O
peak	O
saturation	O
leads	O
to	O
a	O
significant	O
systematic	O
error	O
in	O
the	O
determination	O
of	O
CBV	O
and	O
CBF	O
values	O
and	O
has	O
necessarily	O
to	O
be	O
taken	O
into	O
account	O
for	O
dynamic	O
contrast	O
-	O
enhanced	O
MR	O
perfusion	O
studies	O
.	O

Rice	B-GENE
dwarf	I-GENE
phytoreovirus	I-GENE
segment	I-GENE
S12	I-GENE
transcript	I-GENE
is	O
tricistronic	O
in	O
vitro	O
.	O

We	O
found	O
no	O
correlation	O
between	O
plasma	O
COP	O
and	O
body	O
weight	O
at	O
the	O
same	O
age	O
(	O
r2	O
=	O
0	O
.	O
05	O
,	O
P	O
=	O
0	O
.	O
155	O
)	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
encodes	O
a	O
40	O
-	O
kDa	O
nuclear	O
protein	O
,	O
Tax	B-GENE
,	O
which	O
stimulates	O
transcription	O
from	O
three	O
21	O
-	O
base	O
pair	O
(	O
bp	O
)	O
repeats	O
in	O
its	O
U3	O
region	O
.	O

The	O
other	O
two	O
clones	O
,	O
Ash	B-GENE
-	I-GENE
m	I-GENE
and	I-GENE
-	I-GENE
s	I-GENE
,	O
had	O
nucleotide	O
sequences	O
identical	O
with	O
Ash	B-GENE
-	I-GENE
l	I-GENE
cDNA	O
in	O
the	O
amino	O
-	O
terminal	O
region	O
.	O

A	O
note	O
on	O
some	O
consequences	O
of	O
UV	O
vision	O
in	O
birds	O
.	O

Two	O
US	O
commercial	O
cultivars	O
(	O
Tehama	O
and	O
Vina	O
)	O
,	O
three	O
European	O
commercial	O
cultivars	O
(	O
Esterhazy	O
,	O
139	O
,	O
G120	O
)	O
and	O
five	O
New	O
Zealand	O
selections	O
(	O
Rex	O
,	O
Dublin	O
'	O
s	O
Glory	O
,	O
Meyric	O
,	O
McKinster	O
,	O
Stanley	O
)	O
were	O
evaluated	O
.	O

Diagnosis	O
:	O
progressive	O
multifocal	O
leukoencephalopathy	O
.	O

Our	O
results	O
suggest	O
that	O
WASP	B-GENE
activates	O
transcription	O
following	O
TCR	B-GENE
stimulation	O
in	O
a	O
manner	O
that	O
is	O
independent	O
of	O
its	O
role	O
in	O
Arp2	B-GENE
/	I-GENE
3	I-GENE
-	O
directed	O
actin	B-GENE
polymerization	O
.	O

Mouse	B-GENE
growth	I-GENE
hormone	I-GENE
transcription	I-GENE
factor	I-GENE
Zn	I-GENE
-	I-GENE
16	I-GENE
:	O
unique	O
bipartite	O
structure	O
containing	O
tandemly	O
repeated	O
zinc	O
finger	O
domains	O
not	O
reported	O
in	O
rat	B-GENE
Zn	I-GENE
-	I-GENE
15	I-GENE
.	O

Furthermore	O
,	O
stable	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
chicken	O
Notch1	B-GENE
or	O
Notch2	B-GENE
in	O
a	O
B	O
cell	O
line	O
results	O
in	O
a	O
down	O
-	O
regulation	O
of	O
surface	O
IgM	B-GENE
expression	O
,	O
which	O
is	O
accompanied	O
by	O
the	O
reduction	O
of	O
IgH	B-GENE
gene	I-GENE
transcripts	I-GENE
.	O

Deep	O
tans	O
were	O
induced	O
over	O
the	O
backs	O
of	O
volunteers	O
with	O
repeated	O
exposure	O
to	O
longwave	O
ultraviolet	O
radiation	O
(	O
UV	O
-	O
A	O
)	O
.	O

Postcoital	O
contraception	O
:	O
a	O
family	O
planning	O
study	O
.	O

Merlie	O
,	O
Cold	O
Spring	O
Harbor	O
Symp	O
.	O

The	O
human	O
cDNA	O
was	O
used	O
to	O
demonstrate	O
that	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
-	I-GENE
alpha	I-GENE
could	O
rapidly	O
stimulate	O
MARCKS	B-GENE
gene	I-GENE
transcription	O
in	O
the	O
human	O
promyelocytic	O
leukemia	O
cell	O
line	O
HL60	O
.	O

Interleukin	B-GENE
-	I-GENE
1	I-GENE
levels	O
remained	O
low	O
throughout	O
the	O
course	O
.	O

Intracellular	O
localization	O
studies	O
using	O
the	O
mDAP	B-GENE
-	I-GENE
3	I-GENE
/	O
EGFP	B-GENE
fusion	O
protein	O
,	O
cell	O
fractionation	O
and	O
protease	O
protection	O
experiments	O
localized	O
mDAP	B-GENE
-	I-GENE
3	I-GENE
to	O
the	O
mitochondrial	O
matrix	O
.	O

This	O
compound	O
is	O
the	O
main	O
bioactive	O
metabolite	O
of	O
trimebutine	O
II	O
(	O
Debridat	O
,	O
CAS	O
39133	O
-	O
31	O
-	O
8	O
)	O
,	O
an	O
antispasmodic	O
widely	O
used	O
for	O
intestinal	O
diseases	O
since	O
1969	O
.	O

Unexpectedly	O
,	O
all	O
ENK	B-GENE
-	I-GENE
specific	I-GENE
motifs	I-GENE
formed	O
specific	O
and	O
highly	O
abundant	O
protein	O
-	O
DNA	O
complexes	O
when	O
nuclear	O
extracts	O
from	O
the	O
human	O
tumor	O
cell	O
line	O
(	O
HeLa	O
)	O
,	O
which	O
does	O
not	O
express	O
ENK	B-GENE
,	O
were	O
used	O
.	O

Negative	O
-	O
staining	O
,	O
refractile	O
mycobacteria	O
in	O
Romanowsky	O
-	O
stained	O
smears	O
.	O

Recombinant	B-GENE
HRMT1L2	I-GENE
protein	I-GENE
encoded	O
by	O
the	O
most	O
common	O
5	O
'	O
-	O
variant	O
exhibited	O
methyltransferase	O
activity	O
in	O
vitro	O
.	O

We	O
have	O
attempted	O
to	O
clone	O
two	O
recessive	O
extragenic	O
suppressors	O
of	O
such	O
ts	O
mutants	O
(	O
sdp1	B-GENE
for	O
mutation	B-GENE
pol3	I-GENE
-	I-GENE
14	I-GENE
and	O
sdp5	B-GENE
-	I-GENE
1	I-GENE
for	O
mutation	B-GENE
pol3	I-GENE
-	I-GENE
11	I-GENE
)	O
by	O
transforming	O
thermoresistant	O
haploid	O
strains	O
pol3	B-GENE
-	I-GENE
14	I-GENE
sdp1	I-GENE
and	O
pol3	B-GENE
-	I-GENE
11	I-GENE
sdp5	I-GENE
-	I-GENE
1	I-GENE
with	O
wild	O
-	O
type	O
genomic	O
libraries	O
in	O
singlecopy	O
or	O
multicopy	O
vectors	O
.	O

RNA	B-GENE
polymerase	I-GENE
IIA	I-GENE
was	O
recovered	O
in	O
transcriptionally	O
active	O
complexes	O
in	O
reactions	O
in	O
which	O
the	O
input	O
enzyme	O
was	O
RNA	B-GENE
polymerase	I-GENE
IIA	I-GENE
.	O

RESULTS	O
:	O
Using	O
information	O
in	O
the	O
dbEST	O
database	O
of	O
expressed	O
sequence	O
tags	O
,	O
we	O
isolated	O
an	O
Arabidopsis	O
thaliana	O
gene	O
(	O
GCR1	B-GENE
)	O
that	O
encodes	O
a	O
protein	O
with	O
seven	O
predicted	O
membrane	O
-	O
spanning	O
domains	O
and	O
other	O
features	O
characteristic	O
of	O
7TM	B-GENE
receptors	I-GENE
.	O

Cytogenetic	O
analysis	O
of	O
LOH	O
mutants	O
by	O
chromosome	O
painting	O
indicated	O
a	O
mosaic	O
of	O
chromosomal	O
aberrations	O
involving	O
chromosome	O
17	O
,	O
in	O
which	O
partial	O
chromosome	O
deletions	O
,	O
amplifications	O
,	O
and	O
multiple	O
translocations	O
appeared	O
heterogeneously	O
in	O
a	O
single	O
mutant	O
.	O

Derivation	O
and	O
initial	O
characterization	O
of	O
a	O
mouse	O
mammary	O
tumor	O
cell	O
line	O
carrying	O
the	O
polyomavirus	B-GENE
middle	I-GENE
T	I-GENE
antigen	I-GENE
:	O
utility	O
in	O
the	O
development	O
of	O
novel	O
cancer	O
therapeutics	O
.	O

The	O
results	O
indicate	O
that	O
folate	O
compounds	O
decrease	O
formate	O
accumulation	O
after	O
methanol	O
by	O
stimulating	O
formate	O
oxidation	O
or	O
utilization	O
and	O
suggest	O
a	O
possible	O
use	O
for	O
folates	O
in	O
the	O
treatment	O
of	O
certain	O
cases	O
of	O
human	O
methanol	O
poisoning	O
.	O

Using	O
gel	O
retardation	O
assays	O
with	O
HepG2	O
nuclear	O
extract	O
,	O
we	O
demonstrated	O
the	O
presence	O
of	O
a	O
specific	O
protein	O
which	O
bound	O
to	O
the	O
NRE	O
fragment	O
.	O

In	O
64	O
%	O
a	O
small	O
cardiac	O
vein	O
does	O
not	O
exist	O
,	O
but	O
its	O
origin	O
,	O
the	O
right	O
marginal	O
vein	O
,	O
joins	O
the	O
system	O
of	O
anterior	O
cardiac	O
veins	O
.	O

These	O
data	O
are	O
consistent	O
with	O
a	O
model	O
in	O
which	O
GATA	B-GENE
-	I-GENE
5	I-GENE
performs	O
a	O
unique	O
temporally	O
and	O
spatially	O
restricted	O
function	O
in	O
the	O
embryonic	O
heart	O
and	O
lung	O
.	O

Although	O
heart	O
rate	O
and	O
diastolic	O
pressure	O
rose	O
in	O
some	O
degree	O
1	O
min	O
after	O
intubation	O
,	O
free	O
and	O
total	O
CA	O
concentrations	O
did	O
not	O
increase	O
during	O
study	O
period	O
.	O

Consistent	O
with	O
ErbB	B-GENE
-	I-GENE
2	I-GENE
being	O
a	O
shared	O
receptor	O
subunit	O
,	O
its	O
tyrosine	O
phosphorylation	O
was	O
increased	O
by	O
both	O
heterologous	O
ligands	O
and	O
it	O
mediated	O
a	O
trans	O
-	O
inhibitory	O
effect	O
of	O
NDF	B-GENE
on	O
EGF	B-GENE
binding	O
.	O

The	O
p97	B-GENE
-	O
depleted	O
nuclei	O
remained	O
largely	O
competent	O
for	O
nuclear	O
protein	O
import	O
.	O

AMDA	O
white	O
paper	O
identifies	O
ways	O
to	O
improve	O
pharmaceutical	O
care	O
in	O
SNFs	O
.	O

Erythrocytic	O
stages	O
of	O
mammalian	O
malarial	O
parasites	O
contain	O
acristate	O
mitochondria	O
whose	O
functions	O
are	O
not	O
well	O
understood	O
.	O

For	O
steers	O
the	O
urinary	O
N	O
values	O
were	O
403	O
and	O
295	O
mg	O
/	O
kg	O
W0	O
.	O
75	O
at	O
200	O
and	O
350	O
kg	O
live	O
weight	O
respectively	O
and	O
total	O
N	O
excretion	O
including	O
faecal	O
N	O
was	O
408	O
and	O
320	O
mg	O
/	O
kg	O
W0	O
.	O
75	O
.	O

In	O
addition	O
,	O
a	O
potent	O
splicing	O
enhancer	O
sequence	O
isolated	O
in	O
the	O
selection	O
specifically	O
binds	O
a	O
20	B-GENE
-	I-GENE
kDa	I-GENE
SR	I-GENE
protein	I-GENE
.	O

Deletion	O
studies	O
identified	O
a	O
distal	O
response	O
element	O
that	O
is	O
responsible	O
for	O
the	O
cytokine	O
response	O
and	O
has	O
properties	O
of	O
an	O
inducible	O
transcriptional	O
enhancer	O
.	O

Therefore	O
,	O
analogs	O
of	O
vitamin	O
D3	O
have	O
been	O
investigated	O
in	O
a	O
number	O
of	O
trials	O
showing	O
improvement	O
of	O
psoriasis	O
.	O

A	O
cause	O
of	O
increase	O
of	O
alkaline	B-GENE
phosphatase	I-GENE
in	O
children	O

On	O
the	O
other	O
hand	O
,	O
the	O
structures	O
of	O
the	O
b	O
-	O
Zip	O
domain	O
are	O
well	O
conserved	O
among	O
these	O
Maf	B-GENE
-	I-GENE
related	I-GENE
proteins	I-GENE
.	O

Cloning	O
of	O
individual	O
ZI	O
domains	O
upstream	O
of	O
a	O
minimal	O
promoter	O
demonstrated	O
that	O
the	O
ZIA	O
,	O
ZIC	O
,	O
and	O
ZID	O
domains	O
,	O
but	O
not	O
the	O
ZIB	O
domain	O
,	O
are	O
TPA	O
responsive	O
.	O

In	O
the	O
clinical	O
study	O
,	O
the	O
defect	O
size	O
shown	O
by	O
BMIPP	O
imaging	O
was	O
greater	O
in	O
anterior	O
than	O
in	O
inferior	O
infarcts	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
correlated	O
well	O
with	O
the	O
risk	O
area	O
revealed	O
by	O
contrast	O
ventriculography	O
(	O
r	O
=	O
0	O
.	O
80	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
CONCLUSION	O
:	O
The	O
above	O
preliminary	O
data	O
,	O
admittedly	O
from	O
a	O
small	O
group	O
of	O
patients	O
,	O
suggest	O
that	O
tomographic	O
BMIPP	O
imaging	O
provides	O
an	O
accurate	O
quantification	O
of	O
defect	O
size	O
by	O
means	O
of	O
a	O
simple	O
threshold	O
technique	O
and	O
,	O
in	O
the	O
subacute	O
phase	O
,	O
permits	O
determination	O
of	O
the	O
amount	O
of	O
myocardium	O
at	O
risk	O
after	O
acute	O
myocardial	O
infarction	O
.	O

The	O
integrity	O
of	O
the	O
cDNA	O
sequence	O
was	O
confirmed	O
by	O
analysis	O
of	O
several	O
overlapping	O
genomic	O
clones	O
that	O
span	O
the	O
GAR1	B-GENE
gene	I-GENE
.	O

Manipulation	O
of	O
the	O
checkpoint	O
regulators	O
involved	O
in	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
may	O
thus	O
provide	O
a	O
novel	O
strategy	O
to	O
cancer	O
therapy	O
.	O

We	O
here	O
demonstrate	O
that	O
a	O
temperature	O
-	O
sensitive	O
fission	O
yeast	O
mutant	O
which	O
has	O
a	O
mutation	O
in	O
a	O
homologous	O
gene	O
,	O
and	O
two	O
of	O
three	O
additional	O
(	O
mtr1	B-GENE
/	O
prp20	B-GENE
/	O
srm1	B-GENE
)	O
mutants	O
accumulate	O
nuclear	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
at	O
37	O
degrees	O
C	O
.	O

Clinically	O
meaningful	O
decreases	O
due	O
to	O
alkalinization	O
alone	O
within	O
30	O
minutes	O
are	O
unlikely	O
.	O

The	O
gene	O
encoding	O
the	O
receptor	O
for	O
macrophage	B-GENE
colony	I-GENE
-	I-GENE
stimulating	I-GENE
factor	I-GENE
1	I-GENE
(	O
CSF	B-GENE
-	I-GENE
1	I-GENE
)	O
,	O
the	O
c	B-GENE
-	I-GENE
fms	I-GENE
protooncogene	I-GENE
,	O
is	O
selectively	O
expressed	O
in	O
immature	O
and	O
mature	O
mononuclear	O
phagocytes	O
and	O
trophoblasts	O
.	O

The	O
most	O
common	O
cause	O
of	O
renal	O
deterioration	O
in	O
the	O
spinal	O
cord	O
injured	O
patient	O
is	O
irreversible	O
vesicoureteral	O
reflux	O
.	O

Isolated	O
proteinuria	O
(	O
i	O
.	O
e	O
.	O
without	O
hematuria	O
and	O
/	O
or	O
pyuria	O
)	O
is	O
a	O
frequent	O
finding	O
.	O

Significant	O
correlations	O
were	O
obtained	O
between	O
changes	O
in	O
SSEP	O
in	O
response	O
to	O
AS	O
and	O
the	O
presence	O
of	O
not	O
deep	O
residual	O
-	O
organic	O
disturbances	O
,	O
so	O
-	O
called	O
"	O
ground	O
"	O
in	O
psychogenic	O
disorders	O
.	O

Patients	O
with	O
a	O
secondary	O
cardiac	O
event	O
had	O
more	O
common	O
Type	O
A	O
behavior	O
patterns	O
and	O
higher	O
Bortner	O
scores	O
than	O
patients	O
without	O
a	O
secondary	O
cardiac	O
event	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
performed	O
with	O
the	O
HNF	B-GENE
-	I-GENE
3	I-GENE
X	O
and	O
Y	O
sites	O
demonstrated	O
that	O
both	O
sites	O
are	O
capable	O
of	O
binding	O
HNF	B-GENE
-	I-GENE
3alpha	I-GENE
and	O
HNF	B-GENE
-	I-GENE
3beta	I-GENE
.	O

An	O
unusual	O
cysteine	O
triplet	O
conserved	O
in	O
the	O
sequences	O
of	O
TB	B-GENE
domains	I-GENE
is	O
localized	O
to	O
the	O
hydrophobic	O
core	O
,	O
at	O
the	O
C	O
-	O
terminus	O
of	O
an	O
alpha	O
-	O
helix	O
.	O

The	O
C	O
/	O
D	O
ratio	O
was	O
equal	O
to	O
or	O
over	O
0	O
.	O
6	O
in	O
9	O
cases	O
(	O
16	O
eyes	O
)	O
,	O
and	O
the	O
values	O
were	O
inconsistent	O
between	O
both	O
eyes	O
in	O
55	O
%	O
of	O
the	O
patients	O
.	O

The	O
Rlm1	B-GENE
protein	I-GENE
,	O
a	O
member	O
of	O
the	O
MADS	B-GENE
box	I-GENE
family	I-GENE
of	O
transcription	O
factors	O
,	O
functions	O
downstream	O
of	O
Mpk1	B-GENE
in	O
the	O
pathway	O
.	O

The	O
observed	O
phenotypes	O
may	O
be	O
explained	O
by	O
(	O
i	O
)	O
a	O
selective	O
disruption	O
of	O
very	B-GENE
-	I-GENE
low	I-GENE
-	I-GENE
density	I-GENE
lipoprotein	I-GENE
secretion	O
due	O
to	O
decreased	O
expression	O
of	O
genes	O
encoding	O
apolipoprotein	B-GENE
B	I-GENE
and	O
microsomal	B-GENE
triglyceride	I-GENE
transfer	I-GENE
protein	I-GENE
,	O
(	O
ii	O
)	O
an	O
increase	O
in	O
hepatic	O
cholesterol	O
uptake	O
due	O
to	O
increased	O
expression	O
of	O
the	O
major	O
high	B-GENE
-	I-GENE
density	I-GENE
lipoprotein	I-GENE
receptor	I-GENE
,	O
scavenger	B-GENE
receptor	I-GENE
BI	I-GENE
,	O
and	O
(	O
iii	O
)	O
a	O
decrease	O
in	O
bile	O
acid	O
uptake	O
to	O
the	O
liver	O
due	O
to	O
down	O
-	O
regulation	O
of	O
the	O
major	O
basolateral	B-GENE
bile	I-GENE
acid	I-GENE
transporters	I-GENE
sodium	I-GENE
taurocholate	I-GENE
cotransporter	I-GENE
protein	I-GENE
and	O
organic	B-GENE
anion	I-GENE
transporter	I-GENE
protein	I-GENE
1	I-GENE
.	O

RESULTS	O
:	O
Surprisingly	O
,	O
PAF	B-GENE
blockade	O
increased	O
mortality	O
after	O
trauma	O
(	O
5	O
of	O
11	O
WEB	O
-	O
2086	O
animals	O
versus	O
1	O
of	O
9	O
vehicle	O
animals	O
;	O
p	O
=	O
0	O
.	O
15	O
)	O
and	O
depressed	O
cardiac	O
index	O
and	O
O2	O
delivery	O
at	O
72	O
hours	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Children	O
'	O
s	O
temperament	O
and	O
maternal	O
socialization	O
at	O
Time	O
1	O
(	O
n	O
=	O
103	O
,	O
aged	O
2	O
-	O
3	O
years	O
)	O
were	O
considered	O
predictors	O
of	O
future	O
conscience	O
,	O
assessed	O
using	O
new	O
observational	O
and	O
narrative	O
measures	O
.	O

The	O
N	O
-	O
terminal	O
small	O
segment	O
of	O
yeast	B-GENE
TAF145	I-GENE
(	O
yTAF145	B-GENE
)	O
binds	O
to	O
TBP	B-GENE
and	O
thereby	O
inhibits	O
TBP	B-GENE
function	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
Of	O
the	O
17	O
men	O
and	O
17	O
women	O
,	O
who	O
were	O
21	O
to	O
80	O
years	O
of	O
age	O
,	O
27	O
had	O
hereditary	O
motor	O
and	O
sensory	O
neuropathy	O
type	O
I	O
and	O
7	O
had	O
acquired	O
demyelinating	O
polyneuropathy	O
.	O

A	O
recent	O
index	O
(	O
Fluorosis	O
Risk	O
Index	O
)	O
developed	O
by	O
Pendrys	O
(	O
1990	O
)	O
is	O
also	O
included	O
in	O
this	O
review	O
.	O

Southern	O
analysis	O
on	O
genomic	O
DNA	O
isolated	O
from	O
tissues	O
and	O
cell	O
lines	O
from	O
several	O
mouse	O
strains	O
using	O
mCD22	B-GENE
cDNA	I-GENE
demonstrated	O
that	O
the	O
Cd22	B-GENE
locus	I-GENE
encoding	O
mCD22	B-GENE
is	O
a	O
single	O
copy	O
gene	O
of	O
<	O
or	O
=	O
30	O
kb	O
.	O

Further	O
,	O
they	O
are	O
consistent	O
with	O
the	O
suggestion	O
that	O
sites	O
homologous	O
to	O
the	O
CAR1	B-GENE
URS	I-GENE
may	O
be	O
situated	O
in	O
the	O
5	O
'	O
-	O
flanking	O
regions	O
of	O
multiple	O
unrelated	O
yeast	O
genes	O
.	O

Relatively	O
little	O
is	O
known	O
regarding	O
the	O
role	O
of	O
5	B-GENE
-	I-GENE
HT2	I-GENE
receptor	I-GENE
activity	O
in	O
male	O
rat	O
sexual	O
behavior	O
.	O

It	O
was	O
demonstrated	O
that	O
the	O
processing	O
signals	O
in	O
the	O
transcript	O
,	O
i	O
.	O
e	O
.	O
both	O
donor	O
splice	O
sites	O
and	O
the	O
polyadenylation	O
site	O
located	O
in	O
the	O
muscle	O
-	O
specific	O
intron	O
,	O
have	O
to	O
be	O
weak	O
.	O

Possible	O
pathogenetic	O
mechanisms	O
of	O
hemopoietic	O
changes	O
in	O
response	O
to	O
space	O
flight	O
effects	O
are	O
described	O
.	O

The	O
patients	O
were	O
divided	O
into	O
3	O
subgroups	O
:	O
1	O
)	O
13	O
N	O
+	O
patients	O
with	O
multiple	O
hot	O
spots	O
(	O
greater	O
than	O
2	O
)	O
(	O
N	O
+	O
IM	O
)	O
;	O
2	O
)	O
24	O
N	O
+	O
patients	O
with	O
single	O
hot	O
spots	O
(	O
less	O
than	O
or	O
equal	O
to	O
2	O
)	O
(	O
N	O
+	O
IS	O
)	O
;	O
3	O
)	O
12	O
N	O
-	O
patients	O
with	O
single	O
hot	O
spots	O
(	O
less	O
than	O
or	O
equal	O
to	O
2	O
)	O
(	O
N	O
-	O
IS	O
)	O
.	O

Xenopus	B-GENE
homolog	I-GENE
of	I-GENE
the	I-GENE
mos	I-GENE
protooncogene	I-GENE
transforms	O
mammalian	O
fibroblasts	O
and	O
induces	O
maturation	O
of	O
Xenopus	O
oocytes	O
.	O

TNF	B-GENE
Treatment	O
of	O
cell	O
activated	O
the	O
p38	B-GENE
MAP	I-GENE
kinase	I-GENE
pathway	O
,	O
as	O
revealed	O
by	O
increased	O
phosphorylation	O
of	O
p38	B-GENE
MAP	I-GENE
kinase	I-GENE
itself	O
,	O
activation	O
of	O
the	O
substrate	O
protein	O
MAPKAP	B-GENE
kinase	I-GENE
-	I-GENE
2	I-GENE
,	O
and	O
culminating	O
in	O
the	O
phosphorylation	O
of	O
the	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
27	I-GENE
(	O
hsp27	B-GENE
)	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
gene	O
has	O
significant	O
homology	O
to	O
the	O
interferon	B-GENE
regulatory	I-GENE
factors	I-GENE
(	O
IRFs	B-GENE
)	O
.	O

Ethylene	O
is	O
involved	O
in	O
endosperm	O
rupture	O
and	O
high	O
-	O
level	O
betaGLU	B-GENE
I	I-GENE
expression	O
;	O
but	O
,	O
it	O
does	O
not	O
affect	O
the	O
spatial	O
and	O
temporal	O
pattern	O
of	O
betaGLU	B-GENE
I	I-GENE
expression	O
.	O

PURPOSE	O
:	O
Previous	O
WR	O
-	O
2721	O
human	O
pharmacokinetic	O
studies	O
were	O
limited	O
to	O
plasma	O
levels	O
in	O
patients	O
receiving	O
platinum	O
-	O
based	O
compounds	O
,	O
and	O
none	O
includes	O
the	O
effects	O
of	O
WR	O
-	O
2721	O
on	O
endogenous	O
thiols	O
.	O

Retinal	O
changes	O
in	O
pigmentary	O
retinopathy	O
in	O
children	O

Bepridil	O
,	O
a	O
calcium	O
antagonist	O
with	O
a	O
half	O
-	O
life	O
of	O
approximately	O
42	O
hours	O
,	O
was	O
compared	O
with	O
placebo	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
crossover	O
trial	O
.	O

Early	O
indicators	O
of	O
the	O
effect	O
of	O
a	O
breast	O
cancer	O
screening	O
program	O
for	O
low	O
-	O
income	O
women	O
.	O

Five	O
of	O
the	O
Aeromonas	O
strains	O
and	O
one	O
of	O
V	O
cholerae	O
non	O
-	O
O1	O
were	O
positive	O
for	O
enterotoxin	O
activity	O
.	O

We	O
have	O
used	O
mutation	O
-	O
directed	O
chemical	O
cross	O
-	O
linking	O
with	O
bis	O
(	O
sulfosuccinimidyl	O
)	O
suberate	O
(	O
BS3	O
)	O
to	O
investigate	O
the	O
architecture	O
of	O
the	O
gp41	B-GENE
oligomer	I-GENE
.	O

NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
/	O
Rel	B-GENE
transcription	O
factors	O
participate	O
in	O
the	O
activation	O
of	O
numerous	O
genes	O
involved	O
in	O
immune	O
regulation	O
/	O
inflammation	O
including	O
cytokines	O
,	O
cell	O
surface	O
receptors	O
,	O
adhesion	O
molecules	O
,	O
and	O
acute	O
phase	O
proteins	O
.	O

Manganese	O
ions	O
were	O
found	O
to	O
be	O
essential	O
for	O
autophosphorylation	O
of	O
BGLF4	B-GENE
,	O
and	O
magnesium	O
can	O
stimulate	O
the	O
activity	O
.	O

Tyrosine	O
phosphorylation	O
of	O
cellular	O
proteins	O
is	O
the	O
earliest	O
identifiable	O
event	O
following	O
T	B-GENE
-	I-GENE
cell	I-GENE
antigen	I-GENE
receptor	I-GENE
(	O
TCR	B-GENE
)	O
stimulation	O
and	O
is	O
essential	O
for	O
activating	O
downstream	O
signaling	O
machinery	O
.	O

A	O
5	O
-	O
month	O
-	O
old	O
infant	O
with	O
persistent	O
congenital	O
stridor	O
and	O
acute	O
respiratory	O
distress	O
is	O
presented	O
.	O

RESULTS	O
:	O
256	O
Periods	O
of	O
TTP	O
or	O
PUNP	O
were	O
reported	O
by	O
men	O
and	O
174	O
by	O
women	O
.	O

Additionally	O
,	O
the	O
enzyme	O
shows	O
activity	O
towards	O
triglycerides	O
such	O
as	O
olive	O
oil	O
and	O
tributyrin	O
and	O
towards	O
egg	O
-	O
yolk	O
emulsions	O
.	O

The	O
Drosophila	B-GENE
melanogaster	I-GENE
suppressor	I-GENE
of	I-GENE
sable	I-GENE
gene	I-GENE
,	O
su	B-GENE
(	I-GENE
s	I-GENE
)	I-GENE
,	O
encodes	O
a	O
novel	O
,	O
150	O
-	O
kDa	O
nuclear	O
RNA	O
binding	O
protein	O
,	O
SU	B-GENE
(	I-GENE
S	I-GENE
)	I-GENE
,	O
that	O
negatively	O
regulates	O
RNA	O
accumulation	O
from	O
mutant	O
alleles	O
of	O
other	O
genes	O
that	O
have	O
transposon	O
insertions	O
in	O
the	O
5	O
'	O
transcribed	O
region	O
.	O

There	O
was	O
no	O
difference	O
in	O
apnea	O
duration	O
between	O
the	O
supine	O
and	O
prone	O
positions	O
.	O

The	O
interaction	O
between	O
DDB	B-GENE
and	O
E2F1	B-GENE
can	O
also	O
be	O
detected	O
by	O
coimmunoprecipitation	O
experiments	O
.	O

Multiple	O
SWI6	B-GENE
-	O
dependent	O
cis	O
-	O
acting	O
elements	O
control	O
SWI4	B-GENE
transcription	O
through	O
the	O
cell	O
cycle	O
.	O

Northern	O
analyses	O
of	O
RNAs	O
from	O
mouse	O
tissues	O
and	O
cell	O
lines	O
indicated	O
that	O
p11	B-GENE
mRNA	I-GENE
levels	O
vary	O
widely	O
.	O

In	O
the	O
past	O
,	O
immunology	O
in	O
Singapore	O
was	O
mainly	O
confined	O
to	O
serology	O
for	O
the	O
diagnosis	O
of	O
certain	O
infectious	O
diseases	O
.	O

The	O
method	O
is	O
accurate	O
,	O
with	O
good	O
precision	O
and	O
adequate	O
sensitivity	O
.	O

To	O
determine	O
whether	O
vanadate	O
could	O
inhibit	O
PEPCK	B-GENE
gene	I-GENE
transcription	O
,	O
a	O
series	O
of	O
chimeric	O
genes	O
containing	O
several	O
deletions	O
in	O
the	O
P	B-GENE
-	I-GENE
enolypyruvate	I-GENE
carboxykinase	I-GENE
promoter	I-GENE
between	O
-	O
550	O
and	O
-	O
68	O
was	O
linked	O
to	O
the	O
structural	O
genes	O
for	O
either	O
amino	B-GENE
-	I-GENE
3	I-GENE
-	I-GENE
glycosyl	I-GENE
phosphotransferase	I-GENE
(	O
neo	B-GENE
)	O
or	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
and	O
introduced	O
into	O
hepatoma	O
cells	O
using	O
three	O
methods	O
:	O
(	O
a	O
)	O
infection	O
with	O
a	O
Moloney	O
murine	O
leukemia	O
virus	O
-	O
based	O
retrovirus	O
,	O
(	O
b	O
)	O
transfection	O
and	O
stable	O
selection	O
for	O
neo	B-GENE
expression	O
,	O
or	O
(	O
c	O
)	O
transient	O
expression	O
of	O
chloroamphenicol	B-GENE
acetyltransferase	I-GENE
.	O

During	O
activity	O
III	O
,	O
one	O
patient	O
developed	O
angina	O
.	O

The	O
effects	O
on	O
reflex	O
latencies	O
but	O
not	O
on	O
paCO2	O
or	O
pHa	O
were	O
blocked	O
by	O
naloxone	O
(	O
2	O
mg	O
/	O
kg	O
)	O
,	O
and	O
were	O
not	O
present	O
in	O
morphine	O
-	O
tolerant	O
animals	O
.	O

We	O
hypothesize	O
that	O
proprioception	O
may	O
be	O
used	O
to	O
calibrate	O
the	O
efference	O
copy	O
during	O
development	O
and	O
in	O
response	O
to	O
perturbations	O
by	O
signaling	O
potential	O
mismatches	O
between	O
eye	O
movement	O
information	O
derived	O
from	O
the	O
efferent	O
command	O
and	O
the	O
actual	O
motion	O
of	O
the	O
eye	O
transduced	O
by	O
the	O
proprioceptive	O
organs	O
.	O

Based	O
on	O
analytic	O
precisions	O
,	O
a	O
+	O
/	O
-	O
2	O
%	O
urine	O
-	O
plasma	O
difference	O
was	O
set	O
as	O
the	O
cut	O
-	O
off	O
value	O
.	O

Prior	O
to	O
meals	O
2	O
to	O
3	O
times	O
daily	O
,	O
1	O
-	O
2	O
tablespoons	O
of	O
Alzoon	O
are	O
recommended	O
.	O

The	O
expression	O
of	O
alpha	B-GENE
-	I-GENE
amylase	I-GENE
can	O
be	O
transactivated	O
by	O
the	O
transcription	O
factor	O
GAMyb	B-GENE
,	O
which	O
is	O
itself	O
induced	O
by	O
GA	O
.	O

If	O
facilities	O
for	O
measurements	O
of	O
O2	O
consumption	O
and	O
hence	O
metabolic	O
rate	O
are	O
available	O
,	O
these	O
should	O
be	O
utilized	O
.	O

Furthermore	O
,	O
transfection	O
of	O
cells	O
with	O
the	O
spacer	O
-	O
RING	O
domain	O
alone	O
suppressed	O
the	O
antiapoptotic	O
function	O
of	O
the	O
N	O
-	O
terminal	O
BIR	B-GENE
domain	O
of	O
c	B-GENE
-	I-GENE
IAP1	I-GENE
and	O
induced	O
apoptosis	O
.	O

Mutually	O
exclusive	O
interaction	O
of	O
the	O
adenovirus	B-GENE
E4	I-GENE
-	I-GENE
6	I-GENE
/	I-GENE
7	I-GENE
protein	I-GENE
and	O
the	O
retinoblastoma	B-GENE
gene	I-GENE
product	I-GENE
with	O
internal	O
domains	O
of	O
E2F	B-GENE
-	I-GENE
1	I-GENE
and	O
DP	B-GENE
-	I-GENE
1	I-GENE
.	O

Comparable	O
amounts	O
of	O
alpha	B-GENE
5	I-GENE
beta	I-GENE
1	I-GENE
integrin	I-GENE
were	O
isolated	O
from	O
these	O
cells	O
by	O
chromatography	O
of	O
detergent	O
extracts	O
on	O
a	O
fibronectin	B-GENE
cell	O
-	O
binding	O
fragment	O
affinity	O
column	O
and	O
elution	O
with	O
EDTA	O
.	O

Under	O
the	O
same	O
hematocrit	O
and	O
flow	O
conditions	O
,	O
the	O
rate	O
of	O
oxygen	O
saturation	O
decrease	O
was	O
significantly	O
higher	O
for	O
the	O
sickle	O
cells	O
than	O
for	O
normal	O
cells	O
.	O

Sequence	O
analysis	O
revealed	O
significant	O
differences	O
between	O
the	O
5	O
'	O
region	O
of	O
the	O
beta	O
subunit	O
gene	O
and	O
the	O
corresponding	O
regions	O
of	O
the	O
homologous	B-GENE
GlyR	I-GENE
alpha	I-GENE
subunit	I-GENE
genes	I-GENE
;	O
it	O
also	O
identified	O
a	O
novel	O
exon	O
(	O
exon	O
0	O
)	O
that	O
encodes	O
most	O
of	O
the	O
5	O
'	O
-	O
untranslated	O
portion	O
of	O
the	O
GlyR	B-GENE
beta	I-GENE
mRNA	I-GENE
.	O

The	O
different	O
holoenzyme	B-GENE
RNA	I-GENE
polymerases	I-GENE
generated	O
upon	O
reconstituting	O
these	O
mutants	O
independently	O
with	O
core	B-GENE
RNA	I-GENE
polymerase	I-GENE
(	O
alpha2beta	B-GENE
beta	I-GENE
'	I-GENE
)	O
have	O
shown	O
reduced	O
transcriptional	O
activity	O
in	O
comparison	O
to	O
the	O
enzyme	O
containing	O
wild	B-GENE
-	I-GENE
type	I-GENE
sigma	I-GENE
factor	I-GENE
.	O

Its	O
organization	O
and	O
regulation	O
indicate	O
that	O
the	O
S	B-GENE
.	I-GENE
pombe	I-GENE
URA1	I-GENE
gene	I-GENE
product	I-GENE
appears	O
very	O
similar	O
to	O
the	O
S	B-GENE
.	I-GENE
cerevisiae	I-GENE
URA2	I-GENE
gene	I-GENE
product	I-GENE
.	O

These	O
data	O
show	O
that	O
the	O
alpha	O
-	O
helix	O
domain	O
of	O
p57	B-GENE
(	O
Kip2	B-GENE
)	O
,	O
which	O
is	O
conserved	O
in	O
the	O
Cip	B-GENE
/	O
Kip	B-GENE
proteins	O
,	O
is	O
implicated	O
in	O
protein	O
-	O
protein	O
interaction	O
and	O
confers	O
a	O
specific	O
regulatory	O
mechanism	O
,	O
outside	O
of	O
their	O
Cdk	B-GENE
-	O
inhibitory	O
activity	O
,	O
by	O
which	O
the	O
p57	B-GENE
(	O
Kip2	B-GENE
)	O
family	O
members	O
positively	O
act	O
on	O
myogenic	O
differentiation	O
.	O

Badcock	O
and	O
Westheimer	O
(	O
Spatial	O
Vision	O
1	O
(	O
1	O
)	O
,	O
3	O
-	O
11	O
,	O
1985	O
)	O
showed	O
that	O
a	O
thin	O
vertical	O
line	O
induces	O
nearby	O
zones	O
of	O
attraction	O
and	O
repulsion	O
;	O
this	O
study	O
extends	O
those	O
results	O
by	O
more	O
closely	O
examining	O
the	O
horizontal	O
and	O
vertical	O
extents	O
of	O
the	O
repulsion	O
zone	O
and	O
by	O
using	O
an	O
illusory	O
contour	O
to	O
induce	O
repulsion	O
.	O

Because	O
the	O
human	B-GENE
Antp	I-GENE
TATAA	I-GENE
binding	I-GENE
protein	I-GENE
is	O
expressed	O
in	O
both	O
lymphoid	O
and	O
non	O
-	O
lymphoid	O
cells	O
,	O
we	O
suggest	O
that	O
this	O
homeobox	B-GENE
gene	I-GENE
has	O
evolved	O
a	O
more	O
general	O
transcriptional	O
regulatory	O
function	O
in	O
higher	O
eukaryotic	O
cells	O
.	O

The	O
pyrR	B-GENE
and	O
pyrP	B-GENE
genes	I-GENE
encoded	O
polypeptides	O
with	O
calculated	O
molecular	O
masses	O
of	O
19	O
.	O
9	O
and	O
45	O
.	O
2	O
kDa	O
,	O
respectively	O
.	O

Instead	O
,	O
they	O
contained	O
dendritic	O
cells	O
that	O
express	O
melanogenic	O
marker	O
proteins	O
such	O
as	O
tyrosinase	B-GENE
and	O
tyrosinase	B-GENE
-	I-GENE
related	I-GENE
protein	I-GENE
1	I-GENE
.	O

Since	O
AP	B-GENE
-	I-GENE
1	I-GENE
is	O
an	O
important	O
mediator	O
of	O
tumor	O
promoter	O
action	O
,	O
these	O
findings	O
may	O
explain	O
the	O
anti	O
-	O
tumor	O
-	O
promoting	O
activity	O
of	O
phenolic	O
antioxidants	O
.	O

Mean	O
fluorosis	O
scores	O
,	O
however	O
,	O
were	O
similar	O
.	O

The	O
RAT3	B-GENE
gene	I-GENE
encodes	O
an	O
1157	O
-	O
amino	O
acid	O
protein	O
without	O
similarity	O
to	O
other	O
known	O
proteins	O
.	O

All	O
four	O
domains	O
were	O
linked	O
via	O
proline	O
-	O
threonine	O
-	O
rich	O
peptides	O
.	O

Viruses	O
were	O
isolated	O
from	O
9	O
lungs	O
:	O
7	O
with	O
PI	O
-	O
3V	O
,	O
1	O
with	O
NCP	O
BVDV	O
type	O
1	O
,	O
and	O
1	O
with	O
both	O
BVHV	O
-	O
1	O
and	O
BVDV	O
.	O

Demonstration	O
of	O
tissue	O
lesions	O
after	O
intramuscular	O
injection	O
by	O
determination	O
of	O
creatine	B-GENE
kinase	I-GENE
in	O
blood	O

Most	O
strains	O
(	O
95	O
%	O
)	O
of	O
S	O
.	O
lugdunensis	O
produced	O
a	O
delta	B-GENE
hemolysin	I-GENE
like	O
that	O
seen	O
with	O
nine	O
other	O
species	O
of	O
CNS	O
.	O

The	O
promoter	O
was	O
stimulated	O
8	O
-	O
20	O
-	O
fold	O
by	O
phorbol	O
esters	O
accounting	O
for	O
the	O
previously	O
observed	O
transcriptional	O
activation	O
of	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
beta	I-GENE
.	O

Previously	O
,	O
we	O
reported	O
that	O
scanthrough	O
translation	O
,	O
where	O
the	O
initiating	O
AUG	O
of	O
a	O
primary	O
open	O
reading	O
frame	O
is	O
bypassed	O
,	O
is	O
most	O
likely	O
to	O
account	O
for	O
the	O
presentation	O
of	O
cryptic	O
epitopes	O
from	O
alternative	O
reading	O
frames	O
within	O
the	O
influenza	B-GENE
A	I-GENE
PR	I-GENE
/	I-GENE
8	I-GENE
/	I-GENE
34	I-GENE
nucleoprotein	I-GENE
gene	I-GENE
.	O

SCOB	O
testing	O
of	O
food	O
-	O
restricted	O
animals	O
,	O
using	O
a	O
multiple	O
fixed	O
ratio	O
(	O
FR	O
)	O
/	O
fixed	O
interval	O
(	O
FI	O
)	O
schedule	O
(	O
FR20	O
:	O
FI120	O
)	O
,	O
was	O
conducted	O
prior	O
to	O
each	O
exposure	O
to	O
maintain	O
the	O
operant	O
behavior	O
;	O
the	O
data	O
from	O
Weeks	O
-	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
13	O
were	O
evaluated	O
for	O
evidence	O
of	O
neurotoxicity	O
.	O

Higher	O
fasting	O
serum	O
gastrin	B-GENE
concentration	O
(	O
102	O
.	O
0	O
+	O
/	O
-	O
21	O
.	O
1	O
vs	O
63	O
.	O
3	O
+	O
/	O
-	O
8	O
.	O
3	O
ng	O
.	O
l	O
-	O
1	O
)	O
,	O
and	O
greater	O
postprandial	O
gastrin	B-GENE
release	O
(	O
AUC0	O
-	O
120	O
:	O
16690	O
+	O
/	O
-	O
2648	O
vs	O
10654	O
+	O
/	O
-	O
1283	O
ng	O
.	O
l	O
-	O
1	O
min	O
)	O
were	O
observed	O
after	O
VTP	O
-	O
HM	O
than	O
after	O
VTP	O
-	O
Cas	O
.	O

Mutations	O
within	O
conserved	O
region	O
2	O
(	O
CR2	O
)	O
of	O
E1A	B-GENE
that	O
inhibit	O
the	O
binding	O
of	O
E1A	B-GENE
to	O
the	O
retinoblastoma	B-GENE
gene	I-GENE
product	I-GENE
(	O
pRb	B-GENE
)	O
further	O
enhanced	O
the	O
stimulation	O
of	O
transcription	O
from	O
the	O
PEPCK	B-GENE
promoter	I-GENE
by	O
2	O
3	O
-	O
fold	O
compared	O
with	O
wild	B-GENE
type	I-GENE
E1A	I-GENE
.	O

Several	O
of	O
the	O
exon	O
boundaries	O
correspond	O
to	O
the	O
boundaries	O
of	O
functional	O
domains	O
in	O
the	O
p55	B-GENE
protein	I-GENE
.	O

It	O
is	O
thus	O
one	O
of	O
the	O
key	O
enzymes	O
involved	O
in	O
the	O
triiodothyronine	O
-	O
mediated	O
control	O
of	O
growth	O
,	O
differentiation	O
and	O
basal	O
metabolism	O
in	O
vertebrates	O
.	O

We	O
used	O
stored	O
plasma	O
samples	O
from	O
409	O
patients	O
in	O
the	O
National	O
Institute	O
of	O
Neurological	O
Diseases	O
and	O
Stroke	O
(	O
NINDS	O
)	O
tissue	B-GENE
plasminogen	I-GENE
activator	I-GENE
(	O
t	B-GENE
-	I-GENE
PA	I-GENE
)	O
Stroke	O
Trial	O
to	O
examine	O
the	O
relationship	O
between	O
an	O
apolipoprotein	B-GENE
(	I-GENE
Apo	I-GENE
)	I-GENE
E2	I-GENE
or	O
an	O
Apo	B-GENE
E4	I-GENE
phenotype	O
and	O
a	O
favorable	O
outcome	O
3	O
months	O
after	O
stroke	O
,	O
the	O
risk	O
of	O
intracerebral	O
hemorrhage	O
,	O
and	O
the	O
response	O
to	O
intravenous	O
t	B-GENE
-	I-GENE
PA	I-GENE
therapy	O
.	O

Mapping	O
of	O
intracellular	O
localization	O
domains	O
and	O
evidence	O
for	O
colocalization	O
interactions	O
between	O
the	O
IE110	B-GENE
and	O
IE175	B-GENE
nuclear	O
transactivator	O
proteins	O
of	O
herpes	O
simplex	O
virus	O
.	O

The	O
Stryker	O
frame	O
modification	O
to	O
the	O
standard	O
Dornier	O
HM3	O
lithotriptor	O
allows	O
for	O
improved	O
visualization	O
and	O
easier	O
localization	O
of	O
distal	O
ureteral	O
calculi	O
compared	O
to	O
the	O
standard	O
gantry	O
.	O

Vimentin	B-GENE
positivity	O
was	O
noted	O
in	O
the	O
undifferentiated	O
and	O
fibroblastic	O
components	O
.	O

Both	O
immunophilins	B-GENE
may	O
have	O
important	O
roles	O
in	O
receptor	O
assembly	O
and	O
may	O
represent	O
a	O
new	O
category	O
of	O
ligand	O
-	O
and	O
calcium	O
-	O
dependent	O
modulators	O
of	O
protein	O
function	O
.	O

Cytohesin	B-GENE
-	I-GENE
1	I-GENE
,	O
a	O
protein	O
abundant	O
in	O
cells	O
of	O
the	O
immune	O
system	O
,	O
has	O
been	O
proposed	O
to	O
be	O
a	O
human	O
homolog	O
of	O
the	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
Sec7	I-GENE
gene	I-GENE
product	I-GENE
,	O
which	O
is	O
crucial	O
in	O
protein	O
transport	O
.	O

Increased	O
erythropoietin	B-GENE
synthesis	O
in	O
patients	O
with	O
COLD	O
or	O
left	O
heart	O
failure	O
is	O
related	O
to	O
alterations	O
in	O
renal	O
haemodynamics	O
.	O

These	O
results	O
suggest	O
that	O
Cdc42p	B-GENE
is	O
in	O
fact	O
required	O
for	O
pheromone	O
response	O
and	O
that	O
interaction	O
with	O
the	O
PAK	B-GENE
Ste20p	B-GENE
is	O
critical	O
for	O
that	O
role	O
.	O

The	O
Lp	B-GENE
mouse	I-GENE
mutant	I-GENE
provides	O
a	O
model	O
for	O
the	O
severe	O
human	O
neural	O
tube	O
defect	O
(	O
NTD	O
)	O
,	O
cranio	O
-	O
rachischisis	O
.	O

These	O
results	O
implicate	O
a	O
precursor	O
-	O
specific	O
base	O
-	O
paired	O
structure	O
involving	O
sequences	O
on	O
both	O
sides	O
of	O
the	O
mature	O
cleavage	O
site	O
in	O
the	O
3	O
'	O
processing	O
of	O
human	B-GENE
U2	I-GENE
RNA	I-GENE
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
MAP	B-GENE
kinase	I-GENE
stimulates	O
the	O
hPL	B-GENE
-	I-GENE
B	I-GENE
enhancer	I-GENE
by	O
an	O
NF	B-GENE
-	I-GENE
IL	I-GENE
-	I-GENE
6	I-GENE
-	O
dependent	O
pathway	O
.	O

The	O
discussion	O
focuses	O
primarily	O
on	O
the	O
newer	O
drugs	O
like	O
angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
inhibitors	O
,	O
alpha	B-GENE
-	I-GENE
adrenergic	I-GENE
receptor	I-GENE
blockers	O
,	O
and	O
calcium	O
antagonists	O
.	O

Specific	O
IgE	B-GENE
levels	O
decreased	O
slightly	O
,	O
but	O
always	O
remained	O
within	O
the	O
pathological	O
range	O
.	O

Two	O
patients	O
with	O
recurrent	O
tumors	O
had	O
high	O
S	O
-	O
phase	O
fractions	O
both	O
on	O
the	O
first	O
resected	O
specimens	O
and	O
at	O
the	O
time	O
of	O
the	O
second	O
operation	O
.	O

Comparison	O
of	O
immunoassay	O
kits	O
for	O
detection	O
of	O
staphylococcal	B-GENE
enterotoxins	I-GENE
produced	O
by	O
Staphylococcus	O
aureus	O

Transfection	O
analyses	O
indicated	O
that	O
the	O
expression	O
of	O
Tbxas1	B-GENE
is	O
controlled	O
by	O
a	O
short	O
(	O
70	O
-	O
bp	O
)	O
positive	O
regulatory	O
sequence	O
and	O
several	O
upstream	O
repressive	O
elements	O
.	O

Polycythemia	O
-	O
1973	O
.	O

Computer	O
analysis	O
included	O
digital	O
averaging	O
,	O
followed	O
by	O
digital	O
filtering	O
in	O
different	O
frequency	O
bands	O
in	O
order	O
to	O
determine	O
the	O
frequency	O
range	O
corresponding	O
to	O
notches	O
and	O
slurs	O
.	O

Effect	O
of	O
castration	O
on	O
pituitary	B-GENE
and	I-GENE
serum	I-GENE
LH	I-GENE
and	O
FSH	B-GENE
in	O
testosterone	O
-	O
sterilized	O
rats	O
.	O

265	O
,	O
1102	O
-	O
1110	O
)	O
.	O

Use	O
of	O
free	O
-	O
access	O
minerals	O
.	O

The	O
application	O
of	O
the	O
biotechnology	O
at	O
the	O
plants	O
for	O
treatment	O
of	O
the	O
surface	O
storm	O
waters	O
from	O
the	O
industrial	O
zone	O
Telychka	O
of	O
the	O
city	O
of	O
Kyiv	O
has	O
allowed	O
the	O
content	O
of	O
petroleum	O
in	O
water	O
dropped	O
to	O
the	O
Dnieper	O
to	O
be	O
constantly	O
reduced	O
50	O
-	O
100	O
times	O
.	O

Eight	O
cats	O
infected	O
with	O
H	O
.	O
pylori	O
were	O
used	O
in	O
the	O
study	O
.	O

After	O
a	O
year	O
of	O
planning	O
in	O
the	O
Laboratory	O
Assistants	O
'	O
School	O
in	O
Stockholm	O
:	O
new	O
education	O
for	O
laboratory	O
assistants	O
is	O
now	O
arranged	O

Substantial	O
evidence	O
supports	O
a	O
critical	O
role	O
for	O
the	O
activation	O
of	O
the	O
Raf	B-GENE
-	I-GENE
1	I-GENE
/	O
MEK	B-GENE
/	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
pathway	O
in	O
oncogenic	O
Ras	B-GENE
-	O
mediated	O
transformation	O
.	O

The	O
amino	O
acid	O
sequence	O
alignment	O
of	O
TC	B-GENE
II	I-GENE
with	O
that	O
of	O
other	O
Cbl	B-GENE
binding	I-GENE
proteins	I-GENE
(	O
rat	B-GENE
intrinsic	I-GENE
factor	I-GENE
,	O
human	B-GENE
transcobalamin	I-GENE
I	I-GENE
and	O
porcine	B-GENE
haptocorrin	I-GENE
)	O
revealed	O
only	O
33	O
%	O
overall	O
homology	O
.	O

A	O
reciprocal	O
binding	O
assay	O
using	O
IM	O
-	O
9	O
cells	O
as	O
a	O
source	O
of	O
SHP	B-GENE
-	I-GENE
1	I-GENE
and	O
SHP	B-GENE
-	I-GENE
2	I-GENE
revealed	O
specific	O
association	O
of	O
SHP	B-GENE
-	I-GENE
2	I-GENE
(	O
but	O
not	O
SHP	B-GENE
-	I-GENE
1	I-GENE
)	O
with	O
a	O
glutathione	B-GENE
S	I-GENE
-	I-GENE
transferase	I-GENE
fusion	I-GENE
incorporating	O
GHR	B-GENE
cytoplasmic	I-GENE
domain	I-GENE
residues	I-GENE
485	I-GENE
-	I-GENE
620	I-GENE
,	O
but	O
only	O
if	O
the	O
fusion	O
was	O
first	O
rendered	O
tyrosine	O
-	O
phosphorylated	O
.	O

Several	O
mutations	O
disrupted	O
the	O
endonuclease	O
and	O
helicase	B-GENE
activities	O
;	O
however	O
,	O
only	O
one	O
amino	B-GENE
-	I-GENE
terminal	I-GENE
-	I-GENE
charge	I-GENE
cluster	I-GENE
mutant	I-GENE
protein	I-GENE
(	O
D40A	O
-	O
D42A	O
-	O
D44A	O
)	O
completely	O
lost	O
AAV	O
hairpin	O
DNA	O
binding	O
activity	O
.	O

The	O
antinociceptive	O
properties	O
,	O
as	O
measured	O
by	O
the	O
tail	O
-	O
flick	O
and	O
hot	O
-	O
plate	O
tests	O
,	O
and	O
the	O
motor	O
effects	O
of	O
an	O
intrathecally	O
-	O
administered	O
benzodiazepine	O
agonist	O
midazolam	O
,	O
alone	O
,	O
and	O
in	O
combination	O
with	O
morphine	O
,	O
was	O
examined	O
in	O
rats	O
.	O

Insulin	B-GENE
-	I-GENE
like	I-GENE
growth	I-GENE
factor	I-GENE
1	I-GENE
(	O
IGF	B-GENE
-	I-GENE
1	I-GENE
)	O
in	O
burn	O
patients	O
.	O

The	O
84	B-GENE
.	I-GENE
1C	I-GENE
mAb	I-GENE
recognizes	O
a	O
site	O
on	O
IgE	B-GENE
which	O
is	O
identical	O
or	O
very	O
close	O
to	O
the	O
Fc	B-GENE
epsilon	I-GENE
R	I-GENE
binding	I-GENE
site	I-GENE
,	O
and	O
95	O
.	O
3	O
recognizes	O
a	O
site	O
on	O
IgE	B-GENE
which	O
is	O
related	O
,	O
but	O
not	O
identical	O
to	O
the	O
Fc	B-GENE
epsilon	I-GENE
R	I-GENE
binding	I-GENE
site	I-GENE
.	O

The	O
models	O
were	O
tested	O
by	O
studying	O
their	O
response	O
to	O
disturbances	O
of	O
the	O
afferent	O
signal	O
from	O
the	O
bladder	O
.	O

Abrogation	O
of	O
p53	B-GENE
function	O
by	O
E6	B-GENE
resulted	O
in	O
an	O
increase	O
in	O
the	O
spontaneous	O
mutation	O
frequencies	O
at	O
the	O
heterozygous	O
thymidine	B-GENE
kinase	I-GENE
(	O
TK	B-GENE
)	O
locus	O
but	O
not	O
at	O
the	O
hemizygous	O
hypoxanthine	B-GENE
phosphoribosyl	I-GENE
transferase	I-GENE
(	O
HPRT	B-GENE
)	O
locus	O
.	O

CONCLUSIONS	O
:	O
ChromaFlo	O
-	O
enhanced	O
IVUS	O
demonstrates	O
colorized	O
blood	O
flow	O
inside	O
the	O
vessel	O
lumen	O
,	O
which	O
is	O
helpful	O
in	O
distinguishing	O
echolucent	O
disease	O
from	O
luminal	O
blood	O
flow	O
and	O
can	O
also	O
be	O
used	O
to	O
perform	O
peripheral	O
interventions	O
in	O
patients	O
with	O
renal	O
failure	O
or	O
allergy	O
,	O
avoiding	O
the	O
use	O
of	O
contrast	O
media	O
.	O

In	O
contrast	O
to	O
the	O
selective	O
expression	O
of	O
the	O
receptor	O
,	O
FL	B-GENE
expression	O
was	O
detected	O
in	O
90	O
-	O
100	O
%	O
of	O
the	O
various	O
cell	O
types	O
of	O
leukemia	O
cell	O
lines	O
from	O
all	O
hematopoietic	O
cell	O
lineages	O
.	O

The	O
cDNA	O
has	O
an	O
open	O
reading	O
frame	O
of	O
900	O
amino	O
acids	O
capable	O
of	O
encoding	O
a	O
97	O
-	O
kDa	O
protein	O
.	O

Antihistamines	O
in	O
asthma	O
.	O

In	O
view	O
of	O
the	O
presence	O
of	O
SECIS	O
elements	O
in	O
the	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
of	O
bacterial	B-GENE
selenoproteins	I-GENE
,	O
we	O
examine	O
the	O
effects	O
in	O
the	O
type	B-GENE
1	I-GENE
deiodinase	I-GENE
of	O
extending	O
the	O
ORF	O
into	O
the	O
SECIS	O
element	O
,	O
and	O
find	O
that	O
this	O
dramatically	O
inhibits	O
SECIS	O
function	O
.	O

In	O
the	O
8	O
patients	O
the	O
difference	O
betweent	O
he	O
mean	O
diastolic	O
values	O
of	O
delta	O
PU	O
and	O
delta	O
PM	O
was	O
-	O
0	O
.	O
54	O
+	O
/	O
-	O
1	O
.	O
0	O
(	O
SD	O
)	O
mmHg	O
.	O

For	O
immunological	O
methods	O
,	O
identification	O
of	O
such	O
antigens	O
with	O
intermolecular	O
variability	O
,	O
e	O
.	O
g	O
.	O
,	O
the	O
structural	O
aescin	O
analogs	O
,	O
is	O
of	O
unknown	O
validity	O
.	O

CONCLUSION	O
:	O
The	O
MTD	O
for	O
CPT	O
-	O
11	O
administered	O
in	O
a	O
3	O
consecutive	O
-	O
days	O
-	O
every	O
-	O
3	O
weeks	O
schedule	O
in	O
this	O
patient	O
population	O
is	O
115	O
mg	O
/	O
m2	O
/	O
day	O
.	O

The	O
hormonal	O
response	O
to	O
a	O
standardized	O
bicycle	O
exercise	O
test	O
was	O
studied	O
in	O
11	O
male	O
cadets	O
exposed	O
to	O
a	O
course	O
of	O
107	O
h	O
of	O
continuous	O
activity	O
with	O
less	O
than	O
2	O
h	O
sleep	O
.	O

Under	O
our	O
conditions	O
,	O
the	O
combination	O
O3	O
/	O
UV	O
did	O
not	O
improve	O
the	O
degradation	O
rate	O
obtained	O
by	O
ozonation	O
.	O

A	O
second	O
important	O
molecule	O
in	O
TCR	B-GENE
signal	O
transduction	O
is	O
the	O
guanine	B-GENE
nucleotide	I-GENE
binding	I-GENE
protein	I-GENE
,	O
p21ras	B-GENE
,	O
which	O
is	O
coupled	O
to	O
the	O
TCR	B-GENE
by	O
a	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
dependent	O
mechanism	O
.	O

However	O
,	O
while	O
the	O
sequence	O
similarity	O
between	O
the	O
membrane	O
exons	O
of	O
avian	B-GENE
mIgY	I-GENE
and	O
mammalian	B-GENE
mIgG	I-GENE
and	I-GENE
IgE	I-GENE
is	O
striking	O
,	O
the	O
overall	O
similarity	O
with	O
Xenopus	B-GENE
mIgY	I-GENE
is	O
very	O
low	O
.	O

2	O
)	O
The	O
time	O
-	O
sharing	O
principle	O
was	O
applied	O
to	O
gain	O
high	O
stability	O
.	O

The	O
contribution	O
that	O
alternative	O
splicing	O
events	O
in	O
c	B-GENE
-	I-GENE
myb	I-GENE
expression	O
may	O
make	O
on	O
c	B-GENE
-	I-GENE
myb	I-GENE
function	O
remains	O
to	O
be	O
elucidated	O
.	O

The	O
Nostoc	O
petBD	B-GENE
genes	I-GENE
are	O
not	O
closely	O
linked	O
to	O
the	O
psbB	B-GENE
gene	I-GENE
(	O
encoding	O
the	O
51	O
-	O
kDa	O
photosystem	B-GENE
II	I-GENE
polypeptide	I-GENE
)	O
and	O
do	O
not	O
contain	O
introns	O
as	O
do	O
the	O
closely	O
related	O
chloroplast	O
genes	O
.	O

The	O
first	O
case	O
of	O
HCV	O
seroconversion	O
in	O
Portugal	O
after	O
the	O
introduction	O
of	O
HCV	O
NAT	O
screening	O
.	O

Detection	O
of	O
exercise	O
-	O
induced	O
asynergy	O
by	O
M	O
-	O
mode	O
echocardiography	O
.	O

Colorectal	O
cancer	O
was	O
shown	O
to	O
disproportionately	O
overburden	O
Ashkenazi	O
Jews	O
,	O
who	O
may	O
also	O
be	O
at	O
increased	O
risk	O
for	O
ovarian	O
,	O
pancreatic	O
and	O
stomach	O
cancer	O
,	O
and	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

Statins	B-GENE
:	O
lower	O
lipids	O
and	O
better	O
bones	O
?	O

Although	O
statins	O
are	O
widely	O
used	O
as	O
cholesterol	O
-	O
lowering	O
drugs	O
,	O
a	O
recent	O
study	O
suggests	O
that	O
these	O
compounds	O
have	O
anabolic	O
effects	O
on	O
bone	O
and	O
could	O
be	O
developed	O
into	O
new	O
treatments	O
for	O
common	O
metabolic	O
bone	O
diseases	O
such	O
as	O
osteoporosis	O

We	O
propose	O
a	O
model	O
in	O
which	O
Sro7	B-GENE
function	O
is	O
involved	O
in	O
the	O
targeting	O
of	O
the	O
myosin	B-GENE
proteins	I-GENE
to	O
their	O
intrinsic	O
pathways	O
.	O

A	O
study	O
of	O
chromosomes	O
of	O
lymphocytes	O
from	O
patients	O
treated	O
with	O
hycanthone	O
.	O

The	O
rate	O
of	O
enzymic	O
stimulation	O
induced	O
by	O
a	O
given	O
nitrate	O
correlates	O
closely	O
with	O
the	O
rate	O
of	O
measured	O
NO	O
production	O
from	O
the	O
nitrate	O
molecule	O
.	O

We	O
conclude	O
that	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
telomere	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
,	O
like	O
many	O
transcription	O
factors	O
,	O
has	O
separable	O
DNA	O
-	O
binding	O
and	O
protein	O
-	O
protein	O
interaction	O
domains	O
.	O

The	O
calcium	O
requirement	O
for	O
hypothermic	O
storage	O
of	O
the	O
cardiac	O
explant	O
.	O

A	O
subset	O
of	O
these	O
DMP1	B-GENE
recognition	I-GENE
sequences	I-GENE
containing	O
a	O
GGA	O
trinucleotide	O
core	O
can	O
also	O
function	O
as	O
Ets	B-GENE
-	I-GENE
responsive	I-GENE
elements	I-GENE
.	O

However	O
,	O
by	O
immobilized	O
metal	O
affinity	O
chromatography	O
assay	O
,	O
self	O
-	O
association	O
of	O
PR	B-GENE
-	I-GENE
A	I-GENE
was	O
3	O
.	O
5	O
-	O
fold	O
more	O
efficient	O
than	O
that	O
of	O
either	O
the	O
DhLBD	O
or	O
hLBD	O
constructs	O
.	O

A	O
large	O
deletion	O
in	O
the	O
CTD	B-GENE
-	I-GENE
binding	I-GENE
motif	I-GENE
blocks	O
down	O
-	O
regulation	O
but	O
does	O
not	O
affect	O
the	O
essential	O
function	O
of	O
Nrd1	B-GENE
.	O

Modeling	O
also	O
revealed	O
a	O
very	O
hydrophobic	O
surface	O
due	O
to	O
the	O
absence	O
of	O
H12	O
,	O
exposing	O
residues	O
from	O
H3	O
,	O
loop	O
3	O
-	O
4	O
,	O
H4	O
,	O
and	O
H11	O
.	O

These	O
similarities	O
suggest	O
that	O
these	O
E2	B-GENE
proteins	I-GENE
are	O
structurally	O
and	O
evolutionarily	O
related	O
.	O

Anti	B-GENE
-	I-GENE
CRK	I-GENE
antibodies	I-GENE
detect	O
a	O
53kDa	O
protein	O
in	O
extracts	O
of	O
C	O
.	O
fasciculata	O
in	O
agreement	O
with	O
the	O
size	O
predicted	O
from	O
the	O
nucleotide	O
sequence	O
of	O
the	O
cloned	O
gene	O
.	O

When	O
two	O
-	O
dimensional	O
polyacrylamide	O
gel	O
electrophoretic	O
patterns	O
of	O
[	O
35S	O
]	O
methionine	O
-	O
labeled	O
proteins	O
secreted	O
from	O
cells	O
infected	O
with	O
parental	O
and	O
recombinant	O
viruses	O
were	O
compared	O
,	O
a	O
spot	O
missing	O
from	O
the	O
latter	O
corresponded	O
in	O
molecular	O
weigh	O
and	O
isoelectric	O
point	O
with	O
that	O
predicted	O
from	O
the	O
N1L	B-GENE
ORF	I-GENE
.	O

Secretory	B-GENE
IgA	I-GENE
and	O
serum	B-GENE
immunoglobulins	I-GENE
as	O
indices	O
of	O
the	O
local	O
immunity	O
of	O
the	O
intestinal	O
mucosa	O
in	O
acute	O
leukemias	O

A	O
20	O
-	O
base	O
pair	O
oligonucleotide	O
containing	O
this	O
nonamer	O
confers	O
up	O
-	O
regulation	O
by	O
hypoxia	O
and	O
inhibition	O
by	O
unsaturated	O
fatty	O
acids	O
when	O
placed	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
in	O
a	O
lacZ	B-GENE
reporter	I-GENE
construct	I-GENE
.	O

Fecal	O
samples	O
were	O
collected	O
at	O
the	O
beginning	O
and	O
end	O
of	O
each	O
trial	O
period	O
and	O
were	O
analyzed	O
for	O
gastrointestinal	O
nematode	O
eggs	O
and	O
Giardia	O
cyst	O
.	O

The	O
MET4	B-GENE
gene	O
was	O
cloned	O
,	O
and	O
its	O
sequence	O
reveals	O
that	O
it	O
encodes	O
a	O
protein	O
related	O
to	O
the	O
family	O
of	O
the	O
bZIP	B-GENE
transcriptional	I-GENE
activators	I-GENE
.	O

Immunofluorescence	O
studies	O
in	O
C2C12	O
myotubes	O
show	O
that	O
Smad2	B-GENE
and	O
MEF2A	B-GENE
co	O
-	O
localise	O
in	O
the	O
nucleus	O
of	O
multinuclear	O
myotubes	O
during	O
differentiation	O
.	O

Tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
signaling	O
to	O
stress	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
SAPK	B-GENE
)	O
/	O
Jun	B-GENE
NH2	I-GENE
-	I-GENE
terminal	I-GENE
kinase	I-GENE
(	O
JNK	B-GENE
)	O
and	O
p38	B-GENE
.	O

Inefficacy	O
of	O
phosphine	O
fumigation	O
against	O
ticks	O
.	O

The	O
tumor	B-GENE
-	I-GENE
suppressor	I-GENE
protein	I-GENE
p53	I-GENE
is	O
involved	O
in	O
maintaining	O
genomic	O
stability	O
.	O

Gel	O
filtration	O
and	O
co	O
-	O
immunoprecipitation	O
analyses	O
reveal	O
that	O
Mad2p	B-GENE
tightly	O
associates	O
with	O
another	O
spindle	O
checkpoint	O
component	O
,	O
Mad1p	B-GENE
.	O

Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
from	O
somatic	O
cell	O
hybrids	O
showed	O
that	O
endothelial	B-GENE
-	I-GENE
TACC	I-GENE
-	I-GENE
related	I-GENE
cDNA	I-GENE
maps	O
to	O
chromosome	O
10	O
.	O

AMY	B-GENE
-	I-GENE
1	I-GENE
was	O
localized	O
in	O
the	O
cytoplasm	O
in	O
cells	O
expressing	O
c	B-GENE
-	I-GENE
myc	I-GENE
at	O
low	O
levels	O
,	O
but	O
in	O
the	O
nucleus	O
in	O
the	O
cells	O
of	O
a	O
high	O
c	B-GENE
-	I-GENE
myc	I-GENE
expression	O
in	O
transiently	O
transfected	O
cells	O
.	O

The	O
paramyxovirus	B-GENE
fusion	I-GENE
(	I-GENE
F	I-GENE
)	I-GENE
protein	I-GENE
mediates	O
membrane	O
fusion	O
.	O

This	O
region	O
of	O
hsp90	B-GENE
mediates	O
ATP	O
-	O
independent	O
chaperone	O
activity	O
,	O
overlaps	O
the	O
hsp90	B-GENE
dimerization	I-GENE
domain	I-GENE
,	O
and	O
includes	O
structural	O
elements	O
important	O
for	O
steroid	B-GENE
receptor	I-GENE
interaction	O
.	O

Maternal	O
lactation	O

A	O
particularly	O
striking	O
HpaII	B-GENE
tiny	O
fragment	O
island	O
,	O
extending	O
over	O
nearly	O
2	O
,	O
000	O
base	O
pairs	O
,	O
surrounds	O
the	O
USF2	B-GENE
translation	I-GENE
initiation	I-GENE
site	I-GENE
.	O

A	O
724	O
-	O
bp	O
segment	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
consisting	O
of	O
the	O
proximal	O
E	O
-	O
box	O
flanked	O
upstream	O
by	O
a	O
mammalian	O
-	O
specific	O
352	O
-	O
bp	O
region	O
was	O
sufficient	O
for	O
maximal	O
transcriptional	O
activation	O
in	O
postconfluent	O
BC3H1	O
myoblasts	O
.	O

Comparisons	O
with	O
other	O
known	O
germins	B-GENE
and	O
germin	B-GENE
-	I-GENE
like	I-GENE
proteins	I-GENE
indicate	O
that	O
these	O
Arabidopsis	O
GLP	B-GENE
subfamilies	O
are	O
unique	O
from	O
wheat	O
germin	B-GENE
.	O

Also	O
,	O
the	O
amplitude	O
of	O
the	O
oscillatory	O
potentials	O
(	O
O1	O
+	O
O2	O
+	O
O3	O
+	O
O4	O
)	O
was	O
significantly	O
reduced	O
in	O
the	O
early	O
postoperative	O
period	O
.	O

Serum	B-GENE
insulin	I-GENE
-	I-GENE
like	I-GENE
growth	I-GENE
factor	I-GENE
I	I-GENE
(	O
IGF	B-GENE
-	I-GENE
I	I-GENE
)	O
SD	O
score	O
increased	O
from	O
-	O
2	O
.	O
2	O
and	O
-	O
4	O
.	O
2	O
in	O
men	O
and	O
women	O
,	O
respectively	O
,	O
to	O
1	O
.	O
8	O
and	O
-	O
0	O
.	O
9	O
at	O
6	O
months	O
and	O
0	O
.	O
8	O
and	O
-	O
0	O
.	O
7	O
at	O
12	O
months	O
.	O

The	O
cDNA	O
segment	O
is	O
flanked	O
by	O
the	O
immunoglobulin	B-GENE
gene	I-GENE
recombination	I-GENE
signal	I-GENE
sequences	I-GENE
so	O
that	O
the	O
cDNA	O
segment	O
can	O
invert	O
and	O
the	O
human	B-GENE
IL	I-GENE
-	I-GENE
2R	I-GENE
L	I-GENE
chain	I-GENE
is	O
subsequently	O
expressed	O
under	O
the	O
control	O
of	O
the	O
SV40	B-GENE
promoter	I-GENE
.	O

Glycemic	O
response	O
to	O
malted	O
,	O
popped	O
and	O
roller	O
dried	O
wheat	O
-	O
legume	O
based	O
foods	O
in	O
normal	O
subjects	O
.	O

Sequence	O
comparisons	O
strongly	O
suggest	O
that	O
the	O
S27a	B-GENE
and	O
the	O
ubiquitin	B-GENE
coding	O
sequences	O
found	O
in	O
the	O
genome	O
of	O
CP	O
Rit	O
were	O
both	O
derived	O
from	O
a	O
bovine	O
mRNA	O
encoding	O
a	O
hybrid	O
protein	O
with	O
the	O
structure	O
NH2	O
-	O
ubiquitin	B-GENE
-	O
S27a	B-GENE
-	O
COOH	O
.	O

The	O
previously	O
described	O
enhanced	O
translation	O
of	O
spinach	O
L12	B-GENE
mRNA	I-GENE
from	O
its	O
two	O
tandem	O
AUG	O
codons	O
and	O
the	O
two	O
functional	O
rpl12	B-GENE
genes	I-GENE
in	O
Arabidopsis	O
probably	O
provide	O
two	O
mechanisms	O
for	O
generating	O
the	O
four	O
copies	O
of	O
L12	B-GENE
/	I-GENE
chloroplast	I-GENE
ribosome	I-GENE
,	O
qualitatively	O
different	O
from	O
those	O
attempted	O
in	O
eubacteria	O
.	O

In	O
such	O
conditions	O
,	O
the	O
following	O
kinetic	O
reactions	O
have	O
been	O
studied	O
:	O
N2	O
(	O
A	O
)	O
+	O
N2	O
(	O
A	O
)	O
-	O
-	O
>	O
N2	O
(	O
C	O
,	O
B	O
,	O
V	O
'	O
)	O
+	O
N2	O
(	O
X	O
)	O
,	O
N2	O
(	O
A	O
)	O
+	O
N2	O
(	O
X	O
,	O
V	O
>	O
5	O
)	O
-	O
-	O
>	O
N2	O
(	O
X	O
)	O
+	O
N2	O
(	O
B	O
,	O
V	O
'	O
)	O
in	O
pure	O
N2	O
post	O
-	O
discharges	O
and	O
N2	O
(	O
A	O
)	O
+	O
CH4	O
-	O
-	O
>	O
products	O
,	O
C	O
+	O
N	O
+	O
M2	O
-	O
-	O
>	O
CN	O
(	O
B	O
,	O
V	O
'	O
)	O
+	O
M2	O
,	O
N2	O
(	O
X	O
,	O
V	O
>	O
4	O
)	O
+	O
CN	O
-	O
-	O
>	O
N2	O
(	O
X	O
)	O
+	O
CN	O
(	O
B	O
,	O
A	O
,	O
V	O
'	O
)	O
,	O
in	O
N2	O
-	O
1	O
%	O
CH4	O
post	O
-	O
discharges	O
.	O

Nucleotide	O
sequence	O
analysis	O
revealed	O
that	O
TAR	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
is	O
very	O
similar	O
to	O
the	O
CREB2	B-GENE
protein	I-GENE
.	O

Oncogenic	O
signalling	O
by	O
E2F1	B-GENE
has	O
recently	O
been	O
linked	O
to	O
stabilization	O
and	O
activation	O
of	O
the	O
tumour	O
suppressor	O
p53	B-GENE
(	O
refs	O
1	O
,	O
3	O
,	O
4	O
)	O
.	O

Congruent	O
with	O
empirical	O
predictions	O
,	O
the	O
most	O
homesick	O
children	O
perceived	O
low	O
control	O
over	O
homesickness	O
and	O
separation	O
,	O
and	O
coped	O
by	O
relinquishing	O
control	O
.	O

Working	O
session	O
report	O
:	O
in	O
vivo	O
-	O
in	O
vitro	O
screening	O
.	O

The	O
frequency	O
of	O
positive	O
anti	B-GENE
-	I-GENE
GM1	I-GENE
antibody	I-GENE
titers	O
in	O
the	O
Guillain	O
-	O
Barre	O
syndrome	O
patients	O
with	O
PEN	O
19	O
isolates	O
was	O
higher	O
than	O
that	O
in	O
the	O
Guillain	O
-	O
Barre	O
syndrome	O
and	O
Fisher	O
'	O
s	O
syndrome	O
patients	O
without	O
PEN	O
19	O
isolates	O
.	O

Primary	O
and	O
secondary	O
structural	O
elements	O
required	O
for	O
synthesis	O
of	O
barley	O
yellow	O
dwarf	O
virus	O
subgenomic	O
RNA1	O
.	O

TBP	B-GENE
can	O
be	O
phosphorylated	O
in	O
vitro	O
by	O
extracts	O
of	O
U937	O
cells	O
or	O
by	O
bacterially	O
expressed	O
activated	O
ERK2	B-GENE
;	O
the	O
phosphorylation	O
sites	O
were	O
mapped	O
to	O
ERK	B-GENE
kinase	I-GENE
consensus	I-GENE
sites	I-GENE
in	O
the	O
TBP	B-GENE
amino	I-GENE
-	I-GENE
terminal	I-GENE
domain	I-GENE
.	O

Although	O
RAD17	B-GENE
,	O
RAD24	B-GENE
and	O
MEC3	B-GENE
are	O
not	O
required	O
for	O
cell	O
cycle	O
arrest	O
when	O
S	O
phase	O
is	O
inhibited	O
by	O
hydroxyurea	O
(	O
HU	O
)	O
,	O
they	O
do	O
contribute	O
to	O
the	O
viability	O
of	O
yeast	O
cells	O
grown	O
in	O
the	O
presence	O
of	O
HU	O
,	O
possibly	O
because	O
they	O
are	O
required	O
for	O
the	O
repair	O
of	O
HU	O
-	O
induced	O
DNA	O
damage	O
.	O

DESIGN	O
:	O
Serum	O
aldosterone	O
and	O
plasma	B-GENE
renin	I-GENE
activity	O
were	O
measured	O
supine	O
prior	O
to	O
and	O
60	O
,	O
90	O
,	O
120	O
minutes	O
after	O
oral	O
captopril	O
,	O
25	O
mg	O
.	O

Serotonin	O
concentration	O
in	O
the	O
blood	O
of	O
patients	O
with	O
hemorrhagic	O
fever	O
with	O
renal	O
syndrome	O

We	O
report	O
the	O
construction	O
of	O
an	O
approximately	O
1	O
.	O
7	O
-	O
Mb	O
sequence	O
-	O
ready	O
YAC	O
/	O
BAC	O
clone	O
contig	O
of	O
8p22	O
-	O
p23	O
.	O

We	O
have	O
found	O
that	O
the	O
expression	O
of	O
GTPase	B-GENE
-	O
deficient	O
mutants	O
of	O
alpha	B-GENE
12	I-GENE
(	O
alpha	B-GENE
12Q229L	I-GENE
)	O
or	O
alpha	B-GENE
13	I-GENE
(	O
alpha	B-GENE
13Q226L	I-GENE
)	O
leads	O
to	O
robust	O
activation	O
of	O
the	O
Jun	B-GENE
kinase	I-GENE
/	O
stress	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
JNK	B-GENE
/	O
SAPK	B-GENE
)	O
pathway	O
.	O

The	O
abluminal	O
surface	O
is	O
often	O
almost	O
entirely	O
encircled	O
by	O
a	O
thick	O
layer	O
of	O
fibrillary	O
connective	O
tissue	O
.	O

The	O
effect	O
of	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
inhibitor	O
on	O
reperfusion	O
injury	O
of	O
the	O
brain	O
under	O
hypothermic	O
circulatory	O
arrest	O
.	O

Seven	O
of	O
these	O
had	O
counterparts	O
in	O
the	O
US	O
of	O
herpes	O
simplex	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
,	O
pseudorabies	O
virus	O
(	O
PRV	O
)	O
,	O
and	O
equine	O
herpesvirus	O
type	O
1	O
(	O
EHV	O
-	O
1	O
)	O
.	O

Deregulation	O
of	O
their	O
expression	O
may	O
contribute	O
to	O
malignant	O
transformation	O
associated	O
with	O
HTLV	O
-	O
1	O
infection	O
.	O

CONCLUSIONS	O
:	O
In	O
addition	O
to	O
the	O
superiority	O
of	O
octafluoropropane	O
-	O
filled	O
microspheres	O
to	O
air	O
-	O
filled	O
microspheres	O
for	O
LV	O
opacification	O
,	O
the	O
efficacy	O
of	O
OCTA	O
is	O
relatively	O
unaffected	O
by	O
impaired	O
LV	O
function	O
and	O
is	O
less	O
susceptible	O
to	O
the	O
effects	O
of	O
poor	O
echogenicity	O
than	O
AIR	O
.	O

The	O
effect	O
of	O
acetazolamide	O
(	O
ACZ	O
)	O
on	O
HCO3	O
-	O
and	O
Cl	O
-	O
activities	O
in	O
inner	O
ear	O
fluid	O
was	O
investigated	O
by	O
ion	O
-	O
selective	O
microelectrode	O
methods	O
.	O

Pseudomembranous	O
conjunctivitis	O
following	O
bone	O
marrow	O
transplantation	O
:	O
immunopathological	O
and	O
ultrastructural	O
study	O
of	O
one	O
case	O
.	O

In	O
support	O
of	O
this	O
interpretation	O
we	O
demonstrate	O
that	O
MQ9b	B-GENE
binds	O
strongly	O
5	O
of	O
17	O
motif	O
-	O
positive	O
,	O
pathogen	O
-	O
derived	O
synthetic	O
peptides	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
the	O
PERE	B-GENE
formed	O
three	O
major	O
complexes	O
(	O
P1	O
,	O
P2	O
and	O
P3	O
)	O
with	O
proteins	O
in	O
nuclear	O
extracts	O
from	O
HeLa	O
or	O
293	O
cells	O
.	O

We	O
also	O
review	O
the	O
role	O
of	O
grains	O
in	O
the	O
formation	O
of	O
complex	O
molecules	O
in	O
interstellar	O
molecular	O
clouds	O
.	O

99mTc	O
phytate	O
,	O
198Au	O
colloid	O
,	O
and	O
99mTc	O
antimony	O
sulfide	O
have	O
been	O
used	O
;	O
the	O
last	O
appears	O
to	O
have	O
been	O
the	O
most	O
satisfactory	O
.	O

The	O
present	O
data	O
also	O
indicate	O
that	O
patients	O
with	O
TGBM	O
nephropathy	O
often	O
have	O
concomitant	O
IgA	B-GENE
nephropathy	O
and	O
mesangial	O
proliferative	O
glomerulonephritis	O
.	O

We	O
previously	O
showed	O
that	O
this	O
proteolysis	O
1	O
)	O
can	O
be	O
acutely	O
promoted	O
by	O
the	O
phorbol	O
ester	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
2	O
)	O
requires	O
a	O
metalloprotease	B-GENE
activity	O
,	O
3	O
)	O
generates	O
both	O
shed	O
GHBP	B-GENE
and	O
a	O
membrane	B-GENE
-	I-GENE
associated	I-GENE
GHR	I-GENE
transmembrane	I-GENE
/	I-GENE
cytoplasmic	I-GENE
domain	I-GENE
remnant	O
,	O
and	O
4	O
)	O
results	O
in	O
down	O
-	O
regulation	O
of	O
GHR	B-GENE
abundance	O
and	O
GH	B-GENE
signaling	O
.	O

Praziquantel	O
and	O
Albendazole	O
were	O
found	O
effective	O
in	O
the	O
treatment	O
of	O
neurocysticercosis	O
,	O
but	O
because	O
of	O
serious	O
side	O
effects	O
encountered	O
in	O
some	O
cases	O
,	O
the	O
drugs	O
should	O
be	O
used	O
cautiously	O
in	O
selected	O
cases	O
only	O
.	O

The	O
tip	O
of	O
the	O
button	O
caused	O
a	O
perforation	O
of	O
the	O
posterior	O
stomach	O
wall	O
,	O
leading	O
to	O
death	O
.	O

Postnatal	O
volumetric	O
development	O
of	O
the	O
prefrontal	O
cortex	O
in	O
the	O
rat	O
.	O

All	O
groups	O
were	O
challenged	O
subsequently	O
with	O
naloxone	O
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
)	O
in	O
the	O
distinctive	O
environment	O
and	O
then	O
observed	O
for	O
signs	O
of	O
opiate	O
withdrawal	O
.	O

In	O
contrast	O
,	O
the	O
PPSF	O
+	O
DBP	O
side	O
showed	O
large	O
amounts	O
of	O
bone	O
formation	O
,	O
and	O
bone	O
almost	O
covered	O
the	O
implant	O
.	O

The	O
role	O
of	O
DNA	O
rearrangement	O
and	O
alternative	O
RNA	O
processing	O
in	O
the	O
expression	O
of	O
immunoglobulin	B-GENE
delta	I-GENE
genes	I-GENE
.	O

In	O
silicosis	O
,	O
significant	O
relationships	O
between	O
patients	O
and	O
sons	O
were	O
not	O
seen	O
with	O
respect	O
to	O
arterial	O
blood	O
gas	O
determinations	O
and	O
ventilatory	O
responses	O
except	O
for	O
Paco2	O
of	O
patients	O
and	O
hypercapnic	O
ventilatory	O
responses	O
of	O
sons	O
.	O

Blood	O
GSH	B-GENE
-	I-GENE
Px	I-GENE
activity	O
was	O
measured	O
with	O
a	O
spectrophotometer	O
,	O
using	O
a	O
modification	O
of	O
a	O
previously	O
described	O
assay	O
.	O

The	O
TraD	B-GENE
protein	I-GENE
(	I-GENE
83	I-GENE
,	I-GENE
899	I-GENE
Da	I-GENE
)	I-GENE
contains	O
three	O
hydrophobic	O
regions	O
,	O
of	O
which	O
two	O
are	O
located	O
near	O
the	O
amino	O
-	O
terminal	O
region	O
.	O

However	O
,	O
by	O
an	O
NS35	B-GENE
-	I-GENE
specific	I-GENE
RNA	I-GENE
capture	O
assay	O
,	O
the	O
multimers	O
were	O
shown	O
to	O
possess	O
the	O
RNA	O
-	O
binding	O
activity	O
previously	O
demonstrated	O
for	O
NS35	B-GENE
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
The	O
sexually	O
transmitted	O
diseases	O
(	O
STD	O
)	O
control	O
program	O
for	O
female	O
sex	O
workers	O
(	O
FSW	O
)	O
in	O
Lima	O
,	O
Peru	O
,	O
provided	O
periodic	O
serological	O
tests	O
for	O
syphilis	O
and	O
cervical	O
smears	O
for	O
gonococci	O
,	O
but	O
not	O
medication	O
for	O
STD	O
or	O
condoms	O
.	O

Hydrocortisone	O
seems	O
to	O
be	O
unable	O
to	O
hinder	O
the	O
postdenervation	O
changes	O
in	O
the	O
muscle	O
membrane	O
whereas	O
high	O
doses	O
of	O
the	O
hormone	O
are	O
able	O
to	O
induce	O
changes	O
in	O
the	O
muscle	O
membrane	O
.	O

RESULTS	O
:	O
An	O
herpetic	O
seroconversion	O
is	O
observed	O
with	O
presence	O
of	O
type	O
I	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
I	O
)	O
nucleic	O
acids	O
in	O
the	O
recipient	O
'	O
s	O
aqueous	O
humor	O
.	O

Sp1	B-GENE
and	O
two	O
Sp3	B-GENE
isoforms	I-GENE
were	O
detected	O
as	O
the	O
primary	O
cellular	O
constituents	O
of	O
DNA	O
-	O
protein	O
complexes	O
formed	O
with	O
the	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
-	I-GENE
proximal	I-GENE
site	I-GENE
.	O

The	O
first	O
open	O
reading	O
frame	O
of	O
the	O
blueberry	O
scorch	O
carlavirus	O
(	O
BBScV	O
)	O
genome	O
encodes	O
a	O
putative	O
replication	O
-	O
associated	O
protein	O
of	O
223	O
kDa	O
(	O
p223	B-GENE
)	O
.	O

Spontaneous	O
sensitization	O
to	O
cross	O
-	O
reacting	O
chemicals	O
in	O
a	O
proportion	O
of	O
control	O
animals	O
is	O
strongly	O
suggested	O
,	O
somewhat	O
akin	O
to	O
spontaneous	O
sensitization	O
in	O
patients	O
with	O
anaphylactoid	O
reactions	O
to	O
neuromuscular	O
blockers	O
on	O
first	O
exposure	O
,	O
and	O
in	O
whom	O
IgE	B-GENE
antibodies	I-GENE
are	O
detected	O
.	O

This	O
may	O
account	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
the	O
ability	O
of	O
excess	O
wt	B-GENE
p53	I-GENE
to	O
inhibit	O
cell	O
proliferation	O
and	O
to	O
interfere	O
with	O
neoplastic	O
processes	O
.	O

IgG	B-GENE
and	O
IgM	B-GENE
antibody	O
activity	O
was	O
determined	O
by	O
adding	O
a	O
1	O
:	O
100	O
dilution	O
of	O
serum	O
to	O
plates	O
coated	O
with	O
A60	B-GENE
antigen	I-GENE
.	O

For	O
monocytes	O
,	O
as	O
measured	O
on	O
the	O
Hematrak	O
,	O
it	O
was	O
13	O
.	O
4	O
%	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
-	O
DEDDDL	O
sequence	O
stabilizes	O
GDP	O
binding	O
to	O
Ran	B-GENE
,	O
and	O
that	O
the	O
domain	O
is	O
required	O
for	O
high	O
affinity	O
interaction	O
with	O
a	O
Ran	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
,	O
HTF9A	B-GENE
/	O
RanBP1	B-GENE
.	O

The	O
major	O
transcription	O
factors	O
controlling	O
arginine	O
metabolism	O
in	O
Escherichia	O
coli	O
and	O
Bacillus	O
subtilis	O
,	O
ArgR	B-GENE
and	O
AhrC	B-GENE
,	O
respectively	O
,	O
are	O
homologous	O
multimeric	O
proteins	O
that	O
form	O
l	O
-	O
arginine	O
-	O
dependent	O
DNA	O
-	O
binding	O
complexes	O
capable	O
of	O
repressing	O
transcription	O
of	O
the	O
biosynthetic	O
genes	O
(	O
both	O
)	O
,	O
activating	O
transcription	O
of	O
catabolic	O
genes	O
(	O
AhrC	B-GENE
only	O
)	O
or	O
facilitating	O
plasmid	O
dimer	O
resolution	O
(	O
both	O
)	O
.	O

Based	O
on	O
the	O
current	O
literature	O
,	O
the	O
mechanisms	O
involved	O
in	O
the	O
toxicity	O
of	O
OA	B-GENE
indicate	O
three	O
major	O
effects	O
:	O
(	O
1	O
)	O
inhibition	O
of	O
mitochondrial	O
respiration	O
correlated	O
with	O
a	O
depletion	O
of	O
ATP	O
;	O
(	O
2	O
)	O
inhibition	O
of	O
tRNA	B-GENE
-	I-GENE
synthetase	I-GENE
accompanied	O
by	O
a	O
reduced	O
protein	O
synthesis	O
;	O
and	O
(	O
3	O
)	O
enhanced	O
lipid	O
peroxidation	O
.	O

E2F1	B-GENE
-	O
mediated	O
transcriptional	O
inhibition	O
of	O
the	O
plasminogen	B-GENE
activator	I-GENE
inhibitor	I-GENE
type	I-GENE
1	I-GENE
gene	I-GENE
.	O

We	O
also	O
show	O
that	O
p65	B-GENE
binds	O
to	O
these	O
targets	O
with	O
almost	O
equal	O
affinity	O
and	O
that	O
different	O
residues	O
have	O
variable	O
roles	O
in	O
binding	O
different	O
kappaB	B-GENE
targets	I-GENE
.	O

The	O
RNase	B-GENE
MRP	I-GENE
RNA	I-GENE
gene	I-GENE
was	O
deleted	O
by	O
insertional	O
replacement	O
and	O
found	O
to	O
be	O
essential	O
for	O
cellular	O
viability	O
,	O
indicating	O
a	O
critical	O
nuclear	O
role	O
for	O
RNase	B-GENE
MRP	I-GENE
.	O

We	O
have	O
measured	O
the	O
MBF	O
on	O
incisors	O
and	O
its	O
direction	O
in	O
three	O
dimensions	O
for	O
different	O
jaw	O
openings	O
in	O
ten	O
subjects	O
.	O

Its	O
predicted	O
amino	O
acid	O
sequence	O
shows	O
extensive	O
homology	O
to	O
those	O
of	O
Drosophila	B-GENE
hsp70	I-GENE
,	O
trout	B-GENE
hsp70	I-GENE
,	O
Xenopus	B-GENE
hsp70	I-GENE
,	O
yeast	B-GENE
hsp70	I-GENE
,	O
and	O
some	O
homology	O
to	O
the	O
heat	B-GENE
-	I-GENE
inducible	I-GENE
dnaK	I-GENE
gene	I-GENE
product	I-GENE
of	O
Escherichia	O
coli	O
.	O

Reactivities	O
to	O
horse	B-GENE
anti	I-GENE
-	I-GENE
lymphocyte	I-GENE
globulin	I-GENE
.	O

SRE	O
activity	O
is	O
dependent	O
upon	O
the	O
activation	O
by	O
phosphorylation	O
of	O
a	O
ternary	O
complex	O
factor	O
;	O
included	O
among	O
the	O
ternary	O
complex	O
factors	O
is	O
Elk	B-GENE
-	I-GENE
1	I-GENE
.	O

Isolation	O
by	O
PCR	O
of	O
a	O
cDNA	O
clone	O
from	O
pea	O
petals	O
with	O
similarity	O
to	O
petunia	O
and	O
wheat	B-GENE
zinc	I-GENE
finger	I-GENE
proteins	I-GENE
.	O

INTERVENTIONS	O
:	O
Patients	O
received	O
rt	B-GENE
-	I-GENE
PA	I-GENE
,	O
heparin	O
,	O
and	O
aspirin	O
.	O

A	O
poor	O
correlation	O
was	O
also	O
observed	O
between	O
PbB	O
and	O
ALAD	B-GENE
activity	O
of	O
the	O
stearate	O
workers	O
.	O

Binding	O
of	O
meAda	B-GENE
is	O
necessary	O
to	O
activate	O
transcription	O
of	O
the	O
adaptive	O
response	O
genes	O
;	O
accordingly	O
,	O
in	O
vitro	O
transcription	O
of	O
aidB	B-GENE
is	O
dependent	O
on	O
the	O
presence	O
of	O
meAda	B-GENE
.	O

How	O
does	O
a	O
nurse	O
go	O
about	O
maintaining	O
her	O
level	O
of	O
competence	O
when	O
she	O
is	O
one	O
of	O
the	O
few	O
local	O
practitioners	O
in	O
her	O
field	O
?	O

Vancouver	O
sex	O
therapist	O
Bianca	O
Rucker	O
is	O
doing	O
it	O
by	O
cultivating	O
a	O
network	O
of	O
colleagues	O
and	O
mentors	O
in	O
related	O
fields	O
both	O
at	O
home	O
and	O
across	O
the	O
continent	O
.	O

Experience	O
with	O
the	O
tensor	O
fasciae	O
latae	O
free	O
flap	O
.	O

Screening	O
,	O
counseling	O
,	O
and	O
treatment	O
for	O
alcohol	O
and	O
illicit	O
drug	O
use	O
should	O
be	O
essential	O
components	O
in	O
comprehensive	O
HBP	O
care	O
.	O

These	O
findings	O
suggest	O
a	O
functional	O
cross	O
-	O
talk	O
between	O
RB	B-GENE
protein	I-GENE
and	O
p21ras	B-GENE
,	O
which	O
balances	O
the	O
cell	O
phenotype	O
between	O
normal	O
and	O
transformed	O
states	O
.	O

UDP	B-GENE
-	I-GENE
GlcNAc	I-GENE
:	O
alpha	B-GENE
-	I-GENE
6	I-GENE
-	I-GENE
D	I-GENE
-	I-GENE
mannoside	I-GENE
beta	I-GENE
-	I-GENE
1	I-GENE
,	I-GENE
2	I-GENE
-	I-GENE
N	I-GENE
-	I-GENE
acetylglucosaminyltransferase	I-GENE
II	I-GENE
(	O
GnT	B-GENE
II	I-GENE
;	O
EC	B-GENE
2	I-GENE
.	I-GENE
4	I-GENE
.	I-GENE
1	I-GENE
.	I-GENE
143	I-GENE
)	O
is	O
essential	O
for	O
the	O
normal	O
assembly	O
of	O
complex	O
Asn	O
-	O
linked	O
glycans	O
.	O

Initial	O
control	O
of	O
bleeding	O
is	O
similar	O
,	O
but	O
eradication	O
is	O
achieved	O
in	O
fewer	O
sessions	O
with	O
EVL	O
.	O

Processing	O
,	O
secretion	O
,	O
and	O
immunoreactivity	O
of	O
carboxy	B-GENE
terminally	I-GENE
truncated	I-GENE
dengue	I-GENE
-	I-GENE
2	I-GENE
virus	I-GENE
envelope	I-GENE
proteins	I-GENE
expressed	O
in	O
insect	O
cells	O
by	O
recombinant	O
baculoviruses	O
.	O

Problems	O
common	O
to	O
pediatrics	O
and	O
anesthesiology	O

GH	B-GENE
failed	O
to	O
stimulate	O
phosphorylation	O
or	O
activation	O
of	O
Jun	B-GENE
N	I-GENE
-	I-GENE
terminal	I-GENE
kinase	I-GENE
under	O
the	O
conditions	O
used	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
controlled	O
trials	O
where	O
adults	O
with	O
schizophrenia	O
or	O
similar	O
illnesses	O
were	O
randomised	O
to	O
quetiapine	O
,	O
placebo	O
or	O
other	O
neuroleptic	O
drugs	O
and	O
where	O
clinically	O
relevant	O
outcomes	O
were	O
reported	O
.	O

The	O
ERH	B-GENE
expression	O
profile	O
is	O
similar	O
,	O
to	O
that	O
of	O
An3	B-GENE
,	O
which	O
localizes	O
to	O
the	O
animal	O
hemisphere	O
of	O
oocytes	O
and	O
is	O
abundantly	O
expressed	O
in	O
the	O
embryo	O
.	O

Three	O
subgenomes	O
also	O
comprised	O
15	O
to	O
75	O
nucleotides	O
derived	O
from	O
the	O
5	O
'	O
part	O
of	O
the	O
NS2	B-GENE
gene	I-GENE
.	O

Results	O
of	O
the	O
recognition	O
task	O
revealed	O
significant	O
effects	O
of	O
consonant	O
voicing	O
,	O
position	O
and	O
vowel	O
context	O
on	O
syllable	O
recognition	O
.	O

Effect	O
of	O
variations	O
in	O
time	O
interval	O
between	O
treatment	O
with	O
BCG	O
and	O
quartz	O
dust	O
on	O
translocation	O
of	O
quartz	O
dust	O
from	O
the	O
lungs	O
to	O
their	O
regional	O
lymph	O
nodes	O
.	O

It	O
is	O
,	O
however	O
,	O
extremely	O
homologous	O
to	O
a	O
third	O
'	O
non	O
-	O
classical	O
'	O
gene	O
,	O
HLA	B-GENE
-	I-GENE
5	I-GENE
.	I-GENE
4	I-GENE
,	O
and	O
to	O
the	O
chimpanzee	O
gene	O
,	O
Ch28	B-GENE
.	O

Stylohyoid	O
chain	O
ossification	O
:	O
choice	O
of	O
the	O
surgical	O
approach	O
.	O

The	O
p130	B-GENE
and	O
p62	B-GENE
tyrosine	O
-	O
phosphorylated	O
proteins	O
that	O
complexed	O
v	B-GENE
-	I-GENE
Src	I-GENE
SH2	B-GENE
in	O
vitro	O
also	O
associated	O
with	O
v	B-GENE
-	I-GENE
Src	I-GENE
in	O
v	B-GENE
-	I-GENE
src	I-GENE
-	O
transformed	O
Rat	O
-	O
2	O
cells	O
;	O
this	O
in	O
vivo	O
binding	O
was	O
dependent	O
on	O
the	O
v	B-GENE
-	I-GENE
Src	I-GENE
SH2	B-GENE
domain	O
.	O

A	O
polymorphic	O
bipartite	O
motif	O
signals	O
nuclear	O
targeting	O
of	O
early	O
auxin	O
-	O
inducible	O
proteins	O
related	O
to	O
PS	B-GENE
-	I-GENE
IAA4	I-GENE
from	I-GENE
pea	I-GENE
(	I-GENE
Pisum	I-GENE
sativum	I-GENE
)	I-GENE
.	O

OBJECTIVE	O
:	O
This	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
common	O
cause	O
of	O
asthenopia	O
,	O
mixed	O
astigmatism	O
.	O

Uptake	O
of	O
ofloxacin	O
by	O
Escherichia	O
coli	O

Previously	O
,	O
we	O
showed	O
that	O
the	O
APRE	O
is	O
a	O
cytokine	O
[	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
-	I-GENE
alpha	I-GENE
(	O
TNFalpha	B-GENE
)	O
]	O
-	O
inducible	O
enhancer	O
by	O
binding	O
the	O
heterodimeric	B-GENE
nuclear	I-GENE
factor	I-GENE
-	I-GENE
kappaB	I-GENE
(	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
)	O
complex	O
Rel	B-GENE
A	I-GENE
x	O
NF	B-GENE
-	I-GENE
kappaB1	I-GENE
.	O

Of	O
the	O
remaining	O
seven	O
,	O
five	O
reacted	O
either	O
with	O
immediate	O
and	O
strong	O
symptoms	O
or	O
had	O
spontaneously	O
reduced	O
gluten	B-GENE
intake	O
,	O
or	O
had	O
an	O
acquired	O
IgA	B-GENE
deficiency	O
.	O

The	O
possible	O
roles	O
of	O
HRMT1L1	B-GENE
and	O
HRMT1L2	B-GENE
in	O
human	O
disease	O
are	O
currently	O
unknown	O
.	O

None	O
of	O
the	O
cystometrograms	O
showed	O
uninhibited	O
detrusor	O
contractions	O
.	O

Independent	O
splicing	O
events	O
involve	O
three	O
previously	O
described	O
cassette	O
exons	O
,	O
which	O
are	O
predicted	O
to	O
encode	O
most	O
of	O
the	O
second	O
transmembrane	O
domain	O
.	O

As	O
no	O
complete	O
PPARgamma	B-GENE
antagonists	O
have	O
been	O
described	O
hitherto	O
,	O
we	O
have	O
constructed	O
a	O
dominant	O
-	O
negative	O
mutant	O
receptor	O
to	O
inhibit	O
wild	O
-	O
type	O
PPARgamma	B-GENE
action	O
.	O

A	O
second	O
study	O
group	O
,	O
with	O
intact	O
cardiac	O
innervation	O
,	O
consisted	O
of	O
19	O
patients	O
with	O
stable	O
angina	O
pectoris	O
class	O
I	O
to	O
III	O
.	O

Finally	O
,	O
we	O
present	O
evidence	O
that	O
fimbrin	B-GENE
is	O
a	O
third	O
distinct	O
plastin	B-GENE
isoform	I-GENE
which	O
is	O
specifically	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
small	O
intestine	O
.	O

Sterile	O
mutants	O
of	O
Saccharomyces	O
cerevisiae	O
were	O
isolated	O
from	O
alpha	O
*	O
cells	O
having	O
the	O
a	B-GENE
/	I-GENE
alpha	I-GENE
aar1	I-GENE
-	I-GENE
6	I-GENE
genotype	O
(	O
exhibiting	O
alpha	O
mating	O
ability	O
and	O
weak	O
a	O
mating	O
ability	O
as	O
a	O
result	O
of	O
a	O
defect	O
in	O
a1	B-GENE
-	I-GENE
alpha	I-GENE
2	I-GENE
repression	O
)	O
.	O

PRL	B-GENE
-	I-GENE
1	I-GENE
is	O
able	O
to	O
dephosphorylate	O
phosphotyrosine	O
substrates	O
,	O
and	O
mutation	O
of	O
the	O
active	O
-	O
site	O
cysteine	O
residue	O
abolishes	O
this	O
activity	O
.	O

In	O
the	O
absence	O
of	O
histological	O
criteria	O
,	O
which	O
it	O
is	O
difficult	O
to	O
demand	O
in	O
view	O
of	O
the	O
variability	O
of	O
results	O
and	O
potential	O
dangers	O
of	O
endomyocardial	O
biopsy	O
involving	O
such	O
thin	O
and	O
fragile	O
ventricular	O
walls	O
,	O
the	O
diagnosis	O
of	O
ACRV	O
is	O
based	O
upon	O
the	O
concomitant	O
existence	O
of	O
:	O
(	O
1	O
)	O
electrophysiological	O
criteria	O
:	O
ventricular	O
arrhythmias	O
,	O
in	O
particular	O
sustained	O
monomorphous	O
VT	O
,	O
with	O
the	O
particular	O
feature	O
of	O
a	O
very	O
high	O
degree	O
of	O
sensitivity	O
to	O
adrenergic	O
stimulation	O
(	O
exercise	O
)	O
,	O
the	O
existence	O
of	O
late	O
potentials	O
on	O
the	O
high	O
amplification	O
ECG	O
,	O
a	O
highly	O
specific	O
sign	O
,	O
though	O
unfortunately	O
of	O
poor	O
sensitivity	O
in	O
localized	O
froms	O
,	O
those	O
which	O
are	O
most	O
difficult	O
to	O
identify	O
(	O
2	O
)	O
;	O
segmentary	O
morphological	O
and	O
kinetic	O
RV	O
abnormalities	O
,	O
most	O
often	O
resulting	O
in	O
localized	O
akinetic	O
or	O
dyskinetic	O
parietal	O
vaulting	O
,	O
with	O
stasis	O
"	O
in	O
situ	O
"	O
.	O

The	O
present	O
paper	O
elucidates	O
the	O
existing	O
discrepancies	O
,	O
and	O
offers	O
a	O
consistent	O
terminology	O
incorporating	O
also	O
such	O
terms	O
as	O
"	O
additivity	O
"	O
,	O
"	O
potentiation	O
"	O
,	O
and	O
"	O
simple	O
similarity	O
"	O
.	O

Our	O
results	O
demonstrated	O
that	O
50	O
%	O
of	O
the	O
hepatic	O
artery	O
-	O
alone	O
ALT	O
graft	O
showed	O
almost	O
normal	O
structure	O
histologically	O
at	O
1	O
month	O
after	O
grafting	O
,	O
with	O
bile	O
secretion	O
preserved	O
.	O

The	O
transverse	O
relaxation	O
time	O
(	O
T2	O
)	O
and	O
apparent	O
diffusion	O
coefficient	O
of	O
water	O
were	O
determined	O
.	O

Leukemia	B-GENE
-	I-GENE
inhibitory	I-GENE
factor	I-GENE
(	O
LIF	B-GENE
)	O
is	O
a	O
neuropoietin	B-GENE
able	O
to	O
regulate	O
the	O
differentiation	O
and	O
the	O
survival	O
of	O
many	O
cell	O
types	O
,	O
which	O
include	O
some	O
neuronal	O
populations	O
.	O

The	O
lemdr1	B-GENE
gene	I-GENE
was	O
cloned	O
in	O
the	O
expression	O
vector	O
pALTNEO	O
and	O
transfected	O
into	O
wild	O
-	O
type	O
L	O
.	O
enriettii	O
and	O
the	O
resulting	O
transfected	O
cells	O
were	O
resistant	O
to	O
vinblastine	O
but	O
at	O
lower	O
levels	O
than	O
in	O
the	O
selected	O
mutant	O
cells	O
.	O

We	O
describe	O
a	O
genetic	O
system	O
for	O
further	O
characterizing	O
the	O
role	O
of	O
the	O
extreme	O
C	O
-	O
terminus	O
of	O
the	O
beta	O
subunit	O
of	O
E	B-GENE
.	I-GENE
coli	I-GENE
RNA	I-GENE
polymerase	I-GENE
.	O

Release	O
of	O
this	O
selective	O
pressure	O
,	O
however	O
,	O
gave	O
way	O
to	O
homologous	O
resolution	O
of	O
the	O
cointegrate	O
structures	O
.	O

When	O
ligated	O
to	O
the	O
proIL	B-GENE
-	I-GENE
1	I-GENE
beta	I-GENE
cap	I-GENE
site	I-GENE
-	I-GENE
proximal	I-GENE
region	I-GENE
(	O
located	O
between	O
-	O
131	O
to	O
+	O
12	O
)	O
,	O
both	O
the	O
proIL	B-GENE
-	I-GENE
1	I-GENE
beta	I-GENE
and	O
the	O
simian	B-GENE
virus	I-GENE
40	I-GENE
enhancer	I-GENE
elements	I-GENE
functioned	O
more	O
efficiently	O
in	O
monocytes	O
than	O
in	O
HeLa	O
cells	O
,	O
which	O
are	O
not	O
normally	O
competent	O
for	O
IL	B-GENE
-	I-GENE
1	I-GENE
beta	I-GENE
expression	O
.	O

The	O
network	O
evolution	O
was	O
interpreted	O
by	O
an	O
approach	O
based	O
on	O
the	O
Flory	O
model	O
.	O

Molecular	O
cloning	O
and	O
expression	O
of	O
human	B-GENE
UDP	I-GENE
-	I-GENE
d	I-GENE
-	I-GENE
Xylose	I-GENE
:	I-GENE
proteoglycan	I-GENE
core	I-GENE
protein	I-GENE
beta	B-GENE
-	I-GENE
d	I-GENE
-	I-GENE
xylosyltransferase	I-GENE
and	O
its	O
first	O
isoform	B-GENE
XT	I-GENE
-	I-GENE
II	I-GENE
.	O

The	O
gene	O
is	O
1	O
,	O
139	O
base	O
pairs	O
(	O
bp	O
)	O
long	O
,	O
and	O
,	O
like	O
other	O
members	O
of	O
the	O
SIG	B-GENE
family	I-GENE
,	O
the	O
beta	B-GENE
TG	I-GENE
gene	I-GENE
is	O
divided	O
into	O
3	O
exons	O
.	O

Nucleotide	O
sequence	O
,	O
genome	O
organization	O
and	O
phylogenetic	O
analysis	O
of	O
pineapple	O
mealybug	O
wilt	O
-	O
associated	O
virus	O
-	O
2	O
.	O

However	O
,	O
serial	O
passages	O
of	O
fetal	O
lamb	O
kidney	O
(	O
FLK	O
)	O
cells	O
,	O
which	O
are	O
sensitive	O
to	O
infection	O
with	O
BLV	O
,	O
after	O
transient	O
transfection	O
revealed	O
that	O
mutation	O
of	O
a	O
second	O
tyrosine	O
residue	O
in	O
the	O
N	O
-	O
terminal	O
motif	O
completely	O
prevented	O
the	O
propagation	O
of	O
the	O
virus	O
.	O

Using	O
a	O
conditional	O
-	O
lethal	O
mutant	O
allele	O
of	O
SUP45	B-GENE
(	O
sup45	B-GENE
-	I-GENE
2	I-GENE
)	O
and	O
a	O
combination	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
approaches	O
,	O
we	O
demonstrate	O
that	O
the	O
product	O
of	O
the	O
SUP45	B-GENE
gene	I-GENE
(	O
Sup45p	B-GENE
or	O
eRF1	B-GENE
)	O
is	O
a	O
factor	O
required	O
for	O
translation	O
termination	O
in	O
yeast	O
.	O

Expression	O
of	O
lacZ	B-GENE
from	O
the	O
promoter	O
of	O
the	O
Escherichia	B-GENE
coli	I-GENE
spc	I-GENE
operon	I-GENE
cloned	O
into	O
vectors	O
carrying	O
the	O
W205	O
trp	B-GENE
-	O
lac	B-GENE
fusion	O
.	O

Treadmill	O
training	O
at	O
least	O
for	O
2	O
weeks	O
can	O
reduce	O
the	O
infarction	O
size	O
and	O
edema	O
caused	O
by	O
MCA	O
occlusion	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
addition	O
,	O
a	O
microsatellite	O
repeat	O
polymorphism	O
with	O
a	O
heterozygosity	O
of	O
71	O
%	O
at	O
the	O
RET	B-GENE
locus	I-GENE
and	O
a	O
restriction	O
fragment	O
length	O
polymorphism	O
with	O
a	O
heterozygosity	O
of	O
42	O
%	O
detected	O
by	O
a	O
lambda	O
clone	O
from	O
the	O
D10S94	B-GENE
locus	I-GENE
have	O
been	O
developed	O
for	O
high	O
-	O
resolution	O
genetic	O
linkage	O
mapping	O
and	O
predictive	O
diagnostic	O
testing	O
.	O

We	O
have	O
now	O
tested	O
all	O
known	O
mammalian	B-GENE
Groucho	I-GENE
family	I-GENE
members	I-GENE
for	O
their	O
ability	O
to	O
interact	O
specifically	O
with	O
individual	O
Tcf	B-GENE
/	O
Lef	B-GENE
family	O
members	O
.	O

A	O
cDNA	O
clone	O
corresponding	O
to	O
the	O
putative	O
GA	B-GENE
20	I-GENE
-	O
oxidase	B-GENE
genomic	O
sequence	O
was	O
constructed	O
with	O
the	O
reverse	O
transcription	O
-	O
PCR	O
method	O
,	O
and	O
the	O
identity	O
of	O
the	O
cDNA	O
clone	O
was	O
confirmed	O
by	O
analyzing	O
the	O
capability	O
of	O
the	O
fusion	O
protein	O
expressed	O
in	O
Escherichia	O
coli	O
to	O
convert	O
GA53	B-GENE
to	O
GA44	B-GENE
and	O
GA19	B-GENE
to	O
GA20	B-GENE
.	O

Parasitological	O
and	O
pathological	O
findings	O
in	O
capuchin	O
monkeys	O
infected	O
with	O
Schistosoma	O
japonicum	O
or	O
Schistosoma	O
mansoni	O
.	O

The	O
5	O
'	O
-	O
terminus	O
of	O
the	O
p	B-GENE
-	I-GENE
gvpF	I-GENE
-	I-GENE
M	I-GENE
mRNA	I-GENE
was	O
located	O
169	O
nucleotides	O
upstream	O
of	O
p	B-GENE
-	I-GENE
gvpF	I-GENE
within	O
p	B-GENE
-	I-GENE
gvpE	I-GENE
.	O

There	O
were	O
differences	O
between	O
males	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
for	O
most	O
of	O
the	O
characteristics	O
studied	O
.	O

We	O
also	O
isolated	O
two	O
alternatively	O
spliced	O
forms	O
of	O
human	B-GENE
CD6	I-GENE
cDNA	I-GENE
lacking	O
sequences	O
encoding	O
membrane	O
-	O
proximal	O
regions	O
of	O
the	O
cytoplasmic	O
domain	O
which	O
maintain	O
the	O
same	O
reading	O
frame	O
as	O
CD6	B-GENE
-	O
PB1	B-GENE
.	O

The	O
arrangement	O
of	O
these	O
cutoff	O
-	O
levels	O
leads	O
to	O
a	O
sensitivity	O
of	O
85	O
%	O
at	O
a	O
specificity	O
of	O
55	O
%	O
for	O
Protein	B-GENE
S100	I-GENE
when	O
measured	O
by	O
RIA	O
,	O
and	O
to	O
a	O
sensitivity	O
of	O
77	O
%	O
at	O
a	O
specificity	O
of	O
61	O
%	O
when	O
measured	O
by	O
LIA	O
.	O

This	O
revealed	O
a	O
minimum	O
of	O
six	O
novel	O
OSBP	B-GENE
-	I-GENE
related	I-GENE
proteins	I-GENE
,	O
designated	O
ORP	B-GENE
-	I-GENE
1	I-GENE
to	O
ORP	B-GENE
-	I-GENE
6	I-GENE
.	O

Instead	O
,	O
mRNA	O
of	O
2	O
.	O
0	O
and	O
2	O
.	O
8	O
kb	O
are	O
detected	O
in	O
varying	O
abundance	O
.	O

These	O
results	O
were	O
compared	O
with	O
the	O
estimates	O
of	O
penetration	O
from	O
steady	O
-	O
state	O
calculations	O
,	O
square	O
root	O
of	O
time	O
calculations	O
,	O
and	O
a	O
biologically	O
based	O
mathematical	O
model	O
.	O

Which	O
cineangiographically	O
assessed	O
anatomic	O
variable	O
correlates	O
best	O
with	O
functional	O
measurements	O
of	O
stenosis	O
severity	O
?	O

A	O
comparison	O
of	O
quantitative	O
analysis	O
of	O
the	O
coronary	O
cineangiogram	O
with	O
measured	O
coronary	O
flow	O
reserve	O
and	O
exercise	O
/	O
redistribution	O
thallium	O
-	O
201	O
scintigraphy	O
.	O

Climatic	O
treatment	O
of	O
children	O
with	O
respiratory	O
allergy	O

These	O
results	O
further	O
support	O
an	O
important	O
role	O
for	O
CBF2	B-GENE
in	O
mediating	O
EBNA2	B-GENE
transactivation	O
;	O
they	O
identify	O
the	O
hnRNP	B-GENE
protein	I-GENE
AUF1	I-GENE
as	O
a	O
major	O
component	O
of	O
CBF2	B-GENE
and	O
are	O
also	O
the	O
first	O
evidence	O
of	O
a	O
cis	O
-	O
acting	O
sequence	O
other	O
than	O
a	O
CBF1	B-GENE
binding	I-GENE
element	I-GENE
that	O
is	O
able	O
to	O
confer	O
responsiveness	O
to	O
EBNA2	B-GENE
.	O

The	O
absolute	O
configuration	O
at	O
C	O
-	O
2	O
in	O
monocrotalic	O
acid	O
.	O

To	O
understand	O
whether	O
Shc	B-GENE
localization	O
in	O
membrane	O
rafts	O
is	O
sufficient	O
to	O
regulate	O
Shc	B-GENE
function	O
,	O
we	O
constructed	O
a	O
Shc	B-GENE
chimera	I-GENE
containing	O
the	O
Ras	B-GENE
membrane	I-GENE
localization	I-GENE
motif	I-GENE
at	O
the	O
C	O
-	O
terminus	O
.	O

CM	O
reduced	O
the	O
nuclear	O
binding	O
activity	O
of	O
transcription	B-GENE
factor	I-GENE
AP	I-GENE
-	I-GENE
1	I-GENE
.	O

Furthermore	O
,	O
competitor	O
containing	O
the	O
YY1	B-GENE
consensus	I-GENE
sequence	I-GENE
competed	O
for	O
protein	B-GENE
B	I-GENE
binding	O
,	O
whereas	O
competitor	O
containing	O
a	O
perfect	O
yeast	B-GENE
ABF	I-GENE
-	I-GENE
1	I-GENE
consensus	I-GENE
sequence	I-GENE
did	O
not	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

With	O
such	O
analysis	O
,	O
one	O
can	O
test	O
hypotheses	O
about	O
the	O
structure	O
of	O
latent	O
variability	O
within	O
a	O
given	O
data	O
set	O
.	O

A	O
general	O
model	O
for	O
ARE	O
-	O
mediated	O
mRNA	O
degradation	O
involving	O
a	O
potential	O
role	O
for	O
certain	O
heterogeneous	O
nuclear	O
ribonucleoproteins	O
and	O
ARE	B-GENE
-	I-GENE
binding	I-GENE
proteins	I-GENE
is	O
proposed	O
.	O

A	O
late	O
diagnosis	O
of	O
retinoblastoma	O
is	O
an	O
unquestionable	O
fact	O
that	O
allows	O
its	O
growth	O
and	O
leads	O
to	O
a	O
deterioration	O
in	O
the	O
outlook	O
.	O

633	O
+	O
/	O
-	O
258	O
aggregates	O
/	O
ml	O
at	O
0	O
rpm	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

A	O
segment	O
of	O
mRNA	O
encoding	O
the	O
leader	O
peptide	O
of	O
the	O
CPA1	B-GENE
gene	I-GENE
confers	O
repression	O
by	O
arginine	O
on	O
a	O
heterologous	O
yeast	O
gene	O
transcript	O
.	O

These	O
observations	O
provide	O
strong	O
support	O
for	O
the	O
idea	O
that	O
expression	O
of	O
mutant	O
tRNA	O
can	O
confer	O
a	O
mutator	O
phenotype	O
,	O
including	O
the	O
UVM	O
-	O
constitutive	O
phenotype	O
observed	O
in	O
mutA	B-GENE
and	O
mutC	B-GENE
cells	O
.	O

Diverse	O
endogenous	O
light	O
chains	O
contribute	O
to	O
basement	O
membrane	O
reactivity	O
in	O
nonautoimmune	O
mice	O
transgenic	O
for	O
an	O
anti	B-GENE
-	I-GENE
laminin	I-GENE
Ig	B-GENE
heavy	I-GENE
chain	I-GENE
.	O

The	O
serum	O
erythropoietin	B-GENE
(	O
EPO	B-GENE
)	O
concentrations	O
of	O
15	O
male	O
triathletes	O
(	O
26	O
.	O
3	O
U	O
.	O
ml	O
-	O
1	O
)	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
45	O
male	O
distance	O
runners	O
(	O
31	O
.	O
6	O
U	O
.	O
ml	O
-	O
1	O
;	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

At	O
the	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
is	O
a	O
domain	O
that	O
contains	O
sequences	O
very	O
similar	O
to	O
those	O
found	O
in	O
the	O
breakpoint	O
cluster	O
region	O
gene	O
product	O
,	O
n	B-GENE
-	I-GENE
chimerin	I-GENE
,	O
and	O
rho	B-GENE
GAP	I-GENE
,	O
all	O
of	O
which	O
have	O
been	O
shown	O
to	O
possess	O
intrinsic	O
GAP	B-GENE
activity	O
on	O
small	B-GENE
GTPases	I-GENE
.	O

Both	O
of	O
these	O
dogs	O
had	O
low	O
serum	O
IgG	B-GENE
(	O
3	O
.	O
5	O
to	O
7	O
.	O
2	O
mg	O
/	O
ml	O
)	O
and	O
the	O
second	O
littermate	O
also	O
had	O
reduced	O
serum	O
IgA	B-GENE
(	O
<	O
0	O
.	O
1	O
to	O
0	O
.	O
15	O
mg	O
/	O
ml	O
)	O
.	O

Studies	O
were	O
performed	O
on	O
several	O
superficial	O
veins	O
from	O
the	O
rabbit	O
face	O
to	O
examine	O
the	O
relationship	O
between	O
beta	B-GENE
adrenoceptor	I-GENE
subtype	I-GENE
distribution	O
,	O
intrinsic	O
myogenic	O
tone	O
and	O
sympathetic	O
nerve	O
innervation	O
.	O

The	O
previously	O
described	O
four	O
sets	O
of	O
13	O
-	O
to	O
18	O
-	O
base	O
-	O
pair	O
interspersed	O
repeat	O
elements	O
between	O
-	O
55	O
and	O
-	O
580	O
provide	O
most	O
of	O
the	O
high	O
basal	O
transcriptional	O
strength	O
,	O
whereas	O
the	O
arrangement	O
of	O
further	O
upstream	O
tandemly	O
repeated	O
NF1	B-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
may	O
contribute	O
significantly	O
to	O
the	O
expanded	O
biological	O
host	O
range	O
for	O
expression	O
of	O
SCMV	B-GENE
IE94	I-GENE
compared	O
with	O
HCMV	B-GENE
IE68	I-GENE
.	O

Lower	O
extremity	O
weight	O
bearing	O
under	O
various	O
standing	O
conditions	O
in	O
independently	O
ambulatory	O
patients	O
with	O
hemiparesis	O
.	O

Overexpression	O
of	O
wild	B-GENE
-	I-GENE
type	I-GENE
p53	I-GENE
also	O
induces	O
apoptosis	O
in	O
an	O
LCL	O
.	O

The	O
blood	O
levels	O
of	O
lactate	O
,	O
pyruvate	O
and	O
amino	O
acids	O
were	O
not	O
elevated	O
.	O

Conclusion	O
:	O
inlet	O
type	O
VSD	O
and	O
perimembranous	O
type	O
TOF	O
have	O
anatomic	O
features	O
in	O
which	O
the	O
proximal	O
His	O
bundle	O
tends	O
to	O
be	O
jeopardized	O
by	O
suturing	O
for	O
VSD	O
closure	O
.	O

Terbutaline	O
;	O
a	O
beta2	O
-	O
adrenergic	O
agonist	O
,	O
and	O
aminophyllin	O
,	O
a	O
phosphodiesterase	O
inhibitor	O
,	O
were	O
given	O
separately	O
,	O
or	O
in	O
combination	O
,	O
to	O
rabbit	O
fetuses	O
on	O
the	O
28th	O
day	O
of	O
gestation	O
.	O

Slap	B-GENE
negatively	O
regulates	O
Src	B-GENE
mitogenic	O
function	O
but	O
does	O
not	O
revert	O
Src	B-GENE
-	O
induced	O
cell	O
morphology	O
changes	O
.	O

Unlike	O
wild	B-GENE
-	I-GENE
type	I-GENE
p53	I-GENE
,	O
the	O
delta	B-GENE
proAE	I-GENE
mutant	I-GENE
cDNA	I-GENE
can	O
be	O
stably	O
expressed	O
in	O
tumor	O
derived	O
cell	O
lines	O
with	O
few	O
immediate	O
detrimental	O
effects	O
.	O

RT	O
-	O
PCR	O
analysis	O
showed	O
that	O
PLP	B-GENE
-	I-GENE
H	I-GENE
as	O
well	O
as	O
PLP	B-GENE
-	I-GENE
C	I-GENE
and	O
PLP	B-GENE
-	I-GENE
D	I-GENE
are	O
expressed	O
in	O
all	O
rat	O
strains	O
examined	O
,	O
confirming	O
that	O
PLP	B-GENE
diversity	O
is	O
not	O
due	O
to	O
strain	O
differences	O
.	O

Previous	O
work	O
showed	O
that	O
repA	B-GENE
(	O
initiator	O
protein	O
)	O
expression	O
requires	O
tap	B-GENE
(	O
leader	O
peptide	O
)	O
translation	O
.	O

Furthermore	O
,	O
LB1	B-GENE
gene	I-GENE
mapped	O
to	O
chromosome	O
13q14	O
,	O
a	O
region	O
that	O
has	O
been	O
involved	O
as	O
a	O
chromosomal	O
breakpoint	O
in	O
DLBL	O
.	O

Thus	O
,	O
the	O
human	B-GENE
D1A	I-GENE
gene	I-GENE
belongs	O
to	O
the	O
category	O
of	O
tissue	O
-	O
specific	O
,	O
regulated	O
genes	O
that	O
have	O
housekeeping	O
-	O
type	O
promoters	O
.	O

This	O
led	O
to	O
the	O
conclusion	O
that	O
the	O
metatarsal	O
artery	O
should	O
be	O
used	O
for	O
toe	O
MP	O
joint	O
grafts	O
,	O
while	O
the	O
unilateral	O
proper	O
digital	O
artery	O
is	O
suitable	O
for	O
toe	O
PIP	O
joint	O
grafts	O
,	O
together	O
with	O
concomitant	O
or	O
dorsal	O
cutaneous	O
vein	O
.	O

In	O
Rat	O
1a	O
cells	O
,	O
m1R	B-GENE
stimulation	O
of	O
phospholipase	B-GENE
C	I-GENE
beta	I-GENE
and	O
the	O
marked	O
rise	O
in	O
intracellular	O
calcium	O
stimulated	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
synthesis	O
,	O
resulting	O
in	O
the	O
activation	O
of	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
.	O

Five	O
patients	O
developed	O
metastatic	O
spread	O
,	O
and	O
all	O
of	O
them	O
died	O
of	O
tumor	O
.	O

The	O
monoexponential	O
rate	O
of	O
clearance	O
of	O
tracer	O
-	O
-	O
obtained	O
from	O
the	O
portion	O
of	O
the	O
residue	O
-	O
detection	O
curve	O
reflecting	O
metabolism	O
of	O
fatty	O
acid	O
incorporated	O
into	O
neutral	O
lipids	O
-	O
-	O
correlated	O
directly	O
with	O
induced	O
changes	O
in	O
tension	O
-	O
time	O
index	O
after	O
injections	O
into	O
the	O
left	O
atrium	O
(	O
r	O
=	O
0	O
.	O
96	O
,	O
n	O
=	O
12	O
)	O
,	O
right	O
atrium	O
(	O
r	O
=	O
0	O
.	O
86	O
,	O
n	O
=	O
14	O
)	O
,	O
and	O
ear	O
vein	O
(	O
r	O
=	O
0	O
.	O
93	O
,	O
n	O
=	O
14	O
)	O
.	O

The	O
optimal	O
care	O
of	O
CHF	O
patient	O
includes	O
the	O
recognition	O
and	O
management	O
of	O
these	O
electrolyte	O
disturbances	O
.	O

Because	O
the	O
mutant	O
defective	O
in	O
DNA	O
binding	O
also	O
fails	O
to	O
stimulate	O
Abf1	B-GENE
ARS1	O
DNA	O
-	O
binding	O
activity	O
,	O
our	O
results	O
suggest	O
that	O
Cdc6	B-GENE
DNA	O
-	O
binding	O
activity	O
may	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
initiation	O
of	O
DNA	O
replication	O
.	O

Tensile	O
bond	O
strengths	O
between	O
resin	O
composite	O
and	O
bovine	O
dentin	O
using	O
dentin	O
adhesive	O
systems	O
(	O
Clearfil	O
Liner	O
Bond	O
II	O
:	O
LB	O
II	O
;	O
Scotchbond	O
Multi	O
-	O
Purpose	O
:	O
MP	O
)	O
bonding	O
systems	O
showed	O
a	O
large	O
scatter	O
among	O
students	O
and	O
dentists	O
.	O

The	O
statistical	O
analysis	O
of	O
data	O
of	O
TRH	B-GENE
test	O
on	O
a	O
sample	O
of	O
57	O
healthy	O
volunteers	O
has	O
permitted	O
an	O
evaluation	O
of	O
the	O
upper	O
limits	O
of	O
the	O
normal	O
thyrotropin	B-GENE
response	O
;	O
the	O
secretory	O
area	O
(	O
As	O
)	O
was	O
shown	O
to	O
be	O
more	O
discriminating	O
.	O

Neither	O
gene	O
possesses	O
a	O
distinct	O
transcriptional	O
start	O
site	O
as	O
shown	O
by	O
nuclease	B-GENE
S1	I-GENE
analysis	O
.	O

The	O
variability	O
is	O
most	O
likely	O
a	O
result	O
of	O
alternative	O
splicing	O
of	O
exons	O
from	O
the	O
primary	O
elastin	B-GENE
transcripts	I-GENE
.	O

OBJECTIVE	O
:	O
Our	O
purpose	O
was	O
to	O
determine	O
the	O
simultaneous	O
concentrations	O
of	O
serum	O
cotinine	O
in	O
both	O
fetal	O
and	O
maternal	O
blood	O
.	O

This	O
conformer	O
features	O
a	O
Type	O
I	O
beta	O
-	O
turn	O
and	O
has	O
extensive	O
hydrophobic	O
contacts	O
with	O
the	O
FKBP12	B-GENE
binding	O
surface	O
.	O

Consistent	O
with	O
the	O
hepatic	O
and	O
epidermal	O
expression	O
of	O
histidase	B-GENE
,	O
this	O
finding	O
suggests	O
that	O
histidase	B-GENE
transcription	O
may	O
be	O
regulated	O
by	O
these	O
factors	O
.	O

The	O
objectives	O
of	O
the	O
present	O
study	O
were	O
to	O
evaluate	O
the	O
effects	O
of	O
adding	O
Equex	O
to	O
a	O
TRIS	O
-	O
extender	O
,	O
diluting	O
the	O
semen	O
in	O
1	O
or	O
2	O
steps	O
,	O
freezing	O
according	O
to	O
2	O
methods	O
,	O
thawing	O
at	O
2	O
rates	O
,	O
and	O
the	O
interactions	O
between	O
these	O
treatments	O
,	O
on	O
the	O
post	O
-	O
thaw	O
survival	O
of	O
dog	O
spermatozoa	O
at	O
38	O
degrees	O
C	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
eIF6	B-GENE
is	O
encoded	O
by	O
a	O
single	O
-	O
copy	O
essential	O
gene	O
.	O

When	O
the	O
degree	O
of	O
exercise	O
was	O
maximal	O
,	O
mPAP	O
was	O
maintained	O
,	O
SVI	O
decreased	O
,	O
HR	O
was	O
unchanged	O
,	O
and	O
CO	O
and	O
VO2	O
decreased	O
.	O

Results	O
of	O
the	O
official	O
inspection	O
of	O
the	O
commercial	O
anti	O
-	O
inflammatory	O
enzyme	O
preparations	O
containing	O
chymotrypsin	B-GENE
and	O
trypsin	B-GENE
by	O
means	O
of	O
modified	O
NF	O
13	O
methods	O

Detection	O
of	O
poisoning	O
by	O
Impila	O
(	O
Callilepis	O
laureola	O
)	O
in	O
a	O
mother	O
and	O
child	O
.	O

Regulation	O
of	O
irgA	B-GENE
by	O
iron	O
in	O
V	O
.	O
cholerae	O
occurs	O
at	O
the	O
transcriptional	O
level	O
,	O
and	O
there	O
is	O
an	O
interrupted	O
dyad	O
symmetric	O
sequence	O
in	O
the	O
vicinity	O
of	O
the	O
promoter	O
that	O
is	O
homologous	O
to	O
Fur	B-GENE
binding	I-GENE
sites	I-GENE
of	O
E	O
.	O
coli	O
.	O

Copyright	O
2001	O
S	O
.	O

We	O
recently	O
characterized	O
a	O
single	O
yeast	B-GENE
hnRNP	I-GENE
methyltransferase	I-GENE
(	O
HMT1	B-GENE
)	O
.	O

We	O
recently	O
characterized	O
a	O
single	O
yeast	B-GENE
hnRNP	I-GENE
methyltransferase	I-GENE
(	O
HMT1	B-GENE
)	O
.	O

This	O
study	O
underlines	O
the	O
importance	O
of	O
terminal	O
SC5b	B-GENE
-	I-GENE
9	I-GENE
complement	I-GENE
complex	I-GENE
as	O
a	O
suitable	O
marker	O
in	O
the	O
evaluation	O
of	O
complement	O
activation	O
during	O
cardiopulmonary	O
bypass	O
.	O

Furthermore	O
,	O
a	O
minor	O
start	O
site	O
was	O
localized	O
179	O
bp	O
upstream	O
of	O
the	O
major	O
site	O
using	O
reverse	B-GENE
transcriptase	I-GENE
-	O
polymerase	O
chain	O
reaction	O
with	O
various	O
P1	O
primers	O
(	O
primer	O
walking	O
)	O
,	O
primer	O
extension	O
,	O
and	O
cDNA	O
cloning	O
.	O

Emphysematous	O
cholecystitis	O
:	O
sonographic	O
findings	O
.	O

Factors	O
influencing	O
the	O
bond	O
strength	O
between	O
glass	O
polyalkenoate	O
(	O
ionomer	O
)	O
cements	O
and	O
dentine	O
.	O

Extramedullary	O
plasmacytoma	O
of	O
the	O
parotid	O
gland	O

LY290181	O
appears	O
to	O
inhibit	O
uPA	B-GENE
promoter	I-GENE
activation	O
by	O
blocking	O
phorbol	O
ester	O
-	O
stimulated	O
binding	O
of	O
nuclear	O
proteins	O
to	O
the	O
uPA	B-GENE
PEA3	B-GENE
/	O
12	O
-	O
0	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
responsive	O
element	O
(	O
TRE	O
)	O
.	O

Methyl	O
mercury	O
intoxication	O
in	O
rat	O
kidneys	O
.	O

The	O
histochemistry	O
and	O
ultrastructure	O
of	O
calcified	O
cerebellar	O
deposits	O
described	O
by	O
Tonge	O
et	O
al	O
.	O

Reward	O
value	O
of	O
prosodic	O
features	O
of	O
language	O
for	O
autistic	O
,	O
mentally	O
retarded	O
,	O
and	O
normal	O
children	O
.	O

The	O
divergence	O
in	O
primary	O
structure	O
between	O
the	O
sheep	O
CRF1	B-GENE
and	O
the	O
other	O
mammalian	B-GENE
CRF1s	I-GENE
is	O
primarily	O
localized	O
to	O
the	O
extracellular	O
amino	O
terminal	O
domain	O
of	O
the	O
receptor	O
(	O
18	O
of	O
22	O
divergent	O
residues	O
,	O
ovine	O
vs	O
human	B-GENE
CRF1	I-GENE
)	O
.	O

Chirality	O
-	O
glass	O
and	O
spin	O
-	O
glass	O
correlations	O
in	O
the	O
two	O
-	O
dimensional	O
random	O
-	O
bond	O
XY	O
model	O
.	O

Chem	O
.	O

We	O
then	O
demonstrated	O
that	O
1	O
)	O
GAL4	B-GENE
-	O
REV	B-GENE
-	O
erbA	B-GENE
alpha	I-GENE
chimeras	O
that	O
contain	O
the	O
'	O
AB	O
'	O
region	O
and	O
lack	O
the	O
'	O
E	O
'	O
region	O
activated	O
transcription	O
of	O
GAL4	B-GENE
response	I-GENE
elements	I-GENE
in	O
the	O
presence	O
of	O
8	O
-	O
Br	O
-	O
cAMP	O
and	O
2	O
)	O
the	O
ligand	O
-	O
binding	O
domain	O
(	O
LBD	O
)	O
contains	O
an	O
active	O
transcriptional	O
silencer	O
.	O

CONCLUSIONS	O
:	O
Our	O
findings	O
suggest	O
that	O
pre	O
-	O
treatment	O
with	O
coenzyme	O
Q10	O
may	O
play	O
a	O
protective	O
role	O
during	O
routine	O
vascular	O
procedures	O
requiring	O
abdominal	O
aortic	O
cross	O
clamping	O
by	O
attenuating	O
the	O
degree	O
of	O
peroxidative	O
damage	O
.	O

The	O
protein	O
folds	O
correctly	O
with	O
two	O
disulfide	O
bonds	O
and	O
a	O
free	O
thiol	O
group	O
at	O
Cys25	O
.	O

The	O
circadian	O
rhythm	O
,	O
however	O
,	O
was	O
not	O
affected	O
and	O
the	O
difference	O
between	O
minimum	O
(	O
12	O
.	O
00	O
h	O
)	O
and	O
maximum	O
(	O
18	O
.	O
50	O
h	O
)	O
serum	O
concentrations	O
was	O
31	O
.	O
3	O
%	O
.	O

In	O
35	O
of	O
those	O
patients	O
DD	O
was	O
measured	O
also	O
with	O
microlatex	O
tests	O
-	O
-	O
Tinaquant	O
and	O
BC	O
d	O
-	O
dimer	O
.	O

J	O
.	O

This	O
site	O
is	O
upstream	O
from	O
the	O
TATA	O
box	O
used	O
in	O
somatic	O
cells	O
.	O

Identical	O
c	B-GENE
-	I-GENE
erbB3	I-GENE
transcripts	I-GENE
are	O
expressed	O
in	O
normal	O
human	O
placental	O
tissues	O
.	O

The	O
Clb5	B-GENE
kinase	I-GENE
,	O
which	O
promotes	O
S	O
phase	O
,	O
remains	O
active	O
during	O
the	O
G2	O
-	O
phase	O
arrest	O
of	O
cells	O
of	O
the	O
parental	O
strain	O
,	O
but	O
its	O
activity	O
declines	O
rapidly	O
in	O
sim	B-GENE
mutants	I-GENE
.	O

We	O
also	O
show	O
that	O
activation	O
of	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
(	O
PKA	B-GENE
)	O
signaling	O
is	O
sufficient	O
to	O
down	O
-	O
regulate	O
caveolin	B-GENE
-	I-GENE
1	I-GENE
protein	I-GENE
expression	O
and	O
promoter	O
activity	O
.	O

Fluorometric	O
methods	O
can	O
also	O
provide	O
information	O
about	O
porphyrin	O
binding	O
sites	O
that	O
is	O
useful	O
in	O
understanding	O
porphyrin	O
transport	O
and	O
clearance	O
.	O

The	O
3	O
.	O
3	O
-	O
fold	O
higher	O
expression	O
in	O
the	O
fetal	O
heart	O
than	O
in	O
the	O
adult	O
heart	O
suggests	O
that	O
HFHZ	B-GENE
mRNA	I-GENE
is	O
downregulated	O
in	O
the	O
process	O
of	O
development	O
.	O

Genomic	O
locus	O
of	O
chCTCF	B-GENE
contains	O
a	O
GC	O
-	O
rich	O
untranslated	O
exon	O
separated	O
from	O
seven	O
coding	O
exons	O
by	O
a	O
long	O
intron	O
.	O

The	O
outer	O
diameter	O
and	O
the	O
thickness	O
of	O
the	O
rotor	O
are	O
60	O
mm	O
and	O
8	O
mm	O
,	O
respectively	O
.	O

No	O
effect	O
was	O
found	O
on	O
grooming	O
behavior	O
.	O

In	O
this	O
study	O
,	O
we	O
elucidate	O
signaling	O
pathways	O
induced	O
by	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
with	O
hypericin	O
.	O

A	O
xylE	B-GENE
transcriptional	I-GENE
fusion	I-GENE
to	O
the	O
putative	O
mxbD	B-GENE
promoter	I-GENE
showed	O
low	O
-	O
level	O
expression	O
in	O
wild	O
-	O
type	O
cells	O
grown	O
on	O
one	O
-	O
carbon	O
(	O
C1	O
)	O
compounds	O
and	O
no	O
detectable	O
expression	O
in	O
cells	O
grown	O
on	O
succinate	O
.	O

Protein	O
phosphatases	O
play	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
the	O
eukaryotic	O
cell	O
cycle	O
and	O
signal	O
transduction	O
.	O

Heat	O
-	O
labile	O
-	O
like	O
enterotoxin	O
(	O
LT	B-GENE
)	O
was	O
produced	O
by	O
26	O
of	O
42	O
stool	O
isolates	O
(	O
62	O
%	O
)	O
,	O
while	O
only	O
1	O
of	O
the	O
42	O
isolates	O
(	O
2	O
%	O
)	O
produced	O
enterotoxinlike	O
activity	O
in	O
suckling	O
mice	O
;	O
65	O
%	O
of	O
the	O
cytotoxin	O
-	O
producing	O
strains	O
also	O
produced	O
an	O
LT	B-GENE
-	I-GENE
like	I-GENE
material	O
.	O

Changes	O
of	O
thirtynine	O
serum	O
protein	O
components	O
following	O
surgical	O
stress	O
.	O

Tolerance	O
in	O
renal	O
transplantation	O
after	O
allogeneic	O
bone	O
marrow	O
transplantation	O
-	O
6	O
-	O
year	O
follow	O
-	O
up	O
.	O

For	O
EPV	O
3	O
,	O
10	O
,	O
or	O
40	O
,	O
the	O
bias	O
exceeded	O
25	O
%	O
for	O
7	O
,	O
3	O
,	O
and	O
1	O
in	O
the	O
8	O
-	O
predictor	O
model	O
respectively	O
,	O
when	O
a	O
conventional	O
selection	O
criterion	O
was	O
used	O
(	O
alpha	O
=	O
0	O
.	O
05	O
)	O
.	O

Transfer	O
RNA	O
genes	O
from	O
Dictyostelium	O
discoideum	O
are	O
frequently	O
associated	O
with	O
repetitive	O
elements	O
and	O
contain	O
consensus	O
boxes	O
in	O
their	O
5	O
'	O
and	O
3	O
'	O
-	O
flanking	O
regions	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
SRm160	B-GENE
/	I-GENE
300	I-GENE
is	O
required	O
for	O
a	O
purine	O
-	O
rich	O
ESE	B-GENE
to	O
promote	O
the	O
splicing	O
of	O
a	O
pre	O
-	O
mRNA	O
derived	O
from	O
the	O
Drosophila	B-GENE
doublesex	I-GENE
gene	I-GENE
.	O

Mature	O
mRNA	O
for	O
cytosolic	B-GENE
phosphoenolpyruvate	I-GENE
carboxykinase	I-GENE
of	I-GENE
the	I-GENE
chicken	I-GENE
is	O
2	O
.	O
8	O
kilobases	O
in	O
length	O
,	O
similar	O
to	O
that	O
previously	O
noted	O
for	O
mRNA	O
coding	O
for	O
the	O
same	O
enzyme	O
in	O
the	O
rat	O
.	O

Polysorbate	O
80	O
did	O
not	O
have	O
a	O
direct	O
stimulant	O
or	O
relaxant	O
effect	O
on	O
either	O
guinea	O
pig	O
ileum	O
or	O
rat	O
uterus	O
,	O
however	O
,	O
it	O
antagonised	O
the	O
contractions	O
induced	O
by	O
acetylcholine	O
,	O
histamine	O
,	O
barium	O
,	O
5	O
-	O
hydroxytryptamine	O
and	O
carbachol	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Further	O
evidence	O
for	O
a	O
clustered	O
organization	O
of	O
FAX	B-GENE
-	O
ZFP	B-GENE
transcription	O
units	O
is	O
provided	O
by	O
Southern	O
blot	O
analysis	O
of	O
large	O
genomic	O
restriction	O
fragments	O
separated	O
by	O
transverse	O
field	O
gel	O
electrophoresis	O
,	O
and	O
by	O
in	O
situ	O
hybridization	O
on	O
intact	O
chromosomes	O
.	O

In	O
adherent	O
macrophages	O
,	O
absence	O
of	O
CD45	B-GENE
led	O
to	O
the	O
hyperphosphorylation	O
and	O
hyperactivation	O
of	O
p56	B-GENE
/	I-GENE
59	I-GENE
(	O
hck	B-GENE
)	O
and	O
p53	B-GENE
/	I-GENE
56	I-GENE
(	O
lyn	B-GENE
)	O
,	O
but	O
not	O
of	O
p58	B-GENE
(	O
c	B-GENE
-	I-GENE
fgr	I-GENE
)	O
.	O

The	O
structural	O
study	O
of	O
peptides	O
belonging	O
to	O
the	O
terminal	O
domains	O
of	O
histone	B-GENE
H1	I-GENE
can	O
be	O
considered	O
as	O
a	O
step	O
toward	O
the	O
understanding	O
of	O
the	O
function	O
of	O
H1	B-GENE
in	O
chromatin	O
.	O

Cold	O
cardioplegia	O
was	O
administered	O
at	O
45	O
mm	O
Hg	O
every	O
20	O
minutes	O
for	O
2	O
hours	O
.	O

These	O
disorders	O
include	O
low	O
-	O
back	O
pain	O
,	O
saddle	O
anesthesia	O
,	O
bilateral	O
sciatica	O
,	O
then	O
motor	O
weakness	O
of	O
the	O
lower	O
extremities	O
or	O
chronic	O
paraplegia	O
and	O
,	O
bladder	O
dysfunction	O
.	O

W	O
.	O
G	O
.	O

The	O
model	O
also	O
predicts	O
that	O
blood	O
flow	O
shunt	O
fraction	O
(	O
Qs	O
/	O
QT	O
)	O
is	O
directly	O
related	O
to	O
the	O
oxygen	O
sine	O
-	O
wave	O
amplitude	O
perturbations	O
transmitted	O
to	O
end	O
-	O
expired	O
air	O
and	O
arterial	O
and	O
mixed	O
-	O
venous	O
blood	O
through	O
two	O
simple	O
equations	O
.	O

No	O
significant	O
differences	O
were	O
identified	O
between	O
groups	O
for	O
pH	O
,	O
PaCO2	O
,	O
intracranial	O
pressure	O
,	O
heart	O
rate	O
,	O
brain	O
temperature	O
,	O
or	O
glucose	O
levels	O
.	O

In	O
our	O
previous	O
studies	O
,	O
transcriptional	O
activation	O
was	O
shown	O
to	O
correlate	O
with	O
IEP86	B-GENE
binding	O
to	O
both	O
the	O
TATA	B-GENE
-	I-GENE
box	I-GENE
binding	I-GENE
protein	I-GENE
(	O
TBP	B-GENE
)	O
and	O
the	O
transcription	O
factor	O
bound	O
upstream	O
.	O

Cloning	O
of	O
a	O
human	O
cDNA	O
encoding	O
a	O
CDC2	B-GENE
-	I-GENE
related	I-GENE
kinase	I-GENE
by	O
complementation	O
of	O
a	O
budding	B-GENE
yeast	I-GENE
cdc28	I-GENE
mutation	O
.	O

These	O
results	O
support	O
the	O
view	O
that	O
clonidine	O
and	O
6	O
-	O
OHDA	O
,	O
but	O
not	O
alpha	O
-	O
MD	O
,	O
have	O
central	O
pressor	O
actions	O
in	O
the	O
rat	O
that	O
oppose	O
their	O
antihypertensive	O
action	O
.	O

Peroxisome	B-GENE
proliferator	I-GENE
-	I-GENE
activated	I-GENE
receptors	I-GENE
(	O
PPARs	B-GENE
)	O
and	O
retinoid	B-GENE
X	I-GENE
receptors	I-GENE
(	O
RXRs	B-GENE
)	O
are	O
nuclear	B-GENE
hormone	I-GENE
receptors	I-GENE
that	O
are	O
activated	O
by	O
fatty	O
acids	O
and	O
9	O
-	O
cis	O
-	O
retinoic	O
acid	O
,	O
respectively	O
.	O

Using	O
mutagenesis	O
,	O
we	O
have	O
identified	O
two	O
mutations	O
of	O
the	O
second	O
actin	B-GENE
-	I-GENE
binding	I-GENE
domain	I-GENE
that	O
can	O
also	O
suppress	O
the	O
act1	B-GENE
mutations	O
of	O
interest	O
.	O

A	O
point	O
mutation	O
in	O
Galphao	B-GENE
and	O
Galphai1	B-GENE
blocks	O
interaction	O
with	O
regulator	O
of	O
G	B-GENE
protein	I-GENE
signaling	O
proteins	O
.	O

Survival	O
was	O
calculated	O
both	O
from	O
the	O
date	O
of	O
onset	O
and	O
from	O
the	O
date	O
of	O
diagnosis	O
.	O

Areas	O
with	O
significantly	O
greater	O
rCBF	O
for	O
targeting	O
were	O
the	O
left	O
motor	O
cortex	O
,	O
left	O
intraparietal	O
sulcus	O
,	O
and	O
left	O
caudate	O
.	O

Activation	O
of	O
PKA	B-GENE
by	O
8	O
-	O
bromo	O
-	O
cyclic	O
AMP	O
or	O
forskolin	O
,	O
and	O
inhibition	O
of	O
PKC	B-GENE
by	O
calphostin	O
C	O
,	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
3TP	B-GENE
activity	O
as	O
well	O
as	O
in	O
vitro	O
ERK	B-GENE
kinase	I-GENE
activity	O
in	O
CRAC	O
.	O

The	O
growing	O
drug	O
problem	O
is	O
also	O
reflected	O
in	O
the	O
increasing	O
number	O
of	O
cases	O
of	O
hepatitis	O
B	O
and	O
of	O
drug	O
-	O
related	O
deaths	O
.	O

We	O
had	O
previously	O
analyzed	O
repair	O
rates	O
of	O
cyclobutane	O
pyrimidine	O
dimers	O
at	O
nucleotide	O
resolution	O
along	O
the	O
human	B-GENE
JUN	I-GENE
gene	I-GENE
in	O
normal	O
fibroblasts	O
and	O
found	O
very	O
efficient	O
repair	O
of	O
sequences	O
near	O
the	O
transcription	O
initiation	O
site	O
but	O
slow	O
repair	O
along	O
the	O
promoter	O
.	O

Radiation	O
-	O
induced	O
changes	O
in	O
the	O
area	O
of	O
alveoli	O
and	O
septa	O
as	O
well	O
as	O
collagen	B-GENE
content	O
were	O
seen	O
11	O
weeks	O
after	O
irradiation	O
.	O

At	O
both	O
companies	O
sites	O
Salmonella	O
enteritidis	O
and	O
Salmonella	O
typhimurium	O
Tr104	O
were	O
also	O
isolated	O
occasionally	O
from	O
various	O
locations	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
C	O
-	O
terminal	O
region	O
of	O
Crk	B-GENE
contains	O
negative	O
regulatory	O
elements	O
important	O
for	O
both	O
Abl	B-GENE
and	O
FAK	B-GENE
dependent	O
signal	O
pathways	O
,	O
and	O
offers	O
a	O
paradigm	O
for	O
an	O
autoinhibitory	O
region	O
in	O
the	O
SH3	B-GENE
linker	O
/	O
C	O
-	O
terminal	O
SH3	B-GENE
domain	O
.	O

The	O
sequence	O
and	O
isolated	O
cDNAs	O
will	O
provide	O
useful	O
reagents	O
for	O
studying	O
the	O
expression	O
of	O
Brca1	B-GENE
in	O
the	O
mouse	O
,	O
and	O
for	O
testing	O
the	O
importance	O
of	O
the	O
evolutionarily	O
conserved	O
domains	O
.	O

Analysis	O
of	O
regulatory	O
regions	O
in	O
the	O
promoter	O
of	O
the	O
ctr4	B-GENE
(	I-GENE
+	I-GENE
)	I-GENE
copper	I-GENE
transporter	I-GENE
gene	I-GENE
in	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
reveals	O
the	O
identity	O
of	O
a	O
conserved	O
copper	O
-	O
signaling	O
element	O
(	O
CuSE	O
)	O
,	O
which	O
is	O
recognized	O
by	O
the	O
transcription	B-GENE
factor	I-GENE
Cuf1	I-GENE
.	O

RVR	B-GENE
'	O
loss	O
of	O
function	O
'	O
studies	O
by	O
constitutive	O
over	O
-	O
expression	O
of	O
a	O
dominant	O
negative	O
RVR	B-GENE
delta	I-GENE
E	I-GENE
resulted	O
in	O
increased	O
levels	O
of	O
p21Cip1	B-GENE
/	O
Waf1	B-GENE
and	O
myogenin	B-GENE
mRNAs	I-GENE
after	O
serum	O
withdrawal	O
.	O

This	O
soluble	O
form	O
of	O
the	O
HGFr	B-GENE
(	O
sHGFr	B-GENE
)	O
bound	O
HGF	B-GENE
with	O
an	O
affinity	O
similar	O
to	O
that	O
of	O
the	O
authentic	O
,	O
membrane	O
-	O
associated	O
receptor	O
.	O

The	O
effect	O
of	O
ligustrazine	O
hydrochloride	O
(	O
LTH	O
)	O
on	O
depressing	O
pulmonary	O
artery	O
hypertension	O
has	O
been	O
proved	O
in	O
recent	O
studies	O
.	O

Splicing	O
of	O
the	O
K	B-GENE
-	I-GENE
SAM	I-GENE
alternative	O
exon	O
of	O
the	O
fibroblast	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
2	I-GENE
gene	I-GENE
is	O
heavily	O
dependent	O
on	O
the	O
U	O
-	O
rich	O
sequence	O
IAS1	B-GENE
lying	O
immediately	O
downstream	O
from	O
its	O
5	O
'	O
splice	O
site	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
a	O
relation	O
in	O
the	O
topography	O
of	O
some	O
visual	O
field	O
areas	O
assessed	O
by	O
SWAP	O
and	O
the	O
inferotemporal	O
neuroretinal	O
rim	O
area	O
,	O
which	O
may	O
play	O
a	O
role	O
in	O
the	O
diagnosis	O
and	O
follow	O
-	O
up	O
of	O
suspected	O
glaucoma	O
.	O

In	O
conclusion	O
,	O
these	O
studies	O
indicate	O
that	O
LiCl	O
(	O
1	O
)	O
decreases	O
histamine	O
-	O
stimulated	O
gastric	O
acid	O
secretion	O
,	O
and	O
(	O
2	O
)	O
diminishes	O
bile	O
-	O
induced	O
disruption	O
of	O
the	O
gastric	O
mucosal	O
barrier	O
in	O
the	O
canine	O
Heidenhain	O
pouch	O
.	O

Diagnosis	O
of	O
phenylalanine	B-GENE
hydroxylase	I-GENE
deficiency	O
(	O
phenylketonuria	O
)	O
.	O

They	O
self	O
-	O
completed	O
the	O
SF	O
-	O
36	O
questionnaire	O
and	O
their	O
QoL	O
was	O
described	O
and	O
retrospectively	O
compared	O
to	O
that	O
of	O
historical	O
controls	O
.	O

Growth	O
of	O
tracheal	O
anastomoses	O
in	O
growing	O
animals	O

Patients	O
with	O
detectable	O
serum	O
TNF	B-GENE
levels	O
had	O
significantly	O
lower	O
serum	O
T3	O
concentrations	O
compared	O
to	O
those	O
with	O
undetectable	O
levels	O
[	O
1	O
.	O
072	O
+	O
/	O
-	O
0	O
.	O
588	O
vs	O
.	O

Finally	O
,	O
antibody	O
binding	O
to	O
site	O
IIIa	O
on	O
the	O
hCG	B-GENE
-	I-GENE
ectodomain	I-GENE
complex	I-GENE
was	O
also	O
hindered	O
by	O
an	O
anti	O
-	O
peptide	O
mAb	O
directed	O
against	O
a	O
peptide	O
encoded	O
by	O
the	O
eighth	O
exon	O
(	O
pE	O
x	O
8	O
)	O
of	O
the	O
LHR	B-GENE
.	O

2	O
.	O

Pressure	O
ulcers	O
.	O

The	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
PaO2	O
increased	O
from	O
80	O
.	O
8	O
+	O
/	O
-	O
26	O
.	O
9	O
mmHg	O
before	O
to	O
89	O
.	O
8	O
+	O
/	O
-	O
27	O
.	O
3	O
mmHg	O
after	O
the	O
infusion	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
PaCO2	O
decreased	O
from	O
42	O
.	O
4	O
+	O
/	O
-	O
8	O
.	O
3	O
to	O
39	O
.	O
6	O
+	O
/	O
-	O
7	O
.	O
9	O
mmHg	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

As	O
well	O
,	O
mixtures	O
of	O
(	O
LA	O
)	O
(	O
12	O
)	O
with	O
the	O
longer	O
chain	O
PEs	O
exhibit	O
unusual	O
biomodal	O
enthalpy	O
variations	O
,	O
suggesting	O
peptide	O
immiscibility	O
in	O
thicker	O
gel	O
state	O
bilayers	O
.	O

The	O
limit	O
between	O
the	O
cecum	O
and	O
the	O
ascending	O
colon	O
was	O
externally	O
marked	O
by	O
the	O
sulcus	O
cecocolicus	O
dorsalis	O
and	O
ventralis	O
.	O

The	O
PSS	B-GENE
gene	I-GENE
was	O
subcloned	O
into	O
a	O
1	O
.	O
1	O
-	O
kb	O
fragment	O
of	O
the	O
yeast	O
DNA	O
on	O
the	O
YEp13	O
vector	O
.	O

The	O
second	O
method	O
,	O
the	O
"	O
macro	O
"	O
assay	O
,	O
has	O
a	O
sensitivity	O
range	O
of	O
0	O
.	O
03	O
-	O
5	O
.	O
0	O
micrograms	O
phosphorus	O
with	O
100	O
-	O
500	O
microliters	O
HClO4	O
.	O

Recently	O
,	O
an	O
alternatively	O
spliced	O
form	O
of	O
c	B-GENE
-	I-GENE
myb	I-GENE
-	I-GENE
encoded	I-GENE
mRNA	I-GENE
has	O
been	O
identified	O
in	O
murine	O
cells	O
containing	O
either	O
normal	O
or	O
rearranged	O
c	B-GENE
-	I-GENE
myb	I-GENE
genes	I-GENE
.	O

The	O
hyperacute	O
phase	O
of	O
posterolateral	O
myocardial	O
infarction	O
.	O

RegA	B-GENE
is	O
a	O
positive	O
yet	O
nonessential	O
regulator	O
of	O
tol	B-GENE
-	O
oprL	B-GENE
expression	O
.	O

Northern	O
(	O
RNA	O
)	O
analysis	O
demonstrated	O
expression	O
of	O
human	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
in	O
all	O
tissues	O
and	O
cell	O
lines	O
tested	O
.	O

A	O
patient	O
suffering	O
from	O
heparin	O
-	O
associated	O
thrombocytopenia	O
(	O
HAT	O
)	O
,	O
recurrent	O
arteriothromboses	O
,	O
and	O
acute	O
renal	O
failure	O
after	O
treatment	O
with	O
standard	O
heparin	O
is	O
described	O
.	O

It	O
is	O
likely	O
that	O
the	O
sequence	O
similarities	O
reflect	O
a	O
common	O
molecular	O
architecture	O
of	O
the	O
two	O
heme	O
binding	O
sites	O
and	O
of	O
a	O
copper	O
binding	O
site	O
in	O
these	O
enzymes	O
.	O

Collectively	O
,	O
this	O
study	O
emphasizes	O
a	O
critical	O
role	O
of	O
Phox2a	B-GENE
as	O
well	O
as	O
its	O
functional	O
synergism	O
with	O
other	O
transcription	O
factors	O
(	O
e	O
.	O
g	O
.	O
,	O
CREB	B-GENE
,	O
AP2	B-GENE
,	O
and	O
Sp1	B-GENE
)	O
in	O
transcriptional	O
activation	O
of	O
the	O
DBH	B-GENE
gene	I-GENE
.	O

The	O
RNA	B-GENE
polymerase	I-GENE
III	I-GENE
-	I-GENE
recruiting	I-GENE
factor	I-GENE
TFIIIB	I-GENE
induces	O
a	O
DNA	O
bend	O
between	O
the	O
TATA	O
box	O
and	O
the	O
transcriptional	O
start	O
site	O
.	O

Our	O
data	O
demonstrate	O
directly	O
that	O
Rpm1r	B-GENE
is	O
transcribed	O
with	O
its	O
substrates	O
,	O
tRNA	B-GENE
met	I-GENE
f	I-GENE
and	O
tRNAPro	B-GENE
,	O
from	O
a	O
promoter	O
located	O
upstream	O
of	O
the	O
tRNA	B-GENE
met	I-GENE
f	I-GENE
gene	I-GENE
and	O
suggest	O
that	O
a	O
portion	O
also	O
originates	O
from	O
a	O
second	O
promoter	O
,	O
located	O
between	O
the	O
tRNA	B-GENE
met	I-GENE
f	I-GENE
gene	I-GENE
and	O
RPM1	B-GENE
.	O

Scanning	O
mutations	O
throughout	O
the	O
AC	O
element	O
interfered	O
with	O
induction	O
but	O
allowed	O
us	O
to	O
define	O
five	O
overlapping	O
sites	O
for	O
regulatory	O
factors	O
in	O
AC	O
and	O
to	O
design	O
probes	O
binding	O
just	O
one	O
or	O
two	O
factors	O
.	O

Blood	O
from	O
dams	O
was	O
collected	O
prior	O
to	O
inoculation	O
and	O
at	O
time	O
of	O
necropsy	O
for	O
measurement	O
of	O
IgM	B-GENE
and	O
IgG	B-GENE
antibodies	I-GENE
to	O
M	O
.	O
pulmonis	O
.	O

Consistent	O
with	O
this	O
model	O
,	O
a	O
synthetic	O
construct	O
containing	O
three	O
tandem	O
copies	O
of	O
the	O
native	O
LDL	B-GENE
receptor	I-GENE
SREBP	B-GENE
site	O
linked	O
to	O
a	O
single	O
Sp1	B-GENE
site	I-GENE
was	O
also	O
significantly	O
activated	O
in	O
a	O
buttonhead	B-GENE
-	O
independent	O
fashion	O
.	O

Alternatively	O
,	O
PC12	O
-	O
E2	O
cells	O
were	O
submitted	O
to	O
treatment	O
with	O
antibodies	O
to	O
the	O
fibroblast	B-GENE
growth	I-GENE
factor	I-GENE
(	I-GENE
FGF	I-GENE
)	I-GENE
receptor	I-GENE
,	O
inhibitors	O
of	O
the	O
nonreceptor	B-GENE
tyrosine	I-GENE
kinase	I-GENE
p59	B-GENE
(	O
fyn	B-GENE
)	O
,	O
PLC	B-GENE
,	O
PKC	B-GENE
and	O
MEK	B-GENE
and	O
an	O
activator	O
of	O
PKC	B-GENE
,	O
phorbol	O
-	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
.	O

Story	O
of	O
a	O
hospital	O
that	O
filmed	O
its	O
employee	O
orientation	O
program	O
.	O

The	O
new	O
semi	O
-	O
synthetic	O
oral	O
cephalosporin	O
,	O
CGP	O
9	O
,	O
000	O
,	O
has	O
been	O
evaluated	O
in	O
a	O
large	O
number	O
of	O
hospitalized	O
patients	O
with	O
urinary	O
infections	O
.	O

The	O
distribution	O
of	O
body	O
fluids	O
following	O
hemorrhage	O
and	O
resuscitation	O
in	O
combat	O
casualties	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
isolated	O
and	O
sequenced	O
several	O
p15E	B-GENE
cDNA	I-GENE
gene	I-GENE
fragments	I-GENE
amplified	O
by	O
means	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
from	O
parental	O
(	O
P815	O
)	O
and	O
xenogenized	O
(	O
P815	O
/	O
DTIC	O
)	O
tumour	O
cells	O
.	O

We	O
have	O
previously	O
identified	O
,	O
by	O
screening	O
a	O
lambda	O
gt11	O
expression	O
library	O
,	O
murine	B-GENE
protein	I-GENE
mXBP	I-GENE
,	O
which	O
binds	O
to	O
a	O
sequence	O
which	O
overlaps	O
the	O
3	O
'	O
end	O
of	O
the	O
murine	B-GENE
class	I-GENE
II	I-GENE
major	I-GENE
histocompatibility	I-GENE
complex	I-GENE
A	I-GENE
alpha	I-GENE
gene	I-GENE
X	I-GENE
box	I-GENE
,	O
a	O
conserved	O
transcription	O
element	O
found	O
upstream	O
of	O
all	O
class	O
II	O
genes	O
.	O

This	O
study	O
indicates	O
that	O
this	O
dose	O
-	O
intense	O
regimen	O
can	O
be	O
safely	O
administered	O
,	O
even	O
with	O
the	O
use	O
of	O
purged	O
marrow	O
,	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
.	O

Cyclin	B-GENE
-	I-GENE
dependent	I-GENE
kinase	I-GENE
-	I-GENE
2	I-GENE
(	O
Cdk2	B-GENE
)	O
forms	O
an	O
inactive	O
complex	O
with	O
cyclin	B-GENE
D1	I-GENE
since	O
Cdk2	B-GENE
associated	O
with	O
cyclin	B-GENE
D1	I-GENE
is	O
not	O
phosphorylated	O
by	O
Cdk7	B-GENE
-	O
cyclin	B-GENE
-	I-GENE
H	I-GENE
.	O

The	O
number	O
of	O
fecal	O
pellets	O
ingested	O
peaked	O
at	O
5	O
to	O
6	O
weeks	O
old	O
(	O
13	O
pellets	O
/	O
day	O
)	O
and	O
gradually	O
decreased	O
,	O
thereafter	O
(	O
2	O
.	O
1	O
pellets	O
at	O
78	O
weeks	O
old	O
,	O
1	O
.	O
5	O
pellets	O
at	O
104	O
weeks	O
old	O
)	O
.	O

Expression	O
of	O
the	O
second	O
gene	O
(	O
XT3	B-GENE
)	O
was	O
found	O
to	O
be	O
conserved	O
in	O
human	O
kidney	O
,	O
and	O
partial	O
sequence	O
was	O
obtained	O
from	O
a	O
human	O
cDNA	O
library	O
.	O

The	O
next	O
twenty	O
years	O
of	O
prevention	O
in	O
Indian	O
country	O
:	O
visionary	O
,	O
complex	O
,	O
and	O
practical	O
.	O

A	O
human	O
cytoplasmic	O
signaling	O
protein	O
has	O
been	O
cloned	O
that	O
possesses	O
the	O
same	O
structural	O
arrangement	O
of	O
SH3	B-GENE
-	O
SH2	B-GENE
-	O
SH3	B-GENE
domains	O
as	O
Grb2	B-GENE
.	O

CO2	O
assimilation	O
by	O
chloroplasts	O
illuminated	O
on	O
filter	O
paper	O
.	O

Liver	O
transplantation	O
in	O
one	O
patient	O
resolved	O
metabolic	O
complications	O
but	O
did	O
not	O
improve	O
PMN	O
count	O
or	O
the	O
infectious	O
status	O
,	O
while	O
neutropenia	O
was	O
corrected	O
by	O
G	B-GENE
-	I-GENE
CSF	I-GENE
.	O

According	O
to	O
the	O
published	O
sequence	O
of	O
the	O
CHS1	B-GENE
gene	I-GENE
,	O
this	O
fragment	O
contains	O
four	O
repeats	O
of	O
a	O
TGAAACA	O
consensus	O
sequence	O
previously	O
identified	O
in	O
the	O
alpha	B-GENE
-	I-GENE
factor	I-GENE
-	O
inducible	O
BAR1	B-GENE
promoter	I-GENE
[	O
Kronstad	O
,	O
J	O
.	O

These	O
lesions	O
were	O
asymptomatic	O
,	O
but	O
both	O
were	O
characterized	O
clinically	O
by	O
central	O
ulceration	O
.	O

Experiments	O
on	O
narcotized	O
cats	O
demonstrated	O
that	O
the	O
derivatives	O
of	O
2	O
-	O
mercaptobenzimidazole	O
possessing	O
the	O
properties	O
of	O
specific	O
bradycardic	O
agents	O
and	O
coded	O
as	O
CM	O
-	O
251	O
,	O
CM	O
-	O
266	O
,	O
and	O
CM	O
-	O
345	O
,	O
reduce	O
the	O
mean	O
rise	O
of	O
segment	O
ST	O
on	O
numerous	O
leads	O
of	O
the	O
epicardial	O
electrogram	O
during	O
5	O
-	O
min	O
occlusion	O
of	O
the	O
anterior	O
descending	O
branch	O
of	O
the	O
left	O
coronary	O
artery	O
.	O

The	O
results	O
suggest	O
that	O
GATA	B-GENE
-	I-GENE
5	I-GENE
may	O
have	O
specific	O
downstream	O
targets	O
and	O
that	O
GATA	B-GENE
-	I-GENE
4	I-GENE
,	I-GENE
-	I-GENE
5	I-GENE
,	I-GENE
and	I-GENE
-	I-GENE
6	I-GENE
can	O
only	O
partially	O
substitute	O
for	O
each	O
other	O
in	O
cardiogenesis	O
.	O

SERS	O
spectra	O
were	O
obtained	O
by	O
vacuum	O
evaporation	O
and	O
casting	O
of	O
p	O
-	O
NTP	O
onto	O
silver	O
island	O
films	O
,	O
and	O
also	O
from	O
colloidal	O
silver	O
solutions	O
.	O

The	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
(	I-GENE
EGF	I-GENE
)	I-GENE
receptor	I-GENE
,	O
which	O
exhibits	O
intrinsic	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
activity	O
,	O
undergoes	O
a	O
rapid	O
,	O
intramolecular	O
self	O
-	O
phosphorylation	O
reaction	O
following	O
EGF	B-GENE
activation	O
.	O

Lysine	B-GENE
-	I-GENE
ketoglutarate	I-GENE
reductase	I-GENE
and	O
saccharopine	B-GENE
dehydrogenase	I-GENE
from	O
Arabidopsis	O
thaliana	O
:	O
nucleotide	O
sequence	O
and	O
characterization	O
.	O

The	O
single	O
most	O
important	O
element	O
,	O
by	O
linker	O
-	O
scanning	O
analysis	O
,	O
is	O
a	O
10	O
-	O
bp	O
region	O
that	O
contains	O
a	O
CCAAT	O
motif	O
.	O

However	O
,	O
tyrA	B-GENE
can	O
be	O
expressed	O
efficiently	O
from	O
an	O
internal	O
promoter	O
which	O
appears	O
to	O
lie	O
within	O
the	O
3	O
'	O
portion	O
of	O
aroF	B-GENE
.	O

Molecular	O
cloning	O
of	O
a	O
novel	O
human	B-GENE
I	I-GENE
-	I-GENE
mfa	I-GENE
domain	I-GENE
-	I-GENE
containing	I-GENE
protein	I-GENE
that	O
differently	O
regulates	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
and	O
HIV	O
-	O
1	O
expression	O
.	O

The	O
rational	O
for	O
the	O
prophylactic	O
treatment	O
,	O
the	O
therapy	O
of	O
the	O
meningopathy	O
and	O
AIL	O
-	O
AIEOP	O
protocols	O
are	O
exposed	O
.	O

Topical	O
L	O
-	O
NNA	O
attenuated	O
the	O
hypercapnic	O
increase	O
of	O
CoBF	O
by	O
52	O
+	O
/	O
-	O
6	O
%	O
and	O
CeBF	O
by	O
29	O
+	O
/	O
-	O
5	O
%	O
after	O
45	O
-	O
min	O
exposure	O
.	O

Duration	O
of	O
remission	O
in	O
advanced	O
gastric	O
cancer	O
patients	O
responding	O
to	O
sequential	O
dose	O
of	O
MTX	O
and	O
5	O
-	O
FU	O

OKA	O
and	O
calyculin	O
A	O
do	O
not	O
decrease	O
OCFRE	B-GENE
DNA	O
-	O
protein	O
interactions	O
,	O
suggesting	O
that	O
important	O
protein	O
-	O
protein	O
interactions	O
are	O
phosphatase	O
regulated	O
.	O

The	O
data	O
indicate	O
that	O
etr	B-GENE
-	I-GENE
1	I-GENE
is	O
essential	O
for	O
muscle	O
development	O
in	O
C	O
.	O
elegans	O
,	O
perhaps	O
by	O
playing	O
a	O
role	O
in	O
post	O
-	O
transcriptional	O
processing	O
of	O
some	O
muscle	O
component	O
,	O
and	O
thus	O
suggesting	O
a	O
possible	O
conservation	O
of	O
gene	O
function	O
with	O
human	B-GENE
CUG	I-GENE
-	I-GENE
bp	I-GENE
.	O

The	O
poly	O
(	O
A	O
)	O
segment	O
of	O
the	O
RNA	O
was	O
selectively	O
cross	O
-	O
linked	O
to	O
the	O
72	O
,	O
000	O
-	O
molecular	O
-	O
weight	O
protein	O
(	O
72K	O
protein	O
)	O
.	O

Nuclease	O
probing	O
and	O
structure	O
-	O
directed	O
mutagenesis	O
revealed	O
that	O
the	O
105	O
-	O
nt	O
TE	O
(	O
TE105	O
)	O
forms	O
a	O
cruciform	O
secondary	O
structure	O
containing	O
four	O
helices	O
connected	O
by	O
single	O
-	O
stranded	O
regions	O
.	O

Though	O
the	O
BACTEC	O
9000	O
MB	O
system	O
is	O
recommended	O
for	O
respiratory	O
specimens	O
,	O
we	O
demonstrated	O
that	O
it	O
can	O
be	O
successfully	O
used	O
also	O
for	O
recovery	O
of	O
mycobacteria	O
from	O
clinical	O
specimens	O
from	O
various	O
extrapulmonary	O
sites	O
.	O

In	O
all	O
instances	O
the	O
apparent	O
alcohol	O
responses	O
were	O
very	O
small	O
and	O
never	O
exceeded	O
a	O
reading	O
of	O
1	O
microgram	O
/	O
100ml	O
for	O
breath	O
samples	O
more	O
than	O
10min	O
post	O
-	O
exposure	O
.	O

O	B-GENE
.	I-GENE
novo	I-GENE
-	I-GENE
ulmi	I-GENE
RNA	I-GENE
-	I-GENE
7	I-GENE
,	O
previously	O
believed	O
to	O
be	O
a	O
satellite	O
-	O
like	O
RNA	O
,	O
is	O
shown	O
to	O
be	O
a	O
defective	O
RNA	O
,	O
derived	O
from	O
OnuMV4	B-GENE
-	I-GENE
Ld	I-GENE
RNA	I-GENE
by	O
multiple	O
internal	O
deletions	O
.	O

SCID	O
V	B-GENE
(	O
D	B-GENE
)	O
J	B-GENE
recombination	O
can	O
be	O
partly	O
rescued	O
in	O
T	O
-	O
lymphocytes	O
by	O
either	O
DNA	O
-	O
damaging	O
agents	O
(	O
gamma	O
-	O
irradiation	O
and	O
bieomycin	O
)	O
or	O
a	O
null	O
mutation	O
of	O
the	O
p53	B-GENE
gene	I-GENE
,	O
possibly	O
because	O
of	O
transiently	O
elevated	O
DNA	O
repair	O
activity	O
in	O
response	O
to	O
DNA	O
damage	O
or	O
to	O
delayed	O
apoptosis	O
in	O
the	O
absence	O
of	O
p53	B-GENE
.	O

Sensitization	O
to	O
hyperlactatemia	O
induced	O
by	O
phenformin	O
after	O
subtotal	O
ablation	O
of	O
the	O
pancreas	O
.	O

Examination	O
of	O
immediate	B-GENE
-	I-GENE
early	I-GENE
transcription	I-GENE
factor	I-GENE
expression	O
during	O
the	O
MDI	O
regimen	O
revealed	O
that	O
RA	O
mediated	O
an	O
elevated	O
,	O
prolonged	O
expression	O
of	O
c	B-GENE
-	I-GENE
Jun	I-GENE
mRNA	I-GENE
accompanied	O
by	O
diminished	O
expression	O
of	O
c	B-GENE
-	I-GENE
Fos	I-GENE
and	O
Jun	B-GENE
-	I-GENE
B	I-GENE
mRNAs	I-GENE
.	O

Circulatory	O
arrest	O
in	O
the	O
operating	O
room	O
.	O

At	O
an	O
ambient	O
temperature	O
of	O
25	O
degrees	O
C	O
,	O
the	O
responses	O
to	O
spinal	O
cooling	O
are	O
reduced	O
during	O
the	O
dark	O
phase	O
.	O

These	O
cells	O
fail	O
to	O
generate	O
the	O
signals	O
to	O
phosphorylate	O
CREB	B-GENE
and	O
produce	O
significantly	O
less	O
of	O
the	O
cytokine	O
Interleukin	B-GENE
-	I-GENE
2	I-GENE
(	O
IL	B-GENE
-	I-GENE
2	I-GENE
)	O
in	O
response	O
to	O
agents	O
that	O
either	O
increase	O
intracellular	O
Ca2	O
+	O
and	O
/	O
or	O
activate	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
.	O

One	O
P1	O
genomic	O
clone	O
and	O
six	O
subsequent	O
plasmid	O
subclones	O
were	O
isolated	O
and	O
analyzed	O
for	O
the	O
exon	O
-	O
intron	O
organization	O
of	O
the	O
Ctpct	B-GENE
gene	I-GENE
.	O

Treating	O
renal	O
anaemia	O
with	O
recombinant	O
human	O
erythropoietin	B-GENE
.	O

Five	O
modalities	O
of	O
nonpharmacologic	O
approaches	O
are	O
recommended	O
at	O
present	O
for	O
lifestyle	O
modification	O
and	O
control	O
of	O
arterial	O
blood	O
pressure	O
elevation	O
:	O
1	O
)	O
weight	O
reduction	O
to	O
ideal	O
body	O
weight	O
,	O
since	O
it	O
reduces	O
risk	O
of	O
hypertension	O
as	O
well	O
as	O
overall	O
cardiovascular	O
morbidity	O
and	O
mortality	O
;	O
2	O
)	O
dietary	O
sodium	O
restriction	O
to	O
less	O
than	O
2	O
g	O
a	O
day	O
,	O
without	O
assurance	O
that	O
it	O
will	O
normalize	O
arterial	O
pressure	O
although	O
it	O
may	O
help	O
reduce	O
dosage	O
and	O
numbers	O
of	O
prescribed	O
antihypertensive	O
drugs	O
;	O
3	O
)	O
moderation	O
of	O
alcohol	O
consumption	O
to	O
less	O
than	O
1	O
ounce	O
a	O
day	O
;	O
4	O
)	O
a	O
regular	O
isotonic	O
exercise	O
program	O
;	O
and	O
5	O
)	O
cessation	O
of	O
tobacco	O
consumption	O
.	O

The	O
activated	O
glucocorticoid	B-GENE
receptor	I-GENE
forms	O
a	O
complex	O
with	O
Stat5	B-GENE
and	O
enhances	O
Stat5	B-GENE
-	O
mediated	O
transcriptional	O
induction	O
.	O

The	O
currently	O
proposed	O
extended	O
arch	O
repair	O
should	O
be	O
reserved	O
for	O
the	O
small	O
group	O
of	O
infants	O
with	O
transverse	O
aortic	O
arch	O
to	O
ascending	O
aorta	O
diameter	O
ratios	O
(	O
arch	O
indices	O
)	O
of	O
less	O
than	O
0	O
.	O
25	O
.	O

We	O
conclude	O
that	O
RPMS	B-GENE
acts	O
as	O
a	O
negative	O
regulator	O
of	O
EBNA2	B-GENE
and	O
Notch	B-GENE
activity	O
through	O
its	O
interactions	O
with	O
the	O
CBF1	B-GENE
-	I-GENE
associated	I-GENE
corepressor	I-GENE
complex	I-GENE
.	O

The	O
4	O
degrees	O
stimuli	O
were	O
found	O
to	O
elicit	O
scalp	O
distributions	O
for	O
the	O
pattern	O
reversal	O
P100	O
and	O
the	O
pattern	O
onset	O
C1	O
consistent	O
with	O
striate	O
and	O
extrastriate	O
visual	O
cortical	O
origins	O
respectively	O
.	O

The	O
human	B-GENE
ABCG1	I-GENE
gene	I-GENE
encodes	O
a	O
member	O
of	O
the	O
ATP	B-GENE
-	I-GENE
binding	I-GENE
cassette	I-GENE
(	O
ABC	B-GENE
)	O
superfamily	O
of	O
transporter	B-GENE
proteins	I-GENE
and	O
is	O
highly	O
induced	O
when	O
macrophages	O
are	O
incubated	O
with	O
oxysterols	O
.	O

Here	O
we	O
describe	O
an	O
in	O
vitro	O
assay	O
where	O
the	O
NS3	B-GENE
-	I-GENE
4A	I-GENE
polyprotein	I-GENE
,	O
NS3	B-GENE
,	O
the	O
serine	B-GENE
proteinase	I-GENE
domain	I-GENE
(	I-GENE
the	I-GENE
N	I-GENE
-	I-GENE
terminal	I-GENE
181	I-GENE
residues	I-GENE
of	I-GENE
NS3	I-GENE
)	I-GENE
,	O
and	O
the	O
NS4A	B-GENE
cofactor	I-GENE
were	O
produced	O
by	O
cell	O
-	O
free	O
translation	O
and	O
tested	O
for	O
trans	O
-	O
processing	O
of	O
radiolabeled	O
substrates	O
.	O

RNA	O
gel	O
retardation	O
and	O
competition	O
analyses	O
indicate	O
that	O
TRP	B-GENE
-	I-GENE
185	I-GENE
binding	O
is	O
strongly	O
dependent	O
on	O
the	O
TAR	O
RNA	O
loop	O
sequences	O
.	O

The	O
genomic	O
and	O
transcriptional	O
complexity	O
of	O
the	O
Crry	B-GENE
and	O
Crry	B-GENE
-	O
ps	B-GENE
genes	O
.	O

These	O
results	O
indicate	O
that	O
the	O
PCNA	B-GENE
gene	I-GENE
is	O
a	O
likely	O
target	O
gene	O
of	O
E2F	B-GENE
.	O

SBF	B-GENE
binds	O
to	O
the	O
promoter	O
prior	O
to	O
the	O
activation	O
of	O
transcription	O
in	O
late	O
G1	O
,	O
suggesting	O
that	O
Cln	B-GENE
/	O
Cdc28	B-GENE
kinase	O
regulates	O
the	O
ability	O
of	O
previously	O
bound	O
SBF	B-GENE
to	O
activate	O
transcription	O
.	O

Altogether	O
these	O
results	O
suggest	O
that	O
,	O
in	O
KG1a	O
cells	O
,	O
TNFalpha	B-GENE
can	O
stimulate	O
in	O
parallel	O
PC	B-GENE
-	I-GENE
PLC	I-GENE
and	O
PLD	B-GENE
,	O
whose	O
lipid	O
products	O
activate	O
in	O
turn	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
MAP	B-GENE
kinase	I-GENE
)	O
and	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
signalling	O
respectively	O
.	O

The	O
RI	B-GENE
alpha	I-GENE
gene	I-GENE
is	O
composed	O
of	O
nine	O
coding	O
exons	O
of	O
varying	O
lengths	O
,	O
separated	O
by	O
introns	O
,	O
giving	O
the	O
gene	O
a	O
total	O
length	O
of	O
at	O
least	O
21	O
kb	O
.	O
our	O
recent	O
cloning	O
of	O
a	O
processed	O
RI	B-GENE
alpha	I-GENE
pseudogene	I-GENE
with	O
a	O
5	O
'	O
-	O
noncoding	O
region	O
different	O
from	O
the	O
previously	O
reported	O
RI	B-GENE
alpha	I-GENE
complementary	I-GENE
RNA	I-GENE
indicated	O
that	O
the	O
RI	B-GENE
alpha	I-GENE
gene	I-GENE
may	O
have	O
multiple	O
leader	O
exons	O
giving	O
rise	O
to	O
alternately	O
spliced	O
messenger	O
RNAs	O
(	O
mRNAs	O
)	O
.	O

While	O
mutations	O
in	O
K	B-GENE
-	I-GENE
Rev	I-GENE
that	O
inactivate	O
any	O
one	O
of	O
these	O
properties	O
also	O
blocked	O
K	B-GENE
-	I-GENE
Rev	I-GENE
-	O
dependent	O
nuclear	O
RNA	O
export	O
,	O
several	O
K	B-GENE
-	I-GENE
Rev	I-GENE
mutants	I-GENE
were	O
comparable	O
to	O
wild	O
type	O
when	O
assayed	O
for	O
any	O
of	O
these	O
individual	O
activities	O
yet	O
nevertheless	O
defective	O
for	O
RNA	O
export	O
.	O

Interspecific	O
backcross	O
analysis	O
using	O
progeny	O
derived	O
from	O
matings	O
of	O
(	O
C57BL	O
/	O
6J	O
x	O
Mus	O
spretus	O
)	O
F1	O
x	O
C57BL	O
/	O
6J	O
mice	O
indicates	O
that	O
the	O
thrombospondin	B-GENE
gene	I-GENE
is	O
tightly	O
linked	O
to	O
the	O
Fshb	B-GENE
,	O
Actcl	B-GENE
,	O
Ltk	B-GENE
,	O
and	O
B2M	B-GENE
loci	I-GENE
on	O
murine	O
chromosome	O
2	O
.	O

Transcription	O
factors	O
containing	O
a	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
bHLH	O
)	O
motif	O
regulate	O
the	O
expression	O
of	O
tissue	O
-	O
specific	O
genes	O
in	O
a	O
number	O
of	O
mammalian	O
and	O
insect	O
systems	O
.	O

This	O
observation	O
suggests	O
that	O
the	O
methyl	O
-	O
directed	O
repair	O
system	O
utilizes	O
the	O
proximal	O
d	O
(	O
GATC	O
)	O
sequence	O
to	O
direct	O
correction	O
.	O

Surprisingly	O
,	O
Northern	O
(	O
RNA	O
)	O
blot	O
analysis	O
and	O
reverse	B-GENE
transcriptase	I-GENE
-	O
PCRs	O
performed	O
after	O
transfection	O
of	O
COS	O
-	O
7	O
or	O
HeLa	O
cells	O
with	O
these	O
viral	O
RNAs	O
revealed	O
that	O
Y88S	B-GENE
and	O
Y88L	B-GENE
RNAs	I-GENE
replicated	O
at	O
only	O
very	O
low	O
levels	O
.	O

FISH	O
using	O
a	O
whole	O
chromosome	O
4	O
paint	O
demonstrated	O
multiple	O
rearrangements	O
involving	O
chromosome	O
4	O
in	O
MCF	O
-	O
7	O
AdVp3000	O
and	O
MCF	O
-	O
7	O
MX	O
,	O
while	O
S1	O
-	O
M1	O
-	O
80	O
contained	O
only	O
a	O
simple	O
reciprocal	O
translocation	O
.	O

Handling	O
on	O
PND	O
9	O
did	O
not	O
result	O
in	O
elevated	O
CORT	O
levels	O
in	O
any	O
of	O
the	O
groups	O
.	O

Tissue	B-GENE
plasminogen	I-GENE
activator	I-GENE
,	O
its	O
inhibitor	O
and	O
other	O
parameters	O
of	O
fibrinolysis	O
in	O
blood	O
of	O
patients	O
operated	O
for	O
mild	O
hypertrophy	O
of	O
the	O
prostate	O

Determination	O
of	O
three	O
-	O
dimensional	O
imaging	O
properties	O
of	O
a	O
light	O
microscope	O
system	O
.	O

METHODS	O
:	O
Fifty	O
-	O
one	O
healthy	O
eyes	O
,	O
169	O
ocular	O
hypertensive	O
eyes	O
with	O
normal	O
visual	O
fields	O
,	O
and	O
132	O
glaucomatous	O
eyes	O
with	O
early	O
visual	O
field	O
defects	O
were	O
evaluated	O
with	O
qualitative	O
and	O
quantitative	O
measures	O
of	O
structural	O
damage	O
to	O
the	O
optic	O
nerve	O
and	O
nerve	O
fiber	O
layer	O
.	O

The	O
rationale	O
for	O
continuous	O
dopaminergic	O
stimulation	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
.	O

Deletion	O
analyses	O
implicate	O
the	O
N	O
-	O
terminal	O
110	O
amino	O
acids	O
of	O
Grb14	B-GENE
and	O
ankyrin	B-GENE
repeats	O
10	O
-	O
19	O
of	O
tankyrase	B-GENE
2	I-GENE
in	O
mediating	O
this	O
interaction	O
.	O

Most	O
of	O
them	O
were	O
situated	O
at	O
Sylvius	O
fissure	O
(	O
13	O
cases	O
)	O
.	O

The	O
results	O
presented	O
suggest	O
that	O
TIQ	O
reduces	O
the	O
turnover	O
rate	O
of	O
the	O
nigrostriatal	O
dopamine	O
neurons	O
after	O
repeated	O
administration	O
for	O
a	O
long	O
period	O
in	O
mice	O
.	O

The	O
STAT	B-GENE
-	I-GENE
1	I-GENE
signaling	O
pathway	O
provides	O
at	O
least	O
one	O
mechanism	O
for	O
activation	O
of	O
the	O
CAEV	B-GENE
LTR	I-GENE
by	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
in	O
monocytes	O
.	O

Patients	O
were	O
subclassified	O
into	O
age	O
-	O
matched	O
groups	O
of	O
primary	O
untreated	O
cancer	O
(	O
21	O
)	O
,	O
recurrent	O
cancer	O
(	O
18	O
)	O
,	O
and	O
"	O
cured	O
"	O
patients	O
who	O
had	O
been	O
free	O
of	O
disease	O
for	O
at	O
least	O
9	O
months	O
(	O
16	O
)	O
.	O

Findings	O
of	O
positive	O
potentials	O
showed	O
that	O
N1	O
originated	O
in	O
the	O
area	O
of	O
ventral	O
gray	O
matter	O
through	O
the	O
ventro	O
-	O
lateral	O
column	O
and	O
N2	O
through	O
the	O
dorsal	O
column	O
.	O

Plasma	O
CCK	B-GENE
levels	O
were	O
determined	O
at	O
regular	O
intervals	O
.	O

Aplastic	O
crisis	O
in	O
sickle	O
cell	O
disorders	O
:	O
bone	O
marrow	O
necrosis	O
and	O
human	O
parvovirus	O
infection	O
.	O

The	O
algorithm	O
also	O
limited	O
TG	O
to	O
20	O
and	O
64	O
%	O
,	O
apoB	B-GENE
to	O
6	O
and	O
20	O
%	O
,	O
and	O
Lp	B-GENE
(	I-GENE
a	I-GENE
)	I-GENE
to	O
15	O
and	O
56	O
%	O
,	O
of	O
low	O
-	O
and	O
high	O
-	O
risk	O
groups	O
,	O
respectively	O
.	O

135	O
students	O
had	O
a	O
count	O
of	O
less	O
than	O
50	O
eggs	O
/	O
10	O
ml	O
.	O
urine	O
and	O
56	O
had	O
more	O
than	O
50	O
eggs	O
/	O
10ml	O
.	O

These	O
probable	O
border	O
sequences	O
are	O
closely	O
related	O
to	O
those	O
of	O
other	O
known	O
T	O
-	O
regions	O
and	O
define	O
a	O
second	O
T	O
-	O
region	O
of	O
pTiChry5	O
,	O
called	O
T	O
-	O
right	O
(	O
TR	O
)	O
,	O
that	O
confers	O
production	O
of	O
the	O
Amadoriopines	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
roles	O
that	O
CCK	B-GENE
and	O
trypsin	B-GENE
inhibitors	O
are	O
believed	O
to	O
play	O
in	O
the	O
negative	O
feedback	O
control	O
of	O
pancreatic	O
exocrine	O
function	O
.	O

Pax	B-GENE
-	I-GENE
3	I-GENE
is	O
a	O
paired	B-GENE
-	I-GENE
type	I-GENE
homeobox	I-GENE
gene	I-GENE
that	O
is	O
specifically	O
expressed	O
in	O
the	O
dorsal	O
and	O
posterior	O
neural	O
tube	O
.	O

A	O
family	O
of	O
RNA	O
molecules	O
in	O
the	O
2	O
.	O
0	O
-	O
2	O
.	O
2	O
-	O
kilobase	O
range	O
identified	O
with	O
a	O
probe	O
from	O
this	O
gene	O
was	O
overexpressed	O
in	O
the	O
resistant	O
cells	O
.	O

By	O
DNase	B-GENE
I	I-GENE
footprint	O
analysis	O
of	O
the	O
PNR	O
element	O
,	O
a	O
palindrome	O
of	O
two	O
high	O
-	O
affinity	O
Ets	B-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
(	O
CTTCCCTGGAAG	O
)	O
was	O
identified	O
.	O

Response	O
to	O
treatment	O
was	O
better	O
in	O
patients	O
with	O
less	O
pretreatment	O
(	O
one	O
-	O
two	O
prior	O
treatments	O
)	O
than	O
in	O
heavily	O
pretreated	O
ones	O
(	O
more	O
than	O
three	O
)	O
and	O
this	O
relation	O
was	O
found	O
to	O
be	O
statistically	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Surprisingly	O
,	O
the	O
COOH	O
-	O
terminal	O
domain	O
of	O
RanGAP1	B-GENE
was	O
also	O
found	O
to	O
harbor	O
a	O
nuclear	O
localization	O
signal	O
.	O

An	O
8	O
-	O
h	O
exposure	O
to	O
10	O
mg	O
DMEA	O
/	O
m3	O
corresponds	O
to	O
a	O
postexposure	O
plasma	O
concentration	O
and	O
2	O
-	O
h	O
postexposure	O
urinary	O
excretion	O
of	O
4	O
.	O
9	O
mumol	O
/	O
l	O
and	O
75	O
mmol	O
/	O
mol	O
creatinine	O
,	O
respectively	O
.	O

Quantitative	O
analysis	O
of	O
the	O
coronary	O
stenosis	O
was	O
assessed	O
before	O
and	O
after	O
PTCA	O
,	O
and	O
the	O
dilatation	O
resulted	O
in	O
an	O
increase	O
in	O
minimal	O
luminal	O
cross	O
-	O
sectional	O
area	O
from	O
1	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
8	O
to	O
2	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
2	O
mm2	O
.	O

Mechanism	O
of	O
enhancement	O
of	O
DNA	O
expression	O
consequent	O
to	O
cointernalization	O
of	O
a	O
replication	O
-	O
deficient	O
adenovirus	O
and	O
unmodified	O
plasmid	O
DNA	O
.	O

CCAAT	B-GENE
/	I-GENE
enhancer	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
isoforms	I-GENE
beta	I-GENE
and	I-GENE
delta	I-GENE
are	O
expressed	O
in	O
mammary	O
epithelial	O
cells	O
and	O
bind	O
to	O
multiple	O
sites	O
in	O
the	O
beta	B-GENE
-	I-GENE
casein	I-GENE
gene	I-GENE
promoter	I-GENE
.	O

We	O
show	O
here	O
that	O
the	O
in	O
vitro	O
transcription	O
extract	O
contains	O
a	O
binding	O
activity	O
that	O
is	O
specific	O
for	O
the	O
initiator	O
element	O
and	O
thus	O
may	O
participate	O
in	O
recruiting	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
to	O
the	O
SL	O
RNA	O
gene	O
promoter	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
has	O
the	O
greatest	O
homology	O
(	O
61	O
%	O
)	O
to	O
the	O
green	B-GENE
alga	I-GENE
Scenedemus	I-GENE
obliquus	I-GENE
plastocyanin	I-GENE
.	O

Chloroplast	B-GENE
mutator	I-GENE
(	O
chm	B-GENE
)	O
of	O
Arabidopsis	O
is	O
a	O
recessive	O
nuclear	O
mutation	O
that	O
causes	O
green	O
and	O
white	O
variegation	O
in	O
leaves	O
and	O
is	O
inherited	O
in	O
a	O
non	O
-	O
Mendelian	O
fashion	O
.	O

(	O
1996a	O
)	O
Biochemistry	O
35	O
,	O
1589	O
-	O
1598	O
]	O
.	O

Subjects	O
with	O
a	O
short	O
postexposure	O
time	O
and	O
a	O
dioxin	O
burden	O
>	O
0	O
.	O
6	O
pg	O
/	O
m3	O
had	O
a	O
significantly	O
higher	O
risk	O
of	O
hypoergy	O
than	O
unexposed	O
subjects	O
(	O
hypoergy	O
I	O
:	O
OR	O
=	O
9	O
.	O
51	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
96	O
-	O
42	O
.	O
02	O
;	O
hypoergy	O
II	O
:	O
OR	O
=	O
2	O
.	O
92	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
14	O
-	O
7	O
.	O
5	O
)	O
.	O

A	O
single	O
1	O
.	O
8	O
-	O
kb	O
transcript	O
mRNA	O
was	O
detected	O
by	O
Northern	O
(	O
RNA	O
)	O
blot	O
analysis	O
,	O
and	O
its	O
5	O
'	O
end	O
maps	O
to	O
a	O
position	O
51	O
bp	O
upstream	O
from	O
the	O
site	O
of	O
initiation	O
of	O
protein	O
synthesis	O
.	O

The	O
enhancer	O
region	O
of	O
Akv	O
murine	O
leukemia	O
virus	O
contains	O
the	O
sequence	O
motif	O
ACAGATGG	O
.	O

The	O
concentrations	O
of	O
vitamin	O
A	O
precursors	O
and	O
vitamin	O
E	O
in	O
the	O
hay	O
were	O
below	O
currently	O
recommended	O
dietary	O
levels	O
for	O
llamas	O
,	O
and	O
alfalfa	O
hay	O
appears	O
to	O
provide	O
an	O
unreliable	O
source	O
of	O
vitamins	O
A	O
and	O
E	O
in	O
this	O
species	O
.	O

Co	O
-	O
administration	O
of	O
5FU	O
,	O
angiotensin	B-GENE
II	I-GENE
and	O
microspheres	O
via	O
the	O
hepatic	O
artery	O
may	O
reduce	O
drug	O
exposure	O
in	O
the	O
systemic	O
compartment	O
and	O
therefore	O
may	O
increase	O
the	O
therapeutic	O
ratio	O
of	O
5FU	O
administration	O
via	O
the	O
hepatic	O
artery	O
.	O

Biol	O
.	O

The	O
reduced	O
NO	O
production	O
in	O
these	O
cells	O
was	O
associated	O
with	O
low	O
levels	O
of	O
mRNA	O
of	O
inducible	B-GENE
NO	I-GENE
synthetase	I-GENE
.	O

Sequence	O
analysis	O
of	O
the	O
isolated	O
genomic	O
clone	O
revealed	O
that	O
the	O
DNA	O
binding	O
domain	O
of	O
this	O
orphan	O
receptor	O
is	O
most	O
homologous	O
to	O
the	O
human	B-GENE
TR2	I-GENE
receptor	I-GENE
.	O

5	O
'	O
-	O
RACE	O
analysis	O
suggested	O
a	O
single	O
transcription	O
initiation	O
site	O
187	O
bp	O
upstream	O
from	O
the	O
translational	O
start	O
site	O
.	O

In	O
contrast	O
,	O
2	O
,	O
397	O
(	O
74	O
%	O
)	O
had	O
one	O
or	O
more	O
risk	O
factors	O
(	O
not	O
low	O
risk	O
)	O
;	O
of	O
these	O
,	O
5	O
.	O
3	O
%	O
died	O
in	O
6	O
weeks	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

It	O
is	O
largely	O
predicted	O
by	O
lupus	O
anticoagulant	O
(	O
estimated	O
by	O
activated	O
partial	O
thromboplastin	B-GENE
time	O
)	O
and	O
/	O
or	O
antibody	O
to	O
cardiolipin	O
.	O

E	O
.	O
,	O
Hession	O
,	O
C	O
.	O
,	O
Goff	O
,	O
D	O
.	O
,	O
Griffiths	O
,	O
B	O
.	O
,	O
Tizard	O
,	O
R	O
.	O
,	O
Newman	O
,	O
B	O
.	O
,	O
Chi	O
-	O
Rosso	O
,	O
G	O
.	O
,	O
and	O
Lobb	O
,	O
R	O
.	O
,	O
(	O
1990	O
)	O
Cell	O
63	O
,	O
1349	O
-	O
1356	O
)	O
.	O

Iodine	O
metabolism	O
in	O
chronic	O
thyroiditis	O
.	O

Schlegel	O
,	O
J	O
.	O

Mutational	O
analysis	O
of	O
mRNA	B-GENE
capping	I-GENE
enzyme	I-GENE
identifies	O
amino	O
acids	O
involved	O
in	O
GTP	O
binding	O
,	O
enzyme	O
-	O
guanylate	O
formation	O
,	O
and	O
GMP	O
transfer	O
to	O
RNA	O
.	O

The	O
concentrations	O
of	O
apo	B-GENE
A	I-GENE
-	I-GENE
I	I-GENE
and	O
apo	B-GENE
A	I-GENE
-	I-GENE
II	I-GENE
of	O
abstainers	O
decreased	O
significantly	O
compared	O
with	O
the	O
corresponding	O
changes	O
in	O
controls	O
.	O

Hormonal	O
regulation	O
of	O
multiple	O
promoters	O
of	O
the	O
rat	B-GENE
mitochondrial	I-GENE
glycerol	I-GENE
-	I-GENE
3	I-GENE
-	I-GENE
phosphate	I-GENE
dehydrogenase	I-GENE
gene	I-GENE
:	O
identification	O
of	O
a	O
complex	O
hormone	O
-	O
response	O
element	O
in	O
the	O
ubiquitous	O
promoter	O
B	O
.	O

Imaging	O
features	O
of	O
splenic	O
epidermoid	O
cyst	O
with	O
pathologic	O
correlation	O
.	O

TNFalpha	B-GENE
and	O
IL	B-GENE
-	I-GENE
6	I-GENE
levels	O
were	O
determined	O
in	O
the	O
culture	O
supernatants	O
.	O

Effects	O
of	O
spatial	O
and	O
temporal	O
smoothing	O
on	O
stimulated	O
brillouin	O
scattering	O
in	O
the	O
independent	O
-	O
hot	O
-	O
spot	O
model	O
limit	O
The	O
influence	O
of	O
laser	O
beam	O
smoothing	O
on	O
stimulated	O
Brillouin	O
backscattering	O
(	O
SBBS	O
)	O
is	O
studied	O
analytically	O
in	O
the	O
limit	O
of	O
the	O
independent	O
hot	O
spot	O
model	O
.	O

To	O
identify	O
the	O
precise	O
location	O
of	O
the	O
phosphorylation	O
site	O
on	O
the	O
64	O
-	O
kDa	O
protein	O
,	O
a	O
step	O
-	O
by	O
-	O
step	O
mutagenesis	O
procedures	O
was	O
followed	O
.	O

Among	O
these	O
,	O
ACT1	B-GENE
was	O
isolated	O
four	O
times	O
,	O
and	O
NSR1	B-GENE
three	O
times	O
.	O

These	O
results	O
suggest	O
that	O
leader	O
-	O
mRNA	O
fusion	O
in	O
coronavirus	O
transcription	O
does	O
not	O
require	O
direct	O
RNA	O
-	O
RNA	O
interaction	O
between	O
complementary	O
sequences	O
.	O

These	O
results	O
suggest	O
that	O
leader	O
-	O
mRNA	O
fusion	O
in	O
coronavirus	O
transcription	O
does	O
not	O
require	O
direct	O
RNA	O
-	O
RNA	O
interaction	O
between	O
complementary	O
sequences	O
.	O

60th	O
birthday	O
of	O
colonel	O
prof	O
.	O

e	O
.	O
cerny	O
m	O
.	O
d	O
.	O

The	O
phenotypes	O
of	O
the	O
ICP0	B-GENE
nonsense	O
mutants	O
were	O
intermediate	O
between	O
those	O
of	O
the	O
wild	O
-	O
type	O
virus	O
and	O
7134	O
in	O
that	O
the	O
more	O
ICP0	B-GENE
-	I-GENE
coding	I-GENE
sequence	I-GENE
expressed	O
by	O
a	O
given	O
nonsense	O
mutant	O
,	O
the	O
more	O
wild	O
type	O
-	O
like	O
was	O
its	O
phenotype	O
.	O

Female	O
mice	O
were	O
significantly	O
more	O
resistant	O
to	O
infection	O
than	O
males	O
.	O

From	O
sequence	O
alignments	O
with	O
phylogenetically	O
related	O
viruses	O
,	O
including	O
tymoviruses	O
,	O
we	O
predicted	O
that	O
p223	B-GENE
contained	O
a	O
papain	B-GENE
-	I-GENE
like	I-GENE
proteinase	I-GENE
domain	I-GENE
with	O
a	O
putative	O
catalytic	O
cysteine994	O
and	O
histidine1075	O
.	O

These	O
results	O
suggest	O
that	O
the	O
c	B-GENE
-	I-GENE
met	I-GENE
gene	I-GENE
is	O
also	O
a	O
target	O
of	O
p53	B-GENE
gene	I-GENE
regulation	O
.	O

The	O
salient	O
clinical	O
features	O
,	O
the	O
problems	O
of	O
management	O
and	O
the	O
modern	O
approaches	O
to	O
the	O
reconstruction	O
of	O
facial	O
deformities	O
seen	O
in	O
this	O
disease	O
are	O
described	O
.	O

She	O
was	O
able	O
to	O
stand	O
unaided	O
by	O
3	O
years	O
of	O
age	O
with	O
then	O
progressive	O
worsening	O
of	O
motor	O
abilities	O
.	O

During	O
skeletal	O
muscle	O
development	O
,	O
different	O
types	O
of	O
muscle	O
fibers	O
are	O
generated	O
,	O
which	O
express	O
different	O
combinations	O
of	O
muscle	O
-	O
specific	O
gene	O
products	O
.	O

Six	O
hours	O
after	O
the	O
last	O
administration	O
,	O
uterus	O
of	O
Gf	O
and	O
Cv	O
mice	O
were	O
weight	O
337	O
.	O
6	O
mg	O
%	O
and	O
423	O
.	O
5	O
mg	O
%	O
respectively	O
,	O
the	O
difference	O
was	O
statistically	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

We	O
examine	O
current	O
models	O
of	O
the	O
effects	O
of	O
aging	O
on	O
mean	O
response	O
time	O
and	O
show	O
how	O
they	O
might	O
be	O
reinterpreted	O
.	O

The	O
possibility	O
of	O
a	O
hereditary	O
disorder	O
leading	O
to	O
a	O
minor	O
defect	O
in	O
elastic	O
fibre	O
structure	O
which	O
could	O
be	O
responsible	O
for	O
the	O
spontaneous	O
lesions	O
is	O
discussed	O
.	O

It	O
is	O
believed	O
that	O
these	O
domains	O
are	O
important	O
for	O
directing	O
specific	O
protein	O
-	O
protein	O
interactions	O
necessary	O
for	O
the	O
proper	O
functioning	O
of	O
Src	B-GENE
.	O

By	O
contrast	O
,	O
all	O
proteins	O
initiated	O
with	O
a	O
methionine	O
placed	O
one	O
residue	O
upstream	O
of	O
the	O
natural	O
N	O
terminus	O
of	O
PR	B-GENE
failed	O
to	O
show	O
specific	O
proteolysis	O
.	O

BSE	O
and	O
farmworkers	O
.	O

Here	O
,	O
we	O
present	O
evidence	O
for	O
a	O
model	O
in	O
which	O
mRNA	O
sequences	O
up	O
to	O
around	O
100	O
nucleotides	O
downstream	O
from	O
the	O
start	O
codon	O
of	O
21K	O
fold	O
back	O
and	O
base	O
-	O
pair	O
to	O
the	O
21K	O
translation	O
initiation	O
region	O
,	O
thereby	O
decreasing	O
the	O
translation	O
initiation	O
frequency	O
.	O

Escherichia	O
coli	O
BL21	O
(	O
DE3	O
)	O
plysS	O
,	O
harbouring	O
a	O
recombinant	O
plasmid	O
containing	O
the	O
catalase	B-GENE
-	O
peroxidase	B-GENE
gene	O
,	O
produced	O
a	O
large	O
amount	O
of	O
proteins	O
that	O
co	O
-	O
migrated	O
on	O
SDS	O
/	O
PAGE	O
with	O
the	O
native	O
enzyme	O
.	O

However	O
,	O
the	O
action	O
of	O
each	O
cognate	O
ligand	O
and	O
the	O
accessory	O
cellular	O
factors	O
that	O
can	O
differentially	O
regulate	O
the	O
transcriptional	O
responses	O
of	O
a	O
heterodimer	O
-	O
DNA	O
complex	O
are	O
not	O
well	O
understood	O
.	O

Using	O
adenoviral	O
transfer	O
of	O
IkappaBalpha	B-GENE
(	O
IkappaBalpha	B-GENE
overexpression	O
)	O
,	O
the	O
production	O
of	O
TNF	B-GENE
-	I-GENE
alpha	I-GENE
induced	O
by	O
whole	O
GBS	O
was	O
inhibited	O
by	O
only	O
20	O
%	O
.	O

METHODS	O
:	O
The	O
former	O
group	O
included	O
patients	O
who	O
had	O
been	O
treated	O
with	O
at	O
least	O
four	O
PGE1	O
alpha	O
-	O
ciclodestrina	O
,	O
short	O
-	O
term	O
treatment	O
cycles	O
per	O
year	O
while	O
the	O
latter	O
was	O
a	O
historical	O
reference	O
group	O
managed	O
without	O
prostaglandins	O
.	O

We	O
describe	O
the	O
identification	O
and	O
initial	O
characterization	O
of	O
neurobeachin	B-GENE
,	O
a	O
neuron	O
-	O
specific	O
multidomain	O
protein	O
of	O
327	O
kDa	O
with	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
(	O
K	O
(	O
d	O
)	O
,	O
10	O
nm	O
)	O
for	O
the	O
type	B-GENE
II	I-GENE
regulatory	I-GENE
subunit	I-GENE
of	I-GENE
protein	I-GENE
kinase	I-GENE
A	I-GENE
(	O
PKA	B-GENE
RII	I-GENE
)	O
.	O

Both	O
groups	O
were	O
subjected	O
to	O
tests	O
of	O
delayed	O
hypersensitivity	O
with	O
Candidin	B-GENE
,	O
Trycophytin	B-GENE
and	O
Tuberculin	B-GENE
.	O

The	O
characterized	O
Y	B-GENE
'	I-GENE
repeated	I-GENE
sequence	I-GENE
families	I-GENE
provide	O
an	O
experimental	O
system	O
in	O
which	O
repeated	O
sequence	O
interactions	O
and	O
subsequent	O
evolution	O
can	O
be	O
studied	O
.	O

Two	O
putative	O
Rev	B-GENE
proteins	I-GENE
with	O
apparent	O
molecular	O
masses	O
of	O
18	O
and	O
16	O
kDa	O
were	O
expressed	O
by	O
p2	B-GENE
/	I-GENE
2	I-GENE
and	O
p176	B-GENE
,	O
while	O
p20	B-GENE
expressed	O
only	O
a	O
16	O
-	O
kDa	O
species	O
.	O

TaqMan	O
analysis	O
of	O
gene	O
expression	O
following	O
chronic	O
FA	O
treatment	O
showed	O
neither	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
leptin	B-GENE
receptor	I-GENE
(	O
Ob	B-GENE
-	I-GENE
R	I-GENE
)	O
mRNA	O
,	O
nor	O
an	O
increase	O
in	O
the	O
negative	O
regulators	O
of	O
STAT	B-GENE
signalling	O
,	O
SOCS3	B-GENE
(	O
suppressors	B-GENE
of	I-GENE
cytokine	I-GENE
signalling	I-GENE
)	O
or	O
cytokine	B-GENE
inducible	I-GENE
sequence	I-GENE
(	O
CIS	B-GENE
)	O
.	O

The	O
hatcher	O
incubators	O
of	O
both	O
companies	O
were	O
also	O
persistently	O
contaminated	O
with	O
Salmonella	O
livingstone	O
and	O
Salmonella	O
thomasville	O
in	O
company	O
A	O
and	O
with	O
Salmonella	O
senftenberg	O
in	O
company	O
B	O
.	O

Overexpression	O
of	O
BAG	B-GENE
-	I-GENE
1	I-GENE
also	O
protected	O
certain	O
cell	O
lines	O
from	O
heat	O
shock	O
-	O
induced	O
cell	O
death	O
.	O

The	O
overall	O
incidence	O
of	O
SIDS	O
was	O
1	O
.	O
43	O
per	O
1	O
,	O
000	O
live	O
births	O
.	O

That	O
sequence	O
strongly	O
promoted	O
the	O
transcription	O
of	O
the	O
promotorless	O
chloramphenicol	B-GENE
acetyltranferase	I-GENE
(	O
CAT	B-GENE
)	O
gene	O
in	O
cells	O
of	O
pancreatic	O
origin	O
(	O
AR	O
-	O
42J	O
)	O
but	O
not	O
in	O
cells	O
of	O
non	O
-	O
pancreatic	O
origin	O
(	O
Rat	O
2	O
and	O
IEC	O
6	O
)	O
.	O

Clinical	O
course	O
and	O
nursing	O
care	O
of	O
patients	O
with	O
decubitus	O
ulcer	O
-	O
-	O
use	O
of	O
pillows	O
stuffed	O
with	O
buckwheat	O
chaff	O

Fructokinase	B-GENE
activity	O
is	O
elevated	O
up	O
to	O
twofold	O
when	O
Z	O
.	O
mobilis	O
was	O
grown	O
on	O
fructose	O
instead	O
of	O
glucose	O
,	O
and	O
there	O
was	O
a	O
parallel	O
increase	O
in	O
frk	B-GENE
mRNA	I-GENE
levels	O
.	O

We	O
have	O
determined	O
the	O
nucleotide	O
(	O
nt	O
)	O
sequence	O
of	O
the	O
7	B-GENE
.	I-GENE
5	I-GENE
-	I-GENE
kb	I-GENE
COR	I-GENE
segment	I-GENE
that	O
encompasses	O
a	O
cluster	O
of	O
six	O
genes	O
(	O
CYC1	B-GENE
,	O
UTR1	B-GENE
,	O
UTR3	B-GENE
,	O
OSM1	B-GENE
,	O
tRNA	B-GENE
(	I-GENE
Gly	I-GENE
)	I-GENE
and	O
RAD7	B-GENE
)	O
located	O
on	O
chromosome	O
X	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

You	O
make	O
the	O
diagnosis	O
.	O

Coronary	O
vasoconstriction	O
caused	O
by	O
endothelin	B-GENE
-	I-GENE
1	I-GENE
is	O
enhanced	O
by	O
ischemia	O
-	O
reperfusion	O
and	O
by	O
norepinephrine	O
present	O
in	O
concentrations	O
typically	O
observed	O
after	O
neonatal	O
cardiopulmonary	O
bypass	O
.	O

RUSH	B-GENE
-	I-GENE
1	I-GENE
beta	I-GENE
is	O
a	O
95	O
-	O
kDa	O
truncated	O
version	O
of	O
RUSH	B-GENE
-	I-GENE
1	I-GENE
alpha	I-GENE
that	O
results	O
from	O
alternative	O
splicing	O
of	O
a	O
57	O
-	O
bp	O
exon	O
as	O
confirmed	O
by	O
genomic	O
cloning	O
.	O

We	O
have	O
therefore	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
doxazosin	O
,	O
a	O
new	O
orally	O
active	O
selective	O
alpha	B-GENE
1	I-GENE
blocker	O
,	O
in	O
patients	O
with	O
systemic	O
hypertension	O
with	O
concomitant	O
airflow	O
limitation	O
.	O

Thus	O
,	O
the	O
positive	O
effect	O
of	O
NS1	B-GENE
on	O
the	O
steady	O
-	O
state	O
levels	O
of	O
P4	B-GENE
transcripts	I-GENE
depends	O
on	O
the	O
amplification	O
of	O
gene	O
copy	O
number	O
and	O
the	O
integrity	O
of	O
the	O
terminal	O
repeats	O
.	O

CONCLUSION	O
:	O
NBP	O
pre	O
-	O
treatment	O
or	O
post	O
-	O
treatment	O
markedly	O
enhanced	O
the	O
rCBF	O
to	O
striatum	O
in	O
RMCAO	O
rats	O
.	O

Intracellular	O
activity	O
studies	O
indicated	O
that	O
,	O
at	O
ten	O
times	O
MBC	O
,	O
only	O
penicillin	O
had	O
any	O
significant	O
activity	O
against	O
intracellular	O
staphylococci	O
,	O
reducing	O
survival	O
by	O
28	O
%	O
.	O

Anti	B-GENE
-	I-GENE
nucleolin	I-GENE
mAb	I-GENE
was	O
used	O
to	O
confirm	O
the	O
antigenic	O
properties	O
of	O
this	O
p95	B-GENE
component	I-GENE
.	O

Transcription	O
of	O
these	O
genes	O
was	O
also	O
elevated	O
in	O
gut	O
and	O
lung	O
during	O
freezing	O
,	O
but	O
mRNA	O
levels	O
in	O
these	O
tissues	O
were	O
lower	O
than	O
in	O
liver	O
.	O

However	O
,	O
mean	O
food	O
intake	O
in	O
the	O
40	O
%	O
group	O
was	O
half	O
that	O
of	O
the	O
ACT	O
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
significantly	O
less	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
than	O
the	O
SEP	O
group	O
,	O
which	O
consumed	O
amounts	O
equivalent	O
to	O
65	O
%	O
of	O
daily	O
requirement	O
.	O

In	O
light	O
of	O
the	O
importance	O
of	O
GnRHR	B-GENE
,	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
transcriptional	O
regulation	O
of	O
the	O
human	B-GENE
GnRHR	I-GENE
(	O
hGnRHR	B-GENE
)	O
gene	O
become	O
a	O
key	O
issue	O
in	O
understanding	O
human	O
reproduction	O
.	O

There	O
was	O
a	O
trend	O
in	O
all	O
studies	O
favouring	O
PVI	O
.	O

The	O
EPO	B-GENE
levels	O
were	O
distinctly	O
increased	O
before	O
transfusion	O
;	O
they	O
did	O
not	O
significantly	O
change	O
just	O
after	O
transfusion	O
,	O
but	O
subsequently	O
decreased	O
.	O

Overexpression	O
of	O
Trdpm1	B-GENE
in	O
a	O
dpm1	B-GENE
(	I-GENE
+	I-GENE
)	I-GENE
:	O
:	O
his7	B-GENE
/	I-GENE
dpm1	I-GENE
(	I-GENE
+	I-GENE
)	I-GENE
S	O
.	O
pombe	O
diploid	O
resulted	O
in	O
a	O
4	O
-	O
fold	O
increase	O
in	O
specific	O
DPM	B-GENE
synthase	I-GENE
activity	O
.	O

A	O
full	O
-	O
length	O
cDNA	O
clone	O
isolated	O
from	O
a	O
rat	O
lung	O
library	O
was	O
predicted	O
to	O
encode	O
a	O
55	O
-	O
kDa	O
protein	O
containing	O
at	O
its	O
amino	O
terminus	O
a	O
targeting	O
domain	O
that	O
binds	O
to	O
the	O
ANP	B-GENE
-	I-GENE
receptor	I-GENE
kinase	I-GENE
-	I-GENE
like	I-GENE
domain	I-GENE
and	O
containing	O
at	O
its	O
carboxyl	O
terminus	O
a	O
putative	O
protein	B-GENE
-	I-GENE
serine	I-GENE
phosphatase	I-GENE
domain	O
.	O

This	O
dynamic	O
response	O
strongly	O
suggests	O
that	O
the	O
p53	B-GENE
and	O
Rb	B-GENE
tumor	O
suppressor	O
pathways	O
are	O
intact	O
in	O
HeLa	O
cells	O
and	O
that	O
repression	O
of	O
HPV	B-GENE
E6	I-GENE
and	O
E7	B-GENE
mobilizes	O
these	O
pathways	O
in	O
an	O
orderly	O
fashion	O
to	O
deliver	O
growth	O
inhibitory	O
signals	O
to	O
the	O
cells	O
.	O

The	O
Y	O
.	O
lipolytica	O
genomic	O
POT1	B-GENE
gene	O
was	O
disrupted	O
by	O
replacing	O
120	O
bp	O
of	O
its	O
coding	O
sequence	O
with	O
2	O
.	O
7	O
kbp	O
of	O
DNA	O
including	O
the	O
Y	O
.	O
lipolytica	O
LEU2	B-GENE
gene	I-GENE
.	O

Electron	O
microscopic	O
picture	O
of	O
the	O
cerebral	O
cortex	O
in	O
rats	O
cooled	O
to	O
22	O
degrees	O
C	O

This	O
enabled	O
the	O
formation	O
of	O
stem	O
-	O
loop	O
templates	O
with	O
the	O
fusion	O
point	O
of	O
the	O
chimeric	O
transcript	O
in	O
the	O
loop	O
and	O
the	O
use	O
of	O
MLL	B-GENE
primers	O
in	O
two	O
-	O
sided	O
PCR	O
.	O

Analysis	O
of	O
the	O
promoter	O
sequence	O
revealed	O
the	O
presence	O
of	O
a	O
major	O
transcriptional	O
start	O
site	O
,	O
a	O
canonical	O
TATA	O
box	O
and	O
putative	O
cis	O
regulatory	O
elements	O
for	O
pituitary	O
specific	O
expression	O
as	O
well	O
as	O
an	O
E	O
-	O
responsive	O
element	O
.	O

The	O
synthetic	O
DNA	O
sequence	O
was	O
constructed	O
to	O
achieve	O
efficient	O
base	O
pairing	O
with	O
Escherichia	B-GENE
coli	I-GENE
16S	I-GENE
ribosomal	I-GENE
RNA	I-GENE
,	O
avoidance	O
of	O
internal	O
secondary	O
structure	O
,	O
and	O
optimal	O
codon	O
usage	O
for	O
high	O
-	O
level	O
protein	O
expression	O
in	O
accord	O
with	O
the	O
known	O
preferences	O
in	O
E	O
.	O
coli	O
.	O

The	O
results	O
from	O
the	O
first	O
five	O
years	O
of	O
follow	O
up	O
in	O
1972	O
showed	O
a	O
4	O
.	O
7	O
-	O
fold	O
excess	O
mortality	O
for	O
ischaemic	O
and	O
other	O
heart	O
diseases	O
(	O
ICD	O
A83	O
-	O
A84	O
)	O
compared	O
with	O
a	O
comparable	O
reference	O
cohort	O
of	O
paper	O
mill	O
workers	O
.	O

Endothelium	O
of	O
the	O
central	O
ear	O
artery	O
of	O
an	O
anesthetized	O
rabbit	O
is	O
damaged	O
by	O
placing	O
artery	O
forceps	O
on	O
the	O
ear	O
directly	O
over	O
the	O
vessel	O
.	O

Comparison	O
of	O
1	O
.	O
5	O
Tesla	O
and	O
0	O
.	O
35	O
Tesla	O
field	O
strength	O
magnetic	O
resonance	O
imaging	O
scans	O
in	O
the	O
morphometric	O
evaluation	O
of	O
the	O
lumbar	O
intervertebral	O
foramina	O
.	O

Stable	O
expression	O
of	O
the	O
chimeric	O
alpha	B-GENE
i	I-GENE
(	I-GENE
54	I-GENE
)	I-GENE
/	I-GENE
s	I-GENE
polypeptide	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
constitutively	O
increased	O
both	O
cAMP	O
synthesis	O
and	O
cAMP	B-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
activity	O
.	O

The	O
specific	O
interaction	O
between	O
a	O
defined	O
structural	O
element	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
mRNA	O
(	O
RRE	B-GENE
,	O
the	O
Rev	B-GENE
response	I-GENE
element	I-GENE
)	O
and	O
the	O
virus	B-GENE
-	I-GENE
encoded	I-GENE
protein	I-GENE
Rev	I-GENE
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
the	O
export	O
of	O
unspliced	O
or	O
singly	O
spliced	O
mRNA	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

Tele	O
-	O
Talk	O
has	O
the	O
extra	O
capability	O
of	O
operating	O
in	O
live	O
conference	O
situations	O
using	O
microphone	O
input	O
.	O

The	O
present	O
study	O
reports	O
visual	O
evoked	O
potential	O
responses	O
to	O
pattern	O
reversal	O
(	O
VEP	O
-	O
P	O
)	O
in	O
ten	O
third	O
trimester	O
pregnant	O
women	O
and	O
changes	O
in	O
latency	O
of	O
NPN	O
complex	O
when	O
compared	O
with	O
these	O
responses	O
in	O
the	O
non	O
pregnant	O
state	O
.	O

No	O
causal	O
relations	O
may	O
be	O
inferred	O
from	O
the	O
correlation	O
between	O
the	O
level	O
of	O
trapezius	O
activity	O
and	O
complaints	O
,	O
though	O
it	O
indicates	O
that	O
individual	O
,	O
inexpedient	O
muscle	O
activity	O
patterns	O
may	O
constitute	O
an	O
important	O
risk	O
factor	O
for	O
development	O
of	O
musculo	O
-	O
skeletal	O
complaints	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
the	O
U1	B-GENE
snRNP	I-GENE
is	O
recruited	O
to	O
the	O
5	O
'	O
splice	O
site	O
by	O
protein	O
/	O
protein	O
interactions	O
involving	O
the	O
SR	B-GENE
domains	O
of	O
the	O
U1	B-GENE
-	I-GENE
70K	I-GENE
protein	I-GENE
and	O
SF2	B-GENE
/	O
ASF	B-GENE
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B-GENE
activation	O
of	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
/	O
Rel	B-GENE
involves	O
phosphorylation	O
and	O
degradation	O
of	O
I	B-GENE
kappa	I-GENE
B	I-GENE
alpha	I-GENE
and	O
RelA	B-GENE
(	I-GENE
p65	I-GENE
)	I-GENE
-	O
mediated	O
induction	O
of	O
the	O
c	B-GENE
-	I-GENE
rel	I-GENE
gene	I-GENE
.	O

Active	O
lambda	B-GENE
and	I-GENE
kappa	I-GENE
antibody	I-GENE
gene	I-GENE
rearrangement	O
in	O
Abelson	O
murine	O
leukemia	O
virus	O
-	O
transformed	O
pre	O
-	O
B	O
cell	O
lines	O
.	O

A	O
centromere	O
in	O
S	O
.	O
cerevisiae	O
consists	O
of	O
a	O
region	O
of	O
DNA	O
,	O
approximately	O
150	O
bp	O
in	O
length	O
,	O
containing	O
three	O
important	O
sequence	O
elements	O
,	O
which	O
are	O
folded	O
with	O
proteins	O
into	O
a	O
specific	O
conformation	O
in	O
the	O
chromatin	O
(	O
the	O
yeast	O
kinetochore	O
)	O
.	O

1	O
(	O
"	O
long	O
method	O
"	O
)	O
and	O
the	O
HML	O
method	O
.	O

Gastric	O
CO2	O
/	O
HCO3	O
was	O
determined	O
in	O
absence	O
of	O
simultaneous	O
inhibition	O
of	O
acid	O
secretion	O
by	O
intra	O
-	O
and	O
extragastric	O
pCO2	O
/	O
pH	O
measurements	O
in	O
23	O
persons	O
and	O
calculated	O
using	O
the	O
equation	O
of	O
Henderson	O
-	O
Hasselbalch	O
.	O

pCO2	O
was	O
measured	O
with	O
use	O
of	O
a	O
new	O
electrode	O
.	O

The	O
rats	O
were	O
used	O
for	O
the	O
study	O
of	O
the	O
effects	O
of	O
sepsis	O
on	O
the	O
utilization	O
of	O
exogenous	O
fat	O
emulsion	O
.	O

Transient	O
overexpression	O
of	O
c	B-GENE
-	I-GENE
Jun	I-GENE
induced	O
tenascin	B-GENE
-	I-GENE
C	I-GENE
expression	O
in	O
primary	O
REF	O
and	O
in	O
FR3T3	O
,	O
an	O
established	O
fibroblast	O
cell	O
line	O
.	O

Ozagrel	O
,	O
ifenprodil	O
,	O
cinnarizine	O
and	O
dilazep	O
were	O
more	O
effective	O
than	O
pentoxifylline	O
in	O
increasing	O
rCBF	O
at	O
the	O
HPC	O
.	O

In	O
contrast	O
to	O
the	O
morphological	O
criteria	O
,	O
the	O
few	O
data	O
available	O
from	O
recent	O
studies	O
at	O
the	O
genetic	O
level	O
have	O
suggested	O
that	O
EPVs	O
infecting	O
different	O
insect	O
orders	O
are	O
phylogenetically	O
distant	O
.	O

D5	B-GENE
/	I-GENE
D1	I-GENE
(	I-GENE
CT	I-GENE
)	I-GENE
or	O
D5	B-GENE
/	I-GENE
D1D	I-GENE
(	I-GENE
CT	I-GENE
)	I-GENE
tail	O
substitution	O
mutants	O
displayed	O
a	O
rank	O
order	O
of	O
potency	O
and	O
agonist	O
affinities	O
virtually	O
mimicking	O
wild	B-GENE
-	I-GENE
type	I-GENE
(	I-GENE
wt	I-GENE
)	I-GENE
D1	I-GENE
receptors	I-GENE
,	O
as	O
indexed	O
by	O
both	O
ligand	O
binding	O
and	O
dopamine	O
-	O
stimulated	O
cAMP	O
accumulation	O
assays	O
,	O
and	O
,	O
similar	O
to	O
wt	O
D1	B-GENE
receptors	I-GENE
,	O
did	O
not	O
exhibit	O
receptor	O
constitutive	O
activity	O
or	O
responsiveness	O
to	O
inverse	O
agonists	O
.	O

2	O
-	O
AP	O
induced	O
marked	O
,	O
steady	O
rises	O
in	O
mRNA	O
accumulation	O
from	O
both	O
transfected	O
and	O
chromosomally	O
integrated	O
HIV	O
-	O
1	O
constructs	O
but	O
no	O
increases	O
from	O
an	O
endogenous	O
gene	O
encoding	O
gamma	B-GENE
-	I-GENE
actin	I-GENE
or	O
glucose	B-GENE
6	I-GENE
-	I-GENE
phosphate	I-GENE
dehydrogenase	I-GENE
.	O

The	O
risk	O
for	O
these	O
complications	O
is	O
increased	O
by	O
the	O
following	O
factors	O
:	O
multiple	O
gestation	O
,	O
the	O
combination	O
of	O
magnesium	O
sulfate	O
and	O
beta	O
-	O
adrenergic	O
agonist	O
,	O
and	O
the	O
use	O
of	O
adrenocortico	O
-	O
steroids	O
to	O
hasten	O
fetal	O
pulmonary	O
maturity	O
.	O

The	O
serum	O
levels	O
of	O
beta	B-GENE
-	I-GENE
human	I-GENE
chorionic	I-GENE
gonadotropin	I-GENE
(	O
HCG	B-GENE
)	O
and	O
placental	B-GENE
alkaline	I-GENE
phosphatase	I-GENE
(	O
PLAP	B-GENE
)	O
were	O
not	O
elevated	O
.	O

Merosin	B-GENE
positive	O
congenital	O
muscular	O
dystrophy	O
with	O
mental	O
deficiency	O
,	O
epilepsy	O
and	O
MRI	O
changes	O
in	O
the	O
cerebral	O
white	O
matter	O
.	O

Gel	O
filtration	O
,	O
sedimentation	O
velocity	O
,	O
and	O
immunoprecipitation	O
experiments	O
revealed	O
that	O
beta4	O
is	O
a	O
component	O
of	O
a	O
multisubunit	O
complex	O
(	O
AP	B-GENE
-	I-GENE
4	I-GENE
)	O
that	O
also	O
contains	O
the	O
sigma4	O
polypeptide	O
and	O
two	O
additional	O
adaptor	O
subunit	O
homologs	O
named	O
mu4	O
(	O
mu	O
-	O
ARP2	O
)	O
and	O
epsilon	O
.	O

The	O
2	O
cDNAs	O
differed	O
in	O
the	O
length	O
of	O
their	O
respective	O
3	O
'	O
untranslated	O
regions	O
,	O
of	O
577	O
bp	O
in	O
Cp	B-GENE
.	I-GENE
F6	I-GENE
and	O
72	O
bp	O
in	O
Cp	B-GENE
.	I-GENE
F10	I-GENE
,	O
in	O
both	O
of	O
which	O
a	O
putative	O
polyadenylation	O
signal	O
was	O
identified	O
.	O

Prevention	O
,	O
differential	O
diagnosis	O
and	O
therapy	O
of	O
travel	O
diarrhea	O

The	O
present	O
investigation	O
conducted	O
in	O
a	O
population	O
of	O
258	O
dentally	O
aware	O
individuals	O
in	O
the	O
age	O
range	O
20	O
-	O
69	O
years	O
,	O
was	O
initiated	O
to	O
elucidate	O
the	O
relationship	O
between	O
tobacco	O
smoking	O
and	O
supragingival	O
calculus	O
,	O
taking	O
into	O
account	O
possible	O
confounding	O
factors	O
such	O
as	O
age	O
,	O
gender	O
,	O
oral	O
hygiene	O
and	O
gingival	O
inflammation	O
.	O

Using	O
Southern	O
blot	O
analysis	O
and	O
restriction	O
mapping	O
of	O
genomic	O
YAC	O
(	O
yeast	O
artificial	O
chromosome	O
)	O
and	O
cosmid	O
clones	O
,	O
we	O
located	O
the	O
human	B-GENE
RIL	I-GENE
gene	I-GENE
240	O
-	O
260	O
kb	O
telomeric	O
to	O
the	O
IRF1	B-GENE
gene	I-GENE
and	O
characterized	O
its	O
genomic	O
structure	O
.	O

Total	O
cholesterol	O
was	O
also	O
reduced	O
at	O
week	O
12	O
by	O
17	O
.	O
0	O
%	O
(	O
20	O
mg	O
/	O
day	O
)	O
and	O
15	O
.	O
7	O
%	O
(	O
20	O
-	O
30	O
mg	O
/	O
day	O
)	O
,	O
and	O
at	O
week	O
52	O
by	O
20	O
.	O
4	O
%	O
(	O
<	O
or	O
=	O
20	O
mg	O
/	O
day	O
)	O
and	O
19	O
.	O
2	O
%	O
(	O
>	O
or	O
=	O
30	O
mg	O
/	O
day	O
)	O
.	O

However	O
,	O
primary	O
transcripts	O
of	O
a	O
variant	B-GENE
tRNA	I-GENE
(	I-GENE
Val	I-GENE
)	I-GENE
(	I-GENE
UAC	I-GENE
)	I-GENE
gene	I-GENE
are	O
processing	O
deficient	O
under	O
standard	O
growth	O
conditions	O
(	O
30	O
degrees	O
C	O
)	O
,	O
due	O
to	O
a	O
slightly	O
altered	O
5	O
'	O
flanking	O
region	O
.	O

Left	O
atrial	O
volumes	O
were	O
greater	O
in	O
old	O
compared	O
with	O
young	O
subjects	O
(	O
maximal	O
:	O
31	O
+	O
/	O
-	O
10	O
cm3	O
/	O
m2	O
vs	O
24	O
+	O
/	O
-	O
8	O
cm3	O
/	O
m2	O
,	O
p	O
=	O
0	O
.	O
02	O
;	O
at	O
onset	O
of	O
atrial	O
systole	O
:	O
23	O
+	O
/	O
-	O
8	O
cm3	O
/	O
m2	O
vs	O
15	O
+	O
/	O
-	O
5	O
cm3	O
/	O
m2	O
,	O
p	O
=	O
0	O
.	O
0002	O
;	O
minimal	O
:	O
13	O
+	O
/	O
-	O
5	O
cm3	O
/	O
m2	O
vs	O
9	O
+	O
/	O
-	O
4	O
cm3	O
/	O
m2	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Effects	O
of	O
long	O
-	O
term	O
parenteral	O
nutrition	O
on	O
gastrin	B-GENE
release	O
in	O
dogs	O
.	O

Cytoskeletal	O
polarization	O
of	O
T	O
cells	O
is	O
regulated	O
by	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
-	O
dependent	O
mechanism	O
.	O

The	O
binding	O
of	O
transcription	O
factor	O
AP	B-GENE
-	I-GENE
1	I-GENE
and	O
vitamin	B-GENE
D	I-GENE
receptor	I-GENE
(	O
VDR	B-GENE
)	O
to	O
the	O
composite	O
AP	B-GENE
-	I-GENE
1	I-GENE
plus	I-GENE
vitamin	I-GENE
-	I-GENE
D	I-GENE
-	I-GENE
responsive	I-GENE
promoter	I-GENE
region	O
(	O
AP	B-GENE
-	I-GENE
1	I-GENE
+	I-GENE
VDRE	I-GENE
)	O
of	O
the	O
human	B-GENE
osteocalcin	I-GENE
gene	I-GENE
was	O
characterized	O
in	O
osteocalcin	B-GENE
-	O
producing	O
(	O
MG	O
-	O
63	O
)	O
and	O
non	O
-	O
producing	O
(	O
U2	O
-	O
Os	O
,	O
SaOs	O
-	O
2	O
)	O
human	O
osteosarcoma	O
cell	O
lines	O
.	O

Comparison	O
of	O
propofol	O
and	O
thiopentone	O
as	O
anaesthetic	O
agents	O
for	O
electroconvulsive	O
therapy	O
.	O

Transfection	O
of	O
non	O
-	O
deleted	O
expression	O
vector	O
into	O
NIH3T3	O
cells	O
results	O
in	O
acquisition	O
of	O
focus	O
-	O
forming	O
activity	O
while	O
a	O
deleted	O
form	O
of	O
expression	O
vector	O
fails	O
to	O
show	O
this	O
activity	O
even	O
in	O
the	O
presence	O
of	O
basic	B-GENE
FGF	I-GENE
.	O

The	O
effect	O
of	O
osmotic	O
flow	O
on	O
the	O
distribution	O
of	O
horseradish	B-GENE
peroxidase	I-GENE
within	O
the	O
intercellular	O
spaces	O
of	O
toad	O
bladder	O
epithelium	O
.	O

3	O
.	O

The	O
binding	O
of	O
NF	B-GENE
-	I-GENE
ATp	I-GENE
,	O
although	O
not	O
NF	B-GENE
-	I-GENE
AT4	I-GENE
,	O
to	O
this	O
enhancer	O
also	O
occurs	O
along	O
with	O
HTLV	O
-	O
I	O
-	O
mediated	O
infection	O
of	O
human	O
peripheral	O
blood	O
T	O
-	O
cells	O
.	O

Recombinant	B-GENE
Ffh	I-GENE
has	O
a	O
melting	O
point	O
of	O
tm	O
=	O
89	O
degreesC	O
.	O

Pilot	O
study	O
of	O
blood	O
coagulation	O
in	O
gout	O
patients	O
.	O

Restriction	O
enzyme	O
mapping	O
,	O
subcloning	O
,	O
and	O
DNA	O
sequencing	O
analysis	O
of	O
recombinant	O
phage	O
lambda	O
and	O
P1	O
clones	O
revealed	O
that	O
exons	O
encoding	O
the	O
1	O
.	O
9	O
-	O
kb	O
mouse	B-GENE
TS	I-GENE
mRNA	I-GENE
are	O
dispersed	O
over	O
>	O
150	O
kb	O
genomic	O
DNA	O
.	O

To	O
better	O
understand	O
the	O
role	O
of	O
Ets	B-GENE
proteins	I-GENE
in	O
Ras	B-GENE
transformation	O
,	O
we	O
have	O
now	O
analyzed	O
the	O
effects	O
of	O
stably	O
expressing	O
a	O
variety	O
of	O
Ets2	B-GENE
constructs	I-GENE
in	O
Ras	B-GENE
-	O
transformed	O
NIH3T3	O
(	O
DT	O
)	O
cells	O
.	O

Peroxisome	B-GENE
proliferator	I-GENE
-	I-GENE
activated	I-GENE
receptors	I-GENE
(	O
PPAR	B-GENE
)	O
modulate	O
transcription	O
by	O
binding	O
to	O
specific	O
peroxisome	O
proliferator	O
-	O
response	O
elements	O
(	O
PPRE	O
)	O
through	O
heterodimerization	O
with	O
the	O
9	B-GENE
-	I-GENE
cis	I-GENE
retinoic	I-GENE
acid	I-GENE
receptor	I-GENE
(	O
RXR	B-GENE
)	O
.	O

The	O
probability	O
of	O
treatment	O
with	O
lamotrigine	O
being	O
maintained	O
for	O
six	O
months	O
was	O
86	O
%	O
,	O
for	O
twelve	O
months	O
61	O
%	O
and	O
for	O
three	O
years	O
31	O
%	O
.	O

Therefore	O
,	O
in	O
order	O
to	O
search	O
for	O
the	O
latent	O
genes	O
,	O
we	O
used	O
allotype	O
-	O
specific	O
oligonucleotides	O
for	O
b5	O
,	O
b6	O
and	O
b9	O
to	O
probe	O
DNAs	O
from	O
both	O
normal	O
and	O
T	O
.	O
brucei	O
-	O
infected	O
rabbits	O
by	O
Southern	O
blotting	O
.	O

Mutational	O
analyses	O
have	O
demonstrated	O
the	O
importance	O
of	O
sequences	O
within	O
the	O
327	O
bp	O
segment	O
that	O
contain	O
a	O
putative	O
cyclic	B-GENE
AMP	I-GENE
responsive	I-GENE
element	I-GENE
binding	I-GENE
protein	I-GENE
(	O
CREB	B-GENE
)	O
binding	O
site	O
for	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
1	I-GENE
and	O
PMA	O
responsiveness	O
and	O
putative	O
PU	B-GENE
-	I-GENE
1	I-GENE
and	O
Sp1	B-GENE
binding	I-GENE
sites	I-GENE
for	O
basal	O
promoter	O
activity	O
.	O

When	O
this	O
CCAAT	O
box	O
was	O
inserted	O
into	O
a	O
heterologous	O
promoter	O
construct	O
,	O
OA	O
induction	O
was	O
dependent	O
on	O
an	O
intact	O
CCAAT	O
box	O
.	O

Hemorrhagic	O
shock	O
and	O
bacterial	O
translocation	O
in	O
a	O
swine	O
model	O
.	O

The	O
Ng	B-GENE
/	I-GENE
RC3	I-GENE
and	O
PKC	B-GENE
-	I-GENE
gamma	I-GENE
genes	I-GENE
have	O
a	O
similar	O
expression	O
pattern	O
in	O
the	O
brain	O
during	O
development	O
.	O

Along	O
with	O
previously	O
mapped	O
genes	O
including	O
Ly	B-GENE
-	I-GENE
1	I-GENE
and	O
CD20	B-GENE
,	O
OSBP	B-GENE
defines	O
a	O
new	O
conserved	O
syntenic	O
group	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
11	O
in	O
the	O
human	O
and	O
the	O
proximal	O
end	O
of	O
chromosome	O
19	O
in	O
the	O
mouse	O
.	O

In	O
a	O
gntR	B-GENE
deletion	I-GENE
mutant	I-GENE
,	O
the	O
expression	O
of	O
a	O
chromosomal	O
gntT	B-GENE
:	O
:	O
lacZ	B-GENE
fusion	O
is	O
both	O
high	O
and	O
constitutive	O
,	O
confirming	O
that	O
GntR	B-GENE
is	O
the	O
negative	O
regulator	O
of	O
gntT	B-GENE
.	O

The	O
chloramphenicol	B-GENE
-	I-GENE
resistance	I-GENE
transposon	I-GENE
Tn4451	B-GENE
undergoes	O
precise	O
conjugative	O
deletion	O
from	O
its	O
parent	O
plasmid	O
plP401	O
in	O
Clostridium	O
perfringens	O
and	O
precise	O
spontaneous	O
excision	O
from	O
multicopy	O
plasmids	O
in	O
Escherichia	O
coli	O
.	O

Also	O
like	O
the	O
thrombin	B-GENE
receptor	I-GENE
,	O
PAR2	B-GENE
can	O
be	O
activated	O
by	O
the	O
hexapeptide	O
corresponding	O
to	O
its	O
tethered	O
ligand	O
sequence	O
independent	O
of	O
receptor	O
cleavage	O
.	O

Pre	B-GENE
-	I-GENE
beta	I-GENE
-	I-GENE
1	I-GENE
lipoprotein	I-GENE
and	O
early	O
detection	O
of	O
risk	O
factors	O
for	O
coronary	O
heart	O
disease	O
.	O

Twenty	O
-	O
two	O
consecutive	O
patients	O
with	O
ischaemic	O
ulcers	O
had	O
tcPO2	O
measured	O
and	O
the	O
ankle	O
/	O
brachial	O
(	O
ABI	O
)	O
and	O
toe	O
/	O
brachial	O
(	O
TBI	O
)	O
indices	O
calculated	O
.	O

Periodic	O
breathing	O
and	O
apnea	O
in	O
preterm	O
infants	O
.	O

Expression	O
of	O
a	O
hybrid	O
protein	O
containing	O
the	O
cytoplasmic	O
C	O
-	O
terminal	O
half	O
of	O
UhpB	B-GENE
fused	O
to	O
glutathione	B-GENE
S	I-GENE
-	I-GENE
transferase	I-GENE
(	O
GST	B-GENE
)	O
also	O
interfered	O
with	O
Uhp	B-GENE
signaling	O
.	O

The	O
concept	O
of	O
"	O
structural	O
identifiability	O
"	O
is	O
employed	O
in	O
this	O
analysis	O
to	O
determine	O
which	O
model	O
parameters	O
can	O
be	O
and	O
which	O
cannot	O
be	O
determined	O
"	O
uniquely	O
"	O
from	O
given	O
input	O
-	O
output	O
data	O
;	O
a	O
step	O
-	O
by	O
-	O
step	O
procedure	O
based	O
on	O
an	O
extension	O
of	O
this	O
concept	O
is	O
presented	O
for	O
adapting	O
the	O
overall	O
approach	O
to	O
the	O
experimental	O
design	O
problem	O
.	O

A	O
five	O
-	O
phase	O
experiment	O
was	O
designed	O
to	O
investigate	O
(	O
a	O
)	O
whether	O
contingent	O
music	O
-	O
listening	O
would	O
act	O
as	O
a	O
reinforcer	O
to	O
increase	O
arithmetic	O
performance	O
of	O
EMR	O
children	O
and	O
(	O
b	O
)	O
whether	O
this	O
contingent	O
reinforcement	O
would	O
affect	O
preference	O
for	O
that	O
reinforcer	O
.	O

Genomic	O
DNA	O
clones	O
containing	O
the	O
T	B-GENE
-	I-GENE
cell	I-GENE
-	I-GENE
specific	I-GENE
human	I-GENE
MAL	I-GENE
gene	I-GENE
were	O
isolated	O
.	O

Since	O
1968	O
,	O
a	O
steep	O
decrease	O
in	O
the	O
number	O
of	O
strains	O
resistant	O
to	O
three	O
or	O
more	O
antibiotics	O
(	O
multiple	O
-	O
resistant	O
)	O
and	O
in	O
strains	O
of	O
the	O
83A	O
complex	O
was	O
noticed	O
.	O

99mTc	O
-	O
HMPAO	O
was	O
distributed	O
in	O
the	O
territories	O
of	O
the	O
ACA	O
and	O
MCA	O
in	O
the	O
two	O
patients	O
who	O
were	O
treated	O
with	O
intraarterial	O
infusion	O
of	O
papaverine	O
from	O
the	O
C4	O
segment	O
,	O
but	O
was	O
distributed	O
only	O
to	O
the	O
territory	O
of	O
the	O
ACA	O
in	O
four	O
patients	O
who	O
were	O
treated	O
with	O
intraarterial	O
infusion	O
of	O
papaverine	O
from	O
the	O
C1	O
segment	O
at	O
1	O
ml	O
/	O
min	O
.	O

Biol	O
.	O

While	O
these	O
findings	O
may	O
reflect	O
the	O
sensitivity	O
of	O
a	O
thick	O
myocardial	O
wall	O
to	O
ischaemia	O
during	O
surgery	O
,	O
the	O
postoperative	O
recovery	O
was	O
not	O
related	O
to	O
the	O
serum	B-GENE
CK	I-GENE
-	I-GENE
MB	I-GENE
level	O
.	O

Morphology	O
of	O
bacteriophages	O
of	O
Klebsiella	O
bacilli	O
.	O

Significantly	O
,	O
two	O
proximal	O
GATA	B-GENE
-	I-GENE
1	I-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
(	O
-	O
118	O
/	O
-	O
113	O
and	O
-	O
98	O
/	O
-	O
93	O
)	O
and	O
a	O
region	O
located	O
within	O
-	O
518	O
to	O
-	O
315bp	O
of	O
the	O
mouse	B-GENE
ALAS2	I-GENE
promoter	I-GENE
were	O
essential	O
for	O
transcriptional	O
activation	O
during	O
chemically	O
induced	O
differentiation	O
of	O
MEL	O
cells	O
,	O
implying	O
their	O
importance	O
in	O
conferring	O
erythroid	O
specificity	O
to	O
the	O
ALAS2	B-GENE
transcriptional	O
activation	O
.	O

In	O
rlf2	B-GENE
mutants	I-GENE
,	O
telomeric	O
chromatin	O
is	O
perturbed	O
:	O
Telomeric	O
silencing	O
is	O
reduced	O
and	O
Rap1p	B-GENE
localization	O
is	O
altered	O
.	O

The	O
MXR	B-GENE
gene	I-GENE
encodes	O
a	O
half	O
-	O
transporter	O
and	O
the	O
absence	O
of	O
cytogenetic	O
evidence	O
of	O
coamplification	O
of	O
other	O
regions	O
suggests	O
that	O
a	O
partner	O
may	O
not	O
be	O
overexpressed	O
,	O
and	O
instead	O
the	O
MXR	B-GENE
half	I-GENE
-	I-GENE
transporter	I-GENE
homodimerizes	O
to	O
mediate	O
drug	O
transport	O
.	O

These	O
kinases	O
belong	O
to	O
a	O
new	O
subfamily	O
related	O
to	O
the	O
Trk	B-GENE
subfamily	I-GENE
.	O

Hybridization	O
signals	O
were	O
also	O
detected	O
with	O
total	O
DNAs	O
of	O
Rhizobium	O
leguminosarum	O
bv	O
.	O
phaseoli	O
,	O
Rhodobacter	O
capsulatus	O
and	O
Escherichia	O
coli	O
,	O
but	O
not	O
those	O
of	O
Xanthomonas	O
campestris	O
pv	O
.	O
campestris	O
and	O
Pseudomonas	O
putida	O
.	O

Nerve	O
stimulation	O
(	O
1	O
.	O
5	O
-	O
12	O
cycles	O
/	O
s	O
)	O
produced	O
frequency	O
-	O
dependent	O
reductions	O
in	O
CBF	O
,	O
a	O
decrease	O
of	O
50	O
percent	O
occurring	O
with	O
the	O
highest	O
frequency	O
.	O

The	O
circadian	O
rhythmicity	O
of	O
sleep	O
was	O
pronounced	O
.	O

The	O
only	O
abundant	O
viral	O
transcript	O
expressed	O
during	O
latency	O
is	O
the	O
latency	B-GENE
-	I-GENE
related	I-GENE
(	O
LR	B-GENE
)	O
RNA	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
the	O
RP	B-GENE
,	O
like	O
the	O
20S	B-GENE
proteasome	I-GENE
,	O
is	O
functionally	O
and	O
structurally	O
conserved	O
among	O
eukaryotes	O
and	O
indicate	O
that	O
the	O
plant	B-GENE
RPT	I-GENE
subunits	I-GENE
,	O
like	O
their	O
yeast	O
counterparts	O
,	O
have	O
non	O
-	O
redundant	O
functions	O
.	O

On	O
the	O
amount	O
and	O
significance	O
of	O
the	O
effective	O
glucose	O
level	O
in	O
tumors	O
.	O

Solution	O
structure	O
and	O
mechanism	O
of	O
the	O
MutT	B-GENE
pyrophosphohydrolase	I-GENE
.	O

Luteinizing	B-GENE
hormone	I-GENE
-	I-GENE
releasing	I-GENE
hormone	I-GENE
analog	O
therapy	O
of	O
uterine	O
fibroid	O
:	O
analysis	O
of	O
results	O
obtained	O
with	O
buserelin	O
administered	O
intranasally	O
and	O
goserelin	O
administered	O
subcutaneously	O
as	O
a	O
monthly	O
depot	O
.	O

NH2	O
-	O
terminal	O
trimming	O
of	O
Xenopus	O
and	O
mammalian	B-GENE
FGF3s	I-GENE
may	O
therefore	O
be	O
a	O
prerequisite	O
of	O
optimal	O
biological	O
activity	O
.	O

Immunohistochemical	O
staining	O
with	O
MIB	B-GENE
-	I-GENE
1	I-GENE
and	O
p53	B-GENE
antibodies	I-GENE
showed	O
low	O
(	O
<	O
1	O
%	O
)	O
and	O
negative	O
reaction	O
.	O

In	O
contrast	O
,	O
exogenous	B-GENE
PTHrP1	I-GENE
-	I-GENE
34	I-GENE
and	I-GENE
1	I-GENE
-	I-GENE
86	I-GENE
peptides	I-GENE
did	O
not	O
significantly	O
affect	O
IL	B-GENE
-	I-GENE
8	I-GENE
production	O
;	O
moreover	O
,	O
PTHrP	B-GENE
-	I-GENE
neutralizing	I-GENE
antibodies	I-GENE
did	O
not	O
inhibit	O
the	O
production	O
of	O
IL	B-GENE
-	I-GENE
8	I-GENE
by	O
transfected	O
PTHrP	B-GENE
.	O

(	O
ii	O
)	O
An	O
AF	O
G	B-GENE
-	I-GENE
CSF	I-GENE
level	O
>	O
2000	O
pg	O
/	O
ml	O
is	O
a	O
strong	O
positive	O
predictor	O
of	O
CAM	O
.	O

Segments	O
with	O
more	O
reduced	O
BMIPP	O
uptake	O
than	O
MIBI	O
uptake	O
(	O
mismatching	O
)	O
showed	O
either	O
normal	O
wall	O
motion	O
or	O
demonstrated	O
inotropic	O
reserve	O
during	O
dobutamine	O
stimulation	O
.	O

A	O
second	O
promoter	O
activity	O
was	O
identified	O
in	O
the	O
region	O
between	O
the	O
two	O
major	O
transcriptional	O
start	O
sites	O
.	O

One	O
CKD	O
patient	O
'	O
s	O
journey	O
.	O

CONTEXT	O
:	O
ThinPrep	O
,	O
AutoPap	O
,	O
and	O
Papnet	O
are	O
3	O
new	O
technologies	O
that	O
increase	O
the	O
sensitivity	O
and	O
cost	O
of	O
cervical	O
cancer	O
screening	O
.	O

Six	O
of	O
the	O
gstC	B-GENE
'	I-GENE
mutants	I-GENE
,	O
primarily	O
in	O
the	O
C	O
-	O
terminal	O
half	O
of	O
C	B-GENE
'	I-GENE
,	O
exhibited	O
a	O
defect	O
in	O
the	O
ability	O
to	O
bind	O
L	B-GENE
protein	I-GENE
.	O

The	O
model	O
is	O
able	O
to	O
anticipate	O
why	O
the	O
effect	O
of	O
water	O
fluoridation	O
on	O
caries	O
prevalence	O
is	O
most	O
pronounced	O
when	O
caries	O
is	O
diagnosed	O
at	O
cavity	O
level	O
.	O

Reversal	O
of	O
the	O
increase	O
in	O
apomorphine	O
-	O
induced	O
stereotypy	O
and	O
aggression	O
in	O
REM	O
sleep	O
deprived	O
rats	O
by	O
dopamine	O
agonist	O
pretreatments	O
.	O

Chem	O
.	O

With	O
both	O
wild	O
-	O
type	O
and	O
the	O
mutant	O
enzymes	O
,	O
ATP	O
activates	O
both	O
[	O
14C	O
]	O
Asp	O
in	O
equilibrium	O
N	O
-	O
carbamyl	O
-	O
L	O
-	O
aspartate	O
(	O
C	O
-	O
Asp	O
)	O
and	O
the	O
[	O
32P	O
]	O
carbamyl	O
phosphate	O
(	O
C	O
-	O
P	O
)	O
in	O
equilibrium	O
Pi	O
exchanges	O
.	O

Histological	O
examination	O
revealed	O
a	O
small	O
simple	O
renal	O
cyst	O
associated	O
with	O
renal	O
cell	O
carcinoma	O
.	O

Flavonoids	O
from	O
Brosimum	O
acutifolium	O
.	O

New	O
Langevin	O
equations	O
for	O
a	O
translating	O
and	O
simultaneously	O
rotating	O
asymmetric	O
top	O
.	O

Analysis	O
with	O
additional	O
anti	O
-	O
peptide	O
antibodies	O
specific	O
for	O
alpha	B-GENE
,	I-GENE
beta	I-GENE
,	I-GENE
or	I-GENE
gamma	I-GENE
PKC	I-GENE
indicated	O
that	O
all	O
three	O
types	O
of	O
PKC	B-GENE
are	O
expressed	O
in	O
JK	O
cells	O
;	O
however	O
,	O
JKPE	O
cells	O
lost	O
a	O
major	O
approximately	O
82	O
kDa	O
immunoreactive	O
cytosolic	O
protein	O
detectable	O
with	O
anti	B-GENE
-	I-GENE
PKC	I-GENE
alpha	I-GENE
antibody	I-GENE
.	O

Effects	O
of	O
Trypanosoma	O
vivax	O
on	O
pregnancy	O
of	O
Yankasa	O
sheep	O
and	O
the	O
results	O
of	O
homidum	O
chloride	O
chemotherapy	O
.	O

Propagation	O
and	O
hormone	O
production	O
by	O
human	O
normal	O
and	O
malignant	O
trophoblast	O
in	O
rats	O
.	O

The	O
imino	O
proton	O
of	O
T3	O
in	O
the	O
O6meG	O
.	O
T	O
12	O
-	O
mer	O
and	O
G3	O
in	O
the	O
O6meG	O
.	O
N	O
12	O
-	O
mer	O
helix	O
,	O
which	O
are	O
associated	O
with	O
the	O
modification	O
site	O
,	O
resonate	O
at	O
unusually	O
high	O
field	O
(	O
8	O
.	O
5	O
to	O
9	O
.	O
0	O
ppm	O
)	O
compared	O
to	O
imino	O
protons	O
in	O
Watson	O
-	O
Crick	O
base	O
pairs	O
(	O
12	O
.	O
5	O
to	O
14	O
.	O
5	O
ppm	O
)	O
.	O

The	O
urinary	O
protein	O
,	O
serum	O
albumin	B-GENE
,	O
BUN	O
and	O
SCr	O
all	O
had	O
very	O
significant	O
improvement	O
.	O

MEKs	B-GENE
and	O
ERKs	B-GENE
inhibited	O
IL	B-GENE
-	I-GENE
6	I-GENE
activation	O
of	O
Stat3	B-GENE
harboring	O
a	O
mutation	O
at	O
serine	O
-	O
727	O
,	O
the	O
major	O
site	O
for	O
serine	O
phosphorylation	O
,	O
similar	O
to	O
inhibition	O
of	O
wild	B-GENE
-	I-GENE
type	I-GENE
Stat3	I-GENE
,	O
and	O
inhibited	O
Janus	B-GENE
kinases	I-GENE
Jak1	B-GENE
and	O
Jak2	B-GENE
upstream	O
of	O
Stat3	B-GENE
in	O
the	O
Jak	B-GENE
-	O
STAT	B-GENE
-	O
signaling	O
pathway	O
.	O

A	O
proposal	O
of	O
50	O
performance	O
indicators	O
divided	O
into	O
five	O
different	O
groups	O
is	O
presented	O
here	O
,	O
namely	O
structural	O
indicators	O
,	O
operational	O
indicators	O
,	O
water	O
and	O
service	O
quality	O
indicators	O
,	O
personnel	O
indicators	O
and	O
economic	O
indicators	O
.	O

Tryptic	O
cleavage	O
and	O
peptide	O
sequence	O
analysis	O
demonstrated	O
that	O
the	O
98	O
-	O
kD	O
protein	O
is	O
identical	O
to	O
a	O
recently	O
cloned	O
protein	O
,	O
special	B-GENE
A	I-GENE
-	I-GENE
T	I-GENE
-	I-GENE
rich	I-GENE
binding	I-GENE
protein	I-GENE
1	I-GENE
(	O
SATB1	B-GENE
)	O
,	O
that	O
binds	O
selectively	O
to	O
nuclear	O
matrix	O
/	O
scaffold	O
-	O
associated	O
regions	O
of	O
DNA	O
(	O
MARs	O
/	O
SARs	O
)	O
.	O

Study	O
of	O
the	O
physico	O
-	O
chemical	O
state	O
of	O
plutonium	O
-	O
239	O
in	O
a	O
citrate	O
solution	O
-	O
blood	O
system	O

The	O
predicted	O
domain	O
structures	O
of	O
FkbB	B-GENE
and	O
FkbC	B-GENE
are	O
analogous	O
to	O
that	O
of	O
FkbA	B-GENE
and	O
comprise	O
30	O
fatty	B-GENE
-	I-GENE
acid	I-GENE
-	I-GENE
synthase	I-GENE
(	O
FAS	B-GENE
)	O
-	O
like	O
domains	O
arranged	O
in	O
6	O
modules	O
.	O

An	O
amino	O
-	O
acid	O
sequence	O
comparison	O
revealed	O
that	O
Bacillus	B-GENE
YM55	I-GENE
-	I-GENE
1	I-GENE
aspartase	I-GENE
shared	O
71	O
%	O
homology	O
with	O
Bacillus	B-GENE
subtilis	I-GENE
aspartase	I-GENE
and	O
49	O
%	O
with	O
Escherichia	O
coli	O
and	O
Pseudomonas	B-GENE
fluorescens	I-GENE
aspartases	I-GENE
.	O

On	O
the	O
other	O
hand	O
,	O
if	O
the	O
measured	O
angle	O
ANB	O
is	O
smaller	O
than	O
the	O
calculated	O
angle	O
,	O
the	O
skeletal	O
relation	O
is	O
Class	O
III	O
.	O

The	O
equivalent	O
of	O
the	O
third	O
ligand	O
,	O
H	O
-	O
87	O
,	O
is	O
T	O
-	O
47	O
in	O
the	O
PSTAIRE	O
sequence	O
motif	O
.	O

To	O
identify	O
additional	O
non	O
-	O
Sir	B-GENE
factors	I-GENE
that	O
affect	O
rDNA	O
silencing	O
,	O
we	O
performed	O
a	O
genetic	O
screen	O
designed	O
to	O
isolate	O
mutations	O
which	O
alter	O
the	O
expression	O
of	O
reporter	O
genes	O
integrated	O
within	O
the	O
rDNA	O
.	O

CONCLUSIONS	O
:	O
Valproate	O
appears	O
to	O
inhibit	O
the	O
glucuronidation	O
of	O
carbamazepine	O
-	O
10	O
,	O
11	O
-	O
trans	O
-	O
diol	O
,	O
and	O
probably	O
also	O
inhibits	O
the	O
conversion	O
of	O
carbamazepine	O
-	O
10	O
,	O
11	O
-	O
epoxide	O
to	O
this	O
trans	O
-	O
diol	O
derivative	O
,	O
rather	O
than	O
simply	O
inhibiting	O
the	O
latter	O
reaction	O
only	O
.	O

Sequencing	O
of	O
a	O
40	O
-	O
kb	O
DNA	O
segment	O
of	O
the	O
FK506	O
gene	O
cluster	O
from	O
Streptomyces	O
sp	O
.	O

S2F	B-GENE
,	O
a	O
leaf	O
-	O
specific	O
trans	O
-	O
acting	O
factor	O
,	O
binds	O
to	O
a	O
novel	O
cis	O
-	O
acting	O
element	O
and	O
differentially	O
activates	O
the	O
RPL21	B-GENE
gene	I-GENE
.	O

This	O
brief	O
review	O
analyses	O
these	O
interactions	O
and	O
defines	O
clinical	O
settings	O
where	O
antibiotic	O
-	O
induced	O
endotoxin	O
release	O
may	O
prove	O
to	O
be	O
clinically	O
relevant	O
.	O

We	O
further	O
demonstrate	O
that	O
the	O
Stress	B-GENE
-	I-GENE
Activated	I-GENE
-	I-GENE
Protein	I-GENE
-	I-GENE
Kinase	I-GENE
(	O
SAPK	B-GENE
)	O
target	O
sites	O
of	O
ATF2	B-GENE
,	O
Thr69	O
and	O
Thr71	O
are	O
not	O
required	O
for	O
the	O
formation	O
of	O
the	O
p300	B-GENE
/	O
CBP	B-GENE
-	O
ATF2	B-GENE
multiprotein	O
complex	O
.	O

Bites	O
by	O
two	O
species	O
of	O
adders	O
(	O
Vipera	O
aspis	O
and	O
Vipera	O
berus	O
)	O
can	O
lead	O
to	O
extensive	O
swelling	O
with	O
multiorgan	O
failure	O
.	O

Tissue	O
pressure	O
,	O
rCBF	O
,	O
and	O
water	O
content	O
were	O
measured	O
from	O
gray	O
matter	O
in	O
the	O
central	O
core	O
and	O
the	O
peripheral	O
margin	O
of	O
the	O
MCA	O
territory	O
over	O
6	O
h	O
after	O
MCAO	O
.	O

A	O
736	O
-	O
bp	O
sequence	O
of	O
the	O
5	O
'	O
flanking	O
region	O
adjacent	O
to	O
the	O
cap	O
site	O
of	O
the	O
human	B-GENE
AFP	I-GENE
gene	I-GENE
shows	O
a	O
61	O
%	O
similarity	O
with	O
the	O
corresponding	O
region	O
of	O
the	O
mouse	B-GENE
AFP	I-GENE
gene	I-GENE
.	O

The	O
titer	O
of	O
anti	B-GENE
HSV	I-GENE
type	I-GENE
1	I-GENE
and	O
anti	B-GENE
HSV	I-GENE
type	I-GENE
2	I-GENE
antibodies	I-GENE
in	O
the	O
mothers	O
'	O
and	O
cord	O
blood	O
was	O
determined	O
and	O
compared	O
.	O

1	O
,	O
among	O
which	O
nine	O
have	O
been	O
cloned	O
and	O
two	O
(	O
potentially	O
functional	O
)	O
sequenced	O
.	O

This	O
suggests	O
that	O
while	O
underpredictions	O
of	O
pain	O
do	O
not	O
hurt	O
more	O
,	O
disruption	O
on	O
primary	O
tasks	O
and	O
physiological	O
impact	O
are	O
higher	O
.	O

In	O
all	O
sessions	O
under	O
IFN	B-GENE
,	O
the	O
latency	O
of	O
the	O
P100	O
component	O
of	O
the	O
VEP	O
was	O
shortened	O
as	O
compared	O
to	O
baseline	O
conditions	O
.	O

The	O
primary	O
structure	O
of	O
the	O
GAL7	B-GENE
5	I-GENE
'	I-GENE
flanking	I-GENE
region	I-GENE
has	O
many	O
features	O
common	O
to	O
those	O
of	O
multicellular	O
eukaryotic	O
genes	O
.	O

The	O
major	O
urinary	O
metabolites	O
were	O
3	O
-	O
(	O
3	O
-	O
carboxyphenyl	O
)	O
-	O
5	O
-	O
hydroxymethyl	O
-	O
2	O
-	O
oxazolidinone	O
and	O
a	O
glucuronide	O
of	O
toloxatone	O
.	O

One	O
complex	O
containing	O
a	O
70	O
D	O
protein	O
was	O
found	O
to	O
be	O
associated	O
specifically	O
with	O
transcriptionally	O
active	O
leukemia	O
cells	O
.	O

Analysis	O
of	O
disassociation	O
rates	O
indicates	O
that	O
the	O
Grf10	B-GENE
-	O
Swi5	B-GENE
-	O
DNA	O
complex	O
has	O
a	O
longer	O
half	O
-	O
life	O
than	O
protein	O
-	O
DNA	O
complexes	O
that	O
contain	O
only	O
Swi5	B-GENE
or	O
Grf10	B-GENE
.	O

Veterinary	O
certification	O
for	O
livestock	O
export	O
.	O

Several	O
genes	O
or	O
transcriptional	O
units	O
were	O
identified	O
,	O
including	O
the	O
3	O
'	O
end	O
of	O
ribosomal	B-GENE
s6	I-GENE
kinase	I-GENE
(	O
Rsk3	B-GENE
)	O
;	O
two	O
apparently	O
intronless	O
and	O
ORF	O
-	O
less	O
genes	O
;	O
and	O
Gpr31	B-GENE
,	O
an	O
intronless	O
,	O
putative	O
G	B-GENE
-	I-GENE
protein	I-GENE
coupled	I-GENE
receptor	I-GENE
.	O

Complex	O
repetitive	O
discharges	O
were	O
observed	O
in	O
muscles	O
of	O
mdx	O
mice	O
but	O
no	O
complex	O
repetitive	O
discharges	O
or	O
other	O
abnormalities	O
were	O
observed	O
in	O
muscles	O
of	O
normal	O
control	O
mice	O
.	O

Unaided	O
attempts	O
to	O
quit	O
smoking	O
are	O
generally	O
unsuccessful	O
.	O

EXAFS	O
measurements	O
around	O
the	O
Ge	O
-	O
K	O
edge	O
have	O
been	O
carried	O
out	O
for	O
liquid	O
Ge	O
-	O
Si	O
alloys	O
for	O
the	O
first	O
time	O
to	O
investigate	O
the	O
local	O
structure	O
around	O
a	O
Ge	O
atom	O
.	O

Improving	O
the	O
evidence	O
base	O
for	O
anaesthesia	O
.	O

Its	O
transcription	O
product	O
,	O
a	O
1	O
.	O
3	O
kb	O
mRNA	O
,	O
is	O
polyadenylated	O
at	O
a	O
site	O
containing	O
consensus	O
eukaryotic	O
polyadenylation	O
signals	O
and	O
mapping	O
87	O
bp	O
downstream	O
of	O
the	O
translation	O
termination	O
codon	O
for	O
CG30	B-GENE
.	O

Mus81p	B-GENE
also	O
shares	O
homology	O
with	O
motifs	O
found	O
in	O
the	O
XPF	B-GENE
endonuclease	I-GENE
superfamily	I-GENE
.	O

Elimination	O
of	O
bagassosis	O
in	O
Louisiana	O
paper	O
manufacturing	O
plant	O
workers	O
.	O

Although	O
not	O
common	O
,	O
the	O
disorder	O
is	O
the	O
most	O
frequently	O
diagnosed	O
disturbance	O
of	O
porphyrin	O
metabolism	O
in	O
many	O
countries	O
,	O
and	O
further	O
insight	O
into	O
its	O
unusual	O
pathogenesis	O
may	O
clarify	O
the	O
hepatotoxic	O
effects	O
of	O
the	O
4	O
etiologic	O
agents	O
.	O

Aggravating	O
process	O
induced	O
by	O
indomethacin	O
on	O
chronic	O
gastric	O
lesion	O
in	O
rat	O
.	O

AP	O
was	O
induced	O
by	O
intraductal	O
infusion	O
of	O
two	O
different	O
concentrations	O
of	O
glycodeoxycholic	O
acid	O
(	O
GDOC	O
17	O
mmol	O
and	O
34	O
mmol	O
)	O
.	O

Plectin	B-GENE
and	O
desmoplakin	B-GENE
have	O
GSR	O
-	O
containing	O
domains	O
at	O
their	O
C	O
-	O
termini	O
and	O
we	O
further	O
demonstrate	O
that	O
the	O
GSR	O
-	O
containing	O
domain	O
of	O
plectin	B-GENE
,	O
but	O
not	O
desmoplakin	B-GENE
,	O
can	O
bind	O
to	O
MTs	O
in	O
vivo	O
.	O

The	O
difficulties	O
to	O
analyse	O
prostaglandins	O
(	O
PG	O
)	O
by	O
gas	O
-	O
liquid	O
chromatography	O
are	O
mainly	O
due	O
to	O
the	O
lack	O
of	O
sensitivity	O
of	O
the	O
gas	O
-	O
chromatograph	O
itself	O
(	O
higher	O
than	O
200	O
ng	O
)	O
and	O
to	O
the	O
poor	O
resolution	O
of	O
the	O
packed	O
columns	O
.	O

Linear	O
regression	O
analysis	O
was	O
performed	O
and	O
the	O
following	O
result	O
was	O
obtained	O
:	O
clearance	O
(	O
HMPAO	O
)	O
=	O
0	O
.	O
07	O
+	O
0	O
.	O
43	O
.	O

rCBF	O
with	O
a	O
high	O
significance	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Two	O
new	O
artifacts	O
in	O
automated	O
coagulation	O
testing	O
.	O

The	O
small	O
copepod	O
Pseudonychocamptus	O
proximus	O
progressively	O
replaced	O
the	O
large	O
Tisbe	O
furcata	O
in	O
sand	O
filters	O
during	O
the	O
fall	O
of	O
1995	O
and	O
was	O
responsible	O
for	O
the	O
large	O
increase	O
in	O
meiofaunal	O
biomass	O
observed	O
after	O
spring	O
1996	O
.	O

In	O
the	O
BF	O
ECT	O
group	O
the	O
-	O
age	O
based	O
dose	O
would	O
have	O
been	O
similarly	O
dependent	O
on	O
the	O
initial	O
seizure	O
threshold	O
level	O
.	O

Interaction	O
of	O
HRI	B-GENE
with	O
Hsc70	B-GENE
was	O
required	O
for	O
the	O
transformation	O
of	O
HRI	B-GENE
,	O
as	O
the	O
Hsc70	B-GENE
antagonist	O
clofibric	O
acid	O
inhibited	O
the	O
folding	O
of	O
HRI	B-GENE
into	O
a	O
mature	O
-	O
competent	O
conformation	O
.	O

Fifteen	O
light	O
for	O
dates	O
infants	O
and	O
their	O
placentae	O
were	O
compared	O
to	O
15	O
well	O
-	O
grown	O
infants	O
and	O
their	O
placentae	O
.	O

Evidence	O
from	O
the	O
structure	O
of	O
a	O
number	O
of	O
cDNA	O
clones	O
,	O
as	O
well	O
as	O
S1	B-GENE
nuclease	I-GENE
and	O
primer	O
extension	O
studies	O
supports	O
the	O
hypothesis	O
that	O
the	O
PTHrP	B-GENE
gene	I-GENE
contains	O
at	O
least	O
two	O
mRNA	O
transcription	O
start	O
points	O
that	O
define	O
two	O
putative	O
regulatory	O
domains	O
.	O

The	O
proteasome	O
is	O
a	O
large	O
complex	O
consisting	O
of	O
two	O
multisubunit	O
structures	O
,	O
the	O
20S	B-GENE
and	O
19S	B-GENE
(	O
PA700	B-GENE
)	O
or	O
P28	B-GENE
complexes	I-GENE
,	O
that	O
combine	O
to	O
form	O
the	O
26S	B-GENE
particles	I-GENE
.	O

Current	O
status	O
of	O
chemotherapy	O
for	O
Hodgkin	O
'	O
s	O
disease	O

Behavioural	O
tests	O
with	O
192	O
specimen	O
of	O
the	O
roman	O
garden	O
snail	O
Helix	O
pomatia	O
L	O
.	O
were	O
performed	O
in	O
order	O
to	O
clarify	O
whether	O
the	O
thermopreferendum	O
of	O
this	O
pulmonate	O
is	O
influenced	O
not	O
only	O
by	O
the	O
temperature	O
of	O
the	O
substratum	O
but	O
also	O
by	O
air	O
temperature	O
.	O

The	O
performance	O
of	O
pH	O
-	O
sensitive	O
particles	O
is	O
attributed	O
to	O
their	O
ability	O
to	O
release	O
the	O
drug	O
selectively	O
in	O
the	O
upper	O
part	O
of	O
the	O
intestine	O
in	O
a	O
molecular	O
or	O
amorphous	O
form	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrated	O
a	O
unique	O
mechanism	O
of	O
action	O
of	O
8	O
-	O
Cl	O
-	O
cAMP	O
in	O
the	O
regulation	O
of	O
these	O
kinase	O
isozymes	O
in	O
HL	O
-	O
60	O
human	O
promyelocytic	O
leukemia	O
cells	O
.	O

Thus	O
,	O
we	O
have	O
separated	O
the	O
signal	O
function	O
from	O
the	O
anchor	O
function	O
of	O
the	O
6	O
.	O
7K	O
SA	O
domain	O
.	O

The	O
SSB	B-GENE
-	O
poly	O
(	O
dT	O
)	O
affinity	O
is	O
too	O
high	O
to	O
measure	O
in	O
buffers	O
containing	O
even	O
5	O
M	O
NaCl	O
;	O
however	O
,	O
in	O
1	O
.	O
8	O
-	O
2	O
.	O
5	O
M	O
NaBr	O
,	O
we	O
measure	O
alpha	O
log	O
Kobsd	O
/	O
alpha	O
log	O
[	O
NaBr	O
]	O
=	O
-	O
5	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
7	O
,	O
with	O
a	O
lower	O
value	O
of	O
omega	O
T	O
/	O
O	O
=	O
130	O
+	O
/	O
-	O
70	O
.	O

Topics	O
reviewed	O
here	O
include	O
:	O
data	O
supporting	O
the	O
association	O
of	O
myositis	O
with	O
cancer	O
and	O
the	O
appropriate	O
evaluations	O
for	O
malignancy	O
in	O
a	O
myositis	O
patient	O
;	O
an	O
approach	O
to	O
the	O
assessment	O
of	O
patients	O
with	O
dermatomyositis	O
sine	O
myositis	O
;	O
the	O
usefulness	O
of	O
the	O
clinicopathological	O
and	O
serological	O
classifications	O
;	O
a	O
discussion	O
of	O
whether	O
childhood	O
and	O
adult	O
myositis	O
are	O
the	O
same	O
or	O
different	O
entities	O
;	O
a	O
review	O
of	O
those	O
prognostic	O
factors	O
to	O
consider	O
in	O
the	O
clinical	O
management	O
of	O
myositis	O
patients	O
;	O
current	O
approaches	O
and	O
their	O
limitations	O
for	O
assessing	O
disease	O
activity	O
and	O
damage	O
.	O

Two	O
classes	O
of	O
inactive	O
receptors	O
were	O
identified	O
:	O
one	O
in	O
which	O
both	O
transcriptional	O
activation	O
and	O
dimerization	O
were	O
compromised	O
and	O
a	O
second	O
in	O
which	O
only	O
transcriptional	O
activation	O
was	O
abolished	O
.	O

Man	O
and	O
insect	O
,	O
past	O
,	O
present	O
,	O
future	O

Agonist	O
-	O
induced	O
receptor	O
internalization	O
,	O
determined	O
as	O
the	O
percent	O
of	O
total	O
[	O
125I	O
]	O
Tyr0	B-GENE
-	I-GENE
oCRF	I-GENE
bound	O
located	O
in	O
the	O
acid	O
-	O
resistant	O
fraction	O
of	O
transfected	O
Cos	O
7	O
cells	O
,	O
increased	O
with	O
time	O
(	O
0	O
-	O
60	O
min	O
at	O
37	O
degrees	O
C	O
)	O
for	O
both	O
wild	O
-	O
type	O
and	O
variant	O
oCRF1	B-GENE
.	O

All	O
of	O
the	O
indigo	O
-	O
producing	O
bacteria	O
had	O
an	O
indoxyl	B-GENE
phosphatase	I-GENE
with	O
a	O
pI	O
of	O
6	O
.	O
4	O
.	O

Toward	O
this	O
end	O
,	O
we	O
prepared	O
synthetic	O
proteins	O
with	O
either	O
the	O
catalytic	O
domain	O
of	O
FAP	B-GENE
-	I-GENE
1	I-GENE
(	I-GENE
C	I-GENE
-	I-GENE
terminal	I-GENE
399	I-GENE
amino	I-GENE
acids	I-GENE
)	I-GENE
or	O
its	O
inactive	O
form	O
(	O
Cys2408	O
-	O
-	O
>	O
Ser	O
)	O
fused	O
to	O
glutathione	B-GENE
-	I-GENE
S	I-GENE
-	I-GENE
transferase	I-GENE
(	O
GST	B-GENE
)	O
.	O

TGF	B-GENE
beta	I-GENE
1	I-GENE
expression	O
is	O
largely	O
governed	O
by	O
three	O
AP	B-GENE
-	I-GENE
1	I-GENE
binding	I-GENE
sites	I-GENE
located	O
in	O
two	O
different	O
promoters	O
of	O
this	O
gene	O
.	O

Structure	O
and	O
expression	O
of	O
the	O
alternative	O
sigma	B-GENE
factor	I-GENE
,	O
RpoN	B-GENE
,	O
in	O
Rhodobacter	O
capsulatus	O
;	O
physiological	O
relevance	O
of	O
an	O
autoactivated	O
nifU2	B-GENE
-	O
rpoN	B-GENE
superoperon	O
.	O

It	O
could	O
be	O
detected	O
exclusively	O
in	O
the	O
culture	O
medium	O
of	O
cDNA	O
-	O
transfected	O
COS	O
cells	O
.	O

Here	O
we	O
focused	O
on	O
the	O
role	O
of	O
the	O
5	O
'	O
proximal	O
regulatory	O
cassette	O
(	O
-	O
190	O
;	O
+	O
53	O
bp	O
)	O
of	O
the	O
rat	B-GENE
enkephalin	I-GENE
(	O
rENK	B-GENE
)	O
gene	O
in	O
the	O
developmental	O
regulation	O
of	O
the	O
enkephalin	B-GENE
phenotype	O
.	O

The	O
observed	O
triplexes	O
depend	O
on	O
the	O
length	O
of	O
the	O
repeat	O
.	O

Artificial	O
ventilation	O
was	O
conducted	O
using	O
a	O
tidal	O
volume	O
of	O
10	O
ml	O
X	O
kg	O
-	O
1	O
and	O
a	O
rate	O
of	O
10	O
to	O
12	O
c	O
X	O
min	O
-	O
1	O
.	O

Accumulations	O
of	O
Tl	O
+	O
1	O
(	O
202Tl	O
label	O
)	O
were	O
6	O
times	O
those	O
for	O
Ga	O
or	O
In	O
in	O
the	O
brain	O
and	O
muscles	O
,	O
and	O
.	O
1	O
times	O
in	O
plasma	O
.	O

The	O
transcription	O
factor	O
Jun	B-GENE
(	O
c	B-GENE
-	I-GENE
Jun	I-GENE
)	O
functions	O
as	O
a	O
recipient	O
of	O
extracellular	O
growth	O
signals	O
and	O
converts	O
them	O
into	O
patterns	O
of	O
gene	O
expression	O
.	O

This	O
paper	O
describes	O
the	O
results	O
of	O
an	O
initial	O
study	O
on	O
the	O
application	O
of	O
linear	O
solvation	O
energy	O
relationships	O
(	O
LSERs	O
)	O
to	O
the	O
prediction	O
of	O
internal	O
standard	O
compounds	O
in	O
reversed	O
-	O
phase	O
liquid	O
chromatographic	O
(	O
RPLC	O
)	O
method	O
development	O
.	O

Phd	B-GENE
antibody	O
-	O
immunoreactive	O
peptides	O
are	O
seen	O
in	O
light	O
-	O
adapted	O
mouse	O
retinal	O
cytosolic	O
and	O
nuclear	O
extracts	O
.	O

The	O
biochemistry	O
of	O
amniotic	O
fluid	O
with	O
poor	O
fetal	O
growth	O
.	O

We	O
obtained	O
the	O
prevalence	O
of	O
IgG	B-GENE
antibodies	I-GENE
against	O
Trypanosoma	O
cruzi	O
among	O
1076	O
blood	O
donors	O
at	O
the	O
Instituto	O
Nacional	O
de	O
Cardiologia	O
"	O
Ignacio	O
Chavez	O
"	O
in	O
Mexico	O
City	O
.	O

Using	O
immunochemical	O
co	O
-	O
precipitation	O
methods	O
,	O
we	O
also	O
found	O
that	O
the	O
two	O
proteins	O
are	O
bound	O
in	O
vivo	O
.	O

The	O
AD	O
components	O
were	O
markedly	O
more	O
dependent	O
on	O
the	O
affective	O
state	O
of	O
the	O
rat	O
then	O
was	O
the	O
V1	O
component	O
.	O

Specific	O
binding	O
was	O
not	O
observed	O
with	O
either	O
the	O
orthologous	O
rat	O
or	O
mouse	O
fragments	O
using	O
human	O
or	O
rodent	O
extracts	O
.	O

Effects	O
of	O
aerosol	O
-	O
vapor	O
JP	O
-	O
8	O
jet	O
fuel	O
on	O
the	O
functional	O
observational	O
battery	O
,	O
and	O
learning	O
and	O
memory	O
in	O
the	O
rat	O
.	O

Our	O
observations	O
suggest	O
that	O
members	O
of	O
the	O
HMG	B-GENE
-	I-GENE
I	I-GENE
family	I-GENE
play	O
an	O
important	O
role	O
in	O
SRF	B-GENE
-	O
dependent	O
transcription	O
and	O
that	O
their	O
effect	O
is	O
mediated	O
primarily	O
by	O
a	O
protein	O
-	O
protein	O
interaction	O
.	O

Expression	O
of	O
the	O
dibasic	O
proprotein	O
processing	O
enzyme	O
furin	B-GENE
is	O
directed	O
by	O
multiple	O
promoters	O
.	O

John	O
leonard	O
dawson	O

Ligand	O
-	O
independent	O
activation	O
of	O
platelet	B-GENE
-	I-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
is	O
a	O
necessary	O
intermediate	O
in	O
lysophosphatidic	O
,	O
acid	O
-	O
stimulated	O
mitogenic	O
activity	O
in	O
L	O
cells	O
.	O

A	O
suspected	O
hypothalamic	O
dysfunction	O
and	O
a	O
slightly	O
impaired	O
pituitary	O
function	O
manifested	O
as	O
GH	B-GENE
deficiency	O
were	O
their	O
common	O
endocrinological	O
features	O
.	O

The	O
NarX	B-GENE
and	O
NarQ	B-GENE
proteins	I-GENE
with	O
amino	O
acid	O
substitutions	O
at	O
the	O
first	O
conserved	O
histidine	O
position	O
were	O
also	O
unable	O
to	O
dephosphorylate	O
NarL	B-GENE
-	O
phosphate	O
in	O
vitro	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
tubular	O
diameter	O
and	O
spg	O
(	O
r	O
=	O
0	O
.	O
68	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
suggesting	O
that	O
tubular	O
diameter	O
measurements	O
in	O
histological	O
sections	O
could	O
be	O
used	O
to	O
predict	O
sperm	O
production	O
.	O

Using	O
immunogold	O
electron	O
microscopy	O
,	O
we	O
found	O
that	O
p58	B-GENE
/	O
p45	B-GENE
and	O
p54	B-GENE
are	O
localized	O
on	O
both	O
sides	O
of	O
the	O
nuclear	O
pore	O
complex	O
,	O
like	O
p62	B-GENE
.	O

[	O
Treatment	O
of	O
early	O
T1	O
small	O
T2N	O
breast	O
cancers	O
.	O

The	O
development	O
of	O
a	O
data	O
base	O
is	O
described	O
which	O
can	O
be	O
used	O
as	O
common	O
reference	O
for	O
ECG	O
computer	O
programs	O
analyzing	O
12	O
or	O
15	O
simultaneously	O
recorded	O
leads	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
minimal	O
requirements	O
for	O
induction	O
of	O
PEPCK	B-GENE
by	O
PKA	B-GENE
and	O
inhibition	O
by	O
insulin	B-GENE
include	O
:	O
1	O
)	O
the	O
CREB	B-GENE
activation	I-GENE
domain	I-GENE
,	O
2	O
)	O
the	O
PEPCK	B-GENE
TATA	I-GENE
sequence	I-GENE
,	O
and	O
3	O
)	O
insulin	B-GENE
-	O
responsive	O
hepatoma	O
cells	O
.	O

Regulation	O
of	O
Gax	B-GENE
homeobox	B-GENE
gene	I-GENE
transcription	O
by	O
a	O
combination	O
of	O
positive	O
factors	O
including	O
myocyte	B-GENE
-	I-GENE
specific	I-GENE
enhancer	I-GENE
factor	I-GENE
2	I-GENE
.	O

At	O
the	O
very	O
high	O
dose	O
levels	O
used	O
,	O
sodium	O
saccharin	O
and	O
sodium	O
cyclamate	O
were	O
weak	O
solitary	O
carcinogens	O
producing	O
4	O
/	O
253	O
and	O
3	O
/	O
228	O
bladder	O
tumours	O
respectively	O
,	O
and	O
the	O
first	O
of	O
these	O
tumours	O
did	O
not	O
appear	O
for	O
more	O
than	O
80	O
weeks	O
.	O

Upon	O
differentiation	O
with	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
transcription	O
of	O
the	O
Rex	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
decreases	O
rapidly	O
.	O

A	O
significant	O
relationship	O
existed	O
during	O
the	O
evolution	O
of	O
the	O
disease	O
between	O
CRS	O
/	O
BW	O
and	O
gas	O
exchange	O
parameters	O
(	O
FIO2	O
and	O
a	O
/	O
AO2	O
ratio	O
)	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
but	O
gas	O
exchange	O
improved	O
earlier	O
than	O
lung	O
mechanics	O
.	O

The	O
experiment	O
results	O
showed	O
:	O
(	O
i	O
)	O
not	O
only	O
1O2	O
,	O
but	O
also	O
free	O
radicals	O
(	O
O2	O
-	O
.	O
.	O
OH	O
and	O
YHPD	O
-	O
.	O
)	O
can	O
be	O
formed	O
by	O
the	O
aid	O
of	O
YHPD	O
;	O
and	O
(	O
ii	O
)	O
as	O
to	O
the	O
ability	O
of	O
producing	O
1O2	O
,	O
YHPD	O
less	O
than	O
BHPD	O
,	O
while	O
for	O
generating	O
O2	O
-	O
.	O
and	O
.	O
OH	O
,	O
YHPD	O
greater	O
than	O
BHPD	O
.	O

Critical	O
evaluation	O
of	O
various	O
methods	O
of	O
determining	O
markers	O
of	O
fetal	O
maturity	O
in	O
amniotic	O
fluid	O

Mitochondrial	B-GENE
Mas70p	I-GENE
signal	I-GENE
anchor	I-GENE
sequence	I-GENE
.	O

To	O
get	O
further	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
that	O
control	O
tal	B-GENE
-	I-GENE
1	I-GENE
expression	O
,	O
we	O
have	O
isolated	O
5	O
'	O
sequences	O
of	O
the	O
murine	O
gene	O
and	O
compared	O
them	O
to	O
their	O
human	O
counterparts	O
.	O

Although	O
the	O
Src	B-GENE
tyrosine	I-GENE
kinase	I-GENE
induces	O
constitutive	O
Stat3	B-GENE
phosphorylation	O
on	O
tyrosine	O
,	O
activation	O
of	O
Stat3	B-GENE
-	O
mediated	O
gene	O
regulation	O
requires	O
both	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B-GENE
.	O

Using	O
appropriate	O
synthetic	O
HSE	O
oligonucleotides	O
,	O
three	O
types	O
of	O
clones	O
with	O
potential	O
HSE	O
binding	O
domains	O
were	O
isolated	O
from	O
a	O
tomato	O
lambda	O
gt11	O
expression	O
library	O
by	O
DNA	O
-	O
ligand	O
screening	O
.	O

The	O
corresponding	O
orifice	O
voltages	O
for	O
the	O
three	O
instruments	O
were	O
20	O
/	O
50	O
/	O
80	O
V	O
(	O
API	O
365	O
)	O
,	O
30	O
/	O
90	O
/	O
130	O
V	O
(	O
API	O
2000	O
)	O
and	O
40	O
/	O
80	O
/	O
120	O
V	O
(	O
API	O
3000	O
)	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
mouse	B-GENE
cytosolic	I-GENE
chaperonin	I-GENE
subunit	I-GENE
gene	I-GENE
Ccta	B-GENE
/	I-GENE
t	I-GENE
-	I-GENE
complex	I-GENE
polypeptide	I-GENE
1	I-GENE
by	O
selenocysteine	B-GENE
tRNA	I-GENE
gene	I-GENE
transcription	I-GENE
activating	I-GENE
factor	I-GENE
family	I-GENE
zinc	I-GENE
finger	I-GENE
proteins	I-GENE
.	O

The	O
recognition	O
specificity	O
of	O
the	O
p55	B-GENE
PDZ	B-GENE
domain	I-GENE
appears	O
to	O
be	O
unique	O
,	O
since	O
the	O
three	O
PDZ	B-GENE
domains	I-GENE
of	O
hDlg	B-GENE
(	O
human	O
lymphocyte	O
homologue	O
of	O
the	O
Drosophila	B-GENE
discs	I-GENE
large	I-GENE
tumor	I-GENE
suppressor	I-GENE
)	O
do	O
not	O
bind	O
the	O
cytoplasmic	O
domain	O
of	O
glycophorin	B-GENE
C	I-GENE
.	O

A	O
synthetic	O
oligonucleotide	O
containing	O
the	O
SRE	O
sequence	O
from	O
the	O
mouse	B-GENE
c	I-GENE
-	I-GENE
fos	I-GENE
gene	I-GENE
promoter	I-GENE
(	O
-	O
299	O
to	O
-	O
322	O
)	O
was	O
radioactively	O
labeled	O
,	O
used	O
as	O
a	O
probe	O
for	O
the	O
mobility	O
shift	O
assay	O
and	O
Southwestern	O
(	O
DNA	O
-	O
protein	O
)	O
blotting	O
,	O
and	O
also	O
used	O
for	O
sequence	O
-	O
specific	O
affinity	O
chromatography	O
.	O

Buflomedil	O
(	O
i	O
.	O
v	O
.	O
)	O
induced	O
a	O
dose	O
-	O
dependent	O
increase	O
of	O
cardiac	O
output	O
at	O
0	O
.	O
16	O
-	O
0	O
.	O
64	O
mg	O
/	O
kg	O
,	O
biphasic	O
changes	O
at	O
1	O
.	O
28	O
and	O
2	O
.	O
56	O
mg	O
/	O
kg	O
and	O
a	O
marked	O
decrease	O
and	O
subsequent	O
slight	O
increase	O
at	O
a	O
large	O
dose	O
of	O
5	O
.	O
12	O
mg	O
/	O
kg	O
.	O

Hence	O
,	O
the	O
replacement	O
of	O
Phe	O
-	O
62	O
with	O
Ser	O
specifically	O
affects	O
a	O
determinant	O
on	O
the	O
lambda	B-GENE
I	I-GENE
light	I-GENE
chain	I-GENE
that	O
is	O
necessary	O
for	O
the	O
intracellular	O
transport	O
of	O
this	O
molecule	O
.	O

Cytosolic	B-GENE
acetyl	I-GENE
-	I-GENE
CoA	I-GENE
synthetase	I-GENE
(	O
AceCS1	B-GENE
)	O
activates	O
acetate	O
to	O
supply	O
the	O
cells	O
with	O
acetyl	O
-	O
CoA	O
for	O
lipid	O
synthesis	O
.	O

Domain	O
II	O
is	O
highly	O
homologous	O
to	O
the	O
LDL	B-GENE
receptor	I-GENE
and	O
contains	O
four	O
repeats	O
with	O
perfect	O
conservation	O
of	O
all	O
6	O
consecutive	O
cysteines	O
.	O

Microcirculatory	O
oxygenation	O
and	O
shunting	O
in	O
sepsis	O
and	O
shock	O
.	O

The	O
Sarns	O
51F	O
cavoatrial	O
cannula	O
decompressed	O
the	O
venous	O
system	O
as	O
efficiently	O
as	O
the	O
double	O
caval	O
cannulas	O
.	O

However	O
,	O
no	O
genetic	O
alteration	O
was	O
detected	O
in	O
any	O
of	O
the	O
cancers	O
examined	O
.	O

Delayed	O
mortality	O
of	O
mice	O
following	O
inhalation	O
of	O
acute	O
doses	O
of	O
CH2O	O
,	O
SO2Cl2	O
,	O
and	O
Br2	O
.	O

Experimental	O
chlorpromazine	O
cataracts	O
.	O

Echo	O
modulation	O
in	O
Pr3	O
+	O
:	O
YAlO3	O
.	O

There	O
was	O
no	O
evidence	O
of	O
any	O
persistent	O
oscillation	O
within	O
the	O
ULF	O
band	O
.	O

Cephradine	O
250	O
mg	O
at	O
night	O
for	O
12	O
months	O
was	O
given	O
as	O
a	O
prophylactic	O
measure	O
to	O
33	O
female	O
patients	O
of	O
mean	O
age	O
41	O
.	O
6	O
years	O
,	O
who	O
had	O
a	O
history	O
in	O
the	O
preceding	O
12	O
months	O
of	O
between	O
three	O
and	O
24	O
(	O
median	O
=	O
7	O
)	O
episodes	O
of	O
frequency	O
and	O
/	O
or	O
dysuria	O
.	O

The	O
Cdk2	B-GENE
-	O
cyclin	B-GENE
-	I-GENE
D1	I-GENE
complex	O
did	O
not	O
phosphorylate	O
any	O
tested	O
substrates	O
,	O
such	O
as	O
H1	B-GENE
histone	I-GENE
,	O
pRB	B-GENE
,	O
SV40	B-GENE
large	I-GENE
T	I-GENE
antigen	I-GENE
,	O
p53	B-GENE
,	O
E2F	B-GENE
-	I-GENE
1	I-GENE
or	O
a	O
preparation	O
of	O
nuclear	O
proteins	O
from	O
HeLa	O
cells	O
;	O
in	O
contrast	O
,	O
Cdk2	B-GENE
-	O
cyclin	B-GENE
-	I-GENE
E	I-GENE
and	O
Cdk2	B-GENE
-	O
cyclin	B-GENE
-	I-GENE
A	I-GENE
phosphorylated	O
these	O
proteins	O
.	O

However	O
,	O
other	O
regions	O
of	O
the	O
plasmid	O
are	O
also	O
efficiently	O
repaired	O
.	O

The	O
relatively	O
mild	O
defects	O
observed	O
in	O
Rpd3	B-GENE
mutants	I-GENE
suggest	O
that	O
the	O
recently	O
identified	O
Groucho	B-GENE
and	O
dCtBP	B-GENE
corepressor	I-GENE
proteins	I-GENE
do	O
not	O
function	O
solely	O
through	O
the	O
recruitment	O
of	O
histone	B-GENE
deacetylases	I-GENE
.	O

The	O
severity	O
of	O
clinical	O
course	O
was	O
expressed	O
by	O
means	O
of	O
SOFA	O
score	O
(	O
group	O
A	O
0	O
.	O
3	O
-	O
1	O
-	O
1	O
.	O
3	O
point	O
,	O
group	O
B	O
2	O
.	O
2	O
-	O
2	O
.	O
9	O
-	O
2	O
.	O
6	O
point	O
,	O
group	O
C	O
7	O
.	O
4	O
-	O
8	O
.	O
3	O
-	O
7	O
.	O
7	O
point	O
)	O
and	O
APACHE	O
II	O
score	O
(	O
group	O
A	O
3	O
.	O
7	O
-	O
7	O
.	O
6	O
-	O
8	O
.	O
1	O
point	O
,	O
group	O
B	O
8	O
.	O
6	O
-	O
11	O
.	O
1	O
-	O
10	O
.	O
5	O
point	O
,	O
group	O
C	O
16	O
.	O
3	O
-	O
15	O
.	O
2	O
-	O
14	O
.	O
3	O
point	O
)	O
.	O

A	O
mutant	O
(	O
residues	O
1	O
-	O
332	O
)	O
showed	O
complete	O
Ca2	O
+	O
/	O
CaM	B-GENE
-	O
dependent	O
activity	O
.	O

The	O
PETCO2	O
measurement	O
during	O
precordial	O
compression	O
predicted	O
the	O
success	O
of	O
defibrillation	O
with	O
return	O
of	O
spontaneous	O
circulation	O
.	O

These	O
data	O
further	O
define	O
a	O
role	O
for	O
TRADD	B-GENE
and	O
TRAF2	B-GENE
in	O
JNK	B-GENE
activation	O
and	O
confirm	O
that	O
LMP1	B-GENE
utilizes	O
signalling	O
mechanisms	O
used	O
by	O
the	O
TNF	B-GENE
receptor	I-GENE
/	O
CD40	B-GENE
family	O
to	O
elicit	O
its	O
pleiotropic	O
activities	O
.	O

CONCLUSION	O
:	O
Our	O
study	O
shows	O
that	O
(	O
1	O
)	O
total	O
body	O
BMD	O
and	O
femoral	O
neck	O
BMD	O
were	O
significantly	O
higher	O
in	O
the	O
study	O
group	O
that	O
performed	O
weight	O
-	O
bearing	O
exercises	O
than	O
in	O
control	O
subjects	O
,	O
(	O
2	O
)	O
swimming	O
exercise	O
had	O
no	O
effect	O
on	O
BMD	O
,	O
and	O
(	O
3	O
)	O
although	O
swimming	O
is	O
not	O
a	O
bone	O
-	O
building	O
exercise	O
,	O
it	O
can	O
significantly	O
improve	O
shoulder	O
,	O
back	O
,	O
and	O
grip	O
muscle	O
strength	O
.	O

After	O
base	O
-	O
line	O
CBF	O
was	O
established	O
,	O
hexamethonium	O
bromide	O
(	O
2	O
mg	O
/	O
kg	O
iv	O
)	O
,	O
ipratropium	O
bromide	O
(	O
0	O
.	O
5	O
microgram	O
/	O
kg	O
iv	O
)	O
,	O
indomethacin	O
(	O
2	O
mg	O
/	O
kg	O
iv	O
)	O
,	O
or	O
intravenous	O
0	O
.	O
9	O
%	O
saline	O
was	O
administered	O
.	O

These	O
results	O
demonstrate	O
the	O
existence	O
of	O
different	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
isoforms	I-GENE
and	O
define	O
a	O
family	O
of	O
genes	O
encoding	O
distinct	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
catalytic	I-GENE
subunits	I-GENE
that	O
can	O
associate	O
with	O
p85	B-GENE
.	O

Xylose	O
-	O
and	O
arabinose	O
-	O
containing	O
polymers	O
were	O
better	O
digested	O
than	O
was	O
cellulose	O
for	O
both	O
breads	O
.	O

Cycles	O
were	O
repeated	O
every	O
3	O
weeks	O
.	O

The	O
immune	O
system	O
is	O
closely	O
integrated	O
with	O
the	O
neuroendocrine	O
system	O
,	O
and	O
infection	O
-	O
induced	O
increases	O
in	O
cytokines	O
such	O
as	O
IL	B-GENE
-	I-GENE
1	I-GENE
,	O
IL	B-GENE
-	I-GENE
6	I-GENE
and	O
TNF	B-GENE
have	O
numerous	O
effects	O
on	O
the	O
central	O
nervous	O
system	O
.	O

Thus	O
,	O
the	O
tri	O
-	O
snRNP	O
-	O
specific	O
27K	O
protein	O
could	O
potentially	O
be	O
involved	O
in	O
SR	B-GENE
protein	O
-	O
mediated	O
protein	O
/	O
protein	O
interactions	O
and	O
,	O
additionally	O
,	O
its	O
phosphorylation	O
state	O
could	O
modulate	O
pre	O
-	O
mRNA	O
splicing	O
.	O

Here	O
we	O
localize	O
a	O
transferable	O
40	O
-	O
amino	O
acid	O
region	O
within	O
the	O
LBDs	B-GENE
of	O
RXR	B-GENE
,	O
RAR	B-GENE
,	O
TR	B-GENE
,	O
and	O
chicken	B-GENE
ovalbumin	I-GENE
upstream	I-GENE
promoter	I-GENE
transcription	I-GENE
factor	I-GENE
that	O
is	O
critical	O
for	O
determining	O
identity	O
in	O
the	O
heterodimeric	O
interaction	O
and	O
for	O
high	O
-	O
affinity	O
DNA	O
binding	O
.	O

P	B-GENE
-	I-GENE
CIP1	I-GENE
,	O
a	O
novel	O
protein	O
that	O
interacts	O
with	O
the	O
cytosolic	O
domain	O
of	O
peptidylglycine	B-GENE
alpha	I-GENE
-	I-GENE
amidating	I-GENE
monooxygenase	I-GENE
,	O
is	O
associated	O
with	O
endosomes	O
.	O

Null	O
mutations	O
in	O
daf	B-GENE
-	I-GENE
3	I-GENE
suppress	O
mutations	O
in	O
genes	O
encoding	O
this	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
signal	O
,	O
its	O
receptors	O
,	O
and	O
associated	O
Smad	B-GENE
signal	I-GENE
transduction	I-GENE
proteins	I-GENE
.	O

daf	B-GENE
-	I-GENE
3	I-GENE
encodes	O
a	O
Smad	B-GENE
protein	I-GENE
that	O
is	O
most	O
closely	O
related	O
to	O
mammalian	B-GENE
DPC4	I-GENE
,	O
and	O
is	O
expressed	O
throughout	O
development	O
in	O
many	O
of	O
the	O
tissues	O
that	O
are	O
remodeled	O
during	O
dauer	O
development	O
.	O

Specifically	O
,	O
this	O
study	O
determined	O
the	O
influence	O
of	O
:	O
(	O
1	O
)	O
an	O
awareness	O
strategy	O
,	O
(	O
2	O
)	O
a	O
non	O
-	O
awareness	O
strategy	O
,	O
(	O
3	O
)	O
a	O
Five	O
-	O
Step	O
Approach	O
strategy	O
and	O
(	O
4	O
)	O
a	O
control	O
condition	O
.	O

Mean	O
increase	O
of	O
milk	O
protein	O
yield	O
was	O
46	O
g	O
/	O
d	O
with	O
Met	O
plus	O
Lys	O
,	O
and	O
mean	O
increase	O
of	O
true	O
protein	O
content	O
was	O
1	O
.	O
1	O
g	O
/	O
kg	O
of	O
milk	O
.	O

Two	O
points	O
are	O
indicated	O
:	O
first	O
,	O
the	O
photosensitized	O
damage	O
of	O
YHPD	O
is	O
interrelated	O
to	O
not	O
only	O
1O2	O
,	O
but	O
also	O
free	O
radicals	O
(	O
O2	O
-	O
.	O
.	O
OH	O
and	O
YHPD	O
-	O
.	O
)	O
;	O
second	O
,	O
although	O
the	O
photosensitized	O
damage	O
of	O
YHPD	O
is	O
stronger	O
than	O
that	O
of	O
BHPD	O
,	O
yet	O
the	O
photosensitized	O
damage	O
is	O
negatively	O
correlated	O
to	O
the	O
yield	O
of	O
1O2	O
but	O
positively	O
correlated	O
to	O
those	O
of	O
O2	O
-	O
.	O
and	O
OH	O
.	O

Introductory	O
remarks	O
.	O

In	O
contrast	O
,	O
a	O
similar	O
fragment	O
lacking	O
the	O
38	O
-	O
base	O
-	O
pair	O
region	O
had	O
no	O
such	O
stabilizing	O
effect	O
.	O

Mutation	O
of	O
the	O
octamer	O
element	O
also	O
significantly	O
reduced	O
the	O
ability	O
of	O
HDAC1	B-GENE
to	O
confer	O
repression	O
of	O
inducible	O
HLA	B-GENE
-	I-GENE
DRA	I-GENE
promoter	I-GENE
activation	O
.	O

The	O
AtERF	B-GENE
genes	I-GENE
were	O
differentially	O
regulated	O
by	O
ethylene	O
and	O
by	O
abiotic	O
stress	O
conditions	O
,	O
such	O
as	O
wounding	O
,	O
cold	O
,	O
high	O
salinity	O
,	O
or	O
drought	O
,	O
via	O
ETHYLENE	B-GENE
-	I-GENE
INSENSITIVE2	I-GENE
(	O
EIN2	B-GENE
)	O
-	O
dependent	O
or	O
-	O
independent	O
pathways	O
.	O

Effect	O
of	O
heparin	O
on	O
the	O
inactivation	O
of	O
serum	B-GENE
lipoprotein	I-GENE
lipase	I-GENE
by	O
the	O
liver	O
in	O
unanesthetized	O
dogs	O
.	O

Staphylococcus	O
aureus	O
and	O
CNS	O
showed	O
high	O
or	O
moderate	O
resistance	O
rates	O
to	O
methicillin	O
(	O
DMPPC	O
)	O
.	O

The	O
prevalence	O
of	O
tobacco	O
dependence	O
diagnosed	O
according	O
to	O
the	O
ICD	O
-	O
10	O
criteria	O
was	O
higher	O
in	O
alcohol	O
-	O
dependent	O
individuals	O
(	O
58	O
.	O
1	O
%	O
)	O
than	O
in	O
nondrinkers	O
or	O
social	O
drinkers	O
(	O
12	O
.	O
8	O
%	O
)	O
.	O

Bacteriostatic	O
and	O
bacteriacidal	O
activity	O
of	O
hydroxy	O
-	O
9	O
ellipticine	O
in	O
vitro	O

In	O
vitro	O
interaction	O
studies	O
,	O
using	O
proteins	O
fused	O
to	O
glutathione	B-GENE
-	I-GENE
S	I-GENE
-	I-GENE
transferase	I-GENE
,	O
showed	O
that	O
RBP	B-GENE
-	I-GENE
J	I-GENE
kappa	I-GENE
and	O
Su	B-GENE
(	I-GENE
H	I-GENE
)	I-GENE
bind	O
directly	O
to	O
the	O
RAM23	B-GENE
regions	I-GENE
of	O
mouse	B-GENE
Notch1	I-GENE
and	O
Drosophila	B-GENE
Notch	I-GENE
,	O
respectively	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
DnaA	B-GENE
may	O
contact	O
the	O
beta	O
subunit	O
of	O
RNA	B-GENE
polymerase	I-GENE
during	O
activation	O
of	O
the	O
pR	B-GENE
promoter	I-GENE
.	O

Physiol	O
.	O

The	O
presence	O
of	O
truncated	O
receptor	O
isoforms	O
in	O
diverse	O
species	O
suggests	O
that	O
these	O
proteins	O
may	O
have	O
important	O
functional	O
roles	O
in	O
regulating	O
EGFR	B-GENE
activity	O
.	O

Naltrexone	O
has	O
been	O
recently	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
for	O
the	O
treatment	O
of	O
alcohol	O
dependence	O
.	O

It	O
is	O
present	O
in	O
the	O
nucleus	O
of	O
the	O
cells	O
in	O
which	O
it	O
is	O
expressed	O
and	O
can	O
phosphorylate	O
and	O
activate	O
the	O
cyclic	B-GENE
AMP	I-GENE
response	I-GENE
element	I-GENE
binding	I-GENE
proteins	I-GENE
CREB	B-GENE
and	O
CREM	B-GENE
tau	I-GENE
in	O
a	O
manner	O
analogous	O
to	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
.	O

The	O
telomerase	B-GENE
RNA	I-GENE
-	I-GENE
protein	I-GENE
complex	I-GENE
responsible	O
for	O
maintenance	O
of	O
telomeric	O
DNA	O
at	O
chromosome	O
ends	O
,	O
is	O
usually	O
inactive	O
in	O
most	O
primary	O
somatic	O
human	O
cells	O
,	O
but	O
is	O
specifically	O
activated	O
with	O
in	O
vitro	O
immortalization	O
and	O
during	O
tumorigenesis	O
.	O

These	O
results	O
demonstrate	O
that	O
a	O
diverse	O
set	O
of	O
carboxyl	O
-	O
terminal	O
sequence	O
motifs	O
and	O
posttranslational	O
modifications	O
lead	O
to	O
functional	O
Ras	B-GENE
proteins	I-GENE
in	O
yeast	O
.	O

We	O
postulate	O
that	O
CaM	B-GENE
binding	O
by	O
HIV	B-GENE
envelope	I-GENE
proteins	I-GENE
is	O
likely	O
to	O
exert	O
diverse	O
modulatory	O
effects	O
,	O
and	O
the	O
mechanism	O
for	O
HIV	O
-	O
induced	O
cytotoxicity	O
may	O
involve	O
,	O
in	O
part	O
,	O
inhibition	O
of	O
CaM	B-GENE
-	O
regulated	O
cellular	O
functions	O
.	O

Further	O
,	O
Ser	O
/	O
Thr	O
phosphorylation	O
of	O
downstream	O
molecules	O
Akt	B-GENE
and	O
p70	B-GENE
S6	I-GENE
kinase	I-GENE
was	O
inhibited	O
.	O

An	O
approximately	O
2	B-GENE
-	I-GENE
kilobase	I-GENE
B2	I-GENE
transcript	I-GENE
was	O
expressed	O
in	O
all	O
alfalfa	O
organs	O
tested	O
.	O

In	O
addition	O
,	O
expected	O
decreases	O
in	O
ATIC	B-GENE
enzymatic	O
function	O
in	O
ATIC	B-GENE
-	O
ALK	B-GENE
-	O
containing	O
lymphomas	O
may	O
render	O
these	O
tumors	O
more	O
sensitive	O
to	O
antifolate	O
drugs	O
such	O
as	O
methotrexate	O
.	O

We	O
conclude	O
that	O
c	B-GENE
-	I-GENE
Myb	I-GENE
regulates	O
the	O
RAG	B-GENE
-	I-GENE
2	I-GENE
promoter	I-GENE
in	O
T	O
cells	O
by	O
binding	O
to	O
this	O
consensus	B-GENE
c	I-GENE
-	I-GENE
Myb	I-GENE
binding	I-GENE
site	I-GENE
.	O

We	O
show	O
that	O
the	O
mouse	O
genome	O
contains	O
four	O
copies	O
of	O
the	O
ubc	B-GENE
-	I-GENE
9	I-GENE
gene	I-GENE
.	O

The	O
present	O
chemotherapy	O
of	O
AE	O
is	O
based	O
on	O
the	O
administration	O
of	O
benzimidazole	O
carbamate	O
derivatives	O
,	O
such	O
as	O
mebendazole	O
and	O
albendazole	O
.	O

Microscopic	O
anatomy	O
and	O
cell	O
population	O
dynamics	O
.	O

The	O
malate	B-GENE
synthase	I-GENE
gene	I-GENE
,	O
MLS1	B-GENE
,	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
is	O
transcriptionally	O
regulated	O
by	O
the	O
carbon	O
source	O
in	O
the	O
growth	O
medium	O
.	O

IMPLICATIONS	O
:	O
Given	O
the	O
small	O
size	O
of	O
this	O
study	O
and	O
the	O
inconsistency	O
of	O
results	O
among	O
the	O
few	O
prospective	O
studies	O
of	O
ovarian	O
cancer	O
conducted	O
to	O
test	O
these	O
associations	O
,	O
replications	O
of	O
these	O
findings	O
are	O
highly	O
desirable	O
.	O

The	O
carboxyl	O
-	O
terminal	O
transactivation	O
domain	O
of	O
heat	B-GENE
shock	I-GENE
factor	I-GENE
1	I-GENE
is	O
negatively	O
regulated	O
and	O
stress	O
responsive	O
.	O

Ras	B-GENE
-	I-GENE
and	I-GENE
ultra	I-GENE
-	I-GENE
violet	I-GENE
-	I-GENE
responsive	I-GENE
protein	I-GENE
kinases	I-GENE
that	O
phosphorylate	O
c	B-GENE
-	I-GENE
Jun	I-GENE
on	O
serine	O
residues	O
at	O
positions	O
63	O
and	O
73	O
and	O
stimulate	O
its	O
transcriptional	O
activity	O
have	O
been	O
identified	O
.	O

Amikacin	O
was	O
the	O
most	O
stable	O
and	O
tobramycin	O
was	O
the	O
least	O
stable	O
aminoglycoside	O
under	O
the	O
conditions	O
tested	O
.	O

Secretion	O
in	O
milk	O
and	O
transplacental	O
transfer	O
of	O
two	O
iodized	O
oils	O
,	O
Lipiodol	O
UF	O
and	O
Oriodol	O
,	O
in	O
rabbits	O
.	O

The	O
hBRAG	B-GENE
gene	I-GENE
was	O
localized	O
to	O
the	O
long	O
arm	O
of	O
chromosome	O
10	O
(	O
10q26	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
Lung	O
elastance	O
(	O
EL	O
)	O
and	O
resistance	O
(	O
RL	O
)	O
were	O
calculated	O
from	O
measurements	O
of	O
airway	O
pressure	O
,	O
esophageal	O
pressure	O
,	O
and	O
airway	O
flow	O
in	O
five	O
anesthetized	O
,	O
paralyzed	O
dogs	O
during	O
sinusoidal	O
forcing	O
at	O
a	O
constant	O
mean	O
airway	O
pressure	O
of	O
10	O
cmH2O	O
in	O
a	O
wide	O
range	O
of	O
breathing	O
frequencies	O
(	O
0	O
.	O
2	O
to	O
1	O
.	O
0	O
Hz	O
in	O
intervals	O
of	O
0	O
.	O
2	O
)	O
and	O
tidal	O
volumes	O
(	O
50	O
,	O
100	O
,	O
200	O
,	O
and	O
to	O
300	O
mL	O
)	O
.	O

Habituation	O
of	O
completely	O
isolated	O
neurons	O
of	O
the	O
edible	O
snail	O
to	O
electrical	O
stimulation	O
.	O

Additionally	O
,	O
MIP	B-GENE
-	I-GENE
2A	I-GENE
antagonizes	O
cell	O
growth	O
regulatory	O
role	O
of	O
MBP	B-GENE
-	I-GENE
1	I-GENE
.	O

The	O
average	O
deviations	O
in	O
the	O
X	O
-	O
ray	O
counts	O
of	O
the	O
constant	O
elements	O
from	O
the	O
series	O
means	O
were	O
used	O
to	O
correct	O
the	O
recorded	O
count	O
of	O
the	O
variable	O
element	O
in	O
each	O
block	O
.	O

At	O
temperatures	O
permissive	O
for	O
transformation	O
,	O
6m2	O
cells	O
contain	O
P58gag	B-GENE
produced	O
from	O
the	O
4	O
.	O
0	O
-	O
kilobase	O
(	O
kb	O
)	O
viral	O
RNA	O
genome	O
and	O
P85gag	B-GENE
-	O
mos	B-GENE
translated	O
from	O
a	O
3	O
.	O
5	O
-	O
kb	O
spliced	O
mRNA	O
.	O

ENV	B-GENE
also	O
was	O
secreted	O
from	O
P	O
.	O
pastoris	O
using	O
the	O
S	B-GENE
.	I-GENE
cerevisiae	I-GENE
alpha	I-GENE
-	I-GENE
factor	I-GENE
prepro	I-GENE
secretion	I-GENE
leader	I-GENE
and	O
the	O
S	B-GENE
.	I-GENE
cerevisiae	I-GENE
invertase	I-GENE
signal	I-GENE
sequence	I-GENE
.	O

Functional	O
rearranged	O
antibody	O
genes	O
were	O
detected	O
with	O
JH	B-GENE
and	O
VH	B-GENE
heavy	I-GENE
chain	I-GENE
probes	O
and	O
with	O
Jk	B-GENE
and	O
Vk	B-GENE
light	I-GENE
chain	I-GENE
probes	O
.	O

Differential	O
association	O
of	O
products	O
of	O
alternative	O
transcripts	O
of	O
the	O
candidate	O
tumor	B-GENE
suppressor	I-GENE
ING1	I-GENE
with	O
the	O
mSin3	B-GENE
/	O
HDAC1	B-GENE
transcriptional	O
corepressor	O
complex	O
.	O

A	O
Golgi	O
study	O
of	O
the	O
sixth	O
layer	O
of	O
the	O
cerebral	O
cortex	O
.	O

During	O
both	O
encephalopathy	O
episodes	O
,	O
CSF	O
protein	O
and	O
immunoglobulin	B-GENE
G	I-GENE
(	O
IgG	B-GENE
)	O
levels	O
were	O
elevated	O
without	O
an	O
increased	O
IgG	B-GENE
index	O
or	O
IgG	B-GENE
synthesis	O
rate	O
.	O

Significantly	O
lower	O
heart	O
rate	O
reactivity	O
and	O
significantly	O
less	O
pronounced	O
left	O
temporal	O
artery	O
pulse	O
amplitude	O
responses	O
were	O
found	O
in	O
non	O
-	O
medicated	O
TH	O
subjects	O
than	O
in	O
controls	O
.	O

Treatment	O
of	O
unstable	O
angina	O
:	O
role	O
of	O
antithrombotic	O
therapy	O
.	O

Expression	O
of	O
h6	O
.	O
1	O
in	O
COS	O
-	O
1	O
cells	O
led	O
to	O
the	O
production	O
of	O
a	O
typical	O
type	B-GENE
IV	I-GENE
PDE	I-GENE
activity	O
in	O
that	O
cAMP	O
,	O
but	O
not	O
cGMP	O
,	O
served	O
as	O
substrate	O
and	O
its	O
activity	O
was	O
insensitive	O
to	O
either	O
Ca2	O
+	O
/	O
CaM	B-GENE
or	O
cGMP	O
but	O
was	O
inhibited	O
by	O
low	O
concentrations	O
of	O
rolipram	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

The	O
hybrid	O
viruses	O
were	O
found	O
to	O
accumulate	O
to	O
high	O
levels	O
in	O
infected	O
plants	O
,	O
to	O
form	O
stable	O
virions	O
,	O
and	O
to	O
be	O
mechanically	O
transmissible	O
.	O

The	O
mean	O
times	O
to	O
detection	O
of	O
all	O
mycobacteria	O
with	O
BACTEC	O
9000	O
MB	O
and	O
BACTEC	O
460	O
TB	O
were	O
similar	O
(	O
10	O
.	O
3	O
and	O
10	O
.	O
0	O
days	O
,	O
respectively	O
)	O
.	O

The	O
amino	O
acid	O
sequences	O
of	O
the	O
predicted	O
RfbA	B-GENE
and	O
RfbB	B-GENE
homologs	I-GENE
showed	O
identities	O
of	O
75	O
.	O
7	O
%	O
(	O
87	O
.	O
9	O
%	O
total	O
similarity	O
)	O
and	O
78	O
.	O
0	O
%	O
(	O
86	O
.	O
5	O
%	O
total	O
similarity	O
)	O
,	O
respectively	O
.	O

In	O
vitro	O
penetration	O
tests	O
of	O
human	O
sperm	O
into	O
cervical	O
mucus	O
were	O
introduced	O
in	O
order	O
to	O
study	O
the	O
interaction	O
between	O
sperm	O
and	O
cervical	O
mucus	O
.	O

Striking	O
sequence	O
similarities	O
(	O
57	O
and	O
53	O
%	O
)	O
were	O
observed	O
with	O
yeast	O
mitochondrial	O
proteins	O
,	O
SMF1	B-GENE
and	O
SMF2	B-GENE
,	O
especially	O
within	O
putative	O
functional	O
domains	O
:	O
exon	O
6	O
encoding	O
the	O
second	O
transmembrane	O
spanning	O
domain	O
,	O
site	O
of	O
the	O
murine	B-GENE
susceptibility	I-GENE
mutation	O
;	O
and	O
exon	O
11	O
encoding	O
a	O
conserved	O
transport	O
motif	O
.	O

We	O
also	O
examined	O
the	O
relationship	O
between	O
the	O
side	O
of	O
sinusitis	O
and	O
the	O
cleft	O
side	O
in	O
patients	O
with	O
unilateral	O
cleft	O
palate	O
.	O

Malaria	O
had	O
diminished	O
significantly	O
by	O
the	O
early	O
1940s	O
,	O
and	O
this	O
paper	O
queries	O
whether	O
that	O
reduction	O
was	O
due	O
to	O
the	O
control	O
projects	O
of	O
the	O
thirties	O
,	O
and	O
,	O
if	O
so	O
,	O
whether	O
such	O
projects	O
should	O
be	O
a	O
model	O
for	O
the	O
current	O
developing	O
world	O
,	O
where	O
malaria	O
is	O
a	O
growing	O
problem	O
today	O
.	O

The	O
nucleotide	O
sequences	O
of	O
the	O
human	B-GENE
and	I-GENE
murine	I-GENE
ornithine	I-GENE
decarboxylase	I-GENE
mRNAs	I-GENE
share	O
an	O
85	O
%	O
homology	O
,	O
even	O
in	O
their	O
3	O
'	O
-	O
noncoding	O
regions	O
.	O

These	O
data	O
locate	O
the	O
aniridia	B-GENE
gene	I-GENE
(	O
AN2	B-GENE
)	O
and	O
a	O
recurrent	O
T	B-GENE
-	I-GENE
cell	I-GENE
leukemia	I-GENE
breakpoint	I-GENE
(	O
TCL2	B-GENE
)	O
in	O
the	O
marker	O
sequence	O
,	O
on	O
opposite	O
sides	O
of	O
MIC1	B-GENE
.	O

Dopaminergic	O
modulation	O
of	O
transcallosal	O
activity	O
of	O
cat	O
motor	O
cortical	O
neurons	O
.	O

In	O
vivo	O
association	O
between	O
Shb	B-GENE
-	O
SH3	B-GENE
domain	O
proteins	O
v	B-GENE
-	I-GENE
Src	I-GENE
and	O
Eps8	B-GENE
was	O
detected	O
by	O
coimmunoprecipitation	O
.	O

IE2	B-GENE
-	O
IE2	B-GENE
interactions	O
were	O
mapped	O
to	O
a	O
domain	O
containing	O
a	O
putative	O
helix	O
-	O
turn	O
-	O
helix	O
motif	O
located	O
near	O
the	O
C	O
terminus	O
of	O
IE2	B-GENE
,	O
between	O
amino	O
acids	O
456	O
and	O
539	O
.	O

There	O
are	O
,	O
however	O
,	O
several	O
differences	O
between	O
the	O
two	O
new	O
ars	O
sequences	O
.	O

In	O
addition	O
,	O
another	O
derivative	O
of	O
pCMVJS21	O
(	O
pCMVJS21DeltaGP	O
)	O
in	O
which	O
the	O
gag	B-GENE
,	O
pol	B-GENE
(	O
and	O
orf	B-GENE
-	I-GENE
x	I-GENE
)	O
coding	O
sequences	O
were	O
deleted	O
also	O
gave	O
transformed	O
foci	O
.	O

In	O
contrast	O
,	O
over	O
-	O
expression	O
of	O
RAR	B-GENE
beta	I-GENE
only	O
poorly	O
restored	O
differentiation	O
,	O
although	O
it	O
could	O
replace	O
RAR	B-GENE
gamma	I-GENE
for	O
the	O
activation	O
of	O
target	O
genes	O
.	O

Effect	O
of	O
the	O
methods	O
of	O
cutaneous	O
administration	O
of	O
methyl	O
isobutyl	O
ketone	O
on	O
its	O
toxicity	O

Analysis	O
of	O
the	O
protein	O
sequences	O
of	O
these	O
two	O
replicases	B-GENE
,	O
together	O
with	O
previously	O
characterized	O
H	B-GENE
.	I-GENE
pylori	I-GENE
plasmid	I-GENE
replication	I-GENE
proteins	I-GENE
,	O
supports	O
the	O
formation	O
of	O
a	O
distinct	O
class	O
of	O
H	B-GENE
.	I-GENE
pylori	I-GENE
plasmid	I-GENE
proteins	I-GENE
.	O

In	O
adulthood	O
these	O
rats	O
were	O
hyperactive	O
and	O
learned	O
the	O
active	O
avoidance	O
response	O
later	O
than	O
the	O
controls	O
.	O

At	O
Cabras	O
(	O
Oristano	O
)	O
,	O
a	O
town	O
characterized	O
by	O
a	O
high	O
incidence	O
of	O
thalassaemia	O
and	O
G6PD	B-GENE
deficiency	O
less	O
than	O
half	O
the	O
people	O
between	O
18	O
and	O
35	O
have	O
a	O
fair	O
knowledge	O
of	O
genetic	O
diseases	O
and	O
of	O
their	O
prevention	O
.	O

The	O
438	B-GENE
bp	I-GENE
EcoRI	I-GENE
fragment	I-GENE
,	O
which	O
was	O
detected	O
by	O
Southern	O
hybridization	O
,	O
reveals	O
an	O
open	O
reading	O
frame	O
which	O
encodes	O
a	O
protein	O
of	O
103	O
amino	O
acids	O
.	O

The	O
coding	O
sequences	O
of	O
the	O
Crry	B-GENE
gene	I-GENE
encompass	O
over	O
25	O
kb	O
of	O
DNA	O
,	O
whereas	O
the	O
Crry	B-GENE
-	O
ps	B-GENE
sequences	O
are	O
included	O
within	O
a	O
single	O
5	B-GENE
.	I-GENE
6	I-GENE
-	I-GENE
kb	I-GENE
Eco	I-GENE
-	I-GENE
R1	I-GENE
fragment	I-GENE
.	O

Thus	O
,	O
included	O
in	O
the	O
KG1a	O
EST	O
dataset	O
are	O
candidates	O
for	O
new	O
human	O
genes	O
that	O
may	O
play	O
roles	O
in	O
hematopoietic	O
differentiative	O
progression	O
and	O
lineage	O
commitment	O
.	O

These	O
cells	O
produced	O
P2Y	B-GENE
(	I-GENE
11	I-GENE
)	I-GENE
mRNA	I-GENE
during	O
culture	O
.	O

Patient	O
characteristics	O
associated	O
with	O
deep	O
wounds	O
as	O
well	O
as	O
patient	O
and	O
wound	O
characteristics	O
predictive	O
of	O
the	O
extent	O
of	O
healing	O
and	O
time	O
required	O
for	O
healing	O
were	O
identified	O
.	O

Because	O
the	O
biosynthetic	O
pathway	O
to	O
the	O
vacuole	O
intersects	O
with	O
the	O
endocytic	O
pathway	O
,	O
internalization	O
of	O
a	O
bulk	O
membrane	O
endocytic	O
marker	O
FM	O
4	O
-	O
64	O
was	O
assayed	O
in	O
the	O
sop	B-GENE
mutants	I-GENE
.	O

Propranolol	O
also	O
effectively	O
controlled	O
her	O
familial	O
tremor	O
.	O

Echinostomiasis	O
is	O
aggravated	O
by	O
socioeconomic	O
factors	O
such	O
as	O
poverty	O
,	O
malnutrition	O
,	O
an	O
explosively	O
growing	O
free	O
-	O
food	O
market	O
,	O
a	O
lack	O
of	O
supervised	O
food	O
inspection	O
,	O
poor	O
or	O
insufficient	O
sanitation	O
,	O
other	O
helminthiases	O
,	O
and	O
declining	O
economic	O
conditions	O
.	O

Evoked	O
potential	O
and	O
single	O
unit	O
responses	O
to	O
olfactory	O
nerve	O
volleys	O
in	O
the	O
isolated	O
turtle	O
olfactory	O
bulb	O
.	O

We	O
found	O
that	O
PML	B-GENE
was	O
expressed	O
at	O
a	O
lower	O
level	O
in	O
S	O
,	O
G2	O
,	O
and	O
M	O
phases	O
and	O
at	O
a	O
significantly	O
higher	O
level	O
in	O
G1	O
phase	O
.	O

Mechanisms	O
of	O
visible	O
-	O
light	O
emission	O
from	O
electro	O
-	O
oxidized	O
porous	O
silicon	O
.	O

Each	O
dietary	O
treatment	O
was	O
fed	O
to	O
six	O
pen	O
replicates	O
of	O
five	O
chicks	O
per	O
pen	O
for	O
21	O
d	O
.	O

The	O
localization	O
of	O
ZAP	B-GENE
-	I-GENE
70	I-GENE
to	O
the	O
cell	O
cortex	O
is	O
,	O
therefore	O
,	O
regulated	O
by	O
the	O
activity	O
of	O
SRC	B-GENE
-	I-GENE
family	I-GENE
kinases	I-GENE
,	O
independently	O
of	O
their	O
ability	O
to	O
phosphorylate	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motifs	O
of	O
the	O
TCR	B-GENE
.	O

However	O
,	O
we	O
could	O
not	O
find	O
the	O
homologous	O
regions	O
with	O
guanine	B-GENE
nucleotide	I-GENE
exchange	I-GENE
factors	I-GENE
or	O
GTPase	B-GENE
-	I-GENE
activating	I-GENE
proteins	I-GENE
in	O
the	O
c	B-GENE
-	I-GENE
cbl	I-GENE
gene	I-GENE
.	O

Interleukin	B-GENE
-	I-GENE
8	I-GENE
(	O
IL	B-GENE
-	I-GENE
8	I-GENE
)	O
is	O
a	O
potent	O
inflammatory	O
mediator	O
that	O
belongs	O
to	O
the	O
family	O
of	O
C	B-GENE
-	I-GENE
X	I-GENE
-	I-GENE
C	I-GENE
chemokines	I-GENE
.	O

The	O
227	O
-	O
to	O
-	O
239	O
region	O
blocked	O
ADR1	B-GENE
activity	O
independently	O
of	O
the	O
TAD	B-GENE
present	O
on	O
ADR1	B-GENE
,	O
ADR1	B-GENE
DNA	O
binding	O
,	O
and	O
specific	O
ADH2	B-GENE
promoter	I-GENE
sequences	I-GENE
.	O

Repair	O
of	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
in	O
chromosomal	O
DNA	O
by	O
nonhomologous	O
end	O
-	O
joining	O
(	O
NHEJ	O
)	O
is	O
not	O
well	O
characterized	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

Significant	O
alterations	O
in	O
CBC	O
results	O
and	O
serum	B-GENE
CRP	I-GENE
concentration	O
,	O
compared	O
with	O
baseline	O
values	O
,	O
were	O
lacking	O
in	O
dogs	O
of	O
the	O
control	O
group	O
.	O

Our	O
results	O
show	O
that	O
CVN	B-GENE
specifically	O
recognizes	O
with	O
nanomolar	O
affinity	O
Man	O
(	O
9	O
)	O
GlcNAc	O
(	O
2	O
)	O
and	O
the	O
D1D3	O
isomer	O
of	O
Man	O
(	O
8	O
)	O
GlcNAc	O
(	O
2	O
)	O
.	O

Erythrocyte	O
protoporphyrin	O
concentration	O
increased	O
significantly	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
by	O
14	O
days	O
in	O
dogs	O
fed	O
the	O
basal	O
diet	O
,	O
and	O
remained	O
significantly	O
high	O
relative	O
to	O
that	O
in	O
dogs	O
of	O
the	O
other	O
dietary	O
groups	O
for	O
the	O
remainder	O
of	O
the	O
study	O
.	O

The	O
controversy	O
of	O
significance	O
testing	O
:	O
misconceptions	O
and	O
alternatives	O
.	O

SL1	B-GENE
trans	O
-	O
splicing	O
specified	O
by	O
AU	O
-	O
rich	O
synthetic	O
RNA	O
inserted	O
at	O
the	O
5	O
'	O
end	O
of	O
Caenorhabditis	O
elegans	O
pre	O
-	O
mRNA	O
.	O

The	O
seventh	O
cysteine	O
residue	O
of	O
CTSE	B-GENE
is	O
located	O
within	O
the	O
activation	O
peptide	O
region	O
of	O
the	O
proenzyme	O
.	O

The	O
chick	O
axon	O
-	O
associated	O
surface	O
glycoprotein	O
neurofascin	B-GENE
is	O
implicated	O
in	O
axonal	O
growth	O
and	O
fasciculation	O
as	O
revealed	O
by	O
antibody	O
perturbation	O
experiments	O
.	O

These	O
mutations	O
create	O
stop	O
codons	O
in	O
exon	O
7	O
and	O
8	O
,	O
respectively	O
,	O
and	O
probably	O
result	O
in	O
truncated	O
proteins	O
lacking	O
HLH	O
-	O
Zip	O
or	O
Zip	O
structure	O
.	O

The	O
unphosphorylated	O
form	O
of	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
is	O
designated	O
IIA	O
,	O
whereas	O
the	O
phosphorylated	O
form	O
is	O
designated	O
IIO	O
.	O

Cdk2	B-GENE
formed	O
a	O
complex	O
with	O
cyclin	B-GENE
D1	I-GENE
in	O
this	O
system	O
.	O

Five	O
cell	O
strains	O
of	O
human	O
dermal	O
fibroblasts	O
were	O
each	O
treated	O
with	O
three	O
samples	O
of	O
burn	O
blister	O
fluid	O
and	O
the	O
effect	O
compared	O
with	O
the	O
rate	O
of	O
contraction	O
of	O
free	O
floating	O
fibroblast	O
populated	O
collagen	B-GENE
lattices	O
(	O
FPCL	O
)	O
.	O

Deletion	O
analysis	O
of	O
rOC	B-GENE
promoter	I-GENE
-	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
constructs	O
demonstrates	O
that	O
an	O
AML	B-GENE
-	I-GENE
1	I-GENE
-	I-GENE
binding	I-GENE
sequence	I-GENE
within	O
the	O
proximal	O
promoter	O
(	O
-	O
138	O
to	O
-	O
130	O
nt	O
)	O
contributes	O
to	O
75	O
%	O
of	O
the	O
level	O
of	O
osteocalcin	B-GENE
gene	I-GENE
expression	O
.	O

Trial	O
3	O
broiler	O
chickens	O
were	O
maintained	O
on	O
control	O
feed	O
until	O
they	O
reached	O
3	O
weeks	O
of	O
age	O
at	O
which	O
time	O
they	O
were	O
taken	O
off	O
of	O
feed	O
for	O
2	O
.	O
5	O
hr	O
and	O
then	O
placed	O
on	O
either	O
control	O
feed	O
or	O
feed	O
containing	O
4	O
.	O
0	O
ppm	O
ochratoxin	O
A	O
,	O
and	O
heart	O
rate	O
and	O
blood	O
pressure	O
were	O
measured	O
every	O
half	O
hour	O
through	O
7	O
hr	O
.	O

DIBA	O
was	O
more	O
sensitive	O
and	O
had	O
a	O
better	O
negative	O
predictive	O
value	O
and	O
a	O
lower	O
false	O
negative	O
percentage	O
than	O
DFAT	O
.	O

Teratological	O
studies	O
on	O
SF	O
-	O
837	O
.	O

N	O
.	O
,	O
and	O
Fanning	O
,	O
E	O
.	O

Recent	O
studies	O
using	O
isolated	O
rat	O
adipocytes	O
and	O
chemically	O
synthesized	O
PIG	O
compounds	O
point	O
to	O
IRS1	B-GENE
/	I-GENE
3	I-GENE
tyrosine	O
phosphorylation	O
by	O
p59Lyn	B-GENE
kinase	I-GENE
as	O
the	O
site	O
of	O
cross	O
-	O
talk	O
,	O
the	O
negative	O
regulation	O
of	O
which	O
by	O
interaction	O
with	O
caveolin	B-GENE
is	O
apparently	O
abrogated	O
by	O
PIG	O
.	O

METHODS	O
:	O
rHb1	B-GENE
.	I-GENE
1	I-GENE
or	O
human	B-GENE
serum	I-GENE
albumin	I-GENE
was	O
administered	O
intravenously	O
to	O
fasting	O
male	O
volunteers	O
.	O

We	O
have	O
tested	O
this	O
proposal	O
by	O
carrying	O
out	O
circular	O
dichroism	O
(	O
CD	O
)	O
and	O
NMR	O
experiments	O
on	O
the	O
Skn	B-GENE
domain	I-GENE
and	O
five	O
truncated	O
proteins	O
.	O

During	O
the	O
CR	O
/	O
PP	O
diet	O
only	O
the	O
HS	O
subjects	O
did	O
not	O
show	O
the	O
stress	O
-	O
induced	O
rise	O
in	O
depression	O
,	O
decline	O
in	O
vigour	O
and	O
cortisol	O
elevation	O
that	O
they	O
showed	O
after	O
the	O
PR	O
/	O
CP	O
diet	O
.	O

However	O
,	O
little	O
is	O
known	O
regarding	O
the	O
genomic	O
organization	O
and	O
developmental	O
expression	O
of	O
the	O
caveolin	B-GENE
gene	I-GENE
family	I-GENE
.	O

The	O
gene	O
was	O
uniquely	O
mapped	O
with	O
odds	O
>	O
1	O
,	O
000	O
:	O
1	O
on	O
chromosome	O
3p	O
in	O
Centre	O
d	O
'	O
Etude	O
du	O
Polymorphisme	O
Humain	O
pedigrees	O
.	O

In	O
addition	O
,	O
REP21	O
plants	O
were	O
resistant	O
to	O
an	O
unusually	O
broad	O
range	O
of	O
tobamoviruses	O
including	O
tomato	O
mosaic	O
virus	O
,	O
tobacco	O
mild	O
green	O
mosaic	O
virus	O
,	O
TMV	O
-	O
U5	O
,	O
green	O
tomato	O
atypical	O
mosaic	O
virus	O
,	O
and	O
ribgrass	O
mosaic	O
virus	O
.	O

In	O
the	O
eight	O
patients	O
with	O
persistent	O
generalized	O
lymph	O
-	O
adenopathy	O
(	O
PGL	O
)	O
and	O
nontender	O
,	O
nonenlarging	O
nodes	O
,	O
pathologic	O
analysis	O
revealed	O
lymphoid	O
hyperplasia	O
.	O

In	O
addition	O
,	O
a	O
noncanonical	O
C	B-GENE
/	I-GENE
EBP	I-GENE
-	I-GENE
binding	I-GENE
site	I-GENE
within	O
the	O
Gadd45gamma	B-GENE
promoter	I-GENE
where	O
C	B-GENE
/	I-GENE
EBPbeta	I-GENE
and	O
C	B-GENE
/	I-GENE
EBPdelta	I-GENE
could	O
bind	O
,	O
was	O
identified	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
reporter	O
gene	O
analysis	O
.	O

I	O
.	O

The	O
effect	O
of	O
a	O
constant	O
magnetic	O
field	O
on	O
the	O
phagocytic	O
activity	O
of	O
Paramecia	O

Genes	O
for	O
ocs	B-GENE
element	I-GENE
binding	I-GENE
factors	I-GENE
(	O
OBFs	B-GENE
)	O
,	O
belonging	O
to	O
a	O
specific	O
class	O
of	O
basic	B-GENE
-	I-GENE
region	I-GENE
leucine	I-GENE
zipper	I-GENE
(	I-GENE
bZIP	I-GENE
)	I-GENE
transcription	I-GENE
factors	I-GENE
,	O
have	O
been	O
isolated	O
in	O
a	O
number	O
of	O
plants	O
.	O

Hematopoietic	B-GENE
growth	I-GENE
factors	I-GENE
are	O
being	O
used	O
to	O
accelerate	O
the	O
recovery	O
of	O
myelopoiesis	O
following	O
high	O
-	O
dose	O
chemotherapy	O
in	O
cancer	O
patients	O
.	O

The	O
remainder	O
(	O
18	O
.	O
4	O
%	O
)	O
was	O
with	O
IgA	B-GENE
nephropathy	O
,	O
which	O
was	O
histologically	O
mild	O
.	O

The	O
strong	O
conservation	O
of	O
the	O
inverted	O
terminal	O
repeat	O
sequence	O
may	O
reflect	O
a	O
common	O
integration	O
mechanism	O
for	O
VL30	B-GENE
elements	I-GENE
and	O
MuLV	O
proviruses	O
.	O

In	O
addition	O
serum	B-GENE
IgE	I-GENE
concentrations	O
were	O
not	O
statistically	O
different	O
.	O

The	O
comparison	O
of	O
the	O
expression	O
patterns	O
of	O
the	O
known	O
Kv4	B-GENE
family	I-GENE
members	I-GENE
shows	O
subtype	O
specificity	O
with	O
significant	O
overlaps	O
.	O

We	O
have	O
investigated	O
the	O
requirements	O
of	O
the	O
CH	B-GENE
gene	I-GENE
switch	O
by	O
characterizing	O
two	O
rearranged	B-GENE
gamma	I-GENE
2b	I-GENE
genes	I-GENE
from	O
a	O
gamma	B-GENE
2b	I-GENE
producing	O
mouse	O
myeloma	O
(	O
MPC	O
-	O
11	O
)	O
.	O

In	O
this	O
study	O
we	O
wanted	O
to	O
assess	O
the	O
DR	O
using	O
the	O
'	O
combined	O
test	O
'	O
in	O
an	O
unselected	O
population	O
of	O
self	O
-	O
referred	O
pregnant	O
women	O
at	O
a	O
false	O
-	O
positive	O
rate	O
(	O
FPR	O
)	O
of	O
about	O
5	O
%	O
.	O

No	O
such	O
benefits	O
were	O
seen	O
for	O
children	O
with	O
CD4	B-GENE
+	I-GENE
counts	O
below	O
0	O
.	O
2	O
x	O
10	O
(	O
9	O
)	O
per	O
liter	O
at	O
entry	O
.	O

Southern	O
blot	O
analyses	O
demonstrated	O
a	O
low	O
,	O
if	O
not	O
single	O
,	O
copy	O
number	O
for	O
this	O
gene	O
and	O
conservation	O
of	O
this	O
domain	O
in	O
other	O
vertebrates	O
.	O

We	O
cloned	O
the	O
third	O
human	O
gene	O
for	O
the	O
LD78	B-GENE
,	O
termed	O
LD78	B-GENE
gamma	I-GENE
and	O
the	O
sequence	O
analysis	O
showed	O
that	O
it	O
is	O
a	O
5	O
'	O
-	O
truncated	O
pseudogene	O
.	O

Two	O
mammalian	O
enzymes	O
,	O
the	O
haem	B-GENE
-	I-GENE
controlled	I-GENE
repressor	I-GENE
(	O
HCR	B-GENE
)	O
and	O
the	O
double	B-GENE
-	I-GENE
stranded	I-GENE
RNA	I-GENE
-	I-GENE
activated	I-GENE
inhibitor	I-GENE
(	O
dsI	B-GENE
)	O
,	O
phosphorylate	O
Ser	O
-	O
51	O
of	O
the	O
alpha	O
subunit	O
,	O
thereby	O
inhibiting	O
the	O
exchange	O
of	O
bound	O
nucleotides	O
on	O
,	O
and	O
thus	O
the	O
recycling	O
of	O
,	O
eIF	B-GENE
-	I-GENE
2	I-GENE
.	O

Analysis	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
gene	O
also	O
revealed	O
the	O
presence	O
of	O
multiple	O
TATA	O
and	O
CAAT	O
sequences	O
.	O

Analysis	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
gene	O
also	O
revealed	O
the	O
presence	O
of	O
multiple	O
TATA	O
and	O
CAAT	O
sequences	O
.	O

As	O
a	O
result	O
,	O
we	O
have	O
defined	O
two	O
arginine	O
-	O
rich	O
motifs	O
(	O
ARM1	O
and	O
ARM2	O
)	O
that	O
mediate	O
the	O
RNA	O
binding	O
activity	O
of	O
SU	B-GENE
(	I-GENE
S	I-GENE
)	I-GENE
.	O

Lars	O
has	O
AIDS	O
-	O
-	O
a	O
more	O
dignified	O
life	O
with	O
care	O
at	O
home	O
.	O

Based	O
on	O
16S	B-GENE
rRNA	I-GENE
gene	I-GENE
sequence	I-GENE
analysis	O
,	O
the	O
11	O
species	O
having	O
two	O
tuf	B-GENE
genes	I-GENE
all	O
have	O
a	O
common	O
ancestor	O
,	O
while	O
the	O
six	O
species	O
having	O
only	O
one	O
copy	O
diverged	O
from	O
the	O
enterococcal	O
lineage	O
before	O
that	O
common	O
ancestor	O
.	O

Gel	O
route	O
preparation	O
of	O
low	O
fusing	O
dental	O
porcelain	O
frit	O
.	O

Polypyrimidine	O
and	O
ssDNA	O
binding	O
by	O
the	O
isolated	O
VH	B-GENE
domain	I-GENE
of	O
immunization	O
-	O
induced	O
anti	O
-	O
Z	O
-	O
DNA	O
Ab	O
resembles	O
the	O
activity	O
of	O
natural	O
autoantibodies	O
and	O
suggests	O
that	O
VH	B-GENE
-	O
dependent	O
binding	O
to	O
a	O
ligand	O
mimicked	O
by	O
polypyrimidines	O
may	O
play	O
a	O
role	O
in	O
B	O
cell	O
selection	O
before	O
immunization	O
with	O
Z	O
-	O
DNA	O
.	O

Many	O
human	O
viruses	O
are	O
able	O
to	O
develop	O
suitable	O
strategies	O
for	O
modifying	O
apoptosis	O
in	O
virus	O
-	O
infected	O
cells	O
and	O
in	O
virus	O
-	O
primed	O
T	O
cells	O
.	O

This	O
,	O
together	O
with	O
the	O
data	O
obtained	O
with	O
haloperidol	O
,	O
suggests	O
that	O
a	O
minimal	O
increase	O
in	O
the	O
firing	O
rate	O
of	O
LC	O
cells	O
(	O
+	O
140	O
%	O
)	O
is	O
required	O
before	O
it	O
could	O
influence	O
the	O
turnover	O
of	O
NA	O
,	O
as	O
measured	O
by	O
DOPAC	O
changes	O
.	O

We	O
have	O
been	O
studying	O
the	O
interaction	O
of	O
the	O
oncogenic	O
human	O
polyomavirus	O
BK	O
(	O
BKV	O
)	O
with	O
the	O
tumor	B-GENE
-	I-GENE
suppressor	I-GENE
protein	I-GENE
p53	I-GENE
to	O
understand	O
the	O
biology	O
of	O
this	O
virus	O
as	O
well	O
as	O
to	O
understand	O
the	O
basic	O
mechanisms	O
of	O
p53	B-GENE
transactivation	O
.	O

These	O
results	O
suggest	O
that	O
,	O
for	O
the	O
HML	B-GENE
ARS	O
cluster	O
(	O
ARS303	B-GENE
,	O
ARS320	B-GENE
,	O
and	O
ARS302	B-GENE
)	O
,	O
inactivity	O
of	O
origins	O
is	O
independent	O
of	O
local	O
transcriptional	O
silencing	O
,	O
even	O
though	O
origins	O
and	O
silencers	O
share	O
key	O
cis	O
-	O
and	O
trans	O
-	O
acting	O
components	O
.	O

Guinea	O
pigs	O
weighing	O
300	O
approximately	O
350	O
g	O
were	O
used	O
.	O

The	O
pel	B-GENE
gene	I-GENE
from	O
an	O
Amycolata	O
sp	O
.	O
encoding	O
a	O
pectate	B-GENE
lyase	I-GENE
(	O
EC	B-GENE
4	I-GENE
.	I-GENE
2	I-GENE
.	I-GENE
2	I-GENE
.	I-GENE
2	I-GENE
)	O
was	O
isolated	O
by	O
activity	O
screening	O
a	O
genomic	O
DNA	O
library	O
in	O
Streptomyces	O
lividans	O
TK24	O
.	O

Examination	O
of	O
the	O
immediate	O
sequence	O
5	O
'	O
to	O
the	O
mRNA	O
start	O
site	O
reveals	O
no	O
TATA	O
box	O
and	O
multiple	O
known	O
enhancer	O
sequences	O
.	O

Treatment	O
with	O
oxyphenylbutazone	O
and	O
hydrocortisone	O
failed	O
to	O
inhibit	O
the	O
raised	O
serum	B-GENE
CPN	I-GENE
levels	O
.	O

The	O
lowest	O
detectable	O
concentration	O
was	O
1	O
.	O
0	O
ng	O
/	O
ml	O
in	O
the	O
serum	O
.	O

Northern	O
blot	O
analysis	O
with	O
one	O
of	O
the	O
PARNAs	B-GENE
revealed	O
a	O
highly	O
abundant	O
signal	O
of	O
approximately	O
2	O
.	O
0	O
kilobases	O
(	O
kb	O
)	O
present	O
in	O
all	O
cell	O
lines	O
tested	O
.	O

Otte	O
,	O
Mol	O
.	O

In	O
addition	O
,	O
we	O
identified	O
two	O
mutations	O
,	O
Delta	O
M1281	O
and	O
IVS51	O
+	O
5G	O
-	O
-	O
>	O
A	O
,	O
in	O
a	O
German	O
USH1	B-GENE
patient	O
.	O

These	O
discoloration	O
'	O
s	O
can	O
be	O
treated	O
in	O
several	O
ways	O
but	O
up	O
to	O
lately	O
tooth	O
structure	O
had	O
to	O
be	O
removed	O
in	O
an	O
irreversible	O
manner	O
in	O
order	O
to	O
provide	O
sufficient	O
bulk	O
for	O
the	O
new	O
restorative	O
material	O
.	O

Furthermore	O
,	O
deletion	O
and	O
mutation	O
analyses	O
of	O
the	O
VCAM	B-GENE
-	I-GENE
1	I-GENE
promoter	I-GENE
performed	O
with	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
constructs	I-GENE
revealed	O
that	O
Tax	B-GENE
was	O
trans	O
activating	O
the	O
VCAM	B-GENE
-	I-GENE
1	I-GENE
promoter	I-GENE
via	O
two	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
sites	I-GENE
present	O
at	O
bp	O
-	O
72	O
and	O
-	O
57	O
in	O
the	O
VCAM	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
promoter	I-GENE
,	O
with	O
both	O
of	O
them	O
being	O
required	O
for	O
the	O
Tax	B-GENE
-	O
induced	O
expression	O
of	O
this	O
adhesion	O
molecule	O
.	O

In	O
this	O
study	O
we	O
provide	O
evidence	O
that	O
B	B-GENE
-	I-GENE
Myb	I-GENE
is	O
a	O
direct	O
physiological	O
target	O
for	O
cyclin	B-GENE
A	I-GENE
/	O
Cdk2	B-GENE
.	O

The	O
geometric	O
mean	O
hemagglutination	O
-	O
inhibition	O
antibody	O
titers	O
(	O
GMT	O
)	O
of	O
non	O
-	O
immunized	O
,	O
once	O
-	O
immunized	O
,	O
and	O
twice	O
-	O
immunized	O
chickens	O
were	O
compared	O
at	O
2	O
-	O
week	O
intervals	O
following	O
primary	O
immunization	O
,	O
secondary	O
immunization	O
,	O
and	O
challenge	O
.	O

Analysis	O
of	O
an	O
autopsy	O
population	O
.	O

Factors	O
influencing	O
in	O
vitro	O
skin	B-GENE
permeability	I-GENE
factor	I-GENE
production	O
by	O
Vibrio	O
cholerae	O
.	O

During	O
treatment	O
,	O
the	O
phosphorylation	O
state	O
of	O
Rb	B-GENE
shifted	O
to	O
a	O
hypophosphorylated	O
form	O
.	O

mRNA	O
for	O
the	O
HPV	O
E6	B-GENE
/	O
E7	B-GENE
genes	O
decreased	O
;	O
however	O
,	O
significant	O
changes	O
in	O
the	O
E7	B-GENE
protein	I-GENE
were	O
not	O
observed	O
,	O
while	O
increased	O
levels	O
of	O
Rb	B-GENE
immunoprecipitated	O
with	O
anti	B-GENE
-	I-GENE
E7	I-GENE
antibodies	I-GENE
were	O
observed	O
.	O

Acquired	O
factor	B-GENE
VIII	I-GENE
inhibitor	O
in	O
non	O
-	O
hemophilic	O
patients	O

This	O
study	O
suggests	O
that	O
BSPMs	O
are	O
useful	O
in	O
the	O
assessment	O
of	O
AMI	O
in	O
terms	O
of	O
diagnosis	O
,	O
location	O
and	O
extent	O
of	O
myocardial	O
infarct	O
.	O

Mean	O
growth	O
changes	O
in	O
this	O
Class	O
II	O
sample	O
were	O
comparable	O
to	O
those	O
previously	O
reported	O
for	O
male	O
subjects	O
with	O
Class	O
I	O
malocclusions	O
over	O
the	O
same	O
age	O
period	O
,	O
suggesting	O
a	O
similarity	O
in	O
postpubertal	O
development	O
between	O
these	O
two	O
groups	O
.	O

Oxygen	O
tension	O
of	O
the	O
small	O
lymph	O
vessels	O
(	O
PLO2	O
)	O
of	O
the	O
rabbit	O
hind	O
limb	O
was	O
measured	O
with	O
both	O
a	O
flow	O
-	O
through	O
micro	O
chamber	O
and	O
a	O
polarographic	O
catheter	O
-	O
tip	O
oxygen	O
electrode	O
to	O
obtain	O
experimental	O
data	O
on	O
the	O
source	O
of	O
oxygen	O
in	O
the	O
lymph	O
.	O

Thus	O
,	O
we	O
have	O
identified	O
an	O
activation	O
target	O
of	O
a	O
human	O
activator	O
,	O
Oct	B-GENE
-	I-GENE
1	I-GENE
,	O
within	O
its	O
cognate	O
basal	O
transcription	O
complex	O
.	O

Southern	O
blot	O
hybridization	O
experiments	O
suggest	O
the	O
presence	O
of	O
one	O
copy	O
of	O
Atcys1	B-GENE
,	O
Athyp1	B-GENE
and	O
AKin10	B-GENE
per	O
haploid	O
genome	O
,	O
and	O
Northern	O
blot	O
analysis	O
demonstrates	O
that	O
the	O
three	O
genes	O
are	O
differentially	O
expressed	O
in	O
roots	O
,	O
shoots	O
and	O
leaves	O
.	O

Transcript	O
analysis	O
reveals	O
that	O
lethal	O
B	B-GENE
block	I-GENE
substitutions	O
reduce	O
U6	B-GENE
RNA	I-GENE
synthesis	O
at	O
least	O
10	O
-	O
fold	O
in	O
vivo	O
and	O
20	O
-	O
fold	O
in	O
vitro	O
.	O

The	O
transport	O
of	O
a	O
genetically	O
engineered	O
chimeric	O
transmembrane	O
protein	O
connected	O
to	O
this	O
ER	O
leader	O
sequence	O
was	O
as	O
efficient	O
as	O
that	O
of	O
the	O
original	O
protein	O
from	O
which	O
the	O
ER	O
sequence	O
has	O
been	O
derived	O
.	O

Kidney	O
weight	O
and	O
kidney	O
-	O
to	O
-	O
body	O
weight	O
ratio	O
were	O
significantly	O
elevated	O
at	O
the	O
highest	O
dose	O
level	O
after	O
10	O
weeks	O
and	O
at	O
the	O
two	O
higher	O
dose	O
levels	O
after	O
15	O
weeks	O
of	O
exposure	O
.	O

A	O
brief	O
account	O
of	O
the	O
1988	O
seminar	O
in	O
Shanghai	O
on	O
viral	O
hepatitis	O
A	O

The	O
two	O
-	O
hybrid	O
assay	O
was	O
then	O
performed	O
using	O
full	O
-	O
length	O
genes	O
of	O
CI	B-GENE
,	O
HC	B-GENE
-	I-GENE
Pro	I-GENE
,	O
P1	B-GENE
,	O
P3	B-GENE
,	O
and	O
CP	B-GENE
,	O
but	O
no	O
heterologous	O
interactions	O
were	O
detected	O
.	O

It	O
was	O
concluded	O
that	O
patients	O
with	O
acute	O
respiratory	O
failure	O
requiring	O
artificial	O
ventilation	O
have	O
two	O
componenents	O
of	O
the	O
pulmonary	O
shunt	O
,	O
one	O
parallel	O
with	O
and	O
the	O
other	O
inversely	O
related	O
with	O
the	O
PAO2	O
.	O

I	O
.	O

Urine	O
specimens	O
containing	O
either	O
phencyclidine	O
(	O
PCP	O
)	O
or	O
11	O
-	O
nor	O
-	O
delta	O
9	O
-	O
tetrahydrocannabinol	O
-	O
9	O
-	O
carboxylic	O
acid	O
(	O
9	O
-	O
THC	O
-	O
COOH	O
)	O
were	O
adulterated	O
with	O
sodium	O
chloride	O
,	O
bleach	O
,	O
vinegar	O
,	O
potassium	O
hydroxide	O
,	O
liquid	O
soap	O
,	O
2	O
-	O
propanol	O
,	O
and	O
ammonia	O
.	O

Personal	O
satisfaction	O
in	O
nursing	O
:	O
an	O
encounter	O
with	O
extremely	O
hostile	O
patients	O

The	O
ventilation	O
did	O
not	O
increase	O
when	O
PACO2	O
was	O
increased	O
.	O

This	O
computation	O
is	O
performed	O
by	O
a	O
parallel	O
network	O
of	O
locally	O
connected	O
neuron	O
-	O
like	O
elements	O
.	O

These	O
six	O
amino	O
acids	O
are	O
part	O
of	O
an	O
amphipathic	O
helix	O
that	O
is	O
highly	O
conserved	O
among	O
nuclear	B-GENE
hormone	I-GENE
receptors	I-GENE
and	O
contains	O
the	O
core	O
domain	O
of	O
the	O
ligand	O
-	O
dependent	O
transactivation	O
function	O
,	O
AF	O
-	O
2	O
.	O

With	O
Sair	O
and	O
So2	O
,	O
mean	O
vital	O
capacity	O
was	O
reduced	O
by	O
44	O
%	O
from	O
control	O
.	O

4	O
.	O

CPDs	O
at	O
these	O
three	O
sites	O
may	O
partially	O
displace	O
TFIIIA	B-GENE
,	O
thereby	O
enabling	O
rapid	O
repair	O
.	O

Venkatesan	O
,	O
and	O
D	O
.	O

This	O
generally	O
means	O
an	O
energy	O
intake	O
of	O
1	O
.	O
4	O
to	O
1	O
.	O
6	O
times	O
the	O
energy	O
expenditure	O
,	O
with	O
a	O
N	O
intake	O
of	O
250	O
to	O
400	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Diazepam	O
(	O
3	O
mg	O
/	O
kg	O
)	O
generalized	O
to	O
Ro	O
11	O
-	O
6896	O
whereas	O
the	O
structurally	O
related	O
Ro	O
5	O
-	O
4864	O
(	O
3	O
mg	O
/	O
kg	O
and	O
30	O
mg	O
/	O
kg	O
)	O
did	O
not	O
.	O

axl	O
,	O
a	O
transforming	O
gene	O
isolated	O
from	O
primary	O
human	O
myeloid	O
leukemia	O
cells	O
,	O
encodes	O
a	O
novel	O
receptor	B-GENE
tyrosine	I-GENE
kinase	I-GENE
.	O

Thyrotropin	B-GENE
-	I-GENE
releasing	I-GENE
hormone	I-GENE
-	O
induced	O
contraction	O
of	O
urethral	O
and	O
vaginal	O
muscle	O
.	O

NF	B-GENE
-	I-GENE
kappaB	I-GENE
is	O
involved	O
in	O
the	O
regulation	O
of	O
CD154	B-GENE
(	O
CD40	B-GENE
ligand	I-GENE
)	O
expression	O
in	O
primary	O
human	O
T	O
cells	O
.	O

Since	O
the	O
UfAP	B-GENE
and	O
UTMP	B-GENE
share	O
many	O
biosynthetic	O
and	O
structural	O
features	O
that	O
include	O
site	O
of	O
biosynthesis	O
in	O
the	O
endometrium	O
,	O
P4	O
-	O
responsiveness	O
,	O
the	O
presence	O
of	O
the	O
mannose	O
6	O
-	O
phosphate	O
lysosomal	O
recognition	O
marker	O
,	O
and	O
considerable	O
sequence	O
similarity	O
,	O
the	O
UfAP	B-GENE
and	O
the	O
UTMP	B-GENE
may	O
have	O
homologous	O
function	O
which	O
for	O
both	O
still	O
remains	O
obscure	O
.	O

Although	O
both	O
transfected	O
cell	O
lines	O
contain	O
FGF	B-GENE
-	I-GENE
1	I-GENE
cell	I-GENE
surface	I-GENE
receptors	I-GENE
as	O
judged	O
by	O
crosslinking	O
studies	O
,	O
the	O
wild	O
-	O
type	O
transfectants	O
are	O
refractory	O
to	O
exogenous	O
FGF	B-GENE
-	I-GENE
1	I-GENE
,	O
whereas	O
the	O
mutant	O
transfectants	O
respond	O
normally	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Moreover	O
,	O
promoters	O
containing	O
a	O
TATA	O
box	O
in	O
the	O
absence	O
of	O
Sp1	B-GENE
sites	I-GENE
or	O
Sp1	B-GENE
sites	I-GENE
in	O
the	O
absence	O
of	O
a	O
TATA	O
box	O
were	O
equally	O
inducible	O
in	O
vitro	O
,	O
as	O
was	O
an	O
RNA	B-GENE
polymerase	I-GENE
III	I-GENE
promoter	I-GENE
.	O

As	O
expected	O
,	O
the	O
heparin	O
did	O
produce	O
increased	O
recalcification	O
times	O
and	O
the	O
development	O
of	O
occasional	O
subcutaneous	O
hematomas	O
.	O

NF	B-GENE
kappa	I-GENE
B	I-GENE
was	O
activated	O
to	O
a	O
much	O
greater	O
extent	O
by	O
roscovitine	O
in	O
the	O
WT	O
cells	O
than	O
in	O
Y8	O
cells	O
.	O

The	O
total	O
number	O
of	O
specimens	O
was	O
131	O
with	O
78	O
nonsmokers	O
and	O
53	O
smokers	O
.	O

We	O
obtained	O
quantitative	O
evidence	O
on	O
the	O
coding	O
of	O
interaural	O
time	O
differences	O
(	O
ITDs	O
)	O
of	O
click	O
stimuli	O
by	O
40	O
single	O
neurons	O
in	O
the	O
auditory	O
cortex	O
of	O
anesthetized	O
albino	O
rats	O
.	O

The	O
ewes	O
were	O
returned	O
to	O
normoxia	O
,	O
and	O
monitoring	O
was	O
continued	O
for	O
1	O
h	O
.	O

To	O
illustrate	O
its	O
performance	O
,	O
measurements	O
of	O
photoluminescence	O
in	O
GaAs	O
/	O
AlGaAs	O
heterostructures	O
are	O
presented	O
.	O

The	O
results	O
of	O
these	O
experiments	O
indicate	O
that	O
at	O
least	O
two	O
upstream	O
activator	O
sequences	O
(	O
UAS	O
)	O
mediate	O
maximum	O
induction	O
by	O
galactose	O
.	O

Plasma	B-GENE
renin	I-GENE
activity	O
does	O
not	O
predict	O
the	O
antihypertensive	O
efficacy	O
of	O
chlorthalidone	O
.	O

INTERVENTIONS	O
:	O
Study	O
patients	O
were	O
randomly	O
divided	O
into	O
four	O
parallel	O
groups	O
to	O
receive	O
either	O
terbinafine	O
250	O
mg	O
a	O
day	O
for	O
12	O
or	O
16	O
weeks	O
(	O
groups	O
T12	O
and	O
T16	O
)	O
or	O
itraconazole	O
400	O
mg	O
a	O
day	O
for	O
1	O
week	O
in	O
every	O
4	O
weeks	O
for	O
12	O
or	O
16	O
weeks	O
(	O
groups	O
I3	O
and	O
I4	O
)	O
.	O

The	O
CVA16	B-GENE
.	I-GENE
4	I-GENE
proteolipid	I-GENE
transcript	I-GENE
is	O
the	O
most	O
prevalent	O
of	O
the	O
two	O
proteolipid	O
messages	O
in	O
expanding	O
ovules	O
harvested	O
10	O
d	O
post	O
-	O
anthesis	O
.	O

Toxicity	O
was	O
very	O
mild	O
with	O
both	O
regimens	O
,	O
although	O
sedation	O
was	O
significantly	O
higher	O
in	O
arm	O
B	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

The	O
yeast	O
gene	O
that	O
encodes	O
eIF	B-GENE
-	I-GENE
5	I-GENE
,	O
designated	O
TIF5	B-GENE
,	O
has	O
been	O
isolated	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
to	O
yield	O
a	O
catalytically	O
active	O
eIF	B-GENE
-	I-GENE
5	I-GENE
protein	I-GENE
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
the	O
mouse	B-GENE
NMO1	I-GENE
cDNA	I-GENE
,	O
which	O
encodes	O
the	O
NAD	B-GENE
(	I-GENE
P	I-GENE
)	I-GENE
H	I-GENE
:	I-GENE
menadione	I-GENE
oxidoreductase	I-GENE
[	O
also	O
called	O
NAD	B-GENE
(	I-GENE
P	I-GENE
)	I-GENE
H	I-GENE
:	I-GENE
(	I-GENE
quinone	I-GENE
acceptor	I-GENE
)	I-GENE
oxidoreductase	I-GENE
;	O
quinone	B-GENE
reductase	I-GENE
;	O
azo	B-GENE
dye	I-GENE
reductase	I-GENE
;	O
DT	B-GENE
diaphorase	I-GENE
;	O
EC	B-GENE
1	I-GENE
.	I-GENE
6	I-GENE
.	I-GENE
99	I-GENE
.	I-GENE
2	I-GENE
]	O
.	O

In	O
conclusion	O
,	O
IgM	B-GENE
class	O
CIC	O
is	O
the	O
predominant	O
CIC	O
in	O
acute	O
hepatitis	O
A	O
and	O
correlated	O
with	O
disease	O
activity	O
.	O

Ulcer	O
appeared	O
on	O
the	O
angulus	O
of	O
the	O
stomach	O
at	O
the	O
28th	O
week	O
and	O
resulted	O
in	O
ulcer	O
scar	O
at	O
the	O
42nd	O
week	O
.	O

As	O
expected	O
for	O
a	O
positive	O
SpHE	B-GENE
transcriptional	I-GENE
regulator	I-GENE
,	O
the	O
timing	O
of	O
SpEts4	B-GENE
gene	I-GENE
expression	O
precedes	O
the	O
transient	O
expression	O
of	O
SpHE	B-GENE
in	O
the	O
very	O
early	O
sea	O
urchin	O
blastula	O
.	O

A	O
secondary	O
phosphorylation	O
of	O
CREB341	B-GENE
at	O
Ser129	O
is	O
required	O
for	O
the	O
cAMP	O
-	O
mediated	O
control	O
of	O
gene	O
expression	O
.	O

The	O
activity	O
of	O
the	O
coat	B-GENE
protein	I-GENE
promoter	I-GENE
of	O
chloris	O
striate	O
mosaic	O
virus	O
is	O
enhanced	O
by	O
its	O
own	O
and	O
C1	B-GENE
-	O
C2	B-GENE
gene	O
products	O
.	O

The	O
alterations	O
in	O
differentiation	O
of	O
osteoprogenitor	O
cells	O
,	O
together	O
with	O
the	O
failure	O
of	O
mineralization	O
,	O
resulted	O
in	O
significantly	O
lower	O
rates	O
of	O
bone	O
formation	O
(	O
as	O
measured	O
by	O
fluorochrome	O
labeling	O
)	O
in	O
the	O
magnesium	O
-	O
deficient	O
rats	O
.	O

The	O
sequence	O
of	O
the	O
HIR1	B-GENE
gene	I-GENE
predicts	O
an	O
88	O
-	O
kDa	O
protein	O
with	O
three	O
repeats	O
of	O
a	O
motif	O
found	O
in	O
the	O
G	B-GENE
beta	I-GENE
subunit	I-GENE
of	O
retinal	B-GENE
transducin	I-GENE
and	O
in	O
a	O
yeast	O
transcriptional	O
repressor	O
,	O
Tup1	B-GENE
.	O

Grossly	O
,	O
the	O
experimental	O
vulvitis	O
was	O
identical	O
to	O
the	O
field	O
condition	O
,	O
and	O
bacteria	O
indistinguishable	O
from	O
the	O
inoculated	O
strains	O
were	O
reisolated	O
.	O

This	O
expression	O
assumes	O
:	O
(	O
1	O
)	O
a	O
laminar	O
flow	O
regimen	O
during	O
expiration	O
,	O
and	O
(	O
2	O
)	O
a	O
constant	O
CT	O
value	O
over	O
the	O
range	O
of	O
VT	O
.	O

Enhancer	O
and	O
promoter	O
elements	O
directing	O
activation	O
and	O
glucocorticoid	O
repression	O
of	O
the	O
alpha	B-GENE
1	I-GENE
-	I-GENE
fetoprotein	I-GENE
gene	I-GENE
in	O
hepatocytes	O
.	O

A	O
prospective	O
observational	O
study	O
was	O
conducted	O
to	O
identify	O
early	O
indicators	O
of	O
acute	O
dengue	O
virus	O
infection	O
.	O

One	O
patients	O
had	O
plasma	B-GENE
C	I-GENE
-	I-GENE
peptide	I-GENE
greater	O
than	O
3	O
pM	O
and	O
was	O
therefore	O
excluded	O
from	O
analysis	O
.	O

Measurement	O
of	O
magnesium	O
absorption	O
in	O
man	O
using	O
stable	O
26Mg	O
as	O
a	O
tracer	O
.	O

The	O
median	O
survival	O
is	O
not	O
reached	O
with	O
a	O
median	O
follow	O
-	O
up	O
time	O
of	O
9	O
.	O
6	O
years	O
.	O

Conformational	O
studies	O
combining	O
secondary	O
structure	O
predictions	O
,	O
CD	O
and	O
NMR	O
spectroscopy	O
together	O
with	O
ELISA	O
assays	O
,	O
showed	O
that	O
the	O
greater	O
is	O
the	O
propensity	O
of	O
the	O
epitope	O
for	O
helix	O
formation	O
the	O
higher	O
is	O
the	O
recognition	O
by	O
anti	B-GENE
-	I-GENE
K159	I-GENE
.	O

Prostate	B-GENE
specific	I-GENE
antigen	I-GENE
shows	O
the	O
metastatic	O
cases	O
better	O
[	O
correction	O
of	O
worse	O
]	O
than	O
prostatic	B-GENE
acid	I-GENE
phosphatase	I-GENE
.	O

Simultaneous	O
,	O
bilateral	O
and	O
permanent	O
ventilation	O
with	O
a	O
diaphragm	O
pacing	O
in	O
childhood	O
:	O
the	O
implantation	O
technique	O
and	O
indications	O

The	O
first	O
follow	O
-	O
up	O
was	O
at	O
a	O
nearly	O
constant	O
interval	O
of	O
5	O
.	O
1	O
years	O
in	O
Caerphilly	O
and	O
3	O
.	O
2	O
years	O
in	O
Speedwell	O
;	O
251	O
major	O
IHD	O
events	O
had	O
occurred	O
.	O

Fourteen	O
patients	O
were	O
in	O
the	O
multifocal	O
disease	O
group	O
;	O
13	O
were	O
detected	O
by	O
SPECT	O
and	O
10	O
by	O
TCT	O
.	O

U73	B-GENE
contains	O
C	O
,	O
D	O
and	O
D	O
'	O
boxes	O
and	O
a	O
12	O
-	O
nucleotide	O
antisense	O
complementarity	O
to	O
the	O
28S	B-GENE
ribosomal	I-GENE
RNA	I-GENE
.	O

CONCLUSIONS	O
:	O
XCoe2	B-GENE
may	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
transcriptional	O
cascade	O
that	O
specifies	O
primary	O
neurons	O
in	O
Xenopus	O
embryos	O
:	O
by	O
maintaining	O
Delta	B-GENE
-	O
Notch	B-GENE
signalling	O
,	O
XCoe2	B-GENE
stabilises	O
the	O
higher	O
neural	O
potential	O
of	O
selected	O
progenitor	O
cells	O
that	O
express	O
X	B-GENE
-	I-GENE
ngnr	I-GENE
-	I-GENE
1	I-GENE
,	O
ensuring	O
the	O
transition	O
between	O
neural	O
competence	O
and	O
irreversible	O
commitment	O
to	O
a	O
neural	O
fate	O
;	O
and	O
it	O
promotes	O
neuronal	O
differentiation	O
by	O
activating	O
XNeuroD	B-GENE
expression	O
,	O
directly	O
or	O
indirectly	O
.	O

Negatively	O
supercoiled	O
plasmid	O
pUC19	O
did	O
not	O
compete	O
,	O
whereas	O
an	O
otherwise	O
identical	O
plasmid	O
pUC19	O
(	O
CG	O
)	O
,	O
which	O
contained	O
a	O
(	O
dG	O
-	O
dC	O
)	O
7	O
segment	O
in	O
the	O
Z	O
-	O
form	O
was	O
an	O
excellent	O
competitor	O
.	O

In	O
contrast	O
,	O
an	O
amino	O
-	O
terminal	O
fragment	O
containing	O
the	O
C	O
/	O
H1	O
domain	O
was	O
sufficient	O
for	O
coactivation	O
of	O
Zta	B-GENE
transcription	O
and	O
viral	O
reactivation	O
function	O
.	O

Weak	O
allergenicity	O
of	O
recombinant	B-GENE
hirudin	I-GENE
CGP	I-GENE
39393	I-GENE
(	O
REVASC	O
)	O
in	O
immunocompetent	O
volunteers	O
.	O

TSA	O
treatment	O
,	O
however	O
,	O
did	O
not	O
detectably	O
alter	O
enhancer	O
factor	O
binding	O
or	O
the	O
positioning	O
of	O
nuc	B-GENE
-	I-GENE
1	I-GENE
on	O
the	O
majority	O
of	O
the	O
chromatin	O
templates	O
indicating	O
that	O
protein	O
acetylation	O
and	O
chromatin	O
remodeling	O
may	O
be	O
limiting	O
steps	O
that	O
occur	O
only	O
on	O
transcriptionally	O
competent	O
templates	O
,	O
or	O
that	O
remodeling	O
of	O
nuc	B-GENE
-	I-GENE
1	I-GENE
requires	O
additional	O
factors	O
.	O

Twenty	O
-	O
one	O
percent	O
of	O
these	O
patients	O
had	O
neurologic	O
disease	O
that	O
appeared	O
to	O
be	O
responsible	O
for	O
the	O
tinnitus	O
.	O

The	O
evolution	O
of	O
the	O
CCR5	B-GENE
cis	I-GENE
-	I-GENE
regulatory	I-GENE
region	I-GENE
versus	O
the	O
open	O
reading	O
frame	O
as	O
well	O
as	O
among	O
different	O
domains	O
of	O
the	O
open	O
reading	O
frame	O
differed	O
from	O
one	O
another	O
.	O

A	O
computer	O
program	O
,	O
ACCESS	O
-	O
IAQ	O
,	O
is	O
developed	O
to	O
simulate	O
the	O
airflow	O
pattern	O
,	O
the	O
time	O
history	O
of	O
the	O
contaminant	O
concentrations	O
in	O
the	O
occupied	O
zone	O
,	O
and	O
the	O
inhalation	O
exposures	O
.	O

A	O
potential	O
TATA	O
box	O
is	O
located	O
29	O
base	O
pairs	O
upstream	O
of	O
the	O
first	O
transcription	O
initiation	O
site	O
.	O

The	O
cDNA	O
encoded	O
a	O
mature	O
protein	O
of	O
240	O
amino	O
acids	O
,	O
including	O
a	O
29	O
-	O
amino	O
acid	O
signal	O
sequence	O
.	O

Using	O
a	O
MOS	O
-	O
Hypersil	O
reversed	O
-	O
phase	O
column	O
with	O
a	O
phosphate	O
buffer	O
-	O
-	O
acetonitrile	O
mobile	O
phase	O
,	O
baseline	O
separation	O
of	O
antipyrine	O
,	O
its	O
metabolites	O
3	O
-	O
hydroxymethylantipyrine	O
,	O
norantipyrine	O
and	O
4	O
-	O
hydroxyantipyrine	O
,	O
and	O
the	O
internal	O
standard	O
,	O
phenacetin	O
,	O
was	O
achieved	O
within	O
6	O
min	O
.	O

In	O
all	O
cases	O
,	O
high	O
-	O
level	O
expression	O
of	O
the	O
truncated	B-GENE
avian	I-GENE
integrins	I-GENE
was	O
obtained	O
.	O

